


## **Funding Opportunities Monthly Edition June 2019 Due Dates**

## <u>Introduction</u>

This funding opportunity packet contains information on funding opportunities with deadlines in June 2019. The opportunities are organized in the following order:

- 1. National Institutes of Health (NIH)
- 2. National Science Foundation (NSF)
- 3. Other Federal
- 4. Non Federal

Use the bookmarks to navigate to each section.



SPIN ID	Program	Sponsor Name	Sponsor Number	Deadline Date	Funding
SFIIN ID	Title	Sponsor Name	Sponsor Wulliber	Deadine Date	Amount

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
081353	<u>International Research Ethics Education and Curriculum Development Award (R25 Clinical Trial Not Allowed)</u>	Fogarty International Center/NIH/DHHS	PAR-19- 244	04-Jun-2019	1,150,000 USD

Contact Name Barbara Sina, Ph.D.

Contact Telephone 301-402-9467

Contact Email sinab@mail.nih.gov

**Sponsor Website** 

Program URL https://grants.nih.gov/grants/guide/pa-files/PAR-19-244.html

Deadline Dates (ALL) 04-Jun-2019, 04-Jun-2020, 04-Jun-2021

The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this R25 program is to support educational activities that foster a better understanding of biomedical, behavioral and clinical research and its implications. Courses for Skills Development Mentoring Activities Curriculum or Methods Development The goal of this initiative is to support educational activities that foster a better understanding of the ethics of international biomedical, behavioral and clinical research and enhance the application of research ethics principles in low- and middle-income countries (LMICs). This program aims to increase the number of LMIC research intensive institutions that can provide advanced education in international research ethics. Education programs supported by this initiative will equip scientists, health professionals and academics in these countries with in-depth knowledge of the ethical principles, processes and policies related to international clinical and public health research. Programs should be designed to strengthen the critical competencies needed to provide research ethics education, ethical review leadership and expert consultation to LMIC researchers, their institutions, governments and international research organizations. To accomplish this goal, this FOA will support innovative LMIC masters level research ethics education programs proposing integrated

activities to develop curriculum, courses for skills development, including practicum experiences, and creative mentoring

081350 International Bioethics Research Training Program (D43 Clinical Trial Optional)

approaches.

Fogarty International PAR-19- 04-Jun-2019 1,150,000 USD

Contact Name Barbara Sina, Ph.D.

Contact Telephone 301-402-9467

Synopsis

Contact Email sinab@mail.nih.gov

Sponsor Website

Program URL <a href="https://grants.nih.gov/grants/guide/pa-files/PAR-19-243.html">https://grants.nih.gov/grants/guide/pa-files/PAR-19-243.html</a>



							- 11
SPIN ID	Program Title	Sponsor Name	Sponsor	Number		<b>Deadline Date</b>	Funding Amount
	Deadline Dates (ALL)	04-Jun-2019, 04-Jun-2020, 04-Jun-202 The overall goal of this initiative is to sumiddle-income country (LMIC) research	upport the				
	Synopsis	ethics research that addresses challeng research ethics leadership to their insti U.S. collaborative institutional bioethic mentored research and training compo and leadership in health research instit trainees as the lead investigator of an i research experience in a clinical trial le	itutions, go is doctoral a onents to p outions in the ndepender	vernments and internation and postdoctoral research repare multiple individuals ne LMIC. This Funding Opp of clinical trial; or a separa	nal research orga training program s with ethics expe ortunity Announ te ancillary study	nizations. FIC will so that incorporate ertise for positions cement (FOA) allow to an existing trial	support LMIC- didactic, of scholarship ws support of ; or to gain
054786	Mechanisms of Cancer and Treati	ment-related Symptoms and Toxicities (	R21)	National Cancer Institute/NIH/DHHS	PA-16-258	07-May-2019	275,000 USD
	Contact Name	Ann M. O'Mara					
	Contact Telephone	240-276-7050					
	Contact Email	omaraa@mail.nih.gov					
	Sponsor Website						
	Program URL	http://grants.nih.gov/grants/guide/pa-	-files/PA-16	<u>-258.html</u>			
	Deadline Dates (ALL)	07-May-2019 , 16-Jun-2019 , 07-Sep-20	019				
	Synopsis	National Cancer Institute (NCI) invites i understand the complex interaction of and treatment related symptoms and t would be used to validate and extend t interventions via the R01 funding mechor in combination, in minority, underse to identify, describe, and quantify thes and toxicities. This program will use the	biological, coxicities the findings nanism. Of erved, the earters as	cognitive, behavioral, and roughout the cancer care in larger cohort studies a particular interest is to gail lderly, and pediatric and yesociated with acute and content of the content o	sociocultural factrajectory. Data find/or test novel, n new insights at roung adult popuhronic cancer and	tors that contribute from the prelimina mechanistically-di bout these factors, lations. Specifically d treatment relate	te to cancer ry studies riven either alone y, the FOA aims
057522	Revision Applications for Validation Supported Research Grants (R01)	on of Biomarker Assays Developed Thro	ugh NIH-	National Cancer Institute/NIH/DHHS	PAR-17- 003	11-Jun-2019 [LOI/Pre-App] [Optional]	300,000 USD
	Contact Name	Kelly Y. Kim, Ph.D.					

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Contact Email	kimke@mail.nih.gov				
	Sponsor Website					
	Program URL	http://grants.nih.gov/grants/guide/pa-file	s/PAR-17-003.html			
	Deadline Dates (ALL)	11-Jun-2019 [LOI/Pre-App][Optional], 11-	lul-2019 , 28-Sep-2019 [LOI/F	Pre-App][Optional], 2	28-Oct-2019	
	Synopsis	National Cancer Institute (NCI) invites ap (referred to as "markers" or "biomarkers" to treatment, as well as markers for cancer annotated specimens from NCI-supported validation of the assay. Research projects investigators, assay developers, clinicians, statistical experts are highly encouraged the early stage development of technology or point where they could be integrated into Research Project (RO1) award mechanism	) for cancer detection, diagnor or control and prevention. Re l or other clinical trials or obsequence proposed for this FOA encou statisticians and clinical labor o comprise integral parts of the the conduct of clinical trials, clinical trials as investigation	osis, prognosis, mon search applications ervational cohorts/o rage multi-disciplina tratory staff. Clinical he application. This but rather the adap	itoring, and prediction itoring, and prediction consortia for the pure ity interaction amon laboratory scientist FOA is not intended tion and validation of	on of response tion of well- pose of clinica g scientific (s) and to support of assays to the
054987	Program to Assess the Rigor and I Cancer Detection (R21)	Reproducibility of Exosome-Derived Analyt	es for National Cancer Institute/NIH/DHH	PAR-16- S 277	14-May-2019 [LOI/Pre-App] [Optional]	275,000 USD
	Contact Name	Sudhir Srivastava, Ph.D., M.P.H.				
	Contact Telephone	240-276-7028				
	Contact Email	srivasts@mail.nih.gov				
	Sponsor Website					
	Program URL	http://grants.nih.gov/grants/guide/pa-file	s/PAR-16-277.html			
	Deadline Dates (ALL)	14-May-2019 [LOI/Pre-App][Optional], 13	-Jun-2019			
	Synopsis	National Cancer Institute (NCI) invites app characterization of exosomes and their ca and prognosis of early cancer. This FOA w well as the computational analysis of the Exploratory/Developmental Grant award	rgo for discovery of predictiv Ill promote rigor and reprodu cargo carried in these vesicle	e biomarkers for ris icibility research in b	k assessment, detectoth the isolation of	tion, diagnosis
054985	Program to Assess the Rigor and I Cancer Detection (R01)	Reproducibility of Exosome-Derived Analyt	es for National Cancer Institute/NIH/DHH	PAR-16- S 276	14-May-2019 [LOI/Pre-App] [Optional]	Not Specified

SPIN ID	Program Title	Sponsor Name	Sponsor	Number		Deadline Date	Funding Amount
	Contact Namo	Sudhir Srivastava, Ph.D., M.P.H.					
	Contact Telephone						
		srivasts@mail.nih.gov					
	Sponsor Website	<u> </u>					
	'	http://grants.nih.gov/grants/guide/pa-fil	les/PΔR-1	6-276 html			
		14-May-2019 [LOI/Pre-App][Optional], 1:					
	Synopsis	National Cancer Institute (NCI) invites ap characterization of exosomes and their cand prognosis of early cancer. This FOA well as the computational analysis of the award mechanism.	argo for o	discovery of predictive bion ote rigor and reproducibility	markers for risk ty research in bo	assessment, detectors the the isolation of	tion, diagnosi exosomes as
)55525	Linking the Provider Recommend	ation to Adolescent HPV Vaccine Uptake (	(R03)	National Cancer Institute/NIH/DHHS	PAR-16- 337	16-Jun-2019	100,000 USD
	Contact Name	Sarah Kobrin, Ph.D., MPH					
	Contact Telephone	240-276-6931					
	Contact Email	jerry.suls@nih.gov					
	Sponsor Website						
	Program URL	http://grants.nih.gov/grants/guide/pa-fil	les/PAR-1	<u>.6-337.html</u>			
	Deadline Dates (ALL)	16-Jun-2019					
	Synopsis	National Cancer Institute (NCI) invites ap the effectiveness of a provider's recomm the provider, parent/patient, and clinical that recommendation results in uptake of childhood behavior, immunization promo award mechanism.	nendation setting, of the HP	of the adolescent human can all affect whether a pr / vaccine. This research re	papillomavirus ( ovider makes a r quires expertise	(HPV) vaccine. Chair recommendation, a in cancer prevention	racteristics of and whether on, adult and
065701	Biology of Lung, and Head and Ne	ck Preneoplasias (R21 - Clinical Trial Not	Allowed)	National Cancer Institute/NIH/DHHS	PAR-17- 460	17-May-2019 [LOI/Pre-App] [Optional]	275,000 USD
	Contact Name	Ron Johnson, Ph. D.					

SPIN ID	Program Title	Sponsor Name	Sponsor	Number		Deadline Date	Funding Amount
	Contact Email	rjohnso2@mail.nih.gov					
	Sponsor Website						
	Program URL	https://grants.nih.gov/grants/guide/pa-	files/PAR-	<u> 17-460.html</u>			
	Deadline Dates (ALL)	17-May-2019 [LOI/Pre-App][Optional], 1 [LOI/Pre-App][Optional], 16-Feb-2020, App][Optional], 16-Oct-2020			•		
	Synopsis	National Cancer Institute (NCI) invites a to lung, and head and neck (HN) cancer cancers, these tumors remain a major hinjury to the aerodigestive epithelial fiel initiate these preneoplasias and drive the changes involved in the formation and progression and accelerate development Exploratory/Developmental (R21) grant	s. Despite i ealth prob d have bed neir progre progression at of effect	mproved therapies and a dealem in the United States and en found, relatively little is known to invasive cancer. A further of lung and HN preneoplasion to preventive and therapeut	eper molecular globally. While lown about the nctional under as will enhance	r understanding of e molecular marke e molecular mech estanding of the ke e our knowledge o	f lung and HN ers of early anisms that ey molecular f oncogenic
065699	Biology of Lung, and Head and Ned	ck Preneoplasias (R01 - Clinical Trial Not	Allowed)	National Cancer Institute/NIH/DHHS	PA-17-459 (	05-Jun-2019	Not Specified
	Contact Name	Ron Johnson, Ph. D.					
	Contact Telephone	240 276 6250					
	Contact Email	rjohnso2@mail.nih.gov					
	Sponsor Website						
	Program URL	https://grants.nih.gov/grants/guide/pa-	files/PA-1	<u>'-459.html</u>			
	Deadline Dates (ALL)	05-Jun-2019 , 05-Oct-2019 , 05-Feb-202	0 , 05-Jun-	2020 , 05-Oct-2020			
	Synopsis	National Cancer Institute (NCI) invites to lung, and head and neck (HN) cancer cancers, these tumors remain a major hinjury to the aerodigestive epithelial fiel initiate these preneoplasias and drive the changes involved in the formation and progression and accelerate development Research Project (RO1) award mechanis	s. Despite is ealth probled have been been progression of effect	mproved therapies and a dealem in the United States and en found, relatively little is known to invasive cancer. A fure of lung and HN preneoplasion	eper molecular globally. While lown about the nctional under as will enhance	r understanding of e molecular marke e molecular mech estanding of the ke e our knowledge o	f lung and HN ers of early anisms that ey molecular f oncogenic
06/396	Testing Interventions for Health-El Optional)	nhancing Physical Activity (R01 - Clinical	<u>Trial</u>	National Cancer Institute/NIH/DHHS	PAR-17- 306	05-Jun-2019	Not Specified

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Contact Telephone Contact Email Sponsor Website Program URL	https://grants.nih.gov/grants/guide/pa-f 05-Jun-2019, 07-Sep-2019, 05-Feb-2020 National Institutes of Health (NIH) and it promising research that tests multi-level	o, 07-May-2020, 05-Oct-2020, 02-Jes participating Institutes and Center physical activity intervention prograse health-enhancing physical activity scalable and sustainable for broad untervention delivery, and follow-up	s invite applicati ams acting on at y: 1) in persons c use across the na	least two levels of or groups that can lation. This FOA pro	f the socio- benefit from ovides support
068716	Early Phase Clinical Trials in Imagi Trial Required)	ing and Image-Guided Interventions (R01	Clinical National Cancer Institute/NIH/DHHS	PAR-18- 011	29-May-2019 [LOI/Pre-App] [Optional]	500,000 USD
	Contact Name	Lori A. Henderson, Ph.D.				
	Contact Telephone	240-276-5930				
	Contact Email	hendersonlori@mail.gov				
	Sponsor Website					
	Program URL	https://grants.nih.gov/grants/guide/pa-f	files/PAR-18-011.html			
	Deadline Dates (ALL)	29-May-2019 [LOI/Pre-App][Optional], 2 [LOI/Pre-App][Optional], 14-Feb-2020	8-Jun-2019 , 11-Sep-2019 [LOI/Pre-A	App][Optional], :	11-Oct-2019 , 15-Ja	ın-2020
	Synopsis	National Cancer Institute (NCI) invites a efficacy of imaging agents, as well as an execution therapy, contrast kinetic mode evaluations are early in development, the clinical trials, including patient monitorin imaging agents and methods as well as the intervention (IGI) investigations, if prove through competitive RO1 mechanisms, on Cancer Centers and/or the NCI's National mechanisms.	assessment of imaging systems, imaging, 3-D reconstruction and other of its FOA will provide investigators with a gand laboratory studies. This FOA she evaluation of new agents, system in successful in these early clinical trough clinical trials in the Specia	ge processing, in quantitative tool h support for pil supports novel uns, or methods. The ials, can then be lized Programs o	mage-guided planr is. As many such pr ot (Phase I and II) o ses of known/stan The imaging and in validated in larger of Research Excelle	ning and/or reliminary cancer imaging dard clinical nage-guided r studies nce (SPOREs),

SPIN ID	Program Title	Sponsor Name S	ponsor Number		Deadline Date	Funding Amount
068715	Linking the Provider Recommenda Clinical Trial Optional)	ation to Adolescent HPV Vaccine Uptake (R2	National Cancer Institute/NIH/DHHS	PAR-18- 019	16-Jun-2019	275,000 USD
	Contact Name	Sarah Kobrin, Ph.D., MPH				
	Contact Telephone	240-276-6931				
	Contact Email	kobrins@mail.nih.gov				
	Sponsor Website					
	Program URL	https://grants.nih.gov/grants/guide/pa-file	s/PAR-18-019.html			
	Deadline Dates (ALL)	16-Jun-2019				
		National Cancer Institute (NCI) invites appli the effectiveness of a provider's recommen				
	Synopsis		idation of the adolescent human etting, can all affect whether a pr he HPV vaccine. This research re on, and healthcare delivery. This	papillomaviru ovider makes a quires expertis	s (HPV) vaccine. Cha a recommendation, a e in cancer preventi	racteristics of and whether
069100	Synopsis	the effectiveness of a provider's recomment the provider, parent/patient, and clinical set that recommendation results in uptake of t childhood behavior, immunization promoti	idation of the adolescent human etting, can all affect whether a pr he HPV vaccine. This research re on, and healthcare delivery. This t award mechanism.	papillomaviru ovider makes a quires expertis	s (HPV) vaccine. Cha a recommendation, a e in cancer preventi ne NIH R21	racteristics of and whether
068190	Synopsis	the effectiveness of a provider's recomment the provider, parent/patient, and clinical set that recommendation results in uptake of t childhood behavior, immunization promoti Exploratory/Developmental Research Gran	idation of the adolescent human etting, can all affect whether a pr he HPV vaccine. This research re on, and healthcare delivery. This t award mechanism.	papillomaviru ovider makes a quires expertis FOA will use tl	s (HPV) vaccine. Cha a recommendation, a e in cancer preventi	racteristics of and whether on, adult and
068190	NCI Mentored Clinical Scientist Re Diversity (K08 Clinical Trial Requir	the effectiveness of a provider's recomment the provider, parent/patient, and clinical set that recommendation results in uptake of t childhood behavior, immunization promoti Exploratory/Developmental Research Gran	edation of the adolescent human etting, can all affect whether a property he HPV vaccine. This research resumed in the many and healthcare delivery. This taward mechanism.  In the mode of the adolescent human in the mode in the adolescent human in the mode in the adolescent human in the mode in the adolescent human i	papillomaviru ovider makes a quires expertis FOA will use tl PAR-18-	s (HPV) vaccine. Cha a recommendation, a e in cancer preventi ne NIH R21	racteristics of and whether on, adult and Not
068190	NCI Mentored Clinical Scientist Re Diversity (K08 Clinical Trial Requir	the effectiveness of a provider's recomment the provider, parent/patient, and clinical set that recommendation results in uptake of the childhood behavior, immunization promotion Exploratory/Developmental Research Grantesearch Career Development Award to Promed)  John O. Ojeifo, MD, PhD, MBA.	edation of the adolescent human etting, can all affect whether a property he HPV vaccine. This research resumed on, and healthcare delivery. This taward mechanism.  The sum of the adolescent human is a property of the adol	papillomaviru ovider makes a quires expertis FOA will use tl PAR-18-	s (HPV) vaccine. Cha a recommendation, a e in cancer preventi ne NIH R21	racteristics of and whether on, adult and Not
068190	NCI Mentored Clinical Scientist Re Diversity (K08 Clinical Trial Requir Contact Name Contact Telephone	the effectiveness of a provider's recomment the provider, parent/patient, and clinical set that recommendation results in uptake of the childhood behavior, immunization promotion Exploratory/Developmental Research Grantesearch Career Development Award to Promed)  John O. Ojeifo, MD, PhD, MBA.	edation of the adolescent human etting, can all affect whether a property he HPV vaccine. This research resumed on, and healthcare delivery. This taward mechanism.  The sum of the adolescent human is a property of the adol	papillomaviru ovider makes a quires expertis FOA will use tl PAR-18-	s (HPV) vaccine. Cha a recommendation, a e in cancer preventi ne NIH R21	racteristics of and whether on, adult and Not
068190	NCI Mentored Clinical Scientist Re Diversity (K08 Clinical Trial Requir Contact Name Contact Telephone	the effectiveness of a provider's recomment the provider, parent/patient, and clinical set that recommendation results in uptake of the childhood behavior, immunization promotion Exploratory/Developmental Research Granesearch Career Development Award to Promed)  John O. Ojeifo, MD, PhD, MBA. 240-276-6186	edation of the adolescent human etting, can all affect whether a property he HPV vaccine. This research resumed on, and healthcare delivery. This taward mechanism.  The sum of the adolescent human is a property of the adol	papillomaviru ovider makes a quires expertis FOA will use tl PAR-18-	s (HPV) vaccine. Cha a recommendation, a e in cancer preventi ne NIH R21	racteristics of and whether on, adult and Not
068190	NCI Mentored Clinical Scientist Re Diversity (K08 Clinical Trial Requir Contact Name Contact Telephone Contact Email Sponsor Website	the effectiveness of a provider's recomment the provider, parent/patient, and clinical set that recommendation results in uptake of the childhood behavior, immunization promotion Exploratory/Developmental Research Granesearch Career Development Award to Promed)  John O. Ojeifo, MD, PhD, MBA. 240-276-6186	etting, can all affect whether a proceeding, can all affect whether a procede HPV vaccine. This research reson, and healthcare delivery. This traward mechanism.    National Cancer	papillomaviru ovider makes a quires expertis FOA will use tl PAR-18-	s (HPV) vaccine. Cha a recommendation, a e in cancer preventi ne NIH R21	racteristics of and whether on, adult and Not
068190	NCI Mentored Clinical Scientist Re Diversity (K08 Clinical Trial Requir Contact Name Contact Telephone Contact Email Sponsor Website Program URL	the effectiveness of a provider's recomment the provider, parent/patient, and clinical set that recommendation results in uptake of the childhood behavior, immunization promotion Exploratory/Developmental Research Grantesearch Career Development Award to Promed)  John O. Ojeifo, MD, PhD, MBA.  240-276-6186  ojeifojo@mail.nih.gov	etting, can all affect whether a properting, can all affect whether a properties on, and healthcare delivery. This traward mechanism.  The state of	papillomaviru ovider makes a quires expertis FOA will use tl PAR-18-	s (HPV) vaccine. Cha a recommendation, a e in cancer preventi ne NIH R21	racteristics of and whether on, adult and Not

represents the continuation of a long-standing NIH program that provides support and protected time to individuals with a

behavioral research, including translational research. The NCI-sponsored K08 award is specifically designed to promote career development of clinical scientists from backgrounds that have been shown to be nationally underrepresented in health-related science and for those who are committed to a career in basic biomedical, behavioral or translational cancer research, including research on cancer health disparities. The expectation is that through this sustained period of research career

Synopsis clinical doctoral degree for an intensive, supervised research career development experience in the fields of biomedical and

SPIN ID Program Title Sponsor Name Sponsor Number Deadline Date Amount	SPIN ID	•	Sponsor Name	Sponsor Number	Deadline Date	
--	---------	---	--------------	----------------	---------------	--

development and training, awardees will develop enhanced research capabilities for cancer research careers and be better prepared to compete for research project grants (e.g. R03, R21, or R01) funding. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. This Funding Opportunity Announcement (FOA) will utilize the NIH K08 Clinical Investigator Award (CIA) mechanism.

067444

Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical Trial Not Allowed)

**National Cancer** Institute/NIH/DHHS PAR-18-317

10-Jun-2019 1.025.000 [LOI/Pre-App] USD [Optional]

Contact Name Tracy G. Lively, Ph.D.

Contact Telephone 240-276-5944

Contact Email livelyt@mail.nih.gov

Sponsor Website

Program URL https://grants.nih.gov/grants/guide/pa-files/PAR-18-317.html

10-Jun-2019 [LOI/Pre-App][Optional], 10-Jul-2019, 08-Sep-2019 [LOI/Pre-App][Optional], 08-Oct-2019, 14-Jan-2020 Deadline Dates (ALL) [LOI/Pre-App] [Optional], 13-Feb-2020, 10-Jun-2020 [LOI/Pre-App] [Optional], 10-Jul-2020, 08-Sep-2020 [LOI/Pre-App] App][Optional], 08-Oct-2020

> National Cancer Institute (NCI) invites applications to support the validation of molecular/cellular/imaging markers and assays for cancer detection, diagnosis, prognosis, monitoring, and prediction of response or resistance to treatment, as well as markers for cancer prevention and control. This FOA also includes the validation of pharmacodynamic markers and markers of toxicity. Applicants should have assays that work on human samples and whose importance is well justified for development into clinical assays. As chemotherapies and/or radiation therapies are increasingly combined with immunotherapies to enhance durability of anti-cancer responses, multiple assays for measuring multiple markers, including immune markers, can be developed and validated simultaneously. The UH2 phase of this FOA supports analytical validation of assays for these markers that must be achieved within 2 years before assays may undergo clinical validation. The UH3 phase of this FOA supports clinical validation of established assays for up to 3 years using specimens from retrospective or prospective clinical trials or studies. This FOA may be used to validate existing assays for use in other cancer clinical trials, observational studies, or population studies. Efforts to harmonize clinical laboratory tests, including investigation into the performance and reproducibility of assays across multiple clinical laboratories, are also appropriate for this funding opportunity. Projects proposed for this FOA will require multi-disciplinary interaction and collaboration among scientific investigators, oncologists, statisticians, and clinical laboratory scientists. This FOA is not intended to support early-stage development of technology or the conduct of clinical trials, but is intended for validation of assays to the point where they

could be integrated into clinical trials/studies as investigational assays. Investigators responding to this FOA must address

SPIN ID	Program Title	Sponsor Name	Sponsor	Number		Deadline Date	Funding Amount
		both UH2 and UH3 phases. This FOA wi	ill use the N	IIH UH2/UH3 Phase Innovat	ion Awards Co	ooperative Agreemo	ent award
067443	Assay Validation of High Quality I Trials Not Allowed	Markers for Clinical Studies in Cancer (UI	H3) Clinical	National Cancer Institute/NIH/DHHS	PAR-18- 310	10-Jun-2019 [LOI/Pre-App] [Optional]	750,000 USD
	Contact Name	Tracy G. Lively, Ph.D.					
	Contact Telephone	240-276-5944					
	Contact Email	<u>livelyt@mail.nih.gov</u>					
	Sponsor Website						
	Program URL	https://grants.nih.gov/grants/guide/pa	-files/PAR-	<u>18-310.html</u>			
	Deadline Dates (ALL)	10-Jun-2019 [LOI/Pre-App][Optional], 1 [LOI/Pre-App][Optional], 13-Feb-2020 , App][Optional], 08-Oct-2020					
	Synopsis	National Cancer Institute (NCI) invites a markers and assays for cancer detection treatment, as well as markers for cancer markers and markers of toxicity. Applicitly, applic	n, diagnosi er preventice ants to this for the intended with including ition of estatis FOA may o harmonize clinical laidisciplina entists. This nded for va	s, prognosis, monitoring, and on and control. This FOA also FOA must have an assay(s) ended clinical use of the asson immunotherapies to enhammune markers, can be deblished assays for up to 3 yes be used to validate existing e clinical laboratory tests, in coratories, are also appropring interaction and collaboration of assays to the poil	d prediction of includes the whose performay(s) and marking eloped and versusing speciassays for use including investiate for this fution among scoort early-stagent where they	f response or resist validation of pharm mance has been an ker(s). As chemother of anti-cancer respalidated simultaneous in other trials, obstigation into the pending opportunity, ientific investigator of could be integrate	rance to nacodynamic nalytically erapies and/or onses, multiple ously. The UH3 pective or servational rformance and Projects rs, oncologists, technology or d into clinical
068373	Reducing Overscreening for Brea Adults (R21 Clinical Trial Optiona	st, Cervical, and Colorectal Cancers amo   <u> </u>	ng Older	National Cancer Institute/NIH/DHHS	PA-18-015	16-Jun-2019	275,000 USD
	Contact Name	Erica S. Breslau, Ph.D., M.P.H.,					

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount

Contact Email breslaue@mail.nih.gov

Sponsor Website

Program URL https://grants.nih.gov/grants/guide/pa-files/PA-18-015.html

Deadline Dates (ALL) 16-Jun-2019, 16-Oct-2019

National Cancer Institute (NCI) and National Institute on Aging (NIA) invite applications for research on interventions, based in healthcare settings, designed to reduce overscreening for breast, cervical, or colorectal cancers among average-risk older adults. While ongoing efforts to promote screening have been successful, there is growing concern that these tests may be overused, thereby subjecting adults to unnecessary risks. Overscreening older adults may be driven by factors at the individual, healthcare team, healthcare system and community organization levels. Therefore, research is needed both to understand the factors that drive overuse and to develop and test interventions that will reduce overuse in healthcare delivery systems. Research supported by this FOA should propose to intervene at two or more levels, and should measure outcomes at two or more levels, while accounting for interactions that occur between levels. Research supported by this FOA should enhance knowledge and consequences of overscreening to improve the health, independence, and quality of life of older adults. This FOA will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.

065733 Biology of Lung, and Head and Neck Preneoplasias (R21 - Clinical Trial Not Allowed)

**National Cancer** Institute/NIH/DHHS

PA-17-460 16-Jun-2019

275,000 USD

Contact Name Ron Johnson, Ph. D.

Contact Telephone 240 276 6250

Contact Email rjohnso2@mail.nih.gov

Sponsor Website

Program URL https://grants.nih.gov/grants/guide/pa-files/PA-17-460.html

Deadline Dates (ALL) 16-Jun-2019, 16-Oct-2019, 16-Feb-2020, 16-Jun-2020, 16-Oct-2020

National Cancer Institute (NCI) invites applications investigating mechanistic and biological aspects of preneoplasia leading to lung, and head and neck (HN) cancers. Despite improved therapies and a deeper molecular understanding of lung and HN cancers, these tumors remain a major health problem in the United States and globally. While molecular markers of early injury to the aerodigestive epithelial field have been found, relatively little is known about the molecular mechanisms that initiate these preneoplasias and drive their progression to invasive cancer. A functional understanding of the key molecular changes involved in the formation and progression of lung and HN preneoplasias will enhance our knowledge of oncogenic progression and accelerate development of effective preventive and therapeutic strategies. This FOA will use the NIH Exploratory/Developmental (R21) grant mechanism.

066404 Electronic Nicotine Delivery Systems (ENDS): Basic Mechanisms of Health Effects

**National Cancer** 

PAR-17-

27-Jun-2019

275,000

SPIN ID	Program Title	Sponsor Name Sp	onsor Number		Deadline Date	Funding Amount
	(R21 - Clinical Trial Not Allowed)		Institute/NIH/DHHS	475		USD
	Contact Name Ror	n Johnson, PhD				
	Contact Telephone 240					
	Contact Email <u>rjol</u>	hnso2@mail.nih.gov				
	Sponsor Website	-				
	Program URL <u>htt</u>	ps://grants.nih.gov/grants/guide/pa-files	/PAR-17-475.html			
	Deadline Dates (ALL) 27-	Jun-2019 , 24-Oct-2019 , 27-Oct-2020				
	Synopsis exa	mining how Electronic Nicotine Delivery	Systems (FNDS) aerosols affect i	normal and disc	aaca statas ralavant	
	cell	s, tissues and organs. This FOA will use th	ne NIH R21 Exploratory/Develop			
068218	NCI Mentored Clinical Scientist Resea	s, tissues and organs. This FOA will use the	ne NIH R21 Exploratory/Developote National Cancer	mental Researd		hanism. Not
068218	NCI Mentored Clinical Scientist Researchiversity (K08 No Independent Clinical	ls, tissues and organs. This FOA will use the control of the contr	ne NIH R21 Exploratory/Develop	mental Resear	ch Grant award med	hanism.
068218	NCI Mentored Clinical Scientist Research Diversity (K08 No Independent Clinical Contact Name John	ls, tissues and organs. This FOA will use the career Development Award to Promodal Trials) on O. Ojeifo, MD, PhD, MBA.	ne NIH R21 Exploratory/Developote National Cancer	mental Researd	ch Grant award med	hanism. Not
068218	NCI Mentored Clinical Scientist Research Diversity (K08 No Independent Clinical Contact Name Contact Telephone 240	Is, tissues and organs. This FOA will use the rich Career Development Award to Promodal Trials) In O. Ojeifo, MD, PhD, MBA. D-276-6186	ne NIH R21 Exploratory/Developote National Cancer	mental Researd	ch Grant award med	hanism. Not
068218	NCI Mentored Clinical Scientist Research Diversity (K08 No Independent Clinical Contact Name Contact Telephone 240 Contact Email	ls, tissues and organs. This FOA will use the career Development Award to Promodal Trials) on O. Ojeifo, MD, PhD, MBA.	ne NIH R21 Exploratory/Developote National Cancer	mental Researd	ch Grant award med	hanism. Not
068218	NCI Mentored Clinical Scientist Research Diversity (K08 No Independent Clinical Contact Name Contact Telephone Contact Email Sponsor Website	is, tissues and organs. This FOA will use the rich Career Development Award to Promo al Trials) in O. Ojeifo, MD, PhD, MBA. 0-276-6186 ifojo@mail.nih.gov	ne NIH R21 Exploratory/Developote National Cancer Institute/NIH/DHHS	mental Researd	ch Grant award med	hanism. Not
068218	NCI Mentored Clinical Scientist Research Diversity (K08 No Independent Clinical Contact Name Contact Telephone Contact Email Sponsor Website Program URL http://doi.org/10.1001/http://	Is, tissues and organs. This FOA will use the rich Career Development Award to Promodal Trials) In O. Ojeifo, MD, PhD, MBA. D-276-6186	ne NIH R21 Exploratory/Developote National Cancer Institute/NIH/DHHS	mental Researd	ch Grant award med	hanism. Not

individuals for careers that have a significant impact on the health-related research needs of the nation. This program represents the continuation of a long-standing NIH program that provides support and protected time to individuals with a clinical doctoral degree for an intensive, supervised research career development experience in the fields of biomedical and behavioral research, including translational research. The NCI-sponsored K08 award is specifically designed to promote career Synopsis development of clinical scientists from backgrounds that have been shown to be nationally underrepresented in healthrelated science and for those who are committed to a career in basic biomedical, behavioral or translational cancer research, including research on cancer health disparities. The expectation is that through this sustained period of research career development and training, awardees will develop enhanced research capabilities for cancer research careers and be better prepared to compete for research project grants (e.g. R03, R21, or R01) funding. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this FOA are permitted to propose research

SPIN ID	Program Title	Sponsor Name Sp	onsor Number		Deadline Date	Funding Amount
		experience in a clinical trial led by a mentor ( KO8 Clinical Investigator Award (CIA) mechan		oortunity Annou	ncement (FOA) will	utilize the NI
067236	Multilevel Interventions in Cancer Tests (R01 Clinical Trial Optional)	Care Delivery: Follow-up to Abnormal Scree	ning National Cancer Institute/NIH/DHHS	PA-17-495	05-Jun-2019	Not Specified
	Contact Telephone 2 Contact Email k Sponsor Website Program URL k Deadline Dates (ALL)	Erica S. Breslau, Ph.D., M.P.H., 240-276-6773  preslaue@mail.nih.gov  https://grants.nih.gov/grants/guide/pa-files, 05-Jun-2019, 05-Oct-2019, 05-Feb-2020, 09  National Cancer Institute (NCI) invites applications for breast, cervical dependent on factors at the patient, provided appropriate applications for this FOA should	o-Jun-2020, 05-Oct-2020 cations that develop and test m colorectal, or lung cancers. Im r, clinical team, clinic, healthca	proving follow-ure institution, or	up to abnormal scree community setting d measure outcom	eening tests is g levels.
		more levels, while accounting for interactior Project (R01) award mechanism.	s that occur between and acros	ss levels. This FC	A will use the NIH	
068340	Academic-Industrial Partnerships t	Project (R01) award mechanism.  o Translate and Validate in vivo Cancer Imag		ss levels. This FC PAR-18- 009	0A will use the NIH 05-Jun-2019	
068340	Academic-Industrial Partnerships t Systems (R01 Clinical Trial Optiona  Contact Name   Contact Telephone   Contact Email   Sponsor Website	Project (R01) award mechanism.  o Translate and Validate in vivo Cancer Imag  l)  Houston Baker, Ph.D.	ing National Cancer Institute/NIH/DHHS	PAR-18-		Research Not

technologies are imaging applications in clinical trials, clinical research, non-clinical research, and/or patient care. Among

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		other possibilities, they may include pre- pre-clinical methods, or optimizations of NIH Research Project (R01) award mecha	methods across different co	•	•	•
065402	The Interplay of Cell Death Pathy Therapy (R21)	vays in Cancer Cell Survival and Resistance	National Cancer Institute/NIH/DH	PA-17-449	16-Jun-2019	275,000 USD
	Contact Name	Konstantin Salnikow, Ph.D				
	Contact Telephone	240-276-6230				
	Contact Email	salnikok@mail.nih.gov				
	Sponsor Website					
	Program URL	https://grants.nih.gov/grants/guide/pa-f	iles/PA-17-449.html			
	Deadline Dates (ALL)	16-Jun-2019 , 16-Oct-2019 , 16-Feb-2020	, 16-Jun-2020			
	Synopsis	National Cancer Institute (NCI) invites a drug resistant cancers. Regulated cell de cells from surviving and disseminating. E tumor progression, metastases and resis of cell death coexists in cells but the cross into the intersection of cell death progra and offers the possibility that the specific enhanced, driving naïve and drug resista R21 Exploratory/Developmental Research	ath, especially apoptosis and vasion of cell death mechani tance to therapy. Recent stu stalk of cell death pathways ms will allow for better defired mediators of cell survival mut cancer cells toward effect	necroptosis, are natu sms is one of the halln dies show that the ma in cancer has not been sing markers of cell de ay be inhibited and/o	ral barriers that res narks of cancer con chinery to activate n systematically stu ath pathway at the the mediators of c	trict malignant tributing to different forms died. Research molecular level
065399	The Interplay of Cell Death Pathy Therapy (R01)	vays in Cancer Cell Survival and Resistance	National Cancer Institute/NIH/DH	PA-17-440	05-Jun-2019	Not Specified
	Contact Name	Konstantin Salnikow, Ph.D				
	Contact Telephone	240-276-6230				
	Contact Email	salnikok@mail.nih.gov				
	Sponsor Website					
	Program URL	https://grants.nih.gov/grants/guide/pa-f	iles/PA-17-440.html			
	Deadline Dates (ALL)	05-Jun-2019 , 05-Oct-2019 , 05-Feb-2020	, 05-Jun-2020			
	Synopsis	National Cancer Institute (NCI) invites a drug resistant cancers. Regulated cell de cells from surviving and disseminating. E	ath, especially apoptosis and	necroptosis, are natu	ral barriers that res	trict malignant

SPIN ID	Program Title	Sponsor Name	Sponsor	Number		Deadline Date	Funding Amount
	( i a	tumor progression, metastases and resist of cell death coexists in cells but the cross into the intersection of cell death prograr and offers the possibility that the specific enhanced, driving naïve and drug resistan (R01) award mechanism.	stalk of constants will all mediate	ell death pathways in cancer low for better defining mark rs of cell survival may be inh	has not been a ers of cell deat ibited and/or t	systematically stud th pathway at the the mediators of c	died. Research molecular level ell death
068367	Oral Anticancer Agents: Utilization Clinical Trial Optional)	, Adherence, and Health Care Delivery (R	<u>21</u>	National Cancer Institute/NIH/DHHS	PA-18-014	16-Jun-2019	275,000 USD
	Contact Telephone 2 Contact Email 1 Sponsor Website Program URL 1 Deadline Dates (ALL) 2  Synopsis a	Wendy Nelson, Ph.D. 240-276-6971 nelsonw@mail.nih.gov  https://grants.nih.gov/grants/guide/pa-fi 16-Jun-2019 , 16-Oct-2019 National Cancer Institute (NCI) invites apmedication utilization, delivery, and adhe (3) develop models and strategies to improprimized. Applications should focus reseand/or groups subject to disparities (e.g., minorities). Research may be focused at the team, or health care delivery system levels studies. Observational studies should emponental Research	oplication rence; (2 rove safe arch que elderly p he patien on and ma on astice r	is to: (1) assess and describe ) identify structural, systemi and effective delivery of the stions on at least one of the opulations, members of low at (pediatric, adolescent, or a y include intervention studie nodifiable risk factors for fut	c, and psychosese agents so to following: spectosoconomedult), patientes, observation	social barriers to a hat clinical outcon cific cancer type; o ic groups, racial/e -caregiver, provide nal studies, or mixe	dherence; and nes are class of drugs; thnic er, health care ed-methods
068364	Oral Anticancer Agents: Utilization Clinical Trial Optional)	, Adherence, and Health Care Delivery (R	<u>01</u>	National Cancer Institute/NIH/DHHS	PA-18-004	05-Jun-2019	Not Specified
	Contact Telephone 2 Contact Email <u>r</u> Sponsor Website Program URL <u>l</u>	Wendy Nelson, Ph.D. 240-276-6971 nelsonw@mail.nih.gov https://grants.nih.gov/grants/guide/pa-fi 05-Jun-2019, 05-Oct-2019	les/PA-1	3-004.html			

SPIN ID	Program Title	Sponsor Name	Sponsor	Number		Deadline Date	Funding Amount
		National Cancer Institute (NCI) invites ap medication utilization, delivery, and adhe (3) develop models and strategies to improptimized. Applications should focus rese and/or groups subject to disparities (e.g., minorities). Research may be focused at t team, or health care delivery system level studies. Observational studies should emp NIH Research Project (RO1) award mechan	erence; (2) rove safe earch ques elderly po the patien I, and may phasize m	identify structural, system and effective delivery of the stions on at least one of the opulations, members of low t (pediatric, adolescent, or v include intervention studi	ic, and psychosese agents so to following: spewasocioeconomedult), patientes, observation	social barriers to a hat clinical outcon ecific cancer type; o ic groups, racial/ed -caregiver, provide nal studies, or mixe	dherence; and nes are class of drugs; thnic er, health care ed-methods
IIhXXhX -	Reducing Overscreening for Breas Adults (R01 Clinical Trial Optional	et, Cervical, and Colorectal Cancers among	Older	National Cancer Institute/NIH/DHHS	PA-18-005	05-Jun-2019	Not Specified
	Contact Telephone	Erica S. Breslau, Ph.D., M.P.H., 240-276-6773 breslaue@mail.nih.gov					
	Program URL	https://grants.nih.gov/grants/guide/pa-fil	les/PA-18	<u>-005.html</u>			
	Synopsis	National Cancer Institute (NCI) and Nation in healthcare settings, designed to reduce adults. While ongoing efforts to promote overused, thereby subjecting adults to un individual, healthcare team, healthcare sy understand the factors that drive overuse delivery systems. Research supported by to outcomes at two or more levels, while acc should enhance knowledge and conseque older adults. This FOA will use the NIH Research	e overscre screening necessary ystem and e and to d this FOA s counting to ences of o	ening for breast, cervical, og have been successful, there is risks. Overscreening older community organization leavelop and test intervention bould propose to intervention interactions that occur be verscreening to improve the	r colorectal care is growing control adults may be evels. Thereforms that will reduce at two or modetween levels and the levels and the levels are the levels and the levels are the level	ncers among avera oncern that these to driven by factors e, research is need luce overuse in hea re levels, and shou . Research support	age-risk older tests may be at the ded both to althcare ald measure ted by this FOA
	Linking the Provider Recommenda Clinical Trial Optional)	ation to Adolescent HPV Vaccine Uptake (F	R01	National Cancer Institute/NIH/DHHS	PAR-18- 008	05-Jun-2019	Not Specified
	Contact Name Contact Telephone	Sarah Kobrin, Ph.D., MPH 240-276-6931					

Contact Email <u>kobrins@mail.nih.gov</u>

SPIN ID	Program Title	Sponsor Name	Sponsor	Number		Deadline Date	Funding Amount
	Sponsor Website						
	Program URL	https://grants.nih.gov/grants/guide/	/pa-files/PAR-	<u>18-008.html</u>			
	Deadline Dates (ALL)	05-Jun-2019					
National Cancer Institute (NCI) invites applications for research on how the healthcare delivery system enhances or the effectiveness of a provider's recommendation of the adolescent human papillomavirus (HPV) vaccine. Character the provider, parent/patient, and clinical setting, can all affect whether a provider makes a recommendation, and w that recommendation results in uptake of the HPV vaccine. This research requires expertise in cancer prevention, as childhood behavior, immunization promotion, and healthcare delivery. This FOA will use the NIH Research Project (Favore to the NIH Research Proje							racteristics of and whether on, adult and
Uhlala	Core Infrastructure and Methodo (U01)	logical Research for Cancer Epidemio	logy Cohorts	National Cancer Institute/NIH/DHHS	PAR-17- 233	05-Jun-2019	6,250,000 USD
	Contact Name	Joanne Elena, Ph.D., M.P.H.					
	Contact Telephone	240-276-6818					
	Contact Email	joanne.elena@nih.gov					
	Sponsor Website						
	Program URL	https://grants.nih.gov/grants/guide/	/pa-files/PAR-	17-233.html			
	Deadline Dates (ALL)	05-Jun-2019 , 05-Oct-2019 , 05-Feb-	2020				
	Synopsis	National Cancer Institute (NCI) invite as well as methodological research. sharing with broader scientific commaward mechanism.	This FOA is int	ended to support mainter	nance of existing	CECs infrastructur	e and resourc
062723	Leveraging Population-based Can	cer Registry Data to Study Health Dis	parities (R21)	National Cancer Institute/NIH/DHHS	PA-17-288	16-Jun-2019	275,000 USD
	Contact Name	Kathleen Cronin					
	Contact Telephone	240-276-6836					
	Contact Email	cronink@mail.nih.gov					
	Sponsor Website						
	Program URL	https://grants.nih.gov/grants/guide/	/pa-files/PA-1	7-288.html			
	Deadline Dates (ALL)	16-Jun-2019 , 16-Oct-2019 , 16-Feb-	2020 , 16-Jun-	2020			

Synopsis National Cancer Institute (NCI)) invites applications to efficiently use the existing cancer registry infrastructure by

SPIN ID	Program Title	Sponsor Name	Sponsor	Number		Deadline Date	Funding Amount
		augmenting data already collected with a diagnosed with cancer. Specifically, this F the framework of population-based cancer registries. The studies should be hypotherencouraged to leverage the data already goal of these analyses will be to understa contributing to disparities and their relationary mechanism.	OA will suer registri sis-drivent collected nd why d	upport the study of factors es by the inclusion of data and multidisciplinary app by the registries to invest isparities in cancer treatm	s influencing obso a not routinely co roaches are enco igate the determ ent and outcomo	erved health dispandlected by or linked buraged. Investigationates of health despressions persist by ident	erities within ed to the tors are isparities. The ifying factors
064234	Integration of Individual Residen	tial Histories into Cancer Research (R21)		National Cancer Institute/NIH/DHHS	PA-17-295	16-Jun-2019	275,000 USD
	Contact Name	Zaria Tatalovich, Ph.D.					
	Contact Telephone	240-276-6976					
	Contact Emai	tatalovichzp@mail.nih.gov					
	Sponsor Website						
	Program URL	https://grants.nih.gov/grants/guide/pa-fi	les/PA-17	<u>7-295.html</u>			
	Deadline Dates (ALL)	16-Jun-2019 , 16-Oct-2019 , 16-Feb-2020	, 16-Jun-	2020			
	Synopsis	National Cancer Institute (NCI) invites ag in cancer etiology and outcomes, and to e substantive investigation. This FOA will us	encourage	e the development of com	plex analytical st	rategies in suppo	rt of
064983	Discovery of Small Molecule Imm	nunomodulators for Cancer Therapy (R01)		National Cancer Institute/NIH/DHHS	PAR-17- 331	07-May-2019	Not Specified
	Contact Name	Sundar Venkatachalam, Ph.D.					
	Contact Telephone	240-276-7304					
	Contact Emai	sundarv@nih.gov					
	Sponsor Website						
	Program URL	https://grants.nih.gov/grants/guide/pa-fi	les/PAR-1	<u>17-331.html</u>			
	Deadline Dates (ALL)	07-May-2019 , 05-Jun-2019 , 07-Sep-2019 2020	9 , 05-Oct	-2019 , 07-Jan-2020 , 05-F	eb-2020 , 07-Ma	y-2020 <i>,</i> 05-Jun-20	020 , 07-Sep-
	Synopsis	National Cancer Institute (NCI) offers this molecules that may enhance the ability o molecules could be further developed int	f the imm	nune system to selectively	recognize and at	tack cancer cells.	These small

SPIN ID	Program Title	Sponsor Name	Sponsor	Number		Deadline Date	Funding Amount
		as chemical probes for the discovery a multiple scientific disciplines (immuno pharmacology) are encouraged to esta immunomodulators for cancer therapy	-oncology, t iblish collab	umor biology, screening ted orative teams to discover a	chnology, med nd develop nov	icinal chemistry, ar vel small molecule	
064981	Using Small Molecules and Molecules Mechanisms Contributing to Turn	cular Genetics to Identify Novel Targets for Immune Evasion (R01)	and	National Cancer Institute/NIH/DHHS	PA-17-330	07-May-2019	Not Specified
	Contact Telephone	R. Allan Mufson, Ph.D. 240-276-6231 am214t@nih.gov					
	·	https://grants.nih.gov/grants/guide/pa	a-files/PA-1	7-330.html			
	Deadline Dates (ALL)	07-May-2019 , 05-Jun-2019 , 07-Sep-20 2020	019 , 05-Oc	t-2019 , 07-Jan-2020 , 05-Fe	b-2020 , 07-M	ay-2020 , 05-Jun-20	020 <i>,</i> 07-Sep-
	Synopsis	National Cancer Institute (NCI) offers t of new and novel targets and mechani molecule or molecular genetics approa	sms involve	d in tumor immune evasion	, that may be a	amenable to analys	sis by small
064201	Integration of Individual Resident	ial Histories into Cancer Research (R01)	1	National Cancer Institute/NIH/DHHS	PA-17-298	05-Jun-2019	Not Specified
	Contact Name	Zaria Tatalovich, Ph.D.					
	Contact Telephone	240-276-6976					
	Contact Email	tatalovichzp@mail.nih.gov					
	Sponsor Website						
	Program URL	https://grants.nih.gov/grants/guide/pa	a-files/PA-1	7-298.html			
	Deadline Dates (ALL)	05-Jun-2019 , 05-Oct-2019 , 05-Feb-20	20 , 05-Jun	2020			
	Synopsis	National Cancer Institute (NCI) invites in cancer etiology and outcomes, and to substantive investigation. This FOA will	to encourag	e the development of comp	olex analytical s	strategies in suppo	
061593	Collaborative Research Projects t Translational Research (Collabora	o Enhance Applicability of Mammalian lative R01)	Models for	National Cancer Institute/NIH/DHHS	PAR-17- 244	05-Jun-2019	1,350,000 USD

Contact Name Cheryl L. Marks, PhD

ı	SPIN ID	Program	Sponsor Name	Sponsor Number	Deadline Date	Funding
	SPIN ID	Title	Sponsor Name	Sponsor Number	Deadine Date	Amount

Contact Email marksc@mail.nih.gov

Sponsor Website

Program URL https://grants.nih.gov/grants/guide/pa-files/PAR-17-244.html

Deadline Dates (ALL) 05-Jun-2019, 05-Oct-2019, 05-Feb-2020

National Cancer Institute (NCI) invites applications for collaborative R01 projects from multi-disciplinary teams to expand, improve, or transform the reliability and utility of mammalian cancer and tumor models for translational research. For a linked set of collaborative R01s, each site has its own Program Director(s)/Principal Investigator(s), and the program provides a mechanism for cross-site coordination and communication. Collaborative studies are appropriate to address translational modeling research questions beyond the capacity of a single-site investigation, particularly to accommodate collaborations among sites with diverse expertise, perspectives, and contributions. With this FOA, the NCI intends to encourage submission of multidisciplinary projects devoted to demonstrating that mammalian models or their derivatives used for translational research are robust representations of human biology, are appropriate to test questions of clinical importance, and provide reliable information for patients' benefit. These practical goals contrast with the goals of many mechanistic, NCI-supported R01 projects that employ mammals, or develop and use mammalian cancer models, transplantation tumor models, or models derived from mammalian or human tissues or cells for hypothesis-testing, non-clinical research. Among many other possible endeavors, teams of applicants in response to this FOA could propose demonstrations of how to overcome translational deficiencies of mammalian oncology models, define new uses of mammalian models or their genetics for unexplored translational challenges, advance standard practices for use of translational models, test approaches to validate and credential models, or challenge current practices for how models are used translationally. This FOA will use the NIH Research Project (R01) award mechanism.

062707 Leveraging Population-based Cancer Registry Data to Study Health Disparities (R01)

National Cancer Institute/NIH/DHHS

PA-17-289 05-Jun-2019

Not Specified

Contact Name Kathleen Cronin

Contact Telephone 240-276-6836

Contact Email cronink@mail.nih.gov

Sponsor Website

Program URL https://grants.nih.gov/grants/guide/pa-files/PA-17-289.html

Deadline Dates (ALL) 05-Jun-2019, 05-Oct-2019, 05-Feb-2020, 05-Jun-2020

National Cancer Institute (NCI)) invites applications to efficiently use the existing cancer registry infrastructure by Synopsis augmenting data already collected with additional information needed to understand health disparities among people diagnosed with cancer. Specifically, this FOA will support the study of factors influencing observed health disparities within

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		the framework of population-based cancer registries. The studies should be hypothe encouraged to leverage the data already goal of these analyses will be to understa contributing to disparities and their relati	sis-driven and multidisciplinary a collected by the registries to inve nd why disparities in cancer trea	pproaches are er estigate the deter tment and outco	ncouraged. Investiga minates of health d mes persist by ident	tors are isparities. The ifying factors
069552	NCI Small Grants Program for Car Optional)	ncer Research (NCI Omnibus R03 Clinical T	rial National Cancer Institute/NIH/DHHS	PAR-18- 021	07-May-2019	100,000 USD
	Contact Name Contact Telephone					
	Contact Email					
	Sponsor Website					
	Program URL	https://grants.nih.gov/grants/guide/pa-fi	les/PAR-18-021.html			
	Deadline Dates (ALL)	07-May-2019 , 28-Jun-2019 , 07-Sep-2019	9 , 25-Oct-2019 , 07-Jan-2020			
	Synopsis	National Cancer Institute (NCI) invites apperiod of time with limited resources. The feasibility studies; secondary analysis of emethodology; and development of new rechanism.	e R03 grant mechanism supports existing data; small, self-containe	different types o d research projec	of projects including cts; development of	pilot and research
069612	NCI Transition Career Developme Independent Clinical Trials)	ent Award to Promote Diversity (K22 No	National Cancer Institute/NIH/DHHS	PAR-18- 366	12-Jun-2019	450,000 USD
	Contact Name	Abigail Soyombo, Ph.D., M.B.A.				
	Contact Telephone	240-276-6553				
	Contact Email	abigail.soyombo@nih.gov				
	Sponsor Website					
	Program URL	https://grants.nih.gov/grants/guide/pa-fi	les/PAR-18-366.html			
	Deadline Dates (ALL)	12-Jun-2019 , 12-Oct-2019 , 12-Feb-2020	, 12-Jun-2020 , 12-Oct-2020			
		National Cancer Institute (NCI) invites app	l: .: f .! N .: 10	Institute (NCI) C	aroor Transition Aw	

	Program				_		Funding
SPIN ID	Title	Sponsor Name	ponsor	Number		<b>Deadline Date</b>	Amount
		backgrounds nationally underrepresented "protected time" through salary and resea track faculty position. This Funding Opport research that does not involve leading an i clinical trial. Applicants to this FOA are per investigator. This program will use the NIH	rch sup unity A ndepen mitted t	port for 3 years beginning at nnouncement (FOA) is desig dent clinical trial, a clinical to to propose research experie	the time when ned specifically rial feasibility s nce in a clinica	n the candidate sta y for applicants pro study, or an ancilla I trial led by anoth	arts a tenure- oposing Iry study to a
069610	NCI Transition Career Developme Required)	ent Award to Promote Diversity (K22 Clinical	l Trial	National Cancer Institute/NIH/DHHS	PAR-18- 367	12-Jun-2019	450,000 USD
	Contact Name	Abigail Soyombo, Ph.D., M.B.A.					
	Contact Telephone	240-276-6553					
	Contact Email	abigail.soyombo@nih.gov					
	Sponsor Website						
	Program URL	https://grants.nih.gov/grants/guide/pa-file	es/PAR-	18-367.html			
	Deadline Dates (ALL)	12-Jun-2019 , 12-Oct-2019 , 12-Feb-2020 ,	12-Jun-	2020 , 12-Oct-2020			
	Synopsis	National Cancer Institute (NCI) invites appl purpose of the award is to assist postdoctor assistant professor or equivalent and initiathe Diversity Training Branch (DTB), within (http://crchd.cancer.gov/) invites applicationally underrepresented "protected time" through salary and reseatrack faculty position. This Funding Opport serve as the lead investigator of an indepeexisting trial, as part of their research and Award (K22) mechanism.	oral fello te a suc the Cer ons fror in biom rch supp cunity Ai ndent c	ows or individuals in equivalencessful biomedical career as nter to Reduce Cancer Health m research scientists in poste edical, behavioral, clinical, a port for 3 years beginning at nnouncement (FOA) is designical trial fea	ent positions to an independen Disparities (C doctoral positi nd/or social so the time when ned specifically sibility study, o	o transition to posent research scient CRCHD) ons or equivalent ciences. This award the candidate stay for applicants property a separate ancil	itions of cist. To this end, who are from d will provide arts a tenure-oposing to an
069282	NCI Mentored Research Scientist K01 - Clinical Trial Required)	Development Award to Promote Diversity	(Parent	National Cancer Institute/NIH/DHHS	PAR-18- 365	12-Jun-2019	650,000 USD
	Contact Name	Abigail Soyombo, Ph.D., M.B.A.					
	Contact Telephone	240-276-6553					
	Contact Email	Abigail.Soyombo@mail.nih.gov					

Sponsor Website

Program URL https://grants.nih.gov/grants/guide/pa-files/PAR-18-365.html  Deadline Dates (ALL)  Deadline Dates (ALL)  Deadline Dates (ALL)  National Cancer Institute (NCI) invites applications for the Mentored Research Scientist Development Award. The purpose of the award is to enhance the diversity of the pool of the NCI-funded cancer research workforce by supporting eligible individuals from groups that have been shown to be nationally underrepresented in the biomedical, behavioral, social and clinical sciences. This FOA provides salary and research support for a sustained period of "protected time" for intensive research career development under the guidance of an experienced mentor. The Diversity Training Branch (DTB) of the Synopsis Center to Reduce Cancer Health Dispartitles (CRCHD), at the National Cancer institute (NCI), invites career development award applications (ROI) from individuals from backgrounds that have shown to be nationally underrepresented in health-related sciences. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial continues and trial, a clinical trial, a clinical trial continues and trial, and the development of the properties of the New York of the	SPIN ID	Program Title	Sponsor Name Spo	onsor Number		Deadline Date	Funding Amount	
Contact Name Contact Name Contact Trial Optional)  Contact Telephone Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL)  Synopsis Synop	Deadline Dates (ALL)  12-Jun-2019 , 12-Oct-2019 , 12-Feb-2020 , 12-Jun-2020 , 12-Oct-2020  National Cancer Institute (NCI) invites applications for the Mentored Research Scientist Development Award. The p the award is to enhance the diversity of the pool of the NCI-funded cancer research workforce by supporting eligible individuals from groups that have been shown to be nationally underrepresented in the biomedical, behavioral, soci clinical sciences. This FOA provides salary and research support for a sustained period of "protected time" for intensives research career development under the guidance of an experienced mentor. The Diversity Training Branch (DTB) of the Center to Reduce Cancer Health Disparities (CRCHD), at the National Cancer Institute (NCI), invites career development applications (K01) from individuals from backgrounds that have been shown to be nationally underrepresented in health related sciences. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an trial, as part of their research and career development. This Funding Opportunity Announcement (FOA) will utilize the							
Contact Telephone Contact Email Auntym@mail.nih.gov  Sponsor Website Program URL Deadline Dates (ALL) National Cancer Institute (NCI) invites applications for highly innovative and promising intervention research designed to improve smoking cessation outcomes among socioeconomically disadvantaged populations. Specifically, this FOA is intended to stimulate research efforts aimed at the development of smoking cessation interventions that: 1) are targeted to socioeconomically disadvantaged populations, and 2) could be made scalable for broad population impact. Applicants may propose projects that develop and test novel cessation interventions with the potential to be scaled up, as well as projects that focus on enhancing the effectiveness, quality, accessibility, utilization, and cost-effectiveness of currently scaled smoking cessation interventions. This FOA provides funding for up to 2 years for protocol development and early phase, pilot, or exploratory projects. This FOA will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.  Not Specified	069829					13-Jun-2019		
Scalable Interventions (R01 Clinical Trial Optional)  Institute/NIH/DHHS 251  Specified		Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL)  Na im to Synopsis Synopsis	tps://grants.nih.gov/grants/guide/pa-files/grants.nih.gov/grants/guide/pa-files/grants/guide/pa-files/grants/guide/pa-files/grants/guide/pa-files/grants/guide/pa-files/grants/grants.nih.gov/grants/guide/pa-files/grants-	ations for highly innovative and g socioeconomically disadvantage velopment of smoking cessations, and 2) could be made scalable cessation interventions with the uality, accessibility, utilization, a unding for up to 2 years for prote	ged populations interventions e for broad pope e potential to kend cost-effective collective collective e potential to be collective	s. Specifically, this F that: 1) are targete pulation impact. Appose scaled up, as well weness of currently ent and early phase	OA is intended ed to plicants may I as projects scaled smoking , pilot, or	
	069828	Scalable Interventions (R01 Clinical 7	<u>Frial Optional)</u>			13-Jun-2019		

SPIN ID	Program	Sponsor Name	Sponsor Number	Deadline Date	Funding
SPIN ID	Title	Sponsor warne	Sponsor Number	Deadine Date	Amount

Contact Email huntym@mail.nih.gov

Sponsor Website

Program URL https://grants.nih.gov/grants/guide/pa-files/PAR-18-251.html

Deadline Dates (ALL) 13-Jun-2019

National Cancer Institute (NCI) invites applications for highly innovative and promising intervention research designed to improve smoking cessation outcomes among socioeconomically disadvantaged populations. Specifically, this FOA is intended to stimulate research efforts aimed at the development of smoking cessation interventions that: 1) are targeted to socioeconomically disadvantaged populations, and 2) could be made scalable for broad population impact. Applicants may propose projects that develop and test novel cessation interventions with the potential to be scaled up, as well as projects that focus on enhancing the effectiveness, quality, accessibility, utilization, and cost-effectiveness of currently scaled smoking cessation interventions. This FOA provides funding for up to 5 years for research planning, intervention delivery, and followup activities. This FOA will use the NIH Research Project (R01) award mechanism.

**Synopsis** 

069273

NCI Mentored Research Scientist Development Award to Promote Diversity (Parent PAR-18-650,000 National Cancer 12-Jun-2019 K01 -Independent Clinical Trial Not Allowed) Institute/NIH/DHHS 364 **USD** 

Contact Name Abigail Soyombo, Ph.D., M.B.A.

Contact Telephone 240-276-6553

Contact Email Abigail.Soyombo@mail.nih.gov

Sponsor Website

Program URL https://grants.nih.gov/grants/guide/pa-files/PAR-18-364.html

Deadline Dates (ALL) 12-Jun-2019, 12-Oct-2019, 12-Feb-2020, 12-Jun-2020, 12-Oct-2020

National Cancer Institute (NCI) invites applications for the Mentored Research Scientist Development Award. The purpose of the award is to enhance the diversity of the pool of the NCI-funded cancer research workforce by supporting eligible individuals from groups that have been shown to be nationally underrepresented in the biomedical, behavioral, social and clinical sciences. This FOA provides salary and research support for a sustained period of "protected time" for intensive research career development under the guidance of an experienced mentor. The Diversity Training Branch (DTB) of the Synopsis Center to Reduce Cancer Health Disparities (CRCHD), at the National Cancer Institute (NCI), invites career development award applications (K01) from individuals from backgrounds that have been shown to be nationally underrepresented in healthrelated sciences. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical

trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. This

Funding Opportunity Announcement (FOA) will utilize the NIH Mentored Research Scientist Development Award (KO1)



SPIN ID	Program Title	Sponsor Name	Sponsor	Number		Deadline Date	Funding Amount
		mechanism.					
					5.15.10		
071707	Prevention Research (R21 Clinical	ms (ENDS): Population, Clinical and Applie Trial Optional)	<u>ed</u>	National Cancer Institute/NIH/DHHS	PAR-18- 611	27-Jun-2019	275,000 USD
	Contact Name	Rachel Grana Mayne, PhD, MPH					
	Contact Telephone	240-276-5899					
	Contact Email	rachel.mayne@nih.gov					
	Sponsor Website						
	Program URL	https://grants.nih.gov/grants/guide/pa-fi	les/PAR-1	<u>8-611.html</u>			
	Deadline Dates (ALL)	27-Jun-2019 , 24-Oct-2019 , 27-Jun-2020					
	Synopsis	National Institutes of Health (NIH) and it nicotine delivery systems (ENDS) that exa etiology of use, epidemiology of use, pote populations. This FOA will use the NIH R2	mine pop ential risk	ulation-based, clinical and s, benefits and impacts on	applied preve other tobacco	ntion of disease, in use behavior amo	cluding
072438	Epidemiologic Research on Emerg (R21 Clinical Trial Not Allowed)	ring Risk Factors and Liver Cancer Suscepti	<u>ibility</u>	National Cancer Institute/NIH/DHHS	PA-18-678	16-Jun-2019	275,000 USD
	Contact Name	Tram Kim Lam, Ph.D., MPH					
	Contact Telephone	240-276-6967					
	Contact Email	Tram.Lam@nih.gov					
	Sponsor Website						
	Program URL	https://grants.nih.gov/grants/guide/pa-fi	les/PA-18	<u>-678.html</u>			
	Deadline Dates (ALL)	16-Jun-2019 , 16-Oct-2019 , 16-Feb-2020	, 16-Jun-	2020 , 16-Oct-2020 , 16-Fe	b-2021		
	Synopsis	National Cancer Institute (NCI) invites ap on emerging risk factors (biological, envir hepatitis) associated with the developme United States. This FOA will use the NIH R	onmenta nt of live	, and social) and their inte cancer (hepatocellular can	rplay with estarcinoma and o	ablished risk factors ther histological su	s (e.g., viral
072431	Epidemiologic Research on Emerg (R01 - Clinical Trial Not Allowed)	ging Risk Factors and Liver Cancer Suscepti	ibility	National Cancer Institute/NIH/DHHS	PA-18-677	05-Jun-2019	Not Specified
	Contact Name Contact Telephone	Tram Kim Lam, Ph.D., MPH					



SPIN ID	Program Title	Sponsor Name	Sponsor	Number		Deadline Date	Funding Amount
	Contact Email	Tram.Lam@nih.gov					
	Sponsor Website						
	Program URL	https://grants.nih.gov/grants/guide/pa-fil	iles/PA-18	<u>8-677.html</u>			
	Deadline Dates (ALL)	05-Jun-2019 , 05-Oct-2019 , 05-Feb-2020	, 05-Jun-	2020 , 05-Oct-2020 , 05-Fe	b-2021		
	Synopsis	National Cancer Institute (NCI) invites ap on emerging risk factors (biological, environmental) hepatitis) associated with the developmental United States. This FOA will use the NIH R	onmenta ent of live	l, and social) and their inter cancer (hepatocellular ca	erplay with esta rcinoma and ot	blished risk factors	(e.g., viral
071800	Integration of Imaging and Fluid- Clinical Trial Optional)	Based Tumor Monitoring in Cancer Therap	y (R01	National Cancer Institute/NIH/DHHS	PA-18-629	07-May-2019	Not Specified
	Contact Name	Anne Menkens, Ph.D.					
	Contact Telephone	240-276-6510					
	Contact Email	menkensa@mail.nih.gov					
	Sponsor Website						
	Program URL	https://grants.nih.gov/grants/guide/pa-fil	iles/PA-18	3-629.html			
	Deadline Dates (ALL)	07-May-2019 , 05-Jun-2019 , 07-Sep-2019 2020 , 05-Oct-2020 , 07-Jan-2021 , 05-Feb			eb-2020 , 07-M	ay-2020 , 05-Jun-2	020 , 07-Sep-
	Synopsis	National Cancer Institute (NCI) invites apmonitoring (liquid biopsy) assays during c characterization of therapy response and, mechanism.	ancer the	erapy in patients to detern	nine the optima	I use of those mod	alities in the
070114	NCI Transition Career Developme Allowed)	ent Award (K22 Independent Clinical Trial N	<u>Not</u>	National Cancer Institute/NIH/DHHS	PAR-18- 467	12-Jun-2019	450,000 USD
_	Contact Name	Sonia Jakowlew, Ph.D., Program Director					
	Contact Telephone	240-276-5630					
	Contact Email	jakowles@mail.nih.gov					
	Sponsor Website						
	Program URL	https://grants.nih.gov/grants/guide/pa-fil	iles/PAR-1	18-467.html			
		12-Jun-2019 , 12-Oct-2019 , 12-Feb-2020			b-2021		
		National Cancer Institute (NCI) provides s				n mentored, non-ir	ndependent

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		cancer research positions to independen through salary and research support for the equivalent, beginning at the time when the Announcement (FOA) is designed specifical clinical trial, a clinical trial feasibility stud Transition Award mechanism.	the initial 3 years of the first independence the candidate starts a tenure-track facally for applicants proposing resear	ndent tenure-tra aculty position. T ch that does not	ack faculty position This Funding Oppo t involve leading an	n, or its rtunity n independent
073410		and their Implications in Chronic Disease ression (R21 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PA-18-739	16-Jun-2019	275,000 USD
	Contact Telephone Contact Email					
	Sponsor Website		ilos/DA 19 720 html			
		https://grants.nih.gov/grants/guide/pa-f 16-Jun-2019 , 16-Oct-2019 , 16-Feb-2020		h_2021		
		National Institutes of Health (NIH) and i microbiome in health and disease during the microbiota during lifetime and its infiminority and underserved populations are subjects as related to health and disease human clinical trial proposals in accordant Exploratory/Developmental Research Grant and Control of the control o	ts participating Institutes and Cente aging. This initiative will support reluence in health and disease status ind understand the underlying mechal. This FOA will support basic mechance with the state of the science. The	rs invite applicates of the elderly, in the elderly, in anisms of microlatic, preclinical	designed to evalua cluding those from biota interactions i studies in animal	ite changes in racial/ethnic in aged
117115411	Academic-Industrial Partnerships Treatment (R01 - Clinical Trial Op	for Translation of Technologies for Diagnostional)	osis and National Cancer Institute/NIH/DHHS	PAR-18- 530	07-May-2019	Not Specified
	Contact Name	Miguel Ossandon MS				
	Contact Telephone	240-276-5714				
	Contact Email	ossandom@mail.nih.gov				
	Sponsor Website					
	_	https://grants.nih.gov/grants/guide/pa-f				
	Deadline Dates (ALL)	07-May-2019 , 05-Jun-2019 , 07-Sep-201 2020 , 05-Oct-2020 , 07-Jan-2021	9 , 05-Oct-2019 , 07-Jan-2020 , 05-F	eb-2020 , 07-Ma	ay-2020 , 05-Jun-20	020 , 07-Sep-
	Synopsis	National Institutes of Health (NIH) and its	s participating Institutes and Centers	s invite applicati	ons to stimulate e	fforts to

- 1	SPIN ID	Program	Sponsor Name	Sponsor Number	Deadline Date	Funding
- 1	SPIN ID	Title	Sponsor Name	Sponsor Number		Amount

translate scientific discoveries and engineering developments into methods or tools that address problems in basic research to understand disease, or in applied research to assess risk, detect, prevent, diagnose, treat, and/or manage disease. The rationale is to deliver new capabilities to meet evolving requirements for technologies and methods relevant to the advance of research and delivery of care in pre-clinical, clinical and non-clinical settings, domestic or foreign, for conditions and diseases within the missions of participating institutes. This FOA specifies a partnership structure that is expected to help bridge gaps in knowledge and experience by engaging the strengths of academic, industrial, and other investigators. The partners on each application should establish an inter-disciplinary, multi-institutional research team to work in strategic alliance to implement a coherent strategy to develop and translate a solution to their chosen problem. They are expected to plan, design, and validate that the solution will be suitable for end users. Each partnership should include at least one academic and one industrial organization. Each partnership should plan to transition a technology, method, assay, device, and/or system from a demonstration of possibility to a status useful in the chosen setting. Funding may be requested to enhance, adapt, optimize, validate, and otherwise translate technologies that address problems in biology, pathology, risk assessment, diagnosis, treatment, and/or monitoring of disease status. This FOA defines innovation as likelihood to deliver a new capability to end users. This FOA will support clinical trials that test functionality, or validate performance in the chosen setting. This FOA is not intended to support commercial production, basic research projects, or straight clinical trials that lack translation as the primary motivation. This FOA will use the NIH Research Project (R01) award mechanism.

070100 NCI Transition Career Development Award (K22 Independent Clinical Trial Required)

**National Cancer** Institute/NIH/DHHS

PAR-18-466

12-Jun-2019

450,000 USD

Contact Name Sonia Jakowlew, Ph.D., Program Director

Contact Telephone 240-276-5630

Contact Email jakowles@mail.nih.gov

Sponsor Website

Program URL https://grants.nih.gov/grants/guide/pa-files/PAR-18-466.html

Deadline Dates (ALL) 12-Jun-2019, 12-Oct-2019, 12-Feb-2020, 12-Jun-2020, 12-Oct-2020, 12-Feb-2021

National Cancer Institute (NCI) provides support to facilitate the transition of investigators in mentored, non-independent cancer research positions to independent faculty cancer research positions. This goal is achieved by providing protected time through salary and research support for the initial 3 years of the first independent tenure-track faculty position, or its Synopsis equivalent, beginning at the time when the candidate starts a tenure-track faculty position. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. This program will use the NIH K22 Career Transition Award mechanism.

Exploratory/Developmental Grants Program for Basic Research in Cancer Health Disparities (R21 Clinical Trial Not Allowed)

National Cancer Institute/NIH/DHHS PAR-18-655

18-Jun-2019

275,000 **USD** 



072031

Title ' Amount
----------------

Contact Name Jennifer Isaacs, Ph.D.

Contact Telephone 240-276-6251

Contact Email jennifer.isaacs@nih.gov

Sponsor Website

Program URL https://grants.nih.gov/grants/guide/pa-files/PAR-18-655.html

Deadline Dates (ALL) 18-Jun-2019, 19-Nov-2019, 18-Jun-2020, 19-Nov-2020

National Cancer Institute (NCI) invites applicationsfrom investigators interested in conducting basic research studies into the biological/genetic causes and mechanisms of cancer health disparities. These awards will support pilot and feasibility studies designed to investigate biological/genetic bases of cancer disparities, such as (1) mechanistic studies of biological factors associated with cancer disparities, (2) the development and testing of new methodologies and models, and (3) secondary data analyses. This FOA is also designed to aid and facilitate the growth of a nationwide cohort of scientists with a high level of basic research expertise in cancer health disparities research who can expand available resources and tools, such as biospecimens, patient derived models and methods that are necessary to conduct basic research in cancer health disparities. In addition, the FOA will further the development of scientific areas, providing support for early-stage exploratory projects that lead to future in-depth mechanistic studies (such as RO1 projects) of the biology of cancer health disparities. This FOA will use the NIH R21 Exploratory/Developmental Research award mechanism.

072029 Basic Research in Cancer Health Disparities (R01 Clinical Trial Not Allowed)

National Cancer PAR-18-Institute/NIH/DHHS 654 18-Jun-2019 Not Specified

Contact Name Jennifer Isaacs, Ph.D.

Contact Telephone 240-276-6251

Contact Email jennifer.isaacs@nih.gov

**Sponsor Website** 

Program URL https://grants.nih.gov/grants/guide/pa-files/PAR-18-654.html

Deadline Dates (ALL) 18-Jun-2019 , 19-Nov-2019 , 18-Jun-2020 , 19-Nov-2020

Netional Concert Institute (NCI) invites amplications from

National Cancer Institute (NCI) invites applications from investigators interested in conducting basic, mechanistic research into the biological/genetic causes of cancer health disparities. These research project grants (R01) will support innovative studies designed to investigate biological/genetic bases of cancer disparities, such as (1) mechanistic studies of biological factors associated with cancer disparities, including those related to basic research in cancer biology or cancer prevention strategies, (2) the development and testing of new methodologies and models, and (3) secondary data analyses. This FOA is also designed to aid and facilitate the growth of a nationwide cohort of scientists with a high level of basic research expertise in cancer health disparities research who can expand available resources and tools, such as biospecimens, patient derived models, and methods that are necessary to conduct basic research in cancer health disparities. This FOA will use the NIH

SPIN ID	Program Title	Sponsor Name	Sponsor	Number		Deadline Date	Funding Amount
		Research Project (R01) award mechanis	m.				-
070402	Early-life Factors and Cancer Dev Allowed)	elopment Later in Life (R01 - Clinical Trial	l Not	National Cancer Institute/NIH/DHHS	PA-18-529	07-May-2019	Not Specified
	Contact Name	Somdat Mahabir, Ph.D., M.PH					
	Contact Telephone	240-276-6941					
	Contact Email	mahabir@mail.nih.gov					
	Sponsor Website						
	Program URL	https://grants.nih.gov/grants/guide/pa-	-files/PA-18	8-529.html			
	Deadline Dates (ALL)	07-May-2019 , 05-Jun-2019 , 07-Sep-202 2020 , 05-Oct-2020 , 07-Jan-2021	19 , 05-Oct	-2019 , 07-Jan-2020 , 05-Feb	-2020 , 07-M	ay-2020 , 05-Jun-20	020 , 07-Sep-
	Synopsis	National Institutes of Health (NIH) and it role of early-life factors (maternal-pater cancer development later in life. Given to important role for early-life events and (maternal-paternal, in utero, birth and it later cancer development; 2) how early-predictive markers for cancer risk based cancer prevention strategies. Markers the life exposures with relevant outcomes we mechanistic understanding of how early for the development of effective intervelopmention. This FOA will use the NIH R	rnal, in uter that the cu exposures infancy, pul -life factors d on what h hat predict without hav y-life events	ro, birth and infancy, puberty rent emerging evidence from cancer development, it is not berty, adolescence, and your mediate biological processe appens biologically at early leading to wait decades for cancers and exposures contribute to ling pregnancy or early life the	y, adolescence in limited resonances are devent to life can be ment to life can be may have	e, and young adult earch indicates a pobetter understand s) factors that are a carcinogenesis; an easured and develowould allow assessient. Ultimately, a by of cancer later in	years) in otentially 1) the early-life ssociated with d 3) whether ped for use in ment of early-etter life will allow
070784	National Cancer Institute's Invest Treatment and Diagnosis (R01 Cli	<u> igator-Initiated Early Phase Clinical Trials</u>	for Cancer	National Cancer Institute/NIH/DHHS	PAR-18- 560	07-May-2019	2,499,995 USD
		Lori A. Henderson, Ph.D.		maticate, with prints			335
	Contact Name Contact Telephone						
	·	hendersonlori@mail.nih.gov					
	Sponsor Website						
	·	https://grants.nih.gov/grants/guide/pa-	files/DAD 1	8-560 html			
	Deadline Dates (ALL)	07-May-2019 , 05-Jun-2019 , 07-Sep-202 2020 , 05-Oct-2020 , 07-Jan-2021	19 , 05-Oct	-2019 , 07-Jan-2020 , 05-Feb	-2020 , 07-M	ay-2020 <i>,</i> 05-Jun-20	020 , 07-Sep-

	Brogram					Funding
SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Amount
	Synopsis	National Cancer Institute (NCI) invites an investigator-initiated clinical trials focuse the research mission of the National Cancare strongly encouraged to consult the National goals, research priorities, and st studies that meet the National Institutes provide specific clinical trial information and cancer research are not sought by and (RO1) award mechanism.	d on cancer-targeted diagnostic are Institute's (NCI) Division of Can CI DCTD website at https://dctd.carategies developed to fight cancer of Health (NIH) definition of a clinical described in this FOA. Application	nd therapeutic information cer Treatment and incer.gov/ to lear . Applications subset of the cal trial (see NOT ons that propose	terventions of dire and Diagnosis (DCTE on more about the omitted to this FO/ C-OD-15-015 for de phase III clinical tr	ct relevance to b). Applicants various A must include etails) and ials in any area
11/11121	Using Information Technology to Depression in Oncology Practices	Support Systematic Screening and Treatm (R21Clinical Trial Optional)	nent of National Cancer Institute/NIH/DHHS	PA-18-492	16-Jun-2019	275,000 USD
	Contact Name	Gurvaneet S. Randhawa, M.D., MPH				
	Contact Telephone	240-276-6940				
	Contact Email	gurvaneet.randhawa@nih.gov				
	Sponsor Website					
	Program URL	https://grants.nih.gov/grants/guide/pa-fi	les/PA-18-492.html			
	Deadline Dates (ALL)	16-Jun-2019 , 16-Oct-2019 , 16-Feb-2020	, 16-Jun-2020 , 16-Oct-2020 , 16-F	eb-2021		
	Synopsis	National Cancer Institute (NCI) invites and that support systematic screening and tree new delivery models in a variety of oncoluthe usability and potential effectiveness of NIH R21 Exploratory/Developmental Research	eatment of depression in cancer pa ogy practice settings, especially th of the IT-specific components of th	atients; test the fose serving unde	easibility of impler r-served populatio	nenting these ons; and test
11 /11 1 /u ·		Support Systematic Screening and Treatm		PA-18-493	05-Jun-2019	Not
	Depression in Oncology Practices	<u> </u>	Institute/NIH/DHHS			Specified
		Gurvaneet S. Randhawa, M.D., MPH				
	Contact Telephone					
		gurvaneet.randhawa@nih.gov				
	Sponsor Website		L. /DA 40 400 h !			
		https://grants.nih.gov/grants/guide/pa-fi		. l. 2024		
		05-Jun-2019 , 05-Oct-2019 , 05-Feb-2020			( <del>-</del> )	
	Synopsis	National Cancer Institute (NCI) invites ap	oplications to: identify new, inform	nation technology	ر (۱۲)-enabled deliv	ery models

SPIN ID	Program Title	Sponsor Name	Sponsor	Number		Deadline Date	Funding Amount
		that support systematic screening and tree new delivery models in a variety of oncole effectiveness of these new delivery mode serving under-served populations; and ev use the NIH Research Project (R01) award	ogy pract ls, and thal aluate th	ice settings, especially thos eir components, in a variet e sustainability and scalabil	e serving under y of oncology p	r-served populatio gractice settings, e	ns; test the specially those
070405	<u>Early-life Factors and Cancer Deve</u> <u>Allowed)</u>	elopment Later in Life (R21 Clinical Trial No	<u>ot</u>	National Cancer Institute/NIH/DHHS	PA-18-532	07-May-2019	275,000 USD
	Contact Name	Somdat Mahabir, Ph.D., M.PH					
	Contact Telephone	240-276-6941					
	Contact Email	mahabir@mail.nih.gov					
	Sponsor Website						
	Program URL	https://grants.nih.gov/grants/guide/pa-fi	les/PA-18	<u>8-532.html</u>			
	Deadline Dates (ALL)	07-May-2019 , 16-Jun-2019 , 07-Sep-2019 2020 , 16-Oct-2020 , 07-Jan-2021	9 , 16-Oct	-2019 , 07-Jan-2020 , 16-Fe	b-2020 , 07-Ma	y-2020 , 16-Jun-20	020 , 07-Sep-
	Synopsis	National Institutes of Health (NIH) and its role of early-life factors (maternal-patern cancer development later in life. Given the important role for early-life events and extended (maternal-paternal, in utero, birth and inflater cancer development; 2) how early-lipredictive markers for cancer risk based cancer prevention strategies. Markers the life exposures with relevant outcomes with mechanistic understanding of how early-lipredictive intervention. This FOA will use the NIH R23	al, in uter at the cu cposures fancy, pu fe factors on what h at predict thout hav ife event tions dur	ro, birth and infancy, puber rent emerging evidence from cancer development, it is berty, adolescence, and you mediate biological process appens biologically at early malignancy or pre-malignating to wait decades for can sand exposures contribute ing pregnancy or early life to	ty, adolescence on limited research to be ing adult years tes relevant to be inferenced by the can be ment conditions we cer development to the etiology that may have a	e, and young adult carch indicates a potentiar understand ) factors that are a carcinogenesis; an asured and develoyould allow assessint. Ultimately, a bot of cancer later in a profound impact	years) in otentially 1) the early-life ssociated with d 3) whether use in ment of early-etter life will allow
070406	Early-life Factors and Cancer Deve Allowed)	elopment Later in Life (RO3 Clinical Trial No	<u>ot</u>	National Cancer Institute/NIH/DHHS	PA-18-531	07-May-2019	100,000 USD
	Contact Name	Somdat Mahabir, Ph.D., M.PH					
	Contact Telephone	240-276-6941					
	Contact Email	mahabir@mail.nih.gov					

:	SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount

prevention. This FOA will use the NIH R03 Small Grant Program award mechanism.

Sponsor Website

Program URL https://grants.nih.gov/grants/guide/pa-files/PA-18-531.html

Deadline Dates (ALL)

07-May-2019, 16-Jun-2019, 07-Sep-2019, 16-Oct-2019, 07-Jan-2020, 16-Feb-2020, 07-May-2020, 16-Jun-2020, 07-Sep-2020, 16-Oct-2020, 07-Jan-2021

National Institutes of Health (NIH) and its participating Institutes and Centers invite applications for research focused on the role of early-life factors (maternal-paternal, in utero, birth and infancy, puberty, adolescence, and young adult years) in cancer development later in life. Given that the current emerging evidence from limited research indicates a potentially important role for early-life events and exposures in cancer development, it is necessary to better understand 1) the early-life (maternal-paternal, in utero, birth and infancy, puberty, adolescence, and young adult years) factors that are associated with later cancer development; 2) how early-life factors mediate biological processes relevant to carcinogenesis; and 3) whether predictive markers for cancer risk based on what happens biologically at early life can be measured and developed for use in cancer prevention strategies. Markers that predict malignancy or pre-malignant conditions would allow assessment of early-life exposures with relevant outcomes without having to wait decades for cancer development. Ultimately, a better mechanistic understanding of how early-life events and exposures contribute to the etiology of cancer later in life will allow for the development of effective interventions during pregnancy or early life that may have a profound impact on cancer

Synopsis

Innovative Approaches to Studying Cancer Communication in the New Media Environment (R21 Clinical Trial Optional)

National Cancer PAR-18- 13-Jun-2019 USD 275,000 USD

Contact Name Kelly D. Blake, ScD

Contact Telephone 240-281-5934

Contact Email kelly.blake@nih.gov

Sponsor Website

Program URL https://grants.nih.gov/grants/guide/pa-files/PAR-18-639.html

Deadline Dates (ALL) 13-Jun-2019

National Cancer Institute (NCI) invites applications that seek to apply one or more innovative methodologies in communication research across the cancer control continuum, from prevention, early detection, diagnosis, treatment, and survivorship, to end of life. Applications to this FOA should utilize one or more of the following analytic approaches, methods, and data sources, including but not limited to social media data mining, Natural Language Processing (NLP) techniques, online social network analysis, crowdsourcing research tools (e.g., mTurk), online search data, Ecological Momentary Assessment, neuroscience and biobehavioral approaches to communication, and geographic information systems. Studies should assess outcomes related to cancer prevention and control (e.g., knowledge, attitudes, beliefs,

perceived risk, decision making in screening and treatment, information inequalities, social support, shared decision making,

Synopsis

071890

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		persuasion, caregiving, behavioral intent NIH R21 Exploratory/Developmental Res		cy support, am	ong others). This FC	OA will use the
071889	<u>Innovative Approaches to Studyir</u> <u>Environment (R01 Clinical Trial Op</u>	ng Cancer Communication in the New Men ptional)	dia National Cancer Institute/NIH/DHHS	PAR-18- 638	13-Jun-2019	Not Specified
	Contact Name	Kelly D. Blake, ScD				
	Contact Telephone	240-281-5934				
	Contact Email	kelly.blake@nih.gov				
	Sponsor Website					
	Program URL	https://grants.nih.gov/grants/guide/pa-f	files/PAR-18-638.html			
	Deadline Dates (ALL)	13-Jun-2019				
	Synopsis	National Cancer Institute (NCI) invites ap communication research across the cance survivorship, to end of life. Applications methods, and data sources, including but techniques, online social network analys Momentary Assessment, neuroscience a systems. Studies should assess outcome perceived risk, decision making in screen persuasion, caregiving, behavioral intent NIH Research Project (R01) award mechanical survivorship in the communication of t	ter control continuum, from preventito this FOA should utilize one or most not limited to social media data miss, crowdsourcing research tools (e.g. nd biobehavioral approaches to comes related to cancer prevention and ching and treatment, information inequions, preventive behaviors, and policions, preventive behaviors, and policions.	ion, early deter re of the follow ning, Natural L , mTurk), onlin munication, an ontrol (e.g., kn ualities, social	ction, diagnosis, tre ving analytic approa anguage Processing ne search data, Eco nd geographic infor owledge, attitudes support, shared de	atment, and aches, g (NLP) logical mation , beliefs, cision making,
073406		and their Implications in Chronic Disease ression (R01 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PA-18-738	05-Jun-2019	Not Specified
	Contact Name	Gabriela Riscuta MD, CNS, MS				
	Contact Telephone					
	Contact Email					
	Sponsor Website					
	Program URL	https://grants.nih.gov/grants/guide/pa-f	iles/PA-18-738.html			
	Deadline Dates (ALL)	05-Jun-2019 , 05-Oct-2019 , 05-Feb-2020	) , 05-Jun-2020 , 05-Oct-2020 , 05-Fe	b-2021		
	, ,	National Institutes of Health (NIH) and i microbiome in health and disease during the microbiota during lifetime and its inf	gaging. This initiative will support res	search projects	designed to evalua	ate changes in

SPIN ID	Program Title	Sponsor Name	Sponso	Number		Deadline Date	Funding Amount
		minority and underserved populations are subjects as related to health and disease human clinical trial proposals in accordary award mechanism.	. This FO	A will support basic mechai	nistic, preclinio	cal studies in animal	models and
071719		ntification and Genetic Counseling of Mutureach (U01 Clinical Trial Optional)	<u>ation</u>	National Cancer Institute/NIH/DHHS	PAR-18- 616	05-Jun-2019	Not Specified
	Contact Telephone	goli.samimi@nih.gov					
		https://grants.nih.gov/grants/guide/pa-f	iles/PAR-	<u>18-616.html</u>			
	Deadline Dates (ALL)	05-Jun-2019					
	Synopsis	National Cancer Institute (NCI) invites ap women with a personal or family history individuals at increased risk for cancer in populations. This program will use the NI	of ovaria	n cancer and reaching out clinical contexts and com	to family men nunities, inclu	nbers to identify una ding racially/ethnica	ffected
072357	U.S. Tobacco Control Policies to F Optional)	Reduce Health Disparities (R21 Clinical Tria	<u>l</u>	National Cancer Institute/NIH/DHHS	PAR-18- 674	13-Jun-2019	275,000 USD
	Contact Name	Bob Vollinger, MSPH					
	Contact Telephone	240-276-6919					
	Contact Email	Bob.Vollinger@nih.gov					
	Sponsor Website						
	Program URL	https://grants.nih.gov/grants/guide/pa-f	iles/PAR-	<u>18-674.html</u>			
	Deadline Dates (ALL)	13-Jun-2019 , 11-Oct-2019 , 15-Jun-2020					
	Synopsis	National Cancer Institute (NCI) invites a disparities in tobacco use in the United S innovative tobacco control policies. Appl tobacco use health disparities in vulneral goal of this FOA is to reduce health dispa within these groups. Applicants submittin	tates. Sp icants ma ole popul rities in h	ecifically, this FOA is intend by propose projects in whice ations by utilizing tobacco ealth outcomes thereby re	led to stimulat h the primary prevention an educing the ex	e scientific inquiry for contcome of interest d control strategies. cess disease burden	ocused on is on reducing The long-tern of tobacco us

025 to ensure that applications align with NIH mission priorities in health economics research. This FOA will use the NIH

SPIN ID	Program Title	Sponsor Name	Sponsor	Number		Deadline Date	Funding Amount
		R21 Exploratory/Developmental Research	n Grant a	ward mechanism.			
072358	U.S. Tobacco Control Policies to R Optional	leduce Health Disparities (R01 Clinical Tria	<u>I</u>	National Cancer Institute/NIH/DHHS	PAR-18- 675	13-Jun-2019	Not Specified
	Contact Name	Bob Vollinger, MSPH					
	Contact Telephone	240-276-6919					
	Contact Email	Bob.Vollinger@nih.gov					
	Sponsor Website						
	Program URL	https://grants.nih.gov/grants/guide/pa-fi	les/PAR-	<u>18-675.html</u>			
	Deadline Dates (ALL)	13-Jun-2019 , 11-Oct-2019 , 15-Jun-2020					
	Synopsis	within these groups. Applicants submittir 025 to ensure that applications align with Research Project Grant award mechanisn	cants ma ole popul rities in h ng applica n NIH mis	y propose projects in which ations by utilizing tobacco ealth outcomes thereby restions related to health ecosion priorities in health ecosion	h the primary or prevention and educing the exconomics are en-	outcome of interest I control strategies. ess disease burden couraged to consul	is on reducing The long-term of tobacco use t NOT-OD-16- e the NIH R01
061494	Secondary Analysis and Integration Architecture of Cancer Risk and R	on of Existing Data to Elucidate the Geneticelated Outcomes (RO1)	<u>C</u>	National Cancer Institute/NIH/DHHS	PA-17-239	05-Jun-2019	1,750,000 USD
	Contact Name	Melissa Rotunno, Ph.D.					
	Contact Telephone	240-276-7245					
	Contact Email	rotunnom@mail.nih.gov					
	Sponsor Website						
	Program URL	https://grants.nih.gov/grants/guide/pa-fi	les/PA-1	<u>7-239.html</u>			
	Deadline Dates (ALL)	05-Jun-2019 , 05-Oct-2019 , 05-Feb-2020					
	Synopsis	National Institutes of Health (NIH) and it secondary data analysis and integration of genetic architecture of cancer risk and re relevant to cancer epidemiology by supposith environmental, outcomes, behavioralleverage existing genetic data and performance.	of existing lated out orting the al, lifesty	datasets and database re comes. The goal of this ini- e analysis of existing genet e, and molecular profiles o	sources, with the tiative is to add ic or genomic d data. Applicatio	he ultimate aim to dress key scientific of atasets, possibly in ns to this FOA are of	elucidate the questions combination encouraged to

SPIN ID	Program Title	Sponsor Name	Sponsor Nu	mber		Deadline Date	Funding Amount
	i	nims that are being addressed with existi ntegration of datasets that allow the exp NIH Research Project (R01) award mecha	oloration of i		•		
075883		arch Resources to Encourage Consensus I Precision Medicine (U24 - Clinical Trial (		ational Cancer stitute/NIH/DHHS	PAR-18- 841	14-Jun-2019	2,500,000 USD
	Contact Telephone Contact Email z Sponsor Website Program URL L Deadline Dates (ALL)  Synopsis  ii ( a ii	Huiming Zhang, Ph.D. 240-276-5979  changhui@mail.nih.gov  https://grants.nih.gov/grants/guide/pa-fi 24-Jun-2019, 19-Nov-2019, 15-Jun-2020 National Cancer Institute (NCI) invites applicational Cancer In	plications to plications to ptimized to in appropriate of co-clinical to the property of the patents and in as the prediancer risk strangy teams we support soft.	develop research resource mprove the quality of imagoptimization of the pre-clinical, and finally (c) populations collected from the conparallel (or sequentially) cients' malignancies or prediction, staging, and/or metatification goal for lethal contents and informatics to provide the contents of the	ging results for nical quantitate a web-acce -clinical investion in mouse or leasurement of cancer versustion models reseation opulate the reseation in models reseati	or co-clinical trials. ative imaging meth essible research restigations. Co-clinic human-in-mouse nesions. The co-clinic fumor response to non-lethal disease arch, human investices esearch resource.	The scientific ods, (b) ource with all al trials are nodels of cal trial should o therapies, or e. Applicants gations,
075931	Electronic Nicotine Delivery System (R21 - Clinical Trial Not Allowed)	ns (ENDS): Basic Mechanisms of Health E		ational Cancer astitute/NIH/DHHS	PAR-18- 846	27-Jun-2019	275,000 USD
	Contact Telephone 2 Contact Email <u>r</u> Sponsor Website Program URL <u>Ł</u>	Ron Johnson, PhD 240-276-6228 johnso2@mail.nih.gov https://grants.nih.gov/grants/guide/pa-fi 27-Jun-2019, 24-Oct-2019, 27-Oct-2020		<u>846.html</u>			

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		National Institutes of Health (NIH) an examining how Electronic Nicotine Del cells, tissues and organs. This FOA will	livery Systems (ENDS) aerosols affect	normal and dis	ease states relevant	to human
075939	Electronic Nicotine Delivery System Prevention Research (R21 - Clinica	ms (ENDS): Population, Clinical and Appall Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-18- 848	27-Jun-2019	275,000 USD
	Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis	Rachel Grana Mayne, PhD, MPH 240-276-5899  rachel.mayne@nih.gov  https://grants.nih.gov/grants/guide/pa 27-Jun-2019, 24-Oct-2019, 27-Jun-20  National Institutes of Health (NIH) and nicotine delivery systems (ENDS) that detiology of use, epidemiology of use, populations. This FOA will use the NIH	20 d its participating Institutes and Cente examine population-based, clinical an otential risks, benefits and impacts or	d applied prev	ention of disease, in o use behavior amor	cluding
075934	Electronic Nicotine Delivery System Prevention Research (R01 - Clinical	ms (ENDS): Population, Clinical and Appal Irial Optional)	National Cancer Institute/NIH/DHHS	PAR-18- 847	27-Jun-2019	Not Specified
	Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis	Rachel Grana Mayne, PhD, MPH 240-276-5899 rachel.mayne@nih.gov  https://grants.nih.gov/grants/guide/pa 27-Jun-2019, 24-Oct-2019, 27-Jun-20 National Institutes of Health (NIH) and nicotine delivery systems (ENDS) that detiology of use, ppopulations. This FOA will use the NIH	20 d its participating Institutes and Cente examine population-based, clinical an otential risks, benefits and impacts or	d applied prev	ention of disease, in	cluding
075930	Electronic Nicotine Delivery System (R01 - Clinical Trial Not Allowed)  Contact Name	ms (ENDS): Basic Mechanisms of Healtl	National Cancer Institute/NIH/DHHS	PAR-18- 845	27-Jun-2019	Not Specified

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount			
	Title					Amount			
	Contact Telephone	240-276-6228							
	Contact Email	rjohnso2@mail.nih.gov							
	Sponsor Website								
	Program URL	https://grants.nih.gov/grants/guide/pa	https://grants.nih.gov/grants/guide/pa-files/PAR-18-845.html						
Deadline Dates (ALL) 27-Jun-2019 , 24-Oct-2019 , 27-Jun-2020									
	Synopsis	National Institutes of Health (NIH) and examining how Electronic Nicotine Del cells, tissues and organs. This FOA will	ivery Systems (ENDS) aerosols affect i	normal and dis	ease states relevant				
054497	The Role of Mobile Genetic Eleme	ents in Cancer (R01)	National Cancer Institute/NIH/DHHS	PAR-16- 227	07-May-2019	Not Specified			
	Contact Name	T. Kevin Howcroft, Ph.D.							
	Contact Telephone	240-276-6200							
	Contact Email	Howcrofk@mail.nih.gov							
	Sponsor Website								
	Program URL	http://grants.nih.gov/grants/guide/pa-	files/PAR-16-227.html						
	Deadline Dates (ALL)	07-May-2019 , 05-Jun-2019 , 07-Sep-20	019						
		National Cancer Institute (NCI) and Nathe expression and activity of mobile grancer. For example, although long introduced insertions lead to cancer ceduring cancer evolution or response to processes is also not well understood. specifically investigate mechanisms regarders from the FOA will use the NIH Research Processes.	enetic elements, including long termi erspersed element-1 (LINE-1 or L1) re II heterogeneity and/or adaptive phentherapy is not clear. Similarly, how have an effort to address this knowledge gulating the expression and activity of their activity on tumor heterogeneits.	nal repeat (LTF troelements an notypes that co uman endoger e gap, this FOA mobile geneti	R) and non-LTR retro re active in many car onfer growth or surv nous viruses (HERVs) invites research app c elements in the co	elements, in ncers whether vival advantag affect cancer blications that intext of cell			
054501	Metabolic Reprogramming to Imp	prove Immunotherapy (R01)	National Cancer Institute/NIH/DHHS	PAR-16- 228	07-May-2019	Not Specified			
	Contact Name	Susan A. McCarthy, Ph.D.							



Contact Telephone 240-276-6200

Contact Email mccarths@mail.nih.gov

-					
SPIN ID Program Title	Sponsor Name	Sponsor Number		<b>Deadline Date</b>	Funding Amount
	ı				
Sponsor Websi					
	RL http://grants.nih.gov/grants/guide/p				
Deadline Dates (AL	L) 07-May-2019 , 05-Jun-2019 , 07-Sep				
Synops	that support robust anti-tumor imm sis microenvironment affects immune e	es applications to (a) generate a mechar une responses in vivo, (b) determine ho effector functions, and (c) then use this i nor, the immune response, or both to in rd mechanism.	w the metabo nformation to	ic landscape of the manipulate (reprog	cumor ram) the
054503 Metabolic Reprogramming to In	mprove Immunotherapy (R21)	National Cancer Institute/NIH/DHHS	PAR-16- 229	07-May-2019	275,000 USD
Contact Nam	ne Susan A. McCarthy, Ph.D.				
Contact Telephor	ne 240-276-6200				
Contact Ema	ail mccarths@mail.nih.gov				
Sponsor Websi	te				
Program UI	RL http://grants.nih.gov/grants/guide/g	pa-files/PAR-16-229.html			
Deadline Dates (AL	L) 07-May-2019 , 16-Jun-2019 , 07-Sep	-2019			
Synops	that support robust anti-tumor imm sis microenvironment affects immune e	es applications to (a) generate a mechar une responses in vivo, (b) determine ho effector functions, and (c) then use this i nor, the immune response, or both to in ental (R21) grant mechanism.	w the metabo nformation to	ic landscape of the manipulate (reprog	tumor ram) the
054499 The Role of Mobile Genetic Elec	ments in Cancer (R21)	National Cancer Institute/NIH/DHHS	PAR-16- 226	07-May-2019	275,000 USD
Contact Nam	ne T. Kevin Howcroft, Ph.D.				
Contact Telephor	ne 240-276-6200				
Contact Ema	ail Howcrofk@mail.nih.gov				
Sponsor Websi	te				
Program UI	RL http://grants.nih.gov/grants/guide/p	pa-files/PAR-16-226.html			
Deadline Dates (AL	.L) 07-May-2019 , 16-Jun-2019 , 07-Sep	-2019			
Synops	sis National Cancer Institute (NCI) and N	National Institute on Aging (NIA) invite a	pplications to	investigate mechani	sms regulating

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	9	the expression and activity of mobile general cancer. For example, although long intersomatic L1 insertions lead to cancer cell had during cancer evolution or response to the processes is also not well understood. In a	spersed element-1 (LINE-1 or L1) re neterogeneity and/or adaptive phenerapy is not clear. Similarly, how h	troelements are notypes that cor uman endogenc	e active in many car nfer growth or surv ous viruses (HERVs)	ncers whether ival advantage affect cancer
	s t	specifically investigate mechanisms regulations regulation and assess the impact of the transformation and assess the impact of the transformation will use the NIH Exploratory/Devices.	ating the expression and activity of their activity on tumor heterogene	f mobile genetic ity, cancer evolu	elements in the co	ntext of cell
054597	s t	specifically investigate mechanisms regulater in specifically investigate mechanisms regulater in specifically in the specific	ating the expression and activity of their activity on tumor heterogeneic velopmental (R21) grant mechanism	f mobile genetic ity, cancer evolu	elements in the co	ntext of cell
054597	Cancer-Related Behavioral Research	specifically investigate mechanisms regulatransformation and assess the impact of this FOA will use the NIH Exploratory/Dev	ating the expression and activity of their activity on tumor heterogenei velopmental (R21) grant mechanisi National Cancer	f mobile genetic ity, cancer evolu m. PAR-16-	elements in the co ition, and response	to therapy.  275,000
054597	Cancer-Related Behavioral Research	specifically investigate mechanisms regulateransformation and assess the impact of the This FOA will use the NIH Exploratory/Deventhrough Integrating Existing Data (R21) Richard P. Moser, Ph.D.	ating the expression and activity of their activity on tumor heterogenei velopmental (R21) grant mechanisi National Cancer	f mobile genetic ity, cancer evolu m. PAR-16-	elements in the co ition, and response	to therapy.  275,000
054597	Cancer-Related Behavioral Research Contact Name Contact Telephone	specifically investigate mechanisms regulateransformation and assess the impact of the This FOA will use the NIH Exploratory/Deventhrough Integrating Existing Data (R21) Richard P. Moser, Ph.D.	ating the expression and activity of their activity on tumor heterogenei velopmental (R21) grant mechanisi National Cancer	f mobile genetic ity, cancer evolu m. PAR-16-	elements in the co ition, and response	to therapy.  275,000
054597	Cancer-Related Behavioral Research Contact Name Contact Telephone	specifically investigate mechanisms regulations regulation and assess the impact of the This FOA will use the NIH Exploratory/Deventh through Integrating Existing Data (R21). Richard P. Moser, Ph.D. 240-276-6915	ating the expression and activity of their activity on tumor heterogenei velopmental (R21) grant mechanisi National Cancer	f mobile genetic ity, cancer evolu m. PAR-16-	elements in the co ition, and response	to therapy.  275,000
054597	Cancer-Related Behavioral Research  Contact Name For Contact Telephone Contact Email For Sponsor Website	specifically investigate mechanisms regulations regulation and assess the impact of the This FOA will use the NIH Exploratory/Deventh through Integrating Existing Data (R21). Richard P. Moser, Ph.D. 240-276-6915	ating the expression and activity of their activity on tumor heterogene velopmental (R21) grant mechanisi National Cancer Institute/NIH/DHHS	f mobile genetic ity, cancer evolu m. PAR-16-	elements in the co ition, and response	to therapy.  275,000

National Cancer Institute (NCI) invites applications that seek to integrate two or more independent data sets to answer novel cancer control and prevention questions. The goal is to encourage applications that incorporate Integrative Data Analysis (IDA) methods to study behavioral risk factors for cancer, including tobacco use, sedentary behavior, poor weight management, and lack of medical adherence to screening and vaccine uptake. It is important that the data being integrated are from different sources and types (including both quantitative and qualitative; data may span different levels such as genetic and environmental) and should include at least one source of behavioral data. Importantly, applicants should use existing data sources rather than collect new data. In addition, creating harmonized measures, developing culturally sensitive measures, replicating results and cross-study comparisons will be encouraged. This FOA will use the NIH Exploratory/Developmental (R21) grant mechanism.

054595 Cancer-Related Behavioral Research through Integrating Existing Data (R01)

National Cancer PAR-16-

National Cancer PAR-16- 07-Jun-2019 Not Specified

Contact Name Richard P. Moser, Ph.D.

Contact Telephone 240-276-6915

Contact Email moserr@mail.nih.gov

Sponsor Website



SPIN ID Program Title	Sponsor Name	Sponsor Number		<b>Deadline Date</b>	Funding Amount		
Deadline Dates (ALL)	http://grants.nih.gov/grants/guide/pa-for-107-Jun-2019 National Cancer Institute (NCI) invites a cancer control and prevention question (IDA) methods to study behavioral risk for management, and lack of medical adhermatic are from different sources and types (in genetic and environmental) and should existing data sources rather than collect measures, replicating results and cross-(RO1) award mechanism.	oplications that seek to integrate two s. The goal is to encourage application actors for cancer, including tobacco rence to screening and vaccine uptak cluding both quantitative and qualita include at least one source of behavior	ons that incorpor use, sedentary b ie. It is importan ative; data may s foral data. Impor nonized measure	rate Integrative Darehavior, poor weight that the data being pan different level trantly, applicants sees, developing cultivates.	ta Analysis ght ng integrated Is such as should use urally sensitive		
054533 Neural Regulation of Cancer (R21	L)	National Cancer Institute/NIH/DHHS	PAR-16- 246	27-Jun-2019	275,000 USD		
Contact Name	Chamelli Jhappan, Ph.D.						
Contact Telephone	240-276-6200						
Contact Emai	jhappanc@mail.nih.gov						
Sponsor Website							
Program URI	http://grants.nih.gov/grants/guide/pa-f	iles/PAR-16-246.html					
Deadline Dates (ALL)	27-Jun-2019						
Synopsis	National Cancer Institute (NCI) invites applications for collaborative, transdisciplinary research with both neuroscience and cancer elements, which together will advance current understanding of the nervous system contribution to cancer.  Leveraging the knowledge, tools, experimental models and reagents in neuroscience research to uncover novel mechanisms.						
054529 Neural Regulation of Cancer (R02	L)	National Cancer Institute/NIH/DHHS	PAR-16- 245	27-Jun-2019	Not Specified		
Contact Name	Chamelli Jhappan, Ph.D.						
Contact Telephone	240-276-6200						
Contact Emai	jhappanc@mail.nih.gov						
Sponsor Website							



SPIN ID	Program Title	Sponsor Name	Sponsor	Number		Deadline Date	Funding Amount
	Deadline Dates (ALL) 2				alinany rospars	a with both nouro	ssionso and
	Synopsis u ca	lational Cancer Institute (NCI) invites ap ancer elements, which together will adv everaging the knowledge, tools, experin sed by the nervous system to promote to ancer research including the prevention esearch Project (RO1) award mechanism	ance curr nental mo tumor init and treat	ent understanding of the ne dels and reagents in neuros iation, progression and meta	rvous system c cience research astasis can ultir	ontribution to car n to uncover nove mately inform key	ncer. I mechanisms areas of
076806	Physical Activity and Weight Contro on Biomarkers of Prognosis and Sur	ol Interventions Among Cancer Survivors rvival (R21 Clinical Trial Optional)	:: Effects	National Cancer Institute/NIH/DHHS	PAR-18- 892	07-May-2019	275,000 USD
	Contact Name F	rank M. Perna, Ed.D., Ph.D.					
	Contact Telephone 2	40-276-6782					
	Contact Email <u>p</u>	ernafm@mail.nih.gov					
	Sponsor Website						
	Program URL <u>h</u>	ttps://grants.nih.gov/grants/guide/pa-f	iles/PAR-1	. <u>8-892.html</u>			
		7-May-2019 , 16-Jun-2019 , 07-Sep-201 020 , 16-Oct-2020 , 07-Jan-2021 , 16-Fel				/-2020 , 16-Jun-20	20 , 07-Sep-
	Synopsis Synopsis Synopsis Pfr	lational Cancer Institute (NCI) invites appecific biological or biobehavioral pathwooidance of weight gain) may affect canctivity, alone or in combination with we rognosis among cancer survivors identifican insulin/glucose metabolism, especial ecause many cancer survivor population experience early effects of aging, inclusion rocess are also sought. Applications show actional factorial designs), and will incluse the NIH R21 Exploratory/Development	vays throuser prograight contributed by presenting those on the contributed by the contri	igh which physical activity ar osis and survival. Research a ol (either weight loss or avo evious animal or observation obtained from tumor tissue experience recurrence but a arkers of comorbid diseases operimental designs (e.g., ra lisciplinary approaches that cal science disciplines releva	nd/or weight complications should be all research on sourced from rewill die of complete. Cardiovandomized contibring together int to the pathy	ontrol (either weigh buld test the effect ont gain), on biomal established biomal epeat biopsies whorbid diseases or rescular disease) and rolled clinical trial behavioral interve	th loss or ts of physical rkers of cancer arkers other here available. may d of the aging s (RCTs),
076805	Physical Activity and Weight Contro on Biomarkers of Prognosis and Sur	ol Interventions Among Cancer Survivors rvival (R01 Clinical Trial Optional)	:: Effects	National Cancer Institute/NIH/DHHS	PAR-18- 893	)7-May-2019	Not Specified
	Contact Name F	rank M. Perna, Ed.D., Ph.D.					

ISPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
----------	------------------	--------------	----------------	---------------	-------------------

Contact Telephone 240-276-6782

Contact Email pernafm@mail.nih.gov

Sponsor Website

Program URL https://grants.nih.gov/grants/guide/pa-files/PAR-18-893.html

Deadline Dates (ALL)

07-May-2019, 05-Jun-2019, 07-Sep-2019, 05-Oct-2019, 07-Jan-2020, 05-Feb-2020, 07-May-2020, 05-Jun-2020, 07-Sep-2020, 05-Oct-2020, 07-Jan-2021, 05-Feb-2021, 07-May-2021, 05-Jun-2021, 07-Sep-2021

National Cancer Institute (NCI) invites applications for transdisciplinary and translational research that will identify the specific biological or biobehavioral pathways through which physical activity and/or weight control (either weight loss or avoidance of weight gain) may affect cancer prognosis and survival. Research applications should test the effects of physical activity, alone or in combination with weight control (either weight loss or avoidance of weight gain), on biomarkers of cancer prognosis among cancer survivors identified by previous animal or observational research on established biomarkers other than insulin/glucose metabolism, especially those obtained from tumor tissue sourced from repeat biopsies where available. Because many cancer survivor populations will not experience recurrence but will die of comorbid diseases or may experience early effects of aging, inclusion of biomarkers of comorbid diseases (e.g., cardiovascular disease) and of the aging process are also sought. Applications should use experimental designs (e.g., randomized controlled clinical trials (RCTs), fractional factorial designs), and will include transdisciplinary approaches that bring together behavioral intervention expertise, cancer biology, and other basic and clinical science disciplines relevant to the pathways being studied. This FOA will use the NIH R01 Research Project Grant award mechanism.

Synopsis

Developing Interventions for Health-Enhancing Physical Activity (R21/R33 - Clinical **National Cancer** Trial Optional) Institute/NIH/DHHS

PAR-18-307

16-Jun-2019

1,025,000 USD

Contact Name Frank Perna, Ed.D., Ph.D.

Contact Telephone 240-276-6782

Contact Email pernafm@mail.nih.gov

**Sponsor Website** 

Program URL https://grants.nih.gov/grants/guide/pa-files/PAR-18-307.html

Deadline Dates (ALL) 16-Jun-2019, 07-Sep-2019, 16-Feb-2020, 07-May-2020, 16-Oct-2020, 02-Jan-2021

National Institutes of Health (NIH) and its participating Institutes and Centers invite applications for highly innovative and promising research aimed at developing multi-level physical activity intervention programs acting on at least two levels of the socioecological model and designed to increase health-enhancing physical activity: 1) in persons or groups that can benefit from such activity; and 2) that could be made scalable and sustainable for broad use across the nation. This FOA provides support for up to two years (R21 phase) for research planning activities and feasibility studies, followed by a possible transition to expanded research support (R33 phase) for optimizing the intervention and conducting larger-scale feasibility

067401

SPIN ID	Program Title	Sponsor Name	Sponsor	Number		Deadline Date	Funding Amount
		studies. Transition to the R33 depends on the availability of funds. This program will		•			priorities and
067494	Testing Interventions for Health-Optional)	Enhancing Physical Activity (R01 - Clinical T	<u>rial</u>	National Cancer Institute/NIH/DHHS	PAR-18- 324	05-Jun-2019	Not Specified
	Contact Name	Frank Perna, Ed.D., Ph.D.					
	Contact Telephone	240-276-6782					
	Contact Emai	pernafm@mail.nih.gov					
	Sponsor Website						
	Program URL	https://grants.nih.gov/grants/guide/pa-fil	les/PAR-1	<u> 18-324.html</u>			
	Deadline Dates (ALL)	05-Jun-2019 , 07-Sep-2019 , 05-Feb-2020	, 07-May	-2020 , 05-Oct-2020 , 07-J	an-2021		
		promising research that tests multi-level percentage and designed to increase such activity; and 2) that could be made so NIH R01 Research Project Grant award me	e health-e calable a echanism	enhancing physical activity nd sustainable for broad u	/: 1) in persons	or groups that can	benefit from will use the
076579	Advancing Mechanistic Probiotic Clinical Trial Not Allowed)	Prebiotic and Human Microbiome Researc	ch (R01	National Cancer Institute/NIH/DHHS	PA-18-876	07-May-2019	Not Specified
	Contact Name	Dr. Roberto Flores					
	Contact Telephone	240-276-7119					
	Contact Emai	floresr2@mail.nih.gov					
	Sponsor Website						
	Program URL	https://grants.nih.gov/grants/guide/pa-fil	les/PA-18	3-876.html			
	Deadline Dates (ALL)	07-May-2019 , 05-Jun-2019 , 07-Sep-2019 2020 , 05-Oct-2020 , 07-Jan-2021 , 05-Feb	9 , 05-Oct 5-2021 , 0	-2019 , 07-Jan-2020 , 05-F 7-May-2021 , 05-Jun-2021	eb-2020 , 07-M L , 07-Sep-2021	1ay-2020 , 05-Jun-2	020 , 07-Sep-
		National Institutes of Health (NIH) and its		ting Institutes and Conton			

SPIN ID	Program Title	Sponsor Name	Sponsor	Number		Deadline Date	Funding Amount
		Project (R01) award mechanism.					
053627	<u>Pilot and Feasibility Studies Evalue</u> <u>epitranscriptome</u> ) in Cancer Biological	ating the Role of RNA Modifications (the pgy (R21)		National Cancer Institute/NIH/DHHS	PA-16-177	07-May-2019	275,000 USD
	Contact Name	Jennifer Strasburger					
	Contact Telephone	240-276-6230					
	Contact Email	strasbuj@mail.nih.gov					
	Sponsor Website						
	Program URL	http://grants.nih.gov/grants/guide/pa-file	es/PA-16-	<u> 177.html</u>			
	Deadline Dates (ALL)	07-May-2019 , 16-Jun-2019					
	Synopsis	corresponding writers, readers and erase have been reported to regulate the fate a element of post-transcriptional gene regumechanism.	and functi	on of both coding and non	coding RNAs a	nd are emerging as	a critical
061594	Research Projects to Enhance App Research (R01)	plicability of Mammalian Models for Trans	<u>slational</u>	National Cancer Institute/NIH/DHHS	PAR-17- 245	05-Jun-2019	1,350,000 USD
	<u> </u>	Chandle Made DhD		mstrate/Mm/Dimis	243		
		Cheryl L. Marks, PhD					
	Contact Telephone	marksc@mail.nih.gov					
	Sponsor Website						
	•		ilos/DAD 1	7.245 html			
	Program URL	https://grants.nih.gov/grants/guide/pa-fi 05-Jun-2019, 05-Oct-2019, 05-Feb-2020		7-245.html			

mammalian or human tissues or cells for hypothesis-testing, non-clinical research. Among many other possible endeavors,

applicants in response to this FOA could propose demonstrations of how to overcome translational deficiencies of mammalian oncology models, define new uses of mammalian models or their genetics for unexplored translational

		·					
SPIN ID	Program Title	Sponsor Name	Sponsor	Number		Deadline Date	Funding Amount
		challenges, advance standard practices for challenge current practices for how mode mechanism.		•	•		
061498	Secondary Analysis and Integration Architecture of Cancer Risk and R	on of Existing Data to Elucidate the Geneti Lelated Outcomes (R21)	<u>C</u>	National Cancer Institute/NIH/DHHS	PA-17-243	16-Jun-2019	275,000 USD
	Contact Name	Melissa Rotunno, Ph.D.					
	Contact Telephone	240-276-7245					
	Contact Email	rotunnom@mail.nih.gov					
	Sponsor Website						
	Program URL	https://grants.nih.gov/grants/guide/pa-fi	iles/PA-1	7-243.html			
	Deadline Dates (ALL)	16-Jun-2019 , 16-Oct-2019 , 16-Feb-2020					
	Synopsis	National Institutes of Health (NIH) and it secondary data analysis and integration of genetic architecture of cancer risk and rerelevant to cancer epidemiology by supposition to environmental, outcomes, behavioralleverage existing genetic data and perfor aims that are being addressed with existing integration of datasets that allow the expension of the expension of datasets.	of existing lated out orting the al, lifestyl m innovang data, I	datasets and database reso comes. The goal of this initial e analysis of existing genetic e, and molecular profiles da tive analyses of the existing new or advanced methods of of important scientific quest	ources, with the active is to addror genomic data. Application data. Applicat fanalyses, or r	e ultimate aim to e ess key scientific q itasets, possibly in is to this FOA are e ions may include n novel combination	elucidate the uestions combination encouraged to ew research s and
077667	Increasing Uptake of Evidence-Ba Clinical Trial Optional)	sed Screening in Diverse Adult Population	s (R01	National Cancer Institute/NIH/DHHS	PA-18-932	07-May-2019	Not Specified
	Contact Name	Erica S. Breslau, PhD, MPH					
	Contact Telephone	240-276-6773					
	Contact Email	breslaue@mail.nih.gov					
	Sponsor Website						
	Program URL	https://grants.nih.gov/grants/guide/pa-fi	iles/PA-1	<u>3-932.html</u>			
	Deadline Dates (ALL)	07-May-2019 , 05-Jun-2019 , 07-Sep-2019 2020 , 05-Oct-2020 , 07-Jan-2021 , 05-Fel	9 , 05-Oct o-2021 , 0	:-2019 , 07-Jan-2020 , 05-Fel 97-May-2021 , 05-Jun-2021 ,	o-2020 , 07-Ma 07-Sep-2021 ,	ay-2020 , 05-Jun-20 05-Oct-2021 , 07-	020 , 07-Sep- Jan-2022
	Synopsis	National Institutes of Health (NIH) and it strategies to reduce disparities in the upt					

SPIN ID	Program Title	Sponsor Name	Sponsor	· Number		Deadline Date	Funding Amount			
		effective based on rigorous systematic rethis program announcement, screening in asymptomatic populations. Research supdiverse populations, (2) in diverse clinical health care providers. This FOA will use to	s defined oported b I and con	as a preventive service focu y this initiative should enhan nmunity settings, and/or (3)	ised on detect nce the screen with tradition	ion of an undiagno ing process related	sed disease in I to use: (1) in			
077362	Quantitative Imaging Tools and M Clinical Trial Optional)	Methods for Cancer Response Assessment	(R01	National Cancer Institute/NIH/DHHS	PAR-18- 919	05-Jun-2019	2,500,000 USD			
	Contact Name	Robert J. Nordstrom, Ph.D.								
	Contact Telephone	240-276-5934								
	Contact Email	nordstrr@mail.nih.gov								
	Sponsor Website									
	Program URL	https://grants.nih.gov/grants/guide/pa-f	iles/PAR-	<u>18-919.html</u>						
	Deadline Dates (ALL)	05-Jun-2019 , 05-Oct-2019 , 05-Feb-2020	05-Jun-2019 , 05-Oct-2019 , 05-Feb-2020							
	Synopsis	National Cancer Institute (NCI) invites a optimized quantitative imaging software or in translating imaging software tools from quantitative software tools must have be Imaging Network (QIN) or under other set that successfully completed the tasks of intended to facilitate clinical decision mathose software tools in prospective multisoftware tool can be integrated into clinic Project (R01) award mechanism.	tools cap or planni een devel eparate fu developin sking duri isite clinic	pable of measuring or predicing and validating radiation to oped and optimized during unding. The proposed researing and optimizing the choseing clinical trials. This FOA is cal trials to test software too	ting the respo herapy treatm a performance och effort shou n software too intended to su ll performance	nse of cancer to cli lent strategies in cli e period in the Qual ld be an extension lls or data collection apport the efforts o e and to demonstra	nical therapies, inical trials. The ntitative of the research methods f validating te that the			
079077	Cancer Tissue Engineering Collaboration Technologies for Cancer Research	orative: Enabling Biomimetic Tissue-Engin n (R01 Clinical Trial Optional)	<u>ieered</u>	National Cancer Institute/NIH/DHHS	PAR-19- 113	05-Jun-2019	2,000,000 USD			
	Contact Name	Nastaran Z. Kuhn, Ph.D.								
	Contact Telephone	240-276-7610								
	Contact Email	nas.zahir@nih.gov								
	Sponsor Website									
	Program URL	https://grants.nih.gov/grants/guide/pa-f	iles/PAR-	<u>19-113.html</u>						
	Deadline Dates (ALL)	05-Jun-2019 , 05-Oct-2019 , 05-Feb-2020	) , 05-Jun	-2020 , 05-Oct-2020 , 05-Feb	-2021 , 05-Jur	n-2021 , 05-Oct-202	1			

SPIN ID	Program	Sponsor Name	Snoncor	Number		Deadline Date	Funding				
SPIN ID	Title	Sponsor Warne	эронзог	Number		Deadillie Date	Amount				
	Synopsis	This Funding Opportunity Announcement biomimetic tissue-engineered technologie fields of regenerative medicine, tissue engineerating novel experimental models the hypothesis. The projects supported by this (TEC) Research Program. The Cancer TEC is and ex vivo systems available for cancer promote the exploration of cancer phenorements.	es for car gineering at mimic s FOA wi Program esearch,	ncer research. Collaborative i, biomaterials, and bioeng cancer pathophysiology in Il collectively participate in will (1) catalyze the advand (2) expand the breadth of	e, multidiscipling ineering with context of the context of the Cancer Tistement of innothese systems	nary projects that e ancer biology will b a testable cancer r sue Engineering Co wative, well charact to several cancer ty	ngage the se essential for esearch llaborative terized in vitro				
11/4225	Exploratory/Developmental Bioe Trial Not Allowed)	ngineering Research Grants(EBRG) (R21 Cli	<u>nical</u>	National Cancer Institute/NIH/DHHS	PAR-19- 149	07-May-2019	275,000 USD				
	Contact Name	Miguel R. Ossandon, Ph.D.									
	Contact Telephone	240-276-5714									
	Contact Email	ossandom@mail.nih.gov									
	Sponsor Website										
	Program URL	https://grants.nih.gov/grants/guide/pa-fil	https://grants.nih.gov/grants/guide/pa-files/PAR-19-149.html								
	Deadline Dates (ALL)	07-May-2019, 16-Jun-2019, 07-Sep-2019, 16-Oct-2019, 07-Jan-2020, 16-Feb-2020, 07-May-2020, 16-Jun-2020, 07-Sep- 2020, 16-Oct-2020, 07-Jan-2021, 16-Feb-2021, 07-May-2021, 16-Jun-2021, 07-Sep-2021, 16-Oct-2021, 07-Jan-2022									
	Synopsis	The purpose of this engineering-oriented funding opportunity announcement (FOA) is to encourage submissions of exploratory/developmental Bioengineering Research Grant (EBRG) applications to demonstrate feasibility and potential utility of new capabilities or improvements in quality, speed, efficacy, operability, costs, and/or accessibility of solutions to problems in basic biomedical, pre-clinical, or clinical research, clinical care delivery, or accessibility.									
079333	Exploratory/Developmental Bioe Trial Optional)	ngineering Research Grants (EBRG) (R21 Cl	<u>inical</u>	National Cancer Institute/NIH/DHHS	PAR-19- 150	07-May-2019	275,000 USD				
	Contact Name	Miguel R. Ossandon, Ph.D.									
	Contact Telephone	240-276-5714									
	Contact Email	ossandom@mail.nih.gov									
	Sponsor Website										
	Program URL	https://grants.nih.gov/grants/guide/pa-fil	es/PAR-:	<u>19-150.html</u>							
	Deadline Dates (ALL)	07-May-2019 , 16-Jun-2019 , 07-Sep-2019 , 16-Oct-2019 , 07-Jan-2020 , 16-Feb-2020 , 07-May-2020 , 16-Jun-2020 , 07-Sep- 2020 , 16-Oct-2020 , 07-Jan-2021 , 16-Feb-2021 , 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022									
	Synopsis	The purpose of this engineering-oriented	funding	opportunity announcemen	t (FOA) is to er	ncourage submissio	ns of				

SPIN ID	Program Title	Sponsor Name	Sponsor	Number		Deadline Date	Funding Amount				
		Exploratory/Developmental Bioengineeri utility of new capabilities or improvement problems in basic biomedical, pre-clinical	ts in qua I, or clinic	ity, speed, efficacy, operab al research, clinical care de	ility, costs, and,	or accessibility of	solutions to				
079076	Improving Outcomes in Cancer To Optional)	reatment-Related Cardiotoxicity (R21 Clini	cal Trial	National Cancer Institute/NIH/DHHS	PA-19-111	16-Jun-2019	275,000 USD				
	Contact Name	Nonniekaye Shelburne, MS, CRNP, AOCN									
	Contact Telephone	240-276-6897									
	Contact Email	nshelburne@mail.nih.gov									
	Sponsor Website										
	Program URL	https://grants.nih.gov/grants/guide/pa-f	ttps://grants.nih.gov/grants/guide/pa-files/PA-19-111.html								
	Deadline Dates (ALL)	16-Jun-2019 , 16-Oct-2019 , 16-Feb-2020	5-Jun-2019 , 16-Oct-2019 , 16-Feb-2020 , 16-Jun-2020 , 16-Oct-2020 , 16-Feb-2021 , 16-Jun-2021 , 16-Oct-2021								
	Synopsis	identification and characterization of pat intent is to mitigate cardiovascular dysfur cardiovascular risk prior to treatment and screening, diagnostic, and/or manageme mitigation/management of adverse effect targeted agents, immunomodulatory the	nis Funding Opportunity Announcement (FOA) encourages collaborative applications that will contribute to the entification and characterization of patients at risk of developing cancer treatment-related cardiotoxicity. The primary tent is to mitigate cardiovascular dysfunction while optimizing cancer outcomes. To accomplish this, methods that evalual ardiovascular risk prior to treatment and integrate evidence-based cancer treatment regimens with cardiovascular creening, diagnostic, and/or management strategies are sought. Research applications should focus on initigation/management of adverse effects associated with anti-cancer treatments including: cytotoxic chemotherapies, argeted agents, immunomodulatory therapies and radiation (that occur during cancer treatment and/or long-term urvivorship) as defined by cardiac and/or vascular specific common terminology criteria for adverse events (CTCAE).								
079067	Improving Outcomes in Cancer To Optional)	reatment-Related Cardiotoxicity (R01 Clini	<u>cal Trial</u>	National Cancer Institute/NIH/DHHS	PA-19-112	05-Jun-2019	Not Specified				
	Contact Name	Nonniekaye Shelburne, MS, CRNP, AOCN									
	Contact Telephone	240-276-6897									
	Contact Email	nshelburne@mail.nih.gov									
	Sponsor Website										
	Program URL	https://grants.nih.gov/grants/guide/pa-f	iles/PA-1	9-112.html							
	Deadline Dates (ALL)	05-Jun-2019 , 05-Oct-2019 , 05-Feb-2020	, 05-Jun-	2020 , 05-Oct-2020 , 05-Fe	o-2021 , 05-Jun	-2021 , 05-Oct-202	.1				
	Synopsis	This Funding Opportunity Announcement identification and characterization of pat intent is to mitigate cardiovascular dysful cardiovascular risk prior to treatment and	ients at r nction wl	isk of developing cancer tre nile optimizing cancer outco	atment-related mes. To accom	cardiotoxicity. The plish this, method	e primary s that evaluate				

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount					
		mitigation/management of adverse e targeted agents, immunomodulatory	ement strategies are sought. Research a effects associated with anti-cancer treat therapies and radiation (that occur du nd/or vascular specific common termina	ments includi ing cancer tre	ng: cytotoxic chemo eatment and/or long	therapies, -term					
079769	Biology of Bladder Cancer (R21 C	Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-19- 184	05-Jun-2019	275,000 USD					
	Contact Name	Ron Johnson, Ph. D.									
	Contact Telephone	240-276-6250									
	Contact Email	l rjohnso2@mail.nih.gov									
	Sponsor Website	2									
	Program URL	https://grants.nih.gov/grants/guide/	https://grants.nih.gov/grants/guide/pa-files/PAR-19-184.html								
	Deadline Dates (ALL)	05-Jun-2019 , 05-Oct-2019 , 05-Feb-2 2022	2020 , 05-Jun-2020 , 05-Oct-2020 , 05-Fe	eb-2021 , 05-J	un-2021 , 05-Oct-20	21 , 05-Feb-					
	Synopsis	bladder cancer. Bladder cancer is a sincidence and frequent tumor recurr made in the molecular profiling of black molecular mechanisms driving initiat biological processes of the normal black molecular and cellular functions of the molecular and cellular functions.	ment (FOA) seeks applications investigation investigation in the Urstence, bladder cancer exacts an outsized adder cancers and identification of muttion, progression, and malignancy of blatadder at the molecular, cell and organ late bladder are altered in cancer will aid live multidisciplinary teams and use clini	nited States ard I medical burd ated genes, re dder cancer. F evels is limited our understar	nd globally. Because len. While recent pro latively little is know furthermore, our und d. Fundamental know nding of bladder can	of the high ogress has been on regarding the derstanding of wledge of how cer biology and					
079767	Biology of Bladder Cancer (R01 C	Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-19- 183	05-Jun-2019	Not Specified					
	Contact Name	Ron Johnson, Ph. D.									
	Contact Telephone	240-276-6250									
	Contact Email	l rjohnso2@mail.nih.gov									
	Sponsor Website										
	Program URL	https://grants.nih.gov/grants/guide/	pa-files/PAR-19-183.html								
	Deadline Dates (ALL)	05-Jun-2019 , 05-Oct-2019 , 05-Feb-2 2022	2020 , 05-Jun-2020 , 05-Oct-2020 , 05-Fe	eb-2021 , 05-J	un-2021 , 05-Oct-20	21 , 05-Feb-					

SPIN ID	Program Title	Sponsor Name	Sponsor	Number		Deadline Date	Funding Amount		
	Synopsis ki	his Funding Opportunity Announcement nechanisms of bladder cancer. Bladder of the high incidence and frequent tumo rogress has been made in the molecular nown regarding the molecular mechan ur understanding of biological process undamental knowledge of how molecular nderstanding of bladder cancer biology pecimens or investigate both normal a	cancer is a or recurred ar profiling isms driving es of the national y and inten	a significant health problem lance, bladder cancer exacts and of bladder cancers and idening initiation, progression, and ormal bladder at the moleculular functions of the bladder ventions. Applications that in	ooth in the Un n outsized med tification of m d malignancy of lar, cell and or er are altered involve multidi	ited States and glo dical burden. While nutated genes, rela of bladder cancer. rgan levels is limite n cancer will aid o sciplinary teams a	obally. Because e recent stively little is Furthermore, ed. ur		
079385		Therapeutics Clinical Trials Network (E pries (U24 Clinical Trial Not Allowed)	TCTN)	National Cancer Institute/NIH/DHHS	RFA-CA-19- 008	07-May-2019	Not Specified		
	Contact Name F	ernanda Arnaldez, M.D.							
	Contact Telephone 2	40-276-6565							
	Contact Email <u>f</u> e	ernanda.arnaldez@nih.gov							
	Sponsor Website								
	Program URL <u>h</u>	ttps://grants.nih.gov/grants/guide/rfa	-files/RFA-	<u>CA-19-008.html</u>					
		07-May-2019 , 05-Jun-2019 , 07-Sep-2019 , 05-Oct-2019 , 07-Jan-2020 , 05-Feb-2020 , 07-May-2020 , 05-Jun-2020 , 07-Sep- 2020 , 05-Oct-2020 , 07-Jan-2021 , 05-Feb-2021 , 07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022							
	P N p o Synopsis d a <sub>i</sub> p e.	The purpose of this Funding Opportunity Announcement (FOA) issued by The National Cancer Institute (NCI) is to create Pharmacokinetics Resource Laboratories (PK Laboratories) that will support the Experimental Therapeutics Clinical Trials Network (ETCTN). The PK Laboratories will be expected to organize specimen collection and subsequent analysis of pharmacokinetic endpoints, drug-drug interactions, cytochromes P450 (CYP) interactions, and food effects in ETCTN studies of NCI Investigational New Drug (IND) agents. The overarching goal of the ETCTN PK Laboratories is to advance the clinical development of NCI-IND agents through achieving comprehensive understanding of pharmacokinetic behavior of these agents studied in ETCTN protocols. The ETCTN Pharmacokinetic Resource Laboratories will assure the availability of physicians, clinical pharmacologists, nurses and scientists who have the appropriate expertise in pharmacokinetic studies for early drug development and translational research. This FOA seeks U24 cooperative agreement applications from multidisciplinary groups that will conduct all pharmacokinetic studies for ETCTN early phase clinical trials filed to the IND applications in NCI's Division of Cancer Treatment and Diagnosis (DCTD), Cancer Therapy Evaluation Program (CTEP).							
080277	Modulating Intestinal Microbiota to Cancer (R21 Clinical Trial Not Allow	Enhance Protective Immune Respons ed)	es against	National Cancer Institute/NIH/DHHS	PAK-19- 199	11-May-2019 [LOI/Pre-App] [Optional]	275,000 USD		

SPIN ID	Program Title	Sponsor Name	Sponsor	Number		Deadline Date	Funding Amount
		Young S. Kim, PhD					
	Contact Telephone						
		yk47s@nih.gov					
	Sponsor Website	https://www.taurih.com/www.ta/wwida/w	- fil/DAD	0.400 html			
	Deadline Dates (ALL)	https://grants.nih.gov/grants/guide/p 11-May-2019 [LOI/Pre-App][Optional] [LOI/Pre-App][Optional], 10-Jun-2020 App][Optional], 10-Jun-2021, 09-Oct-	, 10-Jun-201 , 07-Oct-202	9 , 07-Oct-2019 [LOI/Pre-A 0 [LOI/Pre-App][Optional]	, 06-Nov-2020		•
	Synopsis	The purpose of this Funding Opportur action by which gut microbes inhibit con delineating how specific microbes sporadic tumor formation.	or enhance a	nti-tumor immune respons	ses. Thus, rese	arch projects should	be focused
ихи <i>) /</i> Д	Modulating Intestinal Microbiota Cancer (R01 Clinical Trial Not Allo	to Enhance Protective Immune Responsed)	nses against	National Cancer Institute/NIH/DHHS	PAR-19- 198	11-May-2019 [LOI/Pre-App] [Optional]	Not Specified
	Contact Name	Young S. Kim, PhD					
	Contact Telephone	240-276-7115					
	Contact Email	yk47s@nih.gov					
	Sponsor Website						
	Program URL	https://grants.nih.gov/grants/guide/p	oa-files/PAR-2	<u>.9-198.html</u>			
	Deadline Dates (ALL)	11-May-2019 [LOI/Pre-App][Optional] [LOI/Pre-App][Optional], 10-Jun-2020 App][Optional], 10-Jun-2021, 09-Oct-	, 07-Oct-202	0 [LOI/Pre-App][Optional]	, 06-Nov-2020		•
	Synopsis	The purpose of this Funding Opportur action by which gut microbes inhibit on delineating how specific microbes sporadic tumor formation.	or enhance a	nti-tumor immune respons	ses. Thus, rese	arch projects should	be focused
()/()/XX	Cancer Prevention and Control Cl Required)	inical Trials Grant Program (R01 Clinica	al Trial	National Cancer Institute/NIH/DHHS	PAR-18- 559	07-May-2019	Not Specified
	Contact Name	Brandy Heckman-Stoddard, Ph.D., M.I	P.H.				

SPIN ID	Program Title	Sponsor Name	Sponsor I	Number		<b>Deadline Date</b>	Funding Amount
	Contact Telephone	240-276-7048					
	Contact Email	heckmanbm@mail.nih.gov					
	Sponsor Website						
	Program URL	https://grants.nih.gov/grants/guide/pa-fi	iles/PAR-1	<u>8-559.html</u>			
	Deadline Dates (ALL)	07-May-2019 , 05-Jun-2019 , 07-Sep-2019 2020 , 05-Oct-2020 , 07-Jan-2021	9 , 05-Oct-	2019 , 07-Jan-2020 , 05-Feb	-2020 , 07-Ma	y-2020 , 05-Jun-20	)20 , 07-Sep-
	Synopsis	National Cancer Institute (NCI) invites ap the burden of cancer through improveme survivorship related to cancer; with such a practice and/or public health. Application Health (NIH) definition of a clinical trial (so described in this FOA. This FOA does not a therapy in patients. The proposed investig Division of Cancer Prevention and/or the missions. This FOA will use the NIH Resea	ents in ear attributes as submittes NOT-O and will not gator-initi	ly detection, prevention, he , the proposed studies shou ed to this FOA must include D-15-015 for details) and pr ot support clinical trials for s ated projects should be rela on of Cancer Control and Po	althcare delive Id also have the studies that novide specific studies of cand ted to the pro	ery, quality of life, ne potential to imp neet the National I clinical trial inforn ter diagnosis and/o grammatic interes	and/or prove clinical nstitutes of nation as or oncologic sts of the NCI
080575		Planning Studies for Development of Speci (SPOREs) to Investigate Cancer Health Dis		National Cancer Institute/NIH/DHHS	$R \vdash \Delta = (\Delta = 1 Q =$	20-May-2019 [LOI/Pre-App] [Optional]	800,000 USD
	Contact Name	Tiffany Wallace, Ph.D.					
	Contact Telephone	240-276-5114					
	Contact Email	wallaceti@mail.nih.gov					
	Sponsor Website						
	_	https://grants.nih.gov/grants/guide/rfa-fi					
	Deadline Dates (ALL)	20-May-2019 [LOI/Pre-App][Optional], 19 [LOI/Pre-App][Optional], 19-Jun-2020, 18	9-Jun-2019 8-Sep-2020	) , 18-Sep-2019 [LOI/Pre-Ap ) [LOI/Pre-App][Optional], 1	p][Optional], 1 .8-Oct-2020	l8-Oct-2019 , 20-N	1ay-2020
	Synopsis	This Funding Opportunity Announcement are focused upon investigating cancer heart comprehensive cancer health disparities in the P20 awards should be competitive wire addressing cancer health disparities as a contract will contribute to improved prevention disproportionately affect specific racial/en	ealth dispar research p ith other a cross-cutti ion, early c	rities. The P20 grants will su rograms. It is the expectation pplications for a full Special ng research theme. All appl letection, diagnosis, and/or	pport feasibili on that the resized Programs ications must treatment of	ty and planning ac search programs d s of Research Excel propose translatio cancers found to	tivities to build eveloped by lence (SPORE), nal research

SPIN ID	Program	Sponsor Name	Sponsor Number	Deadline Date	Funding
SPIN ID	Title	Sponsor Name	Sponsor Number	Deadine Date	Amount

knowledge of human biology with a translational human endpoint proposed. All the proposed P20 programs must include a minimum of two well-developed translational research projects, as well as contribute significantly to the development of specialized shared resources core facilities, improved research model systems, and collaborative research activities with other institutions, P20 awardees, and/or current SPORE grantees

SPIN ID Program Title		Sponsor Name	Sponsor Number	<b>Deadline Date</b>	Funding Amount		
	Management and Outcomes for Cancer up Care (R01 Clinical Trial Required)	National Cancer Institute/NIH/DHHS	RFA-CA- 19-035	29-May-2019 [LOI/Pre-App] [Optional]	2,500,000 USD		
Contact Name	Michelle Mollica, PhD, MPH, RN, OCN						
Contact Telephone	240-276-7621						
Contact Email	michelle.mollica@nih.gov						
Sponsor Website							
Program URL	https://grants.nih.gov/grants/guide/rfa-files	/RFA-CA-19-035.html					
Deadline Dates (ALL)	adline Dates (ALL) 29-May-2019 [LOI/Pre-App][Optional], 28-Jun-2019						
Synopsis	This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. This FOA solicits applications that develop and test models of care for adult survive of cancer who are transitioning from active treatment to follow-up care. Through this FOA, the NCI intends to support multiplevel interventions that enhance communication, collaboration, and coordination among oncology and non-oncology providers to improve cancer survivor outcomes. Interventions that focus on the needs of racial/ethnic minority or medicall underserved adult survivors and/or those receiving care in community settings (including, but not limited to, community-based cancer centers) are not required but strongly encouraged. NCI seeks to fund applications that represent a broad spectrum of cancer survivors (e.g., variability in demographics, cancer type, clinical characteristics) and care delivery setting (e.g., community settings, integrated healthcare settings).						
081000 RFA-CA-19-039 Early-Stage Dev Cancer Research and Managemen	elopment of Informatics Technologies for ont (U01 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	RFA-CA- 19-039	12-May-2019 [LOI/Pre-App] [Optional]	900,000 USD		
Contact Name	Juli Klemm, Ph.D.						
Contact Telephone	301-480-5778						



Contact Email juli.klemm@nih.gov

SPIN ID	Program	Sponsor Name	Sponsor Number	Deadline Date	Funding
SFIIV ID	Title	Sponsor Ivallie	Sponsor Number	Deadine Date	Amount

Sponsor Website

Program URL https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-19-039.html

Deadline Dates (ALL) 12-May-2019 [LOI/Pre-App][Optional], 11-Jun-2019, 21-Oct-2019 [LOI/Pre-App][Optional], 20-Nov-2019

The purpose of this Funding Opportunity Announcement (FOA) is to invite Cooperative Agreement (U01) applications for the development of enabling informatics technologies to improve the acquisition, management, analysis, and dissemination of data and knowledge across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology, and/or cancer health disparities. As a component of the NCI's Informatics Technology for Cancer Research (ITCR) Program, this FOA focuses on early-stage Synopsis development from prototyping to hardening and adaptation. Early-stage development is defined for the purpose of this FOA as initial tool development or the significant modification of existing tools for new applications. The central mission of ITCR is to promote research-driven informatics technology across the development lifecycle to address priority needs in cancer research. In order to be successful, proposed development plans must have a clear rationale on why the proposed technology is needed and how it will benefit the cancer research field. In addition, mechanisms to solicit feedback from users

RFA-CA-19-041 -- Sustained Support for Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional)

National Cancer Institute/NIH/DHHS

RFA-CA-19-041

12-May-2019 [LOI/Pre-App] [Optional]

Not Specified

Contact Name Juli Klemm, Ph.D.

Contact Telephone 301-480-5778

Contact Email juli.klemm@nih.gov

**Sponsor Website** 

Program URL https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-19-041.html

and collaborators throughout the development process must be included.

Deadline Dates (ALL) 12-May-2019 [LOI/Pre-App][Optional], 11-Jun-2019, 21-Oct-2019 [LOI/Pre-App][Optional], 20-Nov-2019

The purpose of this Funding Opportunity Announcement (FOA) is to invite Cooperative Agreement (U24) applications for the continued development and sustainment of high value informatics research resources to improve the acquisition, management, analysis, and dissemination of data and knowledge across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and Synopsis epidemiology, and/or cancer health disparities. As a component of the NCI's Informatics Technology for Cancer Research (ITCR) Program, this FOA focuses on sustaining operations and improving the user experience and availability of existing, widely-adopted informatics tools and resources. This is in contrast to early-stage and advanced development efforts to generate these tools and resources that are supported by companion ITCR FOAs. The central mission of ITCR is to promote research-driven informatics technology across the development lifecycle to address priority needs in cancer research. In

081087

SPIN ID	Program Title	Sponsor Name	ponsor Number		Deadline Date	Funding Amount
		order to be successful, the proposed susta be maintained and how it has benefitted a assessing and maximizing the value of the between the resource and the targeted res	nd will continue to benefit the cancer res resource to researchers and supporting c	earch field	. In addition, med	chanisms for
081002	RFA-CA-19-039 Early-Stage Dev Cancer Research and Managemen	relopment of Informatics Technologies for nt (U01 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	RFA-CA- 19-039	12-May-2019 [LOI/Pre-App] [Optional]	900,000 USD
	Contact Telephone					
	Contact Email Sponsor Website	juli.klemm@nih.gov				
	Program URL	https://grants.nih.gov/grants/guide/rfa-file	es/RFA-CA-19-039.html			
	Deadline Dates (ALL)	12-May-2019 [LOI/Pre-App][Optional], 11-	Jun-2019 , 21-Oct-2019 [LOI/Pre-App][Op	tional], 20	-Nov-2019	
	Synopsis	The purpose of this Funding Opportunity A development of enabling informatics techn data and knowledge across the cancer rese cancer detection, risk assessment and previous component of the NCI's Informatics Technologies development from prototyping to hardening as initial tool development or the significant to promote research-driven informatics technology is needed and how it will beneficiand collaborators throughout the development.	nologies to improve the acquisition, mana earch continuum including cancer biology vention, cancer control and epidemiology ology for Cancer Research (ITCR) Program ing and adaptation. Early-stage development int modification of existing tools for new a chnology across the development lifecycle ed development plans must have a clear if the cancer research field. In addition, n	gement, a, cancer tro, and/or can, this FOA ent is defin pplications e to addres	nalysis, and disse eatment and diag ncer health dispa focuses on early- ed for the purpo s. The central mis ss priority needs in why the propo	mination of mosis, early arities. As a stage se of this FOA sion of ITCR is n cancer
080998		f Innovative Informatics Methods and and Ind Management (R21 Clinical Trial Optional	National Cancer Institute/NIH/DHHS	RFA-CA- 19-038	12-May-2019 [LOI/Pre-App] [Optional]	275,000 USD
	Contact Name	Juli Klemm, Ph.D.			,	
	Contact Telephone	301-480-5778				
	Contact Email	juli.klemm@nih.gov				



Sponsor Website

SPIN ID	Program Title	Sponsor Name Sp	ponsor Number		Deadline Date	Funding Amount
	Program URL	https://grants.nih.gov/grants/guide/rfa-file	s/RFA-CA-19-038.html			
	Deadline Dates (ALL)	12-May-2019 [LOI/Pre-App][Optional], 11-J	un-2019 , 21-Oct-2019 [LOI/Pre-App][Օր	otional], 20	)-Nov-2019	
	Synopsis	The purpose of this Funding Opportunity Ar applications (R21) for the development of its science addressing priority needs across the diagnosis, early cancer detection, risk assess disparities. As a component of the NCI's Info applications focused on the development of can considerably improve acquisition, manacentral mission of ITCR is to promote resear priority needs in cancer research. In order to method or algorithm is novel and how it will downstream technology development, from FOAs.	nnovative methods and algorithms in bide cancer research continuum including casment and prevention, cancer control are ormatics Technology for Cancer Research for novel computational, mathematical, are agement, analysis, and dissemination of rechdriven informatics technology across to be successful, there must be a clear rall benefit the cancer research field. Poten	omedical cancer biolond epidem h (ITCR) Produced statistical relevant date tionale for ntial applicancer by the develontial	omputing, inform ogy, cancer treatn iology, and/or car ogram, this FOA eal algorithms and ata and/or knowle opment lifecycle to how the propose cants who are interess.	atics, and data nent and neer health encourages methods that edge. The to address ed informatics erested in
11X1 3/1X =	Paul Calabresi Career Developmer Trial Optional)	nt Award for Clinical Oncology (K12 Clinical	National Cancer Institute/NIH/DHHS	PAR-19- 242	18-Jun-2019	Not Specified
	Contact Name	Mark Damico, Ph.D., Program Director				
	Contact Telephone	240-276-5630				
	Contact Email	damicomw@mail.nih.gov				
	Sponsor Website					
	Program URL	https://grants.nih.gov/grants/guide/pa-files	s/PAR-19-242.html			
	Deadline Dates (ALL)	18-Jun-2019 , 17-Jun-2020 , 17-Jun-2021				
	Synopsis	The purpose of the Paul Calabresi Career Declinician-scientists (M.D.s, D.O.s, Pharm.D.s research, and to promote their career deveallows appointment of Scholars proposing t separate ancillary clinical trial to an existing investigator, as part of their research and calabresis and calabresis of their research and calabresis career December 2019.	, nurses with Ph.D.s, or equivalent) train lopment as cancer researchers. This Fun to serve as the lead investigator of an incaption of the proposing to gain research expenses.	ed in clinio ding Oppo Jependent	cal and translation rtunity Announce clinical trial; or po	nal cancer ement (FOA) roposing a
116 ////19 -	Fundamental Science Research on Trial Optional)	Mind and Body Approaches (R21 Clinical	National Center for Complementary and Integrative Health/NIH/DHHS	PA-18- 322	07-May-2019	275,000 USD
	Contact Name	Wen G. Chen, PhD				

SPIN ID	Program Title	Sponsor Name	ponsor Number		Deadline Date	Funding Amount		
	Contact Telephone	301-451-3989						
	Contact Email	chenw@mail.nih.gov						
	Sponsor Website							
	Program URL	https://grants.nih.gov/grants/guide/pa-file						
	Deadline Dates (ALL)	07-May-2019 , 16-Jun-2019 , 07-Sep-2019 , 2020 , 16-Oct-2020 , 07-Jan-2021						
	National Center for Complementary and Integrative Health (NCCIH) invites applications to investigate the fundamental science of mind and body approaches, including mind/brain-focused practices (e.g., meditation, hypnosis), body-based approaches (e.g., acupuncture, massage, spinal manipulation/mobilization), meditative exercise (e.g., yoga, tai chi, qi gor art and music therapies, or integrative approaches combining several components. Studies of pharmacologic approaches exclusively are not included in the scope of this FOA. This FOA will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.					y-based chi, qi gong), oproaches		
067448	<u>Fundamental Science Research or Trial Optional)</u>	n Mind and Body Approaches (R01 Clinical	National Center for Complementary and Integrative Health/NIH/DHHS	PA-18- 323	07-May-2019	Not Specified		
	Contact Name	Wen G. Chen, PhD						
	Contact Telephone	301-451-3989						
	Contact Email	chenw@mail.nih.gov						
	Sponsor Website							
		https://grants.nih.gov/grants/guide/pa-file						
	Deadline Dates (ALL)	07-May-2019 , 05-Jun-2019 , 07-Sep-2019 , 2020 , 05-Oct-2020 , 07-Jan-2021	, 05-Oct-2019 , 07-Jan-2020 , 05-Feb-202	0 , 07-May	-2020 , 05-Jun-20	20 , 07-Sep-		
	Synopsis	National Center for Complementary and Inscience of mind and body approaches, incluapproaches (e.g., acupuncture, massage, spart and music therapies, or integrative apprexclusively are not included in the scope of	uding mind/brain-focused practices (e.g., pinal manipulation/mobilization), medita roaches combining several components.	meditatio tive exerci Studies of	n, hypnosis), bod se (e.g., yoga, tai pharmacologic ap	y-based chi, qi gong), oproaches		
068456		chanistic Studies to Optimize Mind and Body ity Research Topics (R61/R33 Clinical Trial	National Center for Complementary and Integrative Health/NIH/DHHS	PAR-18- 114	31-May-2019	Not Specified		
	Contact Name	Wen G. Chen, PhD						

Contact Telephone 301-451-3989

SPIN ID	Program	Sponsor Name	Sponsor Number	Deadline Date	Funding
31 114 12	Title	Sponsor Hame	Sponsor Number	Deadine Date	Amount

Contact Email chenw@mail.nih.gov

Sponsor Website

Program URL https://grants.nih.gov/grants/guide/pa-files/PAR-18-114.html

Deadline Dates (ALL) 31-May-2019, 28-Jun-2019

National Center for Complementary and Integrative Health (NCCIH) invites applications for a phased research approach to investigate and optimize the mechanisms underlying Mind and Body Interventions. This FOA will support two-phased research applications. The first phase, funded by the R61 mechanism, will provide funding for up to two years to investigate the biological, neurological, physiological, and/or mechanisms or behavioral processes underlying a Mind and Body Intervention (e.g., meditation, spinal manipulation, massage, yoga, tai chi, hypnosis, or acupuncture). The second phase, funded under the R33 mechanism, will provide up to three years of support to: (1) optimize the mechanisms or processes identified in the R61 phase through further modifications to the intervention, (2) study the integration of approaches that

Synopsis may affect the same underlying mechanisms or processes, or (3) further study the relationship between the intervention and the underlying mechanism of action with a relevant target population. This second R33 phase should also aim to provide preliminary evidence that the mechanisms or processes modulated by the interventions are associated with functional outcomes or clinical benefits for specific conditions or disorders. Subject to the availability of funds, transition from the R61 to the R33 phase of the award will be administratively reviewed and will be determined by successful completion of "Go/No-Go Criteria" that need to be clearly specified in the R61 phase application. This FOA is not appropriate for clinical trials with the primary objectives to determine efficacy or effectiveness of clinical outcomes. This FOA will use the NIH R61/R33 Phased Innovation Award mechanism.

**National Center for Complementary** NCCIH Mind and Body Clinical Trial Cooperative Agreement (U01 Clinical Trial PAR-18-Not 068460 31-May-2019 Required) and Integrative Health/NIH/DHHS 118 Specified

Contact Name Lanay Mudd, PhD

Contact Telephone 301-594-9346

Contact Email lanay.mudd@mail.nih.gov

**Sponsor Website** 

Program URL https://grants.nih.gov/grants/guide/pa-files/PAR-18-118.html

Deadline Dates (ALL) 31-May-2019, 28-Jun-2019, 03-Oct-2019, 31-Oct-2019, 31-Jan-2020, 28-Feb-2020

National Center for Complementary and Integrative Health (NCCIH) invites cooperative agreement applications for investigator-initiated clinical trials of mind and body interventions in NCCIH-designated areas of high research priority. Synopsis Applications submitted under this FOA are expected to propose a clinical trial to develop and test adaptive interventions; optimize the intervention by evaluating which element of a complex intervention are critical for changes in outcome; assessing whether the intervention can be delivered with fidelity across sites in preparation for a future multi-site trial; or

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		multi-site trial. It is important, therefore feasibility of recruitment and accrual of pretention of participants throughout the that the intervention has promise of clin	is determining the duration or frequency of, to already have sufficient preliminary dat participants; demonstration of participant a study; completion of final data collection for the treatment of and body interventions for the treatment perative Agreements award mechanism.	a that incleadherence from any report mult	udes: demonstrati to the interventio elated studies; and i-site efficacy or e	on of on as well as d evidence offectiveness
068458		c Studies to Optimize Mind and Body ity Research Topics (R33 Clinical Trial	National Center for Complementary and Integrative Health/NIH/DHHS	PAR-18- 115	31-May-2019	1,500,000 USD
	Contact Name	Wen G. Chen, PhD				
	Contact Telephone	301-451-3989				
	Contact Email	chenw@mail.nih.gov				
	Sponsor Website					
	Program URL	https://grants.nih.gov/grants/guide/pa-f	iles/PAR-18-115.html			
	Deadline Dates (ALL)	31-May-2019 , 28-Jun-2019				
	National Center for Complementary and Integrative Health (NCCIH) invites applications additional research to optimi biological, neurological, physiological mechanisms or behavioral processes underlying Mind and Body Interventions. Applications submitted under this FOA, using the R33 funding mechanism, can receive up to three year support to: (1) optimize previously identified mechanisms or processes underlying a Mind and Body Intervention thro further modifications to the interventions, (2) study the integration of approaches that may affect the same underlying mechanisms or processes, or (3) further study the relationship between the intervention and the underlying mechanism action with a relevant target population. Applicants should also aim to provide preliminary evidence that the mechan processes modulated by the intervention are associated with functional outcome or clinical benefit for specific conditi disorders. This FOA is not appropriate for clinical trials with the primary objectives to determine efficacy or effectiveness. This FOA will use the NIH R33 Exploratory/Developmental Phased Award mechanism.					
IINGGIG	Feasibility Clinical Trials of Mind a Priority Research Topics (R34 Clin	ind Body Interventions for NCCIH High ical Trial Required)	National Center for Complementary and Integrative Health/NIH/DHHS	PAR-18- 417	07-May-2019	450,000 USD
	Contact Name	Lanay M. Mudd, Ph.D.				



Contact Telephone 301-594-9346

Contact Email <u>lanay.mudd@nih.gov</u>

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	-------------------

Sponsor Website

Program URL https://grants.nih.gov/grants/guide/pa-files/PAR-18-417.html

Deadline Dates (ALL)

07-May-2019, 16-Jun-2019, 07-Sep-2019, 16-Oct-2019, 07-Jan-2020, 16-Feb-2020, 07-May-2020, 16-Jun-2020, 07-Sep-2020

National Center for Complementary and Integrative Health (NCCIH) invites applications for early phase clinical trials of mind and body approaches for conditions that have been identified by NCCIH as high priority research topics. This funding opportunity is intended to support feasibility clinical trials, which will provide data that are critical for the planning and design of a subsequent controlled cohort study, clinical efficacy or effectiveness study, or a pragmatic trial. The data collected should be used to fill gaps in scientific knowledge necessary to develop a competitive full-scale clinical trial, including, but not limited Synopsis to the following: adapting an intervention to a specific population; refining the intervention to determine the most appropriate frequency or duration; determining feasibility of recruitment, retention and data collection procedures; examining acceptability of the intervention and control conditions. This FOA will not support randomized clinical trials to test or determine efficacy or effectiveness. Applications that propose solely to write a protocol or manual of operations or to develop infrastructure for a clinical trial are not appropriate for this announcement. The subsequent larger trial should have the potential to make a significant impact on public health. This FOA will use the NIH R34 Planning Grant award mechanism.

Clinical Coordinating Center for NCCIH Multi-Site Investigator-Initiated Clinical 072236 Trials of Mind and Body Interventions (Collaborative UG3/UH3 Clinical Trial Required)

National Center for Complementary and Integrative Health/NIH/DHHS

PAR-18-662

31-May-2019

Not Specified

Contact Name Robin Boineau, M.D., M.A.

Contact Telephone 301-435-6286

Contact Email Robin.Boineau@nih.gov

**Sponsor Website** 

Program URL https://grants.nih.gov/grants/guide/pa-files/PAR-18-662.html

Deadline Dates (ALL) 31-May-2019, 28-Jun-2019, 31-Jan-2020, 28-Feb-2020

National Center for Complementary and Integrative Health (NCCIH) invites applications for investigator-initiated multi-site clinical trials (e.g. efficacy, effectiveness or pragmatic trials) to study the effects of mind and body interventions in NCCIH designated areas of high research priority. Clinical Coordinating Centers should develop and implement the proposed multisite clinical trial. The objective of a Clinical Coordinating Center application is to present the scientific rationale and a comprehensive scientific and operational plan for the clinical trial. Clinical Coordinating Center applications are expected to describe plans for project management, participant recruitment and retention strategies, performance milestones, scientific conduct, and dissemination of results. Clinical Coordinating Center applications submitted under this FOA will utilize a two-

phase, milestone-driven cooperative agreement (UG3/UH3) funding mechanism. In addition, an accompanying Data

SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	clinical project is required. Both a Clinical (DCC) application need to be submitted s mission, strategic vision, and research pri	ed under PAR-18-663 proposing a data and Coordinating Center application and a cordinating Center application by NCCIH. For ities of the NCCIH, applicants are encousts FOA will use the NIH UG3/UH3 Exploratom.	respondin For addit aged to co	g Data Coordinati ional information onsult the NCCIH v	ng Center about the website:
072237 Mind and Body Intervention Mul (Collaborative U24 Clinical Trial F	ti-Site Clinical Trial Data Coordinating Cent Required)	er National Center for Complementary and Integrative Health/NIH/DHHS	PAR-18- 663	31-May-2019	Not Specified
Contact Telephone	Robin.Boineau@nih.gov				
•	https://grants.nih.gov/grants/guide/pa-fi				
Deadline Dates (ALL	) 31-May-2019 , 28-Jun-2019 , 31-Jan-2020				
Synopsi	Coordinating Center (DCC) application the application submitted under PAR-18-662 Center (CCC) application. The objective or project coordination, and administrative, DCC application and a corresponding CCC for which this FOA applies must be relevant center. For additional information about encouraged to consult the NCCIH website the Scientific/Research contact for the arms.	Integrative Health (NCCIH) invites applica at accompanies an investigator-initiated m The DCC application must be specific to th f the DCC application is to propose a comp data management, and biostatistical supp capplication need to be submitted simulta ant to the research mission of the NCCIH are the mission, strategic vision, and research e: (http://www.nccih.nih.gov). Applicants a ea of science for which they are planning to the NIH U24 Resource-Related Research Po	ulti-site cle collabor rehensive ort for the neously for donside priorities are encour o develop	inical trial (Phase rating Clinical Coor plan that provide proposed clinical r consideration by the NCCIH, appaged to contact than application pri	Ill and beyond) rdinating s overall I trial. Both a y NCCIH. Trials y by the licants are ne appropriate ior to
	SA Programs for Scholars Pursuing  Career Development (Admin Supp Clinical	National Center for Complementary and Integrative Health/NIH/DHHS	PA-18- 920	07-May-2019	Not Specified
Contact Name Contact Telephone	Lanay M. Mudd, Ph.D. = 301-594-9346				

Contact Email <u>lanay.mudd@nih.gov</u>

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount			
	Sponsor Website							
	Program URL	https://grants.nih.gov/grants/guide/pa-f	<u>iles/PA-18-920.html</u>					
	Deadline Dates (ALL)	07-May-2019 , 05-Jun-2019 , 07-Sep-2019 2020 , 05-Oct-2020 , 07-Jan-2021 , 05-Fel	May-2019 , 05-Jun-2019 , 07-Sep-2019 , 05-Oct-2019 , 07-Jan-2020 , 05-Feb-2020 , 07-May-2020 , 05-Jun-2020 , 07-Sep 0 , 05-Oct-2020 , 07-Jan-2021 , 05-Feb-2021 , 07-May-2021 , 05-Jun-2021 , 07-Sep-2021					
	Synopsis	National Center for Complementary and Sciences (NCATS) invite applications for A Sciences (NCATS) supported Clinical and clinician-scientist investigators with compresearch on complementary intervention (FOA) solicits applications for administrate	Integrative Health (NCCIH) and National Ce Administrative Supplement to the National C Translational Science Awards (CTSA) prograr plementary and integrative health degrees c as for NCCIH high-priority research topics. Th tive supplements from awardees of the NCA by NCCIH. This FOA will use the NIH Adminis	enter for Advancing Translatenter for Advancing Trans Tenter for Advancing Trans In is to develop a pipeline of Conducting clinical and/or the Inis funding opportunity and IS supported CTSA progra	lational of qualified cranslational nouncement ms. Funding			
078917		nized Controlled Trial of Acupuncture for Repain in Older Adults (UG3/UH3 Clinical T	rial	RFA-AT- 19-005 07-May-2019	Not Specified			
	Contact Name	Robin Boineau, M.D., M.A.						
	Contact Telephone	301-435-6286						
	Contact Email	robin.boineau@nih.gov						
	Sponsor Website							
	Program URL	https://grants.nih.gov/grants/guide/rfa-f	files/RFA-AT-19-005.html					
	Deadline Dates (ALL)	07-May-2019 , 05-Jun-2019 , 07-Sep-2019 2020 , 05-Oct-2020 , 07-Jan-2021 , 05-Fel	9 , 05-Oct-2019 , 07-Jan-2020 , 05-Feb-2020 b-2021 , 07-May-2021 , 05-Jun-2021 , 07-Sep	, 07-May-2020 , 05-Jun-20 o-2021 , 05-Oct-2021 , 07	020 , 07-Sep- Jan-2022			
	Synopsis	This Funding Opportunity Announcement an efficient, large-scale pragmatic trial to older adults (65 years and older) with chreembedded into health care delivery system year milestone-driven planning phase (Unhave met the scientific milestone and feat application must be submitted as a single conducted across two or more health care Collaboratory, which is supported throug NIH HCS Research Collaboratory Program	t (FOA) encourages UG3/UH3 phased coope of evaluate the impact of, and strategies to be pronic low back pain. This FOA requires that the em, "real world" settings. Awards made und G3), with possible transition to an implement as ibility requirements may transition to the the application, following the instructions descrete systems (HCS) and will become part of another the NIH Common Fund (See https://common has established a Collaboratory Coordinating spects of research with HCS. After awards a	rative research application est implement, acupuncture the intervention under studer this FOA will initially sustation phase (UH3). UG3 phree-year UH3 phase. The ribed in this FOA. Trials mid work with the NIH HCS Reportund.nih.gov/hcscollabing Center (CCC) that is pro	ns to conduct re treatment of dy be pport a one- projects that UG3/UH3 ust be esearch oratory). The			

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount		
		(http://rethinkingclinicaltrials.org/about-nthe planning and rapid execution of high in systems.	• • •					
080324	Mechanisms Underlying the Cont Clinical Trial Optional)	ribution of Sleep Disturbances to Pain (R21	National Center for Complementary and Integrative Health/NIH/DHHS	PA-19- 201	16-Jun-2019	275,000 USD		
	Contact Name	Inna Belfer, M.D., Ph.D.						
	Contact Telephone	301-435-1573						
	Contact Email	inna.belfer@nih.gov						
	Sponsor Website							
	Program URL	https://grants.nih.gov/grants/guide/pa-file	es/PA-19-201.html					
	Deadline Dates (ALL)	16-Jun-2019, 16-Oct-2019, 05-Feb-2020, 16-Jun-2020, 16-Oct-2020, 16-Feb-2021, 16-Jun-2021, 16-Oct-2021, 16-Feb-2022						
	Synopsis	The purpose of this FOA is to encourage m mechanisms and processes underlying the development and maintenance of chronic collaborations by experts from multiple fie pharmacologists, chemists, physicists, beh Applications proposing to study the impacunder this FOA.	contribution of sleep and sleep disturbar pain may be very broad. This FOA encour elds—neuroscientists, psychologists, endo avioral scientists, clinicians, caregivers, ar	nces to pai ages inter crinologis nd others i	n perception and disciplinary resea ts, immunologists n relevant fields o	the rch , geneticists, of inquiry.		
080314		ribution of Sleep Disturbances to Pain (R01	National Center for Complementary	PA-19-	05-Jun-2019	Not		
	Clinical Trial Optional)		and Integrative Health/NIH/DHHS	200	05 3411 2015	Specified		
	Contact Name	Inna Belfer, M.D., Ph.D.						
	Contact Telephone	301-435-1573						
	Contact Emai	inna.belfer@nih.gov						
	Sponsor Website							
	Program URL	https://grants.nih.gov/grants/guide/pa-file	es/PA-19-200.html					
	Deadline Dates (ALL)	05-Jun-2019 , 05-Oct-2019 , 05-Feb-2020 , 2022	05-Jun-2020 , 05-Oct-2020 , 05-Feb-2021	, 05-Jun-2	2021 , 05-Oct-202	1 , 05-Feb-		
	Synopsis	The purpose of this FOA is to encourage mechanisms and processes underlying the development and maintenance of chronic	contribution of sleep and sleep disturbar	nces to pai	n perception and	the		

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		pharmacologists, chemists, physicists, b	fields—neuroscientists, psychologists, end ehavioral scientists, clinicians, caregivers, a pact of pain on sleep will be considered low	and others i	n relevant fields o	of inquiry.
U/U/nX	luman Subjects Mechanistic and Optional)	Minimal Risk Studies (R21 Clinical Trial	National Eye Institute/NIH/DHHS	PA-18- 500	07-May-2019	275,000 USD
	Contact Name	Ellen Liberman, Ph.D.				
	Contact Telephone	301-451-2020				
	Contact Email					
	Sponsor Website					
	Program URL	https://grants.nih.gov/grants/guide/pa-	-files/PA-18-500.html			
	Deadline Dates (ALL)	o7-May-2019 , 16-Jun-2019 , 07-Sep-2019 , 16-Oct-2019 , 07-Jan-2020 , 16-Feb-2020 , 07-May-2020 , 2020 , 16-Oct-2020 , 07-Jan-2021				
	Synopsis	supported may be either: those that inv those that are NIH-defined clinical trials	ications that seek to conduct studies of the volve human subjects, but are not NIH-definer and are designed to address either: 1) me tail procedures with minimal risk to subject mechanism.	ned clinical chanisms u	trials (see NOT-OI nderlying human v	D-15-015); or vision in healtl
11/3/94	IEI Institutional Mentored Physic Optional)	cian Scientist Award (K12 Clinical Trial	National Eye Institute/NIH/DHHS	PAR-18- 726	11-Jun-2019	Not Specified
	Contact Name	Neeraj Agarwal, Ph.D., Training Director	-			
	Contact Telephone	301-451-2020				
	Contact Email	agarwalnee@nei.nih.gov				
	Sponsor Website					
	Program URL	https://grants.nih.gov/grants/guide/pa-	-files/PAR-18-726.html			
	Deadline Dates (ALL)	11-Jun-2019 , 11-Jun-2020				
	Synopsis	career development programs which pr initiative is intended to expand and stre in the number of well-trained clinical re	cations from institutions to propose creatine repare clinically-trained vision scientists for another the community of investigators engagers. Searchers is necessary to achieve a pool of age recent advances in ocular genetics, the	independe gaged in cli scientists v	nt research caree nical research. Su vith contemporary	rs. This ch an increase /,

	SPIN ID	Program	Sponsor Name	Sponsor Number	Deadline Date	Funding
•	SPIN ID	Title	Sponsor Name	Sponsor Number	Deadine Date	Amount

behavioral research in order to enhance patient treatment and to increase scientific momentum in these fields. This Funding Opportunity Announcement (FOA) allows appointment of Scholars proposing a separate ancillary study to an existing trial or proposing to gain research experience in a clinical trial led by another investigator, as part of their research and career development. The existing clinical trial must be a NIH-defined clinical trial that fulfills the NIH requirement for either a mechanistic or minimal risk trial. A mechanistic trial is designed to understand a biological or behavioral process, the pathophysiology of a disease, or the mechanism of action of an intervention. A minimal risk trial is one in which the probability and magnitude of harm or discomfort anticipated in the research are not greater in and of themselves than those ordinarily encountered in daily life or during the performance of routine physical or psychological examinations or tests. A proposed research career development program that includes a clinical trial that is not a mechanistic trial and/or involves a level of risk beyond that defined as minimal, will not be supported. Applicants are strongly advised to consult with NEI program staff prior to submitting an application with human subjects to determine the appropriate funding opportunity. This FOA will utilize the Mentored Clinical Scientist Development Program Award (K12) grant mechanism.

081084

NEI Clinical Research Study Planning Grant Program (R34 Clinical Trial Not Allowed)

National Eye Institute/NIH/DHHS

PAR-19-231

16-Jun-2019

300,000 USD

Contact Name Donald Everett, MA

Contact Telephone 301-451-2020

Contact Email everettd@mail.nih.gov

Sponsor Website

Program URL https://grants.nih.gov/grants/guide/pa-files/PAR-19-231.html

16-Jun-2019, 07-Sep-2019, 16-Oct-2019, 07-Jan-2020, 16-Feb-2020, 07-May-2020, 16-Jun-2020, 07-Sep-2020, 16-Oct-Deadline Dates (ALL) 2020, 07-Jan-2021, 16-Feb-2021, 07-May-2021, 16-Jun-2021, 07-Sep-2021, 05-Oct-2021, 07-Jan-2022, 16-Feb-2022, 07-May-2022

The National Eye Institute (NEI) supports large-scale clinical vision research projects, including randomized clinical trials and epidemiologic studies. At the time of submission, applications requesting support for these activities are expected to provide

detailed information regarding the study rationale, design, analytic techniques, protocols and procedures, facilities and environment, organizational structure, and collaborative arrangements. This information is best conveyed in a welldocumented Manual of Procedures (MOP), the development of which represents a costly and time-consuming activity. This FOA is designed to facilitate activities central to the refinement of a study protocol and procedures and the development of a detailed MOP. The NEI Clinical Study Planning Grant may be used to support the development of a MOP, as well as to conduct preliminary studies to refine study procedures or document recruitment potential. The grant must not be used to generate data on the effects of a proposed intervention. This NEI FOA is applicable to both epidemiologic and clinical trial research studies.

055175 Data Coordinating Center for Multi-Site Investigator-Initiated Clinical Trials

National Heart, Lung, and Blood

PAR-16-

13-May-2019

Not

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	(Collaborative U24)		Institute/NIH/DHHS	301		Specified
	<u></u>	Pablo Cure, MD, MPH	· ·			<u>'</u>
	Contact Telephone					
	·	pablo.cure@nih.gov				
	Sponsor Website					
	•	http://grants.nih.gov/grants/guide,	/pa-files/PAR-16-301.html			
	-	13-May-2019 , 13-Jun-2019 , 13-Se				
		proposed in the collaborating Clinic comprehensive plan to provide ove the proposed clinical trial. Both a D application due date for considerat contact for the area of science for will use the NIH U24 Resource-Rela	SPIN Program # 55178). The DCC application cal Coordinating Center (CCC). The object crall project coordination, administration DCC application and a collaborating CCC action by NHLBI. Applicants are encouraged which they are planning to develop an apated Research Projects — Cooperative Agreements of the	tive of the DCC app n, data managemen application must be d to contact the app oplication prior to seements award man	elication is to present, and biostatistic submitted on the propriate Scientifi ubmitting to this lechanism.	ent a al support for same c/Research
067943	Single-Site Investigator-Initiated C	Clinical Trials (R61/R33 Clinical Trial F	Required) Institute/NIH/DHHS	406	13-May-2019	Specified
	Contact Name	Pablo Cure, MD, MPH				
	Contact Telephone	301-435-0065				
	Contact Email	xxxx@mail.nih.gov				
	Sponsor Website					
	Program URL	https://grants.nih.gov/grants/guide	e/pa-files/PAR-18-406.html			
	Deadline Dates (ALL)	13-May-2019 , 13-Jun-2019 , 13-Se	p-2019			
	Synopsis	investigator-initiated single-site clir mission of the NHLBI and meet the mission, strategic vision, and resea	nstitute (NHLBI) invites applications to de nical trials. Applications submitted in res NIH definition of a clinical trial (see NOT rch priorities of the NHLBI, applicants and A will utilize a bi-phasic, milestone-drive	ponse to this FOA r -OD-15-015). For a e encouraged to co	nust be relevant t dditional informa nsult the NHLBI w	o the researd tion about the ebsite:

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		describes the conduct of the trial, as milestones, scientific conduct of the not required. Applicants are encoura coordination. Due to the complex na appropriate Scientific/Research contains	c rationale for the clinical trial and a comprewell as plans for project management, subjectial, and dissemination of results. The multiped to include a PD/PI with expertise in biosture of conducting a clinical trial, applicants act prior to application submission. Staff will use the NIH R61/R33 Exploratory/Developments	ect recruitment ple PD/PI mo tatistics, clini are strongly e be able to as	nt and retention, del is strongly end cal trial design, an encouraged to con sist applicants in	performance couraged but nd ntact the meeting the
068019	Data Coordinating Center for Mul (Collaborative U24 Clinical Trial Re	lti-Site Investigator-Initiated Clinical Trequired)	ials National Heart, Lung, and Blood Institute/NIH/DHHS	PAR-18- 410	13-May-2019	Not Specified
	Contact Name	Pablo Cure, MD, MPH				
	Contact Telephone	301-435-0065				
	Contact Email	pablo.cure@nih.gov				
	Sponsor Website					
	Program URL	https://grants.nih.gov/grants/guide/	oa-files/PAR-18-410.html			
	Deadline Dates (ALL)	13-May-2019 , 13-Jun-2019 , 13-Sep-	2019			
	Synopsis	investigator-initiated multi-site clinic research mission of the NHLBI and m about the mission, strategic vision, as website. This FOA will utilize a coope encourages applications for a collabor for the clinical trial being proposed in application is to present a comprehenand biostatistical support for the prosubmitted on the same application diappropriate Scientific/Research contra	tute (NHLBI) invites applications for a collaboral trials (Phase II and beyond). Trials for whice et the definition of an NIH clinical trial (see not research priorities of the NHLBI, applicant rative agreement mechanism of award and rating Clinical Coordinating Center (PAR-18-the collaborating Clinical Coordinating Centers plan to provide overall project coordinative plan to provide overall project coordinate date for consideration by NHLBI. Application are the the area of science for which they are use the NIH U24 Resource-Related Research	ch this FOA ap NOT-OD-15- ts are encour runs in paralle 407). The DC ter (CCC). The ation, admining at a collaborants are encour	oplies must be reloption of the consult the longer of the longer of the stration, data matering CCC application application application application,	evant to the nal information ne NHLBI ion FOA that is be specific DCC nagement, tion must be the ation prior to
1167 /27	RFA-HL-18-020Integrative Comp TOPMed Data (R01)	outational Biology for Analysis of NHLE	National Heart, Lung, and Blood Institute/NIH/DHHS	RFA-HL- 18-020	07-May-2019	648,000 USD
	Contact Name	Rebecca Beer, Ph.D.				

Contact Telephone 301-594-0977

SPIN ID	Program Title	Sponsor Name	Sponsor Number	1	Daadlina Data	Funding Amount		
		rebecca.beer@nih.gov		·				
	Sponsor Website		SI					
	_		tps://grants.nih.gov/grants/guide/rfa-files/RFA-HL-18-020.html					
	Synopsis	07-May-2019, 05-Jun-2019, 07-Sep-2019, 05-Oct-2019, 07-Jan-2020, 05-Feb-2020, 07-May-2020  National Heart, Lung, and Blood Institute (NHLBI) invites applications for integrated analysis of whole genome, large scale "omic" data generated by the NHLBI's Trans-Omics for Precision Medicine (TOPMed) program and associated phenotype and clinical data using systems approaches. Ultimately, these studies will advance our understanding of the molecular underpinnings of heart, lung, blood, and sleep disease. This FOA will use the NIH Research Project (R01) award mechanism.						
074725		se IIB Small Market Awards to Accelerate es for Heart, Lung, Blood, and Sleep Disord otional)	Niational Heart Tiling and Ricog	RFA-HL- 19-018	09-Jun-2019 [LOI/Pre-App] [Optional]	3,000,000 USD		
	Contact Name	Gary Robinson, Ph.D.						
	Contact Telephone	301-496-2149						
	Contact Email	NHLBI_SBIR@mail.nih.gov						
	Sponsor Website							
	Program URL	https://grants.nih.gov/grants/guide/rfa-	files/RFA-HL-19-018.html					
	Deadline Dates (ALL)	09-Jun-2019 [LOI/Pre-App][Optional], 09	9-Jul-2019 , 09-Jun-2020 [LOI/Pre-App][Opt	ional], 09-Jι	ıl-2020			
	Synopsis	that are developing NHLBI mission-related this FOA is for these products to be furth support ends. Applicants must submit a submit a lithat has already been secured or is anticompleted third-party funding will be equal to or grapheriod. Projects proposed in response to address preclinical and/or clinical stages	e (NHLBI) invites applications to provide suped products that address a rare disease or yner validated so that development can cont Commercialization Plan that includes detailipated during the project period. It is expedienter than one-third of the NHLBI funds be of this FOA must require eventual Federal refore technology development. Clinical trials in HR44 Small Business Innovation Research (	young pedia inue with p Is on any ind cted that th ing request gulatory ap may be pro	ntric populations. rivate funding af dependent thirde level of this inded throughout the proval/clearance posed as appropu	The goal of ter NHLBI party funding lependent ne project , and may		
072487	NHLBI Early Phase Clinical Trials for Clinical Trial Required)	or Therapeutics and/or Diagnostics (R61/F	National Heart, Lung, and Blood Institute/NIH/DHHS	PAR-18- 683	04-Jun-2019	Not Specified		
	Contact Name	Traci Heath Mondoro, Ph.D.						

Contact Telephone 301-435-0065

Contact Email xxxx@mail.nih.gov

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Sponsor Website Program URL Deadline Dates (ALL) Nat diagr to su activ relate FOA	ional Heart, Lung, and Blood Instit nostic and therapeutic interventio pporting clinical trial start-up and ities needed for the implementati ed to the therapeutic/diagnostic in will utilize a bi-phasic, milestone-c	a-files/PAR-18-683.html  19, 07-Jan-2020, 04-Jun-2020, 07-Sep-2020  cute (NHLBI) invites applications for investiga ns for heart, lung, blood, and sleep (HLBS) dis implementation activities, this FOA will provon of the proposed trial. All the activities pro n preparation for the clinical trial. The propodriven mechanism of award where the first p g studies, and site training. This FOA will use	tor-initiated sorders in a ride support oposed in the sed trial ca hase can be	d, Phase I clinical dults and childre for final stage p ne R61 phase mu n be single or mu	1 trials for n. In addition reclinical st be directly ultisite. This
072627	RFA-HL-19-014 Stimulating T4 Implementation of Proven-effective Interverous Diseases and Sleep Disorders into Practallowed)	nentation Research to Optimize ntions for Heart, Lung, and Blood	National Heart, Lung, and Blood I Not Institute/NIH/DHHS	RFA-HL- 19-014	15-May-2019 [LOI/Pre-App] [Optional]	2,425,000 USD
	Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Nat strate	cca.roper@mail.nih.gov s://grants.nih.gov/grants/guide/rf lay-2019 [LOI/Pre-App][Optional], ional Heart, Lung, and Blood Instit egies to identify facilitators and ov	a-files/RFA-HL-19-014.html  14-Jun-2019 , 16-May-2020 [LOI/Pre-App][Coute (NHLBI) invites applications that propose vercome barriers in the adaptation, integration for preventing and/or managing heart, lung,	e to develop on, scale-up	and test T4 imp , and sustainabil	ity of proven-
11/3350	Synopsis (HLB: conte defin	S conditions). The proposed imple exts, and must account for culturated as research to identify strategicice. This FOA will use the NIH Research Award for Early Stage	mentation strategies must be adaptable and and organizational factors. For purposes of es to enhance sustainable uptake of provenearch Project (R01) award mechanism.  National Heart, Lung, and Blood Institute/NIH/DHHS	responsive this FOA, T	to community n 4 Implementatio	eeds and n Research is

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount		
	Contact Name	Henry Chang, MD						
	Contact Telephone	301-435-0050						
	Contact Email	changh@nhlbi.nih.gov						
	Sponsor Website							
	Program URL	https://grants.nih.gov/grants/guide/rfa-	files/RFA-HL-19-015.html					
	Deadline Dates (ALL)	05-May-2019 [LOI/Pre-App][Optional], 0	5-May-2019 [LOI/Pre-App][Optional], 04-Jun-2019 , 05-May-2020 [LOI/Pre-App][Optional], 04-Jun-2020					
National Heart, Lung, and Blood Institute (NHLBI) invites applications for the Physician-Scientist Research Award for Early Stage Investigators. The award is intended to support the independence of physician-scientist faculty committed to acaden careers in heart, lung, and blood diseases and sleep disorders (HLBS) research, and related implementation science. This FC will use the NIH Research Project (R01) award mechanism.								
074710		se IIB Bridge Awards to Accelerate the es for Heart, Lung, Blood, and Sleep Disord	National Heart, Lung, and Blood Institute/NIH/DHHS	RFA-HL- 19-017	09-Jun-2019 [LOI/Pre-App] [Optional]	3,000,000 USD		
	Contact Name	Gary Robinson, Ph.D.						
	Contact Telephone	301-496-2149						
	Contact Email	NHLBI_SBIR@mail.nih.gov						
	Sponsor Website							
	Program URL	https://grants.nih.gov/grants/guide/rfa-	files/RFA-HL-19-017.html					
	Deadline Dates (ALL)	. , , ,	-Jul-2019 , 09-Jun-2020 [LOI/Pre-App][Opt	=-				
	Synopsis	concerns (SBCs) to facilitate and accelerate projects to the commercialization stage investors and/or strategic partners. Applindependent third-party funding that has period. It is expected that the level of this being requested throughout the Phase II to the NHLBI mission and require eventuand/or clinical stages of technology deve	e (NHLBI) invites applications for SBIR Phase the the capital-intensive steps that are requesty promoting partnerships between SBIR/S icants must submit a Commercialization Plase already been secured or is anticipated dues independent third-party funding will be a B Bridge Award project period. Projects proal Federal regulatory approval/clearance. It is left the proposed a ss Innovation Research (SBIR) Grant - Phase	uired to train of the property of the property of the property of the proposed in reproposed proportion of the proposed proposed proposed proportion of the proposed	nsition SBIR/STTR II awardees and thould include de ase IIB Bridge Aw greater than the esponse to this Frojects may addre	t Phase II chird-party tails on any rard project NHLBI funds OA must rela ess preclinica		
11//4XX	NHLBI Early Phase Clinical Trials fo Clinical Trial Required)	or Therapeutics and/or Diagnostics (R33	National Heart, Lung, and Blood Institute/NIH/DHHS	PAR-18- 684	04-Jun-2019	4,545,00 USD		

Institute/NIH/DHHS

Contact Name   Traci Heath Mondoro, Ph.D.   Contact Telephone   301-435-0065   Contact Email   xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx	SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
Contact Telephone Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Deadline Dates (ALL) O4-Jun-2019, 07-Sep-2019, 02-Oct-2019, 07-Jan-2020, 04-Jun-2020, 07-Sep-2020, 02-Oct-2020, 07-Jan-2021 National Heart, Lung, and Blood Institute (NHLBI) invites applications for nvestigator-initiated, phase I clinical trials for diagnostic and therapeutic interventions for heart, lung, blood, and sleep (HLBS) disorders in adults and children. The proposed trial can be single or multisite. Applicants applying for funding under this FOA should be ready to initiate the clinical Synopsis trial within the first quarter of the project period. Discussion, submission, and attainment of applicable regulatory (FDA, DSMB, IRB) approvals, and establishment of drug (and placebe), if applicable) supplies, and any necessary third-party agreements should be established by the time of award. This FOA will use the NIH R33 Exploratory/Developmental Grants Phase II award mechanism.  National Heart, Lung, and Blood PA-19 Contact Name Contact Telephone Contact Telephone Contact Telephone To Synopsis Program URL Program URL Deadline Dates (ALL) Deadline Dates (ALL) Deadline Dates (ALL) Deadline Dates (ALL) Synopsis Program URL Contact Email revisability of the contact Email of the development of more effective means for diagnosing and treating heart, lung, blood, and sleep (HLBS) disorders is often aided by a detailed understanding of normal biology, specifically the nature and operations of the molecular systems and cells that are affected by those diseases. Areas of research interest include studies of fundamental processes that explain of the capability of some individuals to maintain or the restore normal function despite aging or exposure that causes of research interest include studies of fundamental processes that explain areas of research that advance high priority studies of normal biology and resilience as described by Objective 1 of the NHLBI strategic Vision.		Contact Name	Traci Heath Mondoro, Ph.D.				
Sponsor Website Program URL Deadline Dates (ALL) O4-Jun-2019, 07-Sep-2019, 02-Oct-2019, 07-Jan-2020, 04-Jun-2020, 07-Sep-2020, 02-Oct-2020, 07-Jan-2021 National Heart, Lung, and Blood Institute (NHLB) invites applications for nvestigator-initiated, phase I clinical trials for diagnostic and therapeutic interventions for heart, lung, blood, and sleep (HLBS) disorders in adults and children. The proposed trial can be single or multisite. Applicants applying for funding under this FOA should be ready to initiate the clinical Synopsis trial within the first quarter of the project period. Discussion, submission, and attainment of applicable regulatory (FDA, DSMB, IRB) approvals, and establishment of drug (and placebo, if applicable) supplies, and any necessary third-party agreements should be established by the time of award. This FOA will use the NIH R33 Exploratory/Developmental Grants Phase II award mechanism.  New Research Directions that Advance the NHLBI Strategic Vision Normal Biology (R21-Clinical Trial Not Allowed)  New Research Directions that Advance the NHLBI Strategic Vision Normal Institute/NIH/DHHS  Contact Telephone Contact Email ravi balijepalli, Ph.D.  Contact Telephone Contact Email ravi balijepalli, Ph.D.  Contact Email ravi balijepalli@nih.gov  Sponsor Website Program URL Deadline Dates (ALL)  The development of more effective means for diagnosing and treating heart, lung, blood, and sleep (HLBS) disorders is often aided by a detailed understanding of normal biology, specifically the nature and operations of the molecular systems and cells that are affected by those diseases. Areas of research interest include studies of fundamental processes that explain series in others. This Funding Opportunity Announcement (FOA) will support pilot studies by R01-funded investigators in areas of research that advance high priority studies of normal biology and resilience as described by Objective 1 of the NHLBI Strategic Vision.  National Heart, Lung, and Blood PAR-19- 074May-2019 450,000			,				
Sponsor Website Program URL Deadline Dates (ALL) National Heart, Lung, and Blood Institute (NHLB) invites applications for nvestigator-initiated, phase I clinical trials for diagnostic and therapeutic interventions for heart, lung, blood, and sleep (HLBS) disorders in adults and children. The proposed trial can be single or multisite. Applicants applying for funding under this FOA should be ready to initiate the clinical Synopsis Itial within the first quarter of the project period. Discussion, submission, and attainment of applicable regulatory (FDA, DSMB, IRB) approvals, and establishment of drug (and placebo, if applicable) supplies, and any necessary third-party agreements should be establishment of drug (and placebo, if applicable) supplies, and any necessary third-party agreements should be establishment of drug (and placebo, if applicable) supplies, and any necessary third-party agreements should be establishment of drug (and placebo, if applicable) supplies, and any necessary third-party agreements should be establishment of drug (and placebo, if applicable) supplies, and any necessary third-party agreements should be establishment of drug (and placebo, if applicable) supplies, and any necessary third-party agreements should be establishment of drug (and placebo, if applicable) supplies, and any necessary third-party agreements should be establishment of drug (and placebo, if applicable) supplies, and any necessary third-party agreements should be tead to the same of the same		·					
Deadline Dates (ALL)  O4-Jun-2019, 07-Sep-2019, 02-Oct-2019, 07-Jan-2020, 07-Sep-2020, 02-Oct-2020, 07-Jan-2021  National Heart, Lung, and Blood Institute (NHLBI) invites applications for nvestigator-initiated, phase I clinical trials for diagnostic and therapeutic interventions for heart, lung, blood, and sleep (HLBS) disorders in adults and children. The proposed trial can be single or multisite. Applicants applying for funding under this FOA should be ready to initiate the clinical specific proposed trial can be single or multisite. Applicants applying for funding under this FOA should be ready to initiate the clinical Synopsis trial within the first quarter of the project period. Discussion, submission, and attainment of applicable regulatory (FDA, DSMB, IRB) approvals, and established by the time of award. This FOA will use the NIH R33 Exploratory/Developmental Grants Phase II award mechanism.  O78369  New Research Directions that Advance the NHLBI Strategic Vision Normal Phase II award mechanism.  O78369  New Research Directions that Advance the NHLBI Strategic Vision Normal Institute/NIH/DHHS  Contact Name Contact Name Ravi Chandra Balijepalli, Ph.D.  Contact Telephone  O78369  Contact Telephone  O78369  Contact Email Phase (Pade Changra Balijepalli, Ph.D.  Deadline Dates (ALL)  16-Jun-2019, 16-Oct-2019, 16-Feb-2020, 16-Jun-2020, 16-Feb-2021, 16-Jun-2021, 16-Oct-2021  The development of more effective means for diagnosing and treating heart, lung, blood, and sleep (HLBS) disorders is often aided by a detailed understanding of normal biology, specifically the nature and operations of the molecular systems and cells that are affected by those diseases. Areas of research interest include studies of fundamental processes that explain Synopsis  "resilience" – the capability of some individuals to maintain or restore normal function despite aging or exposure that causes disease in others. This Funding Opportunity Announcement (FOA) will support pilot studies by R01-funded investigators in areas of research tha							
National Heart, Lung, and Blood Institute (NHLBI) invites applications for nvestigator-initiated, phase I clinical trials for diagnostic and therapeutic interventions for heart, lung, blood, and sleep (HLBS) disorders in adults and children. The proposed trial can be single or multisite. Applicants applying for funding under this FOA should be ready to initiate the clinical Synopsis trial within the first quarter of the project period. Discussion, submission, and attainment of applicable regulatory (FDA, DSMB, IRB) approvals, and establishment of drug (and placebo, if applicable) supplies, and any necessary third-party agreements should be established by the time of award. This FOA will use the NIH R33 Exploratory/Developmental Grants Phase II award mechanism.  Oracle I award mechanism.  National Heart, Lung, and Blood PA-19- 16-Jun-2019 275,000 USD  Contact Name Contact Telephone		•	https://grants.nih.gov/grants/guide/pa-i	files/PAR-18-684.html			
diagnostic and therapeutic interventions for heart, lung, blood, and sleep (HLBS) disorders in adults and children. The proposed trial can be single or multisite. Applicants applying for funding under this FOA should be ready to initiate the clinical trial within the first quarter of the project period. Discussion, submission, and attainment of applicable regulatory (FDA, DSMB, IRB) approvals, and establishment of drug (and placebo, if applicable) supplies, and any necessary third-party agreements should be established by the time of award. This FOA will use the NIH R33 Exploratory/Developmental Grants Phase II award mechanism.  National Heart, Lung, and Blood PA-19- 16-Jun-2019 275,000 USD  Contact Name Ravi Chandra Balijepalli, Ph.D.  Contact Telephone Contact Email Favi. balijepalli@nih.gov  Sponsor Website Program URL Deadline Dates (ALL) 16-Jun-2019, 16-Oct-2019, 16-Feb-2020, 16-Jun-2020, 16-Oct-2020, 16-Feb-2021, 16-Jun-2021, 16-Oct-2021  The development of more effective means for diagnosing and treating heart, lung, blood, and sleep (HLBS) disorders is often aided by a detailed understanding of normal biology, specifically the nature and operations of the molecular systems and cells that are affected by those diseases. Areas of research interest include studies of fundamental processes that explain "resilience" – the capability of some individuals to maintain or restore normal function despite aging or exposure that causes disease in others. This Funding Opportunity Announcement (FOA) will support pilot studies by R01-funded investigators in areas of research that advance high priority studies of normal biology and resilience as described by Objective 1 of the NHLBI Strategic Vision.  National Heart, Lung, and Blood PAR-19- 02-May-2019 450,000		Deadline Dates (ALL)	04-Jun-2019 , 07-Sep-2019 , 02-Oct-2019	ə , 07-Jan-2020 , 04-Jun-2020 , 07-Sep-202	0 , 02-Oct-2	020 , 07-Jan-2021	<u></u>
Contact Name Contact Telephone Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) The development of more effective means for diagnosing and treating heart, lung, blood, and sleep (HLBS) disorders is often aided by a detailed understanding of normal biology, specifically the nature and operations of the molecular systems and cells that are affected by those diseases. Areas of research interest include studies of fundamental processes that explain "resilience" – the capability of some individuals to maintain or restore normal function despite aging or exposure that causes disease in others. This Funding Opportunity Announcement (FOA) will support pilot studies by R01-funded investigators in areas of research that advance high priority studies of normal biology and resilience as described by Objective 1 of the NHLBI Strategic Vision.  National Heart, Lung, and Blood PAR-19- O7-Mays-2019  A50,000		Synopsis	proposed trial can be single or multisite. trial within the first quarter of the project DSMB, IRB) approvals, and establishmen agreements should be established by the	Applicants applying for funding under this t period. Discussion, submission, and attated to f drug (and placebo, if applicable) supp	s FOA should ainment of a lies, and any	d be ready to initi pplicable regulat necessary third-	ate the clinica ory (FDA, party
Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Deadline Dates (ALL)  Trial Pilot Studies (R24 Clinical Trial Pilot Studies (R24 Clinical Trial Policy In Table (R24 Clinical Trial Policy In Table (R24 Clinical Trial Policy In Table (R24 Clinical Trial Policy In In Table (R24 Clinical Trial Policy In In Table (R24 Clinical Trial Policy In In In Table (R24 Clinical Trial Policy In						16-Jun-2019	
Contact Email Sponsor Website Program URL Deadline Dates (ALL) Deadline Dates (ALL) The development of more effective means for diagnosing and treating heart, lung, blood, and sleep (HLBS) disorders is often aided by a detailed understanding of normal biology, specifically the nature and operations of the molecular systems and cells that are affected by those diseases. Areas of research interest include studies of fundamental processes that explain "resilience" – the capability of some individuals to maintain or restore normal function despite aging or exposure that causes disease in others. This Funding Opportunity Announcement (FOA) will support pilot studies by R01-funded investigators in areas of research that advance high priority studies of normal biology and resilience as described by Objective 1 of the NHLBI Strategic Vision.  National Heart, Lung, and Blood  PAR-19- 07-May-2019  450,000		Contact Name	Ravi Chandra Balijepalli, Ph.D.				
Sponsor Website Program URL Deadline Dates (ALL) The development of more effective means for diagnosing and treating heart, lung, blood, and sleep (HLBS) disorders is often aided by a detailed understanding of normal biology, specifically the nature and operations of the molecular systems and cells that are affected by those diseases. Areas of research interest include studies of fundamental processes that explain "resilience" – the capability of some individuals to maintain or restore normal function despite aging or exposure that causes disease in others. This Funding Opportunity Announcement (FOA) will support pilot studies by R01-funded investigators in areas of research that advance high priority studies of normal biology and resilience as described by Objective 1 of the NHLBI Strategic Vision.  National Heart, Lung, and Blood  PAR-19- O7-May/2019  450,000		Contact Telephone	301-435-0504				
Program URL Deadline Dates (ALL) 16-Jun-2019 , 16-Oct-2019 , 16-Feb-2020 , 16-Jun-2020 , 16-Oct-2020 , 16-Feb-2021 , 16-Jun-2021 , 16-Oct-2021 The development of more effective means for diagnosing and treating heart, lung, blood, and sleep (HLBS) disorders is often aided by a detailed understanding of normal biology, specifically the nature and operations of the molecular systems and cells that are affected by those diseases. Areas of research interest include studies of fundamental processes that explain "resilience" – the capability of some individuals to maintain or restore normal function despite aging or exposure that causes disease in others. This Funding Opportunity Announcement (FOA) will support pilot studies by R01-funded investigators in areas of research that advance high priority studies of normal biology and resilience as described by Objective 1 of the NHLBI Strategic Vision.  National Heart, Lung, and Blood  PAR-19- 07-May-2019 450,000		Contact Email	<u>ravi.balijepalli@nih.gov</u>				
Deadline Dates (ALL)  16-Jun-2019 , 16-Oct-2019 , 16-Feb-2020 , 16-Jun-2020 , 16-Oct-2020 , 16-Feb-2021 , 16-Jun-2021 , 16-Oct-2021  The development of more effective means for diagnosing and treating heart, lung, blood, and sleep (HLBS) disorders is often aided by a detailed understanding of normal biology, specifically the nature and operations of the molecular systems and cells that are affected by those diseases. Areas of research interest include studies of fundamental processes that explain "resilience" – the capability of some individuals to maintain or restore normal function despite aging or exposure that causes disease in others. This Funding Opportunity Announcement (FOA) will support pilot studies by R01-funded investigators in areas of research that advance high priority studies of normal biology and resilience as described by Objective 1 of the NHLBI Strategic Vision.  National Heart, Lung, and Blood  PAR-19-  O7-May-2019  450,000		Sponsor Website					
The development of more effective means for diagnosing and treating heart, lung, blood, and sleep (HLBS) disorders is often aided by a detailed understanding of normal biology, specifically the nature and operations of the molecular systems and cells that are affected by those diseases. Areas of research interest include studies of fundamental processes that explain "resilience" – the capability of some individuals to maintain or restore normal function despite aging or exposure that causes disease in others. This Funding Opportunity Announcement (FOA) will support pilot studies by R01-funded investigators in areas of research that advance high priority studies of normal biology and resilience as described by Objective 1 of the NHLBI Strategic Vision.  National Heart, Lung, and Blood  PAR-19-  O7-May-2019  450,000		Program URL	https://grants.nih.gov/grants/guide/pa-	files/PA-19-049.html			
aided by a detailed understanding of normal biology, specifically the nature and operations of the molecular systems and cells that are affected by those diseases. Areas of research interest include studies of fundamental processes that explain "resilience" – the capability of some individuals to maintain or restore normal function despite aging or exposure that causes disease in others. This Funding Opportunity Announcement (FOA) will support pilot studies by R01-funded investigators in areas of research that advance high priority studies of normal biology and resilience as described by Objective 1 of the NHLBI Strategic Vision.  National Heart, Lung, and Blood  PAR-19- 07-May-2019  450,000		Deadline Dates (ALL)	16-Jun-2019 , 16-Oct-2019 , 16-Feb-2020	) , 16-Jun-2020 , 16-Oct-2020 , 16-Feb-202	21 , 16-Jun-2	021 , 16-Oct-202	1
11/9353 NHTBL Clinical Trial Pilot Studies (R3/L Clinical Trial Cintional)		Synopsis	aided by a detailed understanding of not cells that are affected by those diseases. "resilience" – the capability of some indi disease in others. This Funding Opportur areas of research that advance high prio	mal biology, specifically the nature and op Areas of research interest include studies viduals to maintain or restore normal fund hity Announcement (FOA) will support pilo	perations of s of fundame ction despite ot studies by	the molecular syntal processes the aging or exposul R01-funded inve	stems and at explain re that causes stigators in
	079353 <u>I</u>	NHLBI Clinical Trial Pilot Studies (R	34 Clinical Trial Optional)	· · · · · · · · · · · · · · · · · · ·		07-May-2019	

SPIN ID Progra	Spons	sor Name Sponsor Nui	mber	Deadline Date	Funding Amount
----------------	-------	----------------------	------	---------------	-------------------

Contact Telephone 301-435-0504

Contact Email gweinmann@nih.gov

Sponsor Website desvignp@mail.nih.gov

Program URL https://grants.nih.gov/grants/guide/pa-files/PAR-19-155.html

Deadline Dates (ALL)

07-May-2019, 16-Jun-2019, 07-Sep-2019, 16-Oct-2019, 07-Jan-2020, 16-Feb-2020, 07-May-2020, 16-Jun-2020, 07-Sep-2020 , 16-Oct-2020 , 07-Jan-2021

This Funding Opportunity Announcement (FOA) is to support studies that are scientifically essential, yet also sufficient, for investigators to make definitive decisions that inform the final designs of important Phase II and beyond clinical trials within NHLBI's mission; that is, clinical trials with the primary intent of testing the efficacy, safety, clinical management, or implementation of intervention(s) in the prevention and treatment of heart, lung, blood, and sleep disorders. This mechanism may be used to test the feasibility of novel and efficient (pragmatic) trial designs, as well as determine the feasibility of an intervention, intervention parameters, subject availability, or other information essential to complete the design of a trial. Applications should demonstrate that the proposed studies are both necessary and sufficient to permit definitive decisions about the final design of the subsequent clinical trial. Applicants who propose solely to write a protocol or manual of operations, to develop infrastructure for a clinical trial, or implement a fully designed trial will not be considered appropriate for this announcement. Please note that NHLBI supports other funding opportunities for clinical trialssee https://www.nhlbi.nih.gov/grants-and-training/funding-opportunities-and-contacts/clinical-trials-optimization for information on other NHLBI clinical trial funding opportunity announcements. In contrast to the planning or study start up phase of other NHLBI clinical trial FOAs, the R34 mechanism is intended to provide new information that answers a scientific

question(s) which may be pragmatic in nature and, therefore, informs the final development of a Phase II-IV clinical trial.

Implementation of Shared Decision Making for HLBS Diseases and Conditions National Heart, Lung, and Blood (R01 Clinical Trial Optional)

Institute/NIH/DHHS

PA-19-166

05-Jun-2019

2,499,995 USD

Contact Name Susan T. Shero, BSN, MS

Contact Telephone 301-496-1051

Contact Email sheros@nih.gov

Sponsor Website

Program URL https://grants.nih.gov/grants/guide/pa-files/PA-19-166.html

05-Jun-2019, 07-Sep-2019, 05-Oct-2019, 07-Jan-2020, 05-Feb-2020, 07-May-2020, 05-Jun-2020, 07-Sep-2020, 05-Oct-Deadline Dates (ALL) 2020, 07-Jan-2021, 05-Feb-2021, 07-May-2021, 05-Jun-2021, 07-Sep-2021, 05-Oct-2021, 07-Jan-2022, 05-Feb-2022, 07-May-2022

The purpose of this initiative is to support research that uses evidence-based, practical approaches to increase the uptake of shared decision making (SDM) into routine clinical practice. Objectives are to improve patient-centered care for heart, lung,

079552

						e
SPIN ID	Program Title	Sponsor Name	ponsor Number		Deadline Date	Funding Amount
	Clinical Coordinating Contar for N	blood, and sleep (HLBS) diseases and cond improve quality of care, adherence, and in individual patients. Investigators and multi health information technology, behavioral are encouraged to apply.	formed consent; reduce health disparition disciplinary research teams with experti science, behavioral economics, workflow	es; and deliv se in clinica w design, ar	ver treatments be I implementation	est suited for research, engineering
067982	(Collaborative UG3/UH3 Clinical 1	<u> Multi-Site Investigator-Initiated Clinical Trials</u> <u>Trial Required)</u>	National Heart, Lung, and Blood Institute/NIH/DHHS	PAR-18- 407	13-May-2019	Not Specified
	Contact Telephone Contact Email	pablo.cure@nih.gov				
	Sponsor Website		-/DAD 40 407 html			
	_	https://grants.nih.gov/grants/guide/pa-file 13-May-2019, 13-Jun-2019, 13-Sep-2019	<u> </u>			
		National Heart, Lung, and Blood Institute (Center for investigator-initiated multi-site relevant to the research mission of the NH additional information about the mission, sconsult the NHLBI website: http://www.nhagreement mechanism of award and runs Data Coordinating Center (PAR-18-410). The scientific rationale for the clinical trial and should include plans for project management of the trial, and dissemination of results. Be Coordinating Center (DCC) application must Applicants are strongly encouraged to continuity the NIH UG3/UH3 Explorates.	clinical trials (Phase II and beyond). Trial LBI and meet the NIH definition of a clinistrategic vision, and research priorities of Ibi.nih.gov. This FOA will utilize a bi-phase in parallel with a companion FOA that end e objective of the Clinical Coordinating of a comprehensive scientific and operation, subject recruitment and retention, poth a Clinical Coordinating Center (CCC) to be submitted on the same application fact the appropriate Scientific/Research	s for which cal trial (see f the NHLBI sic, mileston accourages a Center application due date focontact price	this FOA applies re NOT-OD-15-015, applicants are ene-driven cooperapplications for a cation is to present describes it. The emilestones, scies and a collaboration bor to submitting a	must be  i). For  ncouraged to  ative  collaborating  ent the  application  ntific conduct  ng Data  y NHLBI.  n application.
081248	RFA-HL-20-014 Rare Disease Co Disorders (UG3/UH3 Clinical Trial	horts in Heart, Lung, Blood and Sleep Not Allowed)	National Heart, Lung, and Blood Institute/NIH/DHHS	RFA-HL- 20-014	19-May-2019 [LOI/Pre-App] [Optional]	3,977,000 USD
	Contact Name Contact Telephone	Andrei Kindzelski, MD, PhD 301-435-0050				

Contact Email <u>kindzelskial@nhlbi.nih.gov</u>

SPIN ID	Program	Sponsor Name	Sponsor Number	Deadline Date	Funding
SPIN ID	Title	Sponsor Name	Sponsor Number	Deadine Date	Amount

Sponsor Website

Program URL https://grants.nih.gov/grants/guide/rfa-files/RFA-HL-20-014.html

Deadline Dates (ALL) 19-May-2019 [LOI/Pre-App][Optional], 18-Jun-2019, 18-May-2020 [LOI/Pre-App][Optional], 17-Jun-2020

The purpose of this FOA is to fund research centers that will establish longitudinal cohorts in rare HLBS diseases to investigate unaddressed research questions using epidemiologic study designs and methods that are appropriate for conditions affecting fewer than 200,000 persons in the US. These observational cohort studies should be designed to provide an evidence base for future interventional studies, including clinical trials; for developing better diagnostics than those that are currently available; for answering early translational questions; or for broader implementation of guidelines for managing these diseases. This program will provide opportunities to advance rare disease research using genetics and deep phenotyping to characterize the disease and to identify disease sub-types; to use data science methods that integrate clinical and patientreported outcomes with laboratory, imaging, environmental and -omics data to understand the natural history of disease; to Synopsis generate data that differentiate patients with the same morphological phenotype but different genetic mutations and severity of outcomes; to elucidate genotype-phenotype interactions and multisystem phenotyping to develop reliable and valid predictive tools to determine who will respond to which treatments and when to intervene; and to encourage innovative methods such as telemedicine to include participants with rare diseases located in remote locations. This initiative will allow applicants to study rare or related rare diseases, disorders, conditions or syndromes together based on pathogenesis, affected biochemical, cellular or physiological features or organ system involvement. Studying related rare diseases within the same cohort could help understand the nuances, and knowledge gained from one disease could accelerate the advances in related diseases. For example, investigators may propose to study hemoglobin disorders rather

Ethical, Legal, and Social Implications (ELSI) of Genomics 065308 Exploratory/Developmental Research Grant Program (R21)

275,000 National Human Genome Research PA-17-07-May-2019 Institute/NIH/DHHS 446 USD

Contact Name Joy Boyer

Contact Telephone 301-402-4997

Contact Email boyerj@mail.nih.gov

Sponsor Website

Program URL https://grants.nih.gov/grants/guide/pa-files/PA-17-446.html

than only sickle cell anemia or thalassemia.

Deadline Dates (ALL)

07-May-2019, 16-Jun-2019, 07-Sep-2019, 16-Oct-2019, 07-Jan-2020, 16-Feb-2020, 07-May-2020, 16-Jun-2020, 07-Sep-2020

National Institutes of Health (NIH) and its participating Institutes and Centers invite applications that propose to study the Synopsis ethical, legal and social implications (ELSI) of human genome research. These applications should propose single or mixed methods studies that break new ground, extend previous discoveries in new directions or develop preliminary data in

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		1	articular interest are studies that explore the im nic information. This program will use the NIH R	•	•	~ ~
165277	Ethical, Legal, and Social Implicat Exploratory/Developmental Rese		National Human Genome Research Institute/NIH/DHHS	PA-17- 445	07-May-2019	100,000 USD
	Contact Name	Joy Boyer				
	Contact Telephone	301-402-4997				
	Contact Emai	l <u>boyerj@mail.nih.gov</u>				
	Sponsor Website					
	Program URI	https://grants.nih.gov/grants/guide/	/pa-files/PA-17-445.html			
	Deadline Dates (ALL)	07-May-2019 , 16-Jun-2019 , 07-Sep 2020	-2019 , 16-Oct-2019 , 07-Jan-2020 , 16-Feb-202	.0 , 07-May	-2020 , 16-Jun-20	20 , 07-Sep-
	Synopsis	social implications (ELSI) of human g projects, such as those that involve s conceptual analyses, including focus emerging issues. This mechanism ca	nd its participating Institutes and Centers invite genome research. These applications should be single investigators. Of particular interest are posed legal, economic, philosophical, anthropolog an also be used for the collection of preliminary the NIH R03 Small Grant Program award mecha	for small, sorojects that ical, or history data and the	elf-contained rest propose norma prical analyses of	search tive or new or
)73379 <u>I</u>	Investigator-Initiated Genomic M	ledicine Research (R21 Clinical Trial Op	ptional) National Human Genome Research Institute/NIH/DHHS	PAR-18- 736	20-Jun-2019	275,000
						USD
	Contact Name	Christine Chang				USD
	Contact Name Contact Telephone					USD
	Contact Telephone					USD
	Contact Telephone	301-480-2255 christine.chang2@nih.gov				USD
	Contact Telephone Contact Emai Sponsor Website	301-480-2255 christine.chang2@nih.gov	/pa-files/PAR-18-736.html			USD
	Contact Telephone Contact Emai Sponsor Website Program URI	301-480-2255 christine.chang2@nih.gov https://grants.nih.gov/grants/guide/	<del>/pa-files/PAR-18-736.html</del> 2019 , 22-Jan-2020 , 19-Jun-2020 , 21-Sep-2020	) , 20-Oct-2(	020 , 22-Jan-202	
	Contact Telephone Contact Emai Sponsor Website Program URI Deadline Dates (ALL)	https://grants.nih.gov/grants/guide/ 20-Jun-2019, 23-Sep-2019, 21-Oct-Xof, and the implementation of, the u		rch that wil to inform c	l advance our un linical care, and t	L derstanding he health

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
			Institute/NIH/DHHS	735	USD
	Contact Name	Christine Chang			
	Contact Telephone	301-480-2255			
	Contact Email	christine.chang2@nih.gov			
	Sponsor Website				
	Program URL	https://grants.nih.gov/grants/guide/p	a-files/PAR-18-735.html		
	Deadline Dates (ALL)	20-Jun-2019 , 23-Sep-2019 , 21-Oct-20	019 , 22-Jan-2020 , 19-Jun-2020 , 21-Sep-2020	0 , 20-Oct-2020 , 22-Jan-20	21
	Synopsis	of, and the implementation of, the use	nstitute (NHGRI) invites applications for resea e of genomic information about an individual A will use the NIH Research Project (R01) awa	to inform clinical care, and	_
IIhh Jux	thical, Legal, and Social Implication	ons (ELSI) of Genomics Research Projec	National Human Genome Research Institute/NIH/DHHS	PA-17- 444 07-May-2019	Not Specified
	Contact Name	Joy Boyer			
	Contact Telephone	301-402-4997			
	Contact Email	boyerj@mail.nih.gov			
	Sponsor Website				
	Program URL	https://grants.nih.gov/grants/guide/p	a-files/PA-17-444.html		
	Deadline Dates (ALL)	07-May-2019 , 05-Jun-2019 , 07-Sep-2 2020	2019 , 05-Oct-2019 , 07-Jan-2020 , 05-Feb-202	20 , 07-May-2020 , 05-Jun-2	.020 , 07-Sep-
	Synopsis	ethical, legal and social implications (E or mixed methods. Proposed approac approaches, legal, economic and norm	It its participating Institutes and Centers invited (ELSI) of human genome research. Applications thes may include but are not limited to data-grative analyses, and other types of analytical agement of stakeholders. This program will us	s may propose studies usin generating qualitative and o and conceptual research m	g either single quantitative nethodologies,
0.76/11.7	Novel Approaches for Relating Ge Clinical Trial Not Allowed)	netic Variation to Function and Disease	e (R21 National Human Genome Research Institute/NIH/DHHS	PA-18- 867 16-Jun-2019	275,000 USD
	Contact Name	Lisa D. Brooks, Ph.D.			
	Contact Telephone	301-547-1387			

Contact Email <u>Lisa.Brooks@nih.gov</u>

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount		
	Sponsor Website							
	Program URL	https://grants.nih.gov/grants/guide/pa-file	es/PA-18-867.html					
	Deadline Dates (ALL)	16-Jun-2019 , 16-Oct-2019 , 16-Feb-2020 , 16-Jun-2020 , 16-Oct-2020 , 16-Feb-2021 , 16-Jun-2021						
	Synopsis	National Human Genome Research Institu approaches to study how genetic variants human health and disease processes or ho Exploratory/Developmental Research Gran	lead to differences in function and to stu w this knowledge can be used clinically.	idy how suc	ch functional diffe	erences affect		
11/15/115	Novel Approaches for Relating Ge Clinical Trial Not Allowed)	enetic Variation to Function and Disease (RO	1 National Human Genome Research Institute/NIH/DHHS	PA-18- 868	05-Jun-2019	Not Specified		
	Contact Name	Lisa D. Brooks, Ph.D.						
	Contact Telephone	301-547-1387						
	Contact Email	<u>Lisa.Brooks@nih.gov</u>						
	Sponsor Website							
	Program URL	https://grants.nih.gov/grants/guide/pa-files/PA-18-868.html						
	Deadline Dates (ALL)	05-Jun-2019 , 05-Oct-2019 , 05-Feb-2020 ,	05-Jun-2020 , 05-Oct-2020 , 05-Feb-202	1 , 05-Jun-2	2021			
	Synopsis	National Human Genome Research Institution approaches to study how genetic variants human health and disease processes or ho (R01) award mechanism.	lead to differences in function and to stu	idy how suc	ch functional diffe	erences affect		
066539	Comparative Genomics Research	Program (R01-Clinical Trial Not Allowed)	National Human Genome Research Institute/NIH/DHHS	PAR-17- 482	05-Jun-2019	Not Specified		
	Contact Name	Jennifer Troyer, Ph.D						
	Contact Telephone	301-480-3565						
	Contact Email	troyerj@mail.nih.gov						
	Sponsor Website							
	Program URL	https://grants.nih.gov/grants/guide/pa-file	es/PAR-17-482.html					
	Deadline Dates (ALL)	05-Jun-2019 , 05-Oct-2019 , 05-Feb-2020 ,	05-Jun-2020 , 05-Oct-2020					
	Synopsis	National Human Genome Research Instituthat can be used to understand genome st phenotypes. This program supports studie	ructure and function and the relationshi	p between	genomic features	s and		

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
			s related to human health and disease, as well tive genomics research community. This FOA v		•	•
054920 <u>S</u>	erious Adverse Drug Reaction Re	esearch (R21)	National Human Genome Research Institute/NIH/DHHS	PAR-16- 274	07-May-2019	275,000 USD
	Contact Name	Simona Volpi, PhD				
	Contact Telephone	301-443-6453				
	Contact Email	volpis@mail.nih.gov				
	Sponsor Website					
	Program URL	http://grants.nih.gov/grants/guide/p	pa-files/PAR-16-274.html			
	Deadline Dates (ALL)	07-May-2019 , 03-Jun-2019 , 07-Sep-	2019			
	Synopsis	advance the state of knowledge of se	nd its participating Institutes and Centers invite erious adverse drug reactions. Applications acr H Exploratory/Developmental (R21) grant med National Human Genome Research	oss the spec	_	
054918 <u>S</u>	erious Adverse Drug Reaction Re	esearch (R01)	Institute/NIH/DHHS	275	07-May-2019	Specified
	Contact Name	Simona Volpi, PhD				
	Contact Telephone	301-443-6453				
	Contact Email	volpis@mail.nih.gov				
	Sponsor Website					
	Program URL	http://grants.nih.gov/grants/guide/p	pa-files/PAR-16-275.html			
	Deadline Dates (ALL)	07-May-2019 , 03-Jun-2019 , 07-Sep-	2019			
	Synopsis	advance the state of knowledge of se	nd its participating Institutes and Centers invite erious adverse drug reactions. Applications acr H Research Project (R01) award mechanism.		_	
11/38/6	FA-HG-18-002 Novel Nucleic A R21 Clinical Trial Not Allowed)	Acid Sequencing Technology Developm	nent National Human Genome Research Institute/NIH/DHHS	RFA-HG- 18-002	27-Jun-2019	400,000 USD
	Contact Name	İ				

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Sponsor Website Program URL Deadline Dates (ALL)	smithmw@mail.nih.gov  https://grants.nih.gov/grants/guide/rfa-fil 27-Jun-2019 , 10-Sep-2019 , 26-Jun-2020 , National Human Genome Research Institu substantive (no less than an order of magr sequencing. Applicants may propose to de novel system components, or propose imp systems. Exploration of methods other tha are appropriate to achieve the goals of thi	10-Sep-2020  te (NHGRI) invites applications to develophitude) improvement in DNA sequencing, velop novel complete sequencing system provements of at least an order of magnitian those currently in use is highly encour	and practions, investigated improved improved agged. High-	cal methods for cote te challenges un vement to existingerisk/high-payoff	direct RNA derlying key ng applications
073824	RFA-HG-18-001 Novel Nucleic A (R01 Clinical Trial Not Allowed)	award mechanism.  cid Sequencing Technology Development	National Human Genome Research Institute/NIH/DHHS	RFA-HG- 18-001	27-Jun-2019	2,800,000 USD
	Contact Name	Michael W. Smith, Ph.D.				
	Contact Telephone	301-480-3413				
	Contact Email	smithmw@mail.nih.gov				
	Sponsor Website					
	Program URL	https://grants.nih.gov/grants/guide/rfa-fil	es/RFA-HG-18-001.html			
	Deadline Dates (ALL)	27-Jun-2019 , 10-Sep-2019 , 26-Jun-2020 ,	10-Sep-2020			
	Synopsis	National Human Genome Research Institutess than one order of magnitude improve Advances in genomics and more broadly in DNA sequencing throughput increases and sequencing and enable direct RNA sequent higher-throughput etc.) at reasonable cost would make significant contributions to the technology development goals. This FOA versions are sentenced in the second sequenced in the	ment in DNA sequencing, and practical man biomedical research have been greatly to lost decreases. The goal now is to improcing (e.g., longer read lengths, faster turn is with the anticipation that significant ad e mission of NHGRI and the field of geno	nethods for facilitated bove the quandaround tindurances in a mics, include	direct RNA sequity significant and lity and efficience one, greater accuing of these and ling to many of N	encing. sustained y of DNA racy, and related areas
073828	RFA-HG-18-003 Novel Nucleic A (R43/R44 Clinical Trial Not Allowe	cid Sequencing Technology Development d)	National Human Genome Research Institute/NIH/DHHS	RFA-HG- 18-003	27-Jun-2019	Not Specified
	Contact Name	Michael W. Smith, Ph.D.				

Contact Telephone 301-480-3413

SPIN II)	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount

Contact Email smithmw@mail.nih.gov

Sponsor Website

Program URL https://grants.nih.gov/grants/guide/rfa-files/RFA-HG-18-003.html

Deadline Dates (ALL) 27-Jun-2019, 10-Sep-2019, 26-Jun-2020, 10-Sep-2020

that will enable no less than one order of magnitude improvement in DNA sequencing, and practical methods for direct RNA sequencing. Advances in genomics and more broadly in biomedical research have been greatly facilitated by significant and sustained DNA sequencing throughput increases and cost decreases. The goal now is to improve the quality and efficiency of DNA sequencing and enable direct RNA sequencing (e.g., longer read lengths, faster turn-around time, greater accuracy, and higher-throughput etc.) at reasonable costs with the anticipation that significant advances in any of these and related areas would make significant contributions to the mission of NHGRI and the field of genomics, including to many of NHGRI's other technology development goals. This FOA will use the NIH R43/R44 Small Business Innovation Research (SBIR) Grant - Phase I, Phase II, and Fast-Track I mechanism.

National Human Genome Research Institute (NHGRI) invites applications from small businesses to develop novel technologies

80987 RFA-HG-19-012 -- Limited Competition Centers of Excellence in Ethical, Legal and Social Implications (ELSI) Research (CEER) (RM1 Clinical Trial Optional)

National Human Genome Research Institute/NIH/DHHS

RFA-HG-19-012 23-Jun-2019 [LOI/Pre-App] [Optional]

2,600,000 USD

Contact Name Joy Boyer

Contact Telephone 301-480-2247

Contact Email boyerj@mail.nih.gov

Sponsor Website

Program URL https://grants.nih.gov/grants/guide/rfa-files/RFA-HG-19-012.html

Deadline Dates (ALL) 23-Jun-2019 [LOI/Pre-App][Optional], 23-Jul-2019

he National Human Genome Research Institute (NHGRI) is soliciting grant applications for the support of Centers of Excellence in Ethical, Legal and Social Implications (ELSI) Research (CEERs). The CEER Program is designed to support

Synopsis

Excellence in Ethical, Legal and Social Implications (ELSI) Research (CEERs). The CEER Program is designed to support the establishment of sustainable trans-disciplinary research teams with the expertise and flexibility to anticipate, conduct research on, and quickly address a range of cutting edge ethical, legal, and social issues related to genetics and genomics. The Program is intended to create new research opportunities that cross disciplinary boundaries among investigators in diverse fields, such as the genomic sciences, clinical research, clinical and health policy, ethics, law, the humanities, economics, political science, anthropology and other social sciences. In addition to conducting trans-disciplinary research, Centers will disseminate their research findings as well as facilitate the use of their findings to develop relevant research, health and public policies and practices. Finally, Centers will contribute to developing the next generation of ELSI researchers. NHGRI plans to maintain the CEER program at approximately its current level of funding through FY 2023. This

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		= -	cition RFA. Only grantees previously funde our year renewal may apply. Applications f			-
057225	NIAID Career Transition Award (I	<u>(22)</u>	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PAR-16- 434	07-May-2019	Not Specified
	Contact Name	Shawn Drew Gaillard, Ph.D.				
	Contact Telephon	e 240-627-3857				
	Contact Ema	il Shawn.Gaillard@ nih.gov				
	Sponsor Websit	e				
	Program UR	L http://grants.nih.gov/grants/guide/pa-	files/PAR-16-434.html			
	Deadline Dates (ALL	) 07-May-2019 , 12-Jun-2019 , 07-Sep-20	19			
	Synopsi	Award (RSDA), which is intended to ias	cious Diseases (NIAID) provides support for sist postdoctoral fellows' transition to posi- eer as an independent research scientist. T ion Award (K22) mechanism.	ions of assis	tant professor or	equivalent
nasiuu	Limited Competition: Small Rese Recipients (RO3)	arch Grant Program for NIAID K01/K08/K	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PAR-17- 439	07-May-2019	100,000 USD
	Contact Name	Shawn Drew Gaillard, Ph.D.				
	Contact Telephon	e 240-627-3857				
	Contact Ema	Shawn.Gaillard@nih.gov				
	Sponsor Websit	е				
	Program UR	L https://grants.nih.gov/grants/guide/pa	-files/PAR-17-439.html			
	Deadline Dates (ALL	07-May-2019 16-Jun-2019 07-Sen-20	19 , 16-Oct-2019 , 07-Jan-2020 , 16-Feb-20	20 , 07-May	-2020 , 16-Jun-20	20 , 07-Sep-
	Synopsi	opportunity to apply for Small Research Through the use of this mechanism, NI/s s conduct research as they complete the mechanism supports different types of small, self-contained research projects;	ious Diseases (NIAID) provides NIAID-support of Grant (R03) support at some point during AID seeks to enhance the capability of its K ir transition to fully independent investigat projects, including pilot and feasibility studies development of research methodology; anded to support research projects that can	the final tw 01, K08, and or status (e. dies; seconda nd developm	o years of their K K23 award recipi g., R01 support). ary analysis of exi ent of new resea	award. ents to The RO3 grant sting data; rch

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		limited resources and that may provide program will use the NIH R03 Small Gra	preliminary data to support a subsequent nt Program grant mechanism.	R01, or equ	ivalent, applicatio	n. This
064979	NIAID Physician-Scientist Pathwa	y to Independence Award (K99/R00)	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PAR-17- 329	07-May-2019	Not Specified
	Contact Name	Shawn Drew Gaillard, Ph.D.				
	Contact Telephone	240-627-3857				
	Contact Emai	shawn.gaillard@nih.gov				
	Sponsor Website					
	Program URL	https://grants.nih.gov/grants/guide/pa	-files/PAR-17-329.html			
	Deadline Dates (ALL)	07-May-2019 , 12-Jun-2019 , 07-Sep-20	19 , 12-Oct-2019 , 07-Jan-2020 , 12-Feb-20	20 <i>,</i> 07-May	<i>-</i> 2020	
	Synopsis	strong cohort of new and talented inde of outstanding postdoctoral researchers independent, tenure-track or equivalen during this transition to help awardees	Pathway to Independence Award (K99/R00 pendent physician-scientists. This program s with a clinical doctorate degree from ment faculty positions. The program will provid launch competitive, independent research scientist workforce shortage. This FOA will thanism.	is designed ntored, post le independ careers in b	to facilitate a tim doctoral research ent NIAID researc iomedical fields a	ely transition positions to h support nd thereby
062665	Therapeutic Strategies for the Co	nverging TB/T2DM/HIV Epidemics (R21)	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PA-17- 282	07-May-2019	275,000 USD
	Contact Name	Daniel Frank, Ph.D.				
	Contact Telephone	301-761-6256				
	Contact Emai	Daniel.Frank@nih.gov				
	Sponsor Website					
	Program URL	https://grants.nih.gov/grants/guide/pa	-files/PA-17-282.html			
	Deadline Dates (ALL)	07-May-2019 , 05-Jun-2019 , 07-Sep-20 2020	19 , 05-Oct-2019 , 07-Jan-2020 , 05-Feb-20	20 , 07-May	<i>-</i> -2020 , 05-Jun-20	20 , 07-Sep-
	Synopsis	Diseases (NIDDK) invite applications for dysregulation caused by Type 2 diabete	ous Diseases (NIAID) and National Institute innovative research to improve our unders is mellitus (DM) and pre-diabetes that caus disease with more frequent treatment fail	standing of es increased	innate and adapti d risk of latent tub	ve immune perculosis (TB)

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		co-infection. This FOA will use the NIH	R21 Exploratory/Developmental Research	Grant awar	d mechanism.	
062648	Therapeutic Strategies for the Co	nverging TB/T2DM/HIV Epidemics (R01)	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PA-17- 283	07-May-2019	Not Specified
	Contact Name	Daniel Frank, Ph.D.				
	Contact Telephone	301-761-6256				
	Contact Emai	Daniel.Frank@nih.gov				
	Sponsor Website					
	Program URI	https://grants.nih.gov/grants/guide/pa	-files/PA-17-283.html			
	Deadline Dates (ALL)	07-May-2019 , 05-Jun-2019 , 07-Sep-20 2020	19 , 05-Oct-2019 , 07-Jan-2020 , 05-Feb-20	020 , 07-May	/-2020 , 05-Jun-202	20 , 07-Sep-
		National Institute of Allergy and Infecti	ous Diseases (NIAID) and National Institute		-	•
	Synopsis	National Institute of Allergy and Infecti Diseases (NIDDK) invite applications for dysregulation caused by Type 2 diabete re-activation and more severe active TE	innovative research to improve our under s mellitus (DM) and pre-diabetes that caus disease with more frequent treatment fa Research Project (R01) award mechanism.	rstanding of ses increase ilure/relapse	innate and adaptived risk of latent tub	ve immune erculosis (TB) context of HI
065010	Synopsis Small Grants on Primary Immuno	National Institute of Allergy and Infecti Diseases (NIDDK) invite applications for dysregulation caused by Type 2 diabete re-activation and more severe active TE co-infection. This FOA will use the NIH	innovative research to improve our under s mellitus (DM) and pre-diabetes that caus disease with more frequent treatment fa	rstanding of ses increase ilure/relapse	innate and adaptived risk of latent tub	ve immune erculosis (TB)
065010	Small Grants on Primary Immuno	National Institute of Allergy and Infecti Diseases (NIDDK) invite applications for dysregulation caused by Type 2 diabete re-activation and more severe active TE co-infection. This FOA will use the NIH	innovative research to improve our under s mellitus (DM) and pre-diabetes that caus disease with more frequent treatment fa Research Project (R01) award mechanism.	rstanding of ses increase ilure/relapse PA-17-	innate and adaptived risk of latent tube and death in the	ve immune erculosis (TB) context of HIV 100,000
065010	Small Grants on Primary Immuno	National Institute of Allergy and Infection Diseases (NIDDK) invite applications for dysregulation caused by Type 2 diabete re-activation and more severe active TE co-infection. This FOA will use the NIH deficiency Diseases (RO3)  Prosso Voulgaropoulou, Ph.D.	innovative research to improve our under s mellitus (DM) and pre-diabetes that caus disease with more frequent treatment fa Research Project (R01) award mechanism.	rstanding of ses increase ilure/relapse PA-17-	innate and adaptived risk of latent tube and death in the	ve immune erculosis (TB) context of HIV 100,000
065010	Small Grants on Primary Immuno  Contact Name Contact Telephone	National Institute of Allergy and Infection Diseases (NIDDK) invite applications for dysregulation caused by Type 2 diabete re-activation and more severe active TE co-infection. This FOA will use the NIH deficiency Diseases (RO3)  Prosso Voulgaropoulou, Ph.D.	innovative research to improve our under s mellitus (DM) and pre-diabetes that caus disease with more frequent treatment fa Research Project (R01) award mechanism.	rstanding of ses increase ilure/relapse PA-17-	innate and adaptived risk of latent tube and death in the	ve immune erculosis (TB) context of HIV 100,000
065010	Small Grants on Primary Immuno  Contact Name Contact Telephone	National Institute of Allergy and Infection Diseases (NIDDK) invite applications for dysregulation caused by Type 2 diabeted re-activation and more severe active TE co-infection. This FOA will use the NIH adeficiency Diseases (RO3)  Frosso Voulgaropoulou, Ph.D. 240-627-3205  I fvoulgaropoulou@niaid.nih.gov	innovative research to improve our under s mellitus (DM) and pre-diabetes that caus disease with more frequent treatment fa Research Project (R01) award mechanism.	rstanding of ses increase ilure/relapse PA-17-	innate and adaptived risk of latent tube and death in the	ve immune erculosis (TB) context of HIV 100,000
065010	Small Grants on Primary Immuno  Contact Name Contact Telephone Contact Emai Sponsor Website	National Institute of Allergy and Infection Diseases (NIDDK) invite applications for dysregulation caused by Type 2 diabeted re-activation and more severe active TE co-infection. This FOA will use the NIH adeficiency Diseases (RO3)  Frosso Voulgaropoulou, Ph.D. 240-627-3205  I fvoulgaropoulou@niaid.nih.gov	innovative research to improve our under s mellitus (DM) and pre-diabetes that caus disease with more frequent treatment fa Research Project (R01) award mechanism. National Institute of Allergy and Infectious Diseases/NIH/DHHS	rstanding of ses increase ilure/relapse PA-17-	innate and adaptived risk of latent tube and death in the	ve immune erculosis (TB) context of HIV 100,000
065010	Small Grants on Primary Immuno  Contact Name Contact Telephone Contact Emai Sponsor Website	National Institute of Allergy and Infection Diseases (NIDDK) invite applications for dysregulation caused by Type 2 diabete re-activation and more severe active TE co-infection. This FOA will use the NIH adeficiency Diseases (RO3)  Frosso Voulgaropoulou, Ph.D. 240-627-3205  I fvoulgaropoulou@niaid.nih.gov  https://grants.nih.gov/grants/guide/pa	innovative research to improve our under s mellitus (DM) and pre-diabetes that caus disease with more frequent treatment fa Research Project (R01) award mechanism. National Institute of Allergy and Infectious Diseases/NIH/DHHS	rstanding of ses increase ilure/relapse PA-17-	innate and adaptived risk of latent tube and death in the	ve immune erculosis (TB) context of HI

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		short period of time with limited resource.  NIH funding in this field are encouraged mechanism.			_	•
いわちいしく	Exploratory/Developmental Inves Diseases (R21)	stigations on Primary Immunodeficiency	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PA-17- 333	16-Jun-2019	275,000 USD
	Contact Name	Frosso Voulgaropoulou, Ph.D.				
	Contact Telephone	240-627-3205				
	Contact Email	fvoulgaropoulou@niaid.nih.gov				
	Sponsor Website					
	Program URL	https://grants.nih.gov/grants/guide/pa-f	iles/PAR-17-333.html			
	Deadline Dates (ALL)	16-Jun-2019				
	Synopsis	investigations on primary immunodeficied current or new animal models including developing innovative therapies for primal clinical data and samples maintained in paddress questions relevant to primary im (R21) grant mechanism.	novel clinical strategies for detecting, ide ary immunodeficiency diseases. In additiorimary immunodeficiency registries, con	ntifying the on, this FOA sortium dat	molecular basis o aims to encouragabases and repos	f, or ge analyses of itories to
		chanistic Understanding of Antibiotic	National Institute of Allergy and	PA-18-	05-Jun-2019	Not
	Resistance Development (R01 Cli		Infectious Diseases/NIH/DHHS	725		Specified
		Ryan Ranallo, Ph.D.				
	Contact Telephone					
		ryan.ranallo@nih.gov				
	Sponsor Website		"I (0.40 T05 I ) I			
	· ·	https://grants.nih.gov/grants/guide/pa-f		24		
		National Institute of Allergy and Infection Critical in the National Action Plan for Costunderstanding the nature of microbial collinease, as well as research exploring con NIH Research Project (R01) award mechan	ous Diseases (NIAID) invites applications f mbating Antibiotic-Resistant Bacteria (CA ommunities, how antibiotics affect them, mbination therapies to address the emer	or select are RB), includi and how th	ng research focus ey can be harness	ed on sed to prevent

SPIN ID	Program Title	Sponsor Name	Sponsor Number		<b>Deadline Date</b>	Funding Amount
073282	Generating New Insights and Mechani Resistance Development (R21 Clinical		National Institute of Allergy and Infectious Diseases/NIH/DHHS	PA-18- 724	16-Jun-2019	275,000 USD
	Contact Name Rya	n Ranallo, Ph.D.				
	Contact Telephone 240	-627-3351				
	Contact Email ryar	n.ranallo@nih.gov				
	Sponsor Website					
	Program URL <u>http</u>	s://grants.nih.gov/grants/guide/pa-	-files/PA-18-724.html			
	Deadline Dates (ALL) 16-J	un-2019 , 16-Oct-2019 , 16-Feb-202	0 , 16-Jun-2020 , 16-Oct-2020 , 16-Feb-202	21		
	criti Synopsis und dise	cal in the National Action Plan for Co erstanding the nature of microbial c	ious Diseases (NIAID) invites applications for combating Antibiotic-Resistant Bacteria (CA communities, how antibiotics affect them, combination therapies to address the emerg search Grant award mechanism.	RB), includi and how th	ing research focus ey can be harness	ed on ed to prevent
076258	Advancing Research Needed to Develor Clinical Trial Not Allowed)	pp a Universal Influenza Vaccine (RO	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PA-18- 859	05-Jun-2019	Not Specified
	Contact Name Diar	ne Post, Ph.D.				
	Contact Telephone 240	-627-3348				
	Contact Email pos	td@niaid.nih.gov				
	Sponsor Website					
	Program URL <u>http</u>	s://grants.nih.gov/grants/guide/pa-	-files/PA-18-859.html			
	Deadline Dates (ALL) 05-J	un-2019 , 05-Oct-2019 , 05-Feb-202	0 , 05-Jun-2020 , 05-Oct-2020 , 05-Feb-202	21 , 05-Jun-	2021	
	Synopsis inclu 2) c	D's mission to develop a universal in uding efforts to: 1) improve understanaracterize influenza immunity and	ious Diseases (NIAID) invites applications for four protect anding of transmission, natural history and correlates of immune protection; and 3) supercharces (RO1) award mechanism.	tion against I pathogene	multiple influenza esis of influenza vi	a strains, rus infection;
076329	Immune Response to Arthropod Blood	Feeding (R21 Clinical Trial Not Allov	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PAR-18- 860	14-Jun-2019	275,000 USD
	Contact Name Ken Contact Telephone 240	tner Singleton, Ph.D. -669-5499				



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Contact Email singleton	kl@niaid.nih.gov			

Sponsor Website

Program URL https://grants.nih.gov/grants/guide/pa-files/PAR-18-860.html

Deadline Dates (ALL) 14-Jun-2019, 14-Feb-2020, 15-Oct-2020

National Institute of Allergy and Infectious Diseases (NIAID) invites applications for .short-term exploratory, developmental, and transdisciplinary research to understand the immunologic events that occur during blood feeding by hematophagous arthropods. The scientific objectives of this initiative are (1) to understand the immunological events in the vertebrate host, Synopsis which occur during and after blood feeding by hematophagous arthropods, at the bite site (skin) and systemically; (2) to identify and characterize the immune modulatory properties of arthropod salivary components; and (3) to understand the immunological events in the hematophagous arthropods following a blood meal. This program will use the NIH Exploratory/Developmental (R21) grant mechanism.

076434 Research to Advance Vaccine Safety (R01 Clinical Trial Not Allowed)

National Institute of Allergy and PA-18-Not 07-May-2019 Infectious Diseases/NIH/DHHS 873 Specified

Contact Name Barbara Mulach, Ph.D.

Contact Telephone 240-627-3322

Contact Email bmulach@niaid.nih.gov

award mechanism.

Sponsor Website

Program URL https://grants.nih.gov/grants/guide/pa-files/PA-18-873.html

Deadline Dates (ALL)

07-May-2019, 05-Jun-2019, 07-Sep-2019, 05-Oct-2019, 07-Jan-2020, 05-Feb-2020, 07-May-2020, 05-Jun-2020, 07-Sep-2020, 05-Oct-2020, 07-Jan-2021, 05-Feb-2021, 05-Jun-2021, 07-Sep-2021

The National Institutes of Health (NIH) and Centers for Disease Control and Prevention (CDC) and their participating Institutes and Centers invite applications to support research that will contribute to the overall understanding of vaccine safety. This research opportunity encourages studies that address scientific areas potentially relevant to vaccine safety, such as: 1) characterization of physiological and immunological responses to vaccines and vaccine components, including different adjuvants; 2) how genetic variations affect immune/physiological responses that may impact vaccine safety; 3) identification of risk factors e.g., infection history, predisposition to or presence of allergic and/or autoimmune disease and biological markers that may be used to assess whether there is a relationship between certain diseases or disorders and licensed vaccines; 4) creation/evaluation of statistical methodologies for analyzing data on vaccine safety, including data available from existing data sources, such as passive reporting systems or healthcare databases; or 5) the application of genomic/molecular technologies and systems biology approaches to evaluate vaccine safety. This FOA aligns with the research goals and objectives outlined in the U.S. National Vaccine Plan. This program will use the NIH Research Project (R01)

**Synopsis** 

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
076435	Research to Advance Vaccine Safe	ety (R21 Clinical Trial Not Allowed)	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PA-18- 872	07-May-2019	275,000 USD
	Contact Name					
	Contact Telephone	240-627-3322				
	Contact Email	bmulach@niaid.nih.gov				
Sponsor Website						
Program URL https://grants.nih.gov/grants/guide/pa-files/PA-18-872.html						
	Deadline Dates (ALL) 07-May-2019 , 16-Jun-2019 , 07-Sep-2019 , 16-Oct-2019 , 07-Jan-2020 , 16-Feb-2020 , 07-May-2020 , 16-Jun-2020 , 16-Jun-2020 , 16-Jun-2021 , 16-Feb-2021 , 16-Jun-2021 , 07-Sep-2021					
	Synopsis	and Centers invite applications to support research opportunity encourages studion characterization of physiological and imadjuvants; 2) how genetic variations affor risk factors e.g., infection history, promarkers that may be used to assess who vaccines; 4) creation/evaluation of statifrom existing data sources, such as passed genomic/molecular technologies and sy	and Centers for Disease Control and Preventer ort research that will contribute to the over the state address scientific areas potentially munological responses to vaccines and variest immune/physiological responses that redisposition to or presence of allergic and/ether there is a relationship between certaistical methodologies for analyzing data on sive reporting systems or healthcare databystems biology approaches to evaluate vaccin the U.S. National Vaccine Plan. This programme award mechanism.	rall underst relevant to v ccine compo may impact or autoimm ain diseases vaccine saf ases; or 5) t cine safety.	anding of vaccine vaccine safety, succine safety, succine safety; 3) une disease and bor disorders and lifety, including data he application of This FOA aligns wi	safety. This h as: 1) different identification iological icensed a available
11/6/61	Advancing Research Needed to De Clinical Trial Not Allowed)	evelop a Universal Influenza Vaccine (RO	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PA-18- 858	16-Jun-2019	275,000 USD
	Contact Name	Diane Post, Ph.D.				
	Contact Telephone	240-627-3348				
	Contact Email	postd@niaid.nih.gov				
	Sponsor Website					
	Program URL	https://grants.nih.gov/grants/guide/pa	-files/PA-18-859.html			
	_		20 , 16-Jun-2020 , 16-Oct-2020 , 16-Feb-20	21 , 16-Jun-	2021	
			tious Diseases (NIAID) invites applications finfluenza vaccine providing durable protec			advance strains,

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		including efforts to: 1) improve understar 2) characterize influenza immunity and co vaccines. This FOA will use the NIH R21 Ex	orrelates of immune protection; and 3) so	upport ratio	nal design of univ	
115/15//	Novel Approaches to Understand and Tick-borne Coinfections (R21)	ling, Preventing and Treating Lyme Disease )	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PA-16- 244	16-Jun-2019	275,000 USD
	Contact Telephone Contact Email Sponsor Website	Maliha.ilias@nih.gov  http://grants.nih.gov/grants/guide/pa-file 16-Jun-2019  NIH invites applications for research that	will contribute to the overall understand opportunity encourages studies that ad e transmission, 4) vector biology and nat	dress divers ural history	e scientific areas ( , 5) vaccines, 6) di	such as 1)
115/15/3	Novel Approaches to Understand and Tick-borne Coinfections (R01)	I ling, Preventing and Treating Lyme Disease		PA-16- 243	05-Jun-2019	Not Specified
	Contact Telephone Contact Email Sponsor Website	Maliha.ilias@nih.gov  http://grants.nih.gov/grants/guide/pa-file 05-Jun-2019  NIH invites applications for research that	will contribute to the overall understand opportunity encourages studies that ad e transmission, 4) vector biology and nat	dress divers ural history	e scientific areas	such as 1)
11/2564	Research (R21 Clinical Trial Not Al	tasets for Advancing Infectious Disease   Ilowed     Ishwar Chandramouliswaran M.S., M.B.A.	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PA-19- 068	16-Jun-2019	275,000 USD

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount		
	•							
	Contact Telephone	301-761-7822						
	Contact Email	ishwar.chandramouliswaran@nih.gov						
	Sponsor Website							
	Program URL	https://grants.nih.gov/grants/guide/pa-f	<u>iles/PA-19-068.html</u>					
	Deadline Dates (ALL)	16-Jun-2019 , 16-Oct-2019 , 16-Feb-2020	, 16-Jun-2020 , 16-Oct-2020 , 16-Feb-20	21 , 16-Jun-2	2021 , 16-Oct-202	1		
	Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to support projects that utilize open-access data, alcombination with other datasets, to address knowledge gaps in basic and/or clinical research in infectious diseases.						
078710	Accelerating Malaria Vaccine Disc	overy (R01 Clinical Trial Not Allowed)	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PA-19- 077	05-Jun-2019	Not Specified		
	Contact Name	Annie Mo, Ph.D.						
	Contact Telephone	240-627-3320						
	Contact Email	moa@niaid.nih.gov						
	Sponsor Website							
	Program URL	https://grants.nih.gov/grants/guide/pa-f	<u>iles/PA-19-077.html</u>					
	Deadline Dates (ALL)	05-Jun-2019 , 05-Oct-2019 , 05-Feb-2020	, 05-Jun-2020 , 05-Oct-2020 , 05-Feb-20	21 , 05-Jun-2	2021 , 05-Oct-202	1		
	Synopsis	The purpose of this Funding Opportunity generate new malaria vaccine candidates opportunity encourages studies that will disease, and/or interrupt transmission ca	s suitable for further downstream develo lead to discovery of new vaccine candida	pment and onterment and on the states that pre-	clinical evaluation event infection, an	. This research neliorate		
U/X/I/	Advancing Development of Rapid Allowed)	Fungal Diagnostics (R01 Clinical Trial Not	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PA-19- 080	05-Jun-2019	Not Specified		
	Contact Name	Dona Love, Ph.D.						
	Contact Telephone	301-761-7788						
	Contact Email	dona.love@nih.gov						
	Sponsor Website							
	Program URL	https://grants.nih.gov/grants/guide/pa-f	<u>iles/PA-19-080.html</u>					
	Deadline Dates (ALL)	05-Jun-2019 , 05-Oct-2019 , 05-Feb-2020	, 05-Jun-2020 , 05-Oct-2020 , 05-Feb-20	21 , 05-Jun-2	2021 , 05-Oct-202	1		
	Synopsis	The purpose of this Funding Opportunity and cost-effective diagnostics for primary			pid, sensitive, spe	cific, simple,		

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
(1 / X / 1 /I	Advancing Development of Rapid F Allowed)	fungal Diagnostics (R01 Clinical Trial Not	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PA-19- 081	16-Jun-2019	275,000 USD
	Contact Name	Dona Love, Ph.D.				
	Contact Telephone	301-761-7788				
	Contact Email <u>c</u>	dona.love@nih.gov				
	Sponsor Website					
	Program URL <u>Ł</u>	nttps://grants.nih.gov/grants/guide/pa-fi	les/PA-19-081.html			
	Deadline Dates (ALL)	16-Jun-2019 , 16-Oct-2019 , 16-Feb-2020	, 16-Jun-2020 , 16-Oct-2020 , 16-Feb-202	1 , 16-Jun-	2021 , 16-Oct-202	1
			Announcement is to support the develop health-care settings (hospitals and point		pid, sensitive, spe	cific, simple,
11/X/14	Molecular and Genetic Characteriza Clinical Trial Not Allowed)	ation of Inborn Errors of Immunity (R21	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PAR-19- 079	16-Jun-2019	275,000 USD
	Contact Name F	Frosso Voulgaropoulou, PhD				
	Contact Telephone 2	240-627-3205				
	Contact Email <u>f</u>	voulgaropoulou@niaid.nih.gov				
	Sponsor Website					
	Program URL <u>Ł</u>	nttps://grants.nih.gov/grants/guide/pa-fi	les/PAR-19-079.html			
	Deadline Dates (ALL) 1	16-Jun-2019 , 16-Oct-2019 , 16-Feb-2020	, 16-Jun-2020 , 16-Oct-2020 , 16-Feb-202	1 , 16-Jun-	2021 , 16-Oct-202	1
	Synopsis i L	characterization of genetic variants in coommunodeficiency diseases and to elucid	Announcement (FOA) is to advance the ending or non-coding genomic regions that reate the molecular, cellular, and immunology immunodeficiency disorders is essential	esult in inb gical mech	oorn errors of imn nanisms of these o	nunity/primary lisorders.
11/X/1X	Molecular and Genetic Characteriza Clinical Trial Not Allowed)	ation of Inborn Errors of Immunity (R01	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PAR-19- 078	05-Jun-2019	Not Specified
	Contact Name F	Frosso Voulgaropoulou, PhD				
	Contact Telephone 2	• ,				
	·	voulgaropoulou@niaid.nih.gov				
	Sponsor Website	-				

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount		
	Program URI	https://grants.nih.gov/grants/guide/na-f	iles/PAR-19-078 html					
		https://grants.nih.gov/grants/guide/pa-files/PAR-19-078.html 05-Jun-2019, 05-Oct-2019, 05-Feb-2020, 05-Jun-2020, 05-Oct-2020, 05-Feb-2021, 05-Jun-2021, 05-Oct-2021						
		The purpose of this Funding Opportunity Announcement (FOA) is to advance the experimental validation and function characterization of genetic variants in coding or non-coding genomic regions that result in inborn errors of immunity/ps immunodeficiency diseases and to elucidate the molecular, cellular, and immunological mechanisms of these disorders. Understanding the genetic basis of primary immunodeficiency disorders is essential for their diagnosis, prognosis, and development of precision therapeutics.						
078789	Research to Advance HBV Cure: Hinfection (R01 Clinical Trial Not Al	HIV/HBV Co-Infection and HBV Mono- llowed)	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PAS-19- 097	07-May-2019	Not Specified		
Contact Name Chris Lambros, PhD								
	Contact Telephone	240-627-3093						
	Contact Email	clambros@niaid.nih.gov						
	Sponsor Website							
	Program URL	https://grants.nih.gov/grants/guide/pa-f	iles/PAS-19-097.html					
	Deadline Dates (ALL)	07-May-2019 , 05-Jun-2019 , 07-Sep-201 2020 , 05-Oct-2020 , 07-Jan-2021 , 05-Fe	9 , 05-Oct-2019 , 07-Jan-2020 , 05-Feb-20 b-2021 , 07-May-2021 , 05-Jun-2021 , 07-	)20 , 07-May -Sep-2021 , (	/-2020 , 05-Jun-20 05-Oct-2021 , 07-J	20 , 07-Sep- an-2022		
		The purpose of this Funding Opportunity translational, and clinical research to ide presence or absence of human immunoc	Announcement (FOA) is to invite applica ntify and address the challenges to achie	tions for sup	oport of innovativ	e basic,		
078717	Novel Approaches to Understand coccidioidomycosis (Valley Fever) (R21 Clinical Trial Not Allowed)	, Prevent, Treat, and Diagnose and Other Select Endemic Fungal Infection	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PA-19- 083	16-Jun-2019	275,000 USD		
	Contact Name	Dona Love, Ph.D.						
	Contact Telephone	301-761-7788						
	Contact Email	dona.love@nih.gov						
	Sponsor Website							
	Program URL	https://grants.nih.gov/grants/guide/pa-f	<u>iles/PA-19-083.html</u>					
	Deadline Dates (ALL)	16-Jun-2019 , 16-Oct-2019 , 16-Feb-2020	, 16-Jun-2020 , 16-Oct-2020 , 16-Feb-20	21 , 16-Jun-2	2021 , 16-Oct-202	1		
	Synopsis	The purpose of this Funding Opportunity understanding of coccidioidomycosis, co	Announcement is to support research acmonly known as Valley Fever, and othe	ctivities that r select end	will contribute to emic fungal diseas	the overall ses including		

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Novel Amoreoches to Understood	histoplasmosis and blastomycosis. This result of the improved detection, prevention and transfer and Discress.	se transmission; 4) natural history and e therapeutics; with the ultimate goal of a	nvironmen	tal factors contrib	uting to
078715	Novel Approaches to Understand coccidioidomycosis (Valley Fever) (R01 Clinical Trial Not Allowed)	and Other Select Endemic Fungal Infection	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PA-19- 082	05-Jun-2019	Not Specified
	Contact Telephone	dona.love@nih.gov				
	· ·	https://grants.nih.gov/grants/guide/pa-file 05-Jun-2019, 05-Oct-2019, 05-Feb-2020,	05-Jun-2020 , 05-Oct-2020 , 05-Feb-202			
	Synopsis	The purpose of this Funding Opportunity A understanding of coccidioidomycosis, com histoplasmosis and blastomycosis. This result is pathogenesis; 2) host response; 3) diseadisease; 5) vaccines; 6) diagnostics; and 7) the improved detection, prevention and tr	monly known as Valley Fever, and other search opportunity encourages studies to see transmission; 4) natural history and enterapeutics; with the ultimate goal of a	select ende hat address nvironmen	emic fungal diseas diverse scientific tal factors contrib	es including areas such as: uting to
072446	NIAID Physician-Scientist Pathway Trial Required)	y to Independence Award (K99/R00 Clinical	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PAR-18- 679	07-May-2019	Not Specified
		Shawn Drew Gaillard, Ph.D.				
	Contact Telephone					
		Shawn.Gaillard@nih.gov				
	Sponsor Website					
	_	https://grants.nih.gov/grants/guide/pa-file			2020	
	Deadline Dates (ALL) Synopsis	07-May-2019, 12-Jun-2019, 07-Sep-2019 National Institute of Allergy and Infectiou Independence Award (K99/R00) program. talented independent physician-scientists. postdoctoral researchers with a clinical do	s Diseases (NIAID) invites applications fo The purpose of the program is to increas This program is designed to facilitate a	or the NIAID se and mair timely tran	Physician-Scientis Stain a strong coho Sition of outstandi	ort of new and

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date 🔠	Funding Amount		
		tenure-track or equivalent faculty position transition to help awardees launch compe address the national physician-scientist we Award/Research Transition Award mechan	titive, independent research careers in orkforce shortage. This FOA will use the	biomedical fi	elds and thereby	help to		
079670	RFA-AI-19-011 Computational Mallowed)	Models of Immunity (U01 Clinical Trial Not	National Institute of Allergy and Infectious Diseases/NIH/DHHS	RFA-AI- 19-011	10-May-2019 [LOI/Pre-App] [Optional]	3,750,000 USD		
	Contact Name	Joseph J. Breen, Ph.D.						
	Contact Telephone	240-292-4123						
	Contact Email	jbreen@niaid.nih.gov						
	Sponsor Website							
	Program URL	https://grants.nih.gov/grants/guide/rfa-fil	es/RFA-AI-19-011.html					
	Deadline Dates (ALL)	10-May-2019 [LOI/Pre-App][Optional], 10-Jun-2019						
	Synopsis	This Funding Opportunity Announcement advance understanding of the mechanism other than HIV, and/or vaccines against su application of computational models of imvalidate and improve the utility and robus computational models and data developed further refinement or direct use in biologic foster the use of computational models of	s required to induce and/or maintain purch pathogens. The main goal of this FO. Inmunity that are refined through iterative thess of the computational models. And under this initiative readily available total experimentation. This program will a	rotective imm A is to advan- ve immunolo other goal of the broade also support	nunity to infectiou ce development a gical experimenta this FOA is to mak r research commu	is pathogens, nd ition to se the unity for		
	RFA-AI-19-029 Emerging Infecti Coordination Center (U01 Clinical		National Institute of Allergy and Infectious Diseases/NIH/DHHS	RFA-AI- 19-029	29-May-2019 [LOI/Pre-App] [Optional]	2,500,000 USD		
	Contact Name	Jean Patterson, Ph.D.						
	Contact Telephone	240-292-4830						
	Contact Email	jean.patterson@nih.gov						
	Sponsor Website							
	Program URL	https://grants.nih.gov/grants/guide/rfa-fil	es/RFA-AI-19-029.html					
	Deadline Dates (ALL)	29-May-2019 [LOI/Pre-App][Optional], 28-	-Jun-2019					
	Synopsis	The purpose of this Funding Opportunity A	Announcement (FOA) is to solicit applica	itions for an	Emerging Infection	us Diseases		

	Program					Funding
SPIN ID	Title	Sponsor Name	Sponsor Number		Deadline Date	Amount
		Research Centers Coordination Center (El CC will oversee and coordinate select asp collection and storage, sharing of reagent awarded EIDRCs, and other USG and inter	ects of each EIDRC's research project(s) is, diagnostics, and resources, and will factorize the second control of the second control	nvolving dat	ta management, s	ample
080664	RFA-AI-19-024 U.SSouth Africa Research - Phase 2 (Infectious Dis	a Program for Collaborative Biomedical eases) (R01 Clinical Trial Optional)	National Institute of Allergy and Infectious Diseases/NIH/DHHS	RFA-AI- 19-024	26-Jun-2019 [LOI/Pre-App] [Optional]	350,000 USD
	Contact Name	Brian Remortel, M.P.H.				
	Contact Telephone	240-292-4816				
	Contact Email	remortelbg@niaid.nih.gov				
	Sponsor Website					
	Program URL	https://grants.nih.gov/grants/guide/rfa-fi	iles/RFA-AI-19-024.html			
	Deadline Dates (ALL)	26-Jun-2019 [LOI/Pre-App][Optional], 26-	Jul-2019			
	Synopsis	The purpose of this Funding Opportunity Biomedical Research into Phase 2. Resea infections; parasitic infections; arboviruse	rch areas supported under this program	include: tub	erculosis; sexually	transmitted
080662	RFA-AI-19-023 U.SSouth Africa Research - Phase 2 (HIV/AIDS) (UC	a Program for Collaborative Biomedical O1 Clinical Trial Optional)	National Institute of Allergy and Infectious Diseases/NIH/DHHS	RFA-AI- 19-023	26-Jun-2019 [LOI/Pre-App] [Optional]	250,000 USD
	Contact Name	Brian Remortel, M.P.H.				
	Contact Telephone	240-292-4816				
	Contact Email	remortelbg@niaid.nih.gov				
	Sponsor Website					
	Program URL	https://grants.nih.gov/grants/guide/rfa-fi	iles/RFA-Al-19-023.html			
	Deadline Dates (ALL)	26-Jun-2019 [LOI/Pre-App][Optional], 26-	Jul-2019			
	Synopsis	The purpose of this Funding Opportunity Biomedical Research into Phase 2. Resea malignancies. This opportunity is specifical Program (IRP) investigators (e.g. those conduction investigators (e.g., those conduction).	rch areas supported under this program ally designed to promote partnerships be nducting research within the laboratorie	include HIV/ tween eligik s and clinics	'AIDS and HIV/AID ble NIH Intramural of the NIH) and e	S-associated Research ligible South

program, the application must include at least one NIH IRP investigator serving as a Project Scientist with an equal role in the

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		conceptualization, design and execution	of the research.			
080644	RFA-AI-19-022 U.SSouth Africa Research - Phase 2 (HIV/AIDS) (RC	a Program for Collaborative Biomedical 01 Clinical Trial Optional)	National Institute of Allergy and Infectious Diseases/NIH/DHHS	RFA-AI- 19-022	26-Jun-2019 [LOI/Pre-App] [Optional]	350,000 USD
	Contact Telephone Contact Email Sponsor Website	remortelbg@niaid.nih.gov				
		https://grants.nih.gov/grants/guide/rfa-fa-fa-fa-fa-fa-fa-fa-fa-fa-fa-fa-fa-f				
		The purpose of this Funding Opportunity Biomedical Research into Phase 2. Reseamalignancies.	Announcement (FOA) is to continue the		-	
080668		a Program for Collaborative Biomedical eases) (U01 Clinical Trial Optional)	National Institute of Allergy and Infectious Diseases/NIH/DHHS	RFA-AI- 19-025	26-Jun-2019 [LOI/Pre-App] [Optional]	250,000 USD
	Contact Name	Brian Remortel, M.P.H.				
	Contact Telephone	240-292-4816				
	Contact Email	remortelbg@niaid.nih.gov				
	Sponsor Website					
	Program URL	https://grants.nih.gov/grants/guide/rfa-l	files/RFA-AI-19-025.html			
	Deadline Dates (ALL)	26-Jun-2019 [LOI/Pre-App][Optional], 26	-Jul-2019			
The purpose of this Funding Opportunity Announcement (FOA) is to continue the U.SSouth Africa Program for Collaborations and the purpose of this Funding Opportunity Announcement (FOA) is to continue the U.SSouth Africa Program for Collaborations and the purpose of this Funding Opportunity Announcement (FOA) is to continue the U.SSouth Africa Program for Collaborations and Collaboration and Include: tuberculosis; sexually transminfections; parasitic infections; arboviruses and emerging/re-emerging viral pathogens; and vector biology and control. Opportunity is specifically designed to promote partnerships between eligible NIH Intramural Research Program (IRP) investigators (e.g., those conducting research within the laboratories and clinics of the NIH) and eligible South African investigators (e.g., those conducting research in eligible laboratories in South Africa). In order to be eligible for this program include at least one NIH IRP investigator serving as a Project Scientist with an equal role in the					transmitted control. This (IRP) frican this program,	

conceptualization, design and execution of the research.

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount	
080693	RFA-AI-19-015 Atopic Dermatitis Centers (U01 Clinical Trial Optiona	Research Network -Clinical Research	National Institute of Allergy and Infectious Diseases/NIH/DHHS	RFA-AI- 19-015	07-Jun-2019 [LOI/Pre-App] [Optional]	2,100,000 USD	
	Contact Name	Michael Minnicozzi, Ph.D.					
	Contact Telephone	301-240-3532					
	Contact Email	minnicozzim@niaid.nih.gov					
	Sponsor Website						
	Program URL	https://grants.nih.gov/grants/guide/rfa-	-files/RFA-AI-19-015.html				
	Deadline Dates (ALL)	07-Jun-2019 [LOI/Pre-App][Optional], 0រ	8-Jul-2019				
	Synopsis	Research Network Clinical Research Cen research projects under the leadership of	ry Announcement (FOA) is to solicit applications (ADRN-CRCs). The ADRN-CRCs will control of the ADRN Leadership Center (ADRN-LC). It of the ADRN. To ac	nduct the A . In parallel	DRN network-wide, , each ADRN-CRC v	e clinical will pursue its	
HIXHIKUX	RFA-AI-19-014 Atopic Dermatitis Clinical Trial Required)	Research Network Leadership Center (I	JM1 National Institute of Allergy and Infectious Diseases/NIH/DHHS	RFA-AI- 19-014	07-Jun-2019 [LOI/Pre-App] [Optional]	1,800,000 USD	
	Contact Name	Michael Minnicozzi, Ph.D.					
	Contact Telephone	301-240-3532					
	Contact Email	minnicozzim@niaid.nih.gov					
	Sponsor Website						
	Program URL	https://grants.nih.gov/grants/guide/rfa-	-files/RFA-AI-19-014.html				
	Deadline Dates (ALL)	07-Jun-2019 [LOI/Pre-App][Optional], 0រ	8-Jul-2019				
	The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications for the NIAID Atopic Dermatitis Research Network Leadership Center (ADRN-LC) for the NIAID ADRN. The ADRN-LC will provide the overall scientific strate and organizational structure to the ADRN and will interact closely with the ADRN Clinical Research Centers (ADRN-CRCs), to support the conduct of multi-site clinical studies and trials under the ADRN.						
	<del>-</del>	rker Discovery and Novel Point-of-Care Detection in HIV-1 Infected and Exposed al)	National Institute of Allergy and Infectious Diseases/NIH/DHHS	RFA-AI- 19-036	30-Jun-2019 [LOI/Pre-App] [Optional]	Not Specified	

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Contact Name	Judi Miller, BSN				
	Contact Telephone	·				
	·	jmillera@niaid.nih.gov				
	Sponsor Website	<u></u>				
	·	https://grants.nih.gov/grants/guide/rfa	-files/RFA-Al-19-036.html			
	_	30-Jun-2019 [LOI/Pre-App][Optional], 3				
	Synopsis	exposed uninfected children (HEU) for i	non-sputum-based tuberculosis (TB) diagr mproved, simplified, rapid and decentraliz novel biomarkers useful for TB diagnosis o llogies.	ed diagnosis	of TB disease. Th	is opportunit
חות ויצוו	Novel RNAs in Virology (including and Therapeutic Discovery (R21 Cl	HIV) and Immune Regulation: Basic Scielinical Trial Not Allowed)	nce National Institute of Allergy and Infectious Diseases/NIH/DHHS	PA-19- 237	16-Jun-2019	275,000 USD
	Contact Name	Chao Jiang, Ph.D.				
	Contact Telephone	301-761-7802				
	Contact Email	chao.jiang@nih.gov				
	Sponsor Website					
	Program URL	https://grants.nih.gov/grants/guide/pa-	-files/PA-19-237.html			
	Deadline Dates (ALL)		9 , 07-Jan-2020 , 16-Feb-2020 , 07-May-20 1ay-2021 , 16-Jun-2021 , 07-Sep-2021 , 16		•	
	Synopsis		y Announcement (FOA) is to support basion velopment, in novel biologically active virable ulation.		•	
(1)×(1/((1))	RFA-AI-19-028 Emerging Infection	ous Diseases Research Centers (U01 Clin	ical National Institute of Allergy and Infectious Diseases/NIH/DHHS	RFA-AI- 19-028	29-May-2019 [LOI/Pre-App] [Optional]	6,000,000 USD
	Contact Name	Jean Patterson, Ph.D.				
	Contact Telephone	240-292-4830				

Contact Email <u>jean.patterson@nih.gov</u>

Sponsor Website

SPIN ID	Program	Sponsor Name	Sponsor Number		Deadline Date	Funding			
SFIN ID	Title	Sponsor Warne	Sponsor Number		Deadine Date	Amount			
	Program URL	https://grants.nih.gov/grants/guide/rfa-f	iles/RFA-AI-19-028.html						
	Deadline Dates (ALL)	29-May-2019 [LOI/Pre-App][Optional], 28	3-Jun-2019						
	The purpose of this Funding Opportunity Announcement (FOA) is to establish a coordinated network of Emerging Infectious Disease Research Centers (EIDRCs) in regions around the globe where emerging and re-emerging infectious disease outbress are likely to occur. Multidisciplinary teams of investigators will conduct pathogen/host surveillance, study pathogen transmission, pathogenesis and immunologic responses in the host, and will develop reagents and diagnostic assays for improved detection for important emerging pathogens and their vectors.								
057400 <u>I</u>	NIAMS Clinical Trial Planning Gran	nt (R34)	National Institute of Arthritis & Musculoskeletal & Skin Diseases/NIH/DHHS	PAR-16- 446	01-Jun-2019 [LOI/Pre-App] [Optional]	300,000 USD			
	Contact Name	Ms. Shahnaz Khan							
	Contact Telephone	301-451-9893							
	Contact Email	Khanshah@mail.nih.gov							
	Sponsor Website								
	Program URL	http://grants.nih.gov/grants/guide/pa-fil	http://grants.nih.gov/grants/guide/pa-files/PAR-16-446.html						
	Deadline Dates (ALL)	01-Jun-2019 [LOI/Pre-App][Optional], 01-	-Jul-2019 , 01-Oct-2019 [LOI/Pre-App][Op	otional], 01-N	01-Nov-2019				
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) invites applications for planning grants for investigator-initiated clinical interventional trials. The R34 planning grant is designed to permit the necessary planning, design, and preparation of documentation prior to implementation of investigator-initiated clinical trials. Completion of Synopsis agreed upon milestones of an R34 planning grant is recommended prior to submission of an application through a U01 clinical trial implementation application that will support the actual implementation and conduct of the study. The plan should be intended to support trials that are hypothesis-driven, milestone-defined, and have the potential for high imposition of the NIAMS. This FOA will utilize the NIH R34 Planning Grant award mechanism.						lanning, letion of the h a U01 The planning			
Uh /95U	Research Grants Using the Resou (R21 Clinical Trial Not Allowed)	rces from the Osteoarthritis Initiative (OAI	National Institute of Arthritis & Musculoskeletal & Skin Diseases/NIH/DHHS	PA-18- 408	07-May-2019	275,000 USD			
	Contact Name	Gayle E. Lester, Ph.D.							
	Contact Telephone	301-594-3511							
	Contact Email	lester1@mail.nih.gov							
	Sponsor Website								
	Program URL	https://grants.nih.gov/grants/guide/pa-f	iles/PA-18-408.html						

PIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Deadline Dates (ALL)	07-May-2019 , 16-Jun-2019 , 07-Sep-2019 2020 , 16-Oct-2020 , 07-Jan-2021 , 16-Feb	9 , 16-Oct-2019 , 07-Jan-2020 , 16-Feb-2 o-2021 , 07-May-2021	020 , 07-May-2020 , 16-Jun-20	020 , 07-Sep-
	Synopsis	National Institute of Arthritis and Muscul applications for research awards that are images. This FOA seeks to expand the use publication of this FOA to the research co NIAMS and others have placed on the use grant mechanism.	focused on the use of the Osteoarthritice of these resources by investigators in mmunity indicates to investigators and	s Initiative (OAI) database, clir the broader research commur peer reviewers the importanc	nical data and nity. The ne that the
h/u//	Research Grants Using the Resour R01 Clinical Trial Not Allowed)	ces from the Osteoarthritis Initiative (OAI)	National Institute of Arthritis & Musculoskeletal & Skin Diseases/NIH/DHHS	PA-18- 409 07-May-2019	275,000 USD
	Contact Name	Gayle E. Lester, Ph.D.			
	Contact Telephone	301-594-3511			
	Contact Email	lester1@mail.nih.gov			
	Sponsor Website				
	Program URL	https://grants.nih.gov/grants/guide/pa-fi	les/PA-18-409.html		
	Deadline Dates (ALL)	07-May-2019 , 05-Jun-2019 , 07-Sep-2019 2020 , 05-Oct-2020 , 07-Jan-2021 , 05-Feb		020 , 07-May-2020 , 05-Jun-20	020 , 07-Sep-
	Synopsis	National Institute of Arthritis and Muscul applications for research awards that are images. This FOA seeks to expand the use publication of this FOA to the research co NIAMS and others have placed on the use mechanism.	focused on the use of the Osteoarthritice of these resources by investigators in mmunity indicates to investigators and	s Initiative (OAI) database, clir the broader research commur peer reviewers the importanc	nical data and nity. The ne that the
14411	Accelerating Basic and Translation	nal Research in Hidradenitis Suppurativa (R	National Institute of Arthritis & Musculoskeletal & Skin Diseases/NIH/DHHS	PA-18- 718 16-Jun-2019	275,000 USD
	Contact Name	Ricardo R. Cibotti, Ph.D.			
	Contact Telephone				

Contact Email ricardo.cibotti@nih.gov

Sponsor Website

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Program URL h	https://grants.nih.gov/grants/guide/pa-f	iles/PA-18-718.html			
	Deadline Dates (ALL) 1	.6-Jun-2019 , 16-Oct-2019 , 16-Feb-2020	, 16-Jun-2020 , 16-Oct-2020 , 16-Feb-2021	1 , 16-Jun-2	021	
	Synopsis b w	tudies aimed at understanding the etiologienetic, epigenetic, biologic, and immunos to accelerate discovery in this field of retter control disease. This FOA intends to with an emphasis on multidisciplinary collevelopment. This FOA is not intended to	uloskeletal and Skin Diseases (NIAMS) invit ogy, and the cellular and molecular mecha ologic factors causing and/or associated wi esearch and to apply new knowledge to im to support a broad range of mechanistic st llaboration for rapid bench-to-bedside excl o support applications proposing epidemio omental Research Grant award mechanism	nisms, incluith Hidraden prove pati udies using hange of in logy studie	uding the environ nitis Suppurativa ents' condition and animal and hum formation and th	mental, . The purpose nd ultimately an models, erapy
073320	Accelerating Basic and Translationa Clinical Trial Not Allowed)	l Research in Hidradenitis Suppurativa (I	National Institute of Arthritis & Musculoskeletal & Skin Diseases/NIH/DHHS	PA-18- 719	05-Jun-2019	Not Specified
	Contact Name R	Ricardo R. Cibotti, Ph.D.				
	Contact Telephone 3	01-451-5888				
	Contact Email <u>r</u> i	icardo.cibotti@nih.gov				
	Sponsor Website					
	Program URL <u>h</u>	https://grants.nih.gov/grants/guide/pa-f	<u>iles/PA-18-719.html</u>			
	Deadline Dates (ALL) 0	95-Jun-2019 , 05-Oct-2019 , 05-Feb-2020	, 05-Jun-2020 , 05-Oct-2020 , 05-Feb-2021	1 , 05-Jun-2	.021	
	Synopsis b w	tudies aimed at understanding the etiologies, end immunos to accelerate discovery in this field of reletter control disease. This FOA intends to the amphasis on multidisciplinary columns.	uloskeletal and Skin Diseases (NIAMS) invitiogy, and the cellular and molecular mechalologic factors causing and/or associated witesearch and to apply new knowledge to imply to support a broad range of mechanistic stillaboration for rapid bench-to-bedside exclusions support applications proposing epidemioward mechanism.	nisms, inclo ith Hidrade nprove pati udies using hange of in	uding the environ nitis Suppurativa ents' condition and animal and hum formation and th	mental, . The purpose nd ultimately an models, erapy
076891	Pre-Application: Research Innovation Musculoskeletal Diseases (X02 Clini	on for Scientific Knowledge (RISK) for ical Trial Not Allowed)	National Institute of Arthritis & Musculoskeletal & Skin Diseases/NIH/DHHS	PAR-18- 900	03-Jun-2019 [LOI/Pre-App] [Optional]	Not Specified

Contact Name Hung Tseng, Ph.D.

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	------------------	--------------	----------------	---------------	-------------------

Contact Telephone 301-496-0810

Contact Email tsengh@mail.nih.gov

Sponsor Website

Program URL https://grants.nih.gov/grants/guide/pa-files/PAR-18-900.html

Deadline Dates (ALL) 03-Jun-2019 [LOI/Pre-App][Optional], 03-Jul-2019

The NIAMS Research Innovation for Scientific Knowledge (RISK) for Musculoskeletal Diseases initiative focuses on innovative research within the NIAMS mission by encouraging applicants to pursue unusual observations, test imaginative hypotheses, investigate creative concepts, and build ground-breaking paradigms, all of which deviate significantly from the current prevailing theories or practice. This FOA is particularly designed to encourage the submission of projects that are considered too risky, premature, controversial, or unconventional for other NIH mechanisms. This FOA intends to support diseasefocused translational studies. We invite research studies aimed at understanding the mechanisms of diseases or conditions relevant to the NIAMS mission, as well as studies aimed at developing or testing diagnostics, therapeutic agents, or preventive interventions up to, but not including, first in human studies. The RISK XO2 and R61/R33 FOAs are not intended to support clinical trials. The RISK program will support the two main scientific areas of NIAMS mission, 1) musculoskeletal diseases and 2) the skin and rheumatic diseases. This XO2 pre-application and the companion R61/R33 (RFA-AR-19-013, SPIN Program # 76342) encourage applications related to musculoskeletal diseases. The X02 pre-application is the highly recommended (not required) first step in the application process for the companion R61/R33 (RFA-AR-19-013). Potential applicants should read both FOAs. Investigators whose X02 pre-applications are evaluated to be highly innovative and most relevant to the RISK program will be notified of the opportunity to submit an R61/R33 application under RFA-AR-19-013.

076889

Pre-Application: Research Innovation for Scientific Knowledge (RISK) for Skin and Rheumatic Diseases (XO2 Clinical Trial Not Allowed)

National Institute of Arthritis & Musculoskeletal & Skin Diseases/NIH/DHHS

PAR-18-899

03-Jun-2019 [LOI/Pre-App] [Optional]

Not **Specified** 

Contact Name Hung Tseng, Ph.D.

**Synopsis** 

Contact Telephone 301-496-0810

Contact Email tsengh@mail.nih.gov

Sponsor Website

Program URL https://grants.nih.gov/grants/guide/pa-files/PAR-18-899.html

Deadline Dates (ALL) 03-Jun-2019 [LOI/Pre-App][Optional], 03-Jul-2019

The NIAMS Research Innovation for Scientific Knowledge (RISK) for Skin and Rheumatic Diseases initiative focuses on innovative research within the NIAMS mission by encouraging applicants to pursue unusual observations, test imaginative hypotheses, investigate creative concepts, and build ground-breaking paradigms, all of which deviate significantly from the current prevailing theories or practice. This FOA is particularly designed to encourage the submission of projects that are

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount	
		considered too risky, premature, controved disease-focused translational studies. We conditions relevant to the NIAMS mission or preventive interventions up to, but not o support clinical trials. The RISK program diseases and 2) the skin and rheumatic de Program # 76410)) encourage application recommended (not required) first step in applicants should read both FOAs. Invest relevant to the RISK program will be notified.	e invite research studies aimed at understan, as well as studies aimed at developing of the including, first in human studies. The RI will support the two main scientific are iseases. This XO2 pre-application and the is related to skin and rheumatic diseases, the application process for the companications whose XO2 pre-applications are expensed.	canding the or testing did SK X02 and lass of NIAMS companion The X02 properties of R61/R33 valuated to	mechanisms of dis agnostics, therape R61/R33 FOAs are 5 mission, 1) musco R61/R33 (RFA- AR- e-application is the (RFA-AR-19-012). be highly innovation	eases or utic agents, not intended uloskeletal -19-012, SPIN e highly Potential re and most	
069762 <u>N</u>	NIBIB Research Project Grant (RO	1 Clinical Trial Required)	National Institute of Biomedical Imaging and Bioengineering/NIH/DHHS	PA-18- 418	07-May-2019	Not Specified	
	Contact Name	Steven H. Krosnick, M.D.					
	Contact Telephone	301-594-3009					
	Contact Email	krosnics@mail.nih.gov					
	Sponsor Website						
	Program URL	https://grants.nih.gov/grants/guide/pa-files/PA-18-418.html					
	Deadline Dates (ALL)	07-May-2019 , 05-Jun-2019 , 07-Sep-2019 2020 , 05-Oct-2020 , 07-Jan-2021	9 , 05-Oct-2019 , 07-Jan-2020 , 05-Feb-20	20 , 07-May	-2020 , 05-Jun-202	20 , 07-Sep-	
NIH invites applications for discrete, specified, circumscribed projects in areas representing the specific interests and competencies of the investigator(s). This NIBIB Funding Opportunity Announcement requires that at least 1 clinical trial proposed. The proposed project must be related to the programmatic interests of the NIBIB. For this Funding Opportunity Announcement, NIBIB will only support R01 applications proposing early-stage clinical trials through Phase I, first-in-hus safety, feasibility or other small clinical trials that inform early-stage technology development. NIBIB will not support applications proposing Phase II, III, IV or pivotal clinical trials or trials in which the primary outcome is efficacy, effectiveness or a post-market concern. This FOA will use the NIH Research Project (R01) award mechanism.					cal trial be oportunity t-in-human,		
Unylaii	NIBIB Trailblazer Award for New a	and Early Stage Investigators (R21 Clinical	National Institute of Biomedical Imaging and Bioengineering/NIH/DHHS	PAR-18- 207	07-May-2019	400,000 USD	
	Contact Name Contact Telephone	Antonio Sastre, Ph.D. 301-402-1373					

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		ail <u>sastrea@mail.nih.gov</u>				
	Sponsor Websit					
	_	RL https://grants.nih.gov/grants/guide/pa-fil				
		L) 07-May-2019, 16-Jun-2019, 07-Sep-2019  National Institute of Biomedical Imaging a Investigators to pursue research programs with the life and behavioral sciences. This independent careers or those who have not developmental, proof of concept, or high hypothesis-driven. Importantly, applicant preliminary data. This program will use the	and Bioengineering (NIBIB) invites applica s of high interest to the NIBIB that integra s FOA invites applications from researcher ot had substantial prior NIH funding. A Tra risk-high impact, and may be technology of s are expected to propose research appro	ite engineer rs who are a ailblazer pro design-dire paches for v	ring and the phys at the early stage oject may be exp cted, discovery-d which there are m	ical sciences of their loratory, riven, or
070275	NIBIB Exploratory/Development Optional)	tal Research Grant Program (R21 Clinical Tria	National Institute of Biomedical Imaging and Bioengineering/NIH/DHHS	PAR-18- 433	07-May-2019	275,000 USD
	Contact Nam	ne Randy King, Ph.D.				
	Contact Telephon	ne 301-451-0707				
	Contact Ema	ail randy.king@nih.gov				
	Sponsor Websit	te				
	Program UF	RL https://grants.nih.gov/grants/guide/pa-file	<u>es/PAR-18-433.html</u>			
	Deadline Dates (AL	L) 07-May-2019 , 16-Jun-2019 , 07-Sep-2019 2020 , 16-Oct-2020 , 07-Jan-2021	, 16-Oct-2019 , 07-Jan-2020 , 16-Feb-202	20 , 07-May-	-2020 <i>,</i> 16-Jun-20	20 , 07-Sep-
	Synops	National Institute of Biomedical Imaging a research programs of interest to the NIBIE to breakthroughs in development of innovatudies may involve considerable risk that research. Applicants are expected to propedemonstrate the feasibility of the propose risk-high impact, and may be technology of NIH Exploratory/Developmental (R21) grants	B (https://www.nibib.nih.gov/research-fully ative techniques, agents, methodologies, should be balanced by the potential high ose novel biomedical research approached project. A project may be exploratory, allesign-directed, discovery-driven, or hypo	nding). hese, models, on impact on es for which developme	e studies are export their application human-health ar there is no prelin ntal, proof of con	ected to lead as. These ad related minary data to cept, or high
070281	Synthetic Biology for Engineerin	g Applications (R01 Clinical Trial Optional)	National Institute of Biomedical Imaging and	PAR-18- 434	07-May-2019	Not Specified

Bioengineering/NIH/DHHS

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount		
	Contact Name	David Rampulla, Ph.D.						
	Contact Telephone	•						
	Contact Email	david.rampulla@nih.gov						
	Sponsor Website							
	Program URL	https://grants.nih.gov/grants/guide/pa-fi	tps://grants.nih.gov/grants/guide/pa-files/PAR-18-434.html					
	Deadline Dates (ALL)	07-May-2019 , 05-Jun-2019 , 07-Sep-2019 2020	9 , 05-Oct-2019 , 07-Jan-2020 , 05-Feb-202	.0 , 07-May-	-2020 , 05-Jun-20	20 , 07-Sep-		
	Synopsis	understanding and application of synthet and technologies in synthetic biology and research plan based on collaborations of	ts participating Institutes and Centers invit tic biology for human health. It will suppor d 2) their application in biomedical researc synthetic biologists with computational so nded. Early Stage Investigators in Synthetic n Project (R01) award mechanism.	t 1) the dev h and huma ientists, cel	elopment of inno in health. An inte I biologists, engir	ovative tools grative neers, and/or		
079063	<u>Limited Competition: NeuroImaging</u> <u>Clinical Trial Not Allowed)</u>	ng Tools & Resources Collaboratory (R24	National Institute of Biomedical Imaging and Bioengineering/NIH/DHHS	RFA-EB- 18-004	07-May-2019	600,000 USD		
	Contact Name	Andrew Weitz, Ph.D.						
	Contact Telephone	301-451-7813						
	Contact Email	andrew.weitz@nih.gov						
	Sponsor Website							
	· ·	https://grants.nih.gov/grants/guide/rfa-f						
			9 , 05-Oct-2019 , 07-Jan-2020 , 05-Feb-202 b-2021 , 07-May-2021 , 05-Jun-2021 , 07-S					
	Synopsis		Announcement (FOA) is to support the Nee research in neuroimaging informatics. The 5-002 (SPIN # 51620).					
078963	HEAL Initiative: Translational Deve Clinical Trial Not Allowed)	elopment of Devices to Treat Pain (U18	National Institute of Biomedical Imaging and Bioengineering/NIH/DHHS	RFA-EB- 18-003	21-May-2019 [LOI/Pre-App] [Optional]	Not Specified		

Contact Name Michael B. Wolfson

SPIN ID	Program	Sponsor Name	Sponsor Number	Deadline Date	Funding	
ľ	SPIN ID	Title	Sponsor Name		Deaumie Date	Amount

Contact Telephone 301-451-4778

Contact Email Michael. Wolfson@nih.gov

Sponsor Website

Program URL https://grants.nih.gov/grants/guide/rfa-files/RFA-EB-18-003.html

the project plan and monitoring of research progress.

21-May-2019 [LOI/Pre-App][Optional], 20-Jun-2019 , 22-Sep-2019 [LOI/Pre-App][Optional], 22-Oct-2019 , 22-Jan-2020 Deadline Dates (ALL) [LOI/Pre-App] [Optional], 21-Feb-2020, 23-May-2020 [LOI/Pre-App] [Optional], 22-Jun-2020, 21-Sep-2020 [LOI/Pre-App] App][Optional], 21-Oct-2020, 23-Jan-2021 [LOI/Pre-App][Optional], 22-Feb-2021

The purpose of this Funding Opportunity Announcement (FOA) is to support preclinical development and demonstration of safe, effective, and non-addictive device-based technologies and approaches to treat pain. The goal of the program is to demonstrate treatment using credible neural targets for device-based interventions and/or diagnostics for pain, building upon the latest mechanistic knowledge about the anatomy and physiology of central, spinal, and peripheral pathways Synopsis involved in pain. Awarded activities will facilitate the translation of new devices up to the stage of readiness for first in human (FIH) clinical trials by overcoming key challenges identified during preliminary proof-of-concept studies. The scope of the program includes technology development and optimization, and studies to prepare for approvals for human use. This is a milestone-driven cooperative agreement program and will involve participation of NIH program staff in the development of

**Funding Sponsor** SPIN ID Program Title **Sponsor Name Deadline Date** Number **Amount** National Institute of Biomedical Imaging PAR-19-079367 Bioengineering Research Partnerships (U01 Clinical Trial Not Allowed) 07-May-2019 Not Specified and Bioengineering/NIH/DHHS 156

Contact Name Seila Selimovic, Ph.D. Program Director

Contact Telephone 301-451-4577

Contact Email seila.selimovic@nih.gov

Sponsor Website

Program URL https://grants.nih.gov/grants/guide/pa-files/PAR-19-156.html

Deadline Dates (ALL)

07-May-2019, 05-Jun-2019, 07-Sep-2019, 05-Oct-2019, 07-Jan-2020, 05-Feb-2020, 07-May-2020, 05-Jun-2020, 07-Sep-2020, 05-Oct-2020, 07-Jan-2021, 05-Feb-2021, 07-May-2021

This Funding Opportunity Announcement (FOA) encourages bioengineering applications that will accelerate the development and adoption of promising tools and technologies that can address important biomedical problems. The objectives are to establish these tools and technologies as robust, well-characterized solutions that fulfill an unmet need and are capable of enhancing our understanding of life science processes or the practice of medicine. Awards will focus on supporting

			-			
SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
070266	Dioonging oring Docoarch Dartner	engage biomedical researchers or clin realize meaningful solutions within 5	integrative, quantitative bioengineering ap nicians throughout the project. The goal of – 10 years.  National Institute of Biomedical Imaging	the program		jects that can
079300	Bioengineering Research Partner	snips (001 Cililical Itial Requireu)	and Bioengineering/NIH/DHHS	157	07-iviay-2019	Not Specified
	Contact Name	Seila Selimovic, Ph.D. Program Directo	or			
	Contact Telephone	301-451-4577				
	Contact Emai	l <u>seila.selimovic@nih.gov</u>				
	Sponsor Website	2				
	Program URI	https://grants.nih.gov/grants/guide/p	pa-files/PAR-19-157.html			
	Deadline Dates (ALL	07-May-2019 , 05-Jun-2019 , 07-Sep-2 2020 , 05-Oct-2020 , 07-Jan-2021 , 05	2019 , 05-Oct-2019 , 07-Jan-2020 , 05-Feb-2 -Feb-2021 , 07-May-2021	2020 , 07-Ma	ny-2020 , 05-Jun-20	)20 , 07-Sep-
	Synopsis	and adoption of promising tools and testablish these tools and technologies enhancing our understanding of life smultidisciplinary teams that apply an	nent (FOA) encourages bioengineering apple technologies that can address important bides as robust, well-characterized solutions that cience processes or the practice of medicin integrative, quantitative bioengineering applicians throughout the project. The goal of — 10 years.	omedical pro at fulfill an u e. Awards v proach to de	oblems. The object nmet need and are will focus on suppo eveloping technolo	tives are to e capable of orting ogies, and
079360	Bioengineering Research Grants	(BRG) (R01 Clinical Trial Required)	National Institute of Biomedical Imaging and Bioengineering/NIH/DHHS	PAR-19- 159	07-May-2019	Not Specified
	Contact Name	Seila Selimovic, Ph.D. Program Directo	or			
	Contact Telephone	301-451-4577				
	Contact Emai	l <u>seila.selimovic@nih.gov</u>				
	Sponsor Website	2				
	Program URI	https://grants.nih.gov/grants/guide/p	pa-files/PAR-19-159.html			
	Deadline Dates (ALL	07-May-2019 , 05-Jun-2019 , 07-Sep-2 2020 , 05-Oct-2020 , 07-Jan-2021 , 05	2019 , 05-Oct-2019 , 07-Jan-2020 , 05-Feb-2 -Feb-2021 , 07-May-2021	2020 , 07-Ma	ay-2020 , 05-Jun-20	)20 , 07-Sep-
	Synopsis	that: 1) apply a multidisciplinary bioe	ity announcement is to encourage collabor ngineering approach to the solution of a bio erate the adoption of promising tools, meth	omedical pro	oblem; and 2) integ	grate, optimize,

		·	·					
SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount		
		developmental, discovery-driven, or h	, or clinical science and practice. An applica ypothesis-driven research and is appropria ng of and solve problems in biological, clin	nte for small t	eams applying an			
079361	Bioengineering Research Grants (	BRG) (R01 Clinical Trial Not Allowed)	National Institute of Biomedical Imaging and Bioengineering/NIH/DHHS	PAR-19- 158	07-May-2019	Not Specified		
	Contact Name	Seila Selimovic, Ph.D. Program Directo	or					
	Contact Telephone	301-451-4577						
	Contact Email	seila.selimovic@nih.gov						
	Sponsor Website							
	Program URL	https://grants.nih.gov/grants/guide/p	a-files/PAR-19-158.html					
	Deadline Dates (ALL)	07-May-2019 , 05-Jun-2019 , 07-Sep-2 2020 , 05-Oct-2020 , 07-Jan-2021 , 05-	-May-2019 , 05-Jun-2019 , 07-Sep-2019 , 05-Oct-2019 , 07-Jan-2020 , 05-Feb-2020 , 07-May-2020 , 05-Jun-2020 , 07-Sep- 20 , 05-Oct-2020 , 07-Jan-2021 , 05-Feb-2021 , 07-May-2021					
The purpose of this funding opportunity announcement is to encourage collaborations between the life and phenomena that: 1) apply a multidisciplinary bioengineering approach to the solution of a biomedical problem; and 2) integrated validate, translate or otherwise accelerate the adoption of promising tools, methods and techniques for a specific clinical problem in basic, translational, or clinical science and practice. An application may propose design-direct developmental, discovery-driven, or hypothesis-driven research and is appropriate for small teams applying an approach to increase our understanding of and solve problems in biological, clinical or translational science.						grate, optimize, ific research or cted,		
050713	Advancing Understanding, Prevent	ntion, and Management of Infections ir Infants (R21)	National Institute of Child Health and Human Development/NIH/DHHS	PA-16-031 (	07-May-2019	275,000 USD		
		Nahida Chakhtoura, MD, MsGH (Obste	<u> </u>					
	Contact Telephone		,					
	·	nahida.chakhtoura@nih.gov						
	Sponsor Website							
	Program URL	http://grants.nih.gov/grants/guide/pa	ı-files/PA-16-031.html					
	Deadline Dates (ALL)	07-May-2019 , 16-Jun-2019 , 07-Sep-2	019					
	Synopsis	translational, epidemiologic and clinic of non-HIV infections transmitted fror NICHD is committed to supporting res	Human Development (NICHD) invites applial studies and trials that improve the unden women to their offspring during pregnanearch that will increase scientific understathe NIH Exploratory/Developmental (R21)	rstanding, pro icy, labor and nding of and	evention and clini delivery, and bre treatments for hig	cal outcomes astfeeding.		

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
057596		rch Using IMPC-Generated Knockout nic or Perinatal Lethality or Subviability	National Institute of Child Health and Human Development/NIH/DHHS	PAR-17- 005	05-Jun-2019	2,499,995 USD
	Contact Name	Lorette C. Javois, PhD				
	Contact Telephone	301-435-6890				
	Contact Email	javoisl@mail.nih.gov				
	Sponsor Website					
	Program URL	http://grants.nih.gov/grants/guide/pa-	files/PAR-17-005.html			
	Deadline Dates (ALL)	05-Jun-2019 , 05-Jul-2019 , 05-Oct-201	9 , 05-Nov-2019			
	Synopsis	Research (NIDCR) invite applications to being generated through the Internation Phenotyping Program (KOMP2) is a mewith plans to generate an additional 6,00 phenotyping of 20,000 KO strains. About or subviable. A large portion of homozyscientific community has the unique oppart of the IMPC adult mouse phenotyping NIH Research Project (R01) award research Project (R01)	Human Development (NICHD) and Nation phenotype and/or perform research on onal Mouse Phenotyping Consortium (IM mber. The KOMP2 KO mouse phenotyping Oo0 over the next five years. Overall, the out 30% of these strains either are or are ygous lethal mutations are expected to he oportunity to leverage these mouse strain oing effort to perform additional in depthemechanism.	embryonic I PC) of which ng effort ha IMPC hope expected to nave viable h	lethal knockout (KC n the NIH Knockout s generated 2,500 is s to achieve broad- be embryonic or p neterozygous phend y are being created	n) mouse strains Mouse mouse strains based erinatal lethal otypes. The and bred as
054197	Preclinical Research on Model Org Outcomes for Disorders Associated Disabilities (R01)	ganisms to Predict Treatment ed with Intellectual and Developmental	National Institute of Child Health and Human Development/NIH/DHHS	PAR-16- 215	07-May-2019	2,499,995 USD
	Contact Name	Melissa A. Parisi, MD, PhD				
	Contact Telephone	301-435-6880				
	Contact Email	parisima@mail.nih.gov				
	Sponsor Website					
	Program URL	http://grants.nih.gov/grants/guide/pa-	files/PAR-16-215.html			
	Deadline Dates (ALL)	07-May-2019 , 05-Jun-2019 , 07-Sep-20	019			
	Synopsis	addressing preclinical research in mode	luman Development (NICHD) invites appel organisms of neurodevelopmental disc nd/or calibrate outcome measures, surro	orders. Appli	cations submitted	to this FOA

SPIN II)	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		disabilitie trials desi to human therapeur interested	s (IDD). In addition, applications gned for safety, toxicity, and ef clinical trials. The goal of this F tic compounds in order to move d in the FOA "Outcome Measure	y translate to human clinical trials for instance of the serion of the perform an inde so to accelerate and improve the proposition of the promising new drug therapies into clines for Use In Treatment Trials of Individuation of the proposition of the propositi	ntrolled and st pendent valid eclinical testir nical trials. Po duals with Inte	tandardized precli ation of efficacy in ng of candidate tro tential applicants	nical animal n animals prior eatments and may be
057398 <u>T</u>	rophoblast Differentiation and F	unction (R	()1)	National Institute of Child Health and Numan Development/NIH/DHHS	PA-16-445	07-May-2019	Not Specified
	Contact Name	Koji Yoshi	naga, Ph.D.				
	Contact Telephone	301-435-6	5992				
	Contact Email						
	Sponsor Website						
	Program URL	http://gra	nts.nih.gov/grants/guide/pa-fil	les/PA-16-445.html			
	Deadline Dates (ALL)	) 07-May-2019 , 05-Jun-2019 , 07-Sep-2019 , 05-Oct-2019 , 07-Jan-2020					
	Synopsis	(NIAID) in fertility ar research implantat	vite applications for outstandinnd pregnancy, including the role will act as a solid foundation to	uman Development (NICHD) and Nation of research in the area of trophoblast does of the immune system. It is anticipate hasten treatments for a number of plantoss, preeclampsia, fetal growth restrictions.	ifferentiation d that fundan cental-based	and function in renental knowledge pregnancy disorde	lation to gained by this ers, such as
059225 <u>F</u>	ertility Status as a Marker for Ov	erall Healt	h (ROT)	National Institute of Child Health and Human Development/NIH/DHHS	PA-17-091	05-Jun-2019	Not Specified
	Contact Name	Susan Tay	mans, PhD				
	Contact Telephone	301-496-6	5517				
	Contact Email	<u>Taymans</u>	<u>@mail.nih.gov</u>				
	Sponsor Website						
	Program URL	https://gr	ants.nih.gov/grants/guide/pa-f	iles/PA-17-091.html			
	Deadline Dates (ALL)	05-Jun-20	019 , 05-Oct-2019 , 05-Feb-2020	)			
	Synopsis			uman Development (NICHD) invites apported in the contract of t			

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		overall he physiolog between strongly s marker fo	ealth. Data suggest that infertili ically or genetically linked with fertility status in both males and uggest that fertility status can be roverall health and therefore a	is known about the extent to which fer ty is not necessarily a unique disease of other diseases and conditions. Recent d females and various somatic diseases be a window into overall health. This FO applications that look at the effects of a use the NIH Research Project (R01) awa	the reproduce pidemiologicand disorders A focuses on disease or dis	ctive axis, but is of c studies demonst s. Taken together studies evaluating sorder on fertility	ften rate links r, these data g fertility as a
IIINXXXX -	afety and Outcome Measures of Pregnant Women (R01 Clinical Tr			lational Institute of Child Health and luman Development/NIH/DHHS	PA-18-038(	07-May-2019	Not Specified
	Contact Name Contact Telephone Contact Email	301-402-9	9340				
	Sponsor Website		<u></u>				
	•		ants.nih.gov/grants/guide/pa-f	iles/PA-18-038.html			
	_						
	Deadline Dates (ALL) 07-May-2019 , 05-Jun-2019 , 07-Sep-2019 , 05-Oct-2019 , 07-Jan-2020  National Institute of Child Health and Human Development (NICHD) invites applications to (1) promote preclinical, translational, clinical and epidemiological research in pain medications use in children or in pregnant women to fill knowle gaps in safe use of the pain medications in these special populations; and (2) develop effective instruments or approaches assess and evaluate maternal and child outcomes of pain medication treatments. There is a need for data on pain medications used in children and pregnant women to be shared and made available to the scientific community for future studies and to encourage replication of findings and meeting the goal of further advancing research in this area. This FOA vuse the NIH Research Project (R01) award mechanism.						o fill knowledge approaches to ain y for future
	Advancing Understanding, Prever Transmitted from Women to thei			ational Institute of Child Health and uman Development/NIH/DHHS	PA-18-092(	07-May-2019	275,000 USD
	Contact Name	Nahida Cl	nakhtoura, MD, MsGH (Obstetri	cs)			
	Contact Telephone	301-435-6	5872				
	Contact Email	nahida.ch	akhtoura@nih.gov				
	Sponsor Website						
	Program URL	https://gr	ants.nih.gov/grants/guide/pa-f	iles/PA-18-092.html			
	·	•	019 , 16-Jun-2019 , 07-Sep-201				
	Synopsis	National I	nstitute of Child Health and Hu	man Development (NICHD) invites appl	ications to sti	mulate investigati	ons including

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount	
		of non-HIV infections transmitted from NICHD is committed to supporting reso	al studies and trials that improve the und n women to their offspring during pregna earch that will increase scientific underst the NIH R21 Exploratory/Developmental	ncy, labor and and and t	delivery, and bre treatments for hi	astfeeding.	
068380		ntion, and Management of Infections ir Infants (R01 Clinical Trial Optional)	National Institute of Child Health and Human Development/NIH/DHHS	PA-18-031 (	07-May-2019	Not Specified	
	Contact Telephone	Nahida Chakhtoura, MD, MsGH (Obste 301-435-6872 nahida.chakhtoura@nih.gov	etrics)				
		. https://grants.nih.gov/grants/guide/pa 07-May-2019 , 05-Jun-2019 , 07-Sep-2					
	Synopsis	translational, epidemiologic and clinical of non-HIV infections transmitted from NICHD is committed to supporting research	Human Development (NICHD) invites app al studies and trials that improve the und n women to their offspring during pregna earch that will increase scientific underst the NIH Research Project (R01) award me	erstanding, pre ncy, labor and anding of and t	evention and clini delivery, and bre	ical outcomes eastfeeding.	
065330	Pregnancy in Women with Disabil	lities (R03)	National Institute of Child Health and Human Development/NIH/DHHS	PA-17-451 [	17-May-2019 [LOI/Pre-App] [Optional]	100,000 USE	
	Contact Name	Maurice Davis, DHA, MPA, MHSA					
	Contact Telephone	301-435-6887					
	Contact Email	Maurice.Davis@mail.nih.gov					
	Sponsor Website						
		https://grants.nih.gov/grants/guide/pa					
	Deadline Dates (ALL)	17-May-2019 [LOI/Pre-App][Optional], 16-Jun-2019 , 16-Sep-2019 [LOI/Pre-App][Optional], 16-Oct-2019 , 17-Jan-2020 [LOI/Pre-App][Optional], 16-Feb-2020 , 17-May-2020 [LOI/Pre-App][Optional], 16-Jun-2020					
	Synopsis	(R03) investigating the incidence, cour include studies to inform preconception	Human Development (NICHD) invites app se, and outcomes of pregnancy among w onal and antenatal counseling and strateguerperium, and the transition to parentho	omen with dis gies for address	abilities. Areas o sing barriers to pi	f interest also renatal care,	

SPIN ID	Program	Sponsor Name	Sponsor Number	-	Deadline Date	Funding
	Title	5,000.000				Amount
		1	omental, and/or sensory disabilities and the nembers of the community in the design a ward mechanism.			_
065329	Pregnancy in Women with Disabi	lities (R01)	National Institute of Child Health and Human Development/NIH/DHHS	PA-17-452	06-May-2019 [LOI/Pre-App] [Optional]	Not Specified
	Contact Name	Maurice Davis, DHA, MPA, MHSA				
	Contact Telephone	301-435-6887				
	Contact Emai	Maurice.Davis@mail.nih.gov				
	Sponsor Website					
	Program URI	https://grants.nih.gov/grants/guide/p	pa-files/PA-17-452.html			
	Deadline Dates (ALL)	11	], 05-Jun-2019 , 05-Sep-2019 [LOI/Pre-App ) , 06-May-2020 [LOI/Pre-App], 05-Jun-202		05-Oct-2019 , 06-J	an-2020
	Synopsis	and outcomes of pregnancy among wand antenatal counseling and strateging puerperium, and the transition to par developmental, and/or sensory disable	Human Development (NICHD) invites appromen with disabilities. Areas of interest are for addressing barriers to prenatal care enthood in order to optimize outcomes for illities and their families. Applicants are enthosed in and conduct of their research. The	also include s e, and manag or women wit ncouraged to	tudies to inform p ement of pregnand th physical, intelled include women w	reconceptional cy, the ctual and ith disabilities
1164777	Small Grants for Secondary Analy Biospecimens (R03)	rses of Existing Data Sets and Stored	National Institute of Child Health and Human Development/NIH/DHHS	PA-17-299	07-May-2019	100,000 USD
_	Contact Name	Regina Bures, PhD				
	Contact Telephone	301-496-9485				
	Contact Emai	regina.bures@nih.gov				
	Sponsor Website					
	Program URI	https://grants.nih.gov/grants/guide/p	pa-files/PA-17-299.html			
	Deadline Dates (ALL)	07-May-2019 , 16-Jun-2019 , 07-Sep-2	2019 , 16-Oct-2019 , 07-Jan-2020 , 16-Feb	-2020 , 07-Ma	ay-2020	
	Synopsis	analyses of publicly available NICHD-f	Human Development (NICHD) invites appointed data sets or stored biospecimens. I utilizing data and biospecimens collected	The goal of th	nis program is to fa	cilitate

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		the NIH Small Research Grant (R03) av	vard mechanism.			
061033	Resource-Related Research Proje of Pediatric Injury (R24)	ects in the Epidemiology and Prevention	National Institute of Child Health and Human Development/NIH/DHHS	PAR-17- 228	19-Jun-2019	684,375,000 USD
	Contact Name	Ruth Brenner, MD, MPH				
	Contact Telephone	301-594-8668				
	Contact Email	brennerr@mail.nih.gov				
	Sponsor Website					
	Program URL	https://grants.nih.gov/grants/guide/p	a-files/PAR-17-228.html			
	Deadline Dates (ALL)	19-Jun-2019 , 23-Oct-2019				
	Synopsis  Characterization of the Adolescer	childhood injuries. Consistent with the on Injury Prevention, Trauma and Emedisability, including, but not limited to	ty, for furthering research in the scientific research priorities of the Pediatric Traun ergency Care, the research resource shoul , motor vehicle crashes, firearms, poisoni se the NIH R24 Resource-Related Research	na and Critic Id focus on a ngs, drownir	al Illness Branch ar reas most likely to ng, self-injurious be	nd the portfolio cause death or
068395	Trial Optional)	THE REPRODUCTIVE TRANSITION (NZT CIMICAL	Human Development/NIH/DHHS	PA-18-045	5 16-Jun-2019	275,000 USD
	Contact Name	Esther Eisenberg, MD MPH				
	Contact Telephone	301-496-6516				
	Contact Email	eisenbes@mail.nih.gov				
	Sponsor Website					
	Program URL	https://grants.nih.gov/grants/guide/p	a-files/PA-18-045.html			
	Deadline Dates (ALL)	16-Jun-2019				
	Synopsis	support outstanding research in the ar technologies and approaches is neede in both males and females. It is anticip	Human Development (NICHD) invites apporea of puberty and the trajectory of sexual doto fill knowledge gaps and advance und ated that the findings of studies supported to ductive competence. This FOA will use the transfer of the competence.	Il developme lerstanding c ed by this FO	ent. Research using of normative sexua A will advance kno	new I development wledge of
068396	Characterization of the Adolescer	nt Reproductive Transition (RO3 Clinical	National Institute of Child Health and	PA-18-046	5 16-Jun-2019	100,000 USD

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	<u>Trial Optional)</u>		Human Development/NIH/DHHS			
	Contact Name	Esther Eisenberg, MD MPH				
	Contact Telephone	301-496-6516				
	Contact Email	eisenbes@mail.nih.gov				
	Sponsor Website					
	Program URL	https://grants.nih.gov/grants/guide/pa-	files/PA-18-046.html			
	Deadline Dates (ALL)	16-Jun-2019				
	Synopsis	support outstanding research in the are technologies and approaches is needed in both males and females. It is anticipa	uman Development (NICHD) invites appl a of puberty and the trajectory of sexual to fill knowledge gaps and advance unde ted that the findings of studies supporte ductive competence. This FOA will use th	development erstanding of r d by this FOA	Research using normative sexual will advance kno	new development wledge of
068392	Safety and Outcome Measures of Pregnant Women (R21 Clinical Tri	Pain Medications Used in Children and ial Optional)	National Institute of Child Health and Human Development/NIH/DHHS	PA-18-043 C	07-May-2019	275,000 USD
	Contact Name	Zhaoxia Ren, MD, PhD				
	Contact Telephone	301-402-9340				
	Contact Email	zren@mail.nih.gov				
	Sponsor Website					
	Program URL	https://grants.nih.gov/grants/guide/pa-	-files/PA-18-043.html			
	Deadline Dates (ALL)	07-May-2019 , 16-Jun-2019 , 07-Sep-20				
	Synopsis	translational, clinical and epidemiologic gaps in safe use of the pain medications assess and evaluate maternal and child	in these special populations; and (2) decoutcomes of pain medication treatments ant women to be shared and made availabilities and meeting the goal of further	ildren or in provelop effective s. There is a neal to the scient	egnant women to instruments or eed for data on p entific communit	o fill knowledge approaches to ain y for future
068393	Safety and Outcome Measures of Pregnant Women (R03 Clinical Tri	Pain Medications Used in Children and ial Optional)	National Institute of Child Health and Human Development/NIH/DHHS	PA-18-044 C	7-May-2019	100,000 USD

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Contact Telephone 3 Contact Email z Sponsor Website Program URL L Deadline Dates (ALL) C Synopsis a	https://grants.nih.gov/grants/guide/p 07-May-2019 , 16-Jun-2019 , 07-Sep-2 National Institute of Child Health and cranslational, clinical and epidemiolog gaps in safe use of the pain medicatio assess and evaluate maternal and chil medications used in children and preg		hildren or in pregnant women evelop effective instruments o ts. There is a need for data on lable to the scientific commur	to fill knowled r approaches to pain iity for future
Unguin	Fertility Status as a Marker for Ove Optional)	use the NIH R03 Small Grant Program rall Health (R21 Clinical Trial	National Institute of Child Health and Human Development/NIH/DHHS	PA-18-049 16-Jun-2019	275,000 US
		Susan Taymans, PhD			
	Contact Telephone	301-496-6517			
	Contact Email 1	<u> FaymansS@mail.nih.gov</u>			
	Sponsor Website				

Program URL https://grants.nih.gov/grants/guide/pa-files/PA-18-049.html

Deadline Dates (ALL) 16-Jun-2019, 16-Oct-2019, 16-Feb-2020

National Institute of Child Health and Human Development (NICHD), National Institute of Environmental Health Sciences (NIEHS), and Office of Disease Prevention (ODP) invite applications for exploratory/developmental research that explores the premise that fertility status can be a marker for overall health. It is clear that chronic conditions such as cancer, diabetes, and obesity can impair fertility, however less is known about the extent to which fertility status can impact or act as a marker for overall health. Data suggest that infertility is not necessarily a unique disease of the reproductive axis, but is often physiologically or genetically linked with other diseases and conditions. Recent epidemiologic studies demonstrate links between fertility status in both males and females and various somatic diseases and disorders. Taken together, these data strongly suggest that fertility status can be a window into overall health. This FOA focuses on studies evaluating fertility as a marker for overall health and therefore applications that look at the effects of a disease or disorder on fertility are outside the scope of this program. This FOA will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadli	ne Date	Funding Amount
		<u>'</u>				
069001	Zika Virus (ZIKV) Complications (R	.21 Clinical Trial Optional)	National Institute of Child Health and Human Development/NIH/DHHS	PA-18-048 07-May	·-2019	275,000 USD
	Contact Name	Nahida Chakhtoura MD, MsGH				
	Contact Telephone	301-435-6872				
	Contact Email	nahida.chakhtoura@nih.gov				
	Sponsor Website					
	Program URL	https://grants.nih.gov/grants/guid	le/pa-files/PA-18-048.html			
	Deadline Dates (ALL)	07-May-2019 , 05-Jun-2019 , 07-Sε	ep-2019 , 05-Oct-2019 , 07-Jan-2020			
	Synopsis	starting in 2015. Disease is seen in between ZIKV infection in pregnan the virus has been found in blood,	947, it has been reported in the Americas sind about 20% of infected people and is usually at women and severe microcephaly in their bactering growing concerns about the risk of tracterist transfusion recipient populations such lopmental (R21) grant mechanism.	self-limited. Howeve abies has been very co ansfusion-transmissio	r, an assoc oncerning. on with par	iation Additionally ticular
068995	Trophoblast Differentiation and F	unction (R21 Clinical Trial Optional)	National Institute of Child Health and Human Development/NIH/DHHS	PA-18-047 07-May	·-2019	275,000 USD
	Contact Name	Koji Yoshinaga, Ph.D.				
	Contact Telephone	301-435-6992				
	Contact Email	ky6a@nih.gov				
	Sponsor Website					
	Program URL	https://grants.nih.gov/grants/guid	le/pa-files/PA-18-047.html			
	Deadline Dates (ALL)	07-May-2019 , 16-Jun-2019 , 07-Sε	ep-2019 , 16-Oct-2019 , 07-Jan-2020			
	Synopsis	(NIAID) invite applications for outs fertility and pregnancy, including the research will act as a solid foundat	and Human Development (NICHD) and National Standing research in the area of trophoblast of the role of the immune system. It is anticipated it is not to hasten treatments for a number of plagnancy loss, preeclampsia, fetal growth restricts of the contractions of the	lifferentiation and funed that fundamental katental-based pregnan	nction in re nowledge ncy disorde	lation to gained by this rs, such as

NIH R21 Exploratory/Developmental Grant award mechanism.

SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
072577 Innovative Therapies and Tools (R01 - Clinical Trial Optional)	s for Screenable Disorders in Newborns	National Institute of Child Health and Human Development/NIH/DHHS	PAR-18- 689	07-May-2019	Not Specified
Contact Na	me Melissa Parisi, MD, PhD				
Contact Telepho	one 301-435-6880				
Contact Em	nail parisima@mail.nih.gov				
Sponsor Webs	site				
Program L	JRL https://grants.nih.gov/grants/guide	e/pa-files/PAR-18-689.html			
Deadline Dates (A	07-May-2019 , 05-Jun-2019 , 07-Sep 2020 , 05-Oct-2020 , 07-Jan-2021 , (	p-2019 , 05-Oct-2019 , 07-Jan-2020 , 05-Feb 05-Feb-2021 , 07-May-2021	-2020 , 07-Ma	ay-2020 , 05-Jun-2	020 , 07-Sep-
	newborn screening, as well as "high future. Demonstrating the benefits panel; therefore, for this FOA, a "high significantly benefit from early iden mechanism.	entions for potentially fatal or disabling cond n priority" genetic conditions where screening of treatment is often a primary criterion for gh priority" condition is one where screening atification and treatment. This program will	ng may be pos including a c g is not curre	ssible in the near ondition on a new ntly recommended	born screening
072575 Developmental Pharmacodyna Pediatrics (R01 Clinical Trial Option 1997)	amics and Models of Drug Effects in otional)	National Institute of Child Health and Human Development/NIH/DHHS	PA-18-688	07-May-2019	Not Specified
Contact Na	me George P. Giacoia MD				
Contact Telepho	one 301-496-5589				
Contact Em	nail giacoiag@exchange.nih.gov				
Sponsor Webs	site				
Program U	JRL https://grants.nih.gov/grants/guide	e/pa-files/PA-18-688.html			
Deadline Dates (A	07-May-2019 , 05-Jun-2019 , 07-Sep 2020 , 05-Oct-2020 , 07-Jan-2021 , (	p-2019 , 05-Oct-2019 , 07-Jan-2020 , 05-Feb <sup>.</sup> 05-Feb-2021 , 07-May-2021	-2020 , 07-Ma	ay-2020 , 05-Jun-2	020 , 07-Sep-
Synop	applications for multidisciplinary, in pharmacodynamics. This FOA seeks pharmacodynamics in the pediatric	and Human Development (NICHD) and Nation investigator-initiated basic translational and of signant applications that propose studies to it age groups and allows the determination of opulation. This FOA will use the NIH Research	clinical resear ncrease and e f pharmacoki	ch in developmen establish data on c netic-pharmacody	tal levelopmental namic
072576 <u>Developmental Pharmacodyna</u>	amics and Models of Drug Effects in	National Institute of Child Health and	PA-18-687	07-May-2019	100,000 USD

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Pediatrics (R03 Clinical Trial Option	<u>nal)</u>	Human Development/NIH/DHHS		
	Contact Name	George P. Giacoia MD			
	Contact Telephone	301-496-5589			
	Contact Email	giacoiag@exchange.nih.gov			
	Sponsor Website				
	Program URL	https://grants.nih.gov/grants/guide/p	pa-files/PA-18-687.html		
	Deadline Dates (ALL)	07-May-2019 , 16-Jun-2019 , 07-Sep-2 2020 , 16-Oct-2020 , 07-Jan-2021 , 16-	2019 , 16-Oct-2019 , 07-Jan-2020 , 16-Feb- -Feb-2021 , 07-May-2021	2020 , 07-May-2020 , 16-Jun-2	.020 , 07-Sep-
	Synopsis	applications for multidisciplinary, inverpharmacodynamics. This FOA seeks grapharmacodynamics in the pediatric ag	d Human Development (NICHD) and Natio estigator-initiated basic translational and crant applications that propose studies to inge groups and allows the determination of ulation. This FOA will use the NIH RO3 Sma	clinical research in developmen ncrease and establish data on of f pharmacokinetic-pharmacody	ntal developmental ynamic
070178	Studies in Neonatal and Pediatric Optional)	Resuscitation (R01 Clinical Trial	National Institute of Child Health and Human Development/NIH/DHHS	PA-18-491 07-May-2019	Not Specifie
	Contact Name	Marion Koso-Thomas, M.D, MPH			
	Contact Telephone	301-435-6873			
	Contact Email	kosomari@mail.nih.gov			
	Sponsor Website				
	Program URL	https://grants.nih.gov/grants/guide/p	pa-files/PA-18-491.html		
	Deadline Dates (ALL)	07-May-2019 , 16-Jun-2019 , 07-Sep-2 2020 , 16-Oct-2020 , 07-Jan-2021	2019 , 16-Oct-2019 , 07-Jan-2020 , 16-Feb-	2020 , 07-May-2020 , 16-Jun-2	.020 , 07-Sep-
	Synopsis	related to neonatal and pediatric resucardiovascular and pulmonary physiol on the fetus, resuscitation of children resuscitation practices. Applications computer or other information-technologisting national or regional datasets, thereof. It is anticipated that the resu	Human Development (NICHD) invites apprescitation. Possible topics may include, but logy, optimizing steps of resuscitation, may with malformations, effect of resuscitation an include epidemiological studies, studies ology-based simulations or study designs, opportunistic studies, prospective randomals from well-conducted studies will enable a optimal short- and long-term outcomes	t are not limited to: fetal-neonal magement of third stage of lab- on on long-term outcomes and es utilizing fetal-neonatal animal clinical observational studies, a mized controlled trials, or any of le translation of knowledge int	atal transitional or and its effect post- al models, analyses of pre- combinations to evidence-

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		FOA will use the NIH R03 Small Grant F	Program award mechanism.			
070172	Studies in Neonatal and Pediatric Optional)	Resuscitation (R01 Clinical Trial	National Institute of Child Health and Human Development/NIH/DHHS	PA-18-485	07-May-2019	Not Specified
	Contact Name	Marion Koso-Thomas, M.D, MPH				
	Contact Telephone	301-435-6873				
	Contact Email	kosomari@mail.nih.gov				
	Sponsor Website					
	Program URL	https://grants.nih.gov/grants/guide/pa	a-files/PA-18-485.html			
	Deadline Dates (ALL)	07-May-2019 , 05-Jun-2019 , 07-Sep-2 2020 , 05-Oct-2020 , 07-Jan-2021	019 , 05-Oct-2019 , 07-Jan-2020 , 05-Feb-	2020 , 07-Ma <sup>-</sup>	y-2020 , 05-Jun-20	020 , 07-Sep-
	Synopsis	related to neonatal and pediatric resustant cardiovascular and pulmonary physiologon the fetus, resuscitation of children resuscitation practices. Applications computer or other information-technologisting national or regional datasets, thereof. It is anticipated that the resustant cardiovascular resustant cardiovascular resustant cardiovascular resustant cardiovascular resustant resuscent resustant res	Human Development (NICHD) invites appositation. Possible topics may include, but ogy, optimizing steps of resuscitation, mawith malformations, effect of resuscitation an include epidemiological studies, studies ology-based simulations or study designs, opportunistic studies, prospective randor lts from well-conducted studies will enaba optimal short- and long-term outcomes (RO1) award mechanism.	are not limite nagement of n on long-teri s utilizing feta clinical obser nized controll le translation	ed to: fetal-neona third stage of labo m outcomes and pal-neonatal anima vational studies, a ed trials, or any coof knowledge into	tal transitional or and its effect post- I models, nalyses of pre- ombinations o evidence-
070455		r Pregnancy-Related/Induced Diseases s to Prevent/Treat These Diseases (R01	National Institute of Child Health and Human Development/NIH/DHHS	PAR-18- 511	07-May-2019	Not Specified
	Contact Name	Ekaterini Tsilou, MD				
	Contact Telephone	301-496-6287				
	Contact Email	tsiloue@mail.nih.gov				
	Sponsor Website					
	Program URL	https://grants.nih.gov/grants/guide/p	a-files/PAR-18-511.html			
	Deadline Dates (ALL)	07-May-2019 , 05-Jun-2019 , 07-Sep-2 2020 , 05-Oct-2020 , 07-Jan-2021	019 , 05-Oct-2019 , 07-Jan-2020 , 05-Feb-	2020 , 07-Ma <sup>-</sup>	y-2020 , 05-Jun-20	)20 , 07-Sep-
			Human Development (NICHD) invites app	lications that	will identify moled	cular targets

					_	
SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		1	orders and will lead to the development o the NIH Research Project (R01) award mo		and more effective	medications
072586	Innovative Therapies and Tools for (R21 Clinical Trial Optional)	or Screenable Disorders in Newborns	National Institute of Child Health and Human Development/NIH/DHHS	PAR-18- 691	07-May-2019	275,000 USD
	Contact Name	Melissa Parisi, MD, PhD				
	Contact Telephone	301-435-6880				
	Contact Email	parisima@mail.nih.gov				
	Sponsor Website					
	Program URL	https://grants.nih.gov/grants/guide/p	a-files/PAR-18-691.html			
	Deadline Dates (ALL)	07-May-2019 , 16-Jun-2019 , 07-Sep-2 2020 , 16-Oct-2020 , 07-Jan-2021 , 16-	019 , 16-Oct-2019 , 07-Jan-2020 , 16-Feb- Feb-2021 , 07-May-2021	2020 , 07-M	ay-2020 , 16-Jun-2	020 , 07-Sep-
	Synopsis	development of therapeutic intervent newborn screening, as well as "high pro- future. Demonstrating the benefits of panel; therefore, for this FOA, a "high	I its participating Institutes and Centers in ions for potentially fatal or disabling condriority" genetic conditions where screenin treatment is often a primary criterion for priority" condition is one where screening cation and treatment. This program will upon the condition is the program will upon the condition and treatment.	itions that h g may be po including a c g is not curre	ave been identified issible in the near condition on a new ently recommended	through born screening but would
072588	Innovative Therapies and Tools for (R03 Clinical Trial Optional)	or Screenable Disorders in Newborns	National Institute of Child Health and Human Development/NIH/DHHS	PAR-18- 690	07-May-2019	100,000 USD
	Contact Name	Melissa Parisi, MD, PhD				
	Contact Telephone	301-435-6880				
	Contact Email	parisima@mail.nih.gov				
	Sponsor Website					
	Program URL	https://grants.nih.gov/grants/guide/p	a-files/PAR-18-690.html			
	Deadline Dates (ALL)	07-May-2019 , 16-Jun-2019 , 07-Sep-2 2020 , 16-Oct-2020 , 07-Jan-2021 , 16-	019 , 16-Oct-2019 , 07-Jan-2020 , 16-Feb- Feb-2021 , 07-May-2021	2020 , 07-M	ay-2020 , 16-Jun-2	020 , 07-Sep-
	Synopsis	development of therapeutic intervent newborn screening, as well as "high pi	l its participating Institutes and Centers in ions for potentially fatal or disabling cond riority" genetic conditions where screenin treatment is often a primary criterion for	itions that h	ave been identified ssible in the near	through

SPIN ID	Program Title	Sponsor Name	Sponsor Number	ı	Deadline Date	Funding Amount
		T -	priority" condition is one where screening cation and treatment. This program will			
073287	Research on the Health of Transg Populations (R21 Clinical Trial Op	ender and Gender Nonconforming tional)	National Institute of Child Health and Human Development/NIH/DHHS	PA-18-728 0	7-May-2019	275,000 USD
	Contact Name	Della B. White, PhD				
	Contact Telephone					
	Contact Email	whitede@mail.nih.gov				
	Sponsor Website					
	Program URL	https://grants.nih.gov/grants/guide/p	a-files/PA-18-728.html			
	Deadline Dates (ALL)	07-May-2019 , 16-Jun-2019 , 07-Sep-2 2020 , 16-Oct-2020 , 07-Jan-2021	019 , 16-Oct-2019 , 07-Jan-2020 , 16-Feb-	-2020 , 07-May-	-2020 , 16-Jun-20	)20 , 07-Sep-
	Synopsis	of transgender and gender nonconform gender identity and those individuals we the other. This group encompasses inc	d its participating Institutes and Centers in ming people of all ages, including both yow ho are making or who have made a trandividuals whose gender identity differs from what is traditionally associated and Grant award mechanism.	uth and adults v sition from beir om the sex on th	who are question ng identified as c neir original birth	ning their one gender to n certificate or
073285	Research on the Health of Transg Populations (R01 Clinical Trial Op	ender and Gender Nonconforming tional)	National Institute of Child Health and Human Development/NIH/DHHS	PA-18-729 0	7-May-2019	Not Specified
	Contact Name	Della B. White, PhD				
	Contact Telephone					
	•	whitede@mail.nih.gov				
	Sponsor Website					
	Program URL	https://grants.nih.gov/grants/guide/pa	a-files/PA-18-729.html			
	Deadline Dates (ALL)	07-May-2019 , 05-Jun-2019 , 07-Sep-2 2020 , 05-Oct-2020 , 07-Jan-2021	019 , 05-Oct-2019 , 07-Jan-2020 , 05-Feb-	-2020 , 07-May-	-2020 , 05-Jun-20	020 , 07-Sep-
	Synopsis	National Institutes of Health (NIH) an of transgender and gender nonconform gender identity and those individuals with the second secon	d its participating Institutes and Centers i ming people of all ages, including both yo who are making or who have made a tran dividuals whose gender identity differs fro	nvite applicatio uth and adults v sition from beir	ons for research on who are question are question are gidentified as c	on the health ning their one gender to

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		whose gender expression varies signif use the NIH Research Project (R01) aw	icantly from what is traditionally associate vard mechanism.	ed with or typic	cal for that sex. T	his FOA will
074839	Patient Safety in the Context of P (RO3 - Clinical Trial Optional)	erinatal, Neonatal, and Pediatric Care	National Institute of Child Health and Human Development/NIH/DHHS	PA-18-791 0	07-May-2019	100,000 USD
	Contact Name	Marion Koso-Thomas, M.D, MPH				
	Contact Telephone	301-435-6873				
	Contact Email	kosomari@mail.nih.gov				
	Sponsor Website					
	Program URL	https://grants.nih.gov/grants/guide/p	a-files/PA-18-791.html			
	Deadline Dates (ALL)		.019 , 16-Oct-2019 , 07-Jan-2020 , 16-Feb Feb-2021 , 07-May-2021 , 16-Jun-2021 , (		-2020 , 16-Jun-20	)20 , 07-Sep-
	Synopsis	research projects related to patient sa settings and in intensive care units. Th various domains of medical errors and such errors; and intervention strategie errors. It is anticipated that knowledge	Human Development (NICHD) invites apporterly in the context of perinatal, neonatal are FOA welcomes applications related to (I consequent patient harm; assessing the es at individual, systems, and institutional egained from these projects will help dever children with utmost safety and effective	and pediatric c but not limited factors at vario -levels to help i relop strategies	care both in routi I to): the epidemi ous levels that co reduce and elimi is to deliver highes	ne hospital iology of ntribute to nate medical st quality of
070065	NICHD Exploratory/Development Optional)	al Research Grant (R21 - Clinical Trial	National Institute of Child Health and Human Development/NIH/DHHS	PA-18-482 0	)7-May-2019	275,000 USD
	Contact Name	NICHD Referral Office				
	Contact Telephone					
	Contact Email	NICHDReferral@mail.nih.gov				
	Sponsor Website					
		https://grants.nih.gov/grants/guide/p				
	Deadline Dates (ALL)	07-May-2019 , 16-Jun-2019 , 07-Sep-2 2020 , 16-Oct-2020 , 07-Jan-2021	.019 , 16-Oct-2019 , 07-Jan-2020 , 16-Feb	-2020 , 07-May	-2020 , 16-Jun-20	)20 , 07-Sep-
	, , , , , , , , , , , , , , , , , , ,	research projects that fall within the N	Human Development (NICHD) invites ap NICHD mission by providing support for th onsiderable risk but may lead to a breakth	e early and con	nceptual stages o	f these

SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		ents, methodologies, models, or applicationsesearch. This FOA will use the NIH R21 Exp			
070064 NICHD Small Grant Program (R03	Clinical Trial Optional)	National Institute of Child Health and Human Development/NIH/DHHS	PA-18-481	07-May-2019	100,000 USD
Contact Telephone Contact Email	NICHDReferral@mail.nih.gov				
Sponsor Website Program URL	https://grants.nih.gov/grants/guide/j	<del>oa-files/PA-18-481.html</del> 2019 , 16-Oct-2019 , 07-Jan-2020 , 16-Feb-	2020 07 May	, 2020 16 Jun 20	020 07 San
Deadline Dates (ALL) Synopsis	2020, 16-Oct-2020, 07-Jan-2021 National Institute of Child Health an be carried out in a short period of tim including pilot and feasibility studies;	d Human Development (NICHD) invites apple with limited resources. The R03 activity secondary analysis of existing data; small, gy; and development of new research tech	plications for s code supports self-contained	small research pro s different types o d research projec	ojects that can of projects ts;
070059 NICHD Research Project Grant (RO	01 - Clinical Trial Required)	National Institute of Child Health and Human Development/NIH/DHHS	PA-18-480	07-May-2019	Not Specified
Contact Name	NICHD Referral Office				
Contact Telephone Contact Email Sponsor Website	NICHDReferral@mail.nih.gov				
·	https://grants.nih.gov/grants/guide/j	pa-files/PA-18-480.html			
Deadline Dates (ALL)	07-May-2019 , 05-Jun-2019 , 07-Sep- 2020 , 05-Oct-2020 , 07-Jan-2021	2019 , 05-Oct-2019 , 07-Jan-2020 , 05-Feb-	2020 , 07-May	y-2020 , 05-Jun-20	020 , 07-Sep-
Synopsis	1	d Human Development (NICHD) invites ap NIH Research Project (R01) award mechan		clinical trials that	fall within the
070412 Drug Repurposing for Conditions Women (R01 Clinical Trial Option	Affecting Neonates and Pregnant al)	National Institute of Child Health and Human Development/NIH/DHHS	PAR-18- 506	07-May-2019	Not Specified

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount	
	Contact Name Contact Telephone	Ekaterini Tsilou. MD				
	·	tsiloue@mail.nih.gov				
	Sponsor Website					
	•	https://grants.nih.gov/grants/guide/p	a-files/PAR-18-506.html			
	Deadline Dates (ALL)  O7-May-2019 , 05-Jun-2019 , 07-Sep-2019 , 05-Oct-2019 , 07-Jan-2020 , 05-Feb-2020 , 07-May-2020 , 05-Jun-2020 , 07-Sep-2021 , 07-May-2021 , 07-May-2021 , 07-May-2021					
	Synopsis	National Institute of Child Health and drugs for new neonatal and obstetric i development of drugs appropriate for	Human Development (NICHD) invites appointment, in order to overcome the difficuse in neonates and pregnant women and Research Project (R01) award mechanism	culties associated with the trad d facilitate treatment of these	itional	
074832	Patient Safety in the Context of Pe (R01 - Clinical Trial Optional)	erinatal, Neonatal, and Pediatric Care	National Institute of Child Health and Human Development/NIH/DHHS	PA-18-790 07-May-2019	Not Specified	
	Contact Name	Marion Koso-Thomas, M.D, MPH				
	Contact Telephone	301-435-6873				
	Contact Email	kosomari@mail.nih.gov				
	Sponsor Website					
	•	https://grants.nih.gov/grants/guide/p				
	Deadline Dates (ALL)	07-May-2019 , 05-Jun-2019 , 07-Sep-2 2020 , 05-Oct-2020 , 07-Jan-2021 , 05-	019 , 05-Oct-2019 , 07-Jan-2020 , 05-Feb- Feb-2021 , 07-May-2021 , 05-Jun-2021 , 0	2020 , 07-May-2020 , 05-Jun-20 77-Sep-2021	020 , 07-Sep-	
	Synopsis	National Institute of Child Health and research projects related to patient sa settings and in intensive care units. Th various domains of medical errors and such errors; and intervention strategic errors. It is anticipated that knowledge	Human Development (NICHD) invites appled fety in the context of perinatal, neonatal are FOA welcomes applications related to (black) consequent patient harm; assessing the fees at individual, systems, and institutionale gained from these projects will help development with utmost safety and effectives	lications for a wide range of col and pediatric care both in routi but not limited to): the epidem factors at various levels that co levels to help reduce and elimi elop strategies to deliver highe	ne hospital iology of ntribute to nate medical st quality of	
074138	Identification and Management o Health Conditions in Individuals w Clinical Trial Optional)	f Behavioral Symptoms and Mental vith Intellectual Disabilities (R01 -	National Institute of Child Health and Human Development/NIH/DHHS	PAR-18- 766 07-May-2019	Not Specified	

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Contact Name	Tracy King, MD, MPH				
	Contact Telephone					
	·	tracy.king@nih.gov				
	Sponsor Website					
	·	https://grants.nih.gov/grants/guide/p	pa-files/PAR-18-766.html			
	_	07-May-2019 , 05-Jun-2019 , 07-Sep-2			y-2020 , 05-Jun-20	020 , 07-Sep-
	Synopsis	management of behavioral symptoms areas of interest for this funding oppoidentify behavioral symptoms or diagrapharmacokinetics, safety and efficacy	d Human Development (NICHD) invites appeared mental health conditions in individual retunity are (1) applications to develop and nose mental health conditions in individual of specific psychotropic medications for to This FOA will use the NIH Research Proj	als with intelled walidate assembles with ID, and reatment of b	ectual disabilities ( essment tools that d (2) applications s ehavioral sympto	ID). Specific reliably studying the
11/56//	The Role of Epitranscriptomics in Clinical Trial Not Allowed)	Development and Disease (R01 -	National Institute of Child Health and Human Development/NIH/DHHS	PAR-18- 830	03-Jun-2019	499,999 USD
	Contact Name	Stuart B. Moss, PhD				
	Contact Telephone	301-435-6979				
	Contact Email	mossstua@mail.nih.gov				
	Sponsor Website					
	Program URL	https://grants.nih.gov/grants/guide/p	a-files/PAR-18-830.html			
	Deadline Dates (ALL)	03-Jun-2019 , 03-Mar-2020 , 07-Nov-2	2020 , 03-Jun-2021			
	Synopsis	Institute (NEI) invite applications for reRNA. Evidence is accumulating that R that these modifications are involved modifications as well as their roles in of the FOA is to promote research into	d Human Development (NICHD), National desearch in the area of epitranscriptomics, NA modifications regulate the function of in both development, and in health and departicular biological processes remain either the role of RNA chemical modifications is states and conditions relevant to the scies.)	i.e., the chem both coding a isease. Yet th her poorly und n the initiation	nical modifications and noncoding RN he extent and type derstood or not kn n and progression	of As, suggesting s of these RNA own. The goal of various



075841

Role of Gut Microbiome in Regulating Reproduction and Its Impact on

Fertility Status in Women Living with and Without HIV (R21 Clinical Trial

National Institute of Child Health and

Human Development/NIH/DHHS

PA-18-839 07-May-2019

275,000 USD

SPIN ID	Program	Sponsor Name	Sponsor Number	Deadline Date	Funding
SI III ID	Title	Sponsor Hame	Sponsor Number	Deadinic Date	Amount

## Optional)

Contact Name Ravi Ravindranath, PhD

Contact Telephone 301-435-6889

Contact Email ravindrn@mail.nih.gov

Sponsor Website

Program URL https://grants.nih.gov/grants/guide/pa-files/PA-18-839.html

Deadline Dates (ALL

07-May-2019, 16-Jun-2019, 07-Sep-2019, 16-Oct-2019, 07-Jan-2020, 16-Feb-2020, 07-May-2020, 16-Jun-2020, 07-Sep-2020 . 16-Oct-2020 , 07-Jan-2021 , 16-Feb-2021 , 07-May-2021 , 16-Jun-2021 , 07-Sep-2021

National Institute of Child Health and Human Development (NICHD) invites applications for research related to the role of the gut microbiome in regulating metabolism and reproduction, and its impact on fertility status. The overarching goal is to gain fundamental insight into the possible role of the gut microbiome in regulating reproduction through hypothalamopituitary-gonadal (HPG), hypothalamo-pituitary-adrenal (HPA), and hypothalamo-pituitary-thyroid (HPT) axes in the brain. The results of the study could lead to development of diagnostic markers (signature microbiomes) for reproductive and Synopsis metabolic failure. The project is pertinent to multiple portfolios in the Fertility and Infertility Branch, e.g., basic ovarian biology, fertility preservation, assisted reproductive technology, spermatogenesis and sperm function, and therapeutic interventions to infertility. The emphasis on the gut microbiome and its impact on reproduction through its effects on HPG, HPA, and HPT axes leading to obesity, metabolic syndrome, stress disorders, infection and anxiety is also of interest to the Maternal and Pediatric infectious disease Branch, Pediatric Growth and Nutrition Branch and Intellectual and Developmental

Role of Gut Microbiome in Regulating Reproduction and Its Impact on 075836 Fertility Status in Women Living with and Without HIV (R01 Clinical Trial Optional)

National Institute of Child Health and Human Development/NIH/DHHS

Disabilities Branch. This FOA will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.

PA-18-838 07-May-2019

2,499,995 USD

Contact Name Ravi Ravindranath, PhD

Contact Telephone 301-435-6889

Contact Email ravindrn@mail.nih.gov

Sponsor Website

Program URL https://grants.nih.gov/grants/guide/pa-files/PA-18-838.html

Deadline Dates (ALL)

07-May-2019, 05-Jun-2019, 07-Sep-2019, 05-Oct-2019, 07-Jan-2020, 05-Feb-2020, 07-May-2020, 05-Jun-2020, 07-Sep-2020, 05-Oct-2020, 07-Jan-2021, 05-Feb-2021, 07-May-2021, 05-Jun-2021, 07-Sep-2021

National Institute of Child Health and Human Development (NICHD) invites applications for research related to the role of the gut microbiome in regulating metabolism and reproduction, and its impact on fertility status. The overarching goal is to

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		pituitary-gonadal (HPG), hypothalamo The results of the study could lead to o metabolic failure. The project is pertin biology, fertility preservation, assisted interventions to infertility. The empha- HPA, and HPT axes leading to obesity, Maternal and Pediatric infectious disease	sible role of the gut microbiome in regular-pituitary-adrenal (HPA), and hypothalam development of diagnostic markers (signalent to multiple portfolios in the Fertility a reproductive technology, spermatogenesis on the gut microbiome and its impact metabolic syndrome, stress disorders, integes Branch, Pediatric Growth and Nutriticate NIH Research Project (R01) award mediatric syndrome.	no-pituitary-th ature microbio and Infertility sis and sperm on reproducti fection and an on Branch and	yroid (HPT) axes in the second of the second	n the brain. ctive and covarian rapeutic ects on HPG, erest to the
Uhlkuh	evelopment of Appropriate Ped relivery Systems (R01)	iatric Formulations and Pediatric Drug	National Institute of Child Health and Human Development/NIH/DHHS	PAR-17- 193	07-May-2019	Not Specified
	Contact Name	George P. Giacoia, M.D.				
	Contact Telephone	301-496-5589				
	Contact Email	giacoiag@exchange.nih.gov				
	Sponsor Website					
	Program URL	https://grants.nih.gov/grants/guide/pa	a-files/PAR-17-193.html			
	Deadline Dates (ALL)	07-May-2019 , 05-Jun-2019 , 07-Sep-2	019 , 05-Oct-2019 , 07-Jan-2020 , 05-Feb	-2020 , 07-Ma	y-2020	
	Synopsis	complementary research needs for the	Human Development (NICHD) invites app e development and acceptability of pedia iatric drug delivery systems is also part o ism.	tric drug form	ulations in differe	ent age groups.
	romoting NICHD Areas of Resea ealth (R01)	rch for HIV/AIDS in Maternal and Child	National Institute of Child Health and Human Development/NIH/DHHS	PA-17-262	07-May-2019	Not Specified
	Contact Name	Samantha C. Calabrese, MPH				
	Contact Telephone	301-827-7568				
	Contact Email	samantha.calabrese@nih.gov				
	Sponsor Website					
	Program URL	https://grants.nih.gov/grants/guide/pa	a-files/PA-17-262.html			
	Deadline Dates (ALL)	07-May-2019 , 05-Jun-2019 , 07-Sep-2 2020	019 , 05-Oct-2019 , 07-Jan-2020 , 05-Feb	-2020 , 07-Ma <sup>-</sup>	y-2020 , 05-Jun-20	020 , 07-Sep-
	Synopsis	National Institute of Child Health and	Human Development (NICHD) invites ap	plications for	HIV/AIDS research	n by addressing

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
			NICHD, Maternal and Pediatric Infectious explain our interests over the next three			
Uh 150h	<u>Genetic Susceptibility &amp; Variabilit</u> ( <u>R01)</u>	ty of Human Structural Birth Defects	National Institute of Child Health and Human Development/NIH/DHHS	PAR-17- 236	05-Jun-2019	2,499,995 USD
	Contact Name	Lorette C. Javois, Ph.D.				
	Contact Telephone	301-496-5541				
	Contact Email	javoisl@mail.nih.gov				
	Sponsor Website					
	Program URL	https://grants.nih.gov/grants/guide/	pa-files/PAR-17-236.html			
	Deadline Dates (ALL)	05-Jun-2019 , 05-Oct-2019				
	Synopsis	our understanding of structural birth approaches. Applicants are encouraged developmental biology to identify specific with the susceptibility to and variability will join the NICHD Birth Defects Workersearch progress, exchange ideas, she	nd its participating Institutes and Centers in defects through the use of animal models ged to take advantage of advances in gene ecific genetic, epigenetic, environmental, of ity of structural birth defects in human polyking Group and participate in annual meet hare resources, and foster collaborations rese the NIH Research Project (RO1) award in	in conjuncti tics, biocher or gene/envi oulations. A tings designe elevant to th	on with translation nistry, molecular, a ronment interactio pplicants funded the ed to provide a forc	nal/clinical nd ns associated nrough this FOA um to discuss
060364	Biomarkers: Bridging Pediatric an	d Adult Therapeutics (R21)	National Institute of Child Health and Human Development/NIH/DHHS	PAR-17- 169	07-May-2019	275,000 USD
	Contact Name	George P. Giacoia, MD				
	Contact Telephone	301-496-5589				
	Contact Email	gg65m@nih.gov				
	Sponsor Website					
	Program URL	https://grants.nih.gov/grants/guide/	pa-files/PAR-17-169.html			
	Deadline Dates (ALL)	07-May-2019 , 16-Jun-2019 , 07-Sep-	2019 , 16-Oct-2019 , 07-Jan-2020 , 16-Feb	-2020 , 07-N	lay-2020	
	Synopsis	biomarkers to children. This would in diagnosis, prognosis, and estimation	Human Development (NICHD) invites app clude the application and validation of bio of disease progression, toxicity and respor rrelate with a clinical observation, have be	markers dev se to therap	veloped in adults to by. Projects suppor	pediatric ted by this FOA

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		,	pediatric applications. Discovery of new b his FOA. This program will use the NIH Ex		•	•
061397	Development of Appropriate Ped Delivery Systems (R21)	iatric Formulations and Pediatric Drug	National Institute of Child Health and Human Development/NIH/DHHS	PAR-17- 192	07-May-2019	275,000 USD
	Contact Name	George P. Giacoia, M.D.				
	Contact Telephone	301-496-5589				
	Contact Email	giacoiag@exchange.nih.gov				
	Sponsor Website					
	Program URL	https://grants.nih.gov/grants/guide/pa	a-files/PAR-17-192.html			
	Deadline Dates (ALL)	07-May-2019 , 16-Jun-2019 , 07-Sep-20	019 , 16-Oct-2019 , 07-Jan-2020 , 16-Feb-	2020 , 07-M	ay-2020	
	Synopsis	complementary research needs for the This FOA also encourages the develope encouraged to explore approaches and newly developed techniques superior	Human Development (NICHD) invites appled development and acceptability of pediated development and acceptability of pediated and of novel drug delivery systems in the disconcepts new to the area of pediatric for the ones currently used in the field. Apple FOA will use the NIH Exploratory/Develor	tric drug forn e pediatric p rmulation de plications su	mulations in differe opulation. Investig evelopment and te Ibmitted under this	ent age groups. ators are sting and use s mechanism
061404	<u>Development of Appropriate Ped</u> <u>Delivery Systems (R03)</u>	iatric Formulations and Pediatric Drug	National Institute of Child Health and Human Development/NIH/DHHS	PAR-17- 191	07-May-2019	100,000 USD
	Contact Name	George P. Giacoia, M.D.				
	Contact Telephone	301-496-5589				
	Contact Email	giacoiag@exchange.nih.gov				
	Sponsor Website					
	Program URL	https://grants.nih.gov/grants/guide/pa	a-files/PAR-17-191.html			
	Deadline Dates (ALL)	07-May-2019 , 16-Jun-2019 , 07-Sep-20	019 , 16-Oct-2019 , 07-Jan-2020 , 16-Feb-	2020 , 07-M	ay-2020	
	Synopsis	complementary research needs for the This FOA also encourages the develope encouraged to explore approaches and newly developed techniques superior	Human Development (NICHD) invites appled development and acceptability of pediatement of novel drug delivery systems in the disconcepts new to the area of pediatric forto the ones currently used in the field. Apple FOA will use the NIH RO3 Small Grant Prosecution.	tric drug forn e pediatric p rmulation de plications su	mulations in differe opulation. Investig evelopment and te Ibmitted under this	ent age groups. ators are sting and use

SPIN ID	Program	Sponsor Name	Sponsor Number		Deadline Date	Funding
	Title					Amount
075633	The Role of Epitranscriptomics in Clinical Trial Not Allowed)	Development and Disease (R21 -	National Institute of Child Health and Human Development/NIH/DHHS	PAR-18- 831	03-Jun-2019	275,000 USD
	Contact Name	Stuart B. Moss, PhD				
	Contact Telephone	301-435-6979				
	Contact Email	mossstua@mail.nih.gov				
	Sponsor Website					
	Program URL	https://grants.nih.gov/grants/guide/p	a-files/PAR-18-831.html			
	Deadline Dates (ALL)	03-Jun-2019 , 03-Mar-2020 , 07-Nov-2	.020 , 03-Jun-2021			
	Synopsis	Institute (NEI) invite applications for re RNA. Evidence is accumulating that RI that these modifications are involved modifications as well as their roles in p of the FOA is to promote research into developmental processes and disease	Human Development (NICHD), National (esearch in the area of epitranscriptomics, NA modifications regulate the function of in both development, and in health and diparticular biological processes remain eith the role of RNA chemical modifications is states and conditions relevant to the scie Human Development (NICHD). This FOA will Grant in a sward mechanism.	i.e., the che both coding isease. Yet the er poorly ur in the initiati intific missio	mical modifications g and noncoding RN the extent and type nderstood or not kr on and progression in of the Eunice Ker	s of IAs, suggesting es of these RNA nown. The goal n of various
078591	Small Research Grants for Analyse First Data Resource (R03 - Clinical	es of Data for the Gabriella Miller Kids   Trial Not Allowed)	National Institute of Child Health and Human Development/NIH/DHHS	PAR-19- 069	07-May-2019	200,000 USD
	Contact Name	James N. Coulombe, Ph.D.				
	Contact Telephone	301-451-1390				
	Contact Email	CoulombeJ@mail.nih.gov				
	Sponsor Website					
	Program URL	https://grants.nih.gov/grants/guide/p	a-files/PAR-19-069.html			
	Deadline Dates (ALL)	07-May-2019 , 16-Jun-2019 , 07-Sep-2	019			
	Synopsis	pediatric research data resource popu communities of investigators who stud Gabriella Miller Kids First Pediatric Dat childhood cancer and birth defects col	d the Gabriella Miller Kids First Pediatric Fulated by genome sequence and phenotypedy the genetics of childhood cancers and/ta Resource is to build a collection of curathorts and provide a central portal where control the compress to these data will promote compress to the second control to the compress to the second control to the c	e data that or structura ted genomical and ana	will be of high value I birth defects. The c and phenotypic da alysis tools will be r	e for the goal of the ata from eadily

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount		
		support meritorious small research pr birth defects datasets that are part of	diagnostic capabilities and ultimately mo ojects focused on the development and a the Kids First Data Resource or could be igy appropriate for analyzing genome-wid	nalyses of ch ncluded in th	ildhood cancer and e Kids First Data R	d/or structural esource.		
079181	Academic Research Enhancement Institutions (R15 - Clinical Trial Re	t Award for Undergraduate-Focused equired)	National Institute of Child Health and Human Development/NIH/DHHS	PAR-19- 133	07-May-2019	300,000 USD		
	Contact Name	Mahua Mukhopadhyay, PhD						
	Contact Telephone	301-435-6886						
	Contact Email	mukhopam@mail.nih.gov						
	Sponsor Website							
	Program URL	https://grants.nih.gov/grants/guide/p	a-files/PAR-19-133.html					
	Deadline Dates (ALL)	Deadline Dates (ALL) 07-May-2019, 25-Jun-2019, 07-Sep-2019, 25-Oct-2019, 07-Jan-2020, 25-Feb-2020, 07-May-2020, 25-Jun-2020, 07-Sep 2020, 25-Oct-2020, 07-Jan-2021						
	Synopsis	The purpose of this Academic Research Enhancement Award (AREA) for Undergraduate-Focused Institutions is to support small scale research grants at institutions that do not receive substantial funding from the NIH, with an emphasis on providing biomedical research experiences for undergraduate students and enhancing the research environment at these applicant institutions. Eligible institutions must award baccalaureate science degrees and have received less than 6 million dollars per year of NIH support (total costs) in 4 of the last 7 fiscal years. This funding opportunity announcement (FOA) supports investigator-initiated mechanistic and/or minimal risk clinical trials addressing the mission and research interests the participating NIH institutes. Minimal risk clinical trials are defined as those that do not require FDA oversight, do not intend to formally establish efficacy, and have low risks to potentially cause physical or psychological harm.						
068376	Characterization of the Adolescer Trial Optional)	nt Reproductive Transition (R01 Clinical	National Institute of Child Health and Human Development/NIH/DHHS	PA-18-033	05-Jun-2019	Not Specified		
-	Contact Name	Esther Eisenberg, MD MPH						
	Contact Telephone							
	Contact Email	eisenbes@mail.nih.gov						
	Sponsor Website							
	Program URL	https://grants.nih.gov/grants/guide/p	a-files/PA-18-033.html					
	Deadline Dates (ALL)	05-Jun-2019						
	Synopsis	National Institute of Child Health and	Human Development (NICHD) invites app	lications fron	n the scientific con	nmunity to		

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		technologies and approaches is neede in both males and females. It is anticip	rea of puberty and the trajectory of sexua d to fill knowledge gaps and advance und ated that the findings of studies supporte oductive competence. This FOA will use t	erstanding o	f normative sexual A will advance kno	development wledge of
080581	RFA-HD-20-004 Medical Rehabi Clinical Trial Optional)	litation Research Resource (P2C	National Institute of Child Health and Human Development/NIH/DHHS	RFA-HD- 20-004	27-May-2019 [LOI/Pre-App] [Optional]	3,750,000 USD
	Contact Name	Ralph Nitkin, PhD				
	Contact Telephone	301-402-4206				
	Contact Email	rn21e@nih.gov				
	Sponsor Website					
	_	https://grants.nih.gov/grants/guide/rf				
	Deadline Dates (ALL)	27-May-2019 [LOI/Pre-App][Optional]	, 27-Jun-2019			
	Synopsis	National Institutes of Health, to invite infrastructure center to promote extercreate a national network of research engineering, and/or psychosocial field people with chronic physical disabilities portfolio and is particularly interested approaches; family, caregiver, and con	rtunity Announcement (FOA), issued by N grant applications from institutions/orgar rnal collaboration with the medical rehabicenters that provide access to collateral esthat are particularly relevant to medical es. Specifically, the NIH is interested in addin the following high-priority areas: pedianmunity support; implementation and disbination therapies; and, technology to tra	nizations that ilitation come expertise in b rehabilitatio dressing gaps atric rehabilit semination r	t propose to build munity. The aim of iomedical, behavion research and the in the rehabilitatiation; personalized esearch; clinical tr	e research this FOA is to oral, e needs of on research d medicine
055994	NIDCR Small Research Grants for (R03)	Secondary Analysis of FaceBase Data	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-16- 362	16-Jun-2019	200,000 USD
	Contact Name	Steven B. Scholnick, Ph.D.				
	Contact Telephone					
	Contact Email	scholnis@nidcr.nih.gov				
	Sponsor Website					
	Program URL	http://grants.nih.gov/grants/guide/pa	-files/PAR-16-362.html			
	Deadline Dates (ALL)	16-Jun-2019				

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount		
National Institute of Dental and Craniofacial Research (NIDCR) invites applications for meritorious research projects that conduct secondary data analyses of these FaceBase datasets relevant to craniofacial development, human craniofacial conditions or traits, and animal models of those craniofacial conditions. Informatics projects that integrate data from multiple FaceBase datasets are especially encouraged. This program will use the NIH Small Research Grant (R03) award mechanism.								
055371	NIDCR Mentored Career Development the Dental, Oral and Craniofacial Rese		National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-16- 321	07-May-2019	625,000 USD		
	Contact Telephone Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL)  National Institute of Dental and Craniofacial Research (NIDCR) invites applications for the NIDCR Mentored Career Development Award. The award is designed to enhance the diversity of the independently funded dental, oral and craniofacial research workforce by providing a mentored research experience for eligible postdoctoral fellows and junior faculty who are from groups that have been shown to be underrepresented in the basic and clinical biomedical, behavioral, and social sciences. This award provides salary and research support for a sustained period of protected time for intensive research career development under the guidance of an experienced mentor. This FOA will use the NIH K01 Research Scientist Development Award - Research & Training award mechanism.							
055147	Factors Underlying Differences in Fem Dental, Oral, and Craniofacial Disease		National Institute of Dental and Craniofacial Research/NIH/DHHS	PA-16-296	6 07-May-2019	275,000 USD		
	Sponsor Website Program URL							

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Eactors Underlying Differences in	they affect sex-based differences in (SS), orofacial pain, temporomandib	nune reactivity, genetic variation, enviror DOC-related diseases and conditions includar joint (TMJ) disorder (TMD), salivary this FOA will use the NIH Exploratory/Dev	uding, but not I gland tumors, a	imited to, Sjögren nd human papillor	's Syndrome navirus (HPV)-
	Dental, Oral, and Craniofacial Dis		Craniofacial Research/NIH/DHHS	PA-16-295	07-May-2019	Not Specified
	Contact Telephone Contact Emai Sponsor Website Program URI Deadline Dates (ALL)	amanda.melillo@nih.gov  http://grants.nih.gov/grants/guide/g 07-May-2019 , 05-Jun-2019 , 07-Sep National Institute of Dental and Crar Women's Health (ORWH) invite appl differences in Dental, Oral, and Cran studies aimed at understanding imm they affect sex-based differences in (SS), orofacial pain, temporomandib	niofacial Research (NIDCR), National Instilications for research on mechanisms undiofacial (DOC)-related diseases and condition reactivity, genetic variation, enviror DOC-related diseases and conditions includar joint (TMJ) disorder (TMD), salivary in this FOA will use the NIH Research Project	derlying the ma itions. Specifica nmental triggers luding, but not l gland tumors, a	nifestations of sex Ily, this initiative e , aging, and horm imited to, Sjögren nd human papillor	-based encourages onal changes as 's Syndrome
053538	Precision Imaging of Oral Lesions	(R21-Clinical Trial Not Allowed)	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-18- 788	07-May-2019	275,000 USI
	Contact Name	Chiayeng Wang, Ph.D.				
	Contact Telephone	301-827-4647				
	Contact Emai	chiayeng.wang@nih.gov				
	Sponsor Website					
	Program URI	https://grants.nih.gov/grants/guide/	/pa-files/PAR-18-788.html			
	Deadline Dates (ALL)		-2019 , 16-Oct-2019 , 07-Jan-2020 , 16-Fo 6-Feb-2021 , 07-May-2021 , 16-Jun-2021			
	Synopsis		aniofacial Research (NIDCR) invites applic rate, reproducible, specific, and sensitive			<u>-</u>

treatment, and treatment monitoring for diseases and conditions in the oral cavity and oropharynx. This FOA will use the NIH

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount		
		R21 Exploratory/Developmental Resea	arch Grant award mechanism.					
069114	NIDCR Dentist Scientist Career Tra Investigators (K22 Clinical Trial Re		National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-18- 360	07-May-2019	Not Specified		
	Contact Name	Leslie A. Frieden, PhD						
	Contact Telephone	301-496-4263						
	Contact Email	leslie.frieden@mail.nih.gov						
	Sponsor Website							
	Program URL	https://grants.nih.gov/grants/guide/p	a-files/PAR-18-360.html					
	Deadline Dates (ALL)	07-May-2019, 12-Jun-2019, 07-Sep-2019, 12-Oct-2019, 07-Jan-2020, 12-Feb-2020, 07-May-2020, 12-Jun-2020, 2020, 12-Oct-2020, 07-Jan-2021						
	Synopsis	National Institute of Dental and Craniofacial Research (NIDCR) invites applications for the NIDCR Dentist Scientist Care Transition Award for Intramural Investigators (K22) program. provide highly qualified dentists in NIH Intramural postd fellowship positions with an opportunity to receive further mentored research experience in the NIH Intramural programd then to provide them with independent funding to facilitate the transition of their research programs as new investigators at extramural institutions. This Funding Opportunity Announcement (FOA) is designed specifically for approposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. This FOA will utilize the NIH K22 Care Transition Award mechanism.						
069107		ment Award to Promote Diversity in Research Workforce (K01-Clinical Trial	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-18- 359	07-May-2019	625,000 USD		
	Contact Name	Lynn Mertens King, PhD						
	Contact Telephone	•						
	·	lynn.king@nih.gov						
	Sponsor Website							
	Program URL	https://grants.nih.gov/grants/guide/p	a-files/PAR-18-359.html					
	Deadline Dates (ALL)	07-May-2019 , 12-Jun-2019 , 07-Sep-2 2020 , 12-Oct-2020 , 07-Jan-2021	019 , 12-Oct-2019 , 07-Jan-2020 , 12-Feb-	-2020 , 07-M	ay-2020 , 12-Jun-20	020 , 07-Sep-		
National Institute of Dental and Craniofacial Research (NIDCR) invites applications for the NIDCR Mentored Career  Synopsis Development Award. The award is designed to enhance the diversity of the independently funded dental, oral and craniofacial research workforce by providing a mentored research experience for eligible postdoctoral fellows and junior								

SPIN ID	Program Title	Sponsor Name	Sponsor Number		<b>Deadline Date</b>	Funding Amount
		behavioral, and social sciences. This a intensive research career development Announcement (FOA) is designed spe clinical trial, a clinical trial feasibility s	e been shown to be nationally underrepo ward provides salary and research suppo nt under the guidance of an experienced cifically for applicants proposing to serve tudy, or a separate ancillary study to an e the NIH KO1 Research Scientist Develop	ort for a sustair mentor. This F as the lead invexisting trial, as	ed period of prote unding Opportuni vestigator of an ind part of their rese	ected time for ty dependent arch and
070273	NIDCR Dual Degree Dentist Scient (K99/R00-Clinical Trial Required)	tist Pathway to Independence Award	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-18- 432	07-May-2019	Not Specified
	Contact Name	Leslie A. Frieden, Ph.D.				
	Contact Telephone					
		l <u>leslie.frieden@nih.gov</u>				
	Sponsor Website					
	Program URL	https://grants.nih.gov/grants/guide/g		2020 07.14	2020 42 1 24	22.07.6
	Deadline Dates (ALL)	07-May-2019 , 12-Jun-2019 , 07-Sep- 2020 , 12-Oct-2020 , 07-Jan-2021	2019 , 12-Oct-2019 , 07-Jan-2020 , 12-Fe	o-2020 , 07-Ma	y-2020 , 12-Jun-20	)20 , 07-Sep-
	Synopsis	(K99/R00). The primary purpose of the strong cohort of new and talented incomparison of outstanding dual degrees tenure-track or equivalent faculty positive independent research. The option for training at no more than 3 person-model Announcement (FOA) is designed specifical trial, a clinical trial feasibility services.	ofacial Research (NIDCR) invites applicate Pathway to Independence Award (K99) dependent dual degree dentist scientists dentist scientists from mentored, postdesitions by providing support for two years five years of independent (R00) support on the effort (25% effort) in any year of the cifically for applicants proposing to serve tudy, or a separate ancillary study to an elize the NIH K99/R00 Career Transition A	/R00) program This program Octoral researc S of mentored to is available to e R00 phase. The as the lead invexisting trial, as	is to increase and is designed to fact hositions to indecraining and three accommodate clirhis Funding Oppor yestigator of an indecrate of their rese	maintain a litate a timely pendent, to five years of lical specialty tunity dependent arch and
070589	NIDCR Clinical Trial Planning and Agreement (UG3/UH3 Clinical Tri	· · · · · · · · · · · · · · · · · · ·	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-18- 547	07-May-2019	Not Specified
	Contact Telephone	J Dena Fischer, DDS, MSD, MS 301-594-4876 dena.fischer@nih.gov				

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount		
	Sponsor Website	https://gr	ants.nih.gov/grants/guide/pa-f	iles/PAR-18-547.html				
			7-May-2019 , 06-Jun-2019 , 07-Sep-2019 , 08-Oct-2019 , 07-Jan-2020 , 06-Feb-2020 , 07-May-2020 , 08-Jun-202 020 , 06-Oct-2020 , 07-Jan-2021					
	Synopsis	agreement FOA will in implement requirement the instru study tear equivalent operation Procedure with animobservation determine UH3 phase	nt research applications to plan nitially support a one-year mile station phase of up to five years ents may transition to the UH3 ctions described in this FOA. The and will support activities to t), if needed; the data manager al oversight plans; recruitment es for the subsequent clinical trals, the collection of preliminar anal data from humans to supper individuals' eligibility for partice of the award will support the	acial Research (NIDCR) invites applications for UG3/ and implement clinical trials within the mission of N stone-driven planning phase (UG3), with possible transfer (UH3). Only UG3 projects that have met the scient phase. The UG3/UH3 application must be submitted the UG3 phase will permit the Program Director/Print develop: the final clinical protocol; the Clinical Investment system and other tools for data collection and and retention strategies; and other essential documinal in the UH3 phase. The UG3 planning phase is not ry data on the efficacy of the intervention (such as port the rationale for a clinical trial. Evaluation of the cipation in the future UH3 trial is allowed in the UG3 conduct of one investigator-initiated clinical trial. The	AIDCR. Awards made ansition to a clinical ific milestones and das a single application of the application of	de under this al trial I feasibility ation, followin to finalize the (or ent, safety and Manual of clinical studies e collection of population to		

Basic and Translational Oral Health Research Related to HIV/AIDS (R21 072634 Clinical Trial Not Allowed)

National Institute of Dental and Craniofacial Research/NIH/DHHS

PA-18-695 07-May-2019

275,000 USD

Contact Name Gallya Gannot, DMD, Ph.D.

Contact Telephone 301-451-5096

Contact Email gallya.gannot@nih.gov

Sponsor Website

Program URL https://grants.nih.gov/grants/guide/pa-files/PA-18-695.html

Deadline Dates (ALL)

07-May-2019, 16-Jun-2019, 07-Sep-2019, 16-Oct-2019, 07-Jan-2020, 16-Feb-2020, 07-May-2020, 16-Jun-2020, 07-Sep-2020 , 16-Oct-2020 , 07-Jan-2021

National Institute of Dental and Craniofacial Research (NIDCR) invites applications for innovative basic and translational Synopsis research into mechanisms of HIV transmission, persistence, pathogenesis and co-morbidities in the oral cavity. This FOA will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.

072628 Basic and Translational Oral Health Research Related to HIV/AIDS (R01

National Institute of Dental and

PA-18-699 07-May-2019

Not Specified



SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Clinical Trial Not Allowed)		Craniofacial Research/NIH/DHHS			
	Contact Name	Gallya Gannot, DMD, Ph.D.				
	Contact Telephone	301-451-5096				
	Contact Email	gallya.gannot@nih.gov				
	Sponsor Website					
		https://grants.nih.gov/grants/guide/p				
	Deadline Dates (ALL)	07-May-2019 , 05-Jun-2019 , 07-Sep-2 2020 , 05-Oct-2020 , 07-Jan-2021	019 , 05-Oct-2019 , 07-Jan-2020 , 05-Fe	b-2020 , 07-Ma	ay-2020 , 05-Jun-2	020 , 07-Sep-
	Synopsis		iofacial Research (NIDCR) invites applica smission, persistence, pathogenesis and vard mechanism.			
074728	Precision Imaging of Oral Lesions	(R01- Clinical Trial Not Allowed)	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-18- 787	07-May-2019	Not Specified
	Contact Name	Chiayeng Wang, Ph.D.				
	Contact Telephone	301-827-4647				
	Contact Email	chiayeng.wang@nih.gov				
	Sponsor Website					
	Program URL	https://grants.nih.gov/grants/guide/p	a-files/PAR-18-787.html			
	Deadline Dates (ALL)	07-May-2019 , 05-Jun-2019 , 07-Sep-2 2020 , 05-Oct-2020 , 07-Jan-2021 , 05-	019 , 05-Oct-2019 , 07-Jan-2020 , 05-Fe Feb-2021 , 07-May-2021 , 05-Jun-2021	b-2020 , 07-Ma , 07-Sep-2021	ay-2020 , 05-Jun-2	020 , 07-Sep-
	Synopsis	adaptation, optimization, and validation	d its participating Institutes and Center on of accurate, reproducible, specific, a nonitoring for diseases and conditions invard mechanism.	nd sensitive ima	aging approaches	to improve
076575	Biologic Factors Underlying Denta Disparities (R21 - Clinical Trial Not		National Institute of Dental and Craniofacial Research/NIH/DHHS	PA-18-874	07-May-2019	275,000 USD
	Contact Name	Darien Weatherspoon, DDS, MPH				
	Contact Telephone	301-594-5394				
	Contact Email	darien.weatherspoon@mail.nih.gov				
	Sponsor Website					

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount		
		l. ,, , . ,						
	•	https://grants.nih.gov/grants/guide/p						
	Deadline Dates (ALL) 07-May-2019, 16-Jun-2019, 07-Sep-2019, 16-Oct-2019, 07-Jan-2020, 16-Feb-2020, 07-May-2020, 16-Jun-2020, 07-Jan-2021, 16-Feb-2021, 07-May-2021, 16-Jun-2021, 07-Sep-2021							
National Institute of Dental and Craniofacial Research (NIDCR) and National Institute on Minority Health and Health Disparities (NIMHD) invite applications for investigator-initiated studies designed to identify and understand biologic (microbial, immune, genetic) that contribute to disparities in dental, oral, and craniofacial disease onset, progression persistence. This FOA will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.								
076573	Biologic Factors Underlying Denta Disparities (R01 - Clinical Trial Not	·	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-18- 875	07-May-2019	Not Specified		
	Contact Name	Darien Weatherspoon, DDS, MPH						
	Contact Telephone	301-594-5394						
	Contact Email	darien.weatherspoon@mail.nih.gov						
	Sponsor Website							
	Program URL	https://grants.nih.gov/grants/guide/p	a-files/PAR-18-875.html					
	Deadline Dates (ALL)		019 , 05-Oct-2019 , 07-Jan-2020 , 05-Feb- Feb-2021 , 07-May-2021 , 05-Jun-2021 , (		y-2020 , 05-Jun-20	020 , 07-Sep-		
	Synopsis	Disparities (NIMHD) invite applications (microbial, immune, genetic) that cont	iofacial Research (NIDCR) and National Inc s for investigator-initiated studies designe tribute to disparities in dental, oral, and c Research Project (R01) award mechanism	ed to identify a raniofacial dis	and understand bi	ologic factors		
060091	NIDCR Prospective Observational Cooperative Agreement (U01)	or Biomarker Clinical Validation Study	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-17- 154	07-May-2019	Not Specified		
	Contact Name	Dena Fischer, DDS, MSD, MS						
	Contact Telephone	301-594-4876						
	Contact Email	dena.fischer@nih.gov						
	Sponsor Website							
	Program URL	https://grants.nih.gov/grants/guide/p	a-files/PAR-17-154.html					
	Deadline Dates (ALL)	07-May-2019 , 05-Jun-2019 , 07-Sep-2	019 , 05-Oct-2019 , 07-Jan-2020					
	Synopsis		ofacial Research (NIDCR) invites applications that require prospective collection of da					

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		a/biospecimens collected as part of 1 Research Project Cooperative Agre	a previous cooperative agreement award ements award mechanism.	d from NIDCR	. This program wi	ll use the NIH
072035	NIDCR Behavioral and Social Interventing Implementation Cooperative Agreem Required)		National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-18- 656	07-May-2019	Not Specified
	Contact Telephone 301	lissa W. Riddle, PhD I-451-3888 dleme@mail.nih.gov				
Program URL https://grants.nih.gov/grants/guide/pa-files/PAR-18-656.html  O7-May-2019, 06-Jun-2019, 07-Sep-2019, 08-Oct-2019, 07-Jan-2020, 06-Feb-2020, 07-May-2020, 08-Jun-2020, 07-Jan-2020, 06-Feb-2020, 07-May-2020, 08-Jun-2020, 07-Jan-2021						
National Institute of Dental and Craniofacial Research (NIDCR) invites research applications to plan an behavioral and social intervention clinical trials. Studies appropriate for this announcement include trate to develop and test behavior change interventions for preventing and treating dental, oral, or craniofact as interventions that are used as tools to understand mechanisms of behavior change. Awards made un initially support a milestone-driven planning phase (UG3) for up to 2 years, with possible transition to a implementation phase of up to five years (UH3). Only UG3 projects that have met the scientific milestor requirements may transition to the UH3 phase. The UG3/UH3 application must be submitted as a single the instructions described in this FOA. The UG3 phase for behavioral and social intervention clinical trisscientific and operational planning activities. Scientific planning activities include small-scale data collect scientific and operational planning activities. Scientific planning activities include small-scale data collect scientific and operational planning activities. Scientific planning activities include small-scale data collect scientific and operational planning activities include small-scale data collect scientific and operational planning activities include small-scale data collection procedures; printervention training and fidelity monitoring procedures). Operational planning activities include, at an development of: the final clinical protocol; the intervention manual or equivalent; the data management tools for data and quality management, safety and operational oversight plans; recruitment and retent other essential documents such as the Manual of Procedures for the subsequent clinical trial in the UH phase of the award will support the conduct of investigator-initiated intervention research at all stages mechanistic research and intervention development (e.g., Stage 0 & I) through implementation and cost research (Stages IV/V). This FOA will use the NIH UG3/UH3 Exploratory/Devel						
079222	NIDCR Dual Degree Dentist Scientist F (K99/R00 Independent Basic Experiment		National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-19- 141	07-May-2019	Not Specified

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
·					
	Required)				

Contact Name Leslie A. Frieden, PhD

Contact Telephone 301-496-4263

Contact Email leslie.frieden@nih.gov

Sponsor Website

Program URL https://grants.nih.gov/grants/guide/pa-files/PAR-19-141.html

Deadline Dates (ALL

07-May-2019, 12-Jun-2019, 07-Sep-2019, 12-Oct-2019, 07-Jan-2020, 12-Feb-2020, 07-May-2020, 12-Jun-2020, 07-Sep-2020, 12-Oct-2020, 07-Jan-2021, 12-Feb-2021, 07-May-2021, 12-Jun-2021, 07-Sep-2021, 12-Oct-2021, 07-Jan-2022

The purpose of the NIDCR Dentist Scientist Pathway to Independence Award (K99/R00) program is to increase and maintain a strong cohort of new and talented independent dual degree dentist scientists. This program is designed to facilitate a timely transition of outstanding dual degree dentist scientists from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions by providing support for two years of mentored training and three to five years of independent research. The option for five years of independent (R00) support is available to accommodate clinical training in an advanced specialty education program at no more than 3 person-months effort (25% effort) in any year of the R00 phase. This Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-Synopsis 18-212 as "prospective basic science studies involving human participants." These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should submit under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of

phenomena without specific application towards processes or products in mind. Studies conducted with specific applications toward processes or products in mind should submit under the appropriate 'Clinical Trials Required' FOA (PAR-18-432). Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA (PAR-19-144).

NIDCR Dual Degree Dentist Scientist Pathway to Independence Award 079225 (K99/R00 Independent Clinical Trial Not Allowed)

National Institute of Dental and Craniofacial Research/NIH/DHHS PAR-19-07-May-2019 144

Not Specified

Contact Name Leslie A. Frieden, PhD

Contact Telephone 301-496-4263

Contact Email leslie.frieden@nih.gov

Sponsor Website

Program URL https://grants.nih.gov/grants/guide/pa-files/PAR-19-144.html

07-May-2019, 12-Jun-2019, 07-Sep-2019, 12-Oct-2019, 07-Jan-2020, 12-Feb-2020, 07-May-2020, 12-Jun-2020, 07-Sep-Deadline Dates (ALL) 2020, 12-Oct-2020, 07-Jan-2021, 12-Feb-2021, 07-May-2021, 12-Jun-2021, 07-Sep-2021, 12-Oct-2021, 07-Jan-2022

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Synopsis	involve leading an independent clinical are permitted to propose research experial or an ancillary clinical trial as lead basic experimental studies in humans participants" should apply to the composition of the compositio	nent (FOA) is designed specifically for apal trial, a clinical trial feasibility study, or a perience in a clinical trial led by a mento investigator, should apply to the compareferred to in NOT-OD-18-212 as "prospoanion Basic Experimental Studies with Playendence Award (K99/R00) program is eigree dentist scientists. This program is eigree dentist scientists. This program is eigree from mentored, postdoctoral researing support for two years of mentored transported to the compared to the co	an ancillary cling or co-mentor inion FOA (PAF) ective basic so Humans FOA (Fas to increase andesigned to factor positions to accommodat	nical trial. Applicar Applicants propo R-18-432). Applicat ience studies invo PAR-19- 141). The nd maintain a stro cilitate a timely tra o independent, ter ee to five years of e clinical training i	nts to this FOA prints proposing living human purpose of the ng cohort of ensition of the nure-track or independent nan advanced
11/42//	NIDCR Small Research Grants for Statistical Methodology Developn	Oral Health Data Analysis and nent (R03 Clinical Trial Not Allowed)	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-19- 145	07-May-2019	200,000 USD
	Contact Name	Darien Weatherspoon, DDS, MPH				
	Contact Telephone	301-594-5394				
	Contact Email	darien.weatherspoon@nih.gov				
	Sponsor Website					
	Program URL	https://grants.nih.gov/grants/guide/p	a-files/PAR-19-145.html			
	Deadline Dates (ALL)		019 , 16-Oct-2019 , 07-Jan-2020 , 16-Feb Feb-2021 , 07-May-2021 , 16-Jun-2021 ,			
	Synopsis	analyses of existing oral or craniofacia	nnouncement is to support meritorious database resources, or to develop need of craniofacial databases. The RO3 graprogram areas.	ded statistical r	methodology for a	nalyzing oral
079337	NIDCR Dentist Scientist Career Tra Investigators (K22 Independent B Required)	ansition Award for Intramural asic Experimental Studies with Humans	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-19- 151	07-May-2019	Not Specified
	Contact Name	Leslie A. Frieden, PhD				
	Contact Telephone	301-496-4263				
	Contact Email	leslie.frieden@nih.gov				

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		1				
	Sponsor Website					
	Program URL	https://grants.nih.gov/grants/guide/p				
	Deadline Dates (ALL)		2019 , 12-Oct-2019 , 07-Jan-2020 , 12-Fe -Feb-2021 , 07-May-2021 , 12-Jun-2021			
	Synopsis	highly qualified dentists in NIH Intrameresearch experiences in the NIH Intractives archevilla. This Funding Oppor studies involving humans, referred to These studies fall within the NIH define that should submit under this FOA incexperimentally manipulate independent purpose of understanding the fundame products in mind. Studies conducted to companion 'Clinical Trial Required' FO	entist Career Transition Award for Intrartural postdoctoral fellowship positions was mural program to extramural institution tunity Announcement (FOA) is designed in NOT-OD-18-212 as "prospective basinition of a clinical trial and also meet the clude studies that prospectively assign heart variables) and that assess biomedicate nental aspects of phenomena without specific applications toward proces of (PAR-18-360). Applicants not planning trial led by another investigator, must approach to the contract of	vith opportunity s as new invest specifically for c science studie definition of bauman participal or behavioral occific applications or products an independe	y to transition from igators with indep basic science exp es involving human asic research. Type nts to conditions ( outcomes in human on towards proces in mind should ap nt clinical trial, or	m mentored pendent erimental in participants." es of studies i.e., ans for the asses or oply to the proposing to
079343	NIDCR Dentist Scientist Career Tra Investigators (K22 Independent C		National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-19- 152	07-May-2019	Not Specified
	Contact Name	Leslie A. Frieden, PhD				
	Contact Telephone	301-496-4263				
	Contact Email	leslie.frieden@nih.gov				
	Sponsor Website	:				
	Program URL	https://grants.nih.gov/grants/guide/p	pa-files/PAR-19-152.html			
	Deadline Dates (ALL)		2019 , 12-Oct-2019 , 07-Jan-2020 , 12-Fe -Feb-2021 , 07-May-2021 , 12-Jun-2021			
	Synopsis	highly qualified dentists in NIH Intram research experiences in the NIH Intrai research funding. This Funding Oppor that does not involve leading an index Applicants to this FOA are permitted t	entist Career Transition Award for Intrar nural postdoctoral fellowship positions we mural program to extramural institution tunity Announcement (FOA) is designed pendent clinical trial, a clinical trial feasil to propose research experience in a clinical an ancillary clinical trial as lead investig	vith opportunity s as new invest specifically for bility study, or a lical trial led by a	y to transition fror igators with indep applicants propos an ancillary clinica a mentor or co-me	m mentored pendent sing research trial. entor.

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount	
			licants proposing basic experimental stud nvolving human participants" should apply L).				
079369	NIDCR Mentored Career Developmental Oral and Craniofacial Newsperimental Studies with Human	•	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-19- 161	07-May-2019	Not Specified	
	Contact Name	Lynn Mertens King, Ph.D.					
	Contact Telephone	301-594-5006					
		lynn.king@nih.gov					
	Sponsor Website						
	-	https://grants.nih.gov/grants/guide/pa					
	LIGACIDA LISTAC I ALL II	Dates (ALL) 07-May-2019, 12-Jun-2019, 07-Sep-2019, 12-Oct-2019, 07-Jan-2020, 12-Feb-2020, 07-May-2020, 12-Jun-2020, 2020, 12-Oct-2020, 07-Jan-2021, 12-Feb-2021, 07-May-2021, 12-Jun-2021, 07-Sep-2021, 12-Oct-2021, 07-Jan					
	Synopsis	The purpose of this NIDCR Mentored C dental, oral and craniofacial research of fellows and early career faculty from d biomedical and behavioral sciences. The for intensive research career developed Announcement is for basic science exp basic science studies involving human meet the definition of basic research. assign human participants to condition or behavioral outcomes in humans for application towards processes or prod products in mind should submit under	Career Development Award is to enhance workforce by providing a mentored resear iverse backgrounds, including those who his award provides salary and research suppend under the guidance of an experience perimental studies involving humans, refer participants." These studies fall within the Types of studies that should submit undens (i.e., experimentally manipulate independent of the purpose of understanding the fundamental in mind. Studies conducted with specific appropriate 'Clinical Trial Required' Not proposing to gain research experience	the diversity och experience are from group opport for a subdementor. The red to in NO e NIH definition of this FOA incondent variable mental aspectation of the polication of	of the independer of the independer of eligible poster ups underrepreser istained period of a clinical trial clude studies that les) and that assests of phenomena wors toward proces R-18-359). Application	ntly funded doctoral nted in the protected time tunity prospective al and also prospectively as biomedical without specific sses or ants not	
079378		ment Award to Promote Diversity in Workforce (K01 Independent Clinical	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-19- 160	07-May-2019	Not Specified	
	Contact Name Contact Telephone	Lynn Mertens King, Ph.D. 301-594-5006					

SPIN ID Program Title Sponsor Name Sponsor Number Deadline Date Amount	nding nount
--	----------------

Contact Email lynn.king@nih.gov

Sponsor Website

Program URL https://grants.nih.gov/grants/guide/pa-files/PAR-19-160.html

Deadline Dates (ALL)

07-May-2019, 12-Jun-2019, 07-Sep-2019, 12-Oct-2019, 07-Jan-2020, 12-Feb-2020, 07-May-2020, 12-Jun-2020, 07-Sep-2020, 12-Oct-2020, 07-Jan-2021, 12-Feb-2021, 07-May-2021, 12-Jun-2021, 07-Sep-2021, 12-Oct-2021, 07-Jan-2022

The purpose of this NIDCR Mentored Career Development Award is to enhance the diversity of the independently funded dental, oral and craniofacial research workforce by providing a mentored research experience for eligible postdoctoral fellows and early career faculty from diverse backgrounds, including those who are from groups underrepresented in the biomedical and behavioral sciences. This award provides salary and research support for a sustained period of protected time Synopsis for intensive research career development under the guidance of an experienced mentor. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or an ancillary study to an ongoing clinical trial as lead investigator, should apply to the companion FOA (PAR-18-359).

079182

Research Enhancement Award Program (REAP) for Health Professional Schools and Graduate Schools (R15 Clinical Trial Not Allowed)

National Institute of Dental and Craniofacial Research/NIH/DHHS PAR-19-134

07-May-2019

300,000 USD

Contact Name Alicia Dombroski, Ph.D.

Contact Telephone 301-594-4805

Contact Email adombroski@mail.nih.gov

Sponsor Website

Program URL https://grants.nih.gov/grants/guide/pa-files/PAR-19-134.html

07-May-2019, 25-Jun-2019, 07-Sep-2019, 25-Oct-2019, 07-Jan-2020, 25-Feb-2020, 07-May-2020, 25-Jun-2020, 07-Sep-Deadline Dates (ALL) 2020 , 25-Oct-2020 , 07-Jan-2021

The purpose of the Research Enhancement Award Program (REAP) for Health Professional Schools and Graduate Schools is to stimulate basic and clinical research in educational institutions that provide baccalaureate or advanced degrees for a significant number of the Nation's research scientists, but that have not been major recipients of NIH support. REAP grants create opportunities for scientists and institutions otherwise unlikely to participate extensively in NIH research programs to Synopsis contribute to the Nation's biomedical and behavioral research effort. REAP grants are intended to support small-scale research projects proposed by faculty members of eligible, domestic institutions, to expose undergraduate and/or graduate students at health professional schools or graduate schools to meritorious research projects, and to strengthen the research environment of the applicant institution. Eligible institutions must award NIH-relevant baccalaureate or advanced degrees in

health professions and have received less than \$6 million per year of NIH support (total costs) in 4 of the last 7 fiscal years. In

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		this FOA, a college is a stand-alone en	itity and not a component of a university	system.		
079633	Achieving Tissue Robustness Thro Plasticity (R21 Clinical Trial Not Al		National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-19- 173	16-Jun-2019	275,000 USD
	Contact Name	Preethi Chander, PhD				
	Contact Telephone	301-827-4620				
	Contact Email	preethi.chander@nih.gov				
	Sponsor Website					
	Program URL	https://grants.nih.gov/grants/guide/g	pa-files/PAR-19-173.html			
	Deadline Dates (ALL)	16-Jun-2019 , 16-Oct-2019 , 16-Feb-2 2022	020 , 16-Jun-2020 , 16-Oct-2020 , 16-Feb	-2021 , 16-Ju	n-2021 , 16-Oct-202	21 , 16-Feb-
		role of immune system plasticity in he encourages applications that will seek dynamically maintain its functional roderived from this research will facilitation	ent (FOA) encourages state-of-the-art, sy ealth and in the pathogenesis of dental, of to determine mechanisms underlying the le against internal and external perturba to development of novel, personalized in the degenerative processes toward regene	oral, and cran he ability or ir ations. The ex mmunomodu	iofacial (DOC) diseanability of the immupectation is that ne latory-based therag	ises. This FOA une system to w knowledge pies that shift
079632	Achieving Tissue Robustness Thro Plasticity (R01 Clinical Trial Not Al		National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-19- 172	05-Jun-2019	Not Specified
	Contact Name	Preethi Chander, PhD				
	Contact Telephone	301-827-4620				
	Contact Email	preethi.chander@nih.gov				
	Sponsor Website					
	Program URL	https://grants.nih.gov/grants/guide/g	pa-files/PAR-19-172.html			
	Deadline Dates (ALL)	05-Jun-2019 , 05-Oct-2019 , 05-Feb-2 2022	020 , 05-Jun-2020 , 05-Oct-2020 , 05-Feb	-2021 , 05-Ju	n-2021 , 05-Oct-202	21 , 05-Feb-
		role of immune system plasticity in he encourages applications that will seek dynamically maintain its functional ro	ent (FOA) encourages state-of-the-art, sy ealth and in the pathogenesis of dental, o to determine mechanisms underlying the le against internal and external perturba te development of novel, personalized in	oral, and cran he ability or ir ations. The ex	iofacial (DOC) diseanability of the immupectation is that ne	ises. This FOA une system to w knowledge

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		the balance between degenerative ar specific manner across the lifespan.	d regenerative processes toward regene	eration diseas	e management in a	patient-
056642	NIDCR Small Grant Program for N	lew Investigators (RO3)	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-16- 409	07-May-2019	200,000 USD
	Contact Name	Preethi Chander, PhD				
	Contact Telephone	301-827-4620				
	Contact Email	preethi.chander@nih.gov				
	Sponsor Website					
	Program URL	http://grants.nih.gov/grants/guide/pa	a-files/PAR-16-409.html			
	Deadline Dates (ALL)	07-May-2019 , 16-Jun-2019 , 07-Sep-2	2019			
	Synopsis	establishing an independent research feasibility studies and developmental	orts basic and clinical research conducte career in oral, dental and craniofacial re research projects with the intention of cearch Project Grant (R01) or equivalent	search. This Fobtaining suffi	RO3 program suppo cient preliminary d	rts pilot or ata for a
080508	RFA-DE-19-010 Limited Compe Tissue Regeneration Consortium	tition: Dental, Oral and Craniofacial (U24 Clinical Trial Not Allowed)	National Institute of Dental and Craniofacial Research/NIH/DHHS	RFA-DE- 19-010	11-May-2019 [LOI/Pre-App] [Optional]	4,000,000 USD
	Contact Name	Nadya Lumelsky, PhD				
	Contact Telephone					
	·	l nadyal@nidcr.nih.gov				
	Sponsor Website					
	Program URL	https://grants.nih.gov/grants/guide/r	fa-files/RFA-DE-19-010.html			
		11-May-2019 [LOI/Pre-App][Optional				
	Synopsis	Oral and Craniofacial Tissue Regeneral regeneration and reconstruction of de Resource Centers (RCs) and associate DOCTRC effort. In Stage 3, the RCs will	nity Announcement (FOA) is to provide solution Consortium (DOCTRC) that will facily ental, oral and craniofacial (DOC) tissues d Interdisciplinary Translational Projects I capitalize on their available clinical, scient technical support, research capacity, a	itate advance to clinical tria (ITPs) that ha entific, indust	ment of promising als. DOCTRC is compose to been built durin rial, regulatory and	strategies for cosed of the g Stage 2 of the

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		During Sta engineeri Exemptio will be TE	age 3, the DOCTRC will comploing and regenerative medicine in (IND/IDE) applications for su	and guide them to complete pre-clinical sete validation, manufacturing, and precli (TE/RM) products and will develop Inveolation to the Food and Drug Adminis IDE in place and associated clinical study	nical testing o stigational Ne tration (FDA).	of the most promises Drug/Device The outcome of t	sing tissue he DOCTRC
	Short-term Mentored Career Enh Craniofacial Research for Mid-Car Independent Clinical Trial Not Allo	eer and Se		National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-19- 238	12-Jun-2019	Not Specified
	Contact Name	Lynn Mer	tens King, PhD				
	Contact Telephone	301-594-5	5006				
	Contact Email	Lynn.King	<u>@nih.gov</u>				
	Sponsor Website						
	Program URL	https://gr	ants.nih.gov/grants/guide/pa	-files/PAR-19-238.html			
	Deadline Dates (ALL)		-Jan-2021 , 12-Feb-2021 , 07-N	.9 , 07-Jan-2020 , 12-Feb-2020 , 07-May- Иау-2021 , 12-Jun-2021 , 07-Sep-2021 , 1			
	Synopsis	awards in genomics investigat enhance t investigat and (b) es introducti specificall feasibility	dental, oral and craniofacial ( , bioinformatics and computa ors with short-term training in their existing research program ors who seek training with invitablished investigators in other ion of DOC research into an exp	ant (FOA) encourages applications for sho DOC) research with a focus on behavioral tional biology research. The intent of this in the theories, tools, methods or approa in. Two categories of candidates are targ vestigators from another field, in order to the fields who seek training with DOC reseated in the fields who seek training with DOC reseated earch that does not involve leading an interial. Applicants to this FOA are permitten	al and social s s program is t ches of anoth eted: (a) estal o enrich their earch investig pportunity Ar adependent cl	ciences, and on good provide mid-care er scientific area, blished DOC reseat existing DOC reseators in order to for anouncement (FO) linical trial, a clinical trial, a clinic	enetics, eer and senior in order to rch arch program; acilitate the A) is designed al trial
081341	RFA-DE-20-001 Oral Health in P Non-Communicable Diseases (RO			National Institute of Dental and Craniofacial Research/NIH/DHHS	RFA-DE- 20-001	29-Jun-2019 [LOI/Pre-App] [Optional]	Not Specified

Contact Name Gallya Gannot, DMD, Ph.D.

	Drogram					Funding	
SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Amount	
	Contact Telephone 30	01-451-5096 Illya.gannot@nih.gov					
	Sponsor Website	<u>iiya.gaiiiot@iiii.gov</u>					
	•	tps://grants.nih.gov/grants/guide/rfa	a-files/RFA-DF-20-001 html				
Deadline Dates (ALL) 29-Jun-2019 [LOI/Pre-App][Optional], 29-Jul-2019							
	Synopsis en ou	atus of people living with HIV (PLWH) pports efforts to understand the comocourages identification of approache	nt (FOA) encourages research to addre with an emphasis on PWLH who also abined effects of HIV, antiretroviral the serior prevention and treatment of oral Ds. These efforts could help to generate with HIV.	have non-comm erapy (ART), and diseases and as	nunicable diseases NCDs on oral heases ssessment of treat	(NCDs). It alth, and it tment	
056149	Assay Development and Screening to Agents for Diseases of Interest to the	Discover Therapeutic or Imaging  NIDDK (R01)	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PA-16-374	07-May-2019	Not Specific	
	Contact Name Aa	aron C. Pawlyk, Ph.D.					
	Contact Telephone 30	1-451-7299					
	Contact Email <u>pa</u>	awlykac@mail.nih.gov					
	Sponsor Website						
	Program URL <u>ht</u>	tp://grants.nih.gov/grants/guide/pa-	files/PA-16-374.html				
	Deadline Dates (ALL) 07	7-May-2019 , 05-Jun-2019 , 07-Sep-20	019				
	co to me me Synopsis th	the NIDDK. It is expected that state of ediators of disease pathogenesis are olecules that modulate or monitor the interested in assays utilizing phenoty e groundwork for future therapeutic	estive and Kidney Diseases (NIDDK) involved in the art measures of basic cellular prolineorporated into these novel assays. Seese processes or events in an unbiased pic readouts that provide opportunities and imaging agent discovery and devent to be developed or library to be screen.	s relevant to hea ocesses or mole Such assays shou d and efficient m es to measure di lopment progra	alth related outco cular events that uld be useable in s nanner. In particu sease-relevant en ims. It is expected	mes of intere are key screens for lar, the NIDDI dpoints and la that there is	

application. It is not intended to support research focused on understanding normal biology, disease processes, or

performing later-stage optimization of therapeutic or imaging agents. At the end of the project period, a successful project will have either 1) developed and validated a novel assay suitable for identifying prototype therapeutic or imaging agents or 2) utilized a novel assay to identify prototype therapeutic or imaging agents. This FOA will use the NIH Research Project (R01)

SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	award mechanism.				
068291 Nutrigenetics and Nutrigenomics (R01 Clinical Trial Optional)	Approaches for Nutrition Research	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PA-18-034	07-May-2019	Not Specified
Contact Name	Padma Maruvada				
Contact Telephone	301-594-8884				
Contact Email	maruvadp@mail.nih.gov				
Sponsor Website					
Program URL	https://grants.nih.gov/grants/guide/pa	a-files/PA-18-034.html			
Deadline Dates (ALL)	07-May-2019 , 05-Jun-2019 , 07-Sep-20	019			
Synopsis	nutrigenetics and/or nutrigenomics ap	its participating Institutes and Centers in proaches to nutrition research through c nologies. This FOA will use the NIH Resear	ollaborative i	nteraction among	nutrition
068726 Metabolic Contributions to the N Diabetes: Ancillary Studies (R01 C		National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAR-18- 051	05-Jun-2019	Not Specified
Contact Name	Luke E. Stoeckel, Ph.D.				
Contact Telephone	301-741-9223				
Contact Email	luke.stoeckel@nih.gov				
Sponsor Website					
Program URL	https://grants.nih.gov/grants/guide/pa	a-files/PAR-18-051.html			
Deadline Dates (ALL)	05-Jun-2019				
Synopsis	_	estive and Kidney Diseases (NIDDK) invited increased risk for neurocognitive impairm () award mechanism.			
062358 NIDDK Central Repositories Non-	renewable Sample Access (X01)	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAR-17- 270	28-Jun-2019	Not Specified
Contact Name	Rebekah S. Rasooly, Ph.D.				

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Contact Telephone	301-594-6007				
	Contact Email	rasoolyr@mail.nih.gov				
	Sponsor Website					
	Program URL	https://grants.nih.gov/grants/guide/p	a-files/PAR-17-270.html			
	Deadline Dates (ALL)	28-Jun-2019 , 31-Oct-2019 , 03-Mar-20	020 , 30-Jun-2020			
	Synopsis	renewable samples from one or more www.niddkrepository.org. Applicants	gestive and Kidney Diseases (NIDDK) invitory of these studies. Information about the second the NIDDI have the NIDDI HIS X01 Resource Access Award mechanism	amples availa K Central Repo	ble can be found a	at
I IKUUI I/I	NIDDK Multi-Center Clinical Study Frial Not Allowed)	Cooperative Agreement (U01 Clinical	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAR-18- 414	07-May-2019	Not Specified
	Contact Name	Tracy Rankin, Ph.D., M.P.H.				
	Contact Telephone	301-594-4748				
	Contact Email	rankint@mail.nih.gov				
	Sponsor Website					
		https://grants.nih.gov/grants/guide/p				
	Deadline Dates (ALL)	07-May-2019 , 05-Jun-2019 , 07-Sep-2 2020 , 05-Oct-2020 , 07-Jan-2021	019 , 05-Oct-2019 , 07-Jan-2020 , 05-Feb-	-2020 , 07-Ma	y-2020 , 05-Jun-20	020 , 07-Sep-
	Synopsis	center clinical trials involving three or to change clinical practice and/or publ must be completed prior to submissio first apply for an implementation plan	estive and Kidney Diseases (NIDDK) invite more clinical centers. Proposed trials sho ic health, and focus on a disease relevant n and are not permitted under this FOA. A ning cooperative agreement (U34; see PA couraged prior to the submission of eithe	uld be hypoth to the missic Applicants wh AR-18-423). Co	nesis-driven, have on of NIDDK. Plann o require a planni onsultation with N	the potential ing activities ng phase may IDDK
HAUXXU -	NIDDK Multi-Center Clinical Trial ( Trial Required)	Cooperative Agreement (U01 Clinical	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAR-18- 415	07-May-2019	Not Specified
	Contact Name Contact Telephone	Marva Moxey-Mims, M.D 301-594-7717				

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Contact Email Sponsor Website	mimsm@mail.nih.gov				
	•	https://grants.nih.gov/grants/guide/p	pa-files/PAR-18-415.html			
	_		2019 , 05-Oct-2019 , 07-Jan-2020 , 05-Feb	o-2020 , 07-May	/-2020 , 05-Jun-20	020 , 07-Sep-
	Synopsis	center clinical trials involving three or to change clinical practice and/or pub must be completed prior to submission first apply for an implementation plan	estive and Kidney Diseases (NIDDK) invited more clinical centers. Proposed trials should be also be al	ould be hypothe it to the mission Applicants who AR-18-423). Co	esis-driven, have n of NIDDK. Plann o require a planni nsultation with N	the potential ing activities ng phase may IDDK
069548	Pilot and Feasibility Therapeutic C Endocrine and Metabolic Diseases		National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PA-18-405(	07-May-2019	275,000 USD
	Contact Name	Yan Li				
	Contact Telephone	301-435-3721				
	Contact Email	liy7@mail.nih.gov				
	Sponsor Website					
	Program URL	https://grants.nih.gov/grants/guide/g	pa-files/PA-18-405.html			
		07-May-2019 , 16-Jun-2019 , 07-Sep-2 2020 , 16-Oct-2020 , 07-Jan-2021	2019 , 16-Oct-2019 , 07-Jan-2020 , 16-Feb	o-2020 , 07-May	y-2020 , 16-Jun-20	020 , 07-Sep-
	Synopsis	conducted in humans that will lay the diabetes or selected endocrine and geterm clinical trials in humans to acquidefinitive study impacting clinical care	estive and Kidney Diseases (NIDDK) invite foundation for larger clinical trials relate enetic metabolic diseases within the miss re preliminary data and/or refine power of or health outcomes. This FOA is not apply Developmental (R21) grant mechanism.	d to the prever ion of NIDDK. T calculations tha	ntion and/or trea he program will s It would lead to a	tment of support short- larger, more
Uh914X	Addressing Health Disparities in N Allowed)	IIDDK Diseases (R01 Clinical Trial Not	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PA-18-412(	07-May-2019	Not Specified

SPIN ID Progr Title	am	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		Salina P. Waddy, MD				
	Contact Telephone					
		NIDDKDisparitiesFOA@niddk.nih.gov				
	Sponsor Website		50			
	_	https://grants.nih.gov/grants/guide/pa-1				
	Deadline Dates (ALL)	07-May-2019 , 05-Jun-2019 , 07-Sep-201 National Institute of Diabetes and Digest				
	Synopsis	mitigate health disparities in the develop of Diabetes and Digestive and Kidney Dis diabetes and other endocrine and metals Pylori infection; complications of sickle of metabolic, gastrointestinal, hepatic, and hematologic diseases, including studies i studies or Clinical Trials. Animal research area disease in a minority population. The	seases (NIDDK). Research is encouraged bolic diseases; obesity; nutrition-related cell disease within the NIDDK mission are renal complications from infection with abnormal hemoglobin synthesis. This h will be supported if the research is a contract of the supported if the research is a contract of the supported if the research is a contract of the supported if the research is a contract of the supported if the research is a contract of the supported if the research is a contract of the supported if the support	d in the follow d disorders; he reas; kidney d h HIV; and me s FOA will not clinically relev	ving high priority depatitis C; gallblad liseases; urologic dechanistic research support multi-cen vant model of a NII	iseases: der disease; H. iseases; n in ter clinical
HEUU I /I	Multi-Center Clinical Study ents (U34 Clinical Trial Op	y Implementation Planning Cooperative [	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAR-18- 423	04-May-2019 [LOI/Pre-App] [Optional]	450,000 USD
	Contact Name	Tracy Rankin, Ph.D., M.P.H.				
	Contact Telephone	: 301-594-4748				
	Contact Email	rankint@mail.nih.gov				
	Sponsor Website	:				
	Program URL	https://grants.nih.gov/grants/guide/pa-f	files/PAR-18-423.html			
	Deadline Dates (ALL)	04-May-2019 [LOI/Pre-App][Optional], 0 [LOI/Pre-App][Optional], 02-Nov-2020	3-Jun-2019 , 04-Jan-2020 [LOI/Pre-App	][Optional], 0	)3-Feb-2020 , 03-O	ct-2020
	Synopsis	National Institute of Diabetes and Digest or more centers) clinical studies through agreement (U34). The U34 is designed to Permit assessment of the design and proneeded for the conduct of the study, incledements required for the conduct of the a disease relevant to the mission of NIDI	tive and Kidney Diseases (NIDDK) support a a two-part process that may include and b: 1) Permit early peer review of the rat ptocol of the proposed study; 3) Provide luding a manual of operations; and 4) S e clinical study. The proposed clinical st	orts investigat n implementationale for the e support for Support the de udy should be	tor-initiated, multi- ation planning coo e proposed clinical the development of evelopment of oth e hypothesis-drive	center (three perative study; 2) of documents er essential n and focus on

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount		
		submission of the U34 application Th	nis FOA will utilize the U34 grant mechani	sm.				
069920	NIDDK Mentored Research Scient Trial Required)	ist Development Award (K01 - Clinical	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAR-18- 418	07-May-2019	575,000 USD		
	Contact Name	Lisa M. Spain, Ph.D.						
	Contact Telephone	301-451-9871						
	Contact Email	SpainL@niddk.nih.gov						
	Sponsor Website							
	Program URL	https://grants.nih.gov/grants/guide/p	a-files/PAR-18-418.html					
Deadline Dates (ALL) 07-May-2019 , 12-Jun-2019 , 07-Sep-2019 , 12-Oct-2019 , 07-Jan-2020 , 12-Feb-2020 , 07-May-2020 , 12-Jun-2020 , 07-Sep-2019 , 12-Oct-2019 , 07-Jan-2020 , 12-Feb-2020 , 07-May-2020 , 12-Jun-2020 , 07-Jan-2021								
	Synopsis	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) invites applications for Mentored Research Scientist Development Awards (K01). The awards provide support and protected time for an intensive, supervised career development experience in the biomedical, behavioral, or clinical sciences leading to research independence. The NIDDK invites K01 applications from experienced postdoctoral (two years minimum) and/or recently appointed junior faculty (usually with a Ph.D. degree) in biomedical, behavioral, or clinical sciences who are pursuing careers in research areas supported by the NIDDK. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing t serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to existing trial, as part of their research and career development. The ancillary study must also meet the NIH clinical trial definition. This FOA will utilize the NIH K01 Research Scientist Development Award - Research & Training award mechanism						
069922	NIDDK Mentored Research Scient Trial Required)	ist Development Award (K01 - Clinical	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAR-18- 419	07-May-2019	575,000 USD		
	Contact Name	Lisa M. Spain, Ph.D.						
	Contact Telephone	301-451-9871						
	Contact Email	SpainL@niddk.nih.gov						
	Sponsor Website							
	<u>-</u>	https://grants.nih.gov/grants/guide/p						
	Deadline Dates (ALL)	07-May-2019 , 12-Jun-2019 , 07-Sep-2 2020 , 12-Oct-2020 , 07-Jan-2021	019 , 12-Oct-2019 , 07-Jan-2020 , 12-Feb	-2020 , 07-M	ay-2020 , 12-Jun-20	020 <i>,</i> 07-Sep-		
	Synopsis	National Institute of Diabetes and Dig	gestive and Kidney Diseases (NIDDK) invit	es applicatio	ns for Mentored Re	esearch		

Program			Ft	unding			
SPIN ID Title	Sponsor Name	Sponsor Number	Deadline Date	mount			
	development experience in the biome invites K01 applications from experien (usually with a Ph.D. degree) in biome supported by the NIDDK. This Funding research that does not involve leading clinical trial that is itself comprised of	The awards provide support and protected dical, behavioral, or clinical sciences lead aced postdoctoral (two years minimum) adical, behavioral, or clinical sciences who opportunity Announcement (FOA) is defan independent clinical trial, a clinical trial clinical trial intervention(s). Applicants entor or co-mentor. This FOA will utilize echanism.	ding to research independence. The and/or recently appointed junior factories are pursuing careers in research assigned specifically for applicants probable factories for an ancillary stothis FOA are permitted to propo	NIDDK culty reas oposing study to a se research			
071705 Pilot and Feasibility Studies of HIV within the Mission of NIDDK (R21	/ and Animal Models for HIV Infection Clinical Trial Optional)	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PA-18-615 07-May-2019 2	75,000 USD			
Contact Name	Peter J. Perrin, Ph.D.						
Contact Telephone	301-451-3759						
Contact Email	Peter.Perrin@nih.gov						
Sponsor Website							
Program URL	https://grants.nih.gov/grants/guide/pa-files/PA-18-615.html						
Deadline Dates (ALL)	07-May-2019 , 16-Jun-2019 , 07-Sep-2 2020 , 16-Oct-2020 , 07-Jan-2021	019 , 16-Oct-2019 , 07-Jan-2020 , 16-Feb	o-2020 , 07-May-2020 , 16-Jun-2020	, 07-Sep-			
Synopsis	translational research projects examin National Institute of Diabetes and Dige by the NIH Office of AIDS Research (O	estive and Kidney Diseases (NIDDK) inviting HIV infection, persistence, and como estive and Kidney Diseases (NIDDK) and o AR) in NOT-OD-15-137: NIH HIV/AIDS Resembly will use the NIH Exploratory/Develop	orbidities as they relate to the missic consistent with the scientific prioriti search Priorities and Guidelines for	on of the			
073219 Exploratory/Developmental Clinical Trial Optional)	cal Research Grants in Obesity (R21	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PA-18-720 07-May-2019 2	75,000 USD			
Contact Name	Robert J. Kuczmarski, Dr.P.H.						
Contact Telephone	301-451-8354						
Contact Email	kuczmarskir@mail.nih.gov						
Sponsor Website							

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount	
	Program URL	https://grants.nih.gov/grants/guide/p	a-files/PA-18-720.html				
	Deadline Dates (ALL)	07-May-2019 , 16-Jun-2019 , 07-Sep-2 2020 , 16-Oct-2020 , 07-Jan-2021 , 16-	019 , 16-Oct-2019 , 07-Jan-2020 , 16-Feb Feb-2021 , 07-May-2021	-2020 , 07-Ma	y-2020 , 16-Jun-20	)20 , 07-Sep-	
	Synopsis	exploratory/developmental clinical stu treatment of overweight or obesity in	lits participating Institutes and Centers in udies that will accelerate the developmen adults and/or children. Exploratory epid be supported within this program. This Int mechanism.	nt of effective i emiological re	nterventions for presented with a goa	revention or	
	Secondary Analyses in Obesity, Di Diseases (R21 Clinical Trial Not All	abetes and Digestive and Kidney lowed)	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PA-18-741	07-May-2019	275,000 USD	
	Contact Name	Aynur Unalp-Arida, MD, MSc, PhD					
	Contact Telephone	301-594-8879					
	Contact Email	aynur.unalp-arida@nih.gov					
	Sponsor Website						
	Program URL	https://grants.nih.gov/grants/guide/p	a-files/PA-18-741.html				
	Deadline Dates (ALL)	07-May-2019 , 16-Jun-2019 , 07-Sep-2 2020 , 16-Oct-2020 , 07-Jan-2021 , 16-	019 , 16-Oct-2019 , 07-Jan-2020 , 16-Feb Feb-2021 , 07-May-2021	-2020 , 07-Ma	y-2020 , 16-Jun-20	)20 , 07-Sep-	
	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) invites applications that propose to conduct secondary analyses of existing data sets relevant to diabetes and selected endocrine and metabolic diseases including thyroid, parathyroid and Cushing's diseases and acromegaly; and genetic metabolic disease including cystic fibrosis, lysosomal storage diseases, and disorders of the urea cycle, amino acid metabolism and metal transport where the focus is on peripheral metabolism or organ function; obesity, liver diseases, alimentary GI tract diseases and nutrition; kidney, urologic, and hematologic diseases. The goal of this program is to facilitate research that explores innovative hypotheses through the use of existing data sets or data, for which the primary goal is data analysis and not preparation/presentation data. This program will use the NIH Exploratory/Developmental (R21) grant mechanism.						
11/3/1/15	Pilot and Feasibility Clinical Resea Clinical Trial Optional)	rch Grants in Urologic Disorders (R21	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAR-18- 743	07-May-2019	275,000 USD	
	Contact Name	Ziya Kirkali, M.D.					



Contact Telephone 301-594-7717

SPIN ID Program Title	9	Sponsor Name	Sponsor I	Number	1	Deadline Date	Funding Amount
Contact Er	nail <mark>ziya.kirkali</mark>	@nih.gov			·		
Sponsor Web							
Program (		ints.nih.gov/grants/guide/pa					
Deadline Dates (A		019 , 16-Jun-2019 , 07-Sep-2 Oct-2020 , 07-Jan-2021 , 16-		2019 , 07-Jan-2020 , 16-Feb-2 7-May-2021	020 , 07-May-	2020 , 16-Jun-202	:0 , 07-Sep-
Syno	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) invites applications that propose small scale or pilo and feasibility clinical and translational research studies, including epidemiological studies or clinical trials related to urologic disorders research. Studies should address important clinical and translational questions that are potentially of high clinical and public health impact. It is anticipated that some projects supported by these grants may lead to full-scale clinical studies including diagnostic strategies, epidemiological studies, or randomized clinical trials of prevention, diagnosis or treatment of urologic disorders. This program will use the NIH Exploratory/Developmental (R21) grant mechanism.						d to urologic nigh clinical nical studies
073449 Pilot and Feasibility Clinical Research Grants in Kidney Diseases (R21 Clinical Trial Optional)				titute of Diabetes and nd Kidney H/DHHS	PAR-18- 744 0	7-May-2019	275,000 USD
Contact Na	me Tracy L. Ra	nkin, Ph.D., M.P.H.					
Contact Telepho	one 301-594-47	748					
Contact Er	nail <u>rankint@m</u>	nail.nih.gov					
Sponsor Web	site						
Program (	JRL https://gra	nts.nih.gov/grants/guide/pa	a-files/PAR-1	<u>8-744.html</u>			
Deadline Dates (A		)19 , 16-Jun-2019 , 07-Sep-2 )Cct-2020 , 07-Jan-2021 , 16-		2019 , 07-Jan-2020 , 16-Feb-2 7-May-2021	020 <i>,</i> 07-May-	2020 , 16-Jun-202	.0 , 07-Sep-
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) invites applications that propose small scale or pi and feasibility clinical and translational research studies, including epidemiological studies or clinical trials related to kidner disease research. Studies should address important clinical and translational questions and are potentially of high clinical apublic health impact. It is anticipated that some projects supported by these grants may lead to full-scale clinical studies including diagnostic strategies, epidemiological studies, or randomized clinical trials of diagnosis, prevention, or treatment kidney diseases. This program will use the NIH Exploratory/Developmental (R21) grant mechanism.						d to kidney h clinical and I studies	
SPIN ID Program Title			5	ponsor Name	Sponsor Number	Deadline Date	Funding Amount





600,000

					_	
SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
			and Digestive and Kidney Diseases/NIH/DHHS	730		USD
	Contact Name	Terry Rogers Bishop, Ph.D.				
	Contact Telephone	301-594-7726				
	Contact Email	terry.bishop@nih.gov				
	Sponsor Website					
	Program URL	https://grants.nih.gov/grants/guide/pa	a-files/PAS-18-730.html			
	Deadline Dates (ALL)	07-May-2019 , 05-Jun-2019 , 07-Sep-2 2020 , 05-Oct-2020 , 07-Jan-2021 , 05-	019 , 05-Oct-2019 , 07-Jan-2020 , 05-Feb-: Feb-2021 , 07-May-2021	2020 , 07-Ma	y-2020 , 05-Jun-20	)20 , 07-Sep-
	Synopsis	nonmalignant hematology. Innovative invited. Each project will propose provalidating novel concepts and approacs submitted under this FOA should be marked.	titute on Aging (NIA) have joined together e research project applications that will ste of of principle research that is tightly focus thes that promise to open up new pathwa nore limited in scope (a single central aim) ne NIH Research Project (RO1) award mech	eer the field i sed into one ys for discove and duratior	n new directions a specific aim and is ery. Research app	re directed at lications
11/44/X	Food Specific Molecular Profiles a Dietary Exposure (R01 Clinical Tria	and Biomarkers of Food and Nutrient Intellect	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAR-18- 727	07-May-2019	Not Specified
	Contact Name	Padma Maruvada				
	Contact Telephone	301-594-8884				
	Contact Email	maruvadp@mail.nih.gov				
	Sponsor Website					
	Program URL	https://grants.nih.gov/grants/guide/p	a-files/PAR-18-727.html			
	Deadline Dates (ALL)	07-May-2019 , 05-Jun-2019 , 07-Sep-2 2020 , 05-Oct-2020 , 07-Jan-2021 , 05-	019 , 05-Oct-2019 , 07-Jan-2020 , 05-Feb-: Feb-2021 , 07-May-2021	2020 <i>,</i> 07-Ma	y-2020 , 05-Jun-20	020 , 07-Sep-
	Synopsis	Agriculture (NIFA), invite applications	its participating Institutes and Centers, al for research on food specific molecular sig ative interactions among NIH and the Unit	natures and	biomarkers of die	tary

National Institute on Food Safety (USDA-NIFA) supported nutrition researchers. This FOA will use the NIH Research Project

CDINI ID	Program	Spanner Name	Cuana	u Novech ou		Doodling Date	Funding
SPIN ID	Title	Sponsor Name	Sponso	r Number		Deadline Date	Amount
		(R01) award mechanism.					
072688	High Priority HIV/AIDS Research v Optional)	within the Mission of the NIDDK (R01 Clinica	al Trial	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAS-18- 698	07-May-2019	Not Specified
	Contact Name	Peter J. Perrin, Ph.D.					
	Contact Telephone	301-451-3759					
	Contact Email	Peter.Perrin@nih.gov					
	Sponsor Website						
	Program URL	https://grants.nih.gov/grants/guide/pa-fil	es/PAS	<u>-18-698.html</u>			
	Deadline Dates (ALL)	07-May-2019 , 05-Jun-2019 , 07-Sep-2019 2020 , 05-Oct-2020 , 07-Jan-2021	, 05-0	ct-2019 , 07-Jan-2020 , 05-Feb-202	20 , 07-May	y-2020 , 05-Jun-20	20 , 07-Sep-
	Synopsis	National Institute of Diabetes and Digest the mission of the National Institute of Dia HIV/AIDS research priorities outlined by the https://grants.nih.gov/grants/guide/notic award mechanism.	abetes ne NIH	and Digestive and Kidney Diseases Office of AIDS Research (OAR). Th	(NIDDK) tl ese priorit	hat addresses highies are described i	n priority n
076246	Diet and Physical Activity Assessn	nent Methodology (R21 Clinical Trial Not Al	<u>lowed)</u>	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAR-18- 857	07-May-2019	275,000 USD
	Contact Name	Mary Evans, Ph.D.					
	Contact Telephone	301-594-4578					
	Contact Email	evansmary@niddk.nih.gov					
	Sponsor Website						
	Program URL	https://grants.nih.gov/grants/guide/pa-fil	es/PAR	<u>-18-857.html</u>			
	Deadline Dates (ALL)	07-May-2019 , 16-Jun-2019 , 07-Sep-2019 2020 , 16-Oct-2020 , 07-Jan-2021 , 16-Feb	, 16-0 -2021 ,	ct-2019 , 07-Jan-2020 , 16-Feb-202 07-May-2021 , 16-Jun-2021 , 07-S	20 , 07-May ep-2021	y-2020 , 16-Jun-20	20 , 07-Sep-
	Synopsis	National Institutes of Health (NIH) and its enhance the quality of measurements of development of: novel assessment approadiverse populations or various age groups existing technology; statistical methods/m	dietary aches; l , includ	intake and physical activity. Applic petter methods to evaluate instrur ing children and older adults; imp	cations sub ments; asse roved tech	mitted to this FOA essment tools for nology or applicat	A may include culturally cions of

SPIN ID	Program Title	Sponsor Name	Sponsor Number	C	Deadline Date	Funding Amount
		biases; methods to investigate the multic integrated measurement of diet and phys use the NIH R21 Exploratory/Developmen	sical activity along with the environmenta		• .	•
076238	Diet and Physical Activity Assessn	nent Methodology (R01 Clinical Trial Not A	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PA-18- 856	07-May-2019	Not Specified
	Contact Name	Mary Evans, Ph.D.				
	Contact Telephone	301-594-4578				
	Contact Emai	evansmary@niddk.nih.gov				
	Sponsor Website					
	Program URL	https://grants.nih.gov/grants/guide/pa-fi	iles/PA-18-856.html			
	Deadline Dates (ALL)	07-May-2019 , 05-Jun-2019 , 07-Sep-2019 2020 , 05-Oct-2020 , 07-Jan-2021 , 05-Fel	9 , 05-Oct-2019 , 07-Jan-2020 , 05-Feb-20 b-2021 , 07-May-2021 , 05-Jun-2021 , 07-:	20 , 07-May- Sep-2021	2020 <i>,</i> 05-Jun-20	20 , 07-Sep-
	Synopsis	National Institutes of Health (NIH) and its enhance the quality of measurements of development of: novel assessment approdiverse populations or various age group.	s participating Institutes and Centers invit dietary intake and physical activity. Appli baches; better methods to evaluate instrus, including children and older adults; improdeling to improve assessment and/or thimensionality of diet and physical activity sical activity along with the environmenta	e application cations subments; asses proved technoto correct for y behavior th	nitted to this FOA sment tools for ology or applicat measurement e rough pattern an	A may include culturally ions of rrors or nalysis; or
076166	Time-Sensitive Obesity Policy and Allowed)	d Program Evaluation (R01 Clinical Trial Not	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAR-18- 854	11-Apr-2019	Not Specified
	Contact Name	Mary Evans, Ph.D.				
	Contact Telephone	301-594-4578				
	Contact Emai	evansmary@mail.nih.gov				
	Sponsor Website					
	Program URL	https://grants.nih.gov/grants/guide/pa-fi	iles/PAR-18-854.html			
	Deadline Dates (ALL)	11-Apr-2019 , 10-May-2019 , 10-Jun-2019 2019 , 10-Jan-2020 , 10-Feb-2020 , 10-Ma	9 , 11-Jul-2019 , 09-Aug-2019 , 12-Sep-20: ar-2020 , 07-Apr-2020 , 11-May-2020 , 10	19 , 11-Oct-2 -Jun-2020 , 1	019 , 13-Nov-20 0-Jul-2020 , 11- <i>l</i>	19 , 10-Dec- Aug-2020 , 10

- 1	SPIN ID	Program	Snoncor Namo	Sponsor Number	Deadline Date	Funding
- 1	SPIN ID	Title	Sponsor Name	Sponsor Number	Deadine Date	Amount

Sep-2020, 14-Oct-2020, 10-Nov-2020, 11-Dec-2020, 11-Jan-2021, 10-Feb-2021, 10-Mar-2021, 09-Apr-2021, 10-May-2021 , 11-Jun-2021, 09-Jul-2021, 10-Aug-2021, 10-Sep-2021

National Institutes of Health (NIH) and its participating Institutes and Centers invite applications for time-sensitive research to evaluate a new policy or program that is likely to influence obesity related behaviors (e.g., dietary intake, physical activity, or sedentary behavior) and/or weight outcomes in an effort to prevent or reduce obesity. This FOA is intended to support research where opportunities for empirical study are, by their very nature, only available through expedited review and funding. All applications submitted to this FOA must demonstrate that the evaluation of an obesity related policy and /or program offers an uncommon and scientifically compelling research opportunity that will only be available if the research is initiated with minimum delay. For these reasons, applications submitted to this time-sensitive FOA are not eligible for resubmission. It is intended that eligible applications selected for funding will be awarded within 4 months of the application due date. However, administrative requirements and other unforeseen circumstances may delay issuance dates beyond that timeline. This FOA will utilize the NIH R01 Research Project Grant award mechanism.

**Synopsis** 

078518

Medical Simulators for Practicing Patient Care Providers Skill Acquisition, Outcomes Assessment and Technology Development (R01 Clinical Trial Not Allowed)

National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS

PA-19-065

07-May-2019

Not Specified

Contact Name Jose Serrano, M.D., Ph.D.

Contact Telephone 301-594-8871

Contact Email serranoj@mail.nih.gov

Sponsor Website

Program URL https://grants.nih.gov/grants/guide/pa-files/PA-19-065.html

Deadline Dates (ALL

07-May-2019, 05-Jun-2019, 07-Sep-2019, 05-Oct-2019, 07-Jan-2020, 05-Feb-2020, 07-May-2020, 05-Jun-2020, 07-Sep-2020, 05-Oct-2020, 07-Jan-2021, 05-Feb-2021, 07-May-2021, 05-Jun-2021, 07-Sep-2021, 05-Oct-2021, 07-Jan-2022

The purpose of the Funding Opportunity Announcement (FOA) is to promote the assessment and further development of simulation technologies intended to improve patient safety and healthcare outcomes provided by practicing patient care providers and experienced (not trainee) physicians. The FOA seeks applications directed toward three areas of research: 1) Skill Acquisition: to evaluate strategies and protocols for simulation-based methods for skill acquisition and maintenance by experienced clinicians; 2) Outcomes Assessment: to assess the relationship of simulation-based assessments of skills demonstrated by experienced clinicians with the quality of clinical care delivered by those clinicians, and to identify strategies to increase the quality of simulation-based assessments of skills; and 3) Technology Development: to develop "virtual coaches" by incorporating intelligent technologies into existing simulators to provide adaptive, cognitive assistance to coach experienced practitioners in retaining, retraining and improving performance levels in the context of the user environment (and physiological system as appropriate).

Synopsis

SPIN ID	Program Title	Sponsor Name	Sponso	r Number		Deadline Date	Funding Amount
079079	Stimulating Hematology Investigation Not Allowed)	tion: New Endeavors (SHINE) (R01 Clinical	<u>Trial</u>	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAS-19- 105	05-Jun-2019	Not Specified
	Contact Name	Terry Rogers Bishop, Ph.D.					
	Contact Telephone	301-594-7726					
	Contact Email	terry.bishop@nih.gov					
	Sponsor Website						
	Program URL	https://grants.nih.gov/grants/guide/pa-file	es/PAS	<u>-19-105.html</u>			
	Deadline Dates (ALL)	05-Jun-2019 , 05-Oct-2019 , 05-Feb-2020 ,	, 05-Jun	-2020 , 05-Oct-2020 , 05-Feb-202	1 , 05-Jun-	2021 , 05-Oct-202	1
	Synopsis	nonmalignant hematology research relevance Diseases (NIDDK), National Institute of Aginitiated research project grant application invited to this program that supports grow that are at the leading edge of the field will and Contracts and hyperlinked to this FOA	ing (NIA ns (R01: vth in th ill chang	a), and the National Heart, Lung, a s) in specific areas of basic and ea ne nonmalignant hematology rese	nd Blood I rly translat arch doma	nstitute (NHLBI). ional hematology iin. Specific emer	Investigator- research are ging topics
067709	Investigator-Initiated Clinical Tria (R01 Clinical Trial Required)	ls Targeting Diseases within the Mission of	<u>NIDDK</u>	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PA-18- 330	07-May-2019	Not Specified
	Contact Name	Tracy Rankin, Ph.D., M.P.H.					
	Contact Telephone	301-594-4748					
	Contact Email	rankint@mail.nih.gov					
	Connent Mahaita						
	Sponsor Website						
	•	https://grants.nih.gov/grants/guide/pa-file	es/PA-1	.8-330.html			
	Program URL				20 , 07-Ma	y-2020 , 05-Jun-20	020 , 07-Sep-

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
			nd have a high likelihood that the trial find studied and have the potential to impact 01) award mechanism.			
059676	Biomarkers for Diabetes, Digestive from the NIDDK Repository (R01)	e, Kidney and Urologic Diseases Using Bio	samples National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAR-17- 123	05-Jun-2019	750,000 USD
	Contact Name	Lisa M. Spain, Ph. D.,				
	Contact Telephone	301-451-9871				
	Contact Email	spainl@niddk.nih.gov				
	Sponsor Website					
	Program URL	https://grants.nih.gov/grants/guide/pa-f	files/PAR-17-123.html			
	Deadline Dates (ALL)	05-Jun-2019 , 05-Oct-2019 , 05-Feb-2020	)			
	Synopsis	analysis) of repository-held samples for s will consider both access to repository-he generate scientific discoveries on disease responses. Projects that make good use clinical study and/or trial are highly enco	cive and Kidney Diseases (NIDDK) invites a studies focused on an NIDDK-relevant dise eld samples and funding for assays using t e mechanisms, disease pathogenic process of the associated data from the clinical tri buraged. Exploratory studies and discover rk is justified, and the goal is consistent w arch Project (R01) award mechanism.	tase. The revented in the samples is and studies and study research a	riew of application  These studies a progression, or collies, the original interpretation of the collies.	ons to this FOA re expected to clinical intent of the specially when
080703	Small Grants for New Investigator Research (R21 Clinical Trial Option	rs to Promote Diversity in Health-Related	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAR-19- 222	16-Jun-2019	375,000 USD
	Contact Name	Lawrence Agodoa, M.D.	· ,			
	Contact Telephone					
	·	SmallGrant4Diversity@niddk.nih.gov				
	Sponsor Website					
	·	https://grants.nih.gov/grants/guide/pa-f	files/PAR-19-222.html			
	·	16-Jun-2019 , 07-Sep-2019 , 16-Oct-2019	9 , 07-Jan-2020 , 16-Feb-2020 , 07-May-20 ay-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-	-		•

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Synopsis	diverse backgrounds, including from gro small research projects in the scientific n (NIDDK) and the National Human Genom have/have had less than \$125,000 direct awards). This R21 will support small rese and seeks to facilitate the transition to re supports different types of projects inclu-	Announcement (FOA) is to provide supportupes nationally underrepresented in biometrission areas of the National Institute of Date Research Institute (NHGRI) and (2) who cost of combined research funding (excluterance) that can be carried out in a desearch independence of diverse New Invitating pilot and feasibility studies; secondant of research methodology; and develop	edical and be iabetes and at the time iding NIH tra short period estigators. T ry analysis o	chavioral research Digestive and Kid of award under t Ining and NIH can I of time with lim he R21 grant med f existing data; sr	n to conduct Iney Diseases his FOA will reer ited resources chanism nall, self-
UXU/9h	RFA-DK-19-003 Cystic Fibrosis R Optional)	esearch and Translation Centers (P30 Clir	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	RFA-DK- 19-003	18-Jun-2019 [LOI/Pre-App] [Optional]	3,750,000 USD
	Contact Name	Thomas Eggerman, MD, Ph. D.				
	Contact Telephone	301-594-8813				
	Contact Email	eggermant@mail.nih.gov				
	Sponsor Website					
	Program URL	https://grants.nih.gov/grants/guide/rfa-	files/RFA-DK-19-003.html			
	Deadline Dates (ALL)	18-Jun-2019 [LOI/Pre-App][Optional], 18	3-Jul-2019			
	Synopsis	Centers. CF Research and Translation Co Fibrosis. CF Research and Translation Co a Pilot and Feasibility program; and an A resources to support research to develop strong existing research base in CF. The institutions with documented programs currently funded CF Research and Transl	ort (FOA) invites applications for Cystic Fibruary Centers are designed to support both lare Centers support three primary research dministrative Core with an enrichment proport test new therapies for CF and to fos NIDDK currently supports seven CF Reseatof research excellence in basic and clinical ation Centers may be found at: https://www.sis-research-translation-centers or https://www.sis-research-translation-centers-centers-centers-centers-centers-center	pasic and cline h-related accopram. Core ter collabora rch and Trar CF Research ww.niddk.nil	nical research on tivities: Research e Centers provide ations among inst aslation Centers lo h. Information ab h.gov/research-	Cystic Core services; shared itutions with a ocated at oout the
Uhu/III -	imited Competition: Small Grant Clinical Trial Optional)	Program for NIDDK K01/K08/K23 Recipie	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAR-18- 103	07-May-2019	100,000 USD
	Contact Name	Lisa M. Spain, Ph.D.				
	-					

Contact Telephone 301-451-9871

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount		
	Contact Email	SpainL@niddk.nih.gov						
	Sponsor Website							
	Program URL	https://grants.nih.gov/grants/guide/pa-fil	es/PAR-18-103.html					
	Deadline Dates (ALL)	07-May-2019 , 16-Jun-2019 , 07-Sep-2019						
	K01, K08, and K23 recipients the opportunity to apply for Small Grant (R03) support at some point during the final two years of their K award. Through the use of this mechanism, the NIDDK is seeking to enhance the capability of its K01, K08, and K23 award recipients to conduct research as they complete their transition to fully independent investigator status. The R03 grant mechanism supports different types of projects, including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology. The R03 is, therefore, intended to support research projects that can be carried out in a short period of time with limited resources and that may provide preliminary data to support a subsequent R01, or equivalent, application. This program will use the NIH Small Research Grant (R03) award mechanism.							
080860	Analysis and Measurement of Vira	ition: Follow-up on Subjects, Integrative Da Il Antibodies in The Environmental Determ EDDY) (U01 Clinical Trial Not Allowed)		RFA-DK- 18-512	03-May-2019 [LOI/Pre-App] [Optional]	27,000,000 USD		
	Contact Name	Arthur Castle, Ph.D						
	Contact Telephone	301- 594-7719						
	Contact Email	<u>castlea@niddk.nih.gov</u>						
	Sponsor Website							
	Program URL	https://grants.nih.gov/grants/guide/rfa-fil	es/RFA-DK-18-512.html					
	Deadline Dates (ALL)	03-May-2019 [LOI/Pre-App][Optional], 03-	-Jun-2019					
	Synopsis	This Funding Opportunity Announcement (PD/PI) of the current Data Coordinating C study, an ongoing epidemiological study. I management since the inception of the TE follow TEDDY children and allows funding measurement and analysis of viral antibody.	Center (DCC) for The Environmental Dete This DCC has been involved in study design EDDY Consortium. This FOA provides sup for collaborators to conduct studies on i	rminants of gn and data port for the	Diabetes in the Y and bio sample a TEDDY DCC to co	oung (TEDDY) cquisition and ntinue to		
077971	RFA-DK-18-020 Diabetes Researd	ch Centers (P30 Clinical Trial Optional)	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	RFA-DK- 18-020	20-May-2019 [LOI/Pre-App] [Optional]	6,250,000 USD		

SPIN ID	Program Title	Sponsor Name	Sponso	r Number		<b>Deadline Date</b>	Funding Amount		
	Contact Name Contact Telephone	James F. Hyde, Ph.D.							
	Contact Email	James.Hyde@.nih.gov							
	_	https://grants.nih.gov/grants/guide/rfa-							
	Deadline Dates (ALL) Synopsis	E Dates (ALL)  20-May-2019 [LOI/Pre-App][Optional], 20-Jun-2019  This Funding Opportunity Announcement (FOA) invites applications for Diabetes Research Centers that are designed to support and enhance the national research effort in diabetes, its complications, and related endocrine and metabolic diseases. Diabetes Research Centers support two primary research-related activities: Research Core services and a Pilot and Feasibility (P and F) program. All activities pursued by Diabetes Research Centers are designed to enhance the efficiency, productivity, effectiveness, and multidisciplinary nature of research in Diabetes Research Center topic areas. The NIDDK Diabetes Research Centers program in 2018 consists of 16 Centers each located at outstanding research institutions with documented programs of excellence in diabetes-related research. General information about the NIDDK Diabetes Research Centers program may be found at www.diabetescenters.org.							
	Stimulating Urology Interdisciplin Clinical Trial Optional)	ary Team Opportunity Research (SUITOR)	(R01	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAS-19- 241	05-Jun-2019	Not Specified		
	Contact Name	Tamara G. Bavendam, MD, MS							
	Contact Telephone	301-594-4733							
	Contact Email	tamara.bavendam@nih.gov							
	Sponsor Website								
	Program URL	https://grants.nih.gov/grants/guide/pa-f	files/PAS	<u>-19-241.html</u>					
	Deadline Dates (ALL)	05-Jun-2019 , 05-Oct-2019 , 05-Feb-2020 2022	0 , 05-Jui	n-2020 , 05-Oct-2020 , 05-Feb-202	1 , 05-Jun-2	2021 , 05-Oct-202	1,05-Feb-		
	The Stimulating Urology Interdisciplinary Team Opportunity Research (SUITOR) program is intended to promote innovative, high quality, interdisciplinary research relevant to the mission of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The NIDDK invites investigator-initiated research project grant applications (R01s) in specific areas of basic translational and clinical research in specific benign urologic conditions and diseases where needs and opportunities for progress are particularly timely. Specific research topic areas supported by the SUITOR program, as outlined below, will change over time and will be updated annually through the NIH Guide to Grants and Contracts.								
	Transition to Indonendant Enviro	nmental Health Research (TIEHR) Career A	Award	National Institute of	PAR-18-	12-Jun-2019	375,000		

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	(K01 Clinical Trial Not Allowed)		Environmental Health Sciences/NIH/DHHS	291		USD
	Contact Name	Carol Shreffler, Ph.D.				
	Contact Telephone	919-541-1445				
	Contact Email	Shreffl1@niehs.nih.gov				
	Sponsor Website					
	Program URL	https://grants.nih.gov/grants/guide/pa-file	es/PAR-18-291.html			
	Deadline Dates (ALL)	12-Jun-2019				
	Synopsis	program for newly independent faculty when conclusion of the career development per research funding in the environmental heat specifically for applicants proposing resear feasibility study, or an ancillary study to a clinical trial led by a mentor or co-mentor Research & Training mechanism.	iod the candidates are expected to dalth sciences. This Funding Opportunch that does not involve leading an clinical trial. Applicants to this FOA a	emonstrate the ity Announcemondent cling independent cling re permitted to	y can successfull ent (FOA) is desi nical trial, a clinic propose researc	y compete fo gned cal trial h experience
068837	Transition to Independent Environ (K01 Clinical Trial Required)	nmental Health Research (TIEHR) Career Av	vard National Institute of Environmental Health Sciences/NIH/DHHS	PAR-18- 261	12-Jun-2019	375,000 USD
	Contact Name	Carol Shreffler, Ph.D.				
	Contact Telephone	919-541-1445				
	Contact Email	Shreffl1@niehs.nih.gov				
	Sponsor Website					
	Program URL	https://grants.nih.gov/grants/guide/pa-file	es/PAR-18-261.html			
	Deadline Dates (ALL)	12-Jun-2019				
		National Institute of Environmental Health Environmental Health Research (TIEHR) Ca	· · · · · · · · · · · · · · · · · · ·		•	

Synopsis program for newly independent faculty who intend to pursue research careers in environmental health sciences. At the

conclusion of the career development period the candidates are expected to demonstrate they can successfully compete for research funding in the environmental health sciences. his Funding Opportunity Announcement (FOA) is designed specifically

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount			
		for applicants proposing to serve as the le separate ancillary study to an existing tria Research Scientist Development Award -	l, as part of their research and career			•			
054419	RFA-ES-16-005Mechanism for T Environmental Health Sciences (F	ime-Sensitive Research Opportunities in R21)	National Institute of Environmental Health Sciences/NIH/DHHS	RFA-ES- 16-005	01-May-2019	275,000 USD			
	Contact Name	Ms. Martha I. Barnes, MS							
	Contact Telephone	919-541-3336							
	Contact Emai	<u>barnes@niehs.nih.gov</u>							
	Sponsor Website								
	Program URL	http://grants.nih.gov/grants/guide/rfa-fil	es/RFA-ES-16-005.html						
	Deadline Dates (ALL)	01-May-2019 , 01-Jun-2019 , 01-Jul-2019	, 01-Aug-2019 , 03-Sep-2019						
	Synopsis	National Institute of Environmental Healt an unpredictable event provides a limited exposure data. The primary motivation of emerging environmental public health this need for rapid review and funding (substates research question to be addressed and swapplication due dates and expediting peeto award, is expected to be within 3-4 momechanism.	I window of opportunity to collect hur the FOA is to understand the consequence reats in the U.S. and abroad. A distinguentially shorter than the typical NIH gravifity implemented. The shortened time r review, council concurrence and away	nan biological suences of natu uishing feature ant review/aw neframe will be ard issuance. Tl	samples or environ ral and man-mad of an appropriat ard cycle) in orde achieved by mon ne entire cycle, fr	onmental e disasters or e study is the r for the e frequent om submission			
080739		nmental Health Research (TIEHR) Career Aental Studies with Humans Required)	ward National Institute of Environmental Health Sciences/NIH/DHHS	PAR-19- 225	12-Jun-2019	375,000 USD			
	Contact Name	Carol Shreffler, PhD							
	Contact Telephone	984-287-3322							
	Contact Emai	shreffl1@niehs.nih.gov							
	Sponsor Website								
	<del>-</del>	https://grants.nih.gov/grants/guide/pa-files/PAR-19-225.html							
	Deadline Dates (ALL)	12-Jun-2019 , 07-Sep-2019 , 12-Oct-2019 2020 , 07-Jan-2021 , 12-Feb-2021 , 07-Ma	, 07-Jan-2020 , 12-Feb-2020 , 07-May- y-2021 , 12-Jun-2021 , 07-Sep-2021 , 2	-2020 , 12-Jun- 12-Oct-2021 , (	2020 , 07-Sep-20 07-Jan-2022	20 , 12-Oct-			

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount			
	Synopsis	for newly independent faculty who inter the career development period the cand funding in the environmental health scie experimental studies involving humans, participants." These studies fall within the Types of studies that should submit under (i.e., experimentally manipulate indepent	nental Health (TIEHR) Career Award is a 3-yand to pursue research careers in environmedidates are expected to demonstrate they cances. Note: This Parent Funding Opportunareferred to inNOT-OD-18-212 as "prospective NIH definition of a clinical trial and also er this FOA include studies that prospective dent variables) and that assess biomedicantal aspects of phenomena without specific h specific applications toward processes of equired' PAR 18-261.	ental health can success ity Announ live basic so meet the d ely assign h I or behavio c applicatio	n sciences. At the fully compete for cement is for basicience studies investination of basic luman participant oral outcomes in honorogen.	conclusion of research ic science olving human research. It is to conditions numans for the ses or			
068431	Research to Action: Assessing and Environmental Contaminants (R01	Addressing Community Exposures to Clinical Trial Optional)	National Institute of Environmental Health Sciences/NIH/DHHS	PA-18- 260	05-Jun-2019	Not Specified			
	Contact Name	Symma Finn, PhD							
	Contact Telephone	919-541-4258							
	Contact Email <u>1</u>	finns@niehs.nih.gov							
	Sponsor Website								
	Program URL <u>l</u>	https://grants.nih.gov/grants/guide/pa-f	files/PA-18-260.html						
	Deadline Dates (ALL)	05-Jun-2019							
	National Institute of Environmental Health Sciences (NIEHS) and National Institute of Nursing Research (NINR) invite applications using community-engaged research methods to investigate the potential health risks of environmental exposures of concern to the community and to implement an environmental public health action plan based on research findings. The overall goal is to support changes to prevent or reduce exposure to harmful environmental exposures and improve the health of a community. This FOA will use the NIH Research Project (R01) award mechanism.								
081246		nnovative, Visionary Environmental healt mental Studies with Humans Required)	National Institute of Environmental Health Sciences/NIH/DHHS	RFA-ES- 19-008	21-May-2019 [LOI/Pre-App] [Optional]	6,000,000 USD			



SPIN ID	Program Title	Sponsor Name	Sponso	r Number		Deadline Date	Funding Amount	
	Sponsor Website							
		https://grants.nih.gov/grants/guide/rfa-f						
	Deadline Dates (ALL)	21-May-2019 [LOI/Pre-App][Optional], 2						
	Synopsis	The NIEHS Revolutionizing Innovative, Visionary Environmental health Research (RIVER) program seeks to provide support the majority of the independent research program for outstanding investigators in the Environmental Health Sciences, giving them intellectual and administrative freedom, as well as sustained support to pursue their research in novel directions in order to achieve greater impacts. The program seeks to identify individuals, regardless of career stage, with a potential for continued innovative and impactful research and combine their existing investigator-initiated research into a single award with a duration of up to 8 years and direct costs of \$600,000 and potentially up to \$750,000 based on current NIEHS funding to be consolidated into the award. This funding opportunity is intended for basic experimental studies with humans, referring to in NOT-OD-18-212 as "prospective basic science studies involving human participants". These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that fit within this FOA include studies using human subjects to support a deeper understanding of the mechanisms underlying the effects of environment exposures on human health, including molecular epidemiological studies. See the Comparison of Funding Opportunity Type by Clinical Trial Allowability table for additional guidance. Applicants not planning a basic experimental study with humans must apply to the companion RFA-ES-19-007"Revolutionizing Innovative, Visionary Environmental health Research (RIVER) (R35 Clinical Trial Not Allowed)".						
	RFA-ES-19-007 Revolutionizing Research (RIVER) (R35 Clinical Tria	Innovative, Visionary Environmental healt al Not Allowed)	<u>:h</u>	National Institute of Environmental Health Sciences/NIH/DHHS	RFA-ES- 19-007	21-May-2019 [LOI/Pre-App] [Optional]	6,000,000 USD	
	Contact Name	Jennifer B. Collins						
	Contact Telephone	984-287-3247						
	Contact Email	collins6@niehs.nih.gov						
	Sponsor Website							
	Program URL	https://grants.nih.gov/grants/guide/rfa-fa-fa-fa-fa-fa-fa-fa-fa-fa-fa-fa-fa-f	files/RFA	<u>-ES-19-007.html</u>				
	Deadline Dates (ALL)	21-May-2019 [LOI/Pre-App][Optional], 2	0-Jun-20	19				
	Synopsis	The NIEHS Revolutionizing Innovative, Visionary Environmental health Research (RIVER) program seeks to provide support for the majority of the independent research program for outstanding investigators in the Environmental Health Sciences, giving them intellectual and administrative freedom, as well as sustained support to pursue their research in novel directions in order to achieve greater impacts. The program seeks to identify individuals, regardless of career stage, with a potential for continued innovative and impactful research and combine their existing investigator-initiated research into a single award with a duration of up to 8 years and direct costs of \$600,000 and potentially up to \$750,000 based on current NIEHS funding						

SPIN ID	Program Title	Sponsor Name	Sponso	or Number		<b>Deadline Date</b>	Funding Amount
		to be consolidated into the award. This trial(s). If you are planning a basic expendos "Revolutionizing Innovative, Visional Humans)".	rimental	study with humans, you must appl	y to the co	mpanion RFA-ES-1	L9-
072936	<u>Academic Research Enhancemen</u> (R15 - Clinical Trial Not Allowed)	t Award for Undergraduate-Focused Inst	<u>itutions</u>	National Institute of General Medical Sciences/NIH/DHHS	PAR-18- 714	07-May-2019	300,000 USD
	Contact Name Contact Telephone	Alexandra M. Ainsztein, PhD. 301-594-0943					
	Contact Emai Sponsor Website	Alexandra. Ainsztein@nih.gov					
	Program URL	https://grants.nih.gov/grants/guide/pa-	-files/PAI	R-18-714.html			
	Deadline Dates (ALL)	07-May-2019 , 25-Jun-2019 , 07-Sep-20 2020 , 25-Oct-2020 , 07-Jan-2021 , 25-F			20 , 07-May	-2020 , 25-Jun-20	20 , 07-Sep-
	Synopsis	National Institute of General Medical S (AREA) for Undergraduate-Focused Inst institutions that do not receive substant experiences primarily for undergraduat Eligible institutions must award baccala support (total costs) in 4 of the last 7 fis (AREA) mechanism.	itutions. tial fundi e studen ureate so	The purpose of the award is to surn ng from the NIH, with an emphasists, and enhancing the research envicence degrees, and have received	oport small s on providi vironment a less than 6	scale research grang biomedical reset these applicant million dollars pe	ants at search institutions. r year of NIH
080378	Limited Competition: NIGMS Lega Clinical Trial Not Allowed)	acy Community-Wide Scientific Resource	s (R24	National Institute of General Medical Sciences/NIH/DHHS	PAR-19- 208	14-Jun-2019	Not Specified
	Contact Name	Dr. Mary Ann Wu					
	Contact Telephone						
	Contact Emai	maryann.wu@nih.gov					
	Sponsor Website						
	Program URL	https://grants.nih.gov/grants/guide/pa	-files/PAI	R-19-208.html			
	Deadline Dates (ALL)	14-Jun-2019					
	Synopsis	The purpose of this funding opportunity supported research activities that are corresearchers that NIGMS supports but a	entral to	the mission of NIGMS and demons	strate a higl	n value to a comm	nunity of

SPIN ID	Program Title		Sponsor Name	Sponso	or Number		Deadline Date	Funding Amount
		yet self-su that is ava the most t continuati activities of cannot be	istaining or ready for commer illable to any qualified investig timely, high quality, and cost-e ion of existing resources, not t only, and not for research activ	cializatio gator and efficient p o develo vities. Ur inding ac	t by other Institutes'/Centers' funda. For this initiative, a resource is a provides data, materials, tools, or progress in a field. This funding op p new ones. The support requested der this limited program, only NIC tivity are eligible. Up to three year ort are implemented.	defined as a r services co portunity is ed must be f GMS-sponso	non-hypothesis- insidered essentia designed to supp for funding of ma red "legacy" reso	driven activity al to making oort the intenance urces that
1156557	Engineering Next-Generation Hur (R21)	man Nervou	us System Microphysiological :	Systems	National Institute of Mental Health/NIH/DHHS	PAR-16- 397	07-May-2019	275,000 USD
	Contact Name	David M. I	Panchision, Ph.D.					
	Contact Telephone	301-443-5	5288					
	Contact Email	panchision	nd@mail.nih.gov					
	Sponsor Website	2						
	Program URL	http://gra	nts.nih.gov/grants/guide/pa-f	iles/PAR	<u>16-397.html</u>			
	Deadline Dates (ALL)	07-May-20	019 , 16-Jun-2019 , 07-Sep-20	19 , 16-0	ct-2019 , 07-Jan-2020			
	Synopsis	toward de human bra facilitate a	eveloping next-generation hun ain, spinal, peripheral nervous	nan cell-o system onal defic	ipating Institutes and Centers inviderived microphysiological system and/or sensory end organ circuit poits relevant to complex nervous som.	s (MPS) with physiology in	n improved fidelit n vivo, which will	y to complex ultimately
11565/14	Engineering Next-Generation Hur (R01)	man Nervou	us System Microphysiological S	Systems	National Institute of Mental Health/NIH/DHHS	PAR-16- 398	07-May-2019	Not Specified
	Contact Name	David M. I	Panchision, Ph.D.					
	Contact Telephone	301-443-5	5288					
	Contact Email	panchision	nd@mail.nih.gov					
	Sponsor Website							
	Program URL	http://gra	nts.nih.gov/grants/guide/pa-f	iles/PAR	<u>16-398.html</u>			
	Deadline Dates (ALL)	07-May-20	019 , 05-Jun-2019 , 07-Sep-20	19 , 05-0	ct-2019 , 07-Jan-2020			
	Synopsis				ipating Institutes and Centers inviderived microphysiological system			

SPIN ID	Program Title	Sponsor Name	Sponso	r Number		Deadline Date	Funding Amount
		human brain, spinal, peripheral nervous sy facilitate analysis of higher order functions Research Project (R01) award mechanism.	al defic				•
068701	NIMH Exploratory/Developmenta	al Research Grant (R21 Clinical Trial Not Allo	owed)	National Institute of Mental Health/NIH/DHHS	PA-18- 350	07-May-2019	275,000 USD
	Contact Name	Pim Brouwers, Ph.D.					
	Contact Telephone	240-627-3863					
	Contact Emai	ebrouwer@mail.nih.gov					
	Sponsor Website						
		https://grants.nih.gov/grants/guide/pa-fil					
	Deadline Dates (ALL)	07-May-2019 , 16-Jun-2019 , 07-Sep-2019 2020 , 16-Oct-2020 , 07-Jan-2021	, 16-0	ct-2019 , 07-Jan-2020 , 16-Feb-20	20 , 07-Ma <sup>,</sup>	y-2020 , 16-Jun-20	)20 , 07-Sep-
	Synopsis	National Institute of Mental Health (NIMI the NIMH mission by providing support fo considerable risk but may lead to a breakt models, or strategies, or to the generation major impact on biomedical, behavioral, o program will use the NIH Exploratory/Dev	or the eathrough n of pilo or clinic	arly and conceptual stages of thes or to the development of novel to ot or feasibility data. The prelimina al mental health research, or on t	e projects. echniques, ary work fr	These studies ma agents, methods, om these studies o	y involve measures, could lead to
061878	Clinical Studies of Mental Illness I	Not Involving Clinical Trials (Collaborative R	<u>01)</u>	National Institute of Mental Health/NIH/DHHS	PAR-17- 256	07-May-2019	Not Specified
	Contact Name	Terri Jarosik					
	Contact Telephone	301-443-3858					
	Contact Emai	tjarosik@mail.nih.gov					
	Sponsor Website						
	Program URL	https://grants.nih.gov/grants/guide/pa-fil	les/PAR	<u>-17-256.html</u>			
	Deadline Dates (ALL)	07-May-2019 , 05-Jun-2019 , 07-Sep-2019	, 05-0	ct-2019 , 07-Jan-2020 , 05-Feb-20	20 , 07-Ma	y-2020	
	Synopsis	National Institute of Mental Health (NIMH development, efficacy, or effectiveness tristudies of mental illnesses (e.g. psychopat with HIV/AIDS. Applicants should respond	ials. Pri thology	mary areas of focus include mental, neurodevelopmental trajectories	al health ge s of psycho	enetics, biomarker pathology) also w	studies, an hen associa

the collaborating studies share a specific protocol across the sites and are organized as such in order to increase sample size,

SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount		
	that one site will be submitted as a coord linked set of collaborative R01s, each app	ole diversity and representation. In studies dinating R01 for data management and/or plication has its own Program Director/Prinction, quality control, database managet (R01) award mechanism.	other centr	alized administra tigator and the pr	tion. For a ogram		
065054 Discovery of in vivo Chemical Pro	obes for Novel Brain Targets (R01)	National Institute of Mental Health/NIH/DHHS	PAR-17- 336	07-May-2019	Not Specified		
Contact Nam	e Enrique L. Michelotti, Ph.D.						
Contact Telephon	e 301-443 5415						
Contact Ema	il <u>michelottiel@mail.nih.gov</u>						
Sponsor Websit	е						
Program UR	L https://grants.nih.gov/grants/guide/pa-f	files/PAR-17-336.html					
Deadline Dates (ALL	(L) 07-May-2019, 05-Jun-2019, 07-Sep-2019, 05-Oct-2019, 07-Jan-2020, 05-Feb-2020, 07-May-2020, 05-Jun-2020, 07-Sep-2020						
Synopsi	discovery and development of novel, sm the missions of NIMH, NEI, NIAAA, NIDA, will inform studies of brain disease mech s disease-related biological targets and bio support investigators who have interest brain targets. It is expected that applican	s participating Institutes and Centers invited all molecules for their potential use in uncountries. NIA and/or NIDCD and 2) discovery and/or anisms. Emphasis will be placed on project ological processes. This Funding Opportunand capability to join efforts for the discounts will have in hand the starting compounts analog compounds. This FOA will use the	derstanding or validation ots that provity Announce of in vivery of in vives ("validate	biological process of novel, biologic ide new insight in tement (FOA) into o chemical probe ed hits") for chem	ses relevant to cal targets that nto important ends to es for novel nical		
065058 Discovery of Cell-based Chemica	l Probes for Novel Brain Targets (R21)	National Institute of Mental Health/NIH/DHHS	PAR-17- 335	07-May-2019	275,000 USD		
Contact Nam	e Enrique L. Michelotti, Ph.D.						
Contact Telephon	e 301-443 5415						
Contact Ema	il michelottiel@mail.nih.gov						
Sponsor Websit	е						
Program UR	L https://grants.nih.gov/grants/guide/pa-f	files/PAR-17-335.html					

Deadline Dates (ALL) 07-May-2019, 16-Jun-2019, 07-Sep-2019, 16-Oct-2019, 07-Jan-2020, 16-Feb-2020, 07-May-2020, 16-Jun-2020, 07-Sep-

SPIN ID Program Title	Sponsor Name	Sponso	r Number		Deadline Date	Funding Amount	
Synopsis of f	National Institutes of Health (NIH) and its liscovery and development of novel, small he missions of NIMH, NIA, and/or NIDCI tudies of brain disease mechanisms. Emelated biological targets and biological pliscovery of cell-based chemical probes. Who have interest and capability to join expected that applicants will have in han or testing new analog compounds. This inechanism.	all mole D; and 2) ophasis vorocesse This Furefforts for d the sta	cules for their potential use in under discovery and/or validation of nove vill be placed on projects that proves. The main emphasis of projects so ding Opportunity Announcement or the discovery of cell-based chemotring compounds ("validated hits"	erstanding vel, biologivide new in ubmitted u (FOA) intersical probes	biological procestical targets that we sight into importain the FOA should be supported to support investion to support in the	ses relevant to ill inform ant disease- ould be in the estigators argets. It is and bioassays	
066245 Understanding and Modifying Tem (R01)	poral Dynamics of Coordinated Neural A	ctivity	National Institute of Mental Health/NIH/DHHS	PAR-17- 466	07-May-2019	Not Specified	
Contact Name I	Bettina D. Buhring, Ph.D.						
Contact Telephone	801-443-1576						
Contact Email <u>k</u>	oettina.buhring@mail.nih.gov						
Sponsor Website							
Program URL <u>I</u>	https://grants.nih.gov/grants/guide/pa-f	iles/PAR	<u>-17-466.html</u>				
ווווא במדברו מחוומבמרו	07-May-2019 , 05-Jun-2019 , 07-Sep-201 2020	9 , 05-0	ct-2019 , 07-Jan-2020 , 05-Feb-202	0 , 07-May	-2020 , 05-Jun-20	20 , 07-Sep-	
The National Institute of Mental Health's (NIMH) funding opportunity will support projects that test whether modifying electrophysiological patterns during behavior can improve cognitive, affective, or social processing. Applications should us experimental designs that incorporate active manipulations to address at least one, and ideally more, of the following topi (1) in animals or humans, determine which parameters of neural coordination, when manipulated in isolation, improve particular aspects of cognitive, affective, or social processing; (2) in animals or humans, determine how particular abnormalities at the genomic, molecular, or cellular levels affect the systems-level coordination of electrophysiological patterns during behavior; (3) determine whether in vivo, systems-level electrophysiological changes in behaving animals predict analogous electrophysiological and cognitive improvements in healthy persons or clinical populations; and (4) use biologically-realistic computational models that include systems-level aspects to understand the function and mechanisms which oscillatory and other electrophysiological patterns unfold across the brain to impact cognitive, affective, or social processing. This FOA will use the NIH Research Project (R01) award mechanism.  063784 Cellular and Molecular Biology of Complex Brain Disorders (R21)  National Institute of Mental PAR-17- 16-Jun-2019 275,000							

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
			Health/NIH/DHHS	310		USD
	Contact Name	David Panchision				
	Contact Telephone	301-443-5288				
	Contact Email	panchisiond@mail.nih.gov				
	Sponsor Website					
	Program URL	https://grants.nih.gov/grants/guide/	/pa-files/PAR-17-310.html			
	Deadline Dates (ALL)	16-Jun-2019 , 16-Oct-2019 , 16-Feb-	2020 , 16-Jun-2020			
	Synopsis	alterations associated with complex	NIMH) invites research grant applications of brain disorders on the fundamental cellula 21 Exploratory/Developmental Research G	r and molecula	ar substrates of ne	•
063781	Cellular and Molecular Biology of	Complex Brain Disorders (R01)	National Institute of Mental Health/NIH/DHHS	PAR-17- 309	05-Jun-2019	Not Specified
	Contact Name	David Panchision				
	Contact Telephone	301-443-5288				
	Contact Email	panchisiond@mail.nih.gov				
	Sponsor Website					
	Program URL	https://grants.nih.gov/grants/guide/	/pa-files/PAR-17-309.html			
	Deadline Dates (ALL)	05-Jun-2019 , 05-Oct-2019 , 05-Feb-	2020 , 05-Jun-2020			
	Synopsis	alterations associated with complex	NIMH) invites research grant applications of brain disorders on the fundamental cellula esearch Project (R01) award mechanism.		•	•
	PsychENCODE: Non-coding Functi in the Development of Psychiatric		nd their Role National Institute of Mental Health/NIH/DHHS	PAR-17- 258	06-May-2019 [LOI/Pre-App] [Optional]	Not Specified
	Contact Name	Geetha Senthil, Ph.D.				
	Contact Telephone	301-402-0754				
	Contact Email	senthilgs@mail.nih.gov				
	Sponsor Website					

Program URL https://grants.nih.gov/grants/guide/pa-files/PAR-17-258.html

SPIN ID	Program	Sponsor Name	Spansor	Number		Deadline Date	Funding
SPIN ID	Title	Sponsor Name	Sponsor	· Number		Deadine Date	Amount
	Deadline Dates (ALL) Synopsis	06-May-2019 [LOI/Pre-App][Optional], 06 National Institute of Mental Health (NIMI- human-specific non-coding functional ger elucidate their role(s) in the molecular pa unbiased genome-wide approaches, complete demands outcomes relevant to brain function and of essential to complete the proposed resea mechanism.	H) will sunomic electrophyse putation seased h	pport research in the discovery are ements across brain regions, cell to iology of mental illness. It is expect al methods, and experimental ass uman brains to correlate findings ion. This FOA should be used whe	ypes, and o ted that pr ays to iden with devel n two or m	developmental tir ojects under this tify and characte opment of menta ore collaborating	ne periods to FOA will apply rize functional I illnesses and sites are
	<u>PsychENCODE: Non-coding Function the Development of Psychiatric</u>	ional Elements in the Human Brain and the Disorders (U01)	eir Role	National Institute of Mental Health/NIH/DHHS	PAR-17- 257	06-Jun-2019	Not Specified
	Contact Name	Geetha Senthil, Ph.D.					
	Contact Telephone	301-402-0754					
	Contact Email	senthilgs@mail.nih.gov					
	Sponsor Website						
	Program URL	https://grants.nih.gov/grants/guide/pa-fil	les/PAR-	<u>17-257.html</u>			
	Deadline Dates (ALL)	06-Jun-2019					
	Synopsis	National Institute of Mental Health (NIMI- human-specific non-coding functional ger elucidate their role(s) in the molecular pa unbiased genome-wide approaches, comp genomic elements in both healthy and dis outcomes relevant to brain function and of	nomic ele thophys putation seased h	ements across brain regions, cell t iology of mental illness. It is expec al methods, and experimental ass uman brains to correlate findings	ypes, and o ted that pr ays to iden with devel	developmental tir ojects under this tify and characte opment of menta	ne periods to FOA will apply rize functional I illnesses and
069255		nt Suicide Behavior, Ideation and Self-Harm e Justice System (R34 Clinical Trial Required		National Institute of Mental Health/NIH/DHHS	PAR-18- 228	17-May-2019 [LOI/Pre-App] [Optional]	450,000 USD
	Contact Name	Denise Juliano-Bult, M.S.W.					
	Contact Telephone	301-443-1638					
	Contact Email	djuliano@mail.nih.gov					
	Sponsor Website						
	Program URL	https://grants.nih.gov/grants/guide/pa-fi	les/PAR-	<u>18-228.html</u>			

eadline Date	Funding
cadille Date	Amount
iicidal self-harm cart at early poir gs (e.g., pre-tria ential or multipl	(NSSI) by its of contact detention, e community
he purpose of tl proaches to imp re-requisite to a	nis FOA is to roving
16-Jun-2019	100,000 USD
to cupport race	
ivery in relation anism.	earch designed to Autism
ivery in relation	_
ivery in relation anism.	275,000
1 1 1 1	eness of combine vicidal self-harm tart at early poin gs (e.g., pre-trial ential or multipl rvice settings us effective, enhan- the purpose of the proaches to imp re-requisite to a echanism.

Deadline Dates (ALL) 16-Jun-2019

SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
Synopsis	to elucidate the etiology, epidemiology,	ts participating Institutes and Centers invi diagnosis, treatment, and optimal means n will use the NIH R21 Exploratory/Develo	of service de	livery in relation	to Autism
069757 Research on Autism Spectrum Dis	sorders (R01-Clinical Trial Optional)	National Institute of Mental Health/NIH/DHHS	PA-18- 401	05-Jun-2019	Not Specified
Contact Name	Lisa Gilotty, Ph.D.				
Contact Telephone	301-443-3825				
Contact Email	gilottyl@mail.nih.gov				
Sponsor Website					
Program URL	https://grants.nih.gov/grants/guide/pa-	files/PA-18-401.html			
Deadline Dates (ALL)	05-Jun-2019				
Synopsis	to elucidate the etiology, epidemiology,	ts participating Institutes and Centers invi diagnosis, treatment, and optimal means n will use the NIH Research Project Grant	of service de	livery in relation	-
069678 Targeted Implementation Science Prevention and Treatment (R21 C	e to Achieve 90/90/90 Goals for HIV/AIDS Clinical Trial Optional)	National Institute of Mental Health/NIH/DHHS	PA-18- 280	07-May-2019	275,000 USD
Contact Name	Christopher Gordon, PhD				
Contact Telephone	240-627-3867				
Contact Email	cgordon1@mail.nih.gov				
Sponsor Website					
Program URL	https://grants.nih.gov/grants/guide/pa-	files/PA-18-280.html			
Deadline Dates (ALL)	07-May-2019 , 16-Jun-2019 , 07-Sep-203	19 , 16-Oct-2019 , 07-Jan-2020			
Synopsis	implementation research projects desig needs in the selected community, to ack global leadership. The targets for HIV te initiation that 90% of those diagnosed re and preventive benefit that 90% of thos	MH) and National Institute of Nursing Res ned in partnership with global and domes nieve the 90/90/90 HIV prevention and tro sting are that 90% of all persons living wit eceive timely and effective antiretroviral to e on treatment achieve sustained viral su	tic service pro eatment targe h HIV know t reatment (AF	oviders, to targe ets identified by heir status, for to RT), and for optir	t the particula HIV/AIDS eatment nal treatment
	Exploratory/Developmental Research G	rant award mechanism.			

SPIN ID	Program Title	Sponsor Name	Sponsor	Number		Deadline Date	Funding Amount
	Prevention and Treatment (R01 Cli	inical Trial Optional)		Health/NIH/DHHS	279		Specified
		Christopher Gordon, PhD					
	Contact Telephone	240-627-3867					
	Contact Email	cgordon1@mail.nih.gov					
	Sponsor Website						
	Program URL	https://grants.nih.gov/grants/guide/pa-	files/PA-18	<u>3-279.html</u>			
	Deadline Dates (ALL)	07-May-2019 , 05-Jun-2019 , 07-Sep-201	19 , 05-Oct	-2019 , 07-Jan-2020			
	National Cooperative Drug/Device	global leadership. The targets for HIV test initiation that 90% of those diagnosed reand preventive benefit that 90% of those Research Project (R01) award mechanism Discovery/Development Groups (NCDD)	eceive timese on treatr m. IG) for	ely and effective antiretroviral tre	eatment (Al	RT), and for optir nis FOA will use th 25-May-2019	nal treatment
069587	the Treatment of Mental or Substa Clinical Trial Optional)	ance Use Disorders or Alcohol Addiction	(1101	Health/NIH/DHHS	230	[LOI/Pre-App] [Optional]	Specified
	Contact Name	Linda Brady, Ph.D., Director					
	Contact Telephone	301-443-3563					
	Contact Email	<u>lbrady@mail.nih.gov</u>					
	Sponsor Website						
	Program URL	https://grants.nih.gov/grants/guide/pa-	files/PAR-:	<u>18-230.html</u>			
	וו וואו פסדבוו מחוואבמוו	25-May-2019 [LOI/Pre-App][Optional], 2 [LOI/Pre-App][Optional], 24-Feb-2020	24-Jun-201	9 , 23-Sep-2019 [LOI/Pre-App][O	otional], 23	3-Oct-2019 , 25-Ja	ın-2020
		NIMH, NIAAA and NIDA invite application neuromodulatory tools for basic and clir develop and validate tools (pharmacolognew candidates for mental disorders; an	nical resear gic or neur	rch on mental health, substance o ostimulation) in support of exper	use disorde rimental the	ers (SUDs) or alco erapeutic studies	hol addiction of innovative

pharmacodynamics of promising drug candidates/devices and new indications for novel Investigational New Drug (IND)-ready agents or Pre-Market Approval (PMA)-ready devices for the treatment of mental disorders, SUDs or alcohol addiction. This FOA encourages applications to advance the discovery, preclinical development, and proof of concept (PoC) testing of new,

SPIN ID	Program Title	Sponsor Name Sp	onsor Number		Deadline Date	Funding Amount
		rationally based candidate agents and neuro and to develop novel ligands and circuit-eng drug/device targets. Partnerships between a specified, circumscribed project to be perfor interest and competencies. This FOA will uti	agement devices as tools to further chacademia and industry are strongly end rmed by the named investigator(s) in a	iaracterize e couraged. Tl n area repre	existing or to valid his FOA supports esenting his or he	late new a discrete, r specific
069588	in the second of	Discovery/Development Groups (NCDDG) for ance Use Disorders or Alcohol Addiction (U19	National institute of Mental	PAR-18- 231	25-May-2019 [LOI/Pre-App] [Optional]	Not Specified
	Contact Name	Linda Brady, Ph.D., Director				
	Contact Telephone	301-443-3563				
	Contact Email	<u>lbrady@mail.nih.gov</u>				
	Sponsor Website					
		https://grants.nih.gov/grants/guide/pa-files				
	Deadline Dates (ALL)	25-May-2019 [LOI/Pre-App][Optional], 24-Ju [LOI/Pre-App][Optional], 24-Feb-2020	ın-2019 , 23-Sep-2019 [LOI/Pre-App][C	Optional], 23	3-Oct-2019 , 25-Ja	n-2020
	Synopsis	NIMH, NIAAA and NIDA invite applications neuromodulatory tools for basic and clinical addiction; develop and validate tools (pharm innovative new candidates for mental disord tolerability, and pharmacodynamics of prom Drug (IND)-ready agents or Pre-Market Applications. This FOA encourages applications testing of new, rationally based candidate agalcohol addiction, and to develop novel ligar validate new drug/device targets. Partnersh research program of multiple projects direct broadly based, multidisciplinary and often locooperative Agreements award mechanism	research on mental disorders, substart acologic or neurostimulation) in suppoders; and support early stage human staising drug candidates/devices and new roval (PMA)-ready devices for the treat to advance the discovery, preclinical capents and neurostimulation approached and circuit-engagement devices as ips between academia and industry are ted toward a specific major objective, by ong-term approach. This FOA will utilize	nce use diso ort of exper dudies to rap v indication tment of me developmen es to treat m tools to fur e strongly el pasic theme	rders (SUDs) or all imental therapeupidly assess the sales for novel Investigental disorders, SUt, and proof of contental disorders of ther characterize incouraged. This For program goal,	icohol atic studies of afety, agational New JDs or alcohol ancept (PoC) r SUDs or existing or to OA supports a requiring a
069665	<u>Innovations in Mechanisms and In</u> <u>Prevention and Care Continuum (</u>	terventions to Address Mental Health in HIV R21 Clinical Trial Optional)	National Institute of Mental Health/NIH/DHHS	PA-18- 275	07-May-2019	275,000 USD
	Contact Name	Gregory Greenwood				

Contact Telephone 240-669-5532

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Contact Email Sponsor Website	gregory.greenwood@nih.gov				
	·	https://grants.nih.gov/grants/guide/pa-l	iles/PA-18-275.html			
	Deadline Dates (ALL)		9 , 16-Oct-2019 , 07-Jan-2020			
	Synopsis	advancing understanding of mechanisms modifiable intervention targets; and 2) d	MH) and National Institute on Drug Abuse by which mental health affects HIV preventeveloping and testing expanded intervententinuum (from HIV testing to viral support mechanism.	ention and t	reatment in order rove both mental	to identify health and
069664	Innovations in Mechanisms and In Prevention and Care Continuum (R	terventions to Address Mental Health in RO1 Clinical Trial Optional)	HIV National Institute of Mental Health/NIH/DHHS	PA-18- 274	07-May-2019	Not Specified
	Contact Name	Gregory Greenwood				
	Contact Telephone	240-669-5532				
	Contact Email	gregory.greenwood@nih.gov				
	Sponsor Website					
	Program URL	https://grants.nih.gov/grants/guide/pa-f	iles/PA-18-274.html			
	Deadline Dates (ALL)	07-May-2019 , 05-Jun-2019 , 07-Sep-201	9 , 05-Oct-2019 , 07-Jan-2020			
	Synopsis	advancing understanding of mechanisms modifiable intervention targets; and 2) d	MH) and National Institute on Drug Abuse by which mental health affects HIV preventeveloping and testing expanded intervented continuum (from HIV testing to viral supplementation)	ention and t	reatment in order rove both mental	to identify health and
069253	·	ET and SPECT Imaging Ligands as Biomar iological Studies of CNS Disorders (R01 C	NISTIONSI INCTITIITA OT MIANTSI	PAR-18- 227	07-May-2019	Not Specified
	Contact Name	Enrique Michelotti, Ph.D.				
	Contact Telephone	301-443-5415				
	Contact Email	michelottiel@mail.nih.gov				
	Sponsor Website					
	Program URL	https://grants.nih.gov/grants/guide/pa-l	iles/PAR-18-227.html			

SPIN ID	Program Title	Sponsor Name	Sponso	r Number		Deadline Date	Funding Amount
	Synopsis	07-May-2019, 05-Jun-2019, 07-Sep-2019 National Institutes of Health (NIH) and it organizations/institutions that propose single photon emission computed tomogenesibility evaluation in pre-clinical studi (R01) award mechanism.	s partici the deve graphy (S	opment of novel radioligands for popularity properties. PECT) imaging in human brain, and	oositron en d that inco	nission tomograpl rporate pilot or cl	hy (PET) or inical
	Understanding and Modifying Ten (R21 Clinical Trial Optional)	nporal Dynamics of Coordinated Neural A	Activity	National Institute of Mental Health/NIH/DHHS	PAR-18- 554	07-May-2019	275,000 USD
	Contact Name	Bettina D. Buhring, Ph.D.					
	Contact Telephone	301-443-1576					
	Contact Email	bettina.buhring@mail.nih.gov					
	Sponsor Website						
	Program URL	https://grants.nih.gov/grants/guide/pa-	files/PAF	-18-554.html			
	Deadline Dates (ALL)	07-May-2019 , 16-Jun-2019 , 07-Sep-201 2020 , 16-Oct-2020 , 07-Jan-2021	19 , 16-0	ct-2019 , 07-Jan-2020 , 16-Feb-202	0 <i>,</i> 07-May	/-2020 , 16-Jun-20	020 , 07-Sep-
	Synopsis	National Institute of Mental Health's (N electrophysiological patterns during beh experimental designs that incorporate a (1) in animals or humans, determine wh particular aspects of cognitive, affective, abnormalities at the genomic, molecular patterns during behavior; (3) determine predict analogous electrophysiological a biologically-realistic computational mod which oscillatory and other electrophysi processing. This FOA will use the NIH R2	navior can ctive ma ich parar , or socia r, or cellu whethen nd cogni els that i ological	n improve cognitive, affective, or so nipulations to address at least one neters of neural coordination, whe I processing; (2) in animals or hum lar levels affect the systems-level in vivo, systems-level electrophys tive improvements in healthy pers nclude systems-level aspects to un patterns unfold across the brain to	ocial proce, and idealism manipul nans, deter coordinations or cliniderstand timpact cogical cr	essing. Application ly more, of the folloated in isolation, is mine how particulon of electrophysical populations; a he function and numbers.	llowing topics: improve ilar ological g animals and (4) use nechanisms by
070683	Understanding and Modifying Ten (R01 Clinical Trial Optional)	nporal Dynamics of Coordinated Neural A	Activity	National Institute of Mental Health/NIH/DHHS	PAR-18- 555	07-May-2019	Not Specified
	Contact Name	Bettina D. Buhring, Ph.D.					



Contact Telephone 301-443-1576

Contact Email <u>bettina.buhring@mail.nih.gov</u>

ISPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
----------	---------------	--------------	----------------	---------------	-------------------

Sponsor Website

Program URL https://grants.nih.gov/grants/guide/pa-files/PAR-18-555.html

Deadline Dates (ALL)

07-May-2019, 05-Jun-2019, 07-Sep-2019, 05-Oct-2019, 07-Jan-2020, 05-Feb-2020, 07-May-2020, 05-Jun-2020, 07-Sep-2020, 05-Oct-2020, 07-Jan-2021

National Institute of Mental Health's (NIMH) invites applications for projects that test whether modifying electrophysiological patterns during behavior can improve cognitive, affective, or social processing. Applications must use experimental designs that incorporate active manipulations to address at least one, and ideally more, of the following topics: (1) in animals or humans, determine which parameters of neural coordination, when manipulated in isolation, improve particular aspects of cognitive, affective, or social processing; (2) in animals or humans, determine how particular abnormalities at the genomic, Synopsis molecular, or cellular levels affect the systems-level coordination of electrophysiological patterns during behavior; (3) determine whether in vivo, systems-level electrophysiological changes in behaving animals predict analogous electrophysiological and cognitive improvements in healthy persons or clinical populations; and (4) use biologically-realistic computational models that include systems-level aspects to understand the function and mechanisms by which oscillatory

and other electrophysiological patterns unfold across the brain to impact cognitive, affective, or social processing. This FOA

Initiation of a Mental Health Family Navigator Model to Promote Early Access, 070076 Engagement and Coordination of Needed Mental Health Services for Children and Adolescents (R01 Clinical Trial Required)

National Institute of Mental Health/NIH/DHHS

PAR-18-428

05-Jun-2019

2,500,000 USD

Contact Name Denise Pintello, Ph.D., M.S.W.

Contact Telephone 301-451-1481

Contact Email dpintell@mail.nih.gov

Sponsor Website

Program URL https://grants.nih.gov/grants/guide/pa-files/PAR-18-428.html

will use the NIH Research Project (R01) award mechanism.

Deadline Dates (ALL) 05-Jun-2019, 05-Oct-2019, 05-Feb-2020, 05-Jun-2020, 05-Oct-2020

National Institute of Mental Health (NIMH) invites applications to develop and test the effectiveness and implementation of family navigator models designed to promote early access, engagement and coordination of mental health treatment and services for children and adolescents who are experiencing early symptoms of mental health problems. For the purposes of this FOA, NIMH defines a family navigator model as a health care professional or paraprofessional whose role is to deploy a set of strategies designed to rapidly engage youth and families in needed treatment and services, work closely with the family and other involved treatment and service providers to optimize care and monitor the trajectory of mental health symptoms and outcomes over time. Applicants are encouraged to develop and test the navigator model's ability to promote early access, engagement and coordination of mental health treatment and services for children and adolescents as soon as

SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	symptoms are detected. Of interest are r "personalized match" to the level of need track and monitor the trajectory of clinic outcomes. This FOA will use the NIH Rese	ded service amount, frequency and inter al, functional and behavioral progress to	nsity, and har	ness novel techno	ologies to
070073 First in Human and Early Stage Cl Devices for Psychiatric Disorders	inical Trials of Novel Investigational Drugs (U01 Clinical Trial Required)	or National Institute of Mental Health/NIH/DHHS	PAR-18- 427	07-May-2019	Not Specified
Contact Telephone	lwinsky@mail.nih.gov				
'	https://grants.nih.gov/grants/guide/pa-f	iles/PAR-18-427.html			
Deadline Dates (ALL)	07-May-2019 , 05-Jun-2019 , 07-Sep-201 2020 , 05-Oct-2020 , 07-Jan-2021	9 , 05-Oct-2019 , 07-Jan-2020 , 05-Feb-20	020 <i>,</i> 07-May	-2020 , 05-Jun-20	20 , 07-Sep-
Synopsis	National Institute of Mental Health (NIM investigational drugs or drug candidates will support milestone-driven early stage novel Agents must assess target engagen feasibility for Phase II/proof of concept (I impact on clinically relevant physiologica supports FIH and early feasibility studies efficacy. The overall objective is to facilitate drugs, novel drugs for use in pediatric po to attract private funding for further cliniformation of collaborative partnerships be facilitate psychiatric drug or device devel Agreements award mechanism.	for the treatment of psychiatric disorder trials in pediatric and adult populations nent (brain exposure), pharmacological ePoC) studies in psychiatric disorders. Phall systems (functional measures) and clini (EFS) of novel devices to evaluate target ate rapid collection of data to "de-risk" negliations with psychiatric disorders, and ical development as FDA-approved treative tween the biomedical researchers and	s in areas of First in hum effects, safety se II/PoC stu ical indicator engagement ovel mechan devices or coments. A key biotechnolog	unmet medical not an (FIH) and Phase, and tolerability dies must evaluates of effect. The FC safety, tolerabilism of action investments aspect of this FO gy or industry res	eed. The FOA e Ib studies of to assess ee the drug's OA also ity, and estigational ments in order A is the earchers to
	n of a Mental Health Family Navigator Mod ent and Coordination of Needed Mental He cents (R34 Clinical Trial Required)	National Institute of Mental	PAR-18- 429	16-Jun-2019	450,000 USD
Contact Telephone	Denise Pintello, Ph.D., M.S.W. 301-451-1481 dpintell@mail.nih.gov				

SPIN ID	Program Title	Sponsor Name S	ponsor Number	Deadline Date	Funding Amount
	Sponsor Website		/DAD 40 420 ht vil		
	-	https://grants.nih.gov/grants/guide/pa-file 16-Jun-2019, 16-Oct-2019, 16-Feb-2020,			
	Synopsis	National Institute of Mental Health (NIMH effectiveness and implementation of family coordination of mental health treatment a mental health problems. For the purposes paraprofessional whose role is to deploy a treatment and services, work closely with t monitor the trajectory of mental health syrtest the navigator model's ability to promo services for children and adolescents as somewises for children and adolescents as somewised care strategies, determine the "per and harness novel technologies to track an achieving intended services outcomes. This	) invites applications research application y navigator models designed to promote and services for children and adolescents of this FOA, NIMH defines a family navig set of strategies designed to rapidly engine the family and other involved treatment appropriate and outcomes over time. Applicate early access, engagement and coordinates symptoms are detected. Of interest resonalized match" to the level of needed dimonitor the trajectory of clinical, functive	early access, engagement a who are experiencing early ator model as a health care age youth and families in ne and service providers to op- cants are encouraged to dev nation of mental health trea at are navigator models that service amount, frequency tional and behavioral progre	and symptoms of professional or eeded timize care and yelop and pilot atment and coordinate and intensity,
071755	Research to Support the Reduction (Admin Supp Clinical Trial Optional	n and Elimination of Mental Health Disparit <u>II)</u>	ies National Institute of Mental Health/NIH/DHHS	PA-18- 621 01-Jun-2019	Not Specified
	Contact Name	Andrea Horvath Marques, M.D., Ph.D, M.P.	.н.		
	Contact Telephone	301-646-7320			
	Contact Email	andrea.horvathmarques@nih.gov			
	Sponsor Website				
	Program URL	https://grants.nih.gov/grants/guide/pa-file	es/PA-18-621.html		
	Deadline Dates (ALL)	01-Jun-2019, 01-Jun-2020			
	Synopsis	National Institute of Mental Health (NIMH foster research across the NIMH Strategic Crace and ethnicity, geography, and socioec the scientific scope of the parent grant that status and/or enhances optimal delivery of Administrative Supplement award mechan	Objectives that target the reduction and onomic status in the United States. This tidentifies mechanisms underlying dispart mental health interventions among dive	elimination of mental healt initiative aims to generate rarities or differences in men	h disparities by esearch within tal health
071668	Mentored Career Transition Awar Clinical Trials)	d for Intramural Fellows (K22 No Independe	ent National Institute of Mental Health/NIH/DHHS	PA-18- 614 12-Jun-2019	Not Specified

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	------------------	--------------	----------------	---------------	-------------------

Contact Name Ashlee Van't Veer

Contact Telephone 301-443-3107

Contact Email dnbbstrainingbranch@mail.nih.gov

Sponsor Website

Program URL https://grants.nih.gov/grants/guide/pa-files/PA-18-614.html

Deadline Dates (ALL) 12-Jun-2019, 12-Oct-2019, 12-Feb-2020, 12-Jun-2020, 12-Oct-2020

National Institute of Mental Health (NIMH) invites applications for a two-phase, mentored career development award program that is intended to facilitate a timely transition of qualified postdoctoral fellows in the NIMH Division of Intramural Programs (DIRP) from intramural postdoctoral research positions to extramural, academic tenure-track or equivalent faculty positions at eligible U.S. institutions. Both the intramural and extramural phases will be mentored, and the award will provide research support during the extramural phase to help awardees launch competitive, independent research programs. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. This FOA will use the NIH K22 Career Transition Award mechanism.

070089

<u>Pilot Effectiveness Trials for Post-Acute Interventions and Services to Optimize</u> Longer-term Outcomes (R34 Clinical Trial Required) National Institute of Mental Health/NIH/DHHS

PAR-18-431

16-Jun-2019

Specified

Not

Contact Name Adam Haim, Ph.D.

Contact Telephone 301-435-3593

Contact Email haima@mail.nih.gov

Sponsor Website

Program URL https://grants.nih.gov/grants/guide/pa-files/PAR-18-431.html

Deadline Dates (ALL) 16-Jun-2019, 16-Oct-2019, 16-Feb-2020, 16-Jun-2020, 16-Oct-2020

National Institute of Mental Health (NIMH) invites applications for pilot effectiveness projects to evaluate the preliminary effectiveness of therapeutic and service delivery interventions for the post-acute management of mental health conditions that are matched to the stage of illness in terms of both their focus (e.g., consolidating and maintaining gains from initial treatment, managing residual symptoms/impairment, preventing relapse, promoting adherence and appropriate service use) and intensity/burden. In this pilot phase of effectiveness research, the trial should be designed to evaluate the feasibility, tolerability, acceptability, safety, and potential effectiveness of the approach; to address whether the intervention engages the target(s)/mechanisms(s) that is/are presumed to underlie the intervention effects; and to obtain preliminary data needed as a pre-requisite to a larger-scale effectiveness trial (e.g., comparative effectiveness study, practical trial) designed to definitely test the effectiveness of interventions to improve post-acute outcomes. This FOA will use the NIH R34 Planning

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		Grant award mechanism.				
H / HIXA	Effectiveness Trials for Post-Acute term Outcomes (R01 Clinical Trial	e Interventions and Services to Optimize Lo Required)	onger- National Institute of Mental Health/NIH/DHHS	PAR-18- 430	06-May-2019 [LOI/Pre-App] [Optional]	Not Specified
	Contact Name	Adam Haim, Ph.D.				
	Contact Telephone	301-435-3593				
	Contact Email	haima@mail.nih.gov				
	Sponsor Website					
	Program URL	https://grants.nih.gov/grants/guide/pa-f	iles/PAR-18-430.html			
	Deadline Dates (ALL)	06-May-2019 [LOI/Pre-App][Optional], 09 [LOI/Pre-App][Optional], 05-Feb-2020, 0 App][Optional], 05-Oct-2020	5-Jun-2019 , 05-Sep-2019 [LOI/Pre-App][O 6-May-2020 [LOI/Pre-App][Optional], 05-J		•	
	Synopsis	therapeutic and service delivery interven adults, and older adults. This FOA encour moderators, mediators, and mechanisms matched to the stage of illness in terms of managing residual symptoms/impairmen	MH) invites applications for research projections for the post-acute management of mages clinical trials to establish the effective of action of post-acute phase therapeution both their focus (e.g., consolidating and t, preventing relapse, promoting adherent onger-term outcomes. This FOA will use the	nental heal eness and t and service maintainin ce and app	th conditions affe test hypotheses re tes interventions t g gains from initia ropriate service us	cting youth, egarding hat are Il treatment, se) and
11711/2019	Advancing Basic Neurobiology To (R01 Clinical Trial Not Allowed)	ward Translation Through Assay Developn	nent National Institute of Mental Health/NIH/DHHS	PAR-18- 505.	07-May-2019	Not Specified
	Contact Name	Jamie Driscoll				
	Contact Telephone	301-443-5288				
	Contact Email	jdrisco1@mail.nih.gov				
	Sponsor Website					
	Program URL	https://grants.nih.gov/grants/guide/pa-f	iles/PAR-18-505.html			
	Deadline Dates (ALL)	07-May-2019 , 05-Jun-2019 , 07-Sep-2019 2020 , 05-Oct-2020 , 07-Jan-2021	9 , 05-Oct-2019 , 07-Jan-2020 , 05-Feb-202	20 , 07-May	/-2020 , 05-Jun-20	20 , 07-Sep-
	Synopsis	National Institutes of Health (NIH) and its	s participating Institutes and Centers invite /or glial function. The goal is to adapt state			

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		processes or molecular events that are ke probe mechanisms or perturbations in an measure neurobiological endpoints to acc development efforts. This FOA will use the	unbiased and efficient manner. These celerate basic discovery and support tar	novel assays get identifica	would provide o	oportunities to
071809	RFA-MH-19-130 NIMH Biobeha Scientists (NIMH BRAINS) (R01 Cli	vioral Research Awards for Innovative New inical Trial Optional)	National Institute of Mental Health/NIH/DHHS	RFA-MH- 19-130	20-Jun-2019	1,625,000 USD
	Contact Telephone	kanders1@mail.nih.gov				
	Program URL	https://grants.nih.gov/grants/guide/rfa-fi	les/RFA-MH-19-130.html			
	Deadline Dates (ALL)	20-Jun-2019				
	Synopsis	National Institute of Mental Health (NIM Scientists (BRAINS) award. The award is in exceptionally productive scientists who are career commitment to research in specific launching an innovative clinical, translation transform the understanding, diagnosis, ton the research priorities and gap areas in (RDoC) project. This FOA will use the NIH	ntended to support the research and restree in the early, formative stages of their common mission areas of the NIMH. This award mal, basic or services research program reatment, or prevention of mental disodentified in the NIMH Strategic Plan and	search career careers and v I seeks to ass that holds th rders. The NII I the Researcl	advancement of who plan to make ist these individu e potential to pro MH BRAINS prog	outstanding, e a long term als in ofoundly ram will focus
073671	NIMH Career Transition Award fo Independent Clinical Trial Not Allo	r Tenure-Track Intramural Investigators (Ka owed)	National Institute of Mental Health/NIH/DHHS	PAR-18- 755	12-Jun-2019	900,000 USD
		Ashlee Van't Veer, PhD				
	Contact Telephone					
	Sponsor Website	dnbbstrainingbranch@mail.nih.gov				
	•	https://grants.nih.gov/grants/guide/pa-fil	les/PAR-18-755 html			
		12-Jun-2019 , 12-Oct-2019 , 12-Feb-2020		121		
	Deadine Dates (ALL)	National Institute of Mental Health (NIM)	•		rs at NIMH who a	aim to
	Synopsis	transition from the Division of Intramural	· · · · · · · · · · · · · · · · · · ·	•		

extramural community. Applicants should have a demonstrated record of meritorious research in mental health-related

	Program						Funding
SPIN ID	Title	Sponsor Name	Spons	or Number		Deadline Date	Amount
		fields. This FOA will utilize the NIH Caree	er Transi	tion (K22) award mechanism.			
U/Ibb/	Mentored Career Transition Awar Required)	rd for Intramural Fellows (K22 Clinical Tria	<u>al</u>	National Institute of Mental Health/NIH/DHHS	PA-18- 613	12-Jun-2019	Not Specified
	Contact Name	Ashlee Van't Veer					
	Contact Telephone	301-443-3107					
	Contact Email	dnbbstrainingbranch@mail.nih.gov					
	Sponsor Website						
	Program URL	https://grants.nih.gov/grants/guide/pa-	files/PA	18-613.html			
	Deadline Dates (ALL)	12-Jun-2019 , 12-Oct-2019 , 12-Feb-2020	0 , 12-Ju	n-2020 , 12-Oct-2020			
National Institute of Mental Health (NIMH) invites applications for a two-phase, mentored career development award program that is intended to facilitate a timely transition of qualified postdoctoral fellows in the NIMH Division of Intramura Programs (DIRP) from intramural postdoctoral research positions to extramural, academic tenure-track or equivalent facul positions at eligible U.S. institutions. Both the intramural and extramural phases will be mentored, and the award will provide research support during the extramural phase to help awardees launch competitive, independent research progra This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, part of their research and career development. This FOA will use the NIH K22 Career Transition Award mechanism.							
		nhancement Award to Advance Autism S n-Age Youth (K18 Clinical Trial Required)	ervices	National Institute of Mental Health/NIH/DHHS	RFA-MH- 19-101	22-May-2019 [LOI/Pre-App] [Optional]	Not Specified
	Contact Name	Lauren D. Hill, Ph.D					
	Contact Telephone	301-443-2638					
	Contact Email	hillla@mail.nih.gov					
	Sponsor Website						
	Program URL	https://grants.nih.gov/grants/guide/rfa-	-files/RF	<u> 4-MH-19-101.html</u>			
	Deadline Dates (ALL)	22-May-2019 [LOI/Pre-App][Optional], 2	21-Jun-2	019			
	Synopsis	National Institute of Mental Health (NII their research programs through the acc and transition-age youth, which is beyon research training and career developme investigators with the scientific competer	quisition nd and c nt expe	of new skills and knowledge in the omplementary to their current are iences and a small-scale research	e area of au as of exper project that	tism services rese tise. The program will provide expe	arch for adults will support rienced

SPIN ID	Program Title	Sponsor Name	Sponso	or Number		Deadline Date	Funding Amount
		youth with Autism Spectrum Disorders. Funding Opportunity Announcement (FC of an independent clinical trial, a clinical research and career development. This F	A) is de trial fea	signed specifically for applicants p sibility study, or a separate ancilla	roposing to ry study to	serve as the lead an existing trial, a	l investigator
076019	·	nhancement Award to Advance Autism Sen-Age Youth (K18 Independent Clinical Tri		National Institute of Mental Health/NIH/DHHS	RFA-MH- 19-100	22-May-2019 [LOI/Pre-App] [Optional]	Not Specified
	Contact Name	Lauren D. Hill, Ph.D					
	Contact Telephone	301-443-2638					
	Contact Email	hillla@mail.nih.gov					
	Sponsor Website						
	Program URL	https://grants.nih.gov/grants/guide/rfa-	files/RF/	<u> A-MH-19-100.html</u>			
	Deadline Dates (ALL)	22-May-2019 [LOI/Pre-App][Optional], 2	1-Jun-20	019			
	Synopsis	National Institute of Mental Health (NIN their research programs through the acq and transition-age youth, which is beyon research training and career developmer investigators with the scientific compete youth with Autism Spectrum Disorders. Funding Opportunity Announcement (FC leading an independent clinical trial, a cli FOA are permitted to propose research 6 K18 Career Enhancement Award mechan	uisition d and cont exper ncies re Eligible (A) is de nical triexperien	of new skills and knowledge in the omplementary to their current are sences and a small-scale research puired to conduct research releval candidates are independent invest signed specifically for applicants pal feasibility study, or an ancillary sales.	e area of au as of exper project that nt to service igators at a roposing re study to a c	tism services rese tise. The program will provide expe es for adults or tra ny faculty rank of search that does linical trial. Applic	earch for adults will support erienced ansition-age r level. This not involve cants to this
076937	<u>Leveraging Electronic Medical Red</u> (Collab) Clinical Trial Not Allowed	cords for Psychiatric Genetic Research (R0 )	<u>1</u>	National Institute of Mental Health/NIH/DHHS	PAR-18- 905	05-Jun-2019	Not Specified
	Contact Name	Anjené Addington					
	Contact Telephone	301-443-6653					
	Contact Email	anjene.addinton@nih.gov					
	Sponsor Website						
	Program URL	https://grants.nih.gov/grants/guide/pa-f	iles/PAF	R-18-905.html			
	Deadline Dates (ALL)	05-Jun-2019 , 05-Oct-2019 , 05-Feb-2020	) , 05-Ju	n-2020 , 05-Oct-2020 , 05-Feb-202	1 , 05-Jun-2	021	

	Drogram					_	Funding
SPIN ID	Program Title	Sponsor Name	Sponso	or Number		Deadline Date	Funding Amount
	Synopsis	National Institute of Mental Health (NIM that implement creative, efficient moleculincluding polygenic as well as specific general health systems to conduct analyses that a sultimate objective of this funding opportuation to specific risk loci and networks, understanding, diagnosis, and ultimately its own Program Director(s)/Principal Invector (s)/Principal Invecto	lar epice etic rislidvance unity is and entreatments appropodate contacts.	lemiologic approaches that incorp c variants, in existing large, popular our understanding of the complex the elucidation of the complex int nvironmental factors, in human pot ent of mental disorders. For a link r(s), and the program provides a repriate to address research projects ollaborations among sites with div	orate indivition-based x etiology of grounds of grounds of grounds of grounds of the control of	idual genetic info cohorts, registrie of severe mental of enetic (e.g., polygo which will lead to ollaborative R01s, for cross-site coo yond the capacity	rmation, is and/or disorders. The genic) risk, in better each site has rdination and y of a single-
	everaging Electronic Medical Rec	ords for Psychiatric Genetic Research (R01	<u>L</u>	National Institute of Mental Health/NIH/DHHS	PAR-18- 904	05-Jun-2019	Not Specified
	Contact Name	Anjené Addington					
	Contact Telephone	301-443-6653					
	Contact Email	anjene.addinton@nih.gov					
	Sponsor Website						
	Program URL	https://grants.nih.gov/grants/guide/pa-fi	les/PAF	-18-904.html			
	Deadline Dates (ALL)	05-Jun-2019 , 05-Oct-2019 , 05-Feb-2020	, 05-Jui	n-2020 , 05-Oct-2020 , 05-Feb-202	1,05-Jun-2	2021	
National Institute of Mental Health (NIMH) invites applications for projects that implement creative, efficient molecular epidemiologic approaches that incorporate individual genetic information, including polygenic as well as specific genetic variants, in existing large, population-based cohorts, registries and/or health systems to conduct analyses that advance of understanding of the complex etiology of severe mental disorders. The ultimate objective of this funding opportunity is the elucidation of the complex interplays of genetic (e.g., polygenic) risk, in addition to specific risk loci and networks, and environmental factors, in human populations, which will lead to better understanding, diagnosis, and ultimately treatment mental disorders. This FOA will use the NIH Research Project (R01) award mechanism.						ic genetic risk advance our rtunity is the ks, and	
077196 <u>V</u>		Understanding the Functional Role of DNA Mental Disorders (R01 (Collab) Clinical Tria	-	National Institute of Mental Health/NIH/DHHS	PA-18- 907	07-May-2019	Not Specified
	Contact Name Contact Telephone	Alexander Arguello, PhD 301-827-3547					

Contact Email <u>alexander.arguello@nih.gov</u>

SPIN ID	Program Title	Sponsor Name	Sponso	r Number		Deadline Date	Funding Amount
	Sponsor Website						
	Program URL	https://grants.nih.gov/grants/guide/pa-fi	iles/PA-:	L8-907.html			
		07-May-2019 , 05-Jun-2019 , 07-Sep-2019 2020 , 05-Oct-2020 , 07-Jan-2021 , 05-Fel					
	Synopsis (	National Institute of Mental Health (NIMI bioinformatic and statistical tools to determ to complex etiologies identified through a initiative is to support the development of functionality of genetic variants associated brain diseases, and to ultimately inform rowhen two or more sites are needed to coprogram Director/Principal Investigator a quality control, database management, staward mechanism.	ermine the genome of innovated with representations of the series of the	ne functional relevance of genetic value association or sequencing strative computational methods that the mental illness, taking into account the atment development based on hundred set of collaborations provide a	variants assudies. The facilitate that he added of man biologorative RO mechanisn	sociated with me overarching goal ne elucidation of complexities and sy. This FOA should and for cross-site con for cross-site complexity.	ntal disorders of this the nuances of ld be used t have its own oordination,
11 / / 145		Understanding the Functional Role of DNA Mental Disorders (RO1 Clinical Trial Not Al		National Institute of Mental Health/NIH/DHHS	PA-18- 908	07-May-2019	Not Specified
	Contact Name	Alexander Arguello, PhD					
	Contact Telephone	301-827-3547					
	Contact Email	alexander.arguello@nih.gov					
	Sponsor Website						
	Program URL <u>l</u>	https://grants.nih.gov/grants/guide/pa-fi	iles/PA-:	<u> 18-908.html</u>			
		07-May-2019 , 05-Jun-2019 , 07-Sep-2019 2020 , 05-Oct-2020 , 07-Jan-2021 , 05-Fel					
	Synopsis i	National Institute of Mental Health (NIMI bioinformatic and statistical tools to dete of complex etiologies identified through a initiative is to support the development of functionality of genetic variants associated brain diseases, and to ultimately inform research Project (R01) award mechanism	H) invite ermine the genome of innovated with re novel tre	s applications for the development ne functional relevance of genetic verwide association or sequencing strations that the netive computational methods that the nental illness, taking into account to	t of advance variants assudies. The facilitate the the added of	ed computational sociated with me overarching goal ne elucidation of scomplexities and	al, ntal disorders of this the nuances of
		ing of Pharmacologic or Device-based Mental Disorders (R33- Clinical Trial Req	uired)	National Institute of Mental Health/NIH/DHHS	RFA-MH- 18-703	16-May-2019 [LOI/Pre-App]	Not Specified

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount	
					[Optional]		
					[Optional]		
		Margaret Grabb, Ph.D.					
	Contact Telephone	301-443-3563					
	Contact Email	mgrabb@mail.nih.gov					
	Sponsor Website						
Program URL https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-18-703.html							
	16-May-2019 [LOI/Pre-App][Optional], 15-Jun-2019 , 15-Sep-2019 [LOI/Pre-App][Optional], 15-Oct-2019 , 15-Jan-2020 Deadline Dates (ALL) [LOI/Pre-App][Optional], 14-Feb-2020 , 16-May-2020 [LOI/Pre-App][Optional], 15-Jun-2020 , 15-Sep-2020 [LOI/Pre-App][Optional], 15-Oct-2020						
	Synopsis	National Institute of Mental Health (NIMH) invites applications to support the early stage testing of pharmacologic interventions with novel mechanisms of action or device-based interventions, for the treatment of symptoms or domains of altered functions in individuals with mental illness (e.g., schizophrenia, depression, autism, obsessive compulsive disorder, anxiety, bipolar disorder). Early intervention studies are also encouraged where symptoms of a disorder have been identified in subjects (a prodromal phase), prior to full diagnostic criteria being met. Ultimately, this FOA is intended to support early stage testing of pharmacologic or device-based interventions using a protocol design where the presumed mechanism of action of the intervention is adequately tested, to provide meaningful information where target modulation yields a dosedependent neurophysiological/clinical/behavioral effect. Pediatric, adult and geriatric focused interventions are appropriate for this FOA. This R33 FOA supports single phased clinical trial awards. This FOA will use the NIH R33 Exploratory/Developmental Grants Phase II award mechanism.					
060090 /	Advancing our Understanding of t	the Brain Epitranscriptomics (R21)	National Institute of Mental Health/NIH/DHHS	PAR-17- 152	07-May-2019	275,000 USD	
	Contact Name	Enrique Michelotti, Ph.D.					
	Contact Telephone	,					
	·	mish elettis (@mail nih gay					

Contact Email michelottiel@mail.nih.gov

Sponsor Website

Program URL <a href="https://grants.nih.gov/grants/guide/pa-files/PAR-17-152.html">https://grants.nih.gov/grants/guide/pa-files/PAR-17-152.html</a>

Deadline Dates (ALL) 07-May-2019, 16-Jun-2019, 07-Sep-2019, 16-Oct-2019, 07-Jan-2020, 16-Feb-2020, 07-May-2020

National Institute of Mental Health (NIMH) and National Institute on Drug Abuse (NIDA) applications for research into the functions of modified RNAs in the brain and/or the associated modification proteins that act on RNA (readers, writers, and erasers) and play a role in basic neurobiological and behavioral processes implicated in mental and substance use disorders. This FOA will use the NIH Research Project (R01) award mechanism.

SPIN ID	Program Title	Sponsor Name	Sponso	or Number		Deadline Date	Funding Amount		
059448	HIV Infection Of The Central Nerv	rous System (R01)		National Institute of Mental Health/NIH/DHHS	PA-17- 100	07-May-2019	Not Specified		
	Contact Name	Jeymohan Joseph, Ph.D.							
	Contact Telephone	240-627-3869							
	Contact Email	jjeymoha@mail.nih.gov							
	Sponsor Website								
	Program URL	https://grants.nih.gov/grants/guide/pa	-files/PA-	<u>17-100.html</u>					
	Deadline Dates (ALL)	07-May-2019 , 05-Jun-2019 , 07-Sep-20	019 , 05-0	ct-2019 , 07-Jan-2020					
	Synopsis	National Institutes of Health (NIH) and its participating Institutes and Centers invite applications focused on defining and inderstanding the pathogenic mechanisms involved in Human Immunodeficiency Virus (HIV)-1 induced CNS dysfunction, but ithin the context of viral suppression and Antiretroviral therapy (ART). The FOA further supports research to identify erapeutic targets against which treatments may be developed to prevent the neurobehavioral and neurological coorbidities in HIV-1 infected individuals. Basic and translational research in domestic and international settings are of terest. Multidisciplinary research teams and collaborative alliances are encouraged but not required. This program will use e NIH Research Project (R01) award mechanism.							
060089	Advancing our Understanding of t	the Brain Epitranscriptomics (R01)		National Institute of Mental Health/NIH/DHHS	PAR-17- 153	07-May-2019	Not Specified		
	Contact Name	Enrique Michelotti, Ph.D.							
	Contact Telephone	301-443-5415							
	Contact Email	michelottiel@mail.nih.gov							
	Sponsor Website								
	Program URL	https://grants.nih.gov/grants/guide/pa	-files/PAF	R-17-153.html					
	Deadline Dates (ALL)	07-May-2019 , 05-Jun-2019 , 07-Sep-20	019 , 05-0	ct-2019 , 07-Jan-2020 , 05-Feb-20	20 , 07-May	<b>/-2020</b>			
	National Institute of Mental Health (NIMH) and National Institute on Drug Abuse (NIDA) applications for research into the functions of modified RNAs in the brain and/or the associated modification proteins that act on RNA (readers, writers, and erasers) and play a role in basic neurobiological and behavioral processes implicated in mental and substance use disorders. This FOA will use the NIH Research Project (R01) award mechanism.								
060136	Secondary Data Analyses to Explo	ore NIMH Research Domain Criteria (R03	1	National Institute of Mental Health/NIH/DHHS	PAR-17- 158	16-Jun-2019	100,000 USD		
	Contact Name	Sarah Morris, Ph.D.							

SPIN ID Program Title	Sponsor Name	Sponso	r Number		Deadline Date	Funding Amount
Contact Telephone	301-443-9233					
Contact Email	sarah.morris@nih.gov					
Sponsor Website						
Program URL	https://grants.nih.gov/grants/guide/pa-fi	iles/PAR	<u>-17-158.html</u>			
Deadline Dates (ALL)	16-Jun-2019 , 16-Oct-2019 , 16-Feb-2020	)				
	National Institute of Mental Health (NIMI datasets to investigate constructs identifi hypotheses using the RDoC framework. T	ied in th	e NIMH's Research Domain Criter	ia (RDoC) ir	itiative and to te	st novel
077664 High-Priority Areas for Research L Trial Not Allowed)	everaging EHR and Large-Scale Data (R01	Clinical	National Institute of Mental Health/NIH/DHHS	PAR-18- 929	05-Jun-2019	Not Specified
Contact Name	Farris Tuma, ScD					
Contact Telephone	301-443-9232					
Contact Email	ftuma@mail.nih.gov					
Sponsor Website						
Program URL	https://grants.nih.gov/grants/guide/pa-fi	iles/PAR	<u>-18-929.html</u>			
Deadline Dates (ALL)	05-Jun-2019 , 05-Oct-2019 , 05-Feb-2020	, 05-Jur	-2020 , 05-Oct-2020 , 05-Feb-202	1 , 05-Jun-2	2021	
Synopsis	National Institutes of Health (NIH) and it (VA) invite applications to leverage large-systems (e.g., the Department of Defense Services administrative claims, as well as course, and impact of treatments and ser health and neurological disorders research understand and improve the treatment of depression, traumatic brain injury (TBI), attrajectory patterns of TBI, that may incluabuse disorder and risk for suicide. NIMH understand risk, onset, course, and impact the NIH Research Project (R01) award medical systems.	e (DOD), public o rvices fo ch. There of post tr and risk ide post I also inv	ral-world data from electronic hear Department of Veterans Affairs ( or private health care systems and or mental and neurological disorder is particular interest in leveraging aumatic psychopathology, including for suicide; and 2) characterize pot traumatic stress disorder, depressites innovative approaches to use atments and services for mental controls.	olth records VA), Center networks) rs and to id g EHRs and ng posttrat st-trauma r sion, cognit	(EHRs) from a vars for Medicare ar to understand ris lentify promising administrative damatic stress disonulti-symptom retive impairment, padministrative dat	riety of nd Medicaid k, onset, new mental ata to 1) rder, covery pain, substance a to
062237 Innovative Mental Health Services	s Research Not Involving Clinical Trials (RO	<u>1)</u>	National Institute of Mental Health/NIH/DHHS	PAR-17- 264	05-Jun-2019	Not Specified
Contact Name	Michael C. Freed, Ph.D.					



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	------------------	--------------	----------------	---------------	-------------------

Contact Telephone 301-443-3747

Contact Email michael.freed@nih.gov

Sponsor Website

Program URL https://grants.nih.gov/grants/guide/pa-files/PAR-17-264.html

Deadline Dates (ALL) 05-Jun-2019, 05-Oct-2019, 05-Feb-2020, 05-Jun-2020

National Institute of Mental Health (NIMH) invites applications for innovative research that will inform and support the delivery of high-quality, continuously improving mental health services to benefit the greatest number of individuals with, or at risk for developing, a mental illness. This announcement invites applications for non-clinical trial R01-level projects that address NIMH strategic priorities for mental health services research (see http://www.nimh.nih.gov/about/strategicplanning-reports/strategic-research-priorities/srp-objective-4/index.shtml). Proposed research should seek to: 1) Identify Synopsis mutable factors that impact access, continuity, utilization, quality, value, and outcomes, including disparities in outcomes, or scalability of mental health services in the United States, which may serve as targets in future service delivery intervention development; 2) Develop and test new research tools, technologies, measures, or methods and statistical approaches to study these issues; 3) Integrate and analyze large data sets to understand factors affecting mental health services outcomes using sophisticated computational and predictive analytic approaches; 4) Wherever possible, leverage existing infrastructure and partnerships to accomplish these goals. This FOA will use the NIH Research Project (R01) award mechanism.

077725

Neuromodulation/Neurostimulation Device Development for Mental Health Applications (R01 Clinical Trial Optional)

National Institute of Mental Health/NIH/DHHS

PAR-18-942

05-Jun-2019

Not Specified

Contact Name David McMullen, M.D.

Contact Telephone 301-451-0180

Contact Email david.mcmullen@nih.gov

Sponsor Website

Program URL https://grants.nih.gov/grants/guide/pa-files/PAR-18-942.html

Deadline Dates (ALL) 05-Jun-2019, 05-Oct-2019, 05-Feb-2020, 05-Jun-2020, 05-Oct-2020, 05-Feb-2021

The purpose of this funding opportunity announcement (FOA) is to encourage applications seeking to develop the next generation of brain stimulation devices for treating mental health disorders. Applications are sought that will either 1) develop novel brain stimulation devices or 2) significantly enhance, by means of hardware/software improvements, the effectiveness of brain stimulation devices that are currently U.S. Food and Drug Administration (FDA)-approved or cleared. Novel devices should move beyond existing electrical/magnetic stimulation and develop new stimulation techniques capable of increased spatiotemporal precision as well as multi-focal, closed-loop approaches. Applications seeking to develop new capabilities should focus on significant enhancement of the spatial resolution, depth of delivery, and/or precision of the device. Incremental changes to existing devices (e.g., software updates) are not within the scope of this announcement.

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	-------------------

Applications should be submitted by multi-disciplinary teams with diverse expertise including systems neuroscience, engineering, clinical, and regulatory affairs. Applications submitted to this FOA should promote the development or significant enhancement of novel tools (hardware/software) for brain stimulation in humans. Although the application should focus on the engineering development and bench top testing of the tool, animal and limited human testing necessary to demonstrate initial proof of concept is allowable. Applications to this FOA may propose hypothesis-driven research, but should propose design-directed, developmental, or discovery-driven technology research using integrative approaches. Applications that seek to study scientific or clinical hypotheses that simply utilize devices are outside the scope of this FOA.

Neuromodulation/Neurostimulation Device Development for Mental Health Applications (R21 Clinical Trial Optional)

National Institute of Mental Health/NIH/DHHS

PAR-18-941

16-Jun-2019

275,000 USD

Contact Name David McMullen, M.D.

Contact Telephone 301-451-0180

Contact Email david.mcmullen@nih.gov

Sponsor Website

Program URL https://grants.nih.gov/grants/guide/pa-files/PAR-18-941.html

Deadline Dates (ALL) 16-Jun-2019, 16-Oct-2019, 16-Feb-2020, 16-Jun-2020, 16-Oct-2020, 16-Feb-2021, 16-Jun-2021

National Institute of Mental Health (NIMH) invites applications seeking to develop the next generation of brain stimulation devices for treating mental health disorders. Applications are sought that will either 1) develop novel brain stimulation devices or 2) significantly enhance, by means of hardware/software improvements, the effectiveness of brain stimulation devices that are currently U.S. Food and Drug Administration (FDA)-approved or cleared. Novel devices should move beyond existing electrical/magnetic stimulation and develop new stimulation techniques capable of increased spatiotemporal precision as well as multi-focal, closed-loop approaches. Applications seeking to develop new capabilities should focus on significant enhancement of the spatial resolution, depth of delivery, and/or precision of the device. Incremental changes to existing devices (e.g., software updates) are not within the scope of this announcement. Applications should be submitted by multi-disciplinary teams with diverse expertise including systems neuroscience, engineering, clinical, and regulatory affairs. Applications submitted in response to this FOA should promote the development or significant enhancement of novel tools (hardware/software) for brain stimulation in humans. Although the application should focus on the engineering development and bench top testing of the tool, animals and limited human testing necessary to demonstrate initial proof of concept is allowable. Applications to this FOA are not expected to be hypothesis-driven, but should propose design-directed,

Development and Optimization of Tasks and Measures for Functional Domains of Behavior (R01 Clinical Trial Not Allowed)

National Institute of Mental Health/NIH/DHHS

developmental, or discovery-driven technology research using integrative approaches. Applications that seek to study scientific or clinical hypotheses that simply utilize devices are outside the scope of this FOA. This FOA will utilize the NIH R21

> PAR-18-930

05-Jun-2019

Not Specified



077665

Exploratory/Developmental Research Grant award mechanism.

CDINIID	Program	Creaman Name	Connect Number		Doodling Data	Funding	
SPIN ID	Title	Sponsor Name	Sponsor Number		Deadline Date	Amount	
	0	la N. D					
		Sarah Morris, Ph.D.					
	Contact Telephone						
		sarah.morris@nih.gov					
	Sponsor Website		Sile - /DAD 40 020 leteral				
	· ·	https://grants.nih.gov/grants/guide/pa-		05 1 2	024 05 0 + 202	4	
	Deadline Dates (ALL)		0 , 05-Jun-2020 , 05-Oct-2020 , 05-Feb-2021				
	National Institute of Mental Health (NIMH) and National Institute on Alcohol Abuse and Alcoholism (NIAAA) invite applications for the development and optimization of tasks and/or measures for constructs pertaining to functional aspect of behavior or cognitive/affective processes, for use in laboratory or population-based studies, clinical trials outcomes, or related research. This FOA encourages research that will result in the availability of tasks and measures that demonstrate: good validity as a measure of a specific construct; (2) robust measurement properties; and (3) suitability for use across diverse participants. This FOA will use the NIH Research Project (R01) award mechanism.						
IIhxuhz	·	o Test the Effectiveness of Treatment, Preporative R01 - Clinical Trial Required)	eventive, National Institute of Mental Health/NIH/DHHS	RFA-MH- 18-700	16-May-2019 [LOI/Pre-App] [Optional]	Not Specified	
	Contact Name	Joel Sherrill, Ph.D.					
	Contact Telephone	301-443-2477					
	Contact Email	jsherril@mail.nih.gov					
	Sponsor Website						
	Program URL	https://grants.nih.gov/grants/guide/rfa-	files/RFA-MH-18-700.html				
	Deadline Dates (ALL)		.5-Jun-2019 , 15-Sep-2019 [LOI/Pre-App][Օր L6-May-2020 [LOI/Pre-App][Optional], 15-Ju				
	Synopsis	interventions and to test hypotheses reg FOA supports clinical trials designed to t is already evidence of efficacy, for use in the effectiveness or increase the clinical device-based, rehabilitative and combina- trials to test patient-, provider-, organiza- equity, and/or value of services. The inter-	IMH) invites applications to support clinical garding moderators, mediators, and mechanest the therapeutic value of treatment and community and practice settings. Application impact of pharmacologic, somatic, psychosation interventions to prevent or treat mentional-, or systems-level services interventions treatment properties that require participation of two	nisms of act preventive ions might i cocial (psych tal illness. T ons to impi uncement	tion of these inte interventions for include research notherapeutic, bo This FOA also sup rove access, cont is explicitly focus	erventions. This r which there to evaluate ehavioral), oports clinical cinuity, quality, sed on	

SPIN ID	Program Title	Sponsor Name	Sponsor Nu	ımber	ι	Deadline Date	Funding Amount
		completion of the study. Accordingly, the such in order to increase sample size, accits own Program Director/Principal Invest quality control, database management, storant award mechanism.	elerate recruigator (PD/P	uitment, or increase sample div य) and the program provides a ।	ersity and mechanism	representation.  n for cross-site co	Each site has pordination,
068973	RFA-MH-18-701 Clinical Trials to and Services Interventions (R01 Cli	Test the Effectiveness of Treatment, Previnical Trial Required)		tional Institute of Mental alth/NIH/DHHS	RFA-MH- 18-701	16-May-2019 [LOI/Pre-App] [Optional]	Not Specified
	Contact Telephone	Joel Sherrill, Ph.D. 301-443-2477 jsherril@mail.nih.gov					
	·	https://grants.nih.gov/grants/guide/rfa-f	iles/RFΔ-MH	I-18-701 html			
	Deadline Dates (ALL)	https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-18-701.html 16-May-2019 [LOI/Pre-App][Optional], 15-Jun-2019 , 15-Sep-2019 [LOI/Pre-App][Optional], 15-Oct-2019 , 15-Jan-2020 [LOI/Pre-App][Optional], 14-Feb-2020 , 16-May-2020 [LOI/Pre-App][Optional], 15-Jun-2020 , 15-Sep-2020 [LOI/Pre-App][Optional], 15-Oct-2020					
	Synopsis	National Institute of Mental Health (NII interventions and to test hypotheses regated FOA supports clinical trials designed to te is already evidence of efficacy, for use in the effectiveness or increase the clinical idevice-based, rehabilitative and combinativals to test patient-, provider-, organizated equity, and/or value of services. The interpractice-relevant questions. This FOA will	arding mode st the theral community a mpact of ph tion interver cional-, or system	erators, mediators, and mechan peutic value of treatment and pand practice settings. Application armacologic, somatic, psychosomations to prevent or treat ment stems-level services interventice earch covered under this annou	isms of act preventive ons might i ocial (psych al illness. T ons to impr uncement i	ion of these inte interventions for nclude research notherapeutic, be his FOA also sup ove access, cont s explicitly focus	rventions. This which there to evaluate chavioral), ports clinical inuity, quality,
068977		ing of Pharmacologic or Device-based  Mental Disorders (R61/R33- Clinical Trial		tional Institute of Mental alth/NIH/DHHS	RFA-MH- 18-702	16-May-2019 [LOI/Pre-App] [Optional]	Not Specified
	Contact Telephone	Margaret Grabb, Ph.D. 301-443-3563 mgrabb@mail.nih.gov					

SPIN ID Program Title Sponsor Name Sponsor Number Deadline Date Funding Amount	
--	--

Sponsor Website

Program URL https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-18-702.html

16-May-2019 [LOI/Pre-App][Optional], 15-Jun-2019, 15-Sep-2019 [LOI/Pre-App][Optional], 15-Oct-2019, 15-Jan-2020 Deadline Dates (ALL) [LOI/Pre-App] [Optional], 14-Feb-2020, 16-May-2020 [LOI/Pre-App] [Optional], 15-Jun-2020, 15-Sep-2020 [LOI/Pre-App] App][Optional], 15-Oct-2020

National Institute of Mental Health (NIMH) invites applications to support the early stage testing of pharmacologic interventions with novel mechanisms of action, or device-based interventions, for the treatment of symptoms or domains of altered functions in individuals with mental illness (e.g., schizophrenia, depression, autism, obsessive compulsive disorder, anxiety, bipolar disorder). Early intervention studies are also encouraged where symptoms of a disorder have been identified Synopsis in subjects (a prodromal phase), prior to full diagnostic criteria being met. Ultimately, this FOA is intended to support early stage testing of pharmacologic or device-based interventions using a protocol design where the presumed mechanism of action of the intervention is adequately tested, to provide meaningful information where target modulation yields a dosedependent neurophysiological/clinical/behavioral effect. The R61/R33 FOAs are intended to support biphasic high risk applications. This FOA will use the NIH R61/R33 Exploratory/Developmental Phased Award mechanism.

079331 Drug Discovery For Nervous System Disorders (R21 Clinical Trials Not Allowed)

National Institute of Mental PAR-19-275,000 07-May-2019 USD Health/NIH/DHHS 146

Contact Name Enrique Michelotti, PhD

Contact Telephone 301-443-5415

Contact Email michelottiel@mail.nih.gov

Sponsor Website

Program URL https://grants.nih.gov/grants/guide/pa-files/PAR-19-146.html

Deadline Dates (ALL

07-May-2019, 16-Jun-2019, 07-Sep-2019, 16-Oct-2019, 07-Jan-2020, 16-Feb-2020, 07-May-2020, 16-Jun-2020, 07-Sep-2020, 16-Oct-2020, 07-Jan-2021, 16-Feb-2021, 07-May-2021, 16-Jun-2021, 07-Sep-2021, 16-Oct-2021, 07-Jan-2022

This Funding Opportunity Announcement (FOA) intends to support investigators who have interest and capability in the discovery of novel compounds for the prevention and treatment of nervous system disorders. This FOA is designed to stimulate research in 1) Identification, design, synthesis, and preclinical testing of compounds of candidate therapeutics, 2) Initial hit-to-lead chemistry to improve activity of compounds against the target of interest, 3) Later stage lead optimization Synopsis to improve efficacy and pharmacokinetics, and 4) Initial drug metabolism and pharmacokinetics (DMPK). Emphasis will be placed on projects that provide novel approaches to identify potential therapeutic agents. The R21 grant mechanism is intended to encourage exploratory/developmental research by providing support for the early and conceptual stages of project development. High risk/high payoff projects that lack preliminary data may be most appropriate for this FOA.

Applicants with preliminary data may wish to apply to the companion R01 mechanism (PAR-19-147)

SPIN ID	Program Title	Sponsor Name	Spons	or Number		Deadline Date	Funding Amount
079325 <u>[</u>	Drug Discovery For Nervous Syste	m Disorders (R01 Clinical Trials Not Allo	wed)	National Institute of Mental Health/NIH/DHHS	PAR-19- 147	07-May-2019	Not Specified
	Contact Name	Enrique Michelotti, PhD					
	Contact Telephone	301-443-5415					
	Contact Email	michelottiel@mail.nih.gov					
	Sponsor Website						
	Program URL	https://grants.nih.gov/grants/guide/pa	-files/PA	<u>R-19-147.html</u>			
	Deadline Dates (ALL)	07-May-2019 , 05-Jun-2019 , 07-Sep-20 2020 , 05-Oct-2020 , 07-Jan-2021 , 05-F					
	Synopsis	treatment of nervous system disorders design, synthesis, and preclinical testin activity of compounds against the targe pharmacokinetics; and 4) Initial drug m projects that provide novel approaches	g of comp et of inte etabolisr	pounds of candidate therapeutics; rest; 3) Later stage lead optimization on and pharmacokinetic properties	2) Initial hit on to impro (DMPK). Em	-to-lead chemistr ve efficacy and	y to improve
		Psychosocial Therapeutic and Preventions (R61/R33- Clinical Trial Required)	<u>′e</u>	National Institute of Mental Health/NIH/DHHS	RFA-MH- 18-704	16-May-2019 [LOI/Pre-App] [Optional]	Not Specified
	Contact Name	Ann Wagner, Ph.D.					
	Contact Telephone	301-443-3633					
	Contact Email	awagner@mail.nih.gov					
	Sponsor Website						
	Program URL	https://grants.nih.gov/grants/guide/rfa	-files/RF	<u> A-MH-18-704.html</u>			
	Deadline Dates (ALL)	16-May-2019 [LOI/Pre-App][Optional], [LOI/Pre-App][Optional], 14-Feb-2020 , App][Optional], 15-Oct-2020					
		National Institute of Mental Health (National Institute of Mental Institute of Mental Health (National Institute of Mental In	-		•		•

Synopsis approach. Under this FOA, trials must be designed so that results, whether positive or negative, will provide information of

supports the development and testing of innovative psychosocial intervention approaches where the target and/or the

high scientific utility and will support "go/no-go" decisions about further development or testing of the intervention. This FOA

	SPIN ID	Program	Sponsor Name	Sponsor Number	Deadline Date	Funding
ı	SPIN ID	Title	Sponsor Name	Sponsor Number	Deadine Date	Amount

intervention strategy is novel. Targets might include, but are not limited to, potentially modifiable behavioral, cognitive, affective and/or interpersonal factors or processes, neural circuits or neural activity subserving specific behaviors or cognitive processes, and/or other neurobiological mechanisms associated with risk for, causation of, or maintenance of a mental disorder. Eligible psychosocial intervention strategies might include in-person or technology-assisted delivery, provided the target and/or the intervention strategy is novel. This FOA supports the development and testing of novel psychosocial interventions, as defined above, as monotherapies or as augmentations to standard treatment. Support will be provided for up to two years (R61 phase) for preliminary milestone-driven testing of the intervention's impact on a target (a process or mechanism associated with risk for, causation, or maintenance of a clinical condition), that is, its target engagement. Contingent on meeting "go/no-go" milestones in the R61 phase, up to 3 years of additional support (R33 phase) may be provided for studies to replicate target engagement and relate change in the intervention target/mechanism to clinical benefit. Ultimately, this R61/R33 FOA is intended to speed the translation of emerging basic science findings of mechanisms and processes underlying mental disorders into novel interventions that can be efficiently tested for their promise in restoring function and reducing symptoms for those living with mental disorders, or for preventing mental disorders among those at risk. This FOA will use the NIH R61/R33 Exploratory/Developmental Phased Award mechanism.

RFA-MH-18-705--Development of Psychosocial Therapeutic and Preventive Interventions for Mental Disorders (R33 Clinical Trial Required)

National Institute of Mental Health/NIH/DHHS

RFA-MH-18-705

16-May-2019 [LOI/Pre-App] [Optional]

Not Specified

Contact Name Ann Wagner, Ph.D.

Contact Telephone 301-443-3633

Contact Email awagner@mail.nih.gov

Sponsor Website

Program URL https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-18-705.html

16-May-2019 [LOI/Pre-App][Optional], 15-Jun-2019, 15-Sep-2019 [LOI/Pre-App][Optional], 15-Oct-2019, 15-Jan-2020 Deadline Dates (ALL) [LOI/Pre-App][Optional], 14-Feb-2020, 15-Jun-2020, 16-Jun-2020 [LOI/Pre-App][Optional], 15-Sep-2020 [LOI/Pre-App] App][Optional], 15-Oct-2020

> National Institute of Mental Health (NIMH) invites applications to support the efficient pilot testing of novel psychosocial therapeutic and preventive interventions for mental disorders in adults and children, using an experimental therapeutics approach. Under this FOA, trials must be designed so that results, whether positive or negative, will provide information of high scientific utility and will support "go/no-go" decisions about further development or testing of the intervention. This FOA supports the development and testing of innovative psychosocial intervention approaches where the target and/or the intervention strategy are novel. Targets might include, but are not limited to, potentially modifiable behavioral, cognitive, affective and/or interpersonal factors or processes, neural circuits or neural activity subserving specific behaviors or cognitive

processes, and/or other neurobiological mechanisms associated with risk for, causation of, or maintenance of a mental

Synopsis

SPIN ID	Program	Sponsor Name	Sponsor Number	Deadline Date	Funding
SPIN ID	Title	Sponsor Name	Sponsor Number	Deadine Date	Amount

disorder. Eligible psychosocial intervention strategies might include in-person or technology-assisted delivery, provided the target and/or the intervention strategy is novel. This FOA supports the development and testing of novel psychosocial interventions, as defined above, as monotherapies or as augmentations to standard treatment. Support will be provided for up to 3 years for studies to replicate previous target engagement findings, and relate change in the intervention target/mechanism to clinical benefit. Ultimately, this FOA is intended to speed the translation of emerging basic science findings of mechanisms and processes underlying mental disorders into novel interventions that can be efficiently tested for their promise in restoring function and reducing symptoms for those living with mental disorders, or for preventing mental disorders among those at risk. This FOA will use the NIH R33 Exploratory/Developmental Grants Phase II award mechanism.

RFA-MH-18-706 -- Pilot Effectiveness Trials for Treatment, Preventive and Services National Institute of Mental Interventions (R34- Clinical Trial Required)

Health/NIH/DHHS

RFA-MH-18-706

16-May-2019 [LOI/Pre-App] [Optional]

Not Specified

Contact Name Joel Sherrill, Ph.D.

Contact Telephone 301-443-2477

Contact Email jsherril@mail.nih.gov

Sponsor Website

Program URL https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-18-706.html

16-May-2019 [LOI/Pre-App][Optional], 15-Jun-2019, 15-Sep-2019 [LOI/Pre-App][Optional], 15-Oct-2019, 14-Feb-2020, 15-Deadline Dates (ALL) Feb-2020 [LOI/Pre-App][Optional], 16-May-2020 [LOI/Pre-App][Optional], 15-Jun-2020, 15-Sep-2020 [LOI/Pre-App] App][Optional], 15-Oct-2020

> National Institute of Mental Health (NIMH) invites applications for pilot research consistent with NIMH's priorities for: 1) effectiveness research on preventive and therapeutic interventions with previously demonstrated efficacy, for use with broader target populations or for use in community practice settings, and 2) research on the development and preliminary testing of innovative services interventions. Applications should provide resources for evaluating the feasibility, tolerability, acceptability and safety of approaches to improve mental health/functional outcomes, to modify risk factors, or to improve service delivery, and for obtaining the preliminary data needed as a pre-requisite to a larger-scale intervention trial (e.g., comparative effectiveness study, practical trial) or large-scale services study. In this pilot phase of effectiveness research, NIMH places highest priority on approaches that can be justified in terms of their potential to substantially impact practice and public health and approaches that are empirically grounded. Adaptations or augmentations of efficacious interventions should only be undertaken if there is an empirical rationale for the adaptation target and for the corresponding mechanism by which the adapted intervention or augmentation is expected to substantially enhance outcomes. This FOA is intended to support pilot effectiveness trials that are designed to explicitly address whether the intervention engages the target(s)/mechanism(s) presumed to underlie the intervention effects. This FOA will use the NIH R34 Planning Grant award mechanism.

**Synopsis** 

SPIN ID	Program Title	Sponsor Name	Sponso	or Number		Deadline Date	Funding Amount
01/X0135	Basic Neurodevelopmental Biolog Not Allowed)	gy of Brain Circuits and Behavior (R21 C	linical Trial	National Institute of Mental Health/NIH/DHHS	PAR-19- 028	16-Jun-2019	275,000 USD
	Contact Name	Bettina Buhring					
	Contact Telephone	301-443-1576					
	Contact Email	neurodevelopmentpar@mail.nih.gov					
	Sponsor Website	:					
	Program URL	https://grants.nih.gov/grants/guide/p	a-files/PAF	R-19-028.html			
	Deadline Dates (ALL)	16-Jun-2019 , 16-Oct-2019 , 16-Feb-20	020 , 16-Ju	n-2020 , 16-Oct-2020 , 16-Feb-202	1,16-Jun-2	2021 , 16-Oct-202	1
	Synopsis	This Funding Opportunity Announcem between the maturation of brain circuto build a foundation for understanding development, allowing for the emerge focus on neurodevelopmental trajector animals. This FOA seeks shorter, higher grant applications.	uits and being how into ence of cog ories and ir	haviors across development in roderactions within and among brain is gnitive, affective and social behavious tigate questions using in vivo received.	ents and no regions cha ors. To this neural meas	on-human primat nge during pre- a end, projects sup sures in awake, bo	es. The goal is nd post-natal ported will ehaving
H / X H X H	<u>Basic Neurodevelopmental Biolog</u> <u>Allowed)</u>	gy of Circuits and Behavior (R01 Clinical	Trial Not	National Institute of Mental Health/NIH/DHHS	PAR-19- 027	05-Jun-2019	2,500,000 USD
	Contact Name	Bettina Buhring					
	Contact Telephone	301-443-1576					
	Contact Email	neurodevelopmentpar@mail.nih.gov					
	Sponsor Website	:					
	Program URL	https://grants.nih.gov/grants/guide/p	a-files/PAF	R-19-027.html			
	Deadline Dates (ALL)	05-Jun-2019 , 05-Oct-2019 , 05-Feb-20	020 , 05-Ju	n-2020 , 05-Oct-2020 , 05-Feb-202	1,05-Jun-2	2021 , 05-Oct-202	1
	Synopsis	This Funding Opportunity Announce links between the maturation of brain goal is to build a foundation for under natal development, allowing for the entire of the entire o	circuits ar standing h mergence	nd behaviors across development ion ow interactions within and among of cognitive, affective and social be	n rodents a brain region ehaviors. To	nd non-human pi ons change over p o this end, project	rimates. The re- and post- ts supported
	, ,	will focus on neurodevelopmental traj animals. This FOA uses the R01 grant r grant applications.					

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		1	Health/NIH/DHHS	094	Specified
	Contact Name	Jovier Evans, PhD			
	Contact Telephone	301-443-1369			
	Contact Email	jevans1@mail.nih.gov			
	Sponsor Website				
	Program URL	https://grants.nih.gov/grants/guide/pa-	files/PA-19-094.html		
	Deadline Dates (ALL)	05-Jun-2019 , 05-Oct-2019 , 05-Feb-2020	0 , 05-Jun-2020 , 05-Oct-2020 , 05-Feb-2	021 , 05-Jun-2021 , 05-Oct-20	21
	Synopsis	is sought that will advance understanding regulation in adult mood and anxiety distant atypical maturational trajectories of employing affective dysregulation share the same of the older adult population in general, processing trajectories may lead to very anticipated that such studies may identiclues as to which available intervention strengthen emotional resilience at participated.	sorders, and that will examine whether totion processing. Currently, it is not know a patterns of improved emotional funct. Research that helps to clarify whether to different understandings of the irregulaty novel targets for mental health intervistrategies might be optimally applied to	he irregularities are associated vn whether older adults who so ion with age as have been fout hey do or do not manifest typ rities involved in their dysregu entions or prevention efforts,	d with typical of suffer episodes nd to be typica ical emotion Ilation. It is or provide
078787	Emotion Regulation, Aging and M	lental Disorder (R21 Clinical Trial Not Allo	wed) National Institute of Mental Health/NIH/DHHS	PA-19- 095 16-Jun-2019	275,000 USD
	Contact Name	Jovier Evans, PhD			
	Contact Telephone	301-443-1369			
	Contact Email	jevans1@mail.nih.gov			
	Sponsor Website				
	Program URL	https://grants.nih.gov/grants/guide/pa-	files/PA-19-095.html		
	Deadline Dates (ALL)	16-Jun-2019 , 16-Oct-2019 , 16-Feb-2020	0 , 16-Jun-2020 , 16-Oct-2020 , 16-Feb-2	021 , 16-Jun-2021 , 16-Oct-20	21
	Synopsis	This Funding Opportunity Announcemer emotion regulation and how they may c is sought that will advance understanding regulation in adult mood and anxiety dis	ontribute to mental disorders in middleng of irregularities in the integrative neur	aged and older adults. In part ral-behavioral mechanisms of	icular, research emotion

atypical maturational trajectories of emotion processing. Currently, it is not known whether older adults who suffer episodes

SPIN ID	Program Title	Sponsor Name	Sponso	or Number		Deadline Date	Funding Amount		
		of affective dysregulation share the sam of the older adult population in general processing trajectories may lead to very anticipated that such studies may ident clues as to which available intervention strengthen emotional resilience at parti	Researce differentify novel strategie	h that helps to clarify whether the t understandings of the irregulariti targets for mental health intervent s might be optimally applied to no	y do or do r es involved tions or pre	not manifest typion in their dysregul vention efforts, o	cal emotion ation. It is or provide		
068983	RFA-MH-18-707 Confirmatory E Interventions for Mental Disorder	fficacy Clinical Trials of Non-Pharmacolo s (R01 Clinical Trial Required)	gical	National Institute of Mental Health/NIH/DHHS	RFA-MH- 18-707	16-May-2019 [LOI/Pre-App] [Optional]	Not Specified		
	Contact Name	Sarah Morris, Ph.D							
	Contact Telephone	301-443-9233							
	Contact Email	sarah.morris@nih.gov							
	Sponsor Website								
	Program URL	L https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-18-707.html							
	Deadline Dates (ALL)	16-May-2019 [LOI/Pre-App][Optional], [LOI/Pre-App][Optional], 14-Feb-2020, App][Optional], 15-Oct-2020			•	-			
	Synopsis	National Institute of Mental Health (N pharmacological therapeutic and preverexperimental therapeutics approach. Unwill provide information of high scientific effectiveness testing, or dissemination of behavioral, cognitive, interpersonal, and approaches, or a combination thereof. I rationale, previous demonstration that preliminary efficacy signal, and must ad intervention's efficacy that includes mechange in the mechanism and change in sufficiently-powered efficacy trial to det the NIH R01 Research Project Grant away	ntive intender this ic utility and the intervent the intervent dress an asurement function termine t	rventions for mental disorders in a FOA, trials must be designed so the and will support "go/no-go" decision ervention. Interventions to be studioused (both invasive/surgically implicated  and alters the hypothesized mechanism all or clinical effects. Ultimately, the intervention's potential for sign	adults and controlled include olanted as well and the left of the left of action a is FOA is in	children through a whether positive urther developmen, but are not limitivell as noninvasive pased on a composite of activities	en or negative, ent, ted to re/transcranial) elling scientific tion, a the ip between rt a		
080146	Pilot Services Research Grants Not Allowed)	t Involving Clinical Trials (R34 Clinical Tria	al Not	National Institute of Mental Health/NIH/DHHS	PAR-19- 189	16-Jun-2019	450,000 USD		

SPIN ID	Program Title	Sponsor Name	Sponso	r Number		Deadline Date	Funding Amount
	Contact Name Contact Telephone	Denise Juliano-Bult, M.S.W. 301-443-1638					
	Contact Email	djuliano@mail.nih.gov					
	Sponsor Website	ا د					
	Program URL	https://grants.nih.gov/grants/guide/pa-	files/PAR	<u>-19-189.html</u>			
	Deadline Dates (ALL)	16-Jun-2019 , 16-Oct-2019 , 16-Feb-2020	0 , 16-Jur	-2020 , 16-Oct-2020 , 16-Feb-202	1 , 16-Jun-2	2021 , 16-Oct-202	1
	Synopsis	The purpose of this funding announcement service intervention but is consistent with experimental therapeutics model for all services research do not involve clinical continuity, utilization, quality, value, out which may serve as targets in future interventions of care 4) pilot work on the levalue and effectiveness of services and the interventions should be submitted under	th NIMH interven trials. The tcomes, is ervention tegratin arning mare treatmen	priorities for services research. Whition studies, there is recognition these areas include: 1) studies to idencluding disparities in outcomes, or development 2) development and existing data sets to understand ental health care system model as the Studies focused on the development.	hile NIMH r hat some mentify mutal or scalability d testing of factors affe s a means to	now requires use nission-relevant a ble factors that in y of mental healt new research to ecting access, quado enable practical	of an reas of npact access, h services, ols, measures, lity or I studies of the
080474	Novel Assays to Address Translati Clinical Trial Optional)	ional Gaps in Treatment Development (UC	G3/UH3	National Institute of Mental Health/NIH/DHHS	PAR-19- 214	20-Jun-2019	Not Specified
	Contact Name	Lois Winsky, Ph.D.					
	Contact Telephone	301-443-5288					
	Contact Email	l <u>lwinsky@mail.nih.gov</u>					
	Sponsor Website	د					
	Program URL	https://grants.nih.gov/grants/guide/pa-	files/PAR	<u>-19-214.html</u>			
	Deadline Dates (ALL)	20-Jun-2019 , 18-Oct-2019 , 20-Feb-2020 2022	0 , 19-Jur	1-2020 , 20-Oct-2020 , 19-Feb-202	1 , 21-Jun-2	2021 , 20-Oct-202	1,21-Feb-
	Synopsis	The overall goal of this initiative is to ide research. The funding opportunity announce neurophysiological processes that are disspecies relevant to the therapeutic development of the potential development in their targets. Data will also reveal as	uncemer isrupted elopment opment	ot (FOA) will support efforts to opt within or across mental disorders in pipeline. The initiative will support as preclinical assays for evaluating	imize and e in both hea rt initial pro potential n	evaluate measure Ithy humans and oof of concept stu new drug and dev	s of in another dies aimed at ice therapies

humans is dissimilar, thus establishing a firm basis for limiting speculative extrapolations of preclinical animal findings to

SPIN ID	Program Title	Sponsor Name	Sponso	r Number		Deadline Date	Funding Amount
		humans. The ultimate practical goal of thi identifying coherence of measures and income treatment candidates and thereby has objectives of the FOA will be accomplished committed to advancing the discovery of development. Groups will be tasked with healthy humans. Groups will evaluate assort behavioral manipulations. In this way, phumans, suggesting assays for further development.	consiste asten the d by su in vivo develop ay perfe projects	encies between the preclinical screate development of more effective pporting partnerships among basis physiological measures as tools fooing and optimizing in vivo assays ormance across both species in restantial of specific will reveal the potential of specific	eening pipe treatments and trans r target vali of brain pro sponse to s ic assays to	line and clinical e for mental disor ational neuroscie dation and thera ocesses in both a pecific chemical, translate from a	evaluation of ders. The entists who are peutic nimals and in physiological,
070136		Behavior, Ideation and Self-Harm in Youth System (R01 Clinical Trial Required)	<u>in</u>	National Institute of Mental Health/NIH/DHHS	PAR-18- 479	05-Jun-2019	500,000 USD
	Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL)	https://grants.nih.gov/grants/guide/pa-fil 05-Jun-2019 National Institute of Mental Health (NIMH to both detect and intervene to reduce th youth in contact with the juvenile justice of (e.g., police interaction, the intake intervi- juvenile or family court activities, court dissettings.) This FOA invites intervention stavailable personnel and resources, to enh uptake in diverse settings, and thereby re	H) invite ne risk o system ew) and sposition rategie nance the	es applications for research to test f suicide behavior, suicide ideation Opportunities for detection and d continue through many juvenile on, placement and on-going care in s that are designed to be delivered te implementation of intervention	n, and non- prevention justice setti n either res I in typical s s that prove	suicidal self-harm start at early poi ngs (e.g., pre-tria dential or multip service settings u e effective, enhar	n (NSSI) by nts of contact al detention, ale community sing typically nce their future
081132	Reducing the Duration of Untreat Trial Required)	Research Project Grant award mechanism  ed Psychosis in the United States (R01 Clin		National Institute of Mental Health/NIH/DHHS	PAR-19- 236	05-Jun-2019	Not Specified
	Contact Name	Susan T. Azrin, Ph.D.					<del>-</del>



Contact Telephone 301-443-3267

Contact Email <a href="mailto:susan.azrin@nih.gov">susan.azrin@nih.gov</a>

	Program					Funding	
SPIN ID	Title	Sponsor Name	Sponsor Number	De	eadline Date	Amount	
	Sponsor Website						
	Program URL	https://grants.nih.gov/grants/guide/pa-	files/PAR-19-236.html				
	Deadline Dates (ALL)	05-Jun-2019 , 05-Oct-2019 , 05-Feb-2020 2022	0 , 05-Jun-2020 , 05-Oct-2020 , 05-Feb-20	21 , 05-Jun-202	21 , 05-Oct-202	1 , 05-Feb-	
	Synopsis	disorders. The World Health Organization advocates reducing DUP to 3 months or less. Accordingly, this Funding Opportunity Announcement (FOA) seeks research project grant applications that test practical, reproducible strategies for substantially reducing DUP among persons with FEP in the U.S. by eliminating bottlenecks or closing gaps in the pathway to CSC services. Alternatively, applicants whose work in this area is at a developmental stage should consider applying to the companion R34 FOA PAR-19-235.					
1121122	Reducing the Duration of Untreat Frial Required)	ed Psychosis in the United States (R34 Cli	nical National Institute of Mental Health/NIH/DHHS	PAR-19- 235	16-Jun-2019	450,000 USD	
	Contact Name	Susan T. Azrin, Ph.D.					
	Contact Telephone	301-443-3267					
	Contact Email	susan.azrin@nih.gov					
	Sponsor Website						
	Program URL	https://grants.nih.gov/grants/guide/pa-	files/PAR-19-235.html				
	Deadline Dates (ALL)	16-Jun-2019 , 16-Oct-2019 , 16-Feb-2020 2022	0 , 16-Jun-2020 , 16-Oct-2020 , 16-Feb-20	21 , 16-Jun-202	21 , 16-Oct-202	1,16-Feb-	
	Synopsis	year. The early phase of psychotic illness alter the downward trajectory and poor Unfortunately, numerous studies find a care; in the U.S. treatment is typically de evidence-based Coordinated Specialty C	young adults in the United States experies is widely viewed as a critical opportunity outcomes associated with schizophrenia substantial delay between the onset of polygon between one and three years. Early are (CSC) for early psychosis, and effective psychosis (DUP) and pre-empting the fundamental services.	ofor indicated particular related pso sychotic symptony identification e engagement	prevention, and ychotic disorder oms and the in of FEP, rapid re in CSC services	d a chance to ers. itiation of FEP eferral to are essential	

	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount			
		disorders. The World Health Organization Announcement (FOA) seeks planning rese or institutional settings; (2) map referral pand (4) develop and pilot test feasible strapplicants who have already completed si companion R01 FOA PAR-19-236.	arch project grant applications that (1 pathways to CSC care, (3) identify bottlategies for substantially reducing DUP	) identify a ba enecks and ga among persor	seline rate of DUI aps in the pathwa ns with FEP. Alter	P in community y to CSC care, natively,			
067277 <u>NI</u>	IH SIREN Neurologic Clinical Tria	ls (U01 Clinical Trial Required)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-18- 304	05-Jun-2019	Not Specified			
	Contact Name	Jeremy Brown, MD							
	Contact Telephone	301-594-4481							
	Contact Email	jeremy.brown@nih.gov							
	Sponsor Website								
	Program URL	https://grants.nih.gov/grants/guide/pa-fil	es/PAR-18-304.html						
	Deadline Dates (ALL)	05-Jun-2019 , 05-Oct-2019 , 05-Feb-2020 , 05-Jun-2020 , 05-Oct-2020							
	Synopsis	National Institute of Neurological Disorder neurological emergencies. Successful app SIREN Clinical Coordinating Center (CCC) wand the SIREN Data Coordinating Center (and their affiliated clinical sites will provide uniquely poised to collaborate with other promising interventions for neurological esupported by NINDS will be conducted in existing SIREN infrastructure to apply und Agreements award mechanism.	olicants will collaborate and conduct the vill work with the successful applicant DCC) will provide statistical and data rule on-site implementation of the clinical er US and international consortia necessary and international consortia necessary and strain strain of the NIH StrokeNet, and not within SIR	ne trial within is to implement so anagement so all protocols. The same to concert in stroke treaters. Applicants	the NIH SIREN Ne at the proposed tr support. The NIH The NIH SIREN Ne duct larger, defini atment, recovery, s do not need to b	etwork. The NIH rial efficiently SIREN hubs twork will also itive trials of , or prevention toe part of the			
069085 <u>NI</u>	INDS Exploratory Neuroscience	Research Grant (R21- Clinical Trial Optiona	National Institute of  Neurological Disorders and  Stroke/NIH/DHHS	PA-18- 358	07-May-2019	275,000 USD			
	Contact Name	Timothy LaVaute, PHD							



Contact Telephone 301-496-1447

Contact Email <u>lavautetm@mail.nih.gov</u>

SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
Sponsor Website					
Program URI	https://grants.nih.gov/grants/guide/p	pa-files/PA-18-358.html			
Deadline Dates (ALL	07-May-2019 , 16-Jun-2019 , 07-Sep- 2020 , 16-Oct-2020 , 07-Jan-2021	2019 , 16-Oct-2019 , 07-Jan-2020 , 16-Feb-2	020 <i>,</i> 07-May	-2020 , 16-Jun-20	)20 , 07-Sep-
Synopsis	National Institute of Neurological Disprojects, which fall within the mission projects. These studies often assess the potential to bring about breakthrough	sorders and Stroke (NINDS) invites application of the NINDS. Awards will provide support he feasibility of a novel avenue of investigat oughs in the understanding of important are plogies, or models, of high value to the neur (R21) grant mechanism.	for the early ion and invol eas of neuros	and conceptual s ve considerable r cience, or to the	tages of isk, but have development
069923 NINDS Exploratory Clinical Trials	(U01 Clinical Trial Required)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-18- 420	07-May-2019	Not Specified
Contact Name	Peter R. Gilbert, Sc.M.				
Contact Telephone	301-496-0870				
Contact Emai	pgilbert@nih.gov				
Sponsor Website					
Program URI	https://grants.nih.gov/grants/guide/p	pa-files/PAR-18-420.html			
Deadline Dates (ALL)	07-May-2019 , 05-Jun-2019 , 07-Sep-3	2019 , 05-Oct-2019 , 07-Jan-2020			
Synopsis	clinical trials to the National Institute the mission and research interests of and rehabilitation therapies. Informa	orders and Stroke (NINDS) invites applicatio of Neurological Disorders and Stroke (NIND the NINDS and may evaluate drugs, biological tion about the mission and research interest (). This FOA will use the NIH Research Project	S). The trials s, and device ts of the NINI	must address que s, as well as surg OS can be found a	estions within ical, behaviora
069928 NINDS Efficacy Clinical Trials (U03	L Clinical Trial Required)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-18- 422	07-May-2019	Not Specified
Contact Name	Peter R. Gilbert, ScM				
Contact Telephone	301-496-0870				
Contact Emai	pgilbert@nih.gov				
Sponsor Website	2				

SPIN ID Pro	ogram e	Sponsor Name	Sponsor	Number		Deadline Date	Funding Amount
	Deadline Dates (ALL)  O7-May 2020 ,  Nation trials to  Synopsis mission and rel	05-Oct-2020, 07-Jan-2021 al Institute of Neurological Discontinute of Neurological Discontinute of Neurological Institute of Neurological Institute of the nabilitation therapies. Informatical Informat	2019 , 05-Oco orders and S rological Disc NINDS and r tion about th	t-2019, 07-Jan-2020, 05-Feb-20 troke (NINDS) invites application orders and Stroke (NINDS). The t may evaluate drugs, biologics, ar ne mission and research interest will utilize the Cooperative Agree	ns for investi trials must ac nd devices, a s of the NIN	gator-initiated ef ddress questions s well as surgical, DS can be found a	ficacy clinical within the behavioral at the NINDS
072547 NIND Requi	S Postdoctoral Mentored Career Deired)	velopment Award (K01 Clinical	<u>Trial</u>	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-18- 685	07-May-2019	Not Specified
	Contact Name Stephe Contact Telephone 301-49 Contact Email korns@ Sponsor Website Program URL https:/	6-4188	oa-files/PAR-	-18-685.html			
	Nation Career to devel launch betwee by this strong, critical propos impact Announ clinical	Development Award. The award are lop a potentially impactful resonantially impactful resonantially impactful resonantially impactful resonantially impactful resonantially impactful resonantially implication and K01 award period, the cancer ful research project and the expectment (FOA) is designed spetrial, a clinical trial feasibility substitution in the concept of the cancer o	sorders and ard is intended are project gram. Candid wear of cumular developments are strongly lidate should apertise required are strongly for a tudy, or a second are second are second are strongly for a second are strongly for a second are	stroke (NINDS) invites application of to support the ability of outstant with a comprehensive career of ates are encouraged to apply for lative mentored postdoctoral relative postdoctoral research expent plan, in addition to developmly encouraged early in the postdoctoral red to become a leader in the fupplicants proposing to serve as parate ancillary study to an exis 1 Research Scientist Developme	anding, mendevelopment r support from search expenderience. Because of an importoral eligible dent researcheld. This Furthe lead involuting trial, as	tored postdoctor t plan that will en om this NINDS KO: rience, and may be cause the comple pactful research wility window. By the career with a wanding Opportunity estigator of an ince part of their rese	al researchers able them to I any time be supported tion of a project, is a the end of the ell-developed dependent arch and

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
<u> </u>	Recovery, and Prevention (U01 Clinical Trial	Optional)	Neurological Disorders and Stroke/NIH/DHHS	561		Specified

Contact Name Claudia Scala Moy, PhD

Contact Telephone 301-496-9135

Contact Email moyc@ninds.nih.gov

Sponsor Website

Program URL https://grants.nih.gov/grants/guide/pa-files/PAR-18-561.html

Deadline Dates (ALL) 05-Jun-2019, 05-Oct-2019, 05-Feb-2020, 05-Jun-2020, 05-Oct-2020

National Institute of Neurological Disorders and Stroke (NINDS) invites applications for multi-site exploratory and confirmatory clinical trials focused on promising interventions, as well as biomarker-or outcome measure validation studies that are immediately preparatory to trials in stroke prevention, treatment, and recovery. Successful applicants will collaborate and conduct the trial within the NIH StrokeNet. Following peer review, NINDS will prioritize trials among the highest scoring to be conducted in the NIH StrokeNet infrastructure. The NIH StrokeNet National Coordinating Center (NCC) will work with the successful applicant to implement the proposed study efficiently and the National Data Management Center (NDMC) will provide statistical and data management support. The NIH StrokeNet Regional Coordinating Centers (RCCs) and their affiliated clinical sites will provide recruitment/retention support as well as on-site implementation of the clinical protocol. The NIH StrokeNet network will also be uniquely poised to collaborate with other US and international consortia necessary to conduct larger, definitive trials of promising interventions for stroke treatment, prevention, and recovery. NINDS intends that all multi-center clinical trials in stroke treatment, recovery, or prevention supported by NINDS will be conducted in the NIH StrokeNet and that only in exceptional circumstances will NINDS consider funding multi-site stroke clinical trials outside of this program. Applicants do not need to be part of the existing NIH StrokeNet infrastructure to

apply under this FOA. This program will use the NIH U01 Research Project Cooperative Agreements award mechanism.

Synopsis

		Sponsor Name	Number	Deadline Date	Funding Amount
074766	RFA-NS-18-029 BRAIN Initiative: Exploratory Team-Research BRAIN Circuit Programs - eTeamBCP (U01 Clinical Trial Not Allowed)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	RFA-NS-18- 029	10-Jun-2019	Not Specified

Contact Name
Contact Telephone
Contact Email
Sponsor Website

Contact Name
James Gnadt, PhD
301-496-9964

BrainCircuits@nih.gov



**Synopsis** 

Program URL https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-18-029.html

Deadline Dates (ALL) 10-Jun-2019

National Institutes of Health (NIH) and its participating Institutes and Centers invite applications for the integration of experimental, analytic, and theoretical capabilities for large-scale analysis of neural systems and circuits. This FOA seeks applications for exploratory research studies that use new and emerging methods for large scale recording and manipulation of neural circuits across multiple brain regions. Applications should propose to elucidate the contributions of dynamic circuit activity to a specific behavioral or neural system. Applications should seek to understand circuits of the central nervous system by systematically controlling stimuli and/or behavior while actively recording and/or manipulating relevant dynamic patterns of neural activity and by measuring the resulting behaviors and/or perceptions. Studies should incorporate rich information on cell-types, on circuit functionality and connectivity, and should be performed in conjunction with sophisticated analysis of complex, ethologically relevant behaviors. Applications should propose teams of investigators that seek to cross boundaries of interdisciplinary collaboration by bridging fields and linking theory and data analysis to experimental design. Exploratory studies supported by this FOA are intended to develop experimental capabilities and quantitative, theoretical frameworks in preparation for a future competition for larger-scale, multi-component, Team-Research BRAIN Circuit Programs (U19). This program will use the NIH U01 Research Project Cooperative Agreements award mechanism.

070137

NINDS Faculty Development Award to Promote Diversity in Neuroscience Research (K01 Clinical Trial Required)

National Institute of Neurological Disorders and Stroke/NIH/DHHS

PAR-18-486 07-May-2019 975.000 USD

Contact Name Michelle Jones-London, Ph.D.

Contact Telephone 301-451-7966

Contact Email jonesmiche@ninds.nih.gov

Sponsor Website

Program URL https://grants.nih.gov/grants/guide/pa-files/PAR-18-486.html

Deadline Dates (ALL)

07-May-2019, 12-Jun-2019, 07-Sep-2019, 12-Oct-2019, 07-Jan-2020, 12-Feb-2020, 07-May-2020, 12-Jun-2020, 07-Sep-2020, 12-Oct-2020, 07-Jan-2021

National Institute of Neurological Disorders and Stroke (NINDS) invites applications for the Faculty Development Award to Promote Diversity in Neuroscience Research. The purpose of the NINDS Faculty Development Award to Promote Diversity in Neuroscience Research (K01) is to diversify the pool of independent neuroscience research investigators by providing junior faculty with research cost support, protected research time and career stage appropriate professional development mentorship in neuroscience research. Individuals from backgrounds underrepresented in biomedical research are eligible for support under this award if they have doctoral research degrees (Ph.D. or equivalent) and are in the first 3 years of a faculty tenure track or equivalent position at the time of application. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility

	2					F
SPIN ID	Program Title	Sponsor Name		Sponsor Number	Deadline Date	Funding Amount
	Tools to Ephanco the Study of Dr	accept applications to this FOA that that fall within the NINDS research submitting an application with hum	propo priorit an sub NIH I	existing trial, as part of their research and career decee human mechanistic trials/studies that meet NIH ies. Applicants are strongly advised to consult with ojects to determine the appropriate funding opport K01 Research Scientist Development Award - Resea	's definition of a c NINDS program st unity. This Fundin	S will only linical trial and aff prior to g Opportunity
071757	Clinical Trial Not Allowed)	enatai anu Fediatric Hydrocephalus (	<u>NZI</u>	Disorders and Stroke/NIH/DHHS  PA-18-623	07-May-2019	275,000 USD
	Contact Name	Jill A. Morris, Ph.D.				
	Contact Telephone	301-496-5745				
	Contact Email	jill.morris@nih.gov				
	Sponsor Website					
	Program URL	https://grants.nih.gov/grants/guide	/pa-fil	es/PA-18-623.html		
	Deadline Dates (ALL)	07-May-2019 , 16-Jun-2019 , 07-Sep 2020 , 16-Oct-2020 , 07-Jan-2021 , 1		) , 16-Oct-2019 , 07-Jan-2020 , 16-Feb-2020 , 07-Ma -2021 , 07-May-2021	y-2020 , 16-Jun-20	020 , 07-Sep-
	Synopsis	modify existing cutting-edge tools the of this FOA is to remove barriers to mechanisms and alternative therap prenatal and/or pediatric hydroceplinnovative technologies that will be	hat wi hydro ies (no halus i widel	ers and Stroke (NINDS) invites applications that pro II advance prenatal and/or pediatric hydrocephalus cephalus research that are due to scarcity of tools ton-shunt) in a rigorous manner. Applications should research by generating tools including animal and control y used throughout the neuroscience community to will use the NIH R21 Exploratory/Developmental R	research. The pri to investigate both d aim to transform ell models, novel r understand disea	mary objective the disease the field of methods and se mechanisms
071756	·	and Pediatric Hydrocephalus (R01 Cl	inical	National Institute of Neurological PA-18-622	07-May-2019	Not Specified
	<u>Trial Not Allowed)</u>	I		Disorders and Stroke/NIH/DHHS	5. Way 2015	- tot Specifica
	Contact Name	Jill A. Morris, Ph.D.				
	Contact Telephone	301-496-5745				
	Contact Email	jill.morris@nih.gov				
	Sponsor Website					
		https://grants.nih.gov/grants/guide				
	Deadline Dates (ALL)	07-May-2019 , 05-Jun-2019 , 07-Sep 2020 , 05-Oct-2020 , 07-Jan-2021 , 0	o-2019 05-Feb	, 05-Oct-2019 , 07-Jan-2020 , 05-Feb-2020 , 07-Ma -2021 , 07-May-2021	y-2020 , 05-Jun-20	)20 , 07-Sep-

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
				•	
	Synopsis	prenatal and pediatric hydrocephalus. The developmental etiology (intrinsic factors and infection) of prenatal and/or pediatri	lers and Stroke (NINDS) invites applications for hyponis FOA intends to support hydrocephalus research princluding genetics) and acquired etiology (extrinsic for hydrocephalus. Studies should focus on understanthe pathogenesis of prenatal and/or pediatric hydrocenism.	projects that exam actors including h ading the molecula	ine the emorrhage ar, cellular and
073884	Innovation Grants to Nurture Init Neurotherapeutic Agent Characte (R61/R33 Clinical Trial Not Allowe	erization and In vivo Efficacy Studies	National Institute of Neurological Disorders and Stroke/NIH/DHHS PAR-18-761	07-May-2019	750,000 USD
	Contact Name	Mary Ann Pelleymounter, PhD			
	Contact Telephone	301-496-1779			
	Contact Email	mary.pelleymounter@nih.gov			
	Sponsor Website				
	<u>-</u>	https://grants.nih.gov/grants/guide/pa-fi			
	Deadline Dates (ALL)	07-May-2019 , 19-Jun-2019 , 07-Sep-2019 2020 , 20-Oct-2020 , 07-Jan-2021 , 17-Feb	9 , 17-Oct-2019 , 07-Jan-2020 , 19-Feb-2020 , 07-Ma o-2021 , 07-May-2021	y-2020 , 17-Jun-2(	)20 , 07-Sep-
	Synopsis	pharmacokinetic, and in vivo efficacy stude activity to warrant further development to may include but are not limited to small red Innovation Grants to Nurture Initial Transe entry criteria for the NINDS Cooperative F (CREATE Bio) program for biologics, biote	ers and Stroke (NINDS) invites applications to conduction to demonstrate that proposed therapeutic agents to treat neurological disorders that fall under the NII molecules, biologics or biotechnology-derived productational Efforts (IGNITE) to advance projects to the property of the English to Enable and Advance Translational Enterchnology products, Blueprint Neurotherapeutics Neill utilize the R61/R33 Phased Innovation Award medical	ot(s) have sufficient NDS mission. Ther cts. This FOA is pa point where they of prises for Biologica twork for small m	at biological apeutic agents art of a suite of can meet the sprogram
073885		ial Translational Efforts (IGNITE): Assay utic Agent Identification (R61/R33 Clinical	National Institute of Neurological Disorders and Stroke/NIH/DHHS PAR-18-762	07-May-2019	750,000 USD
	Contact Name	Mary Ann Pelleymounter, PhD			
	Contact Telephone				
	Contact Email	mary.pelleymounter@nih.gov			
	Sponsor Website				

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Program URL	https://grants.nih.gov/grants/guide/pa-	files/PAR-18-762.html		
Deadline Dates (ALL) 07-May-2019 , 19-Jun-2019 , 07-Sep-2019 , 17-Oct-2019 , 07-Jan-2020 , 19-Feb-2020 , 07-May-2020 , 17-Jun-2020 , 07-Jan-2021					
National Institute of Neurological Disorders and Stroke (NINDS) invites applications to develop in vitro and/or ex vivo a and conduct iterative screening efforts to identify and characterize potential therapeutic agents for neurological disor This FOA is part of a suite of Innovation Grants to Nurture Initial Translational Efforts (IGNITE) to advance projects to to point where they can meet the entry criteria for the NINDS Cooperative Research to Enable and Advance Translational Enterprises for Biologics (CREATE Bio) program for biologics, biotechnology products, the Blueprint Neurotherapeutics Network (BPN) for small molecules, or other translational programs. This FOA will utilize the NIH R61/R33 Phased Inno Award mechanism.					
	NINDS Advanced Postdoctoral Ca Diversity in Neuroscience Research	reer Transition Award to Promote ch (K22-Clinical Trial Required)	National Institute of Neurological Disorders and Stroke/NIH/DHHS PAR-18-468	07-May-2019	Not Specified
Contact Name Michelle Jones-London, Ph.D.					
	Contact Telephone	301-451-7966			
	Contact Email	jonesmiche@ninds.nih.gov			
	Sponsor Website				
	Program URL	https://grants.nih.gov/grants/guide/pa-	files/PAR-18-468.html		
	Deadline Dates (ALL)	07-May-2019 , 12-Jun-2019 , 07-Sep-201 2020 , 12-Oct-2020 , 07-Jan-2021	19 , 12-Oct-2019 , 07-Jan-2020 , 12-Feb-2020 , 07-Ma	y-2020 , 12-Jun-20	020 , 07-Sep-
	Synopsis	Career Transition Award to Promote Div with strong training in neuroscience wit productive independent research position research degrees (Ph.D., Ph.D./M.D. or extime of application. This Funding Opport as the lead investigator of an independent existing trial that also meets the definition accept applications to this FOA that prophat fall within the NINDS research prior	ders and Stroke (NINDS) invites applications for the Nersity. This opportunity provides postdoctoral fellow the the resources and tools that will help facilitate a trace. Individuals are eligible for support under this away equivalent) and between 2 and 5 years of postdoctor tunity Announcement (FOA) is designed specifically for the clinical trial, a clinical trial feasibility study, or a secon of a clinical trial, as part of their research and care pose human mechanistic trials/studies that meet NIH rities. Applicants are strongly advised to consult with an with human subjects to determine the appropriate and Award mechanism.	s from underrepre ansition to a stable ard if they have do al prior research t or applicants prop parate ancillary st eer development. I's definition of a co NINDS Scientific/F	esented groups e and octoral raining at the osing to serve udy to an NINDS will only dinical trial and Research

070123 NINDS Advanced Postdoctoral Career Transition Award to Promote

National Institute of Neurological PAR-18-469 07-May-2019

**Not Specified** 

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Diversity in Neuroscience Research	ch (K22-No Independent Clinical Trials)	Disorders and Stroke/NIH/DHHS		
	Contact Name	Michelle Jones-London, Ph.D.			
	Contact Telephone	301-451-7966			
	Contact Email	jonesmiche@ninds.nih.gov			
	Sponsor Website				
		https://grants.nih.gov/grants/guide/pa-f			
Deadline Dates (ALL) 07-May-2019 , 12-Jun-2019 , 07-Sep-2019 , 12-Oct-2019 , 07-Jan-2020 , 12-Feb-2020 , 07-May-2020 , 12-Jun-2020 , 07-Jan-2021					
	Synopsis	Career Transition Award to Promote Diversity is designed to enhance the part neuroscience research. This opportunity neuroscience with the resources and too research position. Individuals are eligible Ph.D./M.D. or equivalent) and between Eunding Opportunity Announcement (FC leading an independent clinical trial, a cli	ers and Stroke (NINDS) invites applications for the Nersity. The NINDS Advanced Postdoctoral Career Traticipation of highly trained early career investigators provides postdoctoral fellows from underrepresents that will help facilitate a transition to a stable and e for support under this award if they have doctoral and 5 years of postdoctoral prior research training DA) is designed specifically for applicants proposing inical trial feasibility study, or an ancillary study to a experience in a clinical trial led by a mentor or commism.	insition Award to Particular and the productive indepures at the time of appures clinical trial. Application Award to Particular and the time of appures clinical trial. Application and the production and the production and the production and the production are producted to Particular and the production and the production are producted to Particular and the producted trial and trial a	Promote sented groupsin ong training in endent (Ph.D., olication. This not involve cants to this
070493	NeuroNEXT Clinical Trials (U01 Cli	inical Trial Optional)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	06-May-2019 [LOI/Pre-App] [Optional]	Not Specified
	Contact Name	Codrin Lungu, MD			
	Contact Telephone	301-496-9135			
	Contact Email	lunguci@ninds.nih.gov			
	Sponsor Website				
	Program URL	https://grants.nih.gov/grants/guide/pa-f	files/PAR-18-528.html		
			5-Jun-2019 , 05-Sep-2019 [LOI/Pre-App][Optional], 06-May-2020 [LOI/Pre-App][Optional], 05-Jun-2020 ,		
	Synopsis	National Institute of Neurological Disord	ers and Stroke (NINDS) invites applications for explo	oratory clinical trial	s of

**Program Funding Deadline Date SPIN ID Sponsor Name Sponsor Number** Title **Amount** 

> investigational agents (drugs, biologics, surgical therapies or devices) that may contribute to the justification for and provide the data required for designing a future trial, for biomarker validation studies, or for proof of mechanism clinical studies. Diseases chosen for study should be based on the NINDS' strategic plan and clinical research interests (www.ninds.nih.gov/funding/areas/index.htm). Successful applicants will be given access to the NeuroNEXT infrastructure. Following peer review, NINDS will prioritize and order trials that are given access to the NeuroNEXT infrastructure. The NeuroNEXT Clinical Coordinating Center (CCC) will work with the successful applicant to efficiently implement the proposed study. The NeuroNEXT Data Coordinating Center (DCC) will provide statistical and data management support. The NeuroNEXT clinical sites will provide recruitment/retention support as well as on-site implementation of the clinical protocol. Applicants do not need to be part of the existing NeuroNEXT infrastructure. This FOA will utilize the NIH U01 Research Project – Cooperative Agreements award mechanism.

NINDS Postdoctoral Mentored Career Development Award (K01 No 072549 Independent Clinical Trial Allowed)

National Institute of Neurological Disorders and Stroke/NIH/DHHS

PAR-18-686 07-May-2019 **Not Specified** 

Contact Name Stephen Korn, PhD

Contact Telephone 301-496-4188

Contact Email korns@mail.nih.gov

Sponsor Website

Program URL https://grants.nih.gov/grants/guide/pa-files/PAR-18-686.html

Deadline Dates (ALL) 07-May-2019, 12-Jun-2019, 07-Sep-2019, 12-Oct-2019, 07-Jan-2020

National Institute of Neurological Disorders and Stroke (NINDS) invites applications for the NINDS Postdoctoral Mentored Career Development Award. The award is intended to support the ability of outstanding, mentored postdoctoral researchers to develop a potentially impactful research project with a comprehensive career development plan that will enable them to launch an independent research program. Candidates are encouraged to apply for support from this NINDS K01 any time between the second through fourth year of cumulative mentored postdoctoral research experience, and may be supported by this NINDS K01 within the first 6 years of cumulative postdoctoral research experience. Because the completion of a strong, well-planned, thorough career development plan, in addition to development of an impactful research project, is a critical aspect of this KO1, applications are strongly encouraged early in the postdoctoral eligibility window. By the end of the proposed K01 award period, the candidate should be poised to begin an independent research career with a well-developed, impactful research project and the expertise required to become a leader in the field. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. This FOA will use the NIH K01 Research Scientist Development Award - Research & Training award mechanism.

070144 NINDS Faculty Development Award to Promote Diversity in Neuroscience

National Institute of Neurological PAR-18-490

07-May-2019

975,000 USD



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Research (K01 Independent Clinic	<u>cal Trial Not Allowed)</u>	Disorders and Stroke/NIH/DHHS		
	Contact Name	Michelle Jones-London, Ph.D.			
	Contact Telephone	301-451-7966			
	Contact Email	jonesmiche@ninds.nih.gov			
	Sponsor Website	ع ا			
	Program URL	https://grants.nih.gov/grants/guide/p	a-files/PAR-18-490.html		
	Deadline Dates (ALL)	07-May-2019 , 12-Jun-2019 , 07-Sep-2 2020 , 12-Oct-2020 , 07-Jan-2021	019 , 12-Oct-2019 , 07-Jan-2020 , 12-Feb-2020 , 07-M	ay-2020 , 12-Jun-20	)20 , 07-Sep-
	Synopsis	Promote Diversity in Neuroscience Res Neuroscience Research (KO1) is to dive faculty with research cost support, pro mentorship in neuroscience research. s support under this award if they have tenure track or equivalent position at a specifically for applicants proposing re feasibility study, or an ancillary study to		nt Award to Promo investigators by proofessional develop omedical research re in the first 3 yea ouncement (FOA) clinical trial, a clinical propose research	te Diversity in oviding junior ment are eligible for rs of a faculty is designed cal trial h experience in
070148	Promoting Research in Basic Neu	uroscience (R01 Clinical Trial Not Allowe	National Institute of Neurological Disorders and Stroke/NIH/DHHS  PAS-18-483	07-May-2019	Not Specified
	Contact Name	Robert Riddle, PhD			
	Contact Telephone	301-496-5745			
	Contact Email	rr260c@nih.gov			
	Sponsor Website	ع ا			
	Program URL	https://grants.nih.gov/grants/guide/p	a-files/PAS-18-483.html		
	Deadline Dates (ALL)	07-May-2019 , 05-Jun-2019 , 07-Sep-2 2020 , 05-Oct-2020 , 07-Jan-2021	019 , 05-Oct-2019 , 07-Jan-2020 , 05-Feb-2020 , 07-M	ay-2020 , 05-Jun-20	)20 , 07-Sep-
	Synopsis		its participating Institutes and Centers invite applicat science. Proposed projects can address any area of ne		-

the participating institutes and should focus on understanding the development, the structure and/or the function of the

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount	
		•	ntal basic research often generates insights relevan Ilate research that is explicitly disease-related. Thi			
070232	RFA-NS-18-018 BRAIN Initiative Stimulation (R01 Clinical Trial Opt	e: Biology and Biophysics of Neural tional)	National Institute of Neurological RFA-NS-18- Disorders and Stroke/NIH/DHHS 018	05-May-2019 [LOI/Pre-App] [Optional]	Not Specified	
	Contact Name	Nick Langhals, PhD				
	Contact Telephone					
		BRAIN-FOAs@nih.gov				
	Sponsor Website					
	· ·	https://grants.nih.gov/grants/guide/rfa-f				
	Deadline Dates (ALL)	05-May-2019 [LOI/Pre-App][Optional], 04-Jun-2019, 04-Sep-2019 [LOI/Pre-App][Optional], 04-Oct-2019, 07-Jan-2020   LOI/Pre-App][Optional], 04-Jun-2020   LOI/Pre-App][Optional], 04-Jun-2020   Collins   Coll				
	Synopsis	characterize, model, and validate the me neuronal cells to various types of stimula are outside the scope of this FOA. Howev of this program, investigators will be requ	ts participating Institutes and Centers invite applications application. Development of new technologies and theraper, activities related to combining multiple record uired to participate in a consortium to develop stain neuromodulation technologies. This FOA will use	esponses of neuron pies, as well as of di ing modalities are a ndards and model s	al and non- isease models illowed. As part systems for the	
070628	RFA-NS-18-021 BRAIN Initiative Recording and Modulation in the (UG3/UH3 Clinical Trial Required)		National Institute of Neurological RFA-NS-18- Disorders and Stroke/NIH/DHHS 021	22-May-2019 [LOI/Pre-App] [Optional]	Not Specified	
	Contact Name	Nick Langhals, PhD				
	Contact Telephone	301-496-1447				
	Contact Email	nick.langhals@nih.gov				
	Sponsor Website					
	Program URL	https://grants.nih.gov/grants/guide/rfa-f	iles/RFA-NS-18-021.html			
	Deadline Dates (ALL)	22-May-2019 [LOI/Pre-App][Optional], 2: [LOI/Pre-App][Optional], 21-Feb-2020, 2	1-Jun-2019 , 21-Sep-2019 [LOI/Pre-App][Optional] 3-May-2020 [LOI/Pre-App][Optional], 22-Jun-2020	, 21-Oct-2019 , 22-J ) , 21-Sep-2020 [LOI	an-2020 /Pre-	

	SPIN ID	Program	Sponsor Name	Sponsor Number	Deadline Date	Funding
١	SPIN ID	Title	Sponsor Name	Sponsor Number	Deadine Date	Amount

App][Optional], 21-Oct-2020

National Institutes of Health (NIH) and its participating Institutes and Centers invite applications for translational and clinical studies for recording and/or stimulating devices to treat nervous system disorders and better understand the human brain. The program will utilize a cooperative agreement mechanism to support the submission of an Investigational Device Exemption (IDE) for a Significant Risk (SR) study or obtain Institutional Review Board (IRB) approval for a Non-Significant Risk (NSR) study, and a subsequent small clinical trial (e.g., Early Feasibility Study). The small clinical trial should provide data to answer key questions about the function or final design of a device. This final device design may require most, if not all, of the non-clinical testing on the path to more advanced clinical trials and market approval. The clinical trial is expected to provide information that cannot be practically obtained through additional nonclinical assessments (e.g., bench top or animal studies) due to the novelty of the device or its intended use. Activities supported in this program include implementation of clinical prototype devices, non-clinical safety and efficacy testing, design verification and validation activities, and pursuit of regulatory approval for, and implementation of, a single small clinical trial. This FOA will use the NIH UG3/UH3 Exploratory/Developmental Phased Award Cooperative Agreement mechanism.

RFA-NS-18-023 -- BRAIN Initiative: Clinical Studies to Advance Next-070636 Generation Invasive Devices for Recording and Modulation in the Human

National Institute of Neurological RFA-NS-18-Disorders and Stroke/NIH/DHHS 023

22-May-2019 [LOI/Pre-App] [Optional]

Not Specified

Central Nervous System (UH3 Clinical Trial Required)

**Synopsis** 

Contact Name Nick Langhals, PhD

Contact Telephone 301-496-1447

Contact Email nick.langhals@nih.gov

Sponsor Website

Program URL https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-18-023.html

22-May-2019 [LOI/Pre-App][Optional], 21-Jun-2019, 21-Sep-2019 [LOI/Pre-App][Optional], 21-Oct-2019, 22-Jan-2020 Deadline Dates (ALL) [LOI/Pre-App] [Optional], 21-Feb-2020, 23-May-2020 [LOI/Pre-App] [Optional], 22-Jun-2020, 21-Sep-2020 [LOI/Pre-App] Appl[Optional], 21-Oct-2020

National Institutes of Health (NIH) and its participating Institutes and Centers invite applications for investigators to pursue a small clinical trial to obtain critical information necessary to advance recording and/or stimulating devices to treat central nervous system disorders and better understand the human brain (e.g., Early Feasibility Study). Clinical studies supported may consist of acute or short-term procedures that are deemed Non-Significant Risk (NSR) by an Institutional Review Board Synopsis (IRB), or Significant Risk (SR) studies that require an Investigational Device Exemption (IDE) from the FDA, such as chronic implants. The clinical trial should provide data to answer key questions about the function or final design of a device. This final device design may require most, if not all, of the non-clinical testing on the path to more advanced clinical trials and market approval. The clinical trial is expected to provide information that cannot be practically obtained through additional non-clinical assessments (e.g., bench top or animal studies) due to the novelty of the device or its intended use. Activities

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		supported by this Funding Opportunity inc of a device. This FOA will use the NIH UH3				or final design
068924	RFA-NS-18-012 Translational N	eural Devices (U44 Clinical Trial Required)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	RFA-NS-18- 012	22-May-2019 [LOI/Pre-App] [Optional]	Not Specified
	Contact Name	Nick Langhals, PhD				
	Contact Telephone	301-496-1447				
	Contact Email	nick.langhals@nih.gov				
	Sponsor Website					
	Program URL	https://grants.nih.gov/grants/guide/rfa-fi	les/RFA-NS-18-012.html			
	Deadline Dates (ALL)	22-May-2019 [LOI/Pre-App][Optional], 21 [LOI/Pre-App][Optional], 21-Feb-2020, 23 App][Optional], 21-Oct-2020	• • • • • • • • • • • • • • • • • • • •			
	Synopsis	National Institute of Neurological Disorder pursue translational activities and small of disorders that affect the nervous or neurological and animal studies, are expected to lead to Drug Administration (FDA) or Institutional cooperative agreement will also support to support a marketing application or to in Research (SBIR) Cooperative Agreements	inical studies to advance the develor omuscular systems. The translational to submission of an Investigational E Review Board (IRB) application for the subsequent small clinical study to inform final device design. This FOA	pment of ther I device activit Device Exempti a Non-Significa o collect safet	apeutic and diagno ies, including trans ion (IDE) to the U.S. ant Risk (NSR) study y and effectiveness	stic devices for lational bench . Food and /. This data required
068913	RFA-NS-18-011 Translational N Required)	eural Devices (UG3/UH3 Clinical Trial	National Institute of Neurological Disorders and Stroke/NIH/DHHS	RFA-NS-18- 011	22-May-2019 [LOI/Pre-App] [Optional]	Not Specified
	Contact Name	Nick Langhals, PhD				
	Contact Telephone	301-496-1447				
	Contact Email	nick.langhals@nih.gov				
	Sponsor Website					
	Program URL	https://grants.nih.gov/grants/guide/rfa-fi	les/RFA-NS-18-011.html			
	Deadline Dates (ALL)	22-May-2019 [LOI/Pre-App][Optional], 21 [LOI/Pre-App][Optional], 21-Feb-2020, 23	-Jun-2019 , 21-Sep-2019 [LOI/Pre-A 3-May-2020 [LOI/Pre-App][Optional]	op][Optional], , 22-Jun-2020	21-Oct-2019 , 22-Ja , 21-Sep-2020 [LOI,	an-2020 /Pre-

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	clinical studies to advance the developmeneuromuscular systems. The translational ead to submission of an Investigational Enstitutional Review Board (IRB) applications the subsequent small clinical tria	ers and Stroke (NINDS) invites applications for tranent of therapeutic, and diagnostic devices for disoral device activities, including translational bench an Device Exemption (IDE) to the U.S. Food and Drug A on for a Non-Significant Risk (NSR) study. This coopal to collect safety and effectiveness data required to will use the NIH UG3/UH3 Exploratory/Development	ders that affect the d animal studies, a Administration (FDA perative agreement to support a marke	e nervous or re expected to A) or will also ting application
057513	NINDS Ruth L. Kirschstein National Training of Postdoctoral Fellows (F	Research Service Award (NRSA) for 32)	National Institute of Neurological Disorders and Stroke/NIH/DHHS PAR-16-458	07-May-2019	Not Specified
	Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL)	nttp://grants.nih.gov/grants/guide/pa-fil 07-May-2019 , 19-Jun-2019 , 07-Sep-2019 National Institute of Neurological Disorce nighly promising postdoctoral candidates program from ~12 months prior to the st postdoctoral position. Based on the early this NINDS F32 seeks to foster early, goal by the candidate that have the potential		to apply for suppo 12 months after s of inclusion of preli or bold and/or inno o incorporate stron	ort from this tarting in minary data, ovative projects g training in
078105	RFA-NS-19-006 BRAIN Initiative:	to the first 3 years of a candidate's activitellowship application and timely comple environment. This FOA will use the NIH F	ty in a specific laboratory or research environment, tion of "mentored training" of the postdoctoral ca 32 Postdoctoral Individual National Research Servi  National Institute of Neurological RFA-NS-19- Disorders and Stroke/NIH/DHHS 006	so as to further er ndidate in a single ce Award mechanis 28-May-2019 [LOI/Pre-App]	courage early
	Contact Name	Stephanie Fertig		[Optional]	

Contact Telephone 301-469-1779

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Sponsor Websit	https://grants.nih.gov/grants/guio 28-May-2019 [LOI/Pre-App][Optio	de/rfa-files/RFA-NS-19-006.html onal], 27-Jun-2019 , 28-Jan-2020 [LOI/Pre-App] 2020 , 28-May-2021 [LOI/Pre-App][Optional], 2		7-Feb-2020 , 28-O	ct-2020
	Synopsi	neuroscience research practice. P described in the planning docume activities: distribution of tools and to existing technology platforms a production and delivery; minor ad technology or software developments.	rement (FOA) supports efforts to disseminate reprojects should be highly relevant to specific go ant "BRAIN 2025: A Scientific Vision." They should reagents; user training on the usage of new to and specialized facilities; minor improvements alaptations to meet the needs of a user communent, rather than dissemination of an existing reals necessary to customize them to the expering needs of neuroscience researchers working to impractical in their current form.	pals of the BRA uld engage in echnologies o to increase th nity. Applicati esource, are r mental needs	AIN Initiative, goa one or more of the or techniques; pro- ne scale/efficiency ions strictly focus not responsive to s of the end users	Is that are ne following viding access of resource ed on this FOA.
077707	Research on Chronic Overlappin Optional)	g Pain Conditions (R01 Clinical Trial	National Institute of Neurological PAD Disorders and Stroke/NIH/DHHS	A-18-937 (	05-Jun-2019	Not Specified
	Contact Name	Michael L. Oshinsky, Ph.D.				
	Contact Telephone	301-451-4460				
	Contact Ema	l michael.oshinsky@nih.gov				
	Sponsor Website	2				
	Program UR	https://grants.nih.gov/grants/guid	de/pa-files/PA-18-937.html			
	Deadline Dates (ALL	) 05-Jun-2019 , 05-Oct-2019 , 05-Fe	b-2020 , 05-Jun-2020 , 05-Oct-2020 , 05-Feb-2	021 , 05-Jun-2	2021 , 05-Oct-202	1
	Synopsi	and translational research that will psychological variables, and clinical with pain. Recent clinical findings	and its participating Institutes and Centers invalue II increase our understanding of the natural his all risk factors responsible for the presence of natural substantial overlap may exist betwoexhibit characteristics of additional chronic parts.	story, prevale nultiple chror ween chronic	nce, biological me nic pain conditions pain conditions. I	echanisms, s in people ndividuals

diagnostic categories. A better understanding is needed of the prevalence of overlapping pain conditions, the underlying etiologies, the progression of these conditions, the evolution of these overlaps, and the therapeutic approaches best suited for treating subjects with these conditions. The main objective of this FOA is the formation of research groups with interests bridging expertise in pain mechanisms with translational and clinical expertise to address important unresolved questions

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount		
		the study of these conditions. Applicants	cants are encouraged to leverage existing ar are encouraged to include researchers with o will enhance the breadth of research and u earch Project (R01) award mechanism.	compl	ementary expertise	from outside		
077714	Research on Chronic Overlapping Allowed)	Pain Conditions (R21 Clinical Trial Not	National Institute of Neurological Disorders and Stroke/NIH/DHHS	939	16-Jun-2019	275,000 USD		
	Contact Name	Michael L. Oshinsky, Ph.D.						
	Contact Telephone	301-451-4460						
	Contact Email	michael.oshinsky@nih.gov						
	Sponsor Website							
	Program URL	https://grants.nih.gov/grants/guide/pa-files/PA-18-939.html						
	Deadline Dates (ALL)	.6-Jun-2019 , 16-Oct-2019 , 16-Feb-2020 , 16-Jun-2020 , 16-Oct-2020 , 16-Feb-2021 , 16-Jun-2021 , 16-Oct-2021						
	Synopsis	and translational research that will incread psychological variables, and clinical risk for with pain. Recent clinical findings suggest diagnosed with one disorder often exhibit diagnostic categories. A better understar etiologies, the progression of these conditions for treating subjects with these conditions bridging expertise in pain mechanisms we about overlapping pain conditions. Applicants the pain field in their research teams where	s participating Institutes and Centers invites ase our understanding of the natural history actors responsible for the presence of multip that substantial overlap may exist between it characteristics of additional chronic painful inding is needed of the prevalence of overlap itions, the evolution of these overlaps, and the same are encouraged to leverage existing an are encouraged to include researchers with the owill enhance the breadth of research and the Exploratory/Developmental Research Grants are encouraged to leverage existing and are encouraged to leve	preva ole chron chron I condi oing pa he then ation or ress im d deve comple nderst	lence, biological me onic pain conditions ic pain conditions. I tions or transition to ain conditions, the conditions, the conditions, the conditions, the conditions of research groups	echanisms, s in people Individuals to other underlying es best suited with interests d questions pertinent to		
070629		e: Next-Generation Invasive Devices for Human Central Nervous System (U44	National Institute of Neurological RFA-NS Disorders and Stroke/NIH/DHHS 022	5-18-	22-May-2019 [LOI/Pre-App] [Optional]	Not Specified		
_	Contact Name	Nick Langhals, PhD						
	Contact Telephone	301-496-1447						
	Contact Email	nick.langhals@nih.gov						

1	SPIN ID	Program	Sponsor Name	Sponsor Number	Deadline Date	Funding
1	31 114 12	Title	Sponsor Name	Sponsor Humber	Deadine Date	Amount

Sponsor Website

Program URL https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-18-022.html

22-May-2019 [LOI/Pre-App][Optional], 21-Jun-2019, 21-Sep-2019 [LOI/Pre-App][Optional], 21-Oct-2019, 22-Jan-2020 Deadline Dates (ALL) [LOI/Pre-App] [Optional], 21-Feb-2020, 23-May-2020 [LOI/Pre-App] [Optional], 22-Jun-2020, 21-Sep-2020 [LOI/Pre-App] App][Optional], 21-Oct-2020

National Institutes of Health (NIH) and its participating Institutes and Centers invite applications from small business concerns (SBCs) to pursue translational non-clinical studies and clinical studies for recording and/or stimulating devices to treat nervous system disorders and thereby better understand the human brain. The program will utilize a cooperative agreement mechanism to support the non-clinical studies necessary for the submission of an Investigational Device Exemption (IDE) for a Significant Risk (SR) study or to obtain Institutional Review Board (IRB) approval for a Non-Significant Risk (NSR) study, and the subsequent small clinical trial (e.g., Early Feasibility Study). Activities supported in this program Synopsis include implementation of clinical prototype devices, non-clinical safety and efficacy testing, design verification and validation activities, and pursuit of regulatory approval for, and implementation of, a single small clinical trial. The small clinical trial should provide data to answer key questions about the function or final design of a device. This final device design may require most, if not all, of the non-clinical testing on the path to more advanced clinical trials and market approval. The clinical trial is expected to provide information that cannot be practically obtained through additional nonclinical assessments (e.g., bench top or animal studies) due to the novelty of the device or its intended use. This FOA will use the NIH U44 Small Business Innovation Research (SBIR) Cooperative Agreement – Fast-Track mechanism.

750.000 USD

Innovation Grants to Nurture Initial Translational Efforts (IGNITE):

073889

Development and Validation of Model Systems and/or Pharmacodynamic National Institute of Neurological PAR-18-763 07-May-2019 Markers to Facilitate Neurotherapeutic Discovery (R61/R33 Clinical Trial Not Disorders and Stroke/NIH/DHHS Allowed)

Contact Name Mary Ann Pelleymounter, PhD

Contact Telephone 301-496-1779

Contact Email mary.pelleymounter@nih.gov

Sponsor Website

Program URL https://grants.nih.gov/grants/guide/pa-files/PAR-18-763.html

07-May-2019, 19-Jun-2019, 07-Sep-2019, 17-Oct-2019, 07-Jan-2020, 19-Feb-2020, 07-May-2020, 17-Jun-2020, 07-Sep-Deadline Dates (ALL) 2020, 20-Oct-2020, 07-Jan-2021, 17-Feb-2021, 07-May-2021

National Institute of Neurological Disorders and Stroke (NINDS) invites applications for the development and validation of: 1) Synopsis animal models and human tissue ex vivo systems that recapitulate the phenotypic and physiologic characteristics of a defined neurological disorder and/or 2) clinically feasible pharmacodynamic markers for therapeutics designed to treat neurological

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		systems, models, r provide fo preclinica focused o	and pharmacodynamic markers model systems and pharmacody easible and meaningful assessm Il and clinical settings. This FOA	ote a significant improvement in the translational rethat will be utilized to facilitate the development of namic markers proposed in applications for this FO ents of efficacy following therapeutic intervention is part of a suite of Innovation Grants to Nurture In early stages of drug discovery. This FOA will utiliz	f neurotherapeution  A would have the path  A would be appl  A would be appl  A would be appl	cs. Ideally, potential to icable in both fforts (IGNITE)
079593	Comparative Effectiveness Rese Clinical Trial Not Allowed)	earch in Clin	ical Neurosciences (UG3/UH3	National Institute of Neurological Disorders and Stroke/NIH/DHHS	07-May-2019	Not Specified
	Contact Nam	ne Adam L. I	Hartman, MD			
	Contact Telephor	ne 301-496-	9135			
	Contact Ema	ail <u>adam.har</u>	tman@nih.gov			
	Sponsor Websi	te				
	Program UI	RL https://gi	rants.nih.gov/grants/guide/pa-f	iles/PAR-19-171.html		
	Deadline Dates (AL	07-May-2 2020 , 14	2019 , 18-Jun-2019 , 07-Sep-201 -Oct-2020 , 07-Jan-2021 , 18-Fe	9 , 18-Oct-2019 , 07-Jan-2020 , 19-Feb-2020 , 07-M b-2021 , 07-May-2021 , 18-Jun-2021 , 07-Sep-2021	ay-2020 , 18-Jun-20 , 14-Oct-2021 , 07-	020 , 07-Sep- Jan-2022
The purpose of this Funding Opportunit prospective observational comparative Stroke (NINDS) (note: only prospective the mission and research interests of the interventions including drugs, biologics,			ve observational comparative e INDS) (note: only prospective of on and research interests of the ions including drugs, biologics, a d in pragmatic study designs tha	Announcement (FOA) is to encourage grant application of the National Institute (Sectiveness research (CER) to the National Institute (Sectional Studies will be considered)). The study NINDS and may evaluate preventive strategies, dia and devices, or surgical, behavioral, and rehabilitation utilize a cost-effective means of prospectively colors.	e of Neurological D must address ques gnostic approache on therapies. NIND	isorders and stions within s, or S is particularly
078981	HEAL Initiative: Translational Donormal)	evices to Tre	eat Pain (U44 Clinical Trial	National Institute of Neurological RFA-NS-19- Disorders and Stroke/NIH/DHHS 017	22-May-2019 [LOI/Pre-App] [Optional]	Not Specified
	Contact Name S	tephanie Fe	rtig, MBA			
	Contact Telephone 3	01-496-1779	Э			
	Contact Email <u>f</u> e	ertigs@nind	s.nih.gov			
	Sponsor Website					

Program URL https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-19-017.html

SPIN ID	Program	Sponsor Name	Sponsor Number	Deadline Date	Funding	
	SPIN ID	Title	Sponsor Name	Sponsor Number	Deadine Date	Amount

22-May-2019 [LOI/Pre-App][Optional], 21-Jun-2019, 21-Sep-2019 [LOI/Pre-App][Optional], 21-Oct-2019, 22-Jan-2020 [LOI/Pre-App] Deadline Dates (ALL) App][Optional], 21-Feb-2020, 23-May-2020 [LOI/Pre-App][Optional], 22-Jun-2020, 21-Sep-2020 [LOI/Pre-App][Optional], 21-Oct-2020, 22-Jan-2021 [LOI/Pre-App][Optional], 21-Feb-2021

> The purpose of this Funding Opportunity Announcement (FOA) is to encourage small business concerns (SBCs) to pursue translational activities and clinical trials to treat pain with innovative, targeted, and non-addictive diagnostic and/or therapeutic devices that improve patient outcomes and decrease or eliminate the need to prescribe opioids. Activities supported in this program include implementation of clinical prototype devices, non-clinical safety and efficacy testing, design verification and validation activities, obtaining an Investigational Device Exemption (IDE) for a Significant Risk (SR) study or Institutional Review Board (IRB) approval for a Non-Significant Risk (NSR) study, as well as a subsequent small clinical trial (e.g., Early Feasibility Study). The clinical trial is expected to provide information about the device function or final design that cannot be practically obtained through additional nonclinical assessments (e.g., bench top or animal studies) due to the novelty of the device or its intended use. This is a milestone-driven cooperative agreement program and will involve participation of NIH program staff in the development of the project plan and monitoring of research progress. This FOA will leverage Public-Private Partnership Programs (PPP) initiated under the NIH BRAIN Initiative, the Office of Strategic Coordination – The Common Fund's Stimulating Peripheral Activity to Relieve Conditions (SPARC) Program, and the NIH HEAL Initiative. These programs include agreements (Memoranda of Understanding, MOU) with a number of device manufacturers willing to make such devices available, including devices and capabilities not yet market approved but appropriate for clinical research. In general, it is expected that the devices' existing safety and utility data will be sufficient to enable new IRB NSR or FDA IDE approval without the need for significant additional non-clinical data. For more

Synopsis

information see https://braininitiative.nih.gov/resources/brain ppp/index.htm, https://commonfund.nih.gov/sparc/newmarkets, and https://www.nih.gov/research-training/medical-research-initiatives/heal-initiative/public-private-partnership. Individuals, institutions, or businesses developing their own devices or that already have established collaborations with device manufacturers are welcome to apply directly to this FOA or any of the companion opportunities.

078978

HEAL Initiative: Translational Devices to Treat Pain (UG3/UH3 Clinical Trial Optional)

National Institute of Neurological RFA-NS-19-Disorders and Stroke/NIH/DHHS 016

22-May-2019 [LOI/Pre-App] [Optional]

**Not Specified** 

Contact Name Michael B. Wolfson Contact Telephone 301-451-4778

Contact Email Michael. Wolfson@nih.gov

Sponsor Website

Program URL https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-19-016.html

Deadline Dates (ALL)

22-May-2019 [LOI/Pre-App][Optional], 21-Jun-2019, 21-Sep-2019 [LOI/Pre-App][Optional], 21-Oct-2019, 22-Jan-2020 [LOI/Pre-App] App][Optional], 21-Feb-2020, 23-May-2020 [LOI/Pre-App][Optional], 22-Jun-2020, 21-Sep-2020 [LOI/Pre-App][Optional], 21-Oct-

	SPIN ID	Program	Sponsor Name	Sponsor Number	Deadline Date	Funding
ľ	SPIN ID	Title	Sponsor Name		Deaumie Date	Amount

2020 , 22-Jan-2021 [LOI/Pre-App][Optional], 21-Feb-2021

The purpose of this Funding Opportunity Announcement (FOA) is to encourage investigators to pursue translational activities and clinical trials to treat pain with innovative, targeted, and non-addictive diagnostic and/or therapeutic devices that improve patient outcomes and decrease or eliminate the need to prescribe opioids. Activities supported in this program include implementation of clinical prototype devices, non-clinical safety and efficacy testing, design verification and validation activities, obtaining an Investigational Device Exemption (IDE) for a Significant Risk (SR) study or Institutional Review Board (IRB) approval for a Non-Significant Risk (NSR) study, as well as a subsequent small clinical trial (e.g., Early Feasibility Study). The clinical trial is expected to provide information about the device function or final design that cannot be practically obtained through additional non-clinical assessments (e.g., bench top or animal studies) due to the novelty of the device or its intended use. This is a milestone-driven cooperative agreement program and will involve participation of NIH program staff in the development of the project plan and monitoring of research progress. This FOA will leverage Public-Private Partnership Programs (PPP) initiated under the NIH BRAIN Initiative, the Office of Strategic Coordination – The Common Fund's Stimulating Peripheral Activity to Relieve Conditions (SPARC) Program, and the HEAL Initiative. These programs include agreements (Memoranda of Understanding, MOU) with a number of device manufacturers willing to make such devices available, including devices and capabilities not yet market approved but appropriate for clinical research. In general, it is expected that the devices' existing safety and utility data will be sufficient to enable new IRB NSR or FDA IDE approval without the need for significant additional non-clinical data. For more

information see https://braininitiative.nih.gov/resources/brain\_ppp/index.htm, https://commonfund.nih.gov/sparc/newmarkets, and https://www.nih.gov/research-training/medical-research-initiatives/heal-initiative/public-private-partnership. Individuals, institutions, or businesses developing their own devices or that already have established collaborations with device manufacturers are welcome to apply directly to this FOA or the companion opportunities.

078982 HEAL Initiative: Clinical Devices to Treat Pain (UH3 Clinical Trial Optional)

National Institute of Neurological RFA-NS-19-Disorders and Stroke/NIH/DHHS 018 22-May-2019 [LOI/Pre-App] [Optional]

Not Specified

Contact Name Nick Langhals, PhD

Contact Telephone 301-496-1447

Synopsis

Contact Email <u>nick.langhals@nih.gov</u>

**Sponsor Website** 

Program URL <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-19-018.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-19-018.html</a>

22-May-2019 [LOI/Pre-App][Optional], 21-Jun-2019, 21-Sep-2019 [LOI/Pre-App][Optional], 21-Oct-2019, 22-Jan-2020 [LOI/Pre-App]

Deadline Dates (ALL) App][Optional], 21-Feb-2020 , 23-May-2020 [LOI/Pre-App][Optional], 22-Jun-2020 , 21-Sep-2020 [LOI/Pre-App][Optional], 21-Oct-2020 , 22-Jan-2021 [LOI/Pre-App][Optional], 21-Feb-2021

Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to encourage investigators to pursue a small clinical trial to

١	SPIN ID	Program	Sponsor Name	Sponsor Number	Deadline Date	Funding
1	SF IIV ID	Title	Sponsor Name	Sponsor Number		Amount

obtain critical information necessary to advance recording and/or stimulating devices to treat pain with innovative, targeted, and non-addictive diagnostic and/or therapeutic devices that improve patient outcomes and decrease or eliminate the need to prescribe opioids. Clinical studies supported may consist of acute or short-term procedures that are deemed Non-Significant Risk (NSR) by an Institutional Review Board (IRB), or Significant Risk (SR) studies that require an Investigational Device Exemption (IDE) from the FDA, such as chronic implants. The clinical trial should provide data to answer key questions about the function or final design of a device and is expected to provide information that cannot be practically obtained through additional non-clinical assessments (e.g., bench top or animal studies) due to the novelty of the device or its intended use. This is a milestone-driven cooperative agreement program and will involve participation of NIH program staff in the development of the project plan and monitoring of research progress. This FOA will leverage Public-Private Partnership Programs (PPP) initiated under the NIH BRAIN Initiative, the Office of Strategic Coordination – The Common Fund's Stimulating Peripheral Activity to Relieve Conditions (SPARC) Program, and the HEAL Initiative. These programs include agreements (Memoranda of Understanding, MOU) with a number of device manufacturers willing to make such devices available, including devices and capabilities not yet market approved but appropriate for clinical research. In general, it is expected that the devices' existing safety and utility data will be sufficient to enable new IRB NSR or FDA IDE approval without the need for significant additional non-clinical data. For more information see https://braininitiative.nih.gov/resources/brain ppp/index.htm, https://commonfund.nih.gov/sparc/newmarkets, and https://www.nih.gov/research-training/medical-research-initiatives/heal-initiative/public-private-partnership. Individuals, institutions, or businesses developing their own devices or that already have established collaborations with device manufacturers are welcome to apply directly to this FOA or any of the companion opportunities.

078983

HEAL Initiative: Optimization of Non-addictive Therapies [Small Molecules and Biologics] to Treat Pain - (U44 Clinical Trial Not Allowed)

National Institute of Neurological RFA-NS-19-Disorders and Stroke/NIH/DHHS 020

04-Jun-2019

**Not Specified** 

Contact Name Michael Oshinsky

Contact Telephone 301-496-9964

Contact Email michael.oshinsky@nih.gov

Sponsor Website

Program URL https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-19-020.html

Deadline Dates (ALL) 04-Jun-2019

The purpose of this funding opportunity announcement (FOA) is to support preclinical optimization and development of safe, effective, and non-addictive small molecule and biologic therapeutics to treat pain. The goal of the program is to accelerate the optimization and development of promising small molecule and biologic hits/leads towards clinical trials. Applicants must Synopsis have a promising hit/lead, robust biological rationale for the intended approach, and identified assays for optimization of the agent. The scope of this program includes optimization and early development activities, IND-enabling studies, and assembly of Investigational New Drug (IND) application. This is a milestone-driven phased cooperative agreement program involving participation of NIH program staff in the development of the project plan and monitoring of research progress.

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
080460	Progression Markers for Cognitive Dementia (R01 Clinical Trial Not A	e Impairment in Parkinson's Disease Illowed)	National Institute of Neurologic Disorders and Stroke/NIH/DHHS	$\nu \Delta \nabla_{-} (q_{-}) (1)$	05-Jun-2019	Not Specified
	Contact Name	Debra Babcock, PhD, MD				
	Contact Telephone	301-496-9964				
	Contact Email	dbabcock@mail.nih.gov				
	Sponsor Website					
	Program URL	https://grants.nih.gov/grants/guide/pa	ı-files/PAS-19-210.html			
	Deadline Dates (ALL) 05-Jun-2019 , 07-Sep-2019 , 05-Oct-2019 , 07-Jan-2020 , 05-Feb-2020 , 07-May-2020 , 05-Jun-2020 , 07-Sep-2020 , 07-Sep-2020 , 07-Sep-2021 , 07-Sep-2021 , 07-Sep-2021 , 07-Sep-2021 , 07-Sep-2021 , 07-Jan-2022					
	Synopsis	The goal of this Funding Opportunity A for onset and progression of cognitive (PDD). The use of well-characterized plongitudinally with clinical assessments	impairment in Parkinson's Disease (P opulations of PD and PDD patients th	D) through Park nat have been, a	cinson's Disease De and can continue to	mentia
054908	Environmental Exposures and He Settings (R21)	alth: Exploration of Non-Traditional	National Institute of Nursing Research/NIH/DHHS	PA-16-273	07-May-2019	275,000 USD
	Contact Name	Mary Roary, PhD				
	Contact Telephone	301-594-2154				
	Contact Email	mary.roary@nih.gov				
	Sponsor Website					
	Program URL	http://grants.nih.gov/grants/guide/pa-	files/PA-16-273.html			
	_	http://grants.nih.gov/grants/guide/pa-07-May-2019, 16-Jun-2019, 07-Sep-20				

maintain health and prevent disease with an emphasis on the individual, family, and community which will advance nursing science. For purposes of this FOA, non-traditional settings include, but are not limited to, places such as community centers;

	D					Francisco e
SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
054907	•	pre-school and non-traditional school er schools, and playgrounds); child and old assisted living and long-term care faciliti alth: Exploration of Non-Traditional	er adult foster care facilities; older es. This FOA will use the NIH Explo National Institute of Nursing	adult day care fa	acilities; half-way h	omes; and
	Settings (R01)	I	Research/NIH/DHHS		<u> </u>	·
		Mary Roary, PhD				
	Contact Telephone					
	Sponsor Website	mary.roary@nih.gov				
	•	http://grants.nih.gov/grants/guide/pa-fi	les/PA-16-263 html			
Deadline Dates (ALL) 07-May-2019 , 05-Jun-2019 , 07-Sep-2019						
	Synopsis	National Institute of Nursing Research (Napplications forinterdisciplinary research reducing health disparities across the life and nursing homes). These settings resuspending homes, and other health conditions/cardiovascular disease, and complex encountered in community settings, phyrespiratory disease. Risk identification at maintain health and prevent disease wit science. For purposes of this FOA, non-tradictional school er schools, and playgrounds); child and old assisted living and long-term care facilitic	n aimed at promoting health, preversions and or those living or spending the lit in exposure to environmental possible diseases; including lower respirator vironmental exposures that may be established function of organs and synd symptom management included han emphasis on the individual, far aditional settings include, but are exposured by the livinonments (e.g., churches, daycar er adult foster care facilities; older	enting and limiting ime in non-tradice llutants and toxically disease, chroise exacerbated by ystems of the fetter prevention and limity, and commenot limited to, place, home-based stadult day care face.	ng symptoms and ditional settings (i.e. ns that result in headic obstructive pulm non-chemical strestus/child/adolescent pehavior changes alunity which will advances such as commischools, dormitories acilities; half-way ho	sease, and playgrounds alth risks, nonary disease, sors ce, and lower ad actions to vance nursing unity centers; s, alternative omes; and
067107	Addressing Chronic Wound Trajec (R21- Clinical Trial Optional)	ctories Through Social Genomics Researc	h National Institute of Nursing Research/NIH/DHHS	PA-17-493	07-May-2019	275,000 USD
	Contact Telephone Contact Email Sponsor Website	tullyla@mail.nih.gov	files/PA-17-493.html			

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Synopsis	07-May-2019, 16-Jun-2019, 07-Sep-20 2020, 16-Oct-2020, 07-Jan-2021  National Institute of Nursing Research approach to chronic wound risk, present environment influences gene expressio (e.g., diabetic ulcers, venous or arterial goes beyond a focus on the wound (i.e. person with the wound. A better under molecular mechanisms is needed to addimproving healing outcomes and quality award mechanism.	NINR) invites applications for clinic ce, progression, and healing. The find in and how this gene expression manulcers) are multidimensional and, a repairing the skin and underlying the standing of social environmental factorics therapeutic strategies aimed	al research that apeld of social genon by in turn impact he s such, there is be sissue) to include a ctors (positive and at reducing chroni	oplies a social genomics focuses on ho ealth outcomes. Conefit to a holistic an approach that for negative) and associated wound risk in administration.	omics ow the social Chronic wounds approach that ocuses on the sociated Idition to
067106	Addressing Chronic Wound Traject (R01- Clinical Trial Optional)	ctories Through Social Genomics Researc	h National Institute of Nursing Research/NIH/DHHS	PA-17-492	07-May-2019	Not Specified
	Contact Name	Lois Tully, PhD				
	Contact Telephone	301-594-5968				
	Contact Email	tullyla@mail.nih.gov				
	Sponsor Website					
	Program URL	https://grants.nih.gov/grants/guide/pa	files/PA-17-492.html			
	Deadline Dates (ALL)	07-May-2019 , 05-Jun-2019 , 07-Sep-20 2020 , 05-Oct-2020 , 07-Jan-2021	19 , 05-Oct-2019 , 07-Jan-2020 , 05-	-Feb-2020 , 07-Ma	y-2020 , 05-Jun-20	)20 , 07-Sep-
	Synopsis	National Institute of Nursing Research approach to chronic wound risk, present environment influences gene expressio (e.g., diabetic ulcers, venous or arterial goes beyond a focus on the wound (i.e. person with the wound. A better under molecular mechanisms is needed to addimproving healing outcomes and quality	ce, progression, and healing. The fig n, and how this gene expression ma ulcers) are multidimensional and, a repairing the skin and underlying t standing of social environmental fac vance therapeutic strategies aimed	eld of social genon by in turn impact he s such, there is be cissue) to include a ctors (positive and at reducing chroni	nics focuses on ho ealth outcomes. Conefit to a holistic an approach that for negative) and asson wound risk in additional for the coneficial for	ow the social Chronic wounds approach that ocuses on the sociated Idition to
065708	Symptom Cluster Characterization	n in Chronic Conditions (R01)	National Institute of Nursing Research/NIH/DHHS	PA-17-462	07-May-2019	Not Specified
	Contact Name Contact Telephone	Michelle R.J. Hamlet, PhD 301-496-9623				

	_					
SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		1				_
	Contact Email	Michelle.hamlet@nih.gov				
	Sponsor Website					
	Program URL	https://grants.nih.gov/grants/guide/pa-f				
	Deadline Dates (ALL)	07-May-2019 , 05-Jun-2019 , 07-Sep-201 2020 , 05-Oct-2020 , 07-Jan-2021	9 , 05-Oct-2019 , 07-Jan-2020 , 05-	Feb-2020 , 07-Ma	ay-2020 , 05-Jun-20	020 , 07-Sep-
	National Institute of Nursing Research (NINR) invites applications for preclinical and clinical research and secondary data analysis on symptom cluster characterization that has potential to inform treatment and interventions that improve functional outcomes and quality of life in patients with chronic conditions. This FOA will use the NIH Research Project (R01) award mechanism.					
066276	Symptom Cluster Characterizatio	n in Chronic Conditions (R21)	National Institute of Nursing Research/NIH/DHHS	PA-17-461	07-May-2019	275,000 USD
	Contact Name	Michelle R.J. Hamlet, PhD				
	Contact Telephone	301-496-9623				
	Contact Email	Michelle.hamlet@nih.gov				
	Sponsor Website					
	Program URL	https://grants.nih.gov/grants/guide/pa-f	iles/PA-17-461.html			
	Deadline Dates (ALL)	07-May-2019 , 16-Jun-2019 , 07-Sep-201 2020 , 16-Oct-2020 , 07-Jan-2021	9 , 16-Oct-2019 , 07-Jan-2020 , 16-	Feb-2020 , 07-Ma	ay-2020 , 16-Jun-20	020 , 07-Sep-
	Synopsis	National Institute of Nursing Research ( analysis on symptom cluster characteriza functional outcomes and quality of life in Exploratory/Developmental Research Gr	ation that has potential to inform to patients with chronic conditions.	reatment and into	erventions that imp	•
066699	New Onset Depressive Symptoms Allowed)	s in Acute Illness (R01 Clinical Trial Not	National Institute of Nursing Research/NIH/DHHS	PA-17-488	07-May-2019	Not Specified
	Contact Name	Martha Matocha, PhD				
	Contact Telephone	301-594-2775				
	Contact Email	matocham@mail.nih.gov				
	Sponsor Website					
	Program URL	https://grants.nih.gov/grants/guide/pa-f	Files/PA-17-488.html			
	Deadline Dates (ALL)	07-May-2019 , 05-Jun-2019 , 07-Sep-201	9 , 05-Oct-2019 , 07-Jan-2020 , 05-	Feb-2020 , 07-Ma	ay-2020 , 05-Jun-20	020 , 07-Sep-

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		2020 , 05-Oct-2020 , 07-Jan-2021				
	Synopsis	National Institute of Nursing Research (I on the etiology of depressive symptoms to depressive symptoms may linger and affer gap in knowledge about the pathobiology the etiological factors that contribute to a holistic approach to managing recovery for mechanism.	that occur in the context of a sudde ect functional recovery long after p y that may underlie these incident and/or mitigate a trajectory of dep	en onset acute illr hysical recovery f depressive sympt ressive symptom	ness. Although it is from an acute insu coms. A greater un s may inform a pe	s known that alt, there is a aderstanding of rsonalized,
068672	Reducing Health Disparities Amor (R21 Clinical Trial Optional)	ng Minority and Underserved Children	National Institute of Nursing Research/NIH/DHHS	PA-18-169	07-May-2019	275,000 USD
	Contact Name	May Roary, PhD				
	Contact Telephone	301-594-2154				
	Contact Email	mary.roary@nih.gov				
	Sponsor Website					
	Program URL	https://grants.nih.gov/grants/guide/pa-f	<u>iles/PA-18-169.html</u>			
	Deadline Dates (ALL)	07-May-2019 , 16-Jun-2019 , 07-Sep-2019	9 , 16-Oct-2019 , 07-Jan-2020			
National Institute of Nursing Research (NINR) and National Institute on Deafness and Other Com (NIDCD) invite applications to conduct research that targets the reduction of health disparities at early childhood development is essential. Specific targeted areas of research include bio-behavi multiple factors that influence child health disparities such as biological (e.g., genetics, cellular, sometimes) social (e.g., peers), economic, in family influences; studies that target the specific health promotion needs of children with a kno disability; and studies that test, evaluate, translate, and disseminate health promotion prevention conducted in traditional and non-traditional settings. This program will use the NIH R21 Explorate					es among children avioral studies tha ar, organ systems) , institutional, and known health cond ntion and interven	. Investing in at incorporate , lifestyle dultural and dition and/or ntions
068671	Reducing Health Disparities Amou (R01 Clinical Trial Optional)	ng Minority and Underserved Children	National Institute of Nursing Research/NIH/DHHS	PA-18-152	07-May-2019	Not Specified
	Contact Name	May Roary, PhD				
	Contact Telephone	301-594-2154				
	Contact Email	mary.roary@nih.gov				
	Sponsor Website					

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Deadline Dates (ALL)  Synopsis	https://grants.nih.gov/grants/guide/pa-for-May-2019, 05-Jun-2019, 07-Sep-201 National Institute of Nursing Research (NIDCD) invite applications to conduct reearly childhood development is essentia multiple factors that influence child heal factors, environmental (e.g., physical and family influences; studies that target the disability; and studies that test, evaluate conducted in traditional and non -traditional and non -trad	9, 05-Oct-2019, 07-Jan-2020  JINR) and National Institute on Dealesearch that targets the reduction of the search that targeted areas of research disparities such as biological (e.g. diffamily environments) social (e.g., specific health promotion needs of translate, and disseminate health	of health disparit th include bio-belg., genetics, cellu peers), economi of children with a promotion prevo	ies among children havioral studies tha lar, organ systems) c, institutional, and known health concention and interver	Investing in at incorporate In
068670		ent in Children and Adolescents (R21	National Institute of Nursing Research/NIH/DHHS	PA-18-168	07-May-2019	275,000 USD
	Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis	Dr. Rebecca Roof  301-594-5971  Rebecca.Roof@nih.gov  https://grants.nih.gov/grants/guide/pa-f 07-May-2019 , 16-Jun-2019 , 07-Sep-201  National Institute of Nursing Research (Nin children and adolescents with chronic and their families. Children with a chronic file FOA encourages research that takes differences, biological and psychological healthcare system factors, technological Exploratory/Developmental Research Gr	19, 16-Oct-2019, 07-Jan-2020  IINR) invites applications for resear conditions. Managing a chronic condition and their families have into consideration various factors factors, family/caregivers and soci advances, and the role of the envi	ndition is an unre a long-term resp that influence se ocultural context	emitting responsibi consibility for self-relf-management su t, family-communit	ility for children management. ch as individual y dynamics,
068669	Chronic Condition Self-Manageme	ent in Children and Adolescents (R01	National Institute of Nursing Research/NIH/DHHS	PA-18-151	07-May-2019	Not Specified
	Contact Name Contact Telephone	Dr. Rebecca Roof 301-594-5971				

Contact Email Rebecca.Roof@nih.gov

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Sponsor Website Program URL	https://grants.nih.gov/grants/guide/pa-f	iles/PA-18-151.html			
	Deadline Dates (ALL)	07-May-2019 , 05-Jun-2019 , 07-Sep-201	9 , 05-Oct-2019 , 07-Jan-2020			
	Synopsis	National Institute of Nursing Research (Nin children and adolescents with chronic and their families. Children with a chronic This FOA encourages research that takes differences, biological and psychological healthcare system factors, technological Project (R01) award mechanism.	conditions. Managing a chronic concept condition and their families have into consideration various factors factors, family/caregivers and socio	ndition is an unre a long-term respo that influence sel ocultural context,	mitting responsibi onsibility for self-r f-management su family-communit	lity for children nanagement. ch as individual y dynamics,
068646	Health Promotion Among Racial a Trial Optional)	and Ethnic Minority Males (R21 Clinical	National Institute of Nursing Research/NIH/DHHS	PA-18-162	07-May-2019	275,000 USD
	Contact Name	Mary C. Roary, Ph.D.				
	Contact Telephone	301-594-2154				
	Contact Email	mary.roary@nih.gov				
	Sponsor Website					
	Program URL	https://grants.nih.gov/grants/guide/pa-f	iles/PA-18-162.html			
	Deadline Dates (ALL)	07-May-2019 , 16-Jun-2019 , 07-Sep-201	9 , 16-Oct-2019 , 07-Jan-2020			
	Synopsis	National Institute of Nursing Research (Northern of minority men. Specifically, this initiative sociodemographic, community, societal, males across the life cycle, and 2) encour linguistically appropriate health-promoti diverse males age 18 and older. This FOA mechanism.	ve is intended to: 1) enhance our uppersonal) influencing the health prorage applications focusing on the dengined to reduce	nderstanding of the comoting behavio evelopment and t e health disparition	he numerous factors of racial and ethe esting of culturally es among racially a	ors (e.g., nnic minority y and and ethnically
068645	Health Promotion Among Racial a Trial Optional)	and Ethnic Minority Males (R01 Clinical	National Institute of Nursing Research/NIH/DHHS	PA-18-144	07-May-2019	Not Specified
	Contact Name	Mary C. Roary, Ph.D.				
	Contact Telephone	301-594-2154				
	Contact Email	mary.roary@nih.gov				
	Sponsor Website					

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Deadline Dates (ALL) Synopsis	https://grants.nih.gov/grants/guide/pa-fi 07-May-2019, 05-Jun-2019, 07-Sep-2019 National Institute of Nursing Research (Ni invite applications that propose to stimula intended to: 1) enhance our understandir influencing the health promoting behavior applications focusing on the development interventions designed to reduce health of will use the NIH Research Project (R01) as	9, 05-Oct-2019, 07-Jan-2020 INR) and National Institute of Diakate and expand research in the hears of the numerous factors (e.g., sors of racial and ethnic minority mand testing of culturally and ling disparities among racially and ethnic	ealth of minority mociodemographic, ales across the life uistically appropri	nen. Specifically, the community, socion cycle, and 2) enconate health-promo	his initiative is etal, personal) ourage ting
068648	Use of Technology to Enhance Pat Clinical Trial Optional)	tient Outcomes and Prevent Illness (R21	National Institute of Nursing Research/NIH/DHHS	PA-18-145	07-May-2019	275,000 USD
	Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL)	Augie Diana, Ph.D.  301-402-6423  dianaa@mail.nih.gov  https://grants.nih.gov/grants/guide/pa-fi 07-May-2019, 16-Jun-2019, 07-Sep-2019 National Institute of Nursing Research (NIDCD) invites applications for clinical readdress patient outcomes. Relevant areas robotics to enhance medication adherence access and adherence, web-based decision intervention development, or intervention technologies to explain and predict patien and d) facilitate effective long-term manaresearch should identify specific patient of interventions proposed should clearly indicentings, and/or in the home and communications.	O, 16-Oct-2019, 07-Jan-2020  NINR) and National Institute on Desearch focused on the development of technology include remote here, on-site (e.g., clinical or home son support tools, and others. Research project trajectories, b) inform interventing memoral of the control of t	ent and utilization calthcare delivery to etting) care delive earch projects may ects that a) incorptions, c) support recially needed. Crom technological acts to ent benefits in env	of technologies the to patients via tele ry, mobile heath to focus on assessmentate emerging an eal-time clinical deficition to this FOA, approaches. The sironments, such a	nat can help chealth, co increase nent, diagnosis, nd cutting edge ecision making, proposed pecific tools or s clinical
068647	Use of Technology to Enhance Pat Clinical Trial Optional)	tient Outcomes and Prevent Illness (R01	National Institute of Nursing Research/NIH/DHHS	PA-18-145	07-May-2019	Not Specified
	Contact Name	Augie Diana, Ph.D.				

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount		
	Contact Telephone	301-402-6423						
	Contact Email	dianaa@mail.nih.gov						
	Sponsor Website							
	Program URL	https://grants.nih.gov/grants/guide/p	a-files/PA-18-145.html					
	Deadline Dates (ALL)	07-May-2019 , 05-Jun-2019 , 07-Sep-2019 , 05-Oct-2019 , 07-Jan-2020						
	Synopsis	National Institute of Nursing Research (NIDCD) invites applications for clinical address patient outcomes. Relevant an robotics to enhance medication adher access and adherence, web-based decintervention development, or interventechnologies to explain and predict paland d) facilitate effective long-term mare research should identify specific patient interventions proposed should clearly settings, and/or in the home and communications.	I research focused on the development reas of technology include remote herence, on-site (e.g., clinical or home strain support tools, and others. Research projection implementation. Research projection trajectories, b) inform interven an agement of chronic illness are espent outcomes expected to improve from indicate how they will enhance paties.	ent and utilization ealthcare delivery etting) care deliver earch projects ma ects that a) incort tions, c) support ecially needed. On technological ent benefits in en	n of technologies they to patients via televery, mobile heath fay focus on assessing porate emerging a real-time clinical discritical to this FOA, approaches. The sayironments, such a	nat can help ehealth, to increase nent, diagnosis, nd cutting edge ecision making, proposed specific tools or as clinical		
068644	Symptom Management in HIV-Inf Conditions (R21 Clinical Trial Option		National Institute of Nursing Research/NIH/DHHS	PA-18-161	07-May-2019	275,000 USD		
	Contact Name	Rebecca Henry, PhD, BSN, RN						
	Contact Telephone	301-594-5976						
	Contact Email	Rebecca.Henry@nih.gov						
	Sponsor Website							
	Program URL	https://grants.nih.gov/grants/guide/p	a-files/PA-18-161.html					
	Deadline Dates (ALL)	07-May-2019 , 16-Jun-2019 , 07-Sep-2	019 , 16-Oct-2019 , 07-Jan-2020					
	Synopsis	National Institute of Nursing Research innovative cost-effective strategies to (HANA) and other comorbidities amon Exploratory/Developmental Research	prevent, identify and manage sympt ng older adults with prolonged HIV in	oms of HIV-assoc	ciated Non-AIDS co	nditions		
068642	Symptom Management in HIV-Inf Conditions (R01 Clinical Trial Option	·	National Institute of Nursing Research/NIH/DHHS	PA-18-143	07-May-2019	Not Specified		
	Contact Name	Rebecca Henry, PhD, BSN, RN						

SPIN ID	Program Title	Sponsor Name	Sponsor Number		<b>Deadline Date</b>	Funding Amount		
	Contact Telephone	301-594-5976						
	•	Rebecca.Henry@nih.gov						
	Sponsor Website							
	·	https://grants.nih.gov/grants/guide/pa-	files/PA-18-143 html					
		7-May-2019, 05-Jun-2019, 07-Sep-2019, 05-Oct-2019, 07-Jan-2020						
	Synopsis	National Institute of Nursing Research (	NINR) invites applications for resear	oms of HIV-assoc	iated Non-AIDS co	nditions		
065717	Symptom Cluster Characterization	on in Chronic Conditions (R21)	National Institute of Nursing Research/NIH/DHHS	PA-17-461	07-May-2019	275,000 USD		
	Contact Name	Michelle R.J. Hamlet, PhD						
	Contact Telephone	301-496-9623						
	Contact Emai	Michelle.hamlet@nih.gov						
	Sponsor Website							
	Program URL	https://grants.nih.gov/grants/guide/pa-	files/PA-17-461.html					
	Deadline Dates (ALL)	07-May-2019 , 16-Jun-2019 , 07-Sep-20 2020 , 16-Oct-2020 , 07-Jan-2021	19 , 16-Oct-2019 , 07-Jan-2020 , 16-	Feb-2020 , 07-M	ay-2020 , 16-Jun-2	020 , 07-Sep-		
	Synopsis	National Institute of Nursing Research analysis on symptom cluster characterize functional outcomes and quality of life i R21 Exploratory/Developmental Resear	ration that has potential to inform t n patients with chronic conditions.	reatment and int	erventions that im	•		
068626	Environmental Exposures and He Settings (R21 Clinical Trial Option	ealth: Exploration of Non-Traditional	National Institute of Nursing Research/NIH/DHHS	PA-18-160	07-May-2019	275,000 USD		
	Contact Name	Mary Roary, PhD						
	Contact Telephone	301-594-2154						
	Contact Emai	mary.roary@nih.gov						
	Sponsor Website							
	Program URL	https://grants.nih.gov/grants/guide/pa-	files/PA-18-160.html					
	Deadline Dates (ALL)	07-May-2019 , 16-Jun-2019 , 07-Sep-20	19					

	SPIN ID	Program	Sponsor Name	Sponsor Number	Deadline Date	Funding
ı	), II <b>Q</b> 10	Title	Sponsor Hame		Deddinie Date	Amount

National Institute of Nursing Research (NINR) and National Institute of Environmental Health Sciences (NIEHS) invite applications for interdisciplinary research aimed at promoting health, preventing and limiting symptoms and disease, and reducing health disparities across the lifespan for those living or spending time in non-traditional settings (i.e. playgrounds and nursing homes). These settings result in exposure to environmental pollutants and toxins that result in health risks, symptoms, and other health conditions/diseases; including lower respiratory disease, chronic obstructive pulmonary disease, cardiovascular disease, and complex environmental exposures that may be exacerbated by non-chemical stressors encountered in community settings, physiological function of organs and systems of the fetus/child/adolescence, and lower respiratory disease. Risk identification and symptom management include prevention and behavior changes and actions to maintain health and prevent disease with an emphasis on the individual, family, and community which will advance nursing science. For purposes of this FOA, non-traditional settings include, but are not limited to, places such as community centers; pre-school and non-traditional school environments (e.g., churches, daycare, home-based schools, dormitories, alternative schools, and playgrounds); child and older adult foster care facilities; older adult day care facilities; half-way homes; and assisted living and long-term care facilities. This FOA will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.

Synopsis

Environmental Exposures and Health: Exploration of Non-Traditional Settings (R01 Clinical Trial Optional)

National Institute of Nursing Research/NIH/DHHS

PA-18-142

07-May-2019

**Not Specified** 

Contact Name Mary Roary, PhD

Contact Telephone 301-594-2154

Contact Email mary.roary@nih.gov

Sponsor Website

Program URL https://grants.nih.gov/grants/guide/pa-files/PA-18-142.html

Deadline Dates (ALL) 07-May-2019, 05-Jun-2019, 07-Sep-2019

National Institute of Nursing Research (NINR) and National Institute of Environmental Health Sciences (NIEHS) invite applications for interdisciplinary research aimed at promoting health, preventing and limiting symptoms and disease, and reducing health disparities across the lifespan for those living or spending time in non-traditional settings (i.e. playgrounds and nursing homes). These settings result in exposure to environmental pollutants and toxins that result in health risks, symptoms, and other health conditions/diseases; including lower respiratory disease, chronic obstructive pulmonary disease, Synopsis cardiovascular disease, and complex environmental exposures that may be exacerbated by non-chemical stressors encountered in community settings, physiological function of organs and systems of the fetus/child/adolescence, and lower respiratory disease. Risk identification and symptom management include prevention and behavior changes and actions to

maintain health and prevent disease with an emphasis on the individual, family, and community which will advance nursing science. For purposes of this FOA, non-traditional settings include, but are not limited to, places such as community centers; pre-school and non-traditional school environments (e.g., churches, daycare, home-based schools, dormitories, alternative

068624

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		schools, and playgrounds); child and olde and assisted living and long-term care fa		•	•	
067127	Implementing the Most Successful Outcomes in U.S. Communities (F	ul Interventions to Improve HIV/AIDS R21- Clinical Trial Optional)	National Institute of Nursing Research/NIH/DHHS	PAR-17-490	07-May-2019	275,000 USD
	Contact Name	Rebecca Henry, PhD, RN				
	Contact Telephone	301-594-5976				
	Contact Email	rebecca.henry@nih.gov				
	Sponsor Website					
	Program URL	https://grants.nih.gov/grants/guide/pa-f	files/PAR-17-490.html			
	Deadline Dates (ALL)	07-May-2019 , 16-Jun-2019 , 07-Sep-201 2020 , 16-Oct-2020 , 07-Jan-2021	9 , 16-Oct-2019 , 07-Jan-2020 , 16-	Feb-2020 , 07-M	ay-2020 , 16-Jun-2	020 , 07-Sep-
	Synopsis	National Institute of Nursing Research (invite applications to translate and adapt to marginalized populations in the Unite to produce improvements in HIV-related durably reach them with timely HIV testi UNAIDS 90-90-90 benchmarks: by 2020, people with diagnosed HIV infection will antiretroviral therapy will have viral support of the product of the	t the most successful global, evider d States (U.S.) with a substantial ris health outcomes in these key poping, prevention and treatment tech 90 percent of all people living with receive sustained antiretroviral the	nce-based HIV-re k of HIV-infectio ulations through nologies that lea HIV will know the erapy and 90 per	elated service proving an and AIDS. The ultook strategies that such the achievement of the status, 90 percent of all people recent all people re	sion strategies timate goal, is cessfully and ent of the percent of all receiving
067124	Implementing the Most Successful Outcomes in U.S. Communities (F	ul Interventions to Improve HIV/AIDS R01- Clinical Trial Optional)	National Institute of Nursing Research/NIH/DHHS	PAR-17-491	07-May-2019	Not Specified
	Contact Name	Rebecca Henry, PhD, RN				
	Contact Telephone	301-594-5976				
	Contact Email	rebecca.henry@nih.gov				
	Sponsor Website					
	Program URL	https://grants.nih.gov/grants/guide/pa-f	files/PAR-17-491.html			
	Deadline Dates (ALL)	07-May-2019 , 05-Jun-2019 , 07-Sep-201 2020 , 05-Oct-2020 , 07-Jan-2021	.9 , 05-Oct-2019 , 07-Jan-2020 , 05-	Feb-2020 , 07-M	ay-2020 , 05-Jun-2	020 , 07-Sep-
	Synopsis	National Institute of Nursing Research ( invite applications to translate and adap				

	-					
SPIN ID	Program Title	Sponsor Name	Sponsor Number		<b>Deadline Date</b>	Funding Amount
		to marginalized populations in the United to produce improvements in HIV-related durably reach them with timely HIV testing UNAIDS 90-90-90 benchmarks: by 2020, 9 people with diagnosed HIV infection will antiretroviral therapy will have viral supp	health outcomes in these key popung, prevention and treatment technoon percent of all people living with receive sustained antiretroviral the	ulations through s nologies that lead HIV will know the erapy and 90 perc	strategies that suc I to the achievemonic Fir HIV status, 90 p ent of all people r	cessfully and ent of the percent of all eceiving
068668	<u>Promoting Caregiver Health Using Optional)</u>	Self-Management (R01 Clinical Trial	National Institute of Nursing Research/NIH/DHHS	PA-18-150	07-May-2019	Not Specified
	Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis	Karen Huss, PhD, RN, APRN-BC, FAAN, FA 301-594-5970 hussk@mail.nih.gov https://grants.nih.gov/grants/guide/pa-f 07-May-2019 , 05-Jun-2019 , 07-Sep-2019 National Institute of Nursing Research (N management. Caregiving is an important growing. Informal caregivers (lay caregiv or neighbors) involved in assisting others delivering care in one's home or care sett caregivers. This FOA will use the NIH Rese	iles/PA-18-150.html 9, 05-Oct-2019, 07-Jan-2020, 05-F JINR) invites applications for resear s science area since the number of pers) are defined as unpaid individu with activities of daily living and/otings (daycare, residential care facil	rch in promoting opeople living long als (spouses, part r medical tasks. I lity). This concep	caregiver health u ger with chronic co ners, family mem Formal caregivers	onditions is bers, friends, are paid,
068660	Addressing Unmet Needs in Personal Symptoms and Improve Quality of the Symptoms and Improve Quality of	ons with Dementia to Decrease Behaviora f Life (R21 Clinical Trial Optional)	National Institute of Nursing Research/NIH/DHHS	PA-18-165	07-May-2019	275,000 USD
	Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis	Lois A. Tully, PhD 301-594-5968 tullyla@mail.nih.gov  https://grants.nih.gov/grants/guide/pa-fi 07-May-2019 , 16-Jun-2019 , 07-Sep-2019 National Institute of Nursing Research (I psychological symptoms of dementia (BP in persons with dementia. This FOA will u	9 , 16-Oct-2019 , 07-Jan-2020 NINR) invites applications for clinica SD) and the association of BPSD wi	th unmet physica	ıl, social, or enviro	nmental needs

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
068667	Palliative Care Needs of Individuals v Family Caregivers (R21 Clinical Trial	with Rare Advanced Diseases and Their Optional)	National Institute of Nursing Research/NIH/DHHS	PA-18-167	07-May-2019	275,000 USD
	Contact Telephone 30 Contact Email acc Sponsor Website Program URL ht Deadline Dates (ALL)	rnn S. Adams, Ph.D. 01-594-8911 damsls@mail.nih.gov ttps://grants.nih.gov/grants/guide/pa-fi 7-May-2019, 16-Jun-2019, 07-Sep-2019	9 , 16-Oct-2019 , 07-Jan-2020	(NCI) invite app	olications for resea	rch to expand
	Synopsis kn	nowledge and increase the evidence bas nprove physical and psychosocial well-b nregivers. This FOA will use the NIH R21	se for palliative care (PC) in advance eing and quality of life among serio	ed rare diseases usly ill individua	, including rare can als and their family	•
068666	Palliative Care Needs of Individuals v Family Caregivers (R01 Clinical Trial	with Rare Advanced Diseases and Their Optional)	National Institute of Nursing Research/NIH/DHHS	PA-18-149	07-May-2019	Not Specified
	Contact Name Ly	nn S. Adams, Ph.D.				
	Contact Telephone 30	01-594-8911				
	Contact Email <u>ad</u>	damsls@mail.nih.gov				
	Sponsor Website					
		tps://grants.nih.gov/grants/guide/pa-fi				
		7-May-2019 , 05-Jun-2019 , 07-Sep-2019				
	Synopsis kn	National Institute of Nursing Research (Nowledge and increase the evidence bashprove physical and psychosocial well-buregivers. This FOA will use the NIH Reseated	se for palliative care (PC) in advance eing and quality of life among serio	ed rare diseases usly ill individua	, including rare can	•
066708	New Onset Depressive Symptoms in Allowed)	Acute Illness (R21 Clinical Trial Not	National Institute of Nursing Research/NIH/DHHS	PA-17-487	07-May-2019	275,000 USD
<del></del>	Contact Name M	artha Matocha, PhD				
	Contact Telephone 30	01-594-2775				
	Contact Email <u>m</u>	atocham@mail.nih.gov				
	Sponsor Website					

	Program			_		Funding
SPIN ID	Title	Sponsor Name	Sponsor Number		Deadline Date	Amount
					•	
		https://grants.nih.gov/grants/guide/pa-f				
	Deadline Dates (ALL)	07-May-2019 , 16-Jun-2019 , 07-Sep-201 2020 , 16-Oct-2020 , 07-Jan-2021	9 , 16-Oct-2019 , 07-Jan-2020 , 16-	Feb-2020 , 16-Ma	ay-2020 , 05-Jun-20	020 , 07-Sep-
		National Institute of Nursing Research (I on the etiology of depressive symptoms of depressive symptoms of depressive symptoms may linger and affect gap in knowledge about the pathobiology the etiological factors that contribute to holistic approach to managing recovery of Research Grant award mechanism.	that occur in the context of a sudd ect functional recovery long after p y that may underlie these incident and/or mitigate a trajectory of dep	en onset acute ill ohysical recovery depressive symporessive symporessive symptom	ness. Although it is from an acute insu toms. A greater un is may inform a pe	known that lt, there is a derstanding of rsonalized,
068658	Addressing Unmet Needs in Person Symptoms and Improve Quality of	ons with Dementia to Decrease Behaviora of Life (R01 Clinical Trial Optional)	National Institute of Nursing Research/NIH/DHHS	PA-18-147	07-May-2019	Not Specified
	Contact Name	Lois A. Tully, PhD				
	Contact Telephone	301-594-5968				
	Contact Email	tullyla@mail.nih.gov				
	Sponsor Website					
	Program URL	https://grants.nih.gov/grants/guide/pa-f	iles/PA-18-147.html			
	Deadline Dates (ALL)	07-May-2019 , 05-Jun-2019 , 07-Sep-201	9 , 05-Oct-2019 , 07-Jan-2020			
	Synopsis	National Institute of Nursing Research (Ipsychological symptoms of dementia (BP in persons with dementia. This FOA will uppersons with demential in persons with demential in	PSD) and the association of BPSD w	rith unmet physica	al, social, or enviro	
068653	<u>Self-Management Interventions a</u> <u>Optimize Functional Capabilities (</u>	and Technologies to Sustain Health and (R21 Clinical Trial Optional)	National Institute of Nursing Research/NIH/DHHS	PA-18-164	07-May-2019	275,000 USD
	Contact Name	Karen Huss, PhD, RN, APRN-BC, FAAN, FA	AAAI			
	Contact Telephone	301-594-5970				
	Contact Email	hussk@mail.nih.gov				
	Sponsor Website					
	Program URL	https://grants.nih.gov/grants/guide/pa-f	iles/PA-18-164.html			
	Deadline Dates (ALL)	07-May-2019 , 16-Jun-2019 , 07-Sep-201	9 , 16-Oct-2019 , 07-Jan-2020			
	Synopsis	National Institute of Nursing Research (I	NINR) and National Institute on De	eafness and Other	Communication D	isorders

	Duanuau					Francisco
SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		(NIDCD) invite applications for clinical requality of life in persons needing assistant disabilities and navigate their environmentallored to individuals' existing functional mental capabilities. Of particular interest cardiac and respiratory insufficiency, move physical or cognitive disabilities. This FOA mechanism.	ce to optimize and maintain existing to the research focus encompasse abilities and interests and is intended in the research designed to maintain from the rement impairment associated with the research designed to maintain from the rement impairment associated with the research designed to maintain from the rement impairment associated with the research designed to maintain from the research designed to maintain the research designed to maintain the research designed to maintain existing the research designed to maintain the research designed the research designed to maintain the research designed the re	ng functional capes maintenance/ ded to enhance functional capab h arthritis, chror	pabilities, prevent/orabilities, prevent/orative care the physical, sensory, or illities in such condonic back pain, strok	delay at can be motor, and itions as e, and other
068651	Self-Management Interventions a Optimize Functional Capabilities (	nd Technologies to Sustain Health and R01 Clinical Trial Optional)	National Institute of Nursing Research/NIH/DHHS	PA-18-146	07-May-2019	Not Specified
	Contact Name	Karen Huss, PhD, RN, APRN-BC, FAAN, FA	AAAI			
	Contact Telephone	301-594-5970				
	Contact Email	hussk@mail.nih.gov				
	Sponsor Website					
	Program URL	https://grants.nih.gov/grants/guide/pa-fi	<u>les/PA-18-146.html</u>			
	Deadline Dates (ALL)	07-May-2019, 05-Jun-2019, 07-Sep-2019	9 , 05-Oct-2019 , 07-Jan-2020			
	Synopsis	National Institute of Nursing Research (NIDCD) invite applications for clinical requality of life in persons needing assistant disabilities and navigate their environmentallored to individuals' existing functional mental capabilities. Of particular interest cardiac and respiratory insufficiency, move physical or cognitive disabilities. This FOA	search on self-management intervo ce to optimize and maintain existin nt. The research focus encompasse abilities and interests and is inten- is research designed to maintain for wement impairment associated wit	entions and teching functional capes maintenance/ded to enhance functional capabh arthritis, chror	nologies that improabilities, prevent/orative care the physical, sensory, relities in such conductoric back pain, strok	ove health and delay at can be motor, and itions as
069974	Building Evidence: Effective Pallia Clinical Trial Optional)	tive/End of Life Care Interventions (R01	National Institute of Nursing Research/NIH/DHHS	PAR-18-173	11-May-2019 [LOI/Pre-App] [Optional]	Not Specified
	Contact Name	Lynn S. Adams, PhD				
	Contact Telephone	301-594-8911				
	Contact Email	adamsIs@mail.nih.gov				

Sponsor Website

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	_	https://grants.nih.gov/grants/guide/pa-f				
	Synopsi	National Institute of Nursing Research (N (EOLPC) interventions/models of care that interventions and models of care are urg adults for those with serious, advanced il and/or models of care. This FOA will use	at are based on individual- and fam ently needed that address racial, et lness. Trials are needed to test effic	ily-centered outce thnic and/or cultucacy and effective	omes. The testing Iral diversity in ch	of EOLPC ildren and
069486	Family-Centered Self-Manageme Optional)	ent of Chronic Conditions (R21 Clinical Trial	National Institute of Nursing Research/NIH/DHHS	PA-18-380	07-May-2019	275,000 USD
	Contact Name	Karen Huss, PhD, RN, APRN-BC, FAAN, FA	AAAI			
	Contact Telephone	301-594-5970				
	Contact Emai	l hussk@mail.nih.gov				
	Sponsor Website					
	Program UR	https://grants.nih.gov/grants/guide/pa-f	iles/PA-18-380.html			
	Deadline Dates (ALL	07-May-2019 , 16-Jun-2019 , 07-Sep-201 2020 , 16-Oct-2020 , 07-Jan-2021	9 , 16-Oct-2019 , 07-Jan-2020 , 16-F	eb-2020 , 07-Ma	y-2020 , 16-Jun-20	020 , 07-Sep-
	Synopsi	National Institute of Nursing Research (Is management (FCSM) in chronic condition mechanism.	• • •		•	
069482	Family-Centered Self-Manageme Optional)	ent of Chronic Conditions (R01 Clinical Trial	National Institute of Nursing Research/NIH/DHHS	PA-18-383	07-May-2019	Not Specified
	Contact Name	Karen Huss, PhD, RN, APRN-BC, FAAN, FA	AAAI			
	Contact Telephone	301-594-5970				
	Contact Emai	l hussk@mail.nih.gov				
	Sponsor Website					
	Program UR	https://grants.nih.gov/grants/guide/pa-f	iles/PA-18-383.html			
	Deadline Dates (ALL	07-May-2019 , 05-Jun-2019 , 07-Sep-201 2020 , 05-Oct-2020 , 07-Jan-2021	9 , 05-Oct-2019 , 07-Jan-2020 , 05-F	eb-2020 , 07-Ma	y-2020 , 05-Jun-20	020 , 07-Sep-
	Synopsi	National Institute of Nursing Research ( management (FCSM) in chronic condition				

	_					l- "
SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
069494		th Chronic Conditions to Promote Effective , Adherence to Treatment and Self- Optional)	National Institute of Nursing Research/NIH/DHHS	PA-18-389	07-May-2019	275,000 USD
	Contact Name	Augie Diana, Ph.D.				
	Contact Telephone	301-402-6423				
	Contact Email	dianaa@mail.nih.gov				
	Sponsor Website					
	Program URL	https://grants.nih.gov/grants/guide/pa-fil	<u>es/PA-18-389.html</u>			
	Deadline Dates (ALL)	07-May-2019 , 16-Jun-2019 , 07-Sep-2019 2020 , 16-Oct-2020 , 07-Jan-2021	, 16-Oct-2019 , 07-Jan-2020 , 16-F	eb-2020 <i>,</i> 07-N	1ay-2020 , 16-Jun-2	)20 , 07-Sep-
	Synopsis	National Institute of Nursing Research (NINR) and National Institute of Biomedical Imaging and Bioengineering (NIBIB) in applications to stimulate research utilizing Mobile Health (mHealth) tools aimed at the improvement of effective patient provider communication, adherence to treatment and self-management of chronic diseases. With the rapid expansion of cellular networks and substantial advancements in Smartphone technologies, it is now possible - and affordable - to train patient data digitally from remote areas to specialists in urban areas, receive real-time feedback, and capture that consultation in a database. These mHealth tools, therefore, may facilitate more timely and effective patient-provider communication through education communication around goal setting, treatment reminders, feedback on patient progrand may improve health outcomes. This announcement encourages the development and testing of interventions utilized mHealth technologies. There is also an interest in studying mHealth technologies in underserved populations. This FOA use the NIH R21 Exploratory/Developmental Research Grant award mechanism.				
069491		th Chronic Conditions to Promote Effective , Adherence to Treatment and Self- Optional)	National Institute of Nursing Research/NIH/DHHS	PA-18-386	07-May-2019	Not Specified
	Contact Name	Augie Diana, Ph.D.				
	Contact Telephone	301-402-6423				
	Contact Email	dianaa@mail.nih.gov				
	Sponsor Website					
	Program URL	https://grants.nih.gov/grants/guide/pa-fil				
	Deadline Dates (ALL)	07-May-2019 , 05-Jun-2019 , 07-Sep-2019 2020 , 05-Oct-2020 , 07-Jan-2021	) , 05-Oct-2019 , 07-Jan-2020 , 05-f	Feb-2020 , 07-N	1ay-2020 , 05-Jun-2	)20 , 07-Sep-
	Synopsis	National Institute of Nursing Research (NI	NR) and National Institute of Biom	edical Imaging	and Bioengineering	(NIBIB) invite

SPIN ID	Program	Sponsor Name	Sponsor Number	Deadline Date	Funding	
1	SPIN ID	Title	Sponsor Name	Sponsor Number	Deadine Date	Amount

applications to stimulate research utilizing Mobile Health (mHealth) tools aimed at the improvement of effective patient provider communication, adherence to treatment and self-management of chronic diseases. With the rapid expansion of cellular networks and substantial advancements in Smartphone technologies, it is now possible - and affordable - to transmit patient data digitally from remote areas to specialists in urban areas, receive real-time feedback, and capture that consultation in a database. These mHealth tools, therefore, may facilitate more timely and effective patient-provider communication through education communication around goal setting, treatment reminders, feedback on patient progress, and may improve health outcomes. This announcement encourages the development and testing of interventions utilizing mHealth technologies. There is also an interest in studying mHealth technologies in underserved populations. This FOA will use the NIH Research Project (R01) award mechanism.

069458

ealthy Habits: Timing for Developing Sustainable Healthy Behaviors in Children and Adolescents (R21 Clinical Trial Optional)

National Institute of Nursing Research/NIH/DHHS

PA-18-354

07-May-2019

275,000 USD

Contact Name Mary C. Roary, Ph.D.

Contact Telephone 301-594-2154

Contact Email mary.roary@nih.gov

Sponsor Website

Program URL https://grants.nih.gov/grants/guide/pa-files/PA-18-354.html

Deadline Dates (ALL)

07-May-2019, 16-Jun-2019, 07-Sep-2019, 16-Oct-2019, 07-Jan-2020, 16-Feb-2020, 07-May-2020, 16-Jun-2020, 07-Sep-2020, 16-Oct-2020, 07-Jan-2021

The sponsors invite applications that employ innovative research to identify mechanisms of influence and/or promote positive sustainable health behavior(s) in children and youth (birth to age 21). Positive health behaviors may include: developing healthy sleep patterns, developing effective self-regulation strategies, adaptive decision-making in risk situations, practicing proper dental hygiene, eating a balanced and nutritious diet, engaging in age-appropriate physical activity and/or participating in healthy relationships. Applications to promote positive health behavior(s) should target social and cultural factors, including, but not limited to: schools, families, communities, population, food industry, age-appropriate learning tools and games, social media, social networking, technology and mass media. Topics to be addressed in this announcement Synopsis include: effective, sustainable processes for influencing young people to make healthy behavior choices; identification of the appropriate stage of influence for learning sustainable lifelong health behaviors; the role of technology and new media in promoting healthy behavior; identification of factors that support healthy behavior development in vulnerable populations, identification of barriers to healthy behaviors; and, identification of mechanisms and mediators that are common to the development of a range of habitual health behaviors. Given the many factors involved in developing sustainable health behaviors, applications from multidisciplinary teams are strongly encouraged. The ultimate goal of this FOA is to promote research that identifies and enhances processes that promote sustainable positive behavior or changes social and cultural

norms that influence health and future health behaviors. This FOA will use the NIH R21 Exploratory/Developmental Research

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		Grant award mechanism.				
069457	Healthy Habits: Timing for Develor Children and Adolescents (R01 Cl	oping Sustainable Healthy Behaviors in inical Trial Optional)	National Institute of Nursing Research/NIH/DHHS	PA-18-355	07-May-2019	Not Specified
	Contact Telephone Contact Email	mary.roary@nih.gov				
	Sponsor Website	https://grants.nih.gov/grants/guide/pa-f	Glac/DA 19 2EE html			
	Deadline Dates (ALL)	07-May-2019, 05-Jun-2019, 07-Sep-201 2020, 05-Oct-2020, 07-Jan-2021		Feb-2020 , 07-Ma	ay-2020 , 05-Jun-20	020 , 07-Sep-
	Synopsis	The sponsors invite applications that empositive sustainable health behavior(s) in developing healthy sleep patterns, devel practicing proper dental hygiene, eating participating in healthy relationships. Apfactors, including, but not limited to: sch tools and games, social media, social net include: effective, sustainable processes appropriate stage of influence for learning promoting healthy behavior; identification identification of barriers to healthy behavelopment of a range of habitual health behaviors, applications from multidiscipling research that identifies and enhances promoting that influence health and future health services are sustainable processes.	oping effective self-regulation stra a balanced and nutritious diet, eng plications to promote positive hea ools, families, communities, popul working, technology and mass me for influencing young people to m ng sustainable lifelong health beha on of factors that support healthy l viors; and, identification of mecha th behaviors. Given the many facto inary teams are strongly encourag ocesses that promote sustainable	tegies, adaptive of tegies, adaptive of gaging in age-appoint behavior(s) should be ation, food indust dia. Topics to be a take healthy behaviors; the role of the behavior developments and mediators involved in developments. The ultimate goositive behavior	n behaviors may in lecision-making in opriate physical acould target social acry, age-appropriated dressed in this action choices; identification in vulnerable ors that are commeloping sustainable to changes social action changes social actions.	clude: risk situations, ctivity and/or and cultural e learning nnouncement fication of the w media in populations, con to the e health co promote and cultural
070322	Self-Management for Health in Cl Optional)	hronic Conditions (R21 Clinical Trial	National Institute of Nursing Research/NIH/DHHS	PA-18-384	07-May-2019	275,000 USD
	Contact Name	Karen Huss, PhD, RN, APRN-BC, FAAN, FA	AAAI			

Contact Name Karen Huss, PhD, RN, APRN-BC, FAAN, FAA.
Contact Telephone 301-594-5970

Contact Email hussk@mail.nih.gov



SPIN ID	Program Title	Sponsor Name	Sponsor Number		<b>Deadline Date</b>	Funding Amount
	Program URL	https://grants.nih.gov/grants/guide/pa-fi				
	Deadline Dates (ALL)	Feb-2020 <i>,</i> 07-Ma	y-2020 , 16-Jun-20	020 , 07-Sep-		
National Institute of Nursing Research (NINR) and National Institute on Aging (NIA) invite applications for research that to build the science of self-management for health in chronic conditions. This FOA focuses on self-management as a mainstream science to reduce the burden of chronic illnesses/conditions. This FOA will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.						
070320	Self-Management for Health in Contional)	hronic Conditions (R01 Clinical Trial	National Institute of Nursing Research/NIH/DHHS	PA-18-376	07-May-2019	Not Specified
	Contact Name	Karen Huss, PhD, RN, APRN-BC, FAAN, FA	AAAI			
	Contact Telephone	301-594-5970				
	Contact Email	hussk@mail.nih.gov				
	Sponsor Website					
	Program URL	https://grants.nih.gov/grants/guide/pa-fi	les/PA-18-376.html			
	Deadline Dates (ALL)	07-May-2019 , 05-Jun-2019 , 07-Sep-2019 2020 , 05-Oct-2020 , 07-Jan-2021	9 , 05-Oct-2019 , 07-Jan-2020 , 05-	Feb-2020 , 07-Ma	y-2020 , 05-Jun-20	020 , 07-Sep-
	Synopsis	National Institute of Nursing Research (N to build the science of self-management mainstream science to reduce the burder award mechanism.	for health in chronic conditions. Th	is FOA focuses or	n self-managemen	t as a
	Biobehavioral and Technological	Interventions to Attenuate Cognitive	National Institute of Nursing			
070317	<u>Decline in Individuals with Cognit</u> Trial Optional)	ive Impairment or Dementia (R21 Clinical	National Institute of Nursing Research/NIH/DHHS	PA-18-347	07-May-2019	275,000 USD
		Lais A Tully Dh D				
		Lois A. Tully, Ph.D.				
	Contact Telephone					
	Sponsor Website	tullyla@mail.nih.gov				
	•	https://grants.nih.gov/grants/guide/pa-fi	les/DA_18_3/7 html			
	<del>-</del>	07-May-2019 16-Jun-2019 07-Son-2019		Feb-2020 , 07-Ma	y-2020 , 16-Jun-20	020 , 07-Sep-

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Synopsis	National Institute of Nursing Research (Not focused on biobehavioral or technological Alzheimer's disease, Lewy body dementic cognitive decline. There is particular interindividual, informal caregivers, or others of interest, as well as research examining It is anticipated that the results of this reimprove their ability to perform activities additionally help to reduce stress, burden Exploratory/Developmental (R21) grant in	al interventions to attenuate cognitive a, vascular dementia), mild cognitive rest in interventions that can be imp in the community. Research to infor g underlying mechanisms and bioma search will help affected individuals s of daily living (ADLs) and instrument, and other poor outcomes in their	ve decline in indice impairment (Moblemented in control the developmenters associated maintain indepental activities of control indepental	viduals with deme CI), or disease- or nmunity settings k nent of such interv with response to ndence and qualit laily living (IADLs)	entia (such as age-related by the affected rentions is also interventions. by of life, and
070314	-	Interventions to Attenuate Cognitive ive Impairment or Dementia (R01 Clinical	National Institute of Nursing Research/NIH/DHHS	PA-18-348 (	07-May-2019	Not Specified
	Contact Name	Lois A. Tully, Ph.D.				
	Contact Telephone	301-594-5968				
	Contact Email	tullyla@mail.nih.gov				
	Sponsor Website					
	Program URL	https://grants.nih.gov/grants/guide/pa-f	iles/PA-18-348.html			
	Deadline Dates (ALL)	07-May-2019 , 05-Jun-2019 , 07-Sep-201 2020 , 05-Oct-2020 , 07-Jan-2021	9 , 05-Oct-2019 , 07-Jan-2020 , 05-Fe	eb-2020 , 07-Ma	y-2020 , 05-Jun-20	)20 , 07-Sep-
	Synopsis	National Institute of Nursing Research (Not focused on biobehavioral or technological Alzheimer's disease, Lewy body dementic cognitive decline. There is particular intestindividual, informal caregivers, or others of interest, as well as research examining It is anticipated that the results of this resimprove their ability to perform activities additionally help to reduce stress, burder Project (R01) award mechanism.	al interventions to attenuate cognitive a, vascular dementia), mild cognitive rest in interventions that can be impain the community. Research to infor g underlying mechanisms and bioma search will help affected individuals s of daily living (ADLs) and instrumen	ve decline in indi e impairment (Mo plemented in con rm the developm rkers associated maintain indepe ntal activities of c	viduals with deme CI), or disease- or nmunity settings be nent of such interviting with response to Indence and quality Isily living (IADLs)	entia (such as age-related by the affected rentions is also interventions. by of life, and
070262	End-of-Life and Palliative Care He Serious, Advanced Illness (R21 Cli	alth Literacy: Improving Outcomes in nical Trial Optional)	National Institute of Nursing Research/NIH/DHHS	PA-18-499 (	07-May-2019	275,000 USD

	Drogram					Funding
SPIN ID	Program Title	Sponsor Name	Sponsor Number		<b>Deadline Date</b>	Funding Amount
	Contact Name	Lynn S. Adams, Ph.D.				
	Contact Telephone	301-594-8911				
	Contact Email	adamsls@nih.gov				
	Sponsor Website					
	Program URL	https://grants.nih.gov/grants/guide/pa-fi	iles/PA-18-499.html			
	Deadline Dates (ALL)	07-May-2019 , 16-Jun-2019 , 07-Sep-2019 2020 , 16-Oct-2020 , 07-Jan-2021 , 16-Fel	9 , 16-Oct-2019 , 07-Jan-2020 , 16- b-2021 , 07-May-2021	Feb-2020 , 07-Ma	y-2020 , 16-Jun-20	)20 , 07-Sep-
	Synopsis	National Institute of Nursing Research (Peffective end-of-life and palliative care (Estrategies, interventions, and models of cindividuals with serious, advanced illness Exploratory/Developmental Research Gra	NINR) invites applications for reseat OLPC) health literacy in diverse sectors care to improve EOLPC health literation and their families and caregivers.	ttings and populat acy, with the goal	tions, and to creat of improving outc	e novel
070260	End-of-Life and Palliative Care He Serious, Advanced Illness (R01 Cli	alth Literacy: Improving Outcomes in nical Trial Optional)	National Institute of Nursing Research/NIH/DHHS	PA-18-498	07-May-2019	Not Specified
	Contact Name	Lynn S. Adams, Ph.D.				
	Contact Telephone	301-594-8911				
	Contact Email	adamsls@nih.gov				
	Sponsor Website					
	Program URL	https://grants.nih.gov/grants/guide/pa-fi	<u>iles/PA-18-498.html</u>			
	Deadline Dates (ALL)	07-May-2019 , 05-Jun-2019 , 07-Sep-2019 2020 , 05-Oct-2020 , 07-Jan-2021 , 05-Fel	9 , 05-Oct-2019 , 07-Jan-2020 , 05- b-2021 , 07-May-2021	Feb-2020 , 07-Ma	y-2020 , 05-Jun-20	)20 , 07-Sep-
	Synopsis	National Institute of Nursing Research (I effective end-of-life and palliative care (E strategies, interventions, and models of c individuals with serious, advanced illness award mechanism.	NINR) invites applications for resea OLPC) health literacy in diverse secare to improve EOLPC health litera	ttings and populat acy, with the goal	tions, and to creat of improving outc	e novel omes for
070341	Community Partnerships to Advan Optional)	nce Research (CPAR) (R21 Clinical Trial	National Institute of Nursing Research/NIH/DHHS	PA-18-381	07-May-2019	275,000 USD
	Contact Name	Augie Diana, Ph.D.				
	Contact Telephone	301-402-6423				

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Contact Email Sponsor Website	dianaa@mail.nih.gov				
	,	https://grants.nih.gov/grants/guide/pa-f	iles/PA-18-381.html			
	Deadline Dates (ALL)	07-May-2019 16-Jun-2019 07-San-2019		Feb-2020 <i>,</i> 07-Ma	y-2020 , 16-Jun-20	)20 , 07-Sep-
	Synopsis	National Institute of Nursing Research (N Community Engaged Research (CEnR) me development and positive health outcom mechanism.	ethodologies that will enhance rela	tionships and lead	d to better interve	ention
070340	Community Partnerships to Adva Optional)	nce Research (CPAR) (R01 Clinical Trial	National Institute of Nursing Research/NIH/DHHS	PA-18-377	07-May-2019	Not Specified
	Contact Name	Augie Diana, Ph.D.				
	Contact Telephone	301-402-6423				
	Contact Email	dianaa@mail.nih.gov				
	Sponsor Website					
	Program URL	https://grants.nih.gov/grants/guide/pa-f	iles/PA-18-377.html			
	Deadline Dates (ALL)	07-May-2019 , 05-Jun-2019 , 07-Sep-2019 2020 , 05-Oct-2020 , 07-Jan-2021	9 , 05-Oct-2019 , 07-Jan-2020 , 05-	Feb-2020 <i>,</i> 07-Ma	y-2020 , 05-Jun-20	)20 , 07-Sep-
		National Institute of Nursing Research (N Community Engaged Research (CEnR) me development and positive health outcom	ethodologies that will enhance rela	tionships and lead	d to better interve	ention
070051	Obesity and Asthma: Awareness Optional)	and Self- Management (R01 Clinical Trial	National Institute of Nursing Research/NIH/DHHS	PA-18-379	07-May-2019	Not Specified
	Contact Name	Karen Huss, PhD, RN, APRN-BC, FAAN, FA	AAI			
	Contact Telephone	301-594-5970				
	Contact Email	hussk@mail.nih.gov				
	Sponsor Website					
	Program URL	https://grants.nih.gov/grants/guide/pa-f	iles/PA-18-379.html			
	Deadline Dates (ALL)	07-May-2019 , 05-Jun-2019 , 07-Sep-2019 2020 , 05-Oct-2020 , 07-Jan-2021	9 , 05-Oct-2019 , 07-Jan-2020 , 05-	Feb-2020 <i>,</i> 07-Ma	y-2020 , 05-Jun-20	)20 , 07-Sep-

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Synopsis		rch (NINR) invites applications for reseant. It seeks to build the science of obestroject (R01) award mechanism.		·	
077785	Biobehavioral Basis of Chronic Pa	in (R01 Clinical Trial Optional)	National Institute of Nursing Research/NIH/DHHS	PA-18-944	07-May-2019	Not Specified
	Contact Name	Lois A. Tully, PhD				
	Contact Telephone	301-594-5968				
	Contact Email	tullyla@mail.nih.gov				
	Sponsor Website					
	Program URL	https://grants.nih.gov/grants/guide/	pa-files/PA-18-944.html			
	Deadline Dates (ALL)		-2019 , 05-Oct-2019 , 07-Jan-2020 , 05-l 5-Feb-2021 , 07-May-2021 , 05-Jun-202			
	Synopsis	the biobehavioral basis of chronic pa assessments and the associated sens Research relating biology and behavi	unity Announcement is to encourage grain. The focus encompasses the individual sory and emotional components that union is needed to better define the individual differences in pain experiences among differences in pain experiences.	ual phenotype, nderpin the ind dual-specific b	genotype, and othe ividual's chronic paiurden of chronic pai	r omic-type n experience. n and to better
077787	Biobehavioral Basis of Chronic Pa	in (R21 Clinical Trial Optional)	National Institute of Nursing Research/NIH/DHHS	PA-18-943	07-May-2019	275,000 USD
	Contact Name	Lois A. Tully, PhD				
	Contact Telephone	301-594-5968				
	Contact Email	tullyla@mail.nih.gov				
	Sponsor Website					
	Program URL	https://grants.nih.gov/grants/guide/	pa-files/PA-18-943.html			
	Deadline Dates (ALL)		-2019 , 16-Oct-2019 , 07-Jan-2020 , 16- 6-Feb-2021 , 07-May-2021 , 16-Jun-202			
	Synopsis	the biobehavioral basis of chronic pa assessments and the associated sens	nity Announcement is to encourage grain. The focus encompasses the individually and emotional components that union is needed to better define the indivi	ual phenotype, nderpin the ind	genotype, and othe ividual's chronic pai	r omic-type n experience.

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		understand the mechanisms underlying dillness.	lifferences in pain experiences amo	ng individuals af	flicted with the sa	me chronic
077789	Applying a Biopsychosocial Persp (R21 Clinical Trial Optional)	ective to Self-Management of Chronic Pair	National Institute of Nursing Research/NIH/DHHS	PA-18-946	07-May-2019	275,000 USD
	Contact Name	Martha Matocha, PhD				
	Contact Telephone	301-594-2775				
	Contact Email	matocham@mail.nih.gov				
	Sponsor Website					
	Program URL	https://grants.nih.gov/grants/guide/pa-fi	<u>les/PA-18-946.html</u>			
	Deadline Dates (ALL)	07-May-2019 , 16-Jun-2019 , 07-Sep-2019 2020 , 16-Oct-2020 , 07-Jan-2021 , 16-Feb	9 , 16-Oct-2019 , 07-Jan-2020 , 16-F o-2021 , 07-May-2021 , 16-Jun-2021	eb-2020 , 07-Ma L , 07-Sep-2021 ,	y-2020 , 16-Jun-20 16-Oct-2021 , 07-	020 , 07-Sep- Jan-2022
	Synopsis	The nurnose of the Funding Opportunity:	announcement is to encourage gra	nt applications fr	om the scientific	community on
077788	Applying a Biopsychosocial Persp (R01 Clinical Trial Optional)	ective to Self-Management of Chronic Pair	National Institute of Nursing Research/NIH/DHHS	PA-18-945	07-May-2019	Not Specified
	Contact Name	Martha Matocha, PhD				
	Contact Telephone	301-594-2775				
	Contact Email	matocham@mail.nih.gov				
		······································				
	Sponsor Website					
	·		l <u>es/PA-18-945.html</u>			
	Program URL	https://grants.nih.gov/grants/guide/pa-fi	0 05 0 at 2010 07 law 2020 05 5	eb-2020 , 07-Ma L , 07-Sep-2021 ,	y-2020 , 05-Jun-20 05-Oct-2021 , 07-	020 , 07-Sep- Jan-2022
	Program URL	https://grants.nih.gov/grants/guide/pa-fi 07-May-2019, 05-Jun-2019, 07-Sep-2019 2020, 05-Oct-2020, 07-Jan-2021, 05-Feb The purpose of the Funding Opportunity	9 , 05-Oct-2019 , 07-Jan-2020 , 05-F o-2021 , 07-May-2021 , 05-Jun-2023 announcement is to encourage gra	l, 07-Sep-2021,	05-Oct-2021,07-	Jan-2022
077974	Program URL  Deadline Dates (ALL)  Synopsis	https://grants.nih.gov/grants/guide/pa-fi 07-May-2019, 05-Jun-2019, 07-Sep-2019 2020, 05-Oct-2020, 07-Jan-2021, 05-Feb The purpose of the Funding Opportunity	9 , 05-Oct-2019 , 07-Jan-2020 , 05-F o-2021 , 07-May-2021 , 05-Jun-2023 announcement is to encourage gra	L , 07-Sep-2021 , nt applications fr	05-Oct-2021,07-	Jan-2022
077974	Program URL  Deadline Dates (ALL)  Synopsis  Addressing Caregiver Symptoms  Trial Optional)	https://grants.nih.gov/grants/guide/pa-fi 07-May-2019, 05-Jun-2019, 07-Sep-2019 2020, 05-Oct-2020, 07-Jan-2021, 05-Feb The purpose of the Funding Opportunity a applying a biopsychosocial perspective to	0, 05-Oct-2019, 07-Jan-2020, 05-F b-2021, 07-May-2021, 05-Jun-2022 announcement is to encourage gra- self-management of chronic pain.  National Institute of Nursing	L , 07-Sep-2021 , nt applications fr	05-Oct-2021 , 07-	Jan-2022 community on
077974	Program URL  Deadline Dates (ALL)  Synopsis  Addressing Caregiver Symptoms  Trial Optional)	https://grants.nih.gov/grants/guide/pa-fi 07-May-2019, 05-Jun-2019, 07-Sep-2019 2020, 05-Oct-2020, 07-Jan-2021, 05-Feb The purpose of the Funding Opportunity a applying a biopsychosocial perspective to through Technological Tools (R21 Clinical Augie Diana, Ph.D.	0, 05-Oct-2019, 07-Jan-2020, 05-F b-2021, 07-May-2021, 05-Jun-2022 announcement is to encourage gra- self-management of chronic pain.  National Institute of Nursing	L , 07-Sep-2021 , nt applications fr	05-Oct-2021 , 07-	Jan-2022 community on

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Deadline Dates (ALL) Synopsis	https://grants.nih.gov/grants/guide/p 07-May-2019 , 16-Jun-2019 , 07-Sep-2 2020 , 16-Oct-2020 , 07-Jan-2021 , 16- The purpose of the Funding Opportun that develop and test tools to address regardless of patient symptoms or cor caregivers, and to promote technological advance the science related to caregive viable tools to address the symptoms	019, 16-Oct-2019, 07-Jan-2020, 16-Feb-2021, 07-May-2021, 16-Jun-2020 ity announcement is to encourage graymptoms in caregivers. The key to additions. Research is needed to enhar ical strategies to alleviate distress in care experience of symptoms, caregiving	21,07-Sep-2021 ant applications this announcemence symptom recorregiver sympto	, 16-Oct-2021, 07- from the scientific ent is the focus on ognition and assess ms. These studies	Jan-2022 community the caregiver, sment in are needed to
077972	Addressing Caregiver Symptoms t	hrough Technological Tools (R01 Clinic	National Institute of Nursing Research/NIH/DHHS	PA-19-023	07-May-2019	Not Specified
Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL)  Synopsis  Contact Email Synopsis  Augie Diana, Ph.D.  301-402-6423  dianaa@mail.nih.gov  https://grants.nih.gov/grants/guide/pa-files/PA-19-023.html  07-May-2019, 05-Jun-2019, 07-Sep-2019, 05-Oct-2019, 07-Jan-2020, 05-Feb-2020, 07-May-2020, 05-Jun-2020, 07-Sep-2021, 05-Oct-2021, 07-Jan-2022  The purpose of the Funding Opportunity announcement is to encourage grant applications from the scientific community that develop and test tools to address symptoms in caregivers. The key to this announcement is the focus on the caregiver gardless of patient symptoms or conditions. Research is needed to enhance symptom recognition and assessment in caregivers, and to promote technological strategies to alleviate distress in caregiver symptoms. These studies are needed advance the science related to caregiver experience of symptoms, caregiving contexts that promote these symptoms, and the promote the pro						
078362	End-of-Life and Palliative Care Ap Symptoms (R21 Clinical Trial Option Contact Name	· · · · · · · · · · · · · · · · · · ·	National Institute of Nursing Research/NIH/DHHS	PAR-19-044	07-May-2019	Not Specified
	Contact Telephone					

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount	
	Program URL Deadline Dates (ALL) Synopsis	The purpose of this funding opportunity a	, 16-Oct-2019 , 07-Jan-2020 , 16-F -2021 , 07-May-2021 , 16-Jun-202 nnouncement (FOA) is to stimulat	1 , 07-Sep-2021 ; e research to exa	, 16-Oct-2021 , 07- amine the multi-di	Jan-2022	
078345	End-of-Life and Palliative Care Ap Symptoms (R01 Clinical Trial Opti	pproaches to Advanced Signs and	nt of complex, advanced signs and  National Institute of Nursing  Research/NIH/DHHS	PAR-19-045	e end of life. 07-May-2019	Not Specified	
	Contact Telephone Contact Email Sponsor Website	kehlka@nih.gov	los/DAD 10 045 html				
	Deadline Dates (ALL)  Synopsis	The nurnose of this funding apportunity appouncement (FOA) is to stimulate research to examine the multi-dimensional					
078414		ailored Palliative and End-of-Life Care for Alaska Native Individuals (R21 Clinical Trial	National Institute of Nursing	PAR-19-058	07-May-2019	275,000 USD	
	Contact Telephone Contact Email Sponsor Website	adamsIs@nih.gov	les/PAR-19-058.html				
	Deadline Dates (ALL)	07-May-2019 , 16-Jun-2019 , 07-Sep-2019 2020 , 16-Oct-2020 , 07-Jan-2021 , 16-Feb	, 16-Oct-2019 , 07-Jan-2020 , 16-F -2021 , 07-May-2021 , 16-Jun-202	1 , 07-Sep-2021	, 16-Oct-2021 , 07-	Jan-2022	
	Synopsis	The purpose of this funding opportunity a use of evidence-based interventions in en individuals with advanced illness and thei	d-of-life and palliative care (EOLPC	-	•		
078411	Strategies to Provide Culturally Ta	ailored Palliative and End-of-Life Care for	National Institute of Nursing	PAR-19-057	07-May-2019	Not Specified	

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Seriously III American Indian and Optional)	Alaska Native Individuals (R01 Clinical T	rial Research/NIH/DHHS			
	Contact Name	Lynn S. Adams, Ph.D.				
	Contact Telephone	301-594-8911				
	Contact Email	adamsls@nih.gov				
	Sponsor Website					
	Program URL	https://grants.nih.gov/grants/guide/pa	ı-files/PAR-19-057.html			
Deadline Dates (ALL) 07-May-2019, 05-Jun-2019, 07-Sep-2019, 05-Oct-2019, 07-Jan-2020, 05-Feb-2020, 07-May-2020, 05-Jun-2020, 07-Jan-2021, 07-May-2021, 07-Sep-2021, 07-Jan-2021, 07-Jan-202						020 , 07-Sep- Jan-2022
		The purpose of this funding opportunit use of evidence-based interventions in individuals with advanced illness and the second control of the purpose of the	y announcement (FOA) is to encoura end-of-life and palliative care (EOLP	ige research that	t will improve and i	ncrease the
078636	Telomeres in Wellness and Disease Trial Optional)	se: A Biobehavioral Approach (R21 Clini	National Institute of Nursing Research/NIH/DHHS	PA-19-073	07-May-2019	Not Specified
	Contact Name	Lois A. Tully, PhD				
	Contact Telephone	301-594-5968				
	Contact Email	tullyla@mail.nih.gov				
	Sponsor Website					
	Program URL	https://grants.nih.gov/grants/guide/pa	ı-files/PA-19-073.html			
	Deadline Dates (ALL)	07-May-2019 , 16-Jun-2019 , 07-Sep-20 2020 , 16-Oct-2020 , 07-Jan-2021 , 16-J				
	Synopsis	The purpose of this funding opportunit telomeres in wellness and disease, and research. A body of research has demondable additional studies are needed to achieve wellness, reducing the risk and burden	to advance the incorporation of telonstrated the contribution of telomente the full potential for incorporating	omere studies int es to health-rela telomere-guide	to biobehavioral pr Ited outcomes; how d approaches for m	ograms of wever, naintaining
078635	Telomeres in Wellness and Diseas Trial Optional)	se: A Biobehavioral Approach (R01 Clini	National Institute of Nursing Research/NIH/DHHS	PA-19-074	07-May-2019	Not Specified
	Contact Name	Lois A. Tully, PhD				
	Contact Telephone	301-594-5968				



SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		·				
	Contact Email	tullyla@mail.nih.gov				
	Sponsor Website					
	Program URL	a-files/PA-19-074.html				
	Deadline Dates (ALL) 07-May-2019 , 05-Jun-2019 , 07-Sep-2019 , 05-Oct-2019 , 07-Jan-2020 , 05-Feb-2020 , 07-May-2020 , 05-Jun-2020 , 07-Jan-2020 , 07-Jan-2021 , 07-Sep-2021 , 07-Sep-2021 , 07-Sep-2021 , 07-Jan-2022 , 07-Jan-20					
		The purpose of this funding opportun telomeres in wellness and disease, an research. A body of research has dem additional studies are needed to achie wellness, reducing the risk and burder	d to advance the incorporation of telo onstrated the contribution of telomer eve the full potential for incorporating	mere studies into es to health-relat telomere-guided	biobehavioral pro ed outcomes; how approaches for m	ograms of vever, aintaining
079185	End-of-Life and Palliative Needs of Serious Illnesses (R01 Clinical Tria	f Adolescents and Young Adults (AYA) I Optional)	with National Institute of Nursing Research/NIH/DHHS	PAR-19-136	07-May-2019	Not Specified
	Contact Name	Lynn S. Adams, Ph.D.				
	Contact Telephone	301-594-8911				
	Contact Email	lynn.adams@nih.gov				
	Sponsor Website					
	Program URL	https://grants.nih.gov/grants/guide/g	a-files/PAR-19-136.html			
	Deadline Dates (ALL)	07-May-2019 , 05-Jun-2019 , 07-Sep-2 2020 , 05-Oct-2020 , 07-Jan-2021 , 05				
		The purpose of this funding opportun wishes, and decision-making processe the Centers for Disease Control and P research focused on specific end-of-list social needs of AYA with serious illness	es of adolescents and young adults (AY revention as youth between 12–24 ye fe/palliative care (EOLPC) models that	A; defined by the ars of age) with se	World Health Org erious, advanced il	anization and Inesses; and
079344	End-of-Life and Palliative Needs of Serious Illnesses (R21 Clinical Trial	f Adolescents and Young Adults (AYA) I Optional)	with National Institute of Nursing Research/NIH/DHHS	PAR-19-153	07-May-2019	275,000 USD
	Contact Name	Lynn S. Adams, Ph.D.				
	Contact Telephone	301-594-8911				
	Contact Email	lynn.adams@nih.gov				



SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount	
		https://grants.nih.gov/grants/guide/pi		Eab 2020 07 Ma	ov 2020 16 lun 2	020 07 Son	
		7-May-2019 , 16-Jun-2019 , 07-Sep-2019 , 16-Oct-2019 , 07-Jan-2020 , 16-Feb-2020 , 07-May-2020 , 16-Jun-2020 , 07-Sep- )20 , 16-Oct-2020 , 07-Jan-2021 , 16-Feb-2021 , 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022					
	T v Synopsis t r	The purpose of this funding opportuni- vishes, and decision-making processes he Centers for Disease Control and Pr esearch focused on specific end-of-life ocial needs of AYA with serious illness	ty announcement (FOA) is to foster ross of adolescents and young adults (A'evention as youth between 12–24 yee/palliative care (EOLPC) models that	esearch on the ur (A; defined by the ears of age) with s	nique perspectives e World Health Orgenious, advanced	, needs, ganization and illnesses; and	
079184	Research Enhancement Award Pro Schools and Graduate Schools (R15	gram (REAP) for Health Professional 5 Clinical Trial Required)	National Institute of Nursing Research/NIH/DHHS	PAR-19-135	07-May-2019	300,000 USD	
	Contact Name	Aichelle R.J. Hamlet, PhD					
	Contact Telephone	01-496-9623					
	Contact Email	amletm@mail.nih.gov					
	Sponsor Website						
	Program URL <u>Ł</u>	ttps://grants.nih.gov/grants/guide/pa	a-files/PAR-19-135.html				
		97-May-2019 , 25-Jun-2019 , 07-Sep-2 2020 , 25-Oct-2020 , 07-Jan-2021 , 25-					
	t s c r Synopsis a r y c	The purpose of the Research Enhancer of stimulate basic and clinical research ignificant number of the Nation's research eate opportunities for scientists and esearch programs to contribute to the upport small-scale research projects pundergraduate and/or graduate stude and to strengthen the research environal award NIH-relevant baccalaureate are of NIH support (total costs) in 4 or omponent of a university system. This ind/or minimal risk clinical trials addresses clinical trials are defined as those tow risks to potentially cause physical and the contraction of the contracti	earch scientists, but that have not be health professional institutions other health professional institutions other health professional and behavioral proposed by faculty members of eligients at health professional schools or ment of the applicant institution. Else or advanced degrees in health professional schools or the last 7 fiscal years. In this FOA a constitution of the last 7 fiscal years and the sessing the mission and research interestant do not require FDA oversight, do	ide baccalaureate en major recipien rwise unlikely to p research effort. If ble, domestic inst graduate schools igible institutions fessions and have college is a stand- t (FOA) supports it ests of the particity onot intend to for	e or advanced deg ts of NIH support. participate extensi REAP grants are in titutions, to expos- to meritorious re (e.g., the universi e received less than alone entity and re investigator-initiat pating NIH institut	rees for a REAP grants evely in NIH tended to e search projects, ty or college) n \$6 million per not a ed mechanistic tes. Minimal	

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount	
			Research/NIH/DHHS				
	Contact Name	Mary C. Roary, Ph.D.					
	Contact Telephone	* *					
		mary.roary@nih.gov					
	Sponsor Website						
	Program URL	https://grants.nih.gov/grants/guide/	pa-files/PA-18-850.html				
	Deadline Dates (ALL)	07-May-2019 16-Jun-2019 07-Sen-2019 16-Oct-2019 07-Jan-2020 16-Feb-2020 07-May-2020 16-Jun-2020					
	Synopsis	adults (those 50 to 64 years of age) t	h (NINR) and National Institute on Agii hat can inform efforts to optimize hea iis FOA will use the NIH R21 Explorator	Ith and wellness	as individuals age,	and prevent	
076049	Prevention Research in Mid-Life A	Adults (R01 Clinical Trial Optional)	National Institute of Nursing Research/NIH/DHHS	PA-18-849	07-May-2019	Not Specified	
	Contact Name	Mary C. Roary, Ph.D.					
	Contact Telephone	301-594-2154					
	Contact Email	mary.roary@nih.gov					
	Sponsor Website						
	Program URL	https://grants.nih.gov/grants/guide/	pa-files/PA-18-849.html				
	Deadline Dates (ALL)		2019 , 05-Oct-2019 , 07-Jan-2020 , 05- 5-Feb-2021 , 07-May-2021 , 05-Jun-202			020 , 07-Sep-	
		adults (those 50 to 64 years of age) t	h (NINR) and National Institute on Agii hat can inform efforts to optimize hea iis FOA will use the NIH Research Proje	Ith and wellness	as individuals age,		
057345	Changes in Cellular Architecture I	During Aging (R01)	National Institute on Aging/NIH/DHHS	PA-16-442	05-Jun-2019	Not Specified	
	Contact Name	Jose Velazquez, Ph.D.					
	Contact Telephone	301-496-6428					
	Contact Email	jvelazqu@mail.nih.gov					
	Sponsor Website						

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		http://grants.nih.gov/grants/guide/pa-file	es/PA-16-442.html			Amount
	Deadline Dates (ALL)	05-Jun-2019 , 05-Oct-2019				
	Synopsis	National Institute on Aging (NIA) invites understanding of the changes in cellular and function, the impact of the cytoskele controlling cellular architecture will be co cytoplasmic communications, and in spat FOA will use the NIH Research Project (RC	rchitecture that occur during the ton on intracellular organelle inte nsidered. There is interest in stud io-temporal relationships during t	aging process. St ractions, and sign ying the role of th	udies on cytoskele aling or regulatory ne cytoskeleton in	ton structure molecules nuclear-
057843	<u>Dynamic Interactions between Sy</u> <u>Brain in Aging and in Alzheimer's</u>	stemic or Non-Neuronal Systems and the Disease (R01)	National Institute on Aging/NIH/DHHS	PAR-17-029	05-Jun-2019	Not Specified
	Contact Name	Suzana Petanceska, Ph.D.				
	Contact Telephone	301-496-9350				
	Contact Email	petanceskas@nia.nih.gov				
	Sponsor Website					
	Program URL	http://grants.nih.gov/grants/guide/pa-file	es/PAR-17-029.html			
	Deadline Dates (ALL)	05-Jun-2019 , 05-Oct-2019				
	Synopsis	NIH invites applications for research proneuronal factors — individually or in combine disease (AD). The goal of this FOA is to suthe basic biology of aging and clinical aging pathways to inform novel prevention or inwill likely involve a broad range of expertidiseases, and other clinical and translation pathophysiology to identify interrelations Project (RO1) award mechanism.	ination – to the pathogenesis, preport innovative multidisciplinary gresearch. Successful studies mantervention strategies for AD and ise including the biology of aging, and specialties focused on systemical	esentation, and/o research that wil y identify critical other dementias geriatrics/geronte c diseases or spec	r progression of Al II integrate the AD processes and pat of aging. Successfuology, neurodegencific tissue/organ	zheimer's science with hophysiological ul applications erative
057847	Improving Quality of Care and Qu Disease and Related Dementias a	rality of Life for Persons with Alzheimer's t the End of Life (RO3)	National Institute on Aging/NIH/DHHS	PAS-17-026	16-Jun-2019	100,000 USD
	Contact Name	Melissa Gerald, Ph.D.				
	Contact Telephone	301-402-4156				
	Contact Email	melissa.gerald@nih.gov				
	Sponsor Website					

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		1				
		http://grants.nih.gov/grants/guide/pa-f	iles/PAS-17-026.html			
	Deadline Dates (ALL)	16-Jun-2019 , 16-Oct-2019				
	Synopsis	National Institute on Aging (NIA) and Nand translational research gaps in the state people with Alzheimer's disease and relanalysis of existing data from longitudin for Stage I behavioral intervention deve (RO3) award mechanism.	eudy of end-of-life care needs in or ated dementias (ADRD) and their f al cohort studies or from administ	der to improve qu amilies. Research rative records or (	that either employ  b) primary data co	end of life of vs (a) secondary llection
056044	Phenotypic and Functional Chara Strategies for Aging-Related Cond	cterization of ApoE2 to Inform Translatio ditions (R21)	n National Institute on Aging/NIH/DHHS	PAR-16-371	16-Jun-2019	275,000 USD
	Contact Name	Nalini Raghavachari, Ph.D.				
	Contact Telephone	301-496-6942				
	Contact Email	nraghavachari@mail.nih.gov				
	Sponsor Website					
	Program URL	http://grants.nih.gov/grants/guide/pa-f	iles/PAR-16-371.html			
	Deadline Dates (ALL)	16-Jun-2019				
	Synopsis	National Institute on Aging (NIA) invite and other variants to improve understar other ApoE alleles), and how they media will aid in the identification of potential diseases by mimicking favorable different the NIH Exploratory/Developmental (R2	nding of physiologic and cellular di ate ApoE e2's differential effects o therapeutic targets for intervention ntial effects of the ApoE e2 variant	fferences attribut n longevity and ri ons that prevent o	able to the ApoE ea sk for age-related c r ameliorate aging-	2 allele (vs. conditions. This related
056041	Phenotypic and Functional Chara Strategies for Aging-Related Cond	cterization of ApoE2 to Inform Translatio ditions (R01)	National Institute on Aging/NIH/DHHS	PAR-16-370	05-Jun-2019	Not Specified
	Contact Name	Nalini Raghavachari, Ph.D.				
	Contact Telephone	301-496-6942				
	Contact Email	nraghavachari@mail.nih.gov				
	Sponsor Website					
	Program URL	http://grants.nih.gov/grants/guide/pa-f	iles/PAR-16-370.html			
	Deadline Dates (ALL)	05-Jun-2019				

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Synopsis in h	National Institute on Aging (NIA) invites mprove understanding of physiologic and ow they mediate ApoE e2's differential dentification of potential therapeutic tarnimicking favorable differential effects of esearch Project (R01) award mechanism	d cellular differences attributable effects on longevity and risk for a gets for interventions that prever f the ApoE e2 variant, while avoic	to the ApoE e2 a ge-related condit nt or ameliorate a	Ilele (vs. other Apo ions. This will aid i ging-related diseas	E alleles), and n the ses by
058111	Clarifying the Relationship between Related Dementias (R21/R33)	n Delirium and Alzheimer's Disease and	National Institute on Aging/NIH/DHHS	PAR-17-03	16-Jun-2019	Not Specified
	Contact Telephone 3	usan Zieman, M.D., Ph.D. 01-496-6761 <u>usan.zieman@nih.gov</u>				
	Program URL <u>h</u>	ttp://grants.nih.gov/grants/guide/pa-file 6-Jun-2019 , 16-Oct-2019	es/PAR-17-037.html			
	Synopsis Synopsis  o  m  d  si	National Institute on Aging (NIA) invites alzheimer's disease and related demential with ADRD are at increased risk to develow DRD, and why patients who experience ognitive impairment or ADRD, often with elirium. Relevant research projects may equential, causative, contributory and/onat lead to the development of delirium imphasis on use of appropriate animal may ith ADRD and vice versa, D) diagnose an atients with co-existing ADRD and delirium reduce the impact of delirium in patier nechanistic insight to improve risk assessed lirium and ADRD. This FOA will use the tudies focused on feasibility or proof-of-chievement of pre-defined investigator-	p delirium, often with a worse prodelirium are at higher risk to devote an accelerated rate of cognitive focus on, but are not limited to, for synergistic pathways underlying against the background of aging odels, C) identify risk factors for a dassess one condition in the settum, or F) test pharmacologic and, ats with ADRD and vice versa. Resement, diagnosis, phenotyping, proceedings of the product of the proceeding of the proceeding of the procedure of the pr	esearch focusing of ognosis compared of subsequents decline compared those that A) provides both ADRD and of the onset and/or ting of the other, for non-pharmaco dearch supported revention, and mathanism to conduction	on understanding value of the those without short- and/or longed to those without vide insight into postellirium, B) elucidate eneration, with parprogression of delification of the cologic strategies to by this FOA is interprogression of the cologic strategies to the this paragement approact exploratory/devent	why persons antecedent term mild preceding ssible common, ite mechanisms ticular rium in those phenotypes of prevent, treat, inded to provide ches for both
058358	Research Career Enhancement Awa Alzheimer's (K18)	ard to Advance Therapy Development fo	National Institute on Aging/NIH/DHHS	PAR-17-052	12-Jun-2019	Not Specified

SPIN ID	Program	Sponsor Namo	Spansor Number		Deadline Date	Funding
SPIN ID	Title	Sponsor Name	Sponsor Number		Deadine Date	Amount
	Contact Telephone	Chyren Hunter, Ph.D. 301-496-9322 Hunterc@mail.nih.gov				
	Sponsor Website					
	·	http://grants.nih.gov/grants/guide/pa-	files/PAR-17-052.html			
	Deadline Dates (ALL)	12-Jun-2019 , 12-Oct-2019				
	Synopsis	National Institute on Aging (NIA) invit development experiences that close ex Alzheimer's Disease (AD) researchers to translational, team-science projects in redirect their expertise toward the stud Award mechanism.	pertise gaps in data science and in o expand their expertise to become AD or AD-related dementias (ADRD	drug discovery. Th more effective in ). This award will a	e goal of the progr leading cross-disci also allow data scie	am is to allow plinary,
059151	Exploratory Analyses of Existing C Biospecimens to Address Clinical		National Institute on Aging/NIH/DHHS	PA-17-089	07-May-2019	275,000 USE
	Contact Name	Chhanda Dutta, Ph.D.				

Contact Telephone 301-496-4161

Contact Email duttac@mail.nih.gov

Sponsor Website

Program URL https://grants.nih.gov/grants/guide/pa-files/PA-17-089.html

Deadline Dates (ALL) 07-May-2019, 16-Jun-2019, 07-Sep-2019, 16-Oct-2019, 07-Jan-2020, 16-Feb-2020, 07-May-2020

National Institute on Aging (NIA) invites applications employing secondary analysis of existing data sets or stored biospecimens, to address clinically related issues on aging changes influencing health across the lifespan, and/or on diseases and disabilities in older persons. Use of cohorts that are linked to electronic health record systems and/or Centers for Medicare and Medicaid Services (CMS) administrative data are especially welcome. This FOA will support activities addressing specific hypotheses in clinical aging research and/or to inform the design and implementation of future epidemiologic or human intervention studies, or current geriatric practice in maintenance of health, management of disease, and prevention of disability. Existing data sets may also be used to develop and test new statistical analytical approaches. Costs for archiving of data to be made publicly available and those associated with data harmonization or assay refinement/validation may be included in the budget, as long as these activities are pertinent to the proposed secondary analyses. This FOA will use the NIH R21 Exploratory/Developmental Grant award mechanism.

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount

PIN ID Program Title		I Shonsor Mame	Sponsor Number	Deadline Date	Funding Amount
Secondary Analyses of Existing Col to Address Clinical Aging Research	horts, Data Sets and Stored Biospecimens Questions (R01)	National Institute on Aging/NIH/DHHS	PA-17-088	07-May-2019	Not Specified
Contact Name	Chhanda Dutta, Ph.D.				
Contact Telephone	301-496-4161				
Contact Email	duttac@mail.nih.gov				
Sponsor Website					
Program URL	https://grants.nih.gov/grants/guide/pa-fil	les/PA-17-088.html			
Deadline Dates (ALL)	07-May-2019 , 05-Jun-2019 , 07-Sep-2019	o, 05-Oct-2019 , 07-Jan-2020 , 05-Feb-20	20 , 07-May	-2020	
Synopsis	National Institute on Aging (NIA) invites a biospecimens, to address clinically related and disabilities in older persons. Use of commedicare and Medicaid Services (CMS) adspecific hypotheses in clinical aging resear human intervention studies, or current get of disability. Existing data sets may also be of data to be made publicly available and included in the budget, as long as these as Research Project (R01) award mechanism	d issues on aging changes influencing head ohorts that are linked to electronic health dministrative data are especially welcome rch and/or to inform the design and impleriatric practice in maintenance of health e used to develop and test new statistica those associated with data harmonizatic ctivities are pertinent to the proposed se	olth across the record system. This FOA vienentation, managementation analytical and or assay r	ne lifespan, and/or of tems and/or Centers will support activitie of future epidemio ent of disease, and p approaches. Costs for efinement/validation	on diseases s for es addressin logic or prevention or archiving on may be

057968 Integrative Research to Understand the Impact of Sex Differences on the Molecular Determinants of AD Risk and Responsiveness to Treatment (R01)

National Institute on Aging/NIH/DHHS

PAR-17033

05-Jun-2019

USD

Contact Name Suzana Petanceska, Ph.D.

Contact Telephone 301-496-9350

Contact Email <u>petanceskas@mail.nih.gov</u>

Sponsor Website

Program URL <a href="http://grants.nih.gov/grants/guide/pa-files/PAR-17-033.html">http://grants.nih.gov/grants/guide/pa-files/PAR-17-033.html</a>

Deadline Dates (ALL) 05-Jun-2019, 05-Oct-2019

National Institute on Aging (NIA) invites applications that apply a cross-disciplinary, team science approach to gain Synopsis comprehensive, mechanistic understanding of the impact of sex differences on the trajectories of brain aging and phenotypes of AD risk and on the responsiveness to pharmacologic and non-pharmacologic interventions. This FOA will use the NIH



SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		Research Project (R01) award mechanisi	m.			
057967		oaches to Advance Drug Repositioning pment for Alzheimer's Disease (R01)	National Institute on Aging/NIH/DHHS	PAR-17- 032	05-Jun-2019	2,500,000 USD
	Contact Name	Suzana Petanceska, Ph.D.				
	Contact Telephone	301-496-9350				
	Contact Email	petanceskas@mail.nih.gov				
	Sponsor Website					
	Program URL	http://grants.nih.gov/grants/guide/pa-fi	iles/PAR-17-032.html			
	Deadline Dates (ALL)	05-Jun-2019 , 05-Oct-2019				
		National Institute on Aging (NIA) invites	s applications that integrate the use of co	mputationa	I approaches to id	lentify
	Synopsis	individual drugs currently used for other drugs or as drug combinations) with pro humans. This FOA will use the NIH Rese	s applications that integrate the use of co r conditions with potential to be efficacion of-of-concept efficacy studies in cell-base arch Project (R01) award mechanism.	us in AD or A d models, a	AD-related demen	tias (as single /or
068467		individual drugs currently used for other drugs or as drug combinations) with pro humans. This FOA will use the NIH Rese	conditions with potential to be efficaciou of-of-concept efficacy studies in cell-base	us in AD or A	AD-related demen	tias (as single
068467	Clarifying the Relationship between Related Dementias (R21/R33 Clinical Related Dementias Related Dementias (R21/R33 Clinical Related Dementias Related Related Dementias Related Re	individual drugs currently used for other drugs or as drug combinations) with pro humans. This FOA will use the NIH Rese	r conditions with potential to be efficaciou of-of-concept efficacy studies in cell-base arch Project (R01) award mechanism.	us in AD or A d models, a PAR-18-	AD-related demen nimal models and	tias (as single /or Not
068467	Clarifying the Relationship between Related Dementias (R21/R33 Clinical Related Dementias Related Dementias (R21/R33 Clinical Related Dementias Related Related Dementias Related Re	individual drugs currently used for other drugs or as drug combinations) with pro humans. This FOA will use the NIH Rese en Delirium and Alzheimer's Disease and ical Trial Optional)  Susan Zieman, M.D., Ph.D.	r conditions with potential to be efficaciou of-of-concept efficacy studies in cell-base arch Project (R01) award mechanism.	us in AD or A d models, a PAR-18-	AD-related demen nimal models and	tias (as single /or Not
068467	Clarifying the Relationship between Related Dementias (R21/R33 Clinical Contact Name Contact Telephone	individual drugs currently used for other drugs or as drug combinations) with pro humans. This FOA will use the NIH Rese en Delirium and Alzheimer's Disease and ical Trial Optional)  Susan Zieman, M.D., Ph.D.	r conditions with potential to be efficaciou of-of-concept efficacy studies in cell-base arch Project (R01) award mechanism.	us in AD or A d models, a PAR-18-	AD-related demen nimal models and	tias (as single /or Not
068467	Clarifying the Relationship between Related Dementias (R21/R33 Clinical Contact Name Contact Telephone	individual drugs currently used for other drugs or as drug combinations) with pro humans. This FOA will use the NIH Rese en Delirium and Alzheimer's Disease and ical Trial Optional)  Susan Zieman, M.D., Ph.D. 301-496-6761  susan.zieman@nih.gov	r conditions with potential to be efficaciou of-of-concept efficacy studies in cell-base arch Project (R01) award mechanism.	us in AD or A d models, a PAR-18-	AD-related demen nimal models and	tias (as single /or Not
068467	Clarifying the Relationship between Related Dementias (R21/R33 Clinical Contact Name Contact Telephone Contact Email Sponsor Website	individual drugs currently used for other drugs or as drug combinations) with pro humans. This FOA will use the NIH Rese en Delirium and Alzheimer's Disease and ical Trial Optional)  Susan Zieman, M.D., Ph.D. 301-496-6761  susan.zieman@nih.gov	r conditions with potential to be efficacion of-of-concept efficacy studies in cell-base arch Project (R01) award mechanism.  National Institute on Aging/NIH/DHHS	us in AD or A d models, a PAR-18-	AD-related demen nimal models and	tias (as single /or Not
068467	Clarifying the Relationship between Related Dementias (R21/R33 Clinical Contact Name Contact Telephone Contact Email Sponsor Website Program URL	individual drugs currently used for other drugs or as drug combinations) with pro humans. This FOA will use the NIH Rese en Delirium and Alzheimer's Disease and ical Trial Optional)  Susan Zieman, M.D., Ph.D. 301-496-6761 susan.zieman@nih.gov	r conditions with potential to be efficacion of-of-concept efficacy studies in cell-base arch Project (R01) award mechanism.  National Institute on Aging/NIH/DHHS	us in AD or A d models, a PAR-18-	AD-related demen nimal models and	tias (as single /or Not

that lead to the development of delirium against the background of aging and/or neurodegeneration, with particular emphasis on use of appropriate animal models, C) identify risk factors for the onset and/or progression of delirium in those with ADRD and vice versa, D) diagnose and assess one condition in the setting of the other, E) identify putative phenotypes of

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		patients with co-existing ADRD and deliri or reduce the impact of delirium in patie mechanistic insight to improve risk asses delirium and ADRD. This FOA will use the studies focused on feasibility or proof-of- achievement of pre-defined investigator-	nts with ADRD and vice versa. Research s sment, diagnosis, phenotyping, prevention R21/R33 phased innovation mechanism concept that may then transition to an i	supported bon, and mare to conduct	y this FOA is intennagement approace exploratory/deve	ded to provide thes for both lopmental
062697	NIA Academic Leadership Career	Award (K07)	National Institute on Aging/NIH/DHHS	PAR-17- 287	07-May-2019	625,000 USD
	Contact Name	Robin A. Barr, D. Phil.				
	Contact Telephone	301-402-7715				
	Contact Email	BarrR@mail.nih.gov				
	Sponsor Website					
	Program URL	https://grants.nih.gov/grants/guide/pa-f	iles/PAR-17-287.html			
	Deadline Dates (ALL)	07-May-2019 , 12-Jun-2019 , 07-Sep-2019 2020	9 , 12-Oct-2019 , 07-Jan-2020 , 12-Feb-20	020 <i>,</i> 07-Ma	y-2020 , 12-Jun-20	)20 , 07-Sep-
	Synopsis	National Institute on Aging (NIA) invites intended to provide support for more ser and geriatric research capacity within the (ATA) mechanism.	nior investigators who have the expertise	e and leader	ship skills to enha	nce the aging
068491		ality of Life for Persons with Alzheimer's t the End of Life (R01 Clinical Trial	National Institute on Aging/NIH/DHHS	PAS-18- 030	05-Jun-2019	Not Specified
	Contact Name	Melissa Gerald, Ph.D.				
	Contact Telephone	301-402-4156				
	Contact Email	melissa.gerald@nih.gov				
	Sponsor Website					
	Program URL	https://grants.nih.gov/grants/guide/pa-f	iles/PAS-18-030.html			
	Deadline Dates (ALL)	05-Jun-2019 , 05-Oct-2019				
	Synopsis	National Institute on Aging (NIA) and Na and translational research gaps in the stu people with Alzheimer's disease and rela	•	mprove qua	ility of life at the e	nd of life of

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Scale Clinical Studies and Seconda	analysis of existing data from longitudina for Stage I behavioral intervention development of the stage I behavioral intervention development of	opment is particularly encouraged.This Fo	OA will use tl	ne NIH Research	
	(R01 Clinical Trial Optional)	I				
		Chhanda Dutta, Ph.D.				
	Contact Telephone					
		duttac@mail.nih.gov				
	Sponsor Website		TI /0.4.0.005			
	· ·	https://grants.nih.gov/grants/guide/pa-f			2020	
	Deadline Dates (ALL)	07-May-2019 , 05-Jun-2019 , 07-Sep-201		-		
	Synopsis	National Institute on Aging (NIA) and National Institute on Aging (NIA) and National Scale physiologic studies in humans or se intervention studies, to increase our und aging changes or to extend healthy human benefit from treatment, and/or obtaining useful in identifying novel molecular targetic scales.	econdary analyses of data and/or stored be lerstanding of the clinical translational po an life span. This includes identification of g information on metformin's human phy	piospecimens etential of me of specific po ysiologic and	s from controlled etformin to delay pulations particu cellular effects tl	clinical deleterious larly likely to nat would be
IIDXIX/	Clarifying the Relationship betwe Related Dementias (R01 Clinical T	en Delirium and Alzheimer's Disease and Trial Optional)	National Institute on Aging/NIH/DHHS	PAR-18- 029	05-Jun-2019	Not Specified
	Contact Name	Susan Zieman, M.D., Ph.D.				
	Contact Telephone	301-496-6761				
	Contact Email	susan.zieman@nih.gov				
	Sponsor Website					
	Program URL	https://grants.nih.gov/grants/guide/pa-f	iles/PAR-18-029.html			
	Deadline Dates (ALL)	05-Jun-2019 , 05-Oct-2019				
	Synopsis	National Institute on Aging (NIA) invites Alzheimer's disease and related dementi with ADRD are at increased risk to develope ADRD, and why patients who experience	op delirium, often with a worse prognosis	focusing on compared t	understanding wood those without a	hy persons antecedent

cognitive impairment or ADRD, often with an accelerated rate of cognitive decline compared to those without preceding

SPIN ID	Program Title	S	ponsor Name	Sponsor Number		Deadline Date	Funding Amount
		sequential, that lead to emphasis or with ADRD a patients wit or reduce th mechanistic	causative, contributory and/ the development of delirium n use of appropriate animal i and vice versa, D) diagnose a th co-existing ADRD and deling the impact of delirium in pations in sassesses	y focus on, but are not limited to, those to or synergistic pathways underlying both A n against the background of aging and/or models, C) identify risk factors for the ons and assess one condition in the setting of fium, or F) test pharmacologic and/or non ents with ADRD and vice versa. Research s ssment, diagnosis, phenotyping, prevention	ADRD and do neurodeger set and/or poster the other, End armacol supported bon, and mar	elirium, B) elucidate neration, with part rogression of delir ) identify putative ogic strategies to part this FOA is inten-	te mechanisms icular ium in those phenotypes of prevent, treat, ded to provide
069782	Multidisciplinary Studies of HIV/A	AIDS and Agin	ng (R21 Clinical Trial Optional	National Institute on Aging/NIH/DHHS	PAR-18- 190	07-May-2019	275,000 USD
	Contact Name	Basil A. Elda	idah, MD, PhD				
	Contact Telephone	301-496-67	61				
	Contact Email	eldadahb@	<u>nia.nih.gov</u>				
	Sponsor Website	2					
	Program URL	https://gran	nts.nih.gov/grants/guide/pa-	files/PAR-18-190.html			
	Deadline Dates (ALL)	07-May-201 2020	19 , 16-Jun-2019 , 07-Sep-201	19 , 16-Oct-2019 , 07-Jan-2020 , 16-Feb-20	020 <i>,</i> 07-Ma	y-2020 , 16-Jun-20	020 , 07-Sep-
	Synopsis	aging by add aspects of a and treatme populations should be co	dressing two overarching ob- ging through the lens of HIV ent of HIV infection, and mar and cultural settings by app onsistent with the scientific	es participating Institutes and Centers invite tives: 1) to improve understanding of be infection and its treatment; and 2) to improve understanding of improvement of HIV-related comorbidities, colying our current understanding of aging priorities outlined by the NIH Office of AID coloratory/Developmental Grant award management and in the interest of the interest	piological, cliprove approprime a	inical, and socio-boaches for testing, pand complication olications appropri	ehavioral prevention, s in different ate to this FOA
069778 <u>I</u>	Multidisciplinary Studies of HIV/A	AIDS and Agin	ng (R01 Clinical Trial Optional	National Institute on Aging/NIH/DHHS	PAR-18- 189	07-May-2019	Not Specified

Contact Name Basil A. Eldadah, MD, PhD Contact Telephone 301-496-6761

Contact Email eldadahb@nia.nih.gov



SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	https://grants.nih.gov/grants/guide/pa-1	files/PAR-18-189.html L9 , 05-Oct-2019 , 07-Jan-2020 , 05-Feb-20	020 . 07-Ma	v-2020 . 05-lun-20	)20 . 07-Sen-
Deadline Dates (ALL) Synopsis	2020  National Institutes of Health (NIH) and it aging by addressing two overarching objuspects of aging through the lens of HIV and treatment of HIV infection, and man populations and cultural settings by apple	es participating Institutes and Centers invicectives: 1) to improve understanding of beinfection and its treatment; and 2) to improve understand 3) to improve understand 3	te application in the second s	ons at the intersectinical, and socio-baches for testing, and complication olications appropr	etion of HIV and ehavioral prevention, as in different iate to this FOA
	15-137. This FOA will use the NIH Resear				
070974 Emotional Function in Normal Ag <u>Trial Not Allowed</u> )	ing and/or MCI and AD/ADRD (R21 Clinica	All National Institute on Aging/NIH/DHHS	PAR-18- 582	07-Jun-2019	275,000 USD
Contact Name	Lis Nielsen, Ph.D.				
Contact Telephone	301-402-4156				
Contact Emai	nielsenli@nia.nih.gov				
Sponsor Website					
Program URL	https://grants.nih.gov/grants/guide/pa-f	files/PAR-18-582.html			
Deadline Dates (ALL)	07-Jun-2019 , 07-Feb-2020 , 08-Jun-2020	)			
Synopsis	function and emotion regulation with ag neurobiological factors in adults who are Alzheimer's disease (AD), and Alzheimer understanding of (1) normative maturati behavioral mechanisms of emotional fur dysfunction might account for any of the targets for interventions or prevention emotion dysregulation or strengthen em AD/ADRD. The R21 Exploratory/Develop	s applications for foundational research dring, to further clarify the trajectories of ce aging normally, as well as in individuals is disease-related dementias (ADRD). The ional shifts in emotional processes, (2) ho notion might manifest in MCI and the earlier neuropsychiatric symptoms observed in efforts, or provide clues to intervention stanctional resilience at different life stages is mental Grant supports exploratory and deptual stages of these projects. This FOrmant award mechanism.	hange in emwith mild controlled goal is three ow dysfunction y stages of A AD/ADRD. Stategies that n normal agevelopment	notion processing ognitive impairme e-fold: to advance on in the integrat AD/ADRD, and/or Such studies may t might be applied ging or disease statal research project	and linked int (MCI), ive neural- (3) how such identify novel to normalize ges in MCI and
070970 Emotional Function in Normal Ag Trial Optional)	ing and/or MCI and AD/ADRD (R01 Clinica	National Institute on Aging/NIH/DHHS	PAR-18- 581	07-Jun-2019	Not Specified

١	SPIN ID	Program	Sponsor Name	Sponsor Number	Deadline Date	Funding
	SPIN ID	Title	Sponsor Name	Sponsor Number	Deadine Date	Amount

Contact Name Lis Nielsen, Ph.D.

Contact Telephone 301-402-4156

Contact Email nielsenli@nia.nih.gov

Sponsor Website

Program URL https://grants.nih.gov/grants/guide/pa-files/PAR-18-581.html

Deadline Dates (ALL) 07-Jun-2019, 07-Feb-2020, 08-Jun-2020

National Institute on Aging (NIA) invites applications for foundational research demonstrating generally improved emotional function and emotion regulation with aging, to further clarify the trajectories of change in emotion processing and linked neurobiological factors in adults who are aging normally, as well as in individuals with mild cognitive impairment (MCI), Alzheimer's disease (AD), and Alzheimer's disease-related dementias (ADRD). The goal is three-fold: to advance understanding of (1) normative maturational shifts in emotional processes, (2) how dysfunction in the integrative neural-Synopsis behavioral mechanisms of emotional function might manifest in MCI and the early stages of AD/ADRD, and/or (3) how such dysfunction might account for any of the neuropsychiatric symptoms observed in AD/ADRD. Such studies may identify novel targets for interventions or prevention efforts, or provide clues to intervention strategies that might be applied to normalize emotion dysregulation or strengthen emotional resilience at different life stages in normal aging or disease stages in MCI and AD/ADRD. This FOA invites Stage 0 (basic research) or Stage I (intervention development/modification) clinical trials, in line

with the NIH Stage Model. This FOA will use the NIH Research Project (R01) award mechanism.

070269

Advancing the Science of Geriatric Palliative Care (R01 - Clinical Trial Optional)

National Institute on Aging/NIH/DHHS PA-18-502 05-Jun-2019

Not Specified

Contact Name Basil Eldadah, MD, PhD

Contact Telephone 301-496-6761

Contact Email eldadahb@nia.nih.gov

Sponsor Website

Program URL https://grants.nih.gov/grants/guide/pa-files/PA-18-502.html

Deadline Dates (ALL) 05-Jun-2019, 05-Oct-2019, 05-Feb-2020

National Institutes of Health (NIH) and its participating Institutes and Centers invite applications for focused on palliative care

in geriatric populations. This FOA covers studies in a variety of settings including hospitals (and specific sites within hospitals including specialty medical or surgical wards, intensive care units, and emergency departments), post-acute care settings, Synopsis outpatient clinics and doctors' offices, patients' homes and other residential settings, assisted living facilities, nursing homes, hospices, and other healthcare or community settings. This FOA encourages both prospective studies and analyses of existing datasets, health and medical records, claims data, or other sources. Leveraging ongoing cohorts, intervention studies, networks, data and specimen repositories, and other existing research resources and infrastructure are encouraged. Study

SPIN ID Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		may include observational ap earch Project (R01) award me	proaches, quasi-experimental designs, and i chanism.	intervention	al studies. This FC	OA will use the
070272 Advancing the Science of COptional)	Geriatric Palliativ	e Care (R21 - Clinical Trial	National Institute on Aging/NIH/DHHS	PA-18-503	16-Jun-2019	275,000 USD
Contact	: Name Basil Elda	adah, MD, PhD				
Contact Tele	phone 301-496	-6761				
Contac	t Email <u>eldadahl</u>	@nia.nih.gov				
Sponsor V	/ebsite					
Progra	ım URL <u>https://g</u>	rants.nih.gov/grants/guide/p	pa-files/PA-18-503.html			
Deadline Date	s (ALL) 16-Jun-2	019 , 16-Oct-2019 , 16-Feb-2	020			
	developm population specialty clinics are and other health are and speciant include comechani	mental research grant applications. This FOA covers studies medical or surgical wards, in ad doctors' offices, patients' har healthcare or community sand medical records, claims daimen repositories, and other observational approaches, quesm. This FOA will use the NIF	d its participating Institutes and Centers invi- ations to develop new tools, methods, and noin a variety of settings including hospitals (and tensive care units, and emergency departments and other residential settings, assiste ettings. This FOA encourages both prospective, or other sources. Leveraging ongoing color existing research resources and infrastructural asi-experimental designs, and limited intervals Research Project (RO1) award mechanism.	nodels focus nd specific s ents), post-a d living facil ive studies a horts, interv ure are enco	ed on palliative ca ites within hospita acute care setting ities, nursing hom nd analyses of exi ention studies, ne uraged. Study des	are in geriatric als including s, outpatient es, hospices, isting datasets, etworks, data signs may
070587 <u>Basic and Translational Res</u> <u>Alzheimer's Disease (R01 - </u>			National Institute on Aging/NIH/DHHS	PAR-18- 544	08-Jun-2019	Not Specified
Contact	Name Lis Nielse	en, Ph.D.				
Contact Tele	phone 301-402	4156				
Contac	t Email <u>nielsenli</u>	<u>@nia.nih.gov</u>				
Sponsor V	/ebsite					
Progra	ım URL <u>https://g</u>	rants.nih.gov/grants/guide/p	pa-files/PAR-18-544.html			
Deadline Date	s (ALL) 08-Jun-2	019 , 07-Feb-2020 , 08-Jun-2	020			
Sy	nopsis and mot	ivational parameters of impa	ites applications for basic research to better ired and intact decision making in both norrize the extent to which basic behavioral and	nal aging an	d Alzheimer's dise	ease (AD).

SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	making are differentially impacted in nor investigate the decision-making factors to financial exploitation and other forms of on the processes involved in decision make with and without AD. Specific opportunit cognitive, emotional and motivational stainplifying choices and offering better depower of attorney, living wells, etc.). This	hat render older adults (with or without of mistreatment and abuse. The FOA also in king to the design of decision-supportive ties include the development of decision- rengths of these populations; tools to ass refaults; and the promotion of timely adop	cognitive im nvites applic interventio supportive i ess decisior otion of opti	pairment) vulnera cations to apply ba ons for midlife and interventions to le nal capacity; strate imal delegation pr	able to asic research older adults everage egies for
073071 Alzheimer's Disease Patient Regis Clinical Trial Not Allowed)		_ National Institute on Aging/NIH/DHHS	PAR-18- 715	05-Jun-2019	Not Specified
Contact Name	Robin A. Barr				
Contact Telephone	301-496-9322				
Contact Emai	BarrR@mail.nih.gov				
Sponsor Website					
Program URI	https://grants.nih.gov/grants/guide/pa-f	iles/PAR-18-715.html			
Deadline Dates (ALL)	05-Jun-2019 , 05-Oct-2019 , 05-Feb-2020	, 05-Jun-2020 , 05-Oct-2020 , 05-Feb-202	21		
Synopsis	National Institute on Aging (NIA) invites is submit revision and or renewal applications cohort study of AD and dementia that is applicants are strongly encouraged to contain This FOA will utilize the NIH U01 Research	ons. The Alzheimer's Disease (AD) Patient linked to an HMO-medical record system ntact their current program officer prior	Registry is or a similar to submission	a population-base record system. Pon to discuss the a	ed longitudinal otential
070482 Sensory and motor system changed disease (R01 Clinical Trial Not Allo	ges as predictors of preclinical Alzheimer's pwed)	National Institute on Aging/NIH/DHHS	PAR-18- 519	07-Jun-2019	Not Specified
Contact Name	Coryse St. Hillaire-Clarke, Ph.D.				
Contact Telephone	301-827-6944				
Contact Emai	coryse.sthillaire-clarke@nih.gov				
Sponsor Website					
Program URI	https://grants.nih.gov/grants/guide/pa-f	iles/PAR-18-519.html			
Deadline Dates (ALL)	07-Jun-2019 , 07-Oct-2019 , 07-Feb-2020	) , 08-Jun-2020 , 08-Oct-2020			
Synopsis	National Institute on Aging (NIA) invites	applications for either basic, clinical, or a	combination	on of basic and cli	nical studies to

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		Alzheimer's disease. Studies may include including cellular, molecular, imaging, pl	e sensory and/or motor systems impact to older adults and/or animal models and raysiological and genetic, to address this need to be sensory and motor assessments is anism.	may employ eed. For clir	a variety of appronical studies, lever	oaches, aging of
0.70550	Basic and Translation Research or Alzheimer's Disease (R21 - Clinica		National Institute on Aging/NIH/DHHS	PAR-18- 538	20-Jun-2019	275,000 USD
	Contact Telephone Contact Email	nielsenli@nia.nih.gov				
	Sponsor Website	https://grants.nih.gov/grants/guide/pa-	files/PAR-18-538 html			
	-	20-Jun-2019 , 20-Feb-2020 , 22-Jun-2020				
		National Institute on Aging (NIA) invites and motivational parameters of impaire Research is sought that will characterize making are differentially impacted in no investigate the decision-making factors of financial exploitation and other forms of on the processes involved in decision making and with and without AD. Specific opportunity cognitive, emotional and motivational standinglifying choices and offering better decisions.	s applications for basic research to better d and intact decision making in both norm the extent to which basic behavioral and rmal aging and AD, investigate the influent that render older adults (with or without of mistreatment and abuse. The FOA also in aking to the design of decision-supportive ties include the development of decision-trengths of these populations; tools to assefaults; and the promotion of timely adopt FOA will use the NIH Exploratory/Develor	nal aging an neural produce of social cognitive im nvites applic interventic supportive tess decision otion of opt	d Alzheimer's disectesses involved in factors on decision pairment) vulners cations to apply be ons for midlife and interventions to lemal capacity; strate imal delegation presented in the strategimal delegation presented in the strategical delegation in the strategical delegation presented in the strategical delegation in the strategical delegation presented in the strategical delegation d	decision on making, and able to esic research older adults everage egies for actices (e.g.,
	Sleep Disorders and Circadian Clo Other Dementias of Aging (R01 Cl	ck Disruption in Alzheimer's Disease and inical Trial Not Allowed)	National Institute on Aging/NIH/DHHS	PAR-18- 497	08-May-2019 [LOI/Pre-App] [Optional]	2,500,000 USD
	Contact Name	Miroslaw Mackiewicz, Ph.D.				
	Contact Telephone					
	Contact Email	mackiewiczm2@mail.nih.gov				

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
			- <u>files/PAR-18-497.html</u> 07-Jun-2019 , 07-Sep-2019 [LOI/Pre-App][ 09-May-2020 [LOI/Pre-App][Optional], 08	•		
	Synopsis	approaches to advance basic and clinical dysfunction in Alzheimer's disease, and	es applications for molecular, cellular, general research on the causes and consequence the roles of sleep and the circadian clock ne NIH Research Project (R01) award mech	es of sleep d as modifiers	leficiency and circ	adian clock
071987	Advanced-Stage Development and for Interdisciplinary Aging Studies	d Utilization of Research Infrastructure (R33 - Clinical Trial Optional)	National Institute on Aging/NIH/DHHS	PAR-18- 644	16-Jun-2019	2,499,995 USD
	Contact Name	Winifred K. Rossi				
	Contact Telephone	301-496-3836				
	Contact Email	rossiw@mail.nih.gov				
	Sponsor Website					
	Program URL	https://grants.nih.gov/grants/guide/pa	-files/PAR-18-644.html			
	Deadline Dates (ALL)	16-Jun-2019				
	Synopsis	stage development and utilization of no interdisciplinary partnerships or collabor mechanism to provide support for expa developed either through PA-12-064, of mature and sustainable research infrast	ational Cancer Institute (NCI) invite applic ovel research infrastructure to advance the orations. This FOA will use the NIH Explora- inded activities. Applicants are expected to r with other NIH or non-NIH support. Thro cructure to support projects that address k H R33 Exploratory/Developmental Grants	e science of tory/Develo o have an ex ugh this awa key interdisc	aging in specific a pmental Grants P disting research inf ard, investigators iplinary aging rese	reas requiring hase II frastructure will develop a
071986	Research Infrastructure Developm (R21/R33 - Clinical Trial Optional)	nent for Interdisciplinary Aging Studies	National Institute on Aging/NIH/DHHS	PAR-18- 645	16-Jun-2019	Not Specified
	Contact Name	Winifred K. Rossi				
	Contact Telephone	301-496-3836				
	Contact Email	rossiw@mail.nih.gov				
	Sponsor Website					
	Program URL	https://grants.nih.gov/grants/guide/pa	-files/PAR-18-645.html			
	Deadline Dates (ALL)	16-Jun-2019				

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	research infrastructure that will advance collaborations. This FOA will use the NII support for initial developmental activitinvestigators will develop a sustainable	lational Cancer Institute (NCI) invite applications to the science of aging in specific areas requiring H Phased Innovation Award (R21/R33) mechanisties, and up to 3 years of R33 support for expansions are search infrastructure to support projects that se the NIHR21/R33 Phased Innovation Award grows to the NIHR21/R34	g interdisciplinary partne sm to provide up to 2 ye ded activities. Through t t address key interdiscip	erships or ears of R21 this award,
n/nunh -	<u>Jnderactive Bladder and Detruso</u> <u>Optional)</u>	r Activity in Aging (R03 Clinical Trial	National Institute on Aging/NIH/DHHS PA-2	18-571 07-May-2019	100,000 USD
	Contact Name	Marcel E. Salive, MD			
	Contact Telephone	301-496-6761			
	Contact Email	saliveme@mail.nih.gov			
	Sponsor Website				
	Program URL	https://grants.nih.gov/grants/guide/pa	-files/PA-18-571.html		
	Deadline Dates (ALL)	07-May-2019 , 16-Jun-2019 , 07-Sep-20 2020 , 16-Oct-2020 , 07-Jan-2021 , 16-F	19 , 16-Oct-2019 , 07-Jan-2020 , 16-Feb-2020 , ( eb-2021 , 07-May-2021	07-May-2020 , 16-Jun-20	020 , 07-Sep-
	Synopsis	underactive bladder (UAB) and detruso should focus on the 1) biology, etiology translation of basic/clinical research int and clinical outcomes of UAB in older advancing age. Pilot/feasibility research consequences in older adults and provided to the consequences of the consequences of the consequences in older adults and provided the consequences of the consequen	s pilot/feasibility projects that propose basic, clip r underactivity (DU) and its consequences in aging and pathophysiology of DU or UAB in animal mage o clinical practice and health decision-making; and dults; and/or 4) epidemiology and risk factors for a supported by this initiative should enhance known de evidence-based guidance in the diagnosis, even H RO3 Small Grant Program award mechanism.	ing and in older persons nodels and/or older adul B) diagnosis, prevention, or the development of D owledge of DU/UAB and	. Applications ts; 2) management U/UAB with I its
070905	Jnderactive Bladder and Detruso Optional)	r Activity in Aging (R21 Clinical Trial	National Institute on Aging/NIH/DHHS PA-2	18-572 07-May-2019	275,000 USD
	Contact Name	Marcel E. Salive, MD			
	Contact Telephone	301-496-6761			
	Contact Email	saliveme@mail.nih.gov			
	Sponsor Website				
	·				

Deadline Dates (ALL) 07-May-2019, 16-Jun-2019, 07-Sep-2019, 16-Oct-2019, 07-Jan-2020, 16-Feb-2020, 07-May-2020, 16-Jun-2020, 07-Sep-

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Synopsis	bladder (UAB) and detrusor underactivity on the 1) biology, etiology and pathoph basic/clinical research into clinical practicular outcomes of UAB in older adults; and/orage. The R21 mechanism is intended to the early and conceptual stages of these DU/UAB and its consequences in older adults.	eb-2021, 07-May-2021 applications that propose basic, clinical, or ty (DU) and its consequences in aging and ysiology of DU or UAB in animal models artice and health decision-making; 3) diagnory 4) epidemiology and risk factors for the encourage exploratory and developmental projects. Research supported by this initial adults and provide evidence-based guidan This FOA will use the NIH R21 Exploratory.	in older per nd/or older a sis, preventi developmen al research p iative should ce in the dia	rsons. Applications adults; 2) translation, management of DU/UAB with projects by providid enhance knowle	s should focus ion of and clinical advancing ng support for dge of n, and
11/119114	nderactive Bladder and Detruso ptional)	r Activity in Aging (R01 Clinical Trial	National Institute on Aging/NIH/DHHS	PA-18-570	07-May-2019	Not Specified
	Contact Name	Marcel E. Salive, MD				
	Contact Telephone	301-496-6761				
	Contact Email	saliveme@mail.nih.gov				
	Sponsor Website					
	Program URL	https://grants.nih.gov/grants/guide/pa	-files/PA-18-570.html			
	Deadline Dates (ALL)	07-May-2019 , 05-Jun-2019 , 07-Sep-20 2020 , 05-Oct-2020 , 07-Jan-2021 , 05-F	19 , 05-Oct-2019 , 07-Jan-2020 , 05-Feb-20 eb-2021 , 07-May-2021	020 <i>,</i> 07-May	y-2020 , 05-Jun-20	)20 , 07-Sep-
	Synopsis	National Institute on Aging (NIA) and Na applications that propose basic, clinical (DU) and its consequences in aging and pathophysiology of DU or UAB in anima practice and health decision making; 3) and/or 4) epidemiology and risk factors initiative should enhance knowledge of	ational Institute of Diabetes and Digestive or translational research on underactive in older persons. Applications should focul models and/or older adults; 2) translatio diagnosis, prevention, management and of for the development of DU/UAB with adv DU/UAB and its consequences in older adult of DU/UAB in older persons. This FOA w	bladder (UA us on the 1) had of basic/clinical outcorrancing age.	B) and detrusor unbiology, etiology a linical research intomes of UAB in old Research support wide evidence-bas	nderactivity and to clinical der adults; ed by this sed guidance in
11/2851	Note:	imer's Disease and Related Dementias	National Institute on Aging/NIH/DHHS	PAR-18- 760	16-Jun-2019	275,000 USD
	Contact Name	John K. Hsiao, M.D.				

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Contact Telephone	301-496-9350				
	Contact Email	jhsiao@nia.nih.gov				
	Sponsor Website					
	Program URL	https://grants.nih.gov/grants/guide/pa-	files/PAR-18-760.html			
	Deadline Dates (ALL)	16-Jun-2019 , 16-Oct-2019 , 16-Feb-2020	0 , 16-Jun-2020 , 16-Oct-2020			
National Institute on Aging (NIA) invites applications to study in vivo synaptic structure and function in Alzheimer's and Synopsis related dementia; and to advance development of methods to study synapses in animal models and humans. This program will use the NIH Exploratory/Developmental (R21) grant mechanism.						
11//6//	Selective Cell and Network Vulner (R01 Clinical Trial Not Allowed)	rability in Aging and Alzheimer's Disease	National Institute on Aging/NIH/DHHS	PAR-18- 706	05-Jun-2019	Not Specified
	Contact Name	Bradley Wise, Ph.D.				
	Contact Telephone	301-496-9350				
	Contact Email	wiseb@mail.nih.gov				
	Sponsor Website					
	Program URL	https://grants.nih.gov/grants/guide/pa-	files/PAR-18-706.html			
	Deadline Dates (ALL)	05-Jun-2019 , 05-Oct-2019				
	Synopsis	brain networks and regions that are vulnunderlying selective vulnerability from c	s applications to define and characterize inerable to brain aging and Alzheimer's distells to networks in AD is critical to fully deap MIH Research Project (R01) award mech	sease (AD). I	Jnderstanding me	chanisms
075498	Alzheimer's Drug-Development Pr	rogram (U01 Clinical Trial Optional)	National Institute on Aging/NIH/DHHS	PAR-18- 820	07-May-2019	5,000,000 USD
	Contact Name	Lorenzo M. Refolo, Ph.D.				
	Contact Telephone	301-594-7576				
	Contact Email	refolol@nia.nih.gov				
	Sponsor Website					
	Program URL	https://grants.nih.gov/grants/guide/pa-	files/PAR-18-820.html			
	Deadline Dates (ALL)	07-May-2019 , 05-Jun-2019 , 07-Sep-201 2020 , 05-Oct-2020 , 07-Jan-2021 , 05-Fe	19 , 05-Oct-2019 , 07-Jan-2020 , 05-Feb-20 eb-2021 , 07-May-2021 , 05-Jun-2021 , 07	020 , 07-Ma -Sep-2021	y-2020 , 05-Jun-20	020 , 07-Sep-
	Synopsis	National Institute on Aging's (NIA) invite	es applications for pre-clinical and early st	age clinical	(Phase I) developn	nent of novel

ISPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
----------	---------------	--------------	----------------	---------------	-------------------

small-molecule and biologic therapeutic agents that prevent Alzheimer's disease (AD), slow its progression or treat its cognitive and behavioral symptoms. Participants in this program will receive funding for therapy development activities such as medicinal chemistry, pharmacokinetics (PK), Absorption, Distribution, Metabolism, Excretion, Toxicology (ADMET), efficacy in animal models, formulation development, chemical synthesis under Good Manufacturing Practices (GMP), Investigational New Drug (IND) enabling studies and initial Phase I clinical testing. This program does not support research on basic mechanisms of disease, mechanisms of drug action, development of biomarkers, devices, non-pharmacological interventions (e.g., exercise, diet, cognitive training), repurposed drugs and combinations therapies, or discovery activities such as high throughput screening and hit optimization. This FOA will utilize the NIH U01 Research Project – Cooperative Agreements award mechanism.

Exploratory Analyses of Adherence Strategies and Data Sets from CALERIE 075525 to Investigate Behavioral and Psychosocial Aspects of Sustained Caloric Restriction in Humans (R21 Clinical Trial Not Allowed)

National Institute on Aging/NIH/DHHS PA-18-826 16-Jun-2019

275,000 **USD** 

Contact Name Giovanna Zappalà, Ph.D., M.P.H.

Contact Telephone 301-827-6240

Contact Email Giovanna.Zappala@nih.gov

Sponsor Website

Program URL https://grants.nih.gov/grants/guide/pa-files/PA-18-826.html

Deadline Dates (ALL) 16-Jun-2019, 16-Oct-2019, 16-Feb-2020, 16-Jun-2020, 16-Oct-2020, 16-Feb-2021, 16-Jun-2021

National Institute on Aging (NIA) invites applications for exploratory research projects (R21) involving secondary analyses of data in the Computerized Tracking System (CTS) database from the CALERIE (Comprehensive Assessment of Long-term Effects of Reducing Intake of Energy) trial to explore behavioral and psychosocial aspects of sustained caloric restriction (CR) in humans, including the translation of the CR adherence strategies used in the trial to promote healthy behaviors, especially for the prevention of weight gain with age. CALERIE was the first trial in humans to specifically focus on the effects of sustained CR. It demonstrated feasibility of sustained human CR (for at least two years) and favorable effects on predictors of longevity, as well as on cardiometabolic risk factors. The sustained weight loss in CALERIE has not been previously attained in any clinical study in non-obese individuals. This FOA will use the NIH Research Project (R01) award mechanism.

Analyses of Adherence Strategies and Data Sets from CALERIE to Explore 075524 Behavioral and Psychosocial Aspects of Sustained Caloric Restriction in Humans (R01 Clinical Trial Not Allowed)

National Institute on Aging/NIH/DHHS PA-18-825 05-Jun-2019

Not **Specified** 

Contact Name Giovanna Zappalà, Ph.D., M.P.H.

Contact Telephone 301-827-6240

Contact Email Giovanna.Zappala@nih.gov



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Theadline pate	Funding Amount
	Sponsor Website				
	Program URL	https://grants.nih.gov/grants/guide/pa-	files/PA-18-825.html		
	Deadline Dates (ALL)	05-Jun-2019 , 05-Oct-2019 , 05-Feb-2020	0 , 05-Jun-2020 , 05-Oct-2020 , 05-Feb-2021 , 05-Jun-	-2021	
	Synopsis	Computerized Tracking System (CTS) data Reducing Intake of Energy) trial to exploincluding the translation of the CR adher prevention of weight gain with age. CAL demonstrated feasibility of sustained huwell as on cardiometabolic risk factors.	s applications for research projects (R01) involving setabase from the CALERIE (Comprehensive Assessment re behavioral and psychosocial aspects of sustained or rence strategies used in the trial to promote healthy ERIE was the first trial in humans to specifically focus iman CR (for at least two years) and favorable effects The sustained weight loss in CALERIE has not been provinced with the NIH Research Project (R01) award mechanism.	at of Long-term Effectaloric restriction (in behaviors, especial on the effects of some predictors of locations of locations).	ects of CR) in humans Ily for the ustained CR. I ongevity, as
075522		Data and Biospecimens to Elucidate n (CR)-Induced Effects in Humans (R21	National Institute on Aging/NIH/DHHS PA-18-824	1 16-Jun-2019	275,000 USD
	Contact Name	Giovanna Zappalà, Ph.D., M.P.H.			
	Contact Telephone	301-827-6240			
	Contact Email	Giovanna.Zappala@nih.gov			
	Sponsor Website				
	Program URL	https://grants.nih.gov/grants/guide/pa-	files/PA-18-824.html		
	Deadline Dates (ALL)	16-Jun-2019 , 16-Oct-2019 , 16-Feb-202	0 , 16-Jun-2020 , 16-Oct-2020 , 16-Feb-2021 , 16-Jun-	2021	
	Synopsis	data and/or stored biospecimens from t Energy) trial. The goal of this funding op detailed understanding of the effects of	s applications for exploratory research projects (R21 he CALERIE (Comprehensive Assessment of Long-term portunity announcement (FOA) is to encourage analycaloric restriction (CR) on risk factors for chronic disease the effects of sustained CR in humans. This FOA was rant award mechanism.	m Effects of Reduci yses that will lead t eases, as well as, th	ing Intake of o a more
	Analyses of CALERIE Data and Bio	specimens to Elucidate Mechanisms of			Not
075519	Caloric Restriction (CR)-Induced E Allowed)	ffects in Humans (R01 Clinical Trial Not	National Institute on Aging/NIH/DHHS PA-18-823	3 05-Jun-2019	Not Specified
	Contact Name	Giovanna Zappalà, Ph.D., M.P.H.			

Contact Telephone 301-827-6240

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount	
	Contact Email	Giovanna.Zappala@nih.gov					
	Sponsor Website						
	Program URL	https://grants.nih.gov/grants/guide/pa-	files/PA-18-823.html				
	Deadline Dates (ALL) 05-Jun-2019 , 05-Oct-2019 , 05-Feb-2020 , 05-Jun-2020 , 05-Oct-2020 , 05-Feb-2021 , 05-Jun-2021						
	Synopsis	National Institute on Aging (NIA) invites applications for research projects (R01) involving secondary analyses of data and/o stored biospecimens from the CALERIE (Comprehensive Assessment of Long- term Effects of Reducing Intake of Energy) tria The goal of this funding opportunity announcement (FOA) is to encourage analyses that will lead to a more detailed understanding of the effects of caloric restriction (CR) on risk factors for chronic diseases, as well as, the cellular/molecular mechanisms mediating the effects of sustained CR in humans. This FOA will use the NIH Research Project (R01) award mechanism.					
070464	Alzheimer's Clinical Trials Consort Trial Required)	ium (ACTC) Clinical Trials (R01 Clinical	National Institute on Aging/NIH/DHHS	PAR-18- 513	05-Jun-2019	Not Specified	
	Contact Name	Laurie Ryan, Ph.D.					
	Contact Telephone	301-496-9350					
	Contact Email	ryanl@mail.nih.gov					
	Sponsor Website						
	Program URL	https://grants.nih.gov/grants/guide/pa-	files/PAR-18-513.html				
	Deadline Dates (ALL)	05-Jun-2019 , 05-Oct-2019 , 05-Feb-2020	0 , 05-Jun-2020 , 05-Oct-2020				
	Synopsis	National Institute on Aging (NIA) invites applications to develop and implement Phase I to III clinical trials of promising pharmacological and non-pharmacological interventions that may prevent, delay, or treat the symptoms of Alzheimer's disease (AD) and other age-related dementias using the Alzheimer's disease Clinical Trials Consortium (ACTC) trial coordination and management infrastructure. This FOA will use the NIH Research Project (R01) award mechanism.					
076587	Early Stage Clinical Trials for the S related Cognitive Decline (R01 Clin	spectrum of Alzheimer's Disease and Agenical Trial Optional)	National Institute on Aging/NIH/DHHS	PAR-18- 877	05-Jun-2019	Not Specified	
	Contact Name	Laurie Ryan					
	Contact Telephone	301-496-9350					
	Contact Email	ryanl@mail.nih.gov					
	Sponsor Website						
	Program URL	https://grants.nih.gov/grants/guide/pa-	files/PAR-18-877.html				
	Deadline Dates (ALL)	05-Jun-2019 , 05-Oct-2019 , 05-Feb-2020	0 , 05-Jun-2020 , 05-Oct-2020 , 05-Feb-20	21 , 05-Jun-	2021		

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Synopsis	develop and implement early stage (Phainterventions in individuals with age-rel	lational Institute of Nursing Research (NIN ase I or II) clinical trials of promising pharmated cognitive decline and in individuals we severe stages of disease, and 2) to stime earch Project (R01) award mechanism.	nacological vith Alzheim	and non-pharmac er's disease (AD) a	ological across the
076590	Late Stage Clinical Trials for the Sprelated Cognitive Decline (R01 Clin	pectrum of Alzheimer's Disease and Age- nical Trial Required)	National Institute on Aging/NIH/DHHS	PAR-18- 878	05-Jun-2019	Not Specified
	Contact Name	Laurie Ryan				
	Contact Telephone	301-496-9350				
	Contact Email	ryanl@mail.nih.gov				
	Sponsor Website					
	Program URL	https://grants.nih.gov/grants/guide/pa-	files/PAR-18-878.html			
	Deadline Dates (ALL)	05-Jun-2019 , 05-Oct-2019 , 05-Feb-202	0 , 05-Jun-2020 , 05-Oct-2020 , 05-Feb-20	21 , 05-Jun-	2021	
	Synopsis	develop and implement late stage (Phasinterventions in individuals with age-rel	lational Institute of Nursing Research (NINse II/III, III) clinical trials of promising pharated cognitive decline and across the Alzhlisease. This FOA will use the NIH Resea	macological eimer's dise	and non-pharmacease (AD) spectrur	cological n from pre-
076718	Limited Competition: Renewal of, Genetics Consortium (U01 Clinica	and Revisions to, the Alzheimer's Diseas I Trial Not Allowed)	e National Institute on Aging/NIH/DHHS	PAR-18- 889	05-Jun-2019	2,500,000 USD
	Contact Name	Marilyn Miller, Ph.D.				
	Contact Telephone	301-496-9350				
	Contact Email	millerm@nia.nih.gov				
	Sponsor Website					
	Program URL	https://grants.nih.gov/grants/guide/pa-	files/PAR-18-889.html			
	Deadline Dates (ALL)	05-Jun-2019 , 05-Oct-2019 , 05-Feb-202	0 , 05-Jun-2020 , 05-Oct-2020 , 05-Feb-20	21 , 05-Jun-	2021	
	Synopsis		the NIA Alzheimer's Disease Genetics Cor of Alzheimer's Disease. This program will unism.			
076719	Limited Competition: Additional S Sequencing Project: Opportunity	sequencing for the Alzheimer's Disease for Revision Requests for Active	National Institute on Aging/NIH/DHHS	PAR-18- 890	05-Jun-2019	2,500,000 USD

SPIN ID	Program	Sponsor Name	Sponsor Number	Deadline Date	Funding
31 111 12	Title	opensor riame		Deddine Date	Amount

## Cooperative Agreements (U01 Clinical Trial Not Allowed)

Contact Name Marilyn Miller, Ph.D.

Contact Telephone 301-496-9350

Contact Email millerm@nia.nih.gov

**Sponsor Website** 

Program URL https://grants.nih.gov/grants/guide/pa-files/PAR-18-890.html

Deadline Dates (ALL) 05-Jun-2019, 05-Oct-2019, 05-Feb-2020, 05-Jun-2020, 05-Oct-2020, 05-Feb-2021, 05-Jun-2021

National Institute on Aging (NIA) invites revision applications to ongoing NIA-supported Cooperative Agreements in the area of the genetics of Alzheimer's Disease and Alzheimer's Disease Related Dementias (AD/ADRD). This Funding Opportunity Announcement (FOA) invites applications specific to sample acquisition, genome wide association studies, whole genome sequencing, quality control checking, variant calling, and data calling that will support the generation of data for the Alzheimer's Disease Sequencing Project Follow-Up Study. This program will use the NIH U01 Research Project Cooperative Agreements award mechanism.

059724 Juvenile Protective Factors and Their Effects on Aging (R03)

Synopsis

PAR-17-200,000 National Institute on Aging/NIH/DHHS 16-Jun-2019 127 **USD** 

Contact Name Chhanda Dutta, Ph.D.

Contact Telephone 301-496-4161

Contact Email duttac@mail.nih.gov

Sponsor Website

Program URL https://grants.nih.gov/grants/guide/pa-files/PAR-17-127.html

Deadline Dates (ALL) 16-Jun-2019, 16-Oct-2019, 16-Feb-2020

National Institute on Aging (NIA) invites applications for 1) descriptive studies to identify putative juvenile protective factors, 2) experimental studies to test hypotheses about their effects on aging and 3) translational studies to characterize potential beneficial and adverse effects of maintaining or modulating the level of juvenile protective factors in adult life. Juvenile protective factors (JPFs), intrinsic to an immature organism, help to maintain or enhance certain physiological functions across all or some stages of postnatal development (i.e., segment of the life span between birth and sexual maturity), but Synopsis diminish or disappear as the organism transitions from one maturational stage to the next. The loss or diminution of JPFs after a given stage of postnatal development or at time of sexual maturity may contribute to the onset of deleterious aging changes (e.g., compromised stem cell function and reparative capacity) across adulthood. This FOA is uniquely focused on animal and clinical studies which involve comparisons between juvenile versus adult states or between stages of postnatal development to identify putative JPFs and their effects on aging. Studies which involve comparisons between young and old

SPIN ID	Program	Sponsor Name	Sponsor Number	Deadline Date	Funding
	Title	oponioor rounic	Sponso Hamise		Amount
		adults will not be supported by	this FOA. This FOA will utilize the NIH R03 Small Grant	t Program award mechanis	sm.
054494	Non-healing Ulcerative Wounds in	n Aging (R21)	National Institute on Aging/NIH/DHHS PA	A-16-231 07-May-2019	275,000 USD
	Contact Name	Marcel E. Salive, MD			
	Contact Telephone	301-496-6761			
	Contact Email	saliveme@mail.nih.gov			
	Sponsor Website				
	Program URL	http://grants.nih.gov/grants/gui	ide/pa-files/PA-16-231.html		
	Deadline Dates (ALL)	07-May-2019 , 16-Jun-2019 , 07-	-Sep-2019		
		i biology, etiology and pathophys	siology of non-healing ulcerative wounds in animal mo	odels and/or older adults:	2) translation
	Synopsis	of basic/clinical research into cli outcomes of non-healing wound healing wounds and their conse	siology of non-healing ulcerative wounds in animal moinical practice and health decision-making; 3) diagnosids in older adults. Research supported by this initiative quences in older adults and provide evidence-based gwounds in older persons. This FOA will use the NIH E	is, prevention, manageme e should enhance knowled guidance in the diagnosis,	nt and clinical dge of non- evaluation,
054521	Synopsis  Mechanisms Mediating Osteoarth	of basic/clinical research into cli outcomes of non-healing wound healing wounds and their conse and/or treatment of non-healing mechanism.	inical practice and health decision-making; 3) diagnosi ds in older adults. Research supported by this initiative quences in older adults and provide evidence-based g	is, prevention, manageme e should enhance knowled guidance in the diagnosis, Exploratory/Development	nt and clinical dge of non- evaluation,
054521	Mechanisms Mediating Osteoarth	of basic/clinical research into cli outcomes of non-healing wound healing wounds and their conse and/or treatment of non-healing mechanism.	inical practice and health decision-making; 3) diagnosids in older adults. Research supported by this initiative quences in older adults and provide evidence-based gwounds in older persons. This FOA will use the NIH E	is, prevention, manageme e should enhance knowled guidance in the diagnosis, Exploratory/Development	nt and clinical dge of non- evaluation, al (R21) grant Not
054521	Mechanisms Mediating Osteoarth	of basic/clinical research into cli outcomes of non-healing wound healing wounds and their conse and/or treatment of non-healing mechanism.  nritis in Aging (R01)  John P. Williams, Ph.D.	inical practice and health decision-making; 3) diagnosids in older adults. Research supported by this initiative quences in older adults and provide evidence-based gwounds in older persons. This FOA will use the NIH E	is, prevention, manageme e should enhance knowled guidance in the diagnosis, Exploratory/Development	nt and clinical dge of non- evaluation, al (R21) grant Not
054521	Mechanisms Mediating Osteoarth  Contact Name  Contact Telephone	of basic/clinical research into cli outcomes of non-healing wound healing wounds and their conse and/or treatment of non-healing mechanism.  nritis in Aging (R01)  John P. Williams, Ph.D.	inical practice and health decision-making; 3) diagnosids in older adults. Research supported by this initiative quences in older adults and provide evidence-based gwounds in older persons. This FOA will use the NIH E	is, prevention, manageme e should enhance knowled guidance in the diagnosis, Exploratory/Development	nt and clinical dge of non- evaluation, al (R21) grant Not
054521	Mechanisms Mediating Osteoarth  Contact Name  Contact Telephone	of basic/clinical research into cli outcomes of non-healing wound healing wounds and their consect and/or treatment of non-healing mechanism.  Pritis in Aging (R01)  John P. Williams, Ph.D. 301-496-6403  williamsj6@mail.nih.gov	inical practice and health decision-making; 3) diagnosids in older adults. Research supported by this initiative quences in older adults and provide evidence-based gwounds in older persons. This FOA will use the NIH E	is, prevention, manageme e should enhance knowled guidance in the diagnosis, Exploratory/Development	nt and clinical dge of non- evaluation, al (R21) grant Not
054521	Mechanisms Mediating Osteoarth  Contact Name  Contact Telephone  Contact Email  Sponsor Website	of basic/clinical research into cli outcomes of non-healing wound healing wounds and their consect and/or treatment of non-healing mechanism.  Pritis in Aging (R01)  John P. Williams, Ph.D. 301-496-6403  williamsj6@mail.nih.gov	inical practice and health decision-making; 3) diagnosi ds in older adults. Research supported by this initiative quences in older adults and provide evidence-based g g wounds in older persons. This FOA will use the NIH E National Institute on Aging/NIH/DHHS PA	is, prevention, manageme e should enhance knowled guidance in the diagnosis, Exploratory/Development	nt and clinical dge of non- evaluation, al (R21) grant Not
054521	Mechanisms Mediating Osteoarth  Contact Name  Contact Telephone  Contact Email  Sponsor Website	of basic/clinical research into cli outcomes of non-healing wound healing wounds and their conseand/or treatment of non-healing mechanism.  Pritis in Aging (R01)  John P. Williams, Ph.D. 301-496-6403  williamsj6@mail.nih.gov  http://grants.nih.gov/grants/gui	inical practice and health decision-making; 3) diagnosi ds in older adults. Research supported by this initiative quences in older adults and provide evidence-based g g wounds in older persons. This FOA will use the NIH E National Institute on Aging/NIH/DHHS PA	is, prevention, manageme e should enhance knowled guidance in the diagnosis, Exploratory/Development	nt and clinical dge of non- evaluation, al (R21) grant Not
054521	Mechanisms Mediating Osteoarth  Contact Name Contact Telephone Contact Email Sponsor Website Program URL	of basic/clinical research into cli outcomes of non-healing wound healing wounds and their conseand/or treatment of non-healing mechanism.  Pritis in Aging (R01)  John P. Williams, Ph.D. 301-496-6403  williamsj6@mail.nih.gov  http://grants.nih.gov/grants/gui 05-Jun-2019  National Institute on Aging invite underutilized models and the te	inical practice and health decision-making; 3) diagnosi ds in older adults. Research supported by this initiative quences in older adults and provide evidence-based g g wounds in older persons. This FOA will use the NIH E National Institute on Aging/NIH/DHHS PA	is, prevention, manageme e should enhance knowled guidance in the diagnosis, Exploratory/Development 4-16-239 05-Jun-2019  the characterization of new lerstanding of the mechan	nt and clinical dge of non- evaluation, al (R21) grant  Not Specified  ew or iisms of

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
					Specified
	Contact Name	Marcel E. Salive, MD			
	Contact Telephone	301-496-6761			
	Contact Email	saliveme@mail.nih.gov			
	Sponsor Website				
	Program URL	http://grants.nih.gov/grants/guide/p	a-files/PA-16-230.html		
	Deadline Dates (ALL)	07-May-2019 , 05-Jun-2019 , 07-Sep-3	2019		
	Synopsis	clinical, or translational research on n Applications are encouraged which for animal models and/or older adults; 2 3) diagnosis, prevention, management this initiative should enhance knowle	National Institute of Nursing Research (NINR) in con-healing ulcerative wounds and their consequeus on the 1) biology, etiology and pathophysio translation of basic/clinical research into clinical and clinical outcomes of non-healing wounds dge of non-healing wounds and their consequences, evaluation, and/or treatment of non-healing ward mechanism.	uences in aging and in old logy of non-healing ulcera al practice and health dec in older adults. Research s nces in older adults and pr	er persons. ative wounds in ision-making; supported by rovide
054522	Mechanisms Mediating Osteoarth	nritis in Aging (R21)	National Institute on Aging/NIH/DHHS PA	N-16-240 16-Jun-2019	275,000 USD
	Contact Name	John P. Williams, Ph.D.			
	Contact Telephone	301-496-6403			
	Contact Email	williamsj6@mail.nih.gov			
	Sponsor Website				
	Program URL	http://grants.nih.gov/grants/guide/p	a-files/PA-16-240.html		
	Deadline Dates (ALL)	16-Jun-2019			
	Synopsis	underutilized models and the testing	plicationsintended to encourage and accelerate of hypotheses that will lead to an improved und hritis and the role of aging in the process. This Fint mechanism.	derstanding of the mechar	
IIINIXSX	Limited Competition: Analysis of I Sequencing Project Follow-Up Stu	Data from NIA's Alzheimer's Disease ody (U01)	National Institute on Aging/NIH/DHHS 21	AR-17- 05-Jun-2019	Not Specified

Contact Name Marilyn Miller, Ph.D.

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Contact Telephone	301-496-9350				
	Contact Email	millerm@nia.nih.gov				
	Sponsor Website					
	Program URL	https://grants.nih.gov/grants/guide/	/pa-files/PAR-17-214.html			
	Deadline Dates (ALL)	05-Jun-2019 , 05-Oct-2019 , 05-Feb-	2020			
			vites applications specific to the analysis of ge a generated under PAR-16-406. This program chanism.			
059722 <u>J</u>	uvenile Protective Factors and Th	neir Effects on Aging (R01)	National Institute on Aging/NIH/DHHS	PAR-17- 126	05-Jun-2019	Not Specified
	Contact Name	Chhanda Dutta, Ph.D.				
	Contact Telephone	301-496-4161				
	Contact Email	duttac@mail.nih.gov				
	Sponsor Website					
	Program URL	https://grants.nih.gov/grants/guide/	/pa-files/PAR-17-126.html			
	Deadline Dates (ALL)	05-Jun-2019 , 05-Oct-2019 , 05-Feb-	2020			
	Synopsis	2) experimental studies to test hypo beneficial and adverse effects of ma protective factors (JPFs), intrinsic to across all or some stages of postnata diminish or disappear as the organis after a given stage of postnatal devechanges (e.g., compromised stem ceanimal and clinical studies which invidevelopment to identify putative JPF	ites applications for 1) descriptive studies to it theses about their effects on aging and 3) traintaining or modulating the level of juvenile pan immature organism, help to maintain or eal development (i.e., segment of the life span m transitions from one maturational stage to elopment or at time of sexual maturity may could function and reparative capacity) across ad olve comparisons between juvenile versus across and their effects on aging. Studies which in FOA. This FOA will utilize the R01 Research Pr	nslational solution of solutio	studies to character actors in adult life. tain physiological f irth and sexual ma The loss or diminution the onset of delethis FOA is uniquely or between stages of parisons between y	rize potential Juvenile unctions turity), but on of JPFs erious aging focused on of postnatal oung and old
057813 <u>/</u>	Aging Research Dissertation Awar	ds to Increase Diversity (R36)	National Institute on Aging/NIH/DHHS	PAR-17- 025	07-May-2019	Not Specified
	Contact Name Contact Telephone	Chyren Hunter, Ph.D. 301-402-4158				

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Contact Email Sponsor Website	hunterc@nia.nih.gov				
	Program URL	http://grants.nih.gov/grants/guide/pa	-files/PAR-17-025.html			
	Deadline Dates (ALL)	07-May-2019 , 16-Jun-2019 , 07-Sep-20	019 , 16-Oct-2019 , 07-Jan-2020			
	Synopsis		s applications for dissertation awards in all cientific research workforce engaged in rese 36 dissertation award mechanism.			_
078245	RFA-AG-20-003 Demography an Coordinating Center (R24 Clinical	d Economics of Aging and AD/ADRD  Trial Not Allowed)	National Institute on Aging/NIH/DHHS	RFA-AG- 20-003	03-May-2019 [LOI/Pre-App] [Optional]	Not Specified
	Contact Name	Georgeanne E. Patmios, M.A.				
	Contact Telephone	301-496-3136				
	Contact Email	PatmiosG@mail.nih.gov				
	Sponsor Website					
	Program URL	https://grants.nih.gov/grants/guide/rf	a-files/RFA-AG-20-003.html			
	Deadline Dates (ALL)	03-May-2019 [LOI/Pre-App][Optional],	03-Jun-2019			
	Synopsis	purpose is to act as a hub, serving the Centers) and Centers on the Demograph Centers on AD/ADRD), as well as the new lines of research in a) the demograph research relevant to AD/ADRD, and to and infrastructure activities that are buyith all participating Center sites to: mactivities and resources to the research database to track and synthesize program foster communication and collaborative	nography and Economics of Aging and AD/A needs of both traditional Centers on the Dephy and Economics of Alzheimer's Disease a eeds of NIA program staff. The goals of the aphy and economics of aging and b) demogrow the number of researchers engaged is uilt around specific research themes. The praintain an active multi-center website; disease and outcomes of Center and CC activitics Staff, and for future program evaluation by the activities within and across both D&E Center for the overall D&E Centers program by NIA	emography and Alzheim overall D&E graphy, econ n these field urpose of the seminate Ce vant stakeho es for the p y NIA; arran nter progran	and Economics of er's Related Deme Ecenter program anomics and health ds through a varietie CC is to work counter research advantage an annual in-pers and with other	Aging (D&E entias (D&E are to seed services by of research ellaboratively ances, centralized reporting to erson meeting; NIA research
	RFA-AG-20-002 Centers on the I Alzheimer's Disease and Alzheime	Demography and Economics of r's Related Dementias (P30 Clinical Tria	National Institute on Aging/NIH/DHHS	RFA-AG- 20-002	03-May-2019 [LOI/Pre-App]	545,000 USD

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
-	Optional)				[Optional]	
	Contact Name	Georgeanne E. Patmios, M.A.				
	Contact Telephone	301-496-3136				
	Contact Email	PatmiosG@mail.nih.gov				
	Sponsor Website					
	Program URL	https://grants.nih.gov/grants/guide/rfa-	files/RFA-AG-20-002.html			
	Deadline Dates (ALL)	03-May-2019 [LOI/Pre-App][Optional], 0	3-Jun-2019			
	Synopsis	research relevant to Alzheimer's Disease encouraged are: a) national and internat care and caregiving; c) economic burden on outcomes for persons with dementia persons with dementia and their care proutcomes in health and long-term care s care; h) effects of population-level health national and international projections of	systems for persons with dementia; g) disp h delivery and care interventions on outco dementia caseload, incidence and preval hoose among three optional Cores. Cente	ADRD). Are and AD/AL atems and loalth care fin incentives a parities in question of percence. Center	as of focus that and DRD; b) demograp ong-term supports ancing policies on offect access, quality and access sons with dementary grant applications.	re especially hy of dementia s and services outcomes for ity and health to dementia tia; and i) ons must
078241	RFA-AG-20-001 Centers on the (P30 Clinical Trial Optional)	Demography and Economics of Aging	National Institute on Aging/NIH/DHHS	RFA-AG- 20-001	03-May-2019 [LOI/Pre-App] [Optional]	545,000 USD
	Contact Name	Georgeanne E. Patmios, M.A.				
	Contact Telephone	301-496-3136				
	Contact Email	PatmiosG@mail.nih.gov				
	Sponsor Website					
	Program URL	https://grants.nih.gov/grants/guide/rfa-	files/RFA-AG-20-001.html			
	Deadline Dates (ALL)	03-May-2019 [LOI/Pre-App][Optional], 0	3-Jun-2019			
	Synopsis	aging, including relevant interdisciplinary	nent Center (P30) grant applications in the y areas rooted in population-based social omic status (SES) disparities at older ages,	science res	earch. Areas of fo	cus that are

reasons for poor U.S. performance in health and mortality in international comparisons; c) trends and dynamics in old-age

SPIN ID Program		Sponsor Name	Sponsor Number		Deadline Date	Funding
Title		Sponsor Name	Sponsor Humber		Deddine Date	Amount
	for chro suppor submit	onic disease, disability and Alzhe ts and services for the disabled e to RFA-AG-19-013. Center grant	nd its sequelae; e) family demography incluimer's Disease and Alzheimer's-Related De elderly population. Applications that wish to applications must include two mandatory work collaboratively with the Coordinatin	ementias (A to focus exc Cores and I	D/ADRD); and f) lo lusively on AD/AD may choose amon	ong-term RD should g three
080399 RFA-AG-20-014 G		es to Alzheimer's Disease (R21	National Institute on Aging/NIH/DHHS	RFA-AG- 20-014	02-Jun-2019 [LOI/Pre-App] [Optional]	275,000 USD
	Contact Name Felipe S	Sierra, Ph.D.				
Cont	act Telephone 301-49	6-6402				
	Contact Email sierraf(	@nia.nih.gov				
Sp	onsor Website					
	Program URL https://	/grants.nih.gov/grants/guide/rfa	-files/RFA-AG-20-014.html			
Deadli	ne Dates (ALL) 02-Jun-	-2019 [LOI/Pre-App][Optional], 0	2-Jul-2019			
	Synopsis the device disease now all gerosci	velopment, etiology and treatme es, a fact recognized by the field of low researchers to address mech ence principles and test the role	nt (FOA) invites applications proposing resont of Alzheimer's disease. Aging is by far the figure of geroscience. Recent advances in the field anistically the role of aging in Alzheimer's of different hallmarks of aging biology are by on Alzheimer's disease will be deemed resonance.	ne main risk ds of basic a disease. Ap specifically	factor for most claging biology and plications that ma appropriate, while	nronic geroscience lke use of
080398 RFA-AG-20-013 G		es to Alzheimer's Disease (R01	National Institute on Aging/NIH/DHHS	RFA-AG- 20-013	02-Jun-2019 [LOI/Pre-App] [Optional]	Not Specified
	Contact Name Felipe S	Sierra, Ph.D.				
Cont	act Telephone 301-49	6-6402				
	Contact Email sierraf(	@nia.nih.gov				
Sp	onsor Website					
	Program URL https://	/grants.nih.gov/grants/guide/rfa	-files/RFA-AG-20-013.html			
Deadli	ne Dates (ALL) 02-Jun-	-2019 [LOI/Pre-App][Optional], 0	2-Jul-2019			
	Synopsis This Fu the dev	nding Opportunity Announceme elopment, etiology and treatme	nt (FOA) invites applications proposing res nt of Alzheimer's disease. Aging is by far th	search on th	e specific role of a factor for most cl	aging biology in hronic

SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	diseases, a fact recognized by the field of now allow researchers to address mecha geroscience principles and test the role of focused solely on aging biology, or solely	nistically the role of aging in Alzheimer's of different hallmarks of aging biology are	disease. Ap specifically	plications that ma appropriate, whil	ke use of
057933 Role of Age-Associated Metabolic (R01)	Changes in Alzheimer's Disease (AD)	National Institute on Aging/NIH/DHHS	PAR-17- 031	05-Jun-2019	Not Specified
Contact Name	Yih-Woei Fridell, Ph.D.				
Contact Telephone	301-496-7847				
Contact Email	<u>yih-woei.fridell@nih.gov</u>				
Sponsor Website					
Program URL	http://grants.nih.gov/grants/guide/pa-fil	es/PAR-17-031.html			
Deadline Dates (ALL)	05-Jun-2019 , 05-Oct-2019 , 05-Feb-2020	)			
Synopsis	National Institute on Aging (NIA) invites cellular bases for age-related change in nuse the NIH Research Project (R01) award	· · · · · · · · · · · · · · · · · · ·		•	
058524 <u>Leveraging Existing Cohort Studie</u> <u>Alzheimer's Disease and Related I</u>	s to Clarify Risk and Protective Factors for Dementias (R01)	National Institute on Aging/NIH/DHHS	PAR-17- 054	05-Jun-2019	Not Specified
Contact Name	Jonathan W. King, Ph.D.				
Contact Telephone	301-402-4156				
Contact Email	kingjo@nia.nih.gov				
Sponsor Website					
Program URL	http://grants.nih.gov/grants/guide/pa-fil	es/PAR-17-054.html			
Deadline Dates (ALL)	05-Jun-2019 , 05-Oct-2019 , 05-Feb-2020				
	National Institute on Aging (NIA) invites	applications that will combine multiple		•	•
Synopsis	and clarify risk and protective factors for Research Project (R01) award mechanisn		ias (AD/ADF	RD). This FOA will (	use the NIH
O58112 Comparative Biology of Neurodeg	Research Project (R01) award mechanisn		PAR-17-	16-Jun-2019	275,000 USD

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Contact Telephone	301-827-4013				
	•	francesca.macchiarini@nih.gov				
	Sponsor Website					
	Program URL	http://grants.nih.gov/grants/guide/pa-f	iles/PAR-17-039.html			
	Deadline Dates (ALL)	16-Jun-2019 , 16-Oct-2019				
	Synopsis	different animal species respond to chal Alzheimer's and other neurodegenerative	s applications for exploratory comparative llenges and damage to cellular physiology we diseases as well as resilience to them, s ction and regeneration. This program will o	pathways th uch as adap	nat might influenc tation to stress, m	te the onset of nacromolecular
081010		of Managing Reduced Iron Stores on in Older Adults with Heart Failure and d)	National Institute on Aging/NIH/DHHS	PA-19-230	05-Jun-2019	Not Specified
	Contact Name	Sergei Romashkan, MD, Ph.D.				
	Contact Telephone	301-435-3047				
	Contact Email	romashks@nia.nih.gov				
	Sponsor Website					
	Program URL	https://grants.nih.gov/grants/guide/pa-	files/PA-19-230.html			
	Deadline Dates (ALL)	05-Jun-2019 , 05-Oct-2019 , 05-Feb-202 2022 , 05-Jun-2022	0 , 05-Jun-2020 , 05-Oct-2020 , 05-Feb-20	21 , 05-Jun-2	2021 , 05-Oct-202	1 , 05-Feb-
	Synonsis		natic clinical trial to establish efficacy of m ts with heart failure and anemia.	anaging red	luced iron stores o	on risk of
081131	Limited Competition: Additional Se Sequencing Project (U01 Clinical T	equencing for the Alzheimer's Disease rial Not Allowed) Activity Code)	National Institute on Aging/NIH/DHHS	PAR-19- 234	05-Jun-2019	Not Specified
	Contact Name	Marilyn Miller, Ph.D.				
	Contact Telephone					
	Contact Email	millerm@nia.nih.gov				
	Sponsor Website					

Deadline Dates (ALL) 05-Jun-2019, 05-Oct-2019, 05-Feb-2020, 05-Jun-2020, 05-Oct-2020, 05-Feb-2021, 05-Jun-2021, 05-Oct-2021, 05-Feb-

Program URL <a href="https://grants.nih.gov/grants/guide/pa-files/PAR-19-234.html">https://grants.nih.gov/grants/guide/pa-files/PAR-19-234.html</a>

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	studies, whole genome sequencing	ement (FOA) invites applications specific to s , quality control checking, variant calling, and Sequencing Project Follow-Up Study.		
056489 <u>S</u>	econdary Analyses of Alcohol and	d Chronic Disease (R01)	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	PA-16-395 07-May-2019	Not Specified
	Contact Telephone	Rosalind Breslow, PhD, MPH 301-594-6231 rbreslow@mail.nih.gov			
	Program URL Deadline Dates (ALL)	http://grants.nih.gov/grants/guide/ 07-May-2019 , 05-Jun-2019 , 07-Se		that propose to conduct secon	dary analyses
	Synopsis	of alcohol as it relates to chronic dis	sease etiology and epidemiology. The goal of viously collected data. This FOA will use the f	this program is to facilitate inn	ovative yet
056492 <u>S</u> 6	econdary Analyses of Alcohol and	d Chronic Disease (RO3)	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	PA-16-394 07-May-2019	100,000 USD
	Contact Name	Rosalind Breslow, PhD, MPH			
	Contact Telephone	301-594-6231			
	Contact Email	rbreslow@mail.nih.gov			
	Sponsor Website				
	Program URL	http://grants.nih.gov/grants/guide/	/pa-files/PA-16-394.html		
	Deadline Dates (ALL)	07-May-2019 , 16-Jun-2019 , 07-Se	p-2019		
	Synopsis	of alcohol as it relates to chronic dis	e and Alcoholism (NIAAA) invites applications sease etiology and epidemiology. The goal of viously collected data. This FOA will use the N	this program is to facilitate inn	ovative yet
066094 <u>S</u>	econdary Analyses of Existing Alc	ohol Research Data (RO3)	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	PA-17-468 07-May-2019	100,000 USD

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Contact Name Contact Telephone	Wenxing Zha, Ph.D. 301-443-0633				
	·	zhaw@mail.nih.gov				
	Sponsor Website					
	·	https://grants.nih.gov/grants/guide/pa-	files/PA-17-468.html			
	Deadline Dates (ALL)	07-May-2019 , 16-Jun-2019 , 07-Sep-202 2020	19 , 16-Oct-2019 , 07-Jan-2020 , 16-Feb-20	)20 , 07-May	/-2020 , 16-Jun-20	)20 , 07-Sep-
	Synopsis	analysis of existing data sets with the go epidemiology and etiology, including ge Existing Alcohol Research Data are inten increase our understanding of the incide population, as well as the risk and prote demonstrate or promote methodological	Alcoholism (NIAAA) invites applications the all of enhancing our understanding of path netics, of alcohol-related problems. Researched to provide support for studies that understanding of alcohol rective factors associated with them. Researched advances in alcohol-related epidemiolog Small Grant Program award mechanism	terns of alcolarch grants fullize current elated problerch that empore and Gene	hol consumption for the Secondary tly available data ems and disorder ploys analytic tecl	, the Analyses of sets to s in the hniques which
066088 <u>S</u>	Secondary Analyses of Existing Ald	cohol Research Data (R01)	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	PA-17-467	07-May-2019	Not Specified
	Contact Name	Wenxing Zha, Ph.D.				
	Contact Telephone	301-443-0633				
	Contact Email	zhaw@mail.nih.gov				
	Sponsor Website					
	Program URL	https://grants.nih.gov/grants/guide/pa-	files/PA-17-467.html			
	Deadline Dates (ALL)	07-May-2019 , 05-Jun-2019 , 07-Sep-202 2020	19 , 05-Oct-2019 , 07-Jan-2020 , 05-Feb-20	)20 , 07-May	/-2020 , 05-Jun-20	)20 , 07-Sep-
	Synopsis	analysis of existing data sets with the go epidemiology and etiology, including ge Existing Alcohol Research Data are inten increase our understanding of the incide population, as well as the risk and prote demonstrate or promote methodological	Alcoholism (NIAAA) invites applications that of enhancing our understanding of patternetics, of alcohol-related problems. Reseated to provide support for studies that utence, prevalence and etiology of alcohol rective factors associated with them. Reseated advances in alcohol-related epidemiologies earch Project (RO1) award mechanism.	terns of alco arch grants fo tilize current elated proble rch that emp	hol consumption or the Secondary tly available data ems and disorder ploys analytic tecl	, the Analyses of sets to s in the hniques which

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
IIhx/IX/	Increasing the Use of Medications Disorders (R01 Clinical Trial Option	s for the Treatment of Alcohol Use nal)	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	PAR-18- 196	07-May-2019	Not Specified
	Contact Name	Lori Ducharme, Ph.D.				
	Contact Telephone	301-451-8507				
	Contact Email	Lori.Ducharme@nih.gov				
	Sponsor Website					
	Program URL	https://grants.nih.gov/grants/guide/pa	ı-files/PAR-18-196.html			
	Deadline Dates (ALL)	07-May-2019 , 05-Jun-2019 , 07-Sep-20	019 , 05-Oct-2019 , 07-Jan-2020 , 05-Feb-2	2020 , 07-Ma	ay-2020	
	Synopsis	increase the public health impact of Fo alcohol use disorder. Significant progre these evidence-based interventions int specialty care settings. The National Ins hypothesis-driven research to identify a addressing their acceptability (to presc	nd Alcoholism (NIAAA) invites applications od and Drug Administration (FDA)-approvess is needed in developing generalizable, to the mainstream of alcohol use disorder stitute on Alcohol Abuse and Alcoholism (effective methods for increasing the utilizeribers and patients), perceived effectivental will use the NIH Research Project (RO1) and and Drug Alcoholism (RO1) and alcoholism (RO1	red pharmac scalable, co treatment, NIAAA) seek ation of curr ess, affordal	otherapies for the st-effective strate in both general me as applications to contly-available me bility, and feasibility, and feasibility.	treatment of gies to move edical and onduct edications, by
063269	Alcohol-Induced Effects on Tissue	Injury and Repair (R21)	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	PA-17-29	6 07-May-2019	275,000 USD
	Contact Name	Bill Dunty, Ph.D.				
	Contact Telephone	301-443-7351				
	Contact Email	duntyw@mail.nih.gov				
	Sponsor Website					
	Program URL	https://grants.nih.gov/grants/guide/pa	<u>-files/PA-17-296.html</u>			
	Deadline Dates (ALL)	07-May-2019 , 16-Jun-2019 , 07-Sep-20 2020	019 , 16-Oct-2019 , 07-Jan-2020 , 16-Feb-2	2020 , 07-Ma	ay-2020 , 16-Jun-20	020 <i>,</i> 07-Sep-
	Synopsis	of tissue injury and repair associated w adversely affect multiple organ systems systems, as well as bone and skeletal m is associated with reduced host capacit	Id Alcoholism (NIAAA) invites applications ith alcohol use in humans. Excessive alcoles including the liver, brain, heart, pancreanuscle. In addition, there is accumulating or for recovery and repair following traumurrently not fully understood. NIAAA is es	nol consump s, lung, kidn evidence tha a. The mech	otion has the poter ey, endocrine and ot long term alcoho anisms for these a	ntial to immune ol consumption ulcohol-induced

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		that elucidates alcohol's effects on comporgan system. This FOA also encourages regeneration. Also encourages are studie understanding of these underlying mech approaches for prognosis, diagnosis, inte R21 Exploratory/Developmental Research	the study of alcohol's effect on stem cell es on molecular and cellular actions of m anisms may provide new avenues for de ervention, and treatment of alcohol-indu	ls, embryoni oderate alco veloping mo	c development, and other consumption or consumption	nd A better ovel
063268 <u>A</u>	Alcohol-Induced Effects on Tissue	Injury and Repair (R01)	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	PA-17-297	7 07-May-2019	Not Specified
	Contact Name	Bill Dunty, Ph.D.				
	Contact Telephone	301-443-7351				
	Contact Email	duntyw@mail.nih.gov				
	Sponsor Website					
	Program URL	https://grants.nih.gov/grants/guide/pa-f	iles/PA-17-297.html			
	Deadline Dates (ALL)	07-May-2019 , 05-Jun-2019 , 07-Sep-201 2020	9 , 05-Oct-2019 , 07-Jan-2020 , 05-Feb-2	020 <i>,</i> 07-Ma	y-2020 , 05-Jun-20	)20 , 07-Sep-
	Synopsis	National Institute on Alcohol Abuse and of tissue injury and repair associated with adversely affect multiple organ systems is systems, as well as bone and skeletal multiple is associated with reduced host capacity effects on tissue injury and repair are curt that elucidates alcohol's effects on comporgan system. This FOA also encourages regeneration. Also encourages are studied understanding of these underlying mechapproaches for prognosis, diagnosis, interesearch Project (RO1) award mechanism	h alcohol use in humans. Excessive alcoholic ncluding the liver, brain, heart, pancreasiscle. In addition, there is accumulating efor recovery and repair following traumarently not fully understood. NIAAA is esplex mechanisms of injury and repair that the study of alcohol's effect on stem cell es on molecular and cellular actions of manisms may provide new avenues for decreention, and treatment of alcohol-industrians.	ool consump s, lung, kidne vidence tha a. The mech pecially inte t are either of s, embryoni oderate alco veloping mo	tion has the poter ey, endocrine and t long term alcoho anisms for these a rested in integration common or specific c development, and one effective and n	itial to immune ol consumption lcohol-induced we research c to each ad A better ovel
116U 73/1 -	everaging Electronic Health Reco	ords for Alcohol Services Research	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	PAR-18- 203	07-May-2019	1,025,000 USD
	Contact Name	Lori Ducharme, Ph.D.				
	Contact Telephone	301-451-8507				
	Contact Email	Lori.Ducharme@nih.gov				

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Sponsor Website				
	Program URL	https://grants.nih.gov/grants/guide/pa	-files/PAR-18-203.html		
			 19 , 05-Oct-2019 , 07-Jan-2020 , 05-Feb-2	2020 , 07-May-2020	
	Synopsis	that leverage electronic clinical records of alcohol use disorders (AUD) in routin sources, it is expected that major data and other electronic resources, such as records, and/or administrative records. patients with AUD, while contributing to health records in the conduct of AUD tractivities and feasibility assessment, fol to the R33 phase will be determined by	to conduct studies that address novel he e clinical care settings. Although projects collection activities will be integrated into patient registries, electronic health recording and understanding of the current utility eatment services research. This FOA problems by possible transition to expanded NIAAA program staff after evaluation of FOA will use the NIH R21/R33 Phased Inn	ealth services questions about to may be supplemented by other or, or obtained from, routine cliuds, data warehouses, billing dadirect relevance for improving conditional remaining barriers to using vides R21 support for research differences research support (R33 phase) the project's achievement of s	the treatment er data nical records ata, pharmacy clinical care for g electronic planning . The transitic pecific
11647118	Epidemiology and Prevention in A Optional)	lcohol Research (R21 - Clinical Trial	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	PA-18-391 07-May-2019	275,000 USD
	Contact Name	Marcia Scott, Ph.D.			
	Contact Telephone	301-402-6328			
	Contact Email	mscott@mail.nih.gov			
	Sponsor Website				
	Program URL	https://grants.nih.gov/grants/guide/pa	-files/PA-18-391.html		
	Deadline Dates (ALL)	07-May-2019 , 16-Jun-2019 , 07-Sep-20	19 , 16-Oct-2019 , 07-Jan-2020 , 16-Feb-	2020 , 07-May-2020	
	Synopsis	of alcohol use, alcohol-related harms, a	I Alcoholism (NIAAA) invites applications nd alcohol use disorders and the prevent program will use the NIH R21 Exploratory	tion of underage drinking, alcol	hol-related
169/119	Epidemiology and Prevention in An Application in Applicational)	lcohol Research (R03 Clinical Trial	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	PA-18-413 07-May-2019	100,000 USD
	Contact Name	Marcia Scott, Ph.D.			
	Contact Telephone	301-402-6328			

Contact Email mscott@mail.nih.gov

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		1			
	Sponsor Website				
	Program URL	https://grants.nih.gov/grants/guide/pa	-files/PA-18-413.html		
	Deadline Dates (ALL)	07-May-2019 , 16-Jun-2019 , 07-Sep-20	19 , 16-Oct-2019 , 07-Jan-2020 , 16-Feb-2	2020 , 07-May-2020	
	Synopsis	of alcohol use, alcohol-related harms, a	d Alcoholism (NIAAA) invites applications and alcohol use disorders and the prevent brogram will use the NIH R03 Small Grant	ion of underage drinking, alco	
069680	Epidemiology and Prevention in A Optional)	Alcohol Research (R01 - Clinical Trial	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	PA-18-390 07-May-2019	Not Specified
	Contact Name	Marcia Scott, Ph.D.			
	Contact Telephone	301-402-6328			
	Contact Email	mscott@mail.nih.gov			
	Sponsor Website				
	Program URL	https://grants.nih.gov/grants/guide/pa	-files/PA-18-390.html		
	Deadline Dates (ALL)	07-May-2019 , 05-Jun-2019 , 07-Sep-20	19 , 05-Oct-2019 , 07-Jan-2020 , 05-Feb-2	2020 , 07-May-2020	
	Synopsis	of alcohol use, alcohol-related harms, a	d Alcoholism (NIAAA) invites applications and alcohol use disorders and the prevent program will use the NIH Research Projec	ion of underage drinking, alco	
071743	<u>Understanding Processes of Reco</u> <u>Disorder (R21 - Clinical Trial Option</u>	very in the Treatment of Alcohol Use onal)	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	PA-18-620 05-Jun-2019	275,000 USD
	Contact Name	Brett T. Hagman			
	Contact Telephone	301-443-0638			
	Contact Email	brett.hagman@nih.gov			
	Sponsor Website				
	Program URL	https://grants.nih.gov/grants/guide/pa	-files/PA-18-620.html		
	Deadline Dates (ALL)	05-Jun-2019 , 16-Oct-2019 , 16-Feb-202	20 , 16-Jun-2020 , 16-Oct-2020 , 16-Feb-2	021	
	Synopsis	and relapse in the treatment of Alcohol that address the following potential top precipitants of relapse; 3) Understandir	nd Alcoholism (NIAAA) invites applications I Use Disorders. Applications high in inno Dics: 1) defining recovery; 2) Examining ne ng mechanisms of mutual help and recove d treatment for AUD. This FOA will use th	vation and significance are hig www and innovative methods to ery; 4) Evaluating recovery sys	hly encouraged examine tems of care;

SPIN ID	Program Title	Sponsor Name	Sponsor Number		<b>Deadline Date</b>	Funding Amount
		(R21) award mechanism.				
	Research on Comparative Effective and Alcohol Interventions (R01 Cl	veness and Implementation of HIV/AIDS linical Trial Optional)	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	PAS-18- 557	06-May-2019 [LOI/Pre-App] [Optional]	2,500,000 USD
	Contact Name	Tatiana Balachova, PhD				
	Contact Telephone	301-443-5726				
	Contact Email	balachovatn@mail.nih.gov				
	Sponsor Website					
	Program URL	https://grants.nih.gov/grants/guide/pa-				
	Deadline Dates (ALL)	06-May-2019 [LOI/Pre-App][Optional], 0 [LOI/Pre-App][Optional], 05-Feb-2020	5-Jun-2019 , 05-Sep-2019 [LOI/Pre-App]	[Optional], (	5-Oct-2019 , 06-Ja	an-2020
	Synopsis	National Institute on Alcohol Abuse and and comparative effectiveness of alcohol investigated, including potentially imporstructural factors that facilitate or inhibit of alcohol use problems. The overall goal improve prevention, care, and outcomes use. This solicitation is divided into two of 1) comparative effectiveness research for retention in appropriate alcohol and HIV settings, and 2) modeling and testing alt interventions and reduce HIV disease tragrant mechanism.	ol-focused interventions among HIV+ indi- tant patient and provider characteristics the delivery of evidence-based services il is to inform clinical decision-making to sacross the continuum of HIV and alcoho- major topics. An application may choose ocused on understanding factors related treater, and achieving and maintaining op- ernative implementation approaches to	viduals. Mul , and the org for HIV+ ind implement of ol problem so to address of to early dete timal treatm improve upt	tiple factors need ganizational, finan lividuals with a raileffective intervent everity and patter one or both. These ection, patient engate and scaling-up	to be cial, and nge of severity ions that will ens of alcohol topics include: gagement and diverse p of effective
072235	Mechanisms of Alcohol Tolerance	e (R21/R33 Clinical Trial Not Allowed)	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	/PAR-18- 659	07-May-2019	Not Specified
	Contact Name	Elizabeth M Powell, PhD				
	Contact Telephone	Elizabeth M Powell, PhD				
	Contact Email	elizabeth.powell3@nih.gov				
	Sponsor Website					
	Program URL	https://grants.nih.gov/grants/guide/pa-	files/PAR-18-659.html			

Deadline Dates (ALL) 07-May-2019, 16-Jun-2019, 07-Sep-2019, 16-Oct-2019, 07-Jan-2020, 16-Feb-2020, 07-May-2020, 16-Jun-2020, 07-Sep-

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Synopsis	underlying the development of alcohol molecular or network mechanisms that predict the development of tolerance ar	d Alcoholism (NIAAA) invites applications use disorders. The intent of this FOA is to regulate sensitivity and tolerance to alcohol the progression to alcohol dependencism, in which secondary data analysis or be expanded in the R33 phase. The trans of the achievement of specific mileston	o: (1) develop whol, and (2) on the ending the second pilot studies which the device the studies which the state of the st	hypotheses aboud develop quantitati ectives will be acco can occur during t R33 phase will be	t cellular, ive models to omplished with the R21 phase, determined
	Understanding Processes of Reco Disorder (R01 Clinical Trial Option	very in the Treatment of Alcohol Use nal)	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	PA-18-619	07-May-2019	Not Specified
	Contact Telephone Contact Email Sponsor Website	brett.hagman@nih.gov  https://grants.nih.gov/grants/guide/pa- 07-May-2019 , 05-Jun-2019 , 07-Sep-202 2020 , 05-Oct-2020 , 07-Jan-2021 , 05-Fe National Institute on Alcohol Abuse and relapse in the treatment of Alcohol that address the following potential top precipitants of relapse; 3) Understandin	 19 , 05-Oct-2019 , 07-Jan-2020 , 05-Feb-2	s that seek to vation and si ew and innov ery; 4) Evalua	o examine process gnificance are hig ative methods to ting recovery syst	ses of recovery hly encouraged examine ems of care;
11/11247	Effects of In Utero Alcohol Exposu Clinical Trial Optional)	ure on Adult Health and Disease (R21	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	PA-18-508	07-May-2019	275,000 USD
	Contact Telephone	Bill Dunty, Ph.D. 301-443-7351 duntyw@mail.nih.gov				

Sponsor Website

Program URL https://grants.nih.gov/grants/guide/pa-files/PA-18-508.html

SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
Deadline Dates (ALL)	07-May-2019 , 16-Jun-2019 , 07-Sep-201 2020 , 16-Oct-2020 , 07-Jan-2021	9 , 16-Oct-2019 , 07-Jan-2020 , 16-Feb-2	.020 , 07-May	y-2020 , 16-Jun-20	020 , 07-Sep-
Synopsis	National Institute on Alcohol Abuse and a exposure may contribute to the etiology developmental origins of health and dise intrauterine conditions may increase the broad range of research to: 1) leverage e in the DOHaD process; 2) investigate the may impact disease outcomes later in life predict adult disease susceptibility in expa possible fetal-basis to adult disease that Project Grant award mechanism.	of chronic diseases and health condition case (DOHaD) concept which suggests the risk for childhood and adulthood diseas existing prospective birth cohorts to definibiological, cellular, and molecular mechae; and 3) identify biomarkers associated posed offspring. Studies supported by the	ns later in life at fetal adap e. The goal one the role of anisms by wh with gestations FOA will prices	e. Central to this to tations in respons of this FOA is to sto sto for maternal alcoho hich prenatal alcohol alcohol exposorovide fundament	heme is the te to adverse imulate a I consumption hol exposure sure that may tal insights into
070391 Effects of In Utero Alcohol Exposu Clinical Trial Optional)	ure on Adult Health and Disease (R01	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	PA-18-507	07-May-2019	Not Specified
Contact Name	Bill Dunty, Ph.D.				
Contact Telephone	301-443-7351				
Contact Email	duntyw@mail.nih.gov				
Sponsor Website					
Program URL	https://grants.nih.gov/grants/guide/pa-f	iles/PA-18-507.html			
Deadline Dates (ALL)	07-May-2019 , 05-Jun-2019 , 07-Sep-201 2020 , 05-Oct-2020 , 07-Jan-2021	9 , 05-Oct-2019 , 07-Jan-2020 , 05-Feb-2	.020 , 07-May	y-2020 , 05-Jun-20	020 , 07-Sep-
Synopsis	National Institute on Alcohol Abuse and a exposure may contribute to the etiology developmental origins of health and dise intrauterine conditions may increase the broad range of research to: 1) leverage e in the DOHaD process; 2) investigate the may impact disease outcomes later in life predict adult disease susceptibility in expa possible fetal-basis to adult disease that (RO1) award mechanism.	of chronic diseases and health condition case (DOHaD) concept which suggests the risk for childhood and adulthood diseas existing prospective birth cohorts to definibiological, cellular, and molecular mechae; and 3) identify biomarkers associated posed offspring. Studies supported by the	ns later in life at fetal adap e. The goal one the role of anisms by wh with gestations is FOA will pr	e. Central to this to tations in respons of this FOA is to sto sto f maternal alcoho hich prenatal alcohol exposorovide fundament	heme is the te to adverse imulate a I consumption hol exposure sure that may tal insights into
076319 Alcohol and Other Drug Interaction	ons: Unintentional Injuries and Overdoses	National Institute on Alcohol Abuse	PA-18-863	07-May-2019	Not

Epidemiology and Prevention (R01 - Clinical Trial Optional)   and Alcoholism/NIH/DHHS   Specified	SPIN ID	Program	Sponsor Namo	Sponsor Number	Deadline Date	Funding
Contact Name Contact Telephone	SPIN ID	Title	Sponsor Name	Sponsor Number	Deadine Date	Amount
Contact Name Contact Telephone						
Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL)  Possible Program URL Deadline Dates (ALL)  O7-May-2019, 05-Jun-2019, 07-Sep-2019, 05-Oct-2019, 07-Jan-2020, 05-Feb-2020, 07-May-2020, 05-Jun-2020, 07-Sep-2021, 07-May-2021, 07-Sep-2021, 07-May-2021, 07-Sep-2021  National Institute on Alcohol Abuse and Alcoholism (MINAA) and National Institute on Drug Abuse (NIDA) invite applications that explore whether and how alcohol and other illicit drugs or illicity used prescription drugs interact to contribute to unintentional injuries and poisonings and how to prevent and/or reduce simultaneous use of alcohol or drugs singly or in combination. This FOA will use the NIH Research Project (R01) award mechanism.  Contact Name Robert Freeman, Ph.D.  Contact Telephone Contact Telephone Contact Telephone Program URL O7-May-2019, 16-Jun-2019, 07-Sep-2021, 16-Get-2021, 07-May-2020, 16-Feb-2020, 07-May-2020, 16-Jun-2020, 07-Sep-2020, 16-Oct-2020, 07-Jan-2021, 16-feb-2021, 07-May-2021, 16-Jun-2021, 07-Sep-2021  National Institute on Alcohol Abuse and Alcoholism (NINAA) and National Institute on Drug Abuse (NIDA) invite applications that explore whether and how alcohol and of their little drugs or illicity used prescription drugs interact to contribute to unintentional injuries and poisonings and how to prevent and/or reduce simultaneous use of alcohol or drugs singly or in combination. This FOA will use the NIH R21 Exploratory/Developmental Grant award mechanism.  PA-18-861 07-May-2019 10-Jun-2020, 07-Sep-2021  Alcohol and Other Drug Interactions: Unintentional Injuries and Overdoses: National Institute on Alcohol Abuse prescription drugs interact to contribute to unintentional injuries and poisonings and how to prevent and/or reduce simultaneous use of alcohol or drugs singly or in combination. This FOA will use the NIH R21 Exploratory/Developmental Grant award mechanism.  PA-18-861 07-May-2019 10-00-00-00-00-00-00-00-00-00-00-0		Epidemiology and Prevention (RO2	L - Clinical Trial Optional)	and Alcoholism/NIH/DHHS		Specified
Contact Email Freeman@mail.nih.gov  Sponsor Website Program URL Deadline Dates (ALL)  Deadline Dates (ALL)  Synopsis  Alcohol and Other Drug Interactions: Unintentional Injuries and Overdoses: Pipidemiology and Prevention (R21 - Clinical Trial Optional)  Contact Email Program URL Deadline Dates (ALL)  Sponsors Website Program URL Deadline Dates (ALL)  Altohol and Other Drug Interactions: Unintentional Injuries and poisonings and how to prevent and/or reduce simultaneous use of alcohol or drugs singly or in combination. This FOA will use the NIH Research Project (R01) award mechanism.  Contact Telephone Contact Telephone Program URL Program URL Program URL Deadline Dates (ALL)  Synopsis  Contact Telephone Sponsor Website Program URL Deadline Dates (ALL)  Synopsis  Alcohol and Other Drug Interactions: Unintentional Injuries and Overdoses: Indicated and Alcoholism (NIAAA) and National Institute on Drug Abuse (NIDA) invite applications that explore whether and poisonings and how to prevent and/or reduce simultaneous use of alcohol or drugs singly or in combination. This FOA will use the NIH Research Project (R01) award mechanism.  Contact Telephone 301-443-8820  Contact Telephone Contact Mame Program URL National Institute on Program URL National Institute on Alcoholism (NIAAA) and National Institute on Drug Abuse (NIDA) invite applications that explore whether and how alcohol and other illict drugs or illicity used prescription drugs interact to contribute to unintentional injuries and poisonings and how to prevent and/or reduce simultaneous use of alcohol or drugs singly or in combination. This FOA will use the NIH R21 Exploratory/Developmental Grant award mechanism.  Program URL Pro		Contact Name	Robert Freeman, Ph.D.			
Sponsor Website Program URL Deadline Dates (ALL) Deadline Dates (ALL) Deadline Dates (ALL) Deadline Dates (ALL) Synopsis National Institute on Alcohol Abuse and Alcoholism (NIAAA) and National Institute on Drug Abuse (NIDA) invite applications that explore whether and how alcohol and other illicit drugs or illicitly used prescription drugs interact to contribute to unintentional injuries and poisonings and how to prevent and/or reduce simultaneous use of alcohol or drugs single or incombination. This FOA will use the NIHR Research Project (R01) award mechanism.  Contact Name Robert Freeman, Ph.D. Contact Telephone 301-443-8820 Contact Telephone 301-443-8820 Contact Temail refreeman@mail.nih.gov Sponsor Website Program URL Deadline Dates (ALL) Deadline Dates (ALL) Deadline Dates (ALL) Deadline Dates (ALL) Synopsis  Alcohol and Other Drug Interactions: Unintentional injuries and Overdoses: National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS  Program URL Deadline Dates (ALL) Deadline Dates (ALL) Deadline Dates (ALL) Or-May-2019, 16-Jun-2019, 07-Sep-2019, 16-Oct-2019, 07-Jan-2020, 16-Feb-2020, 07-May-2020, 16-Jun-2020, 07-Sep-2019, 16-Jun-2019, 07-Sep-2019, 16-Oct-2019, 07-Jan-2020, 16-Feb-2020, 07-May-2021, 16-Feb-2020, 07-May-201, 16-Fe		·				
Program URL Deadline Dates (ALL) National Institute on Alcohol Abuse and Alcoholism (NIAAA) and National Institute on Drug Abuse (NIDA) invite applications that explore whether and how alcohol and other illicit drugs or illicit yused prescription drugs interact to contribute to unintentional injuries and poisonings and how to prevent and/or reduce simultaneous use of alcohol or drugs singly or in combination. This FOA will use the NIH Research Project (R01) award mechanism.  275,000 Deadline Dates (ALL) Dead		Contact Email	rfreeman@mail.nih.gov			
Deadline Dates (ALL)    Deadline Dates (ALL)   2020, 05-Oct-2020, 07-Jan-2021, 05-Det-2021, 07-May-2021, 07-May-2020, 07-Sep-2021   National Institute on Alcohol Abuse and Alcoholism (NIAAA) and National Institute on Drug Abuse (NIDA) invite applications that explore whether and how alcohol and other illicit drugs or illicity used prescription drugs interact to contribute to unintentional injuries and poisonings and how to prevent and/or reduce simultaneous use of alcohol or drugs singly or in combination. This FOA will use the NIH Research Project (R01) award mechanism.    Offsize   Alcohol and Other Drug Interactions: Unintentional Injuries and Overdoses: National Institute on Alcohol Abuse   PA-18-862   O7-May-2019   275,000   USD   USD   PA-18-862   O7-May-2019   PA-18-862   O7-May-2019   O7-May-201		Sponsor Website				
National Institute on Alcohol Abuse and Alcoholism (NIAAA) and National Institute on Drug Abuse (NIDA) invite applications that explore whether and how alcohol and other illicit drugs or illicitity used prescription drugs interact to contribute to unintentional injuries and poisonings and how to prevent and/or reduce simultaneous use of alcohol or drugs singly or in combination. This FOA will use the NIH Research Project (R01) award mechanism.  76324 Alcohol and Other Drug Interactions: Unintentional Injuries and Overdoses: National Institute on Alcohol Abuse PA-18-862 07-May-2019 275,000 USD  Contact Telephone Contact Telephone Program URL Program URL Deadline Dates (ALL) Deadline Dates (ALL) Sponsor Website Program URL Deadline Dates (ALL) Synopsis Synopsis Synopsis Alcohol Abuse and Alcoholism (NIAAA) and National Institute on Drug Abuse (NIDA) invite applications that explore whether and how alcohol and other illicit drugs or illicity used prescription drugs interact to contribute to unintentional Injuries and poisonings and how to prevent and/or reduce simultaneous use of alcohol or drugs singly or in combination. This FOA will use the NIH R21 Exploratory/Developmental Grant award mechanism.  76327 Alcohol and Other Drug Interactions: Unintentional Injuries and Overdoses: National Institute on Alcohol Abuse of alcohol or drugs singly or in combination. This FOA will use the NIH R21 Exploratory/Developmental Grant award mechanism.  76328 Alcohol and Other Drug Interactions: Unintentional Injuries and Overdoses: National Institute on Alcohol Abuse of Alcoholism/NIH/DHHS  76329 Alcohol and Other Drug Interactions: Unintentional Injuries and Overdoses: National Institute on Alcohol Abuse of Alcoholism/NIH/DHHS  76330 Alcohol and Other Drug Interactions: Unintentional Injuries and Overdoses: National Institute on Alcohol Abuse of Alcoholism/NIH/DHHS  76331 Alcohol and Other Drug Interactions: Unintentional Injuries and Overdoses: National Institute on Alcohol Abuse of Alcoholism/NIH/DHHS  76332 Alcohol and Othe		Program URL				
that explore whether and how alcohol and other illicit drugs or illicitly used prescription drugs interact to contribute to unintentional injuries and poisonings and how to prevent and/or reduce simultaneous use of alcohol or drugs singly or in combination. This FOA will use the NIH Research Project (R01) award mechanism.  76324 Alcohol and Other Drug Interactions: Unintentional Injuries and Overdoses: National Institute on Alcohol Abuse Epidemiology and Prevention (R21 - Clinical Trial Optional)  Robert Freeman, Ph.D.  Contact Telephone Contact Telephone Sponsor Website Program URL Program URL Deadline Dates (ALL) Or-May-2019, 16-Jun-2019, 07-Sep-2019, 16-Oct-2019, 07-Jan-2020, 16-Feb-2020, 07-May-2020, 16-Jun-2020, 07-Sep-2021 National Institute on Alcohol Abuse and Alcoholism (NIAAA) and National Institute on Drug Abuse (NIDA) invite applications that explore whether and how alcohol and how to prevent and/or reduce simultaneous use of alcohol or drugs singly or in combination. This FOA will use the NIH R21 Exploratory/Developmental Grant award mechanism.  76327 Alcohol and Other Drug Interactions: Unintentional Injuries and Overdoses: National Institute on Alcohol Abuse Epidemiology and Prevention (R03 - Clinical Trial Optional)  Robert Freeman, Ph.D.  875,000 USD		Deadline Dates (ALL)				020 , 07-Sep-
Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL)  Synopsis Synopsis Synopsis Synopsis Synopsis Combination. This FOA will use the NIH R21 Exploratory/Developmental Grant award mechanism.  O76327 Alcohol and Other Drug Interactions: Unintentional Injuries and Overdoses: Epidemiology and Prevention (R03 - Clinical Trial Optional)  Contact Name Robert Freeman, Ph.D.  and Alcoholism/NIH/DHHS  PA-18-862 07-May-2019 USD  USD  USD  USD  WAA-18-862 07-May-2019 USD  USD  USD  USD  USD  WAA-18-862 07-May-2019 USD  USD  USD  WAA-18-862 07-May-2019 USD  USD  USD  WAA-18-862 07-May-2019 USD  WAA-18-862 07-May-2019 USD  WAA-18-862 07-May-2019 USD  WAA-18-862 07-May-2019 USD  USD		Synopsis	that explore whether and how alcohol unintentional injuries and poisonings a	and other illicit drugs or illicitly used pres and how to prevent and/or reduce simulta	cription drugs interact to conti neous use of alcohol or drugs	ibute to
Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALLI) Contact Telephone Contact Name Robert Freeman, Ph.D. Soprior Sponsor Website Program URL Deadline Dates (ALLI) Contact Name Robert Freeman, Ph.D. Soprior Sponsor Website Program URL Deadline Dates (ALLI) Contact Name Robert Freeman, Ph.D. Soprior Sponsor Website Program URL Deadline Dates (ALLI) Contact Name Robert Freeman, Ph.D. Soprior Sponsor Website Program URL Deadline Dates (ALLI) Program URL Deadline Dates (ALLI) Program URL Deadline Dates (ALLI) Dea	076224	Alcohol and Other Drug Interactio	ns: Unintentional Injuries and Overdos	es: National Institute on Alcohol Abuse	DA 19 962 O7 May 2010	275,000
Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis Synopsis  Synopsis  Alcohol and Other Drug Interactions: Unintentional Injuries and Overdoses: Epidemiology and Prevention (R03 - Clinical Trial Optional)  Contact Name  Contact Telephone  301-443-8820  freeman@mail.nih.gov  freeman@mail.nih.gov  freeman@mail.nih.gov  freeman@mail.nih.gov  107-May-2019, 16-Jun-2020, 16-Feb-2020, 07-May-2020, 16-Feb-2020, 07-May-2020, 16-Jun-2020, 07-Sep-2021  National Institute on Alcohol Abuse and Alcoholism (NIAAA) and National Institute on Drug Abuse (NIDA) invite applications that explore whether and how alcohol and other illicit drugs or illicitly used prescription drugs interact to contribute to unintentional injuries and poisonings and how to prevent and/or reduce simultaneous use of alcohol or drugs singly or in combination. This FOA will use the NIH R21 Exploratory/Developmental Grant award mechanism.  PA-18-861 07-May-2019 100,000  USD	070324	Epidemiology and Prevention (R23	L - Clinical Trial Optional)	and Alcoholism/NIH/DHHS	PA-10-002 U7-Way-2019	USD
Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis  Synopsis  Alcohol and Other Drug Interactions: Unintentional Injuries and Overdoses: Epidemiology and Prevention (R03 - Clinical Trial Optional)  Contact Name  Contact Email Sponsor Website Program URL Attps://grants.nih.gov/grants/guide/pa-files/PA-18-862.html O7-May-2019 , 16-Jun-2020 , 16-Gct-2019 , 07-Jan-2020 , 16-Feb-2020 , 07-May-2020 , 16-Jun-2020 , 07-Sep-2021 O7-May-2019 , 16-Oct-2019 , 07-Jan-2020 , 16-Feb-2021 , 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 National Institute on Alcohol Abuse and Alcoholism (NIAAA) and National Institute on Drug Abuse (NIDA) invite applications that explore whether and how alcohol and other illicit drugs or illicitly used prescription drugs interact to contribute to unintentional injuries and poisonings and how to prevent and/or reduce simultaneous use of alcohol or drugs singly or in combination. This FOA will use the NIH R21 Exploratory/Developmental Grant award mechanism.  O76327  Alcohol and Other Drug Interactions: Unintentional Injuries and Overdoses: National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS  Contact Name  Robert Freeman, Ph.D.		Contact Name	Robert Freeman, Ph.D.			
Sponsor Website Program URL Deadline Dates (ALL) Synopsis Synopsis  Alcohol and Other Drug Interactions: Unintentional Injuries and Overdoses: Contact Name  Sponsor Website Program URL Attps://grants.nih.gov/grants/guide/pa-files/PA-18-862.html O7-May-2019, 16-Jun-2019, 07-Sep-2019, 16-Oct-2019, 07-Jan-2020, 16-Feb-2020, 07-May-2020, 16-Jun-2020, 07-Sep-2020, 16-Oct-2020, 07-Jan-2021, 16-Feb-2021, 07-May-2021, 16-Jun-2021, 07-Sep-2021 National Institute on Alcohol Abuse and Alcoholism (NIAAA) and National Institute on Drug Abuse (NIDA) invite applications that explore whether and how alcohol and other illicit drugs or illicitly used prescription drugs interact to contribute to unintentional injuries and poisonings and how to prevent and/or reduce simultaneous use of alcohol or drugs singly or in combination. This FOA will use the NIH R21 Exploratory/Developmental Grant award mechanism.  O76327 Alcohol and Other Drug Interactions: Unintentional Injuries and Overdoses: National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS  PA-18-861 O7-May-2019 USD  Contact Name  Robert Freeman, Ph.D.		Contact Telephone	301-443-8820			
Program URL Deadline Dates (ALL) Peadline Dates (ALL)  Deadline Dates (ALL)  Program URL Deadline Dates (ALL)  Deadline Dates (ALL)  National Institute on Alcohol Abuse and Alcoholism (NIAAA) and National Institute on Drug Abuse (NIDA) invite applications that explore whether and how alcohol and other illicit drugs or illicitly used prescription drugs interact to contribute to unintentional injuries and poisonings and how to prevent and/or reduce simultaneous use of alcohol or drugs singly or in combination. This FOA will use the NIH R21 Exploratory/Developmental Grant award mechanism.  PA-18-861 07-May-2019  Contact Name  Robert Freeman, Ph.D.		Contact Email	rfreeman@mail.nih.gov			
Deadline Dates (ALL)  O7-May-2019, 16-Jun-2019, 07-Sep-2019, 16-Oct-2019, 07-Jan-2020, 16-Feb-2020, 07-May-2020, 16-Jun-2020, 07-Sep-2020, 16-Oct-2020, 07-Jan-2021, 16-Feb-2021, 07-May-2021, 16-Jun-2021, 07-Sep-2021  National Institute on Alcohol Abuse and Alcoholism (NIAAA) and National Institute on Drug Abuse (NIDA) invite applications that explore whether and how alcohol and other illicit drugs or illicitly used prescription drugs interact to contribute to unintentional injuries and poisonings and how to prevent and/or reduce simultaneous use of alcohol or drugs singly or in combination. This FOA will use the NIH R21 Exploratory/Developmental Grant award mechanism.  O76327 Alcohol and Other Drug Interactions: Unintentional Injuries and Overdoses: Epidemiology and Prevention (R03 - Clinical Trial Optional)  Contact Name Robert Freeman, Ph.D.		Sponsor Website				
Deadline Dates (ALL) 2020 , 16-Oct-2020 , 07-Jan-2021 , 16-Feb-2021 , 07-May-2021 , 16-Jun-2021 , 07-Sep-2021  National Institute on Alcohol Abuse and Alcoholism (NIAAA) and National Institute on Drug Abuse (NIDA) invite applications that explore whether and how alcohol and other illicit drugs or illicitly used prescription drugs interact to contribute to unintentional injuries and poisonings and how to prevent and/or reduce simultaneous use of alcohol or drugs singly or in combination. This FOA will use the NIH R21 Exploratory/Developmental Grant award mechanism.  O76327 Alcohol and Other Drug Interactions: Unintentional Injuries and Overdoses: Epidemiology and Prevention (R03 - Clinical Trial Optional)  Contact Name Robert Freeman, Ph.D.		Program URL	https://grants.nih.gov/grants/guide/p	a-files/PA-18-862.html		
Synopsis  Synopsis  Synopsis  National Institute on Alcohol Abuse and Alcoholism (NIAAA) and National Institute on Drug Abuse (NIDA) invite applications that explore whether and how alcohol and other illicit drugs or illicitly used prescription drugs interact to contribute to unintentional injuries and poisonings and how to prevent and/or reduce simultaneous use of alcohol or drugs singly or in combination. This FOA will use the NIH R21 Exploratory/Developmental Grant award mechanism.  O76327  Alcohol and Other Drug Interactions: Unintentional Injuries and Overdoses: Epidemiology and Prevention (R03 - Clinical Trial Optional)  National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS  PA-18-861 O7-May-2019  USD  Contact Name  Robert Freeman, Ph.D.		Deadline Dates (ALL)	07-May-2019 , 16-Jun-2019 , 07-Sep-2 2020 , 16-Oct-2020 , 07-Jan-2021 , 16-	019 , 16-Oct-2019 , 07-Jan-2020 , 16-Feb-2 Feb-2021 , 07-May-2021 , 16-Jun-2021 , 0	2020 , 07-May-2020 , 16-Jun-20 7-Sep-2021	020 , 07-Sep-
Epidemiology and Prevention (R03 - Clinical Trial Optional)  Contact Name Robert Freeman, Ph.D.  PA-18-861 07-Way-2019 USD		Synopsis	National Institute on Alcohol Abuse a that explore whether and how alcohol unintentional injuries and poisonings a	and Alcoholism (NIAAA) and National Instit and other illicit drugs or illicitly used pres and how to prevent and/or reduce simulta	ute on Drug Abuse (NIDA) invit cription drugs interact to conti neous use of alcohol or drugs :	ibute to
	076327				PA-18-861 07-May-2019	•
Contact Telephone 301-443-8820		Contact Name	Robert Freeman, Ph.D.			
		Contact Telephone	301-443-8820			

Contact Email rfreeman@mail.nih.gov

SPIN ID Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
			·	
Sponsor Website				
Program URL	https://grants.nih.gov/grants/guide/	pa-files/PA-18-861.html		
Deadline Dates (ALL)	07-May-2019 , 16-Jun-2019 , 07-Sep- 2020 , 16-Oct-2020 , 07-Jan-2021 , 10	-2019 , 16-Oct-2019 , 07-Jan-2020 , 16-Feb- 6-Feb-2021 , 07-May-2021 , 16-Jun-2021 , 0	2020 , 07-May-2020 , 16-Jun-20 07-Sep-2021	020 <i>,</i> 07-Sep-
Synopsis	National Institute on Alcohol Abuse that explore whether and how alcoh unintentional injuries and poisonings	and Alcoholism (NIAAA) and National Instict of and other illicit drugs or illicitly used press and how to prevent and/or reduce simultails IH RO3 Small Grant Program award mechan	tute on Drug Abuse (NIDA) invit scription drugs interact to conti aneous use of alcohol or drugs :	ibute to
060834 Mechanisms of Alcohol-associated	d Cancers (R01)	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	PA-17-220 07-May-2019	Not Specified
Contact Name	Bill Dunty, Ph.D.			
Contact Telephone	301-443-7351			
Contact Email	duntyw@mail.nih.gov			
Sponsor Website				
Program URL	https://grants.nih.gov/grants/guide/	pa-files/PA-17-220.html		
Deadline Dates (ALL)	07-May-2019 , 05-Jun-2019 , 07-Sep- 2020	-2019 , 05-Oct-2019 , 07-Jan-2020 , 05-Feb-	2020 , 07-May-2020 , 05-Jun-20	020 , 07-Sep-
Synopsis	research investigating the cellular an classified as carcinogenic to humans Toxicology Program (NTP; 2014) of the carcinogenesis include the upper aer by which alcohol increases cancer ris	and Alcoholism (NIAAA) and National Cand d molecular mechanisms by which alcohol by the International Agency for Research one US Department of Health and Human Se odigestive tract, breast, liver, and colon. A k for certain tissues and organs could lead rovide guidance on safe levels of alcohol counism.	increases cancer risk. Alcohol c n Cancer (IARC; 2010, 2012) an rvices. Target sites for alcohol- better understanding of the m to improved therapeutic appro	onsumption is d the National related olecular basis aches and
060719 Nutrition and Alcohol-Related Hea	alth Outcomes (R21)	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	PA-17-213 07-May-2019	275,000 USD
Contact Name	Rosalind Breslow, Ph.D., M.P.H., R.D.			
Contact Telephone	301-594-6231			
Contact Email	rbreslow@mail.nih.gov			
Sponsor Website				

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount	
	Program URL	https://grants.nih.gov/grants/guide/pa-	-files/PA-17-213.html			
	Deadline Dates (ALL)	07-May-2019 , 16-Jun-2019 , 07-Sep-20	19 , 16-Oct-2019 , 07-Jan-2020 , 16-Feb-2	2020 , 07-May-2020		
	National Institute on Alcohol Abuse and Alcoholism (NIAAA) invite applications that propose to examine associations between nutrition and alcohol-related health outcomes in humans and animal models. The goal of this program Synopsis announcement is to stimulate a broad range of research on the role of nutrition in the development, prevention, and treatment of a variety of alcohol-related health outcomes including alcohol use disorder and chronic disease. This program will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.					
060720	Nutrition and Alcohol-Related He	alth Outcomes (R03)	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	PA-17-212 07-May-2019	100,000 USD	
	Contact Name	Rosalind Breslow, Ph.D., M.P.H., R.D.				
	Contact Telephone	301-594-6231				
	Contact Email	rbreslow@mail.nih.gov				
	Sponsor Website					
	Program URL	https://grants.nih.gov/grants/guide/pa-	-files/PA-17-212.html			
	Deadline Dates (ALL)	07-May-2019 , 16-Jun-2019 , 07-Sep-20	19 , 16-Oct-2019 , 07-Jan-2020 , 16-Feb-2	2020 , 07-May-2020		
	Synopsis	between nutrition and alcohol-related hannouncement is to stimulate a broad r	d health outcomes including alcohol use	nodels. The goal of this progra in the development, prevent	am ion, and	
11///	Genetics of Alcohol Sensitivity an Allowed)	d Tolerance (R01 Clinical Trial Not	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	PA-18-660 07-May-2019	Not Specified	
	Contact Name	Hemin R. Chin, Ph.D.				
	Contact Telephone	301-443-1282				
	Contact Email	chinh@mail.nih.gov				
	Sponsor Website					
	Program URL	https://grants.nih.gov/grants/guide/pa-	-files/PA-18-660.html			
	Deadline Dates (ALL)	07-May-2019 , 05-Jun-2019 , 07-Sep-20 2020 , 05-Oct-2020 , 07-Jan-2021 , 05-F	19 , 05-Oct-2019 , 07-Jan-2020 , 05-Feb-2 eb-2021 , 07-May-2021	2020 , 07-May-2020 , 05-Jun-2	2020 , 07-Sep-	
	Synopsis	National Institute on Alcohol Abuse an	d Alcoholism (NIAAA) invites application	s for novel genetic mechanisr	ns underlying	

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		the development of tolerance and the prand influenced both by genetic and environmental identifying genetic, genomic and epigenetic alcohol. This FOA will use the NIH Resear	ronmental factors. The purpose of this Fo etic factors contributing to the developm	OA is to stimulate and support	efforts on
059896	Public Policy Effects on Alcohol-, I Behaviors and Outcomes (R01)	Marijuana-, and Other Substance-Related	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	PA-17-135 07-May-2019	Not Specified
	Contact Name	Gregory Bloss, M.A.			
	Contact Telephone	301-443-3865			
	Contact Email	Gregory.Bloss@nih.gov			
	Sponsor Website				
	Program URL	https://grants.nih.gov/grants/guide/pa-f	files/PA-17-135.html		
	Deadline Dates (ALL)	07-May-2019 , 05-Jun-2019 , 07-Sep-201	9 , 05-Oct-2019 , 07-Jan-2020 , 05-Feb-2	020 , 07-May-2020	
	Synopsis	National Institute on Alcohol Abuse and policies on health-related behaviors and the FOA is to advance understanding of hits effects on behaviors and outcomes peresearch to examine policy effects that hithat may be supported by this FOA included public policies; evaluations of the effective effects on alcohol-, marijuana-, and other measurement used in studying relations behaviors and outcomes. This FOA will understanding the studying and support of the policies.	outcomes associated with alcohol, marije how public policy may serve as a tool for ertaining to alcohol and other drugs. This have the potential to lead to meaningful de, but are not necessarily limited to: can veness of specific public policies as tools or substance-related behaviors and outcoming between public policies and alcohol-	iuana, and other substances. T improving public health and v s FOA is intended to support in changes in public health. Resect usal analyses of the effects of of for improving public health the omes; and research to advanced -, marijuana-, and other substa	he purpose of velfare through novative arch projects one or multiple rough their methods and
059893	Public Policy Effects on Alcohol-, I Behaviors and Outcomes (R21)	Marijuana-, and Other Substance-Related	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	PA-17-132 07-May-2019	275,000 USD
	Contact Name	Gregory Bloss, M.A.			
	Contact Telephone	301-443-3865			
	Contact Email	Gregory.Bloss@nih.gov			
	Sponsor Website				
	Program URL	https://grants.nih.gov/grants/guide/pa-f	files/PA-17-132.html		
	Deadline Dates (ALL)	07-May-2019 , 16-Jun-2019 , 07-Sep-201	9 , 16-Oct-2019 , 07-Jan-2020 , 16-Feb-2	020 , 07-May-2020	
	Synopsis	National Institute on Alcohol Abuse and	Alcoholism (NIAAA) invites applications	to conduct research on the eff	ects of public

	Ducaven			_		Funding
SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		policies on health-related behaviors and the FOA is to advance understanding of its effects on behaviors and outcomes p research to examine policy effects that I that may be supported by this FOA inclupublic policies; evaluations of the effect effects on alcohol-, marijuana-, and other measurement used in studying relations behaviors and outcomes. This program	how public policy may serve as a tool for ertaining to alcohol and other drugs. The nave the potential to lead to meaningful de, but are not necessarily limited to: caliveness of specific public policies as tool er substance-related behaviors and outcoming between public policies and alcohological.	r improving poing for intenction changes in pure ausal analyses of for improvinumes; and result, marijuana-	ublic health and valed to support in ublic health. Rese of the effects of a public health the search to advance, and other subst	welfare through nnovative arch projects one or multiple nrough their e methods and
HSUXUS	Public Policy Effects on Alcohol-, I Behaviors and Outcomes (RO3)	Marijuana-, and Other Substance-Related	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	PA-17-134	07-May-2019	100,000 USD
	Contact Telephone	Gregory.Bloss@nih.gov				
	·	https://grants.nih.gov/grants/guide/pa-	files/PA-17-134.html			
	Deadline Dates (ALL)	07-May-2019 , 16-Jun-2019 , 07-Sep-201		2020 , 07-May	<sub>/</sub> -2020	
	Synopsis	National Institute on Alcohol Abuse and policies on health-related behaviors and the FOA is to advance understanding of its effects on behaviors and outcomes presearch to examine policy effects that hat may be supported by this FOA inclupublic policies; evaluations of the effect effects on alcohol-, marijuana-, and other measurement used in studying relations behaviors and outcomes. This FOA will to	l outcomes associated with alcohol, mar how public policy may serve as a tool fo ertaining to alcohol and other drugs. The nave the potential to lead to meaningful ide, but are not necessarily limited to: ca iveness of specific public policies as tool er substance-related behaviors and outcomings.	ijuana, and ot r improving pris FOA is inten changes in puausal analyses for improvinomes; and resol-, marijuana-	ther substances. In the sublic health and wanted to support in the sublic health. Rese of the effects of a public health the search to advance and other subst	The purpose of welfare through novative arch projects one or multiple prough their emethods and
060837	Mechanisms of Alcohol-associate	d Cancers (R21)	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	PA-17-219	07-May-2019	275,000 USD
	Contact Name Contact Telephone	Bill Dunty, Ph.D. 301-443-7351				

Contact Email duntyw@mail.nih.gov

SPIN ID	Program Title	Sponsor Name	Sponsor Number	<b>Deadline Date</b>	Funding Amount
	Sponsor Website	https://grants.nih.gov/grants/guida/na	files/DA 17 210 html		
	_	https://grants.nih.gov/grants/guide/pa-07-May-2019 16-Jun-2019 07-Sen-20	<del>·files/PA-17-219.ntml</del> 19 , 16-Oct-2019 , 07-Jan-2020 , 16-Feb-2	2020 07-May-2020 16-Jun-2	020 07-Sen-
		2020	13, 10 000 2013, 07 3411 2020, 10 103 2	1020 , 07 Willy 2020 , 10 Juli 2	020,07 Jep
	Synopsis	research investigating the cellular and r classified as carcinogenic to humans by Toxicology Program (NTP; 2014) of the carcinogenesis include the upper aerod by which alcohol increases cancer risk for	d Alcoholism (NIAAA) and National Cancerolecular mechanisms by which alcohol in the International Agency for Research or US Department of Health and Human Serfgestive tract, breast, liver, and colon. A for certain tissues and organs could lead the guidance on safe levels of alcohol cortain the content award mechanism.	ncreases cancer risk. Alcohol on Cancer (IARC; 2010, 2012) and vices. Target sites for alcohol- better understanding of the moon improved therapeutic appro	onsumption is id the National -related iolecular basis aches and
060718	Nutrition and Alcohol-Related Hea	alth Outcomes (R01)	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	PA-17-211 07-May-2019	Not Specified
	Contact Name	Rosalind Breslow, Ph.D., M.P.H., R.D.			
	Contact Telephone	301-594-6231			
	Contact Email	rbreslow@mail.nih.gov			
	Sponsor Website				
	Program URL	https://grants.nih.gov/grants/guide/pa	files/PA-17-211.html		
	Deadline Dates (ALL)	07-May-2019 , 05-Jun-2019 , 07-Sep-20	19 , 05-Oct-2019 , 07-Jan-2020 , 05-Feb-2	2020 , 07-May-2020	
	Synopsis	between nutrition and alcohol-related hannouncement is to stimulate a broad r	Alcoholism (NIAAA) invite applications to the alth outcomes in humans and animal mange of research on the role of nutrition distribution health outcomes including alcohol use award mechanism.	nodels. The goal of this prograin the development, prevention	m on, and
116 / /IIX -	Typical and Atypical Patterns of La Learners (R21-Clinical Trial Option	anguage & Literacy in Dual Language	National Institute on Deafness & Othe Communication Disorders/NIH/DHHS	PA-18-328 16-Jun-2019	275,000 USD
	Contact Name	Judith A. Cooper, Ph.D			
	Contact Telephone	301-496-5061			
	Contact Email	cooperj@mail.nih.gov			
	Sponsor Website				

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Program URL	https://grants.nih.gov/grants/guide/pa-1	files/PA-18-328.html		
	Deadline Dates (ALL)	16-Jun-2019 , 16-Oct-2019 , 16-Feb-2020	0 , 16-Jun-2020 , 16-Oct-2020		
	Synopsis	Human Development (NICHD) invite app language and literacy development of du advantage of advances in the language s neurobiological, and sociocultural factor	r Communication Disorders (NIDCD) and Nationa blications that will inform our understanding of the ual language learners (DLLs) in the United States. Inciences and related fields to identify and clarify see associated with normal and impaired language 21 Exploratory/Developmental Research Grant as	e typical and atypical Applicants are encou pecific cognitive, linguand literacy acquisition	patterns of raged to take uistic,
Uh / /Uh	Typical and Atypical Patterns of La Learners (R01-Clinical Trial Option	anguage & Literacy in Dual Language nal)	National Institute on Deafness & Other Communication Disorders/NIH/DHHS	316 05-Jun-2019	Not Specified
'	Contact Name	Judith A. Cooper, Ph.D			
	Contact Telephone	301-496-5061			
	Contact Email	cooperj@mail.nih.gov			
	Sponsor Website				
	Program URL	https://grants.nih.gov/grants/guide/pa-f	files/PA-18-316.html		
	Deadline Dates (ALL)	05-Jun-2019 , 05-Oct-2019 , 05-Feb-2020	0 , 05-Jun-2020 , 05-Oct-2020		
	Synopsis	Human Development (NICHD) invite app language and literacy development of du advantage of advances in the language s neurobiological, and sociocultural factor	r Communication Disorders (NIDCD) and Nationa clications that will inform our understanding of the ual language learners (DLLs) in the United States. Inciences and related fields to identify and clarify see associated with normal and impaired language desearch Project (R01) award mechanism.	e typical and atypical Applicants are encou pecific cognitive, lingu	patterns of raged to take uistic,
UhX43X	Improving Outcomes for Disorder Trial Optional)	rs of Human Communication (R21 Clinical	National Institute on Deafness & Other Communication Disorders/NIH/DHHS	288 16-Jun-2019	275,000 USD
	Contact Name	Judith A. Cooper, Ph.D.			
	Contact Telephone	301-496-5061			
	Contact Email	cooperj@nidcd.nih.gov			
	Sponsor Website				
	Program URL	https://grants.nih.gov/grants/guide/pa-f	files/PA-18-288.html		
	Deadline Dates (ALL)	16-Jun-2019 , 16-Oct-2019 , 16-Feb-2020	)		

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	improve the health outcomes for individent health services research in the NIDCD mi	r Communication Disorders (NIDCD) invites applicated uals with deafness and other communication disorgesion areas of hearing, balance, smell, taste, voice omental Research Grant award mechanism.	ders through effect	iveness and
UPX/I33	Improving Outcomes for Disorder Trial Optional)	rs of Human Communication (R01 Clinical	National Institute on Deafness & Other Communication Disorders/NIH/DHHS PA-18-2	87 05-Jun-2019	Not Specified
	Contact Name	Judith A. Cooper, Ph.D.			
	Contact Telephone	301-496-5061			
	Contact Email	cooperj@nidcd.nih.gov			
	Sponsor Website				
	Program URL	https://grants.nih.gov/grants/guide/pa-f	iles/PA-18-287.html		
	Deadline Dates (ALL)	05-Jun-2019 , 05-Oct-2019 , 05-Feb-2020			
	Synopsis	improve the health outcomes for individ	r Communication Disorders (NIDCD) invites applicated uals with deafness and other communication disorables ssion areas of hearing, balance, smell, taste, voice ward mechanism.	ders through effect	iveness and
11657511	Typical and Atypical Patterns of La Learners (R21)	anguage & Literacy in Dual Language	National Institute on Deafness & Other Communication Disorders/NIH/DHHS	48 16-Jun-2019	275,000 USD
	Contact Name	Judith A. Cooper, Ph.D			
	Contact Telephone	301-496-5061			
	Contact Email	cooperj@mail.nih.gov			
	Sponsor Website				
	Program URL	https://grants.nih.gov/grants/guide/pa-f	iles/PA-17-448.html		
	Deadline Dates (ALL)	16-Jun-2019 , 16-Oct-2019 , 16-Feb-2020	) , 16-Jun-2020		
	Synopsis	Human Development (NICHD) invite app language and literacy development of du advantage of advances in the language so	r Communication Disorders (NIDCD) and National lications that will inform our understanding of the lal language learners (DLLs) in the United States. A ciences and related fields to identify and clarify specials associated with normal and impaired language a	typical and atypical pplicants are encou ecific cognitive, ling	patterns of raged to take uistic,

populations. This FOA will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
				·	
069082	NIDCD Cooperative Agreement for Disorders (U01 - Clinical Trial Req	or Clinical Trials in Communication uired)	National Institute on Deafness & Other PAR-18 Communication Disorders/NIH/DHHS 340	3- 22-May-2019 [LOI/Pre-App] [Optional]	Not Specified
	Contact Name	Trinh T. Ly, M.D.			
	Contact Telephone	301-496 5061			
	Contact Email	trinh.ly@nih.gov			
	Sponsor Website				
	Program URL	https://grants.nih.gov/grants/guide/pa-	files/PAR-18-340.html		
	Deadline Dates (ALL)		21-Jun-2019 , 21-Sep-2019 [LOI/Pre-App][Optiona 23-May-2020 [LOI/Pre-App][Optional], 22-Jun-202	=:	
	Synopsis	agreement between an NIDCD Project S criteria: requires FDA oversight, has ann establish efficacy, or has a higher risk to trials are perceived to benefit from close	ner Communication Disorders (NIDCD) invites application and an investigator to support a clinical tripual direct costs equal to or greater than \$500,000 potentially cause physical or psychological harm. In the interaction, oversight, and guidance resulting from the NIDCD Clinical Trials in Communication Disorderative Agreements award mechanism.	rial that meets ANY of o, that is intended to These investigator-in om a cooperative agre	the following formally nitiated clinical eement. Only
069078	NIDCD Clinical Trials in Communic Required)	cation Disorders (R01Clinical Trial	National Institute on Deafness & Other Communication Disorders/NIH/DHHS	334 07-May-2019	2,499,995 USD
	Contact Name	Trinh T. Ly, M.D.			
	Contact Telephone	•			
	Contact Email	trinh.ly@nih.gov			
	Sponsor Website				
	Program URL	https://grants.nih.gov/grants/guide/pa-	files/PA-18-334.html		
	Deadline Dates (ALL)	07-May-2019 , 05-Jun-2019 , 07-Sep-201 2020 , 05-Oct-2020 , 07-Jan-2021	19 , 05-Oct-2019 , 07-Jan-2020 , 05-Feb-2020 , 07-	-May-2020 , 05-Jun-20	020 , 07-Sep-
	Synopsis	low risk clinical trials addressing the mis	ner Communication Disorders (NIDCD) invites appl sion and research interests of NIDCD. Clinical tria OA, not require FDA oversight, are not intended t	ls must meet ALL the	following

have low risks to potentially cause physical or psychological harm. It is advisable that only one clinical trial be proposed in

		-			
SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		each NIDCD Clinical Trials in Communicat award mechanism.	ion Disorders R01 application. This FOA will use th	e NIH Research Pro	ject (R01)
070868	NIDCD Research Career Enhancer (K18 Independent Clinical Trial No	ment Award for Established Investigators ot Allowed)	National Institute on Deafness & Other PAR-18- Communication Disorders/NIH/DHHS 564	07-May-2019	Not Specified
	Contact Name	Alberto L. Rivera-Rentas, Ph.D.			
	Contact Telephone	301-496-1804			
	Contact Email	riverara@nidcd.nih.gov			
	Sponsor Website				
	Program URL	https://grants.nih.gov/grants/guide/pa-fi	iles/PAR-18-564.html		
	Deadline Dates (ALL)	07-May-2019 , 06-Jun-2019 , 07-Sep-2019 2020 , 08-Oct-2020 , 07-Jan-2021	9 , 08-Oct-2019 , 07-Jan-2020 , 06-Feb-2020 , 07-N	lay-2020 , 08-Jun-20	020 , 07-Sep-
	Synopsis	Career Enhancement Award for Establish augment or redirect their research prograthe hearing, balance, smell, taste, voice, sdesigned specifically for applicants propotrial feasibility study, or an ancillary study	Communication Disorders (NIDCD) invites applicated Investigators (K18) program to enable establish ams through the acquisition of new research skills speech and language sciences. This Funding Opportsing research that does not involve leading an index to a clinical trial. Applicants to this FOA are permetor or co-mentor. This FOA will utilize the NIH K18	ned, proven investig to answer question tunity Announceme ependent clinical tri itted to propose res	ators to s relevant to ent (FOA) is al, a clinical earch
070865	NIDCD Research Career Enhancer (K18 Clinical Trial Required)	ment Award for Established Investigators	National Institute on Deafness & Other PAR-18-Communication Disorders/NIH/DHHS 562	07-May-2019	Not Specified
	Contact Name	Alberto L. Rivera-Rentas, Ph.D.			
	Contact Telephone	301-496-1804			
	Contact Email	riverara@nidcd.nih.gov			
	Sponsor Website				
		https://grants.nih.gov/grants/guide/pa-fi			
	Deadline Dates (ALL)	07-May-2019 , 06-Jun-2019 , 07-Sep-2019 2020 , 08-Oct-2020 , 07-Jan-2021	9 , 08-Oct-2019 , 07-Jan-2020 , 06-Feb-2020 , 07-M	lay-2020 , 08-Jun-20	020 , 07-Sep-
	Synopsis	Career Enhancement Award for Establish	Communication Disorders (NIDCD) invites applica ed Investigators (K18) program to enable establish ams through the acquisition of new research skills	ned, proven investig	ators to

SPIN ID	Program	Sponsor Name	Sponsor Number	Deadline Date	Funding
		designed specifically for applicants prop	e, speech and language sciences. This Funding O cosing to serve as the lead investigator of an inc study to an existing trial, as part of their resear ment Award mechanism.	dependent clinical trial,	a clinical trial
11/11859	NIDCD Mentored Career Developr Au.D./Ph.D. Audiologists (K01 No		National Institute on Deafness & Other PAR Communication Disorders/NIH/DHHS 436	07-May-2019	315,000 USD
	Contact Telephone	Alberto L. Rivera-Rentas, Ph.D. 301-496-1804 riverara@nidcd.nih.gov			
	Program URL	https://grants.nih.gov/grants/guide/pa	-files/PAR-18-436.html		
	Deadline Dates (ALL)	07-May-2019 , 18-Jun-2019 , 07-Sep-20 2020 , 15-Oct-2020 , 07-Jan-2021	19 , 17-Oct-2019 , 07-Jan-2020 , 13-Feb-2020 , (	07-May-2020 , 18-Jun-2	020 , 07-Sep-
	Synopsis	Career Development Award for Postdoo and rigorous postdoctoral research and promising Au.D./Ph.D. audiologists who health-related research fields relevant t specifically for applicants proposing res feasibility study, or an ancillary study to	er Communication Disorders (NIDCD) invites ap ctorate Au.D./Ph.D. Audiologists. This award is of career development xperiences in the biomedic have the potential to become productive, indet to NIDCD's mission. This Funding Opportunity A earch that does not involve leading an independent of a clinical trial. Applicants to this FOA are permintor. This FOA will use the NIH KO1 Research Science.	designed to support con cal, behavioral, or clinic pendent investigators i nnouncement (FOA) is o dent clinical trial, a clini itted to propose researd	nprehensive al sciences of n scientific designed cal trial ch experience in
	NIDCD Mentored Career Developm Au.D./Ph.D. Audiologists (K01 Clin		National Institute on Deafness & Other PAR Communication Disorders/NIH/DHHS 435	07-May-2019	315,000 USD
	Contact Telephone Contact Email Sponsor Website Program URL	riverara@nidcd.nih.gov https://grants.nih.gov/grants/guide/pa	<u>-files/PAR-18-435.html</u> 19 , 17-Oct-2019 , 07-Jan-2020 , 13-Feb-2020 , (	07-May-2020 , 18-Jun-2	020 , 07-Sep-

SPIN ID Program Title	:	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
Synopsis	Career Devand rigoro promising health-relaspecifically study, or a	velopment Award for Postdoctous postdoctoral research and on Au.D./Ph.D. audiologists who hated research fields relevant to for applicants proposing to se separate ancillary study to an	Communication Disorders (NIDCD) invited or the Au.D./Ph.D. Audiologists. This award areer development xperiences in the bious have the potential to become productive, NIDCD's mission. This Funding Opportunative as the lead investigator of an independent of their research an Award - Research & Training award medicates.	rd is designe medical, be , independe nity Annound ndent clinica d career dev	ed to support com havioral, or clinica nt investigators in cement (FOA) is de al trial, a clinical tr	prehensive Il sciences of scientific esigned ial feasibility
070693 NIDCD Clinical Research Center Gr	rant (P50 Cl	linical Trial Optional)	National Institute on Deafness & Other Communication Disorders/NIH/DHHS	PAR-18- 556	07-May-2019 [LOI/Pre-App] [Optional]	7,500,000 USD
Contact Name	Lana Sheki	m, Ph.D.				
Contact Telephone	301-496-50	061				
Contact Email	shekiml@r	nidcd.nih.gov				
Sponsor Website						
Program URL	https://gra	ants.nih.gov/grants/guide/pa-f	iles/PAR-18-556.html			
Deadline Dates (ALL)	[LOI/Pre-A		5-Jun-2019 , 04-Sep-2019 [LOI/Pre-App][0 9-May-2020 [LOI/Pre-App][Optional], 08-	•		
Synopsis	Grants des this annou data/tissue studies of t disorder of	signed to advance the diagnosis ncement, Clinical Research is c es from individuals with a comi the prevention, pathogenesis,	Communication Disorders (NIDCD) invited in proceedings of the process of the proc	on of humar with commu search inclu nanagemen	n communication of unication disorders ude but are not lim t or epidemiology	disorders. For s or nited to, of a disease or
070187 NIDCD Early Career Research(ECR)	) Award (R2	21 Clinical Trial Optional)	National Institute on Deafness & Other Communication Disorders/NIH/DHHS	PAR-18- 487	26-Jun-2019	300,000 USD
Contact Name	Bracie Wat	tson, Jr.				



Contact Telephone 301-402-3458

Contact Email watsonb@nidcd.nih.gov

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Deadline Dates (ALL)	clinical research from scientists who are or dissertation research. The research m scientific mission of the NIDCD: hearing,		eer. It cannot be us he biomedical and e NIDCD ECR Awar	sed for thesis behavioral d R21 grant
		research technology. Irrespective of the	odology; translational research; outcomes research; type of project, the intent of the NIDCD ECR Award (s)/PI(s)) to obtain sufficient preliminary data for a suvelopmental (R21) grant mechanism.	R21 is for the Prog	ram
11/118/4	Hearing Health Care for Adults: Im Clinical Trial Optional)	nproving Access and Affordability (R21	National Institute on Deafness & Other Communication Disorders/NIH/DHHS	2 16-Jun-2019	275,000 USD
	Contact Name	Kelly King, Au.D., Ph.D.			
	Contact Telephone	301-402-3458			
	Contact Email	kingke@nidcd.nih.gov			
	Sponsor Website				
	Program URL	https://grants.nih.gov/grants/guide/pa-f	iles/PA-18-382.html		
	Deadline Dates (ALL)	16-Jun-2019 , 16-Oct-2019 , 16-Feb-2020	) , 16-Jun-2020 , 16-Oct-2020		
		health care in adults in support of impro-		eded to strengther e the NIH R21	_
11/11X/X	Hearing Health Care for Adults: Im Clinical Trial Optional)	proving Access and Affordability (R01	National Institute on Deafness & Other Communication Disorders/NIH/DHHS  PA-18-43	8 05-Jun-2019	Not Specified
	Contact Name	Kelly King, Au.D., Ph.D.			
	Contact Telephone	301-402-3458			
	Contact Email	kingke@nidcd.nih.gov			
	Sponsor Website				
	Program URL	https://grants.nih.gov/grants/guide/pa-f	iles/PA-18-438.html		

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	health care in adults in support of impro	o, 05-Jun-2020, 05-Oct-2020 er Communication Disorders (NIDCD) invites app ving access and affordability. Further research is ring health care outcomes in adults. This FOA wil	needed to strengthe	n the evidence
076039		ition: NIDCD National Temporal Bone, ource Registry (U24 Clinical Trial Not	National Institute on Deafness & Other RFA-D Communication Disorders/NIH/DHHS 19-002	24-lun-2019	2,125,000 USD
	Contact Name Contact Telephone	Amy Poremba, Ph.D 301-496-1804			
	Contact Email	porembaa@mail.nih.gov			
	Sponsor Website				
	Program URL	https://grants.nih.gov/grants/guide/rfa-	files/RFA-DC-19-002.html		
	Deadline Dates (ALL)	24-Jun-2019			
	Synopsis	and support critical research on the hum specimens also provides an opportunity vestibular research. This initiative will su growing database for access to detailed and archival human temporal bone tissu research; communicate with scientific armaintain a well-organized nationwide nedevelop and implement a strategy for remethods or techniques for donor recruit donation combined with relevant medicand genetic pathologies; provide educat	r Communication Disorders (NIDCD) invites applian middle and inner ear that cannot be done in for translation from critical animal models to hur pport the Registry by cooperative agreement, to information about the location, condition, and or es around the country that are available as resorted clinical researchers to disseminate information etwork of on-call experts for timely post-mortem exceipt of harvested tissue by nearby temporal bortement and post-mortem tissue procurement; con all histories that will allow linking functional disortion/outreach to the scientific community and to J24 Resource-Related Research Projects — Coope	iving humans. Use of man models for audit: continue to develop ther bioinformatics dances for auditory and nabout the resources harvesting of temporal laboratories; development to morphologica the public about temporatories to morphological	temporal bone ory and and maintain a ata about new vestibular available; ral bone tissues; op new ges' for tissue al, biochemical poral bone
076005	RFA-DC-19-001 NIDCD Hearing and Affordability (R21/R33 Clinica	Healthcare for Adults: Improving Access Il Trials Optional)	National Institute on Deafness & Other RFA-D Communication Disorders/NIH/DHHS 19-00:	()4-liin-2()19	Not Specified
	Contact Name	Kelly King, Au.D., Ph.D.			

Contact Telephone 301-402-3458

S	PIN ID	Program	Sponsor Name	Sponsor Number	Deadline Date	Funding
3		Title	Sponsor Name	Sponsor Number	Deaumie Date	Amount

Contact Email kingke@nidcd.nih.gov

Sponsor Website

Program URL https://grants.nih.gov/grants/guide/rfa-files/RFA-DC-19-001.html

Deadline Dates (ALL) 04-Jun-2019, 04-Feb-2020, 04-Oct-2020, 04-Jun-2021

National Institute on Deafness and Other Communication Disorders (NIDCD) invites applications for research and/or infrastructure needs in emerging scientific areas leading to more accessible and affordable hearing health care for adults with mild to moderate hearing loss. The proposed research aims should be milestone-driven and lead to better hearing healthcare, targeting enhanced access and affordability, in an effort to improve outcomes for adults with hearing loss. The Synopsis total project period for an application submitted in response to this FOA may not exceed five years. This FOA provides support for up to two years (R21 phase) for preliminary/developmental studies, followed by possible transition of up to four years of expanded research and development support (R33), although the total duration of the award may not exceed five years. This FOA requires measurable R21 milestones. This program will use the NIH R21/R33 Phased Innovation Award grant

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
078310	Advancing Research in Augmentative and Alternative Communication (AAC) (R01 Clinical Trial Optional)	National Institute on Deafness & Other Communication Disorders/NIH/DHHS	PA-19-047	07-May-2019	Not Specified

Contact Name Lana Shekim, Ph.D.

Contact Telephone 301-496-5061

Contact Email shekiml@nidcd.nih.gov

mechanism.

Sponsor Website

079193 NIDCD Clinical Research Center Grant (P50 Clinical Trial Optional

Program URL https://grants.nih.gov/grants/guide/pa-files/PA-19-047.html

Deadline Dates (ALL)

07-May-2019, 05-Jun-2019, 07-Sep-2019, 05-Oct-2019, 07-Jan-2020, 05-Feb-2020, 07-May-2020, 05-Jun-2020, 07-Sep-2020 , 05-Oct-2020 , 07-Jan-2021 , 05-Feb-2021 , 07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022

This funding opportunity announcement (FOA) seeks Research Project Grants (R01) applications on Augmentative and Alternative Communication (AAC) to advance our scientific knowledge in the evaluation and treatment of individuals with Synopsis severe speech and physical impairments (SSPI). AAC is a set of tools and strategies that an individual uses to solve everyday communicative challenges. This FOA is for R01s only and encourages a range of research inclusive of basic, clinical, and

translational.

National Institute on Deafness & Other PAR-19-

07-May-2019

7,500,000



SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
			Communication Disorders/NIH/DHHS	137	[LOI/Pre-App] [Optional]	USD
	Contact Name	Lana Shekim, Ph.D.				
	Contact Telephone	301-496-5061				
	Contact Email	shekiml@nidcd.nih.gov				
	Sponsor Website					
	Program URL	https://grants.nih.gov/grants/guid	de/pa-files/PAR-19-137.html			
	Deadline Dates (ALL)	[LOI/Pre-App][Optional], 06-Feb-2	onal], 06-Jun-2019 , 04-Sep-2019 [LOI/Pre-App 2020 , 09-May-2020 [LOI/Pre-App][Optional], ( Feb-2021 , 06-Jun-2021 , 06-Oct-2021		•	
	Synopsis	Center Grants designed to advance disorders. For this announcement disorders or data/tissues from ind limited to, studies of the prevention	s and Other Communication Disorders (NIDCE e the diagnosis, prevention, treatment, and a t, Clinical Research is defined as research involviduals with a communication disorder. Exanon, pathogenesis, pathophysiology, diagnosis, lance, smell, taste, voice, speech, or language	melioration of living individual ples of such treatment, i	of human commun uals with communi research include b management or ep	ication cation out are not idemiology of
079239	NIDCD Mentored Career Develop Au.D./Ph.D. Audiologists (K01 Ind with Humans Required)	ment Award for Postdoctorate dependent Basic Experimental Stud	National Institute on Deafness & Other Communication Disorders/NIH/DHHS	PAR-19- 142	07-May-2019	315,000 USD
	Contact Name	Alberto L. Rivera-Rentas, Ph.D.				
	Contact Telephone	301-496-1804				
	Contact Email	riverara@mail.nih.gov				
	Sponsor Website					
	Program URL	https://grants.nih.gov/grants/guid	de/pa-files/PAR-19-142.html			
	Deadline Dates (ALL)	07-May-2019 , 18-Jun-2019 , 07-S 2020 , 15-Oct-2020 , 07-Jan-2021	ep-2019 , 17-Oct-2019 , 07-Jan-2020 , 13-Feb-	·2020 , 07-M	ay-2020 , 18-Jun-20	020 , 07-Sep-
	Synopsis	support comprehensive and rigoro	red Career Development Award for Postdocto ous postdoctoral research and career develop promising Au.D./Ph.D. audiologists who have	ment experi	ences in the biome	dical,

independent investigators in scientific health-related research fields relevant to NIDCD's mission. This Mentored Career

Title Amount
--------------

Development Award for Postdoctorate Au.D./Ph.D. Audiologists Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as "prospective basic science studies involving human participants." These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should submit under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Studies conducted with specific applications toward processes or products in mind should submit under the appropriate 'Independent Clinical Trial Required' (PAR-18-435). Applicants not planning an independent clinical trial, or proposing to gain research in a clinical trial led by another investigator must apply to the companion 'Independent Clinical Trial Not Allowed' (PAR-18-436) FOA.

078368	Advancing Research in Augmentative and Alternative Communication
	Advancing Research in Augmentative and Alternative Communication (AAC) (R21 Clinical Trial Optional)

National Institute on Deafness & Other Communication Disorders/NIH/DHHS

PA-19-046 07-May-2019

275,000 USD

Contact Name Lana Shekim, Ph.D.

Contact Telephone 301-496-5061

Contact Email shekiml@nidcd.nih.gov

Sponsor Website

Program URL https://grants.nih.gov/grants/guide/pa-files/PA-19-046.html

Deadline Dates (ALL

07-May-2019, 16-Jun-2019, 07-Sep-2019, 16-Oct-2019, 07-Jan-2020, 16-Feb-2020, 07-May-2020, 16-Jun-2020, 07-Sep-2020 , 16-Oct-2020 , 07-Jan-2021 , 16-Feb-2021 , 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022

This funding opportunity announcement (FOA) solicits Research Project Grants (R21) applications on augmentative and alternative communication (AAC) to advance our scientific knowledge in the evaluation and treatment of individuals with Synopsis complex communication needs (CCN) or with severe speech and physical impairments (SSPI). AAC is a set of tools and strategies that an individual uses to solve everyday communicative challenges. This FOA is for R21s only and encourages a range of research inclusive of basic, clinical, and translational.

NIDCD Research Career Enhancement Award for Established 079241 Investigators (K18 Independent Basic Experimental Studies with Humans Required)

National Institute on Deafness & Other PAR-19-Communication Disorders/NIH/DHHS 143

07-May-2019

Not Specified

Contact Name Alberto L. Rivera-Rentas, Ph.D.

Contact Telephone 301-496-1804

Contact Email riverara@mail.nih.gov

Sponsor Website

SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
Program	uRL https://grants.nih.gov/grants/guide	:/pa-files/PAR-19-143.html			
Deadline Dates	07 May 2010, 06 Jun 2010, 07 Sor	o-2019 , 08-Oct-2019 , 07-Jan-2020 , 0	6-Feb-2020 , 07-Ma	ay-2020 <i>,</i> 08-Jun-2	020 , 07-Sep-
Syn	established, proven investigators to skills to answer questions relevant to Opportunity Announcement is for but "prospective basic science studies in and also meet the definition of basic prospectively assign human particip biomedical or behavioral outcomes without specific application towards processes or products in mind shou Applicants not planning an independent	in humans for the purpose of underst s processes or products in mind. Studi ld submit under the appropriate FOA: dent clinical trial or basic experimenta experimental study with humans led	rograms through the oice, speech and lad olving humans, refected in the studies fall within the submit under the ymanipulate indegranding the fundames conducted with PAR-18-562 'Indegral study with human	ne acquisition of nonguage sciences. erred to in NOT-OE the NIH definition of its FOA include studendent variables) nental aspects of particular in specific applications, or proposing to	ew research This Funding 0-18-212 as of a clinical tria dies that and that asses whenomena ans toward ial Required.' o gain research
057394 <u>Drug Abuse Dissertation Res</u>	earch (R36)	National Institute on Drug Abuse/NIH/DHHS	PA-16-443	07-May-2019	100,000 USD
Contact N	Jame Will M. Aklin, Ph.D.				
Contact Telep	hone 301-443-3207				
Contact I	Email aklinwm@mail.nih.gov				
Sponsor We	bsite				
Program	uRL http://grants.nih.gov/grants/guide/	pa-files/PA-16-443.html			
•	(ALL) 07-May-2019 , 16-Jun-2019 , 07-Sep				
Syn	National Institute on Drug Abuse (N FOA will utilize the NIH R36 Disserta	IDA) invites applications for support cation Award mechanism.	f drug abuse docto	oral dissertation re	search. This
056333 Chemistry Science Track Awa	ard for Rapid Transition (C/START) (R03)	National Institute on Drug Abuse/NIH/DHHS	PAR-16- 383	07-May-2019	50,000 US
Contact N	lame Kristopher Bough, Ph.D.				



Contact Telephone 301-443-9800

Contact Email boughk@mail.nih.gov

SPIN ID	Program	Sponsor Name	Sponsor Number	Deadline Date	Funding
51 III ID	Title	oponsor rume	Sponsor Humber	Deddinie Date	Amount
	Sponsor Website				
	•	http://grants.nih.gov/grants/guide/pa			
	Deadline Dates (ALL)	07-May-2019 , 16-Jun-2019 , 07-Sep-2			
	Synopsis	National Institute on Drug Abuse (NID substance use disorder (SUD) research chemical/pharmacological pilot resear opportunity to gather preliminary dat development funding opportunities the NIH Small Research Grant (R03) award	n. ESIs are invited to submit applicati rch projects. Importantly, the C/STAF a in support of subsequent research nat, in the long term, help to launch t	ons for small scale, innovative RT award is intended to enable an grants (e.g., R21/R33 [CHEM], R21	ESI the L or R01) or drug
068420	Marijuana, Prescription Opioid, or Use Among Older Adults (R03 Clir	Prescription Benzodiazepine Drug nical Trial Optional)	National Institute on Drug Abuse/NIH/DHHS	PA-18-080 07-May-2019	100,000 USD
	Contact Name	Shelley Su, Ph.D.			
	Contact Telephone	301-402-3869			
	Contact Email	shelley.su@nih.gov			
	Sponsor Website				
	Program URL	https://grants.nih.gov/grants/guide/p	a-files/PA-18-080.html		
	Deadline Dates (ALL)	07-May-2019 , 16-Jun-2019 , 07-Sep-2	2019 , 16-Oct-2019 , 07-Jan-2020 , 16	-Feb-2020 , 07-May-2020	
		National Institute on Drug Abuse (NII the determinants of these types of drubehaviors, and public health conseque with earlier onset of drug use who are the age of 50. Applications are encour epidemiological approaches. The insig drug use in later life, as well as its conto identify risk factors and to guide cli award mechanism.	ug use and/or characterizes the resultences. This initiative will focus on two now entering this stage of adult developed to utilize broad methodologies this gleaned from this initiative are consequences in the aging brain and on	ting neurobiological alterations, and distinct populations of older additions of older additions of older additions of older additionals who inition ranging from basic science, clinical to our understanding of the behavior. This knowledge may har	ssociated Ilts: individuals ate drug use afte al, and determinants of ve the potential
068414	Marijuana, Prescription Opioid, or Use Among Older Adults (R21 Clir	Prescription Benzodiazepine Drug nical Trial Optional)	National Institute on Drug Abuse/NIH/DHHS	PA-18-079 07-May-2019	275,000 USD
	Contact Name	Shelley Su, Ph.D.			
	Contact Telephone	301-402-3869			

Contact Email shelley.su@nih.gov

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Deadline Dates (ALL)  O7-Ma  Natio the de behavi with ea  Synopsis the age epiden drug u to ider	nal Institute on Drug Abuse (NII terminants of these types of dru ors, and public health conseque arlier onset of drug use who are of 50. Applications are encour niological approaches. The insigs in later life, as well as its con	O19, 16-Oct-2019, 07-Jan-2020, 16-Feb- DA) and National Institute on Aging (NIA) ag use and/or characterizes the resulting ences. This initiative will focus on two dist now entering this stage of adult develop aged to utilize broad methodologies rang hts gleaned from this initiative are critical sequences in the aging brain and on behanical practices in older populations. This F	invite applica neurobiologic inct population ment or indiving from basion I to our under vior. This kno	tions for research al alterations, assons of older adults: iduals who initiate ascience, clinical, astanding of the dewledge may have	ociated : individuals e drug use after and eterminants of
068413	Marijuana, Prescription Opioid, or Prescr Use Among Older Adults (R01 Clinical Tri		National Institute on Drug Abuse/NIH/DHHS	PA-18-061	07-May-2019	Not Specified
	Deadline Dates (ALL)  O7-Ma  Natio the de behavi with ea  Synopsis the age epiden drug u to ider	//grants.nih.gov/grants/guide/py-2019, 05-Jun-2019, 07-Sep-2nal Institute on Drug Abuse (NII terminants of these types of drug ors, and public health consequentier onset of drug use who are e of 50. Applications are encountiological approaches. The insigns in later life, as well as its consequential contents.	a-files/PA-18-061.html 019, 05-Oct-2019, 07-Jan-2020, 05-Feb- DA) and National Institute on Aging (NIA) ug use and/or characterizes the resulting ences. This initiative will focus on two dist now entering this stage of adult develop aged to utilize broad methodologies rang hts gleaned from this initiative are critica sequences in the aging brain and on beha- nical practices in older populations. This F	invite applica neurobiologic inct population ment or indiving from basion I to our under ivior. This kno	tions for research al alterations, asso ons of older adults: iduals who initiate c science, clinical, a estanding of the de wledge may have	ociated: individuals drug use after and eterminants of the potential
060675	RFA-DA-18-003NIDA Translational Avar Development of Medication to Treat Sub (UG3/UH3)		National Institute on Drug Abuse/NIH/DHHS	RFA-DA- 18-003	25-Jun-2019 [LOI/Pre-App] [Optional]	1,000,000 USD

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Contact Telephone 3 Contact Email i Sponsor Website Program URL i Deadline Dates (ALL) 2 Synopsis	https://grants.nih.gov/grants/guide/rfa 25-Jun-2019 [LOI/Pre-App][Optional], 2 National Institute on Drug Abuse (NIDA vision and expertise to translate resear stemming from tobacco, cannabis, coca demonstrate the ability to develop mol continuum. The ultimate goal of this FO		reatment of S cription opiat nd advance t oroval. This Fo	ubstance Use Disc e use. Eligible app hem in the drug de	rders (SUDs) licants must evelopment
069187	Integrative Research on Polysubsta Clinical Trial Optional)	ance Abuse and Addiction (R21/R33	National Institute on Drug Abuse/NIH/DHHS	PAR-18- 084	07-May-2019	Not Specified
	Contact Name	Shelley Su, Ph.D.				
	Contact Telephone	301-402-3869				
	Contact Email <u>s</u>	shelley.su@nih.gov				
	Sponsor Website					
	Program URL <u>I</u>	https://grants.nih.gov/grants/guide/pa	-files/PAR-18-084.html			
	Deadline Dates (ALL)	07-May-2019 , 16-Jun-2019 , 07-Sep-20	19			
	Synopsis <sup>I</sup>	neurobiological alterations, associated or are similar to, those observed in sing oipeline, consisting of basic science resolated dual objectives will be accomplistican occur in any of these translational stansocans.	its participating Institutes and Centers in behaviors, and public health consequence le drug use; (2) promote integrative poly earch in animals, human-based laborator hed with a Phased Innovation (R21/R33) stages during the R21 phase and these fire R33 phase, allowing for bi-directional regrant mechanism.	ces arising from substance recovery investigation mechanism, andings will be	m polysubstance usearch along a traitons, and epidemiolewhere polysubstaitrapidly back- or fo	use differ from, nslational ogical studies. nce research orward-
069197	Target Assessment, Engagement a Substance Use Disorders Treatmer Optional)		National Institute on Drug Abuse/NIH/DHHS	PAR-18- 086	17-May-2019 [LOI/Pre-App] [Optional]	Not Specified

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Contact Name Will M. A	vlin Ph D			

Contact Name Will M. Aklin, Ph.D.

Contact Telephone 301-443-3207

Contact Email aklinwm@mail.nih.gov

Sponsor Website

Program URL https://grants.nih.gov/grants/guide/pa-files/PAR-18-086.html

Deadline Dates (ALL) 17-May-2019 [LOI/Pre-App][Optional], 16-Jun-2019

National Institute on Drug Abuse (NIDA), National Cancer Institute (NCI), and National Institute on Alcohol Abuse and Alcoholism (NIAAA) invite that focus on early-stage, treatment generation and pilot clinical trials that are consistent with an experimental therapeutic approach. This approach requires the identification of a theory-derived target based on putative mechanisms of alcohol, tobacco and other drug use, and clear hypotheses about how a treatment directed at changing the target can lead to clinical benefits. Studies of novel treatments include, but are not limited to behavioral, pharmacological, Synopsis physiological, learning- and device-based treatment approaches. This FOA provides support for up to two years (Phase I; R21) for protocol development, target identification and studies to confirm target engagement (i.e., link targets with tangible outcomes); followed by up to 3 years of support (Phase II; R33) for replication studies of addiction treatment across 2 or more settings. Specifically, this latter phase will focus on clinical trials that apply the target in a treatment setting (development, refinement, and/or adaptation) to evaluate the feasibility of conducting a larger trial. This FOA will use the NIH R21/R33 Phased Innovation Award award mechanism.

Target Assessment, Engagement and Data Replicability to Improve 069194 Substance Use Disorders Treatment Outcomes (R33 Clinical Trial Optional)

National Institute on Drug Abuse/NIH/DHHS

PAR-18-085

17-May-2019 [LOI/Pre-App] [Optional]

Not Specified

Contact Name Will M. Aklin, Ph.D.

Contact Telephone 301-443-3207

Contact Email aklinwm@mail.nih.gov

**Sponsor Website** 

Program URL https://grants.nih.gov/grants/guide/pa-files/PAR-18-085.html

Deadline Dates (ALL) 17-May-2019 [LOI/Pre-App][Optional], 16-Jun-2019

National Institute on Drug Abuse (NIDA), National Cancer Institute (NCI), and National Institute on Alcohol Abuse and

Alcoholism (NIAAA) invite applications that focus on data replication and the scalability of novel, targeted addiction treatments. Consistent with an experimental therapeutics approach, studies that would fall under the R33 (Phase II) would include studies with theory-derived targets (based on putative mechanisms of ATOD) and clearly defined hypotheses about how the proposed treatment directed at changing the target relates to clinical outcomes. In addition, studies that include preliminary efficacy with respect to target engagement and validation (i.e., data to establish the relation between target and

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		are not limited to behavioral, pharmac combined approaches. This FOA provious Specifically, this phase will focus on cli adaptation) to evaluate the efficacy and mechanisms and processes underlying efficiently tested and replicated for the build on data that have been demonst	ccomes) are essential to the Phase II arm cological, biologics-based, cognitive, devictes support for replication studies of add nical trials that apply the target in a treat of replicability of larger trials. Ultimately, treatments or replication of strategies in eir promise to address substance use discrated with sufficient signal of target engage.	ce-based, inte iction treatme ment setting the goal of th ito novel inter order outcome agement from	rpersonal, physiolo ent across 2 or mor (testing, refinemer iis FOA is to replica evention approache es. Furthermore, th an analogous R21-	e settings.  It, and/or  te findings of  state that can be  lese studies  like study to
069802		es for System-Level Implementation of eatment Services (R34 Clinical Trial	National Institute on Drug Abuse/NIH/DHHS	PAR-18- 223	17-Jun-2019 [LOI/Pre-App] [Optional]	450,000 USD
	Contact Name	Tisha Wiley, Ph.D.				
	Contact Telephone	301-594-4381				
	Contact Email	tisha.wiley@nih.gov				
	Sponsor Website					
	Program URL	https://grants.nih.gov/grants/guide/pa	a-files/PAR-18-223.html			
	Deadline Dates (ALL)		17-Jul-2019 , 14-Oct-2019 [LOI/Pre-App][ 14-Oct-2020 [LOI/Pre-App][Optional], 13		-Nov-2019 , 17-Jun	-2020
	Synopsis	testing of interventions, models, and/ointerventions, guidelines, or principles	its participating Institutes and Centers in or frameworks that examine system-level to improve the delivery, uptake, quality, ces. This FOA will use the NIH R34 Planning	l implementat and sustainal	ion of evidence-ba pility of substance	sed
069798	Multi-Site Studies for System-Leve Prevention and Treatment Service	el Implementation of Substance Use es (R01 Clinical Trial Optional)	National Institute on Drug Abuse/NIH/DHHS	PAR-18- 222	17-Jun-2019 [LOI/Pre-App] [Optional]	2,500,000 USD
	Contact Name	Tisha Wiley, Ph.D.				
	Contact Telephone	301-594-4381				
	Contact Email	tisha.wiley@nih.gov				
	Sponsor Website					

Program URL https://grants.nih.gov/grants/guide/pa-files/PAR-18-222.html

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Deadline Dates (ALL) Synopsis	17-Jun-2019 [LOI/Pre-App][Optional], [LOI/Pre-App][Optional], 17-Jul-2020, National Institutes of Health (NIH) and testing of interventions, models, and/	I its participating Institutes and Center or frameworks that examine system-le	rs invite applica evel implement	tions for the develo ation of evidence-b	pment and ased
	, ,	interventions, guidelines, or principles and treatment interventions and servi		•	•	use preventio
n /n//u	Synthetic Psychoactive Drugs and Their Deleterious Effects (R21- Cl	Strategic Approaches to Counteract inical Trial Optional)	National Institute on Drug Abuse/NIH/DHHS	PAR-18- 509	07-May-2019	275,000 USD
	Contact Name	Rao Rapaka, PhD				
	Contact Telephone	301-435-1304				
	Contact Email	rrapaka@nida.nih.gov				
	Sponsor Website					
	Program URL	https://grants.nih.gov/grants/guide/p	a-files/PAR-18-509.html			
	Deadline Dates (ALL)	07-May-2019 , 16-Jun-2019 , 07-Sep-2	2019 , 16-Oct-2019 , 07-Jan-2020 , 16-F	eb-2020 , 07-N	1ay-2020	
	Synopsis	National Institute on Drug Abuse (NID psychoactive drugs, their mechanisms to treat patients in emergency depart Exploratory/Developmental Research	of action, their health effects, and dements and long range treatment. This	velopment of p	revention strategies	
11/11/1/1/	Synthetic Psychoactive Drugs and Their Deleterious Effects (R01- Cl	Strategic Approaches to Counteract inical Trial Optional)	National Institute on Drug Abuse/NIH/DHHS	PAR-18- 510	07-May-2019	Not Specified
	Contact Name	Rao Rapaka, PhD				
	Contact Telephone	301-435-1304				
	Contact Email	rrapaka@nida.nih.gov				
	Sponsor Website					
	Program URL	https://grants.nih.gov/grants/guide/p	a-files/PAR-18-510.html			
	Deadline Dates (ALL)	07-May-2019 , 05-Jun-2019 , 07-Sep-2	2019 , 05-Oct-2019 , 07-Jan-2020 , 05-F	eb-2020 , 07-M	1ay-2020	
	Synopsis	National Institute on Drug Abuse (NID psychoactive drugs, their mechanisms to treat patients in emergency depart	of action, their health effects, and de	velopment of p	revention strategies	s and strategie

award mechanism.

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
074442	International Research Collaboration Research (R01 Clinical Trial Option	tion on Drug Abuse and Addiction nal)	National Institute on Drug Abuse/NIH/DHHS	PA-18-773	07-May-2019	Not Specified
	Contact Name	Steven Gust, Ph.D., Director				
	Contact Telephone	301-443-6480				
	Contact Email	ipdirector@nida.nih.gov				
	Sponsor Website					
	Program URL	https://grants.nih.gov/grants/guide/j	oa-files/PA-18-773.html			
	Deadline Dates (ALL)	07-May-2019 , 05-Jun-2019 , 07-Sep- 2020 , 05-Oct-2020 , 07-Jan-2021 , 05		5-Feb-2020 , 07-M	ay-2020 , 05-Jun-20	020 , 07-Sep-
		advantage of unusual opportunities t	ilat exist outside the office states to	decess talent, res	odices, population	13, 01
	Synopsis	environmental conditions in other co advance U.S. health sciences; Demon research plan is relevant to the NIDA (https://www.drugabuse.gov/about- international scientific priority areas investigator from a U.S. institution an NIH Research Project (R01) award me	mission and objectives, review the Nonida/2016-2020-nida-strategic-plan). (https://www.drugabuse.gov/internada a non-U.S. citizen partner living an	mission and object IDA Strategic Plan Where feasible, a ational/research-p	ctives. To determin pplications should riorities); and Inclu	e whether your address NIDA's de an
070450		advance U.S. health sciences; Demon research plan is relevant to the NIDA (https://www.drugabuse.gov/about-international scientific priority areas investigator from a U.S. institution an NIH Research Project (R01) award me	strate specific relevance to the NIDA mission and objectives, review the Nida/2016-2020-nida-strategic-plan). (https://www.drugabuse.gov/internad a non-U.S. citizen partner living an	mission and object IDA Strategic Plan Where feasible, a ational/research-p	ctives. To determin pplications should riorities); and Inclu	e whether your address NIDA's de an
070450	Synthetic Psychoactive Drugs and Their Deleterious Effects (R03 Clin	advance U.S. health sciences; Demon research plan is relevant to the NIDA (https://www.drugabuse.gov/about-international scientific priority areas investigator from a U.S. institution an NIH Research Project (R01) award me	strate specific relevance to the NIDA mission and objectives, review the Nida/2016-2020-nida-strategic-plan). (https://www.drugabuse.gov/internated a non-U.S. citizen partner living an echanism.  National Institute on Drug	mission and object IDA Strategic Plan Where feasible, a ational/research-p d working in anoth PAR-18-	pplications should riorities); and Incluner country. This FC	e whether your address NIDA's de an DA will use the
070450	Synthetic Psychoactive Drugs and Their Deleterious Effects (R03 Clin	advance U.S. health sciences; Demon research plan is relevant to the NIDA (https://www.drugabuse.gov/about-international scientific priority areas investigator from a U.S. institution an NIH Research Project (R01) award medical Trial Optional)  Rao Rapaka, PhD	strate specific relevance to the NIDA mission and objectives, review the Nida/2016-2020-nida-strategic-plan). (https://www.drugabuse.gov/internated a non-U.S. citizen partner living an echanism.  National Institute on Drug	mission and object IDA Strategic Plan Where feasible, a ational/research-p d working in anoth PAR-18-	pplications should riorities); and Incluner country. This FC	e whether your address NIDA's de an DA will use the
070450	Synthetic Psychoactive Drugs and Their Deleterious Effects (R03 Clin  Contact Name Contact Telephone	advance U.S. health sciences; Demon research plan is relevant to the NIDA (https://www.drugabuse.gov/about-international scientific priority areas investigator from a U.S. institution an NIH Research Project (R01) award medical Trial Optional)  Rao Rapaka, PhD	strate specific relevance to the NIDA mission and objectives, review the Nida/2016-2020-nida-strategic-plan). (https://www.drugabuse.gov/internated a non-U.S. citizen partner living an echanism.  National Institute on Drug	mission and object IDA Strategic Plan Where feasible, a ational/research-p d working in anoth PAR-18-	pplications should riorities); and Incluner country. This FC	e whether your address NIDA's de an DA will use the
070450	Synthetic Psychoactive Drugs and Their Deleterious Effects (R03 Clin  Contact Name Contact Telephone	advance U.S. health sciences; Demon research plan is relevant to the NIDA (https://www.drugabuse.gov/about-international scientific priority areas investigator from a U.S. institution an NIH Research Project (R01) award medical Trial Optional)  Rao Rapaka, PhD 301-435-1304  rrapaka@nida.nih.gov	strate specific relevance to the NIDA mission and objectives, review the Nida/2016-2020-nida-strategic-plan). (https://www.drugabuse.gov/internated a non-U.S. citizen partner living an echanism.  National Institute on Drug	mission and object IDA Strategic Plan Where feasible, a ational/research-p d working in anoth PAR-18-	pplications should riorities); and Incluner country. This FC	e whether your address NIDA's de an DA will use the
070450	Synthetic Psychoactive Drugs and Their Deleterious Effects (R03 Clin Contact Name Contact Telephone Contact Email Sponsor Website	advance U.S. health sciences; Demon research plan is relevant to the NIDA (https://www.drugabuse.gov/about-international scientific priority areas investigator from a U.S. institution an NIH Research Project (R01) award medical Trial Optional)  Rao Rapaka, PhD 301-435-1304  rrapaka@nida.nih.gov	strate specific relevance to the NIDA mission and objectives, review the Naida/2016-2020-nida-strategic-plan). (https://www.drugabuse.gov/internad a non-U.S. citizen partner living an echanism.  National Institute on Drug Abuse/NIH/DHHS	mission and object IDA Strategic Plan Where feasible, a ational/research-p d working in anoth PAR-18-	pplications should riorities); and Incluner country. This FC	e whether your address NIDA's de an DA will use the
070450	Synthetic Psychoactive Drugs and Their Deleterious Effects (R03 Clin  Contact Name Contact Telephone Contact Email Sponsor Website Program URL	advance U.S. health sciences; Demon research plan is relevant to the NIDA (https://www.drugabuse.gov/about-international scientific priority areas investigator from a U.S. institution an NIH Research Project (R01) award medical Trial Optional)  Rao Rapaka, PhD 301-435-1304  rrapaka@nida.nih.gov	strate specific relevance to the NIDA mission and objectives, review the Nida/2016-2020-nida-strategic-plan). (https://www.drugabuse.gov/internated a non-U.S. citizen partner living an echanism.  National Institute on Drug Abuse/NIH/DHHS	mission and object IDA Strategic Plan Where feasible, a ational/research-p d working in anoth PAR-18- 527	pplications should riorities); and Incluner country. This FO	e whether your address NIDA's de an DA will use the
070450	Synthetic Psychoactive Drugs and Their Deleterious Effects (R03 Clin  Contact Name Contact Telephone Contact Email Sponsor Website Program URL	advance U.S. health sciences; Demon research plan is relevant to the NIDA (https://www.drugabuse.gov/about-international scientific priority areas investigator from a U.S. institution an NIH Research Project (R01) award medical Trial Optional)  Rao Rapaka, PhD 301-435-1304  rrapaka@nida.nih.gov  https://grants.nih.gov/grants/guide/international Institute on Drug Abuse (NIE psychoactive drugs, their mechanism	strate specific relevance to the NIDA mission and objectives, review the Nida/2016-2020-nida-strategic-plan). (https://www.drugabuse.gov/internated a non-U.S. citizen partner living an echanism.  National Institute on Drug Abuse/NIH/DHHS  Da-files/PAR-18-527.html 2019, 16-Oct-2019, 07-Jan-2020, 160 of action, their health effects, and contact the sof action.	mission and object IDA Strategic Plan Where feasible, a stional/research-pd working in another PAR-18-527  6-Feb-2020, 07-M o deepen our knowlevelopment of present in the strategies of the str	opplications should riorities); and Inclusions This FO 07-May-2019  ay-2020 wledge of the use of evention strategies	e whether your address NIDA's de an DA will use the  100,000 USD  of synthetic s and strategies

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount	
	Abuse/Dependence (R03 Clinical	Trial Optional)	Abuse/NIH/DHHS		USD	
	Contact Name	Cora Lee Wetherington, Ph.D.				
	Contact Telephone	301-435-1319				
	Contact Email	cwetheri@mail.nih.gov				
	Sponsor Website					
	Program URL	https://grants.nih.gov/grants/guide/p	a-files/PA-18-601.html			
	Deadline Dates (ALL)	-May-2019 , 16-Jun-2019 , 07-Sep-2019 , 16-Oct-2019 , 07-Jan-2020 , 16-Feb-2020 , 07-May-2020 , 16-Jun-2020 , 0 20 , 16-Oct-2020 , 07-Jan-2021 , 16-Feb-2021 , 07-May-2021				
	Synopsis	applications to (1) advance identificati mechanisms of those differences, and specific to women or highly relevant to	A) and National Institute on Alcohol Abron of male-female differences in drug a to conduct translational research on the women. Both preclinical and clinical senting Small Grant Program award metals.	and alcohol research outcomes, lose differences, and (2) to adva studies are sought across all are	to uncover the nce research	
073554	NIDA Mentored Clinical Scientist Substance Use and Substance Use Optional)	Development Program Award in e Disorder Research (K12 Clinical Trial	National Institute on Drug Abuse/NIH/DHHS	PAR-18- 746 11-Jun-2019	750,000 USD	
	Contact Name	Aria Davis Crump, Sc.D.				
	Contact Telephone	301-435-0881				
	Contact Email	acrump@nida.nih.gov				
	Sponsor Website					
	Program URL	https://grants.nih.gov/grants/guide/p	a-files/PAR-18-746.html			
	Deadline Dates (ALL)	11-Jun-2019 , 28-Aug-2019 , 11-Jun-20	020 , 28-Aug-2020			
		1			_	

National Institute on Drug Abuse (NIDA) invites applications for institutional research career development (K12) programs that propose to support intensive supervised research training and career development experiences for clinician scientists (Scholars) leading to research independence in the area of substance use and substance use disorder research. This FOA allows appointment of scholars proposing to serve as the lead investigator of an independent clinical trial; or proposing a separate ancillary study to an existing trial; or proposing to gain research experience in a clinical trial led by another investigator, as part of their research and career development. For this FOA, clinician scientists may include (but are not limited to) physicians, clinical psychologists, epidemiologists, doctoral level social workers, pharmacists, and behavioral scientists. Scholars are expected to be supported for 3-5 years on consecutive 12-month appointments. Candidates selected for support as scholars must hold a doctorate and commit a minimum of 9 person-months (equivalent to 75% of full-time

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		- · · · · · · · · · · · · · · · · · · ·	nical research and career development a K12 Clinician Scientist Award (Program) (F			osed
070283	Device-Based Treatments for Subs Clinical Trial Optional)	stance Use Disorders (UG3/UH3,	National Institute on Drug Abuse/NIH/DHHS	PAR-18- 494	24-Jun-2019 [LOI/Pre-App] [Optional]	Not Specified
	Contact Name Contact Telephone Contact Email Sponsor Website					
	Deadline Dates (ALL)	https://grants.nih.gov/grants/guide/pa-files/PAR-18-494.html 24-Jun-2019 [LOI/Pre-App][Optional], 24-Jul-2019, 26-Feb-2020 [LOI/Pre-App][Optional], 27-Mar-2020, 24-Jun-2020 [LOI/Pre-App][Optional], 24-Jul-2020				
	Synopsis	development of devices to treat Sub unprecedented opportunities to dev treatments. The objective is to move generating new, FDA approved device development and testing of new dev mechanism of action of a device. The is designed to support a project with provide funding for up to 3 additional milestones will be administratively constructed.	nd its participating Institutes and Centers stance Use Disorders (SUDs). The continuelop neuromodulatory or neurophysiology devices to their next step in the FDA appreciased treatments for SUDs. Application ices or existing devices approved for other UG3/UH3 Cooperative Agreement involuspecific milestones to be accomplished by years following successful completion considered by NIDA and prioritized for training both UG3 and UH3 phases in the application of the ement award mechanism.	ning advances gical devices to proval process in smay focus for indications wes 2 phases. By the end of the UG3. Unsition to the	in technologies offer hat are safe and effect, with the ultimate on the pre-clinical and Applications may earlie UG3 phase, for the period. The UH3 G3 projects that med UH3 phase. Investignation of the UH3 phase.	er ective SUD goal of nd/or clinical evaluate the up to 2 years, 3 phase is to eet their gators
071560	Women & Sex/Gender Differences Abuse/Dependence (R21 Clinical T		National Institute on Drug Abuse/NIH/DHHS	PA-18-602	2 07-May-2019	275,000 USD
	Contact Telephone Contact Email Sponsor Website	Cora Lee Wetherington, Ph.D. 301-435-1319 cwetheri@mail.nih.gov https://grants.nih.gov/grants/guide/	pa-files/PA-18-602.html			

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Deadline Dates (ALL)	07-May-2019 , 16-Jun-2019 , 07-Sep- 2020 , 16-Oct-2020 , 07-Jan-2021 , 10	0-1 ED-2021 , 07-141ay-2021			
	Synopsis	National Institute on Drug Abuse (NI applications to (1) advance identifica mechanisms of those differences, an specific to women or highly relevant alcohol research. This FOA will use the	tion of male-female differences in dr d to conduct translational research o to women. Both preclinical and clini	rug and alcohol rese on those differences cal studies are soug	arch outcomes, to , and (2) to advand ht across all areas	uncover the ce research
11/1556	Women & Sex/Gender Difference Abuse/Dependence (R01 Clinical		National Institute on Drug Abuse/NIH/DHHS	PA-18-603	07-May-2019	Not Specified
	Contact Name	Cora Lee Wetherington, Ph.D.				
	Contact Telephone	301-435-1319				
	Contact Email	cwetheri@mail.nih.gov				
	Sponsor Website					
	Program URL	https://grants.nih.gov/grants/guide/	pa-files/PA-18-603.html			
	Deadline Dates (ALL)	07-May-2019 , 05-Jun-2019 , 07-Sep- 2020 , 05-Oct-2020 , 07-Jan-2021 , 0		5-Feb-2020 , 07-Ma	y-2020 , 05-Jun-20	020 , 07-Sep-
	Synopsis	National Institute on Drug Abuse (NI applications to (1) advance identifica mechanisms of those differences, an specific to women or highly relevant alcohol research. This FOA will use the	tion of male-female differences in dr d to conduct translational research o to women. Both preclinical and clini	rug and alcohol rese on those differences cal studies are soug	arch outcomes, to , and (2) to advan	uncover the ce research
071884	NIDA Small Research Grant Progr	am (R03 Clinical Trial Required)	National Institute on Drug Abuse/NIH/DHHS	PA-18-634	07-May-2019	100,000 USD
	Contact Name	Guifang Lao, Ph.D.				
	Contact Telephone	301- 827-5931				
	Contact Email	laog@nida.nih.gov				
	Sponsor Website					
	Program URL	https://grants.nih.gov/grants/guide/	pa-files/PA-18-634.html			
	Deadline Dates (ALL)	07-May-2019 , 16-Jun-2019 , 07-Sep-	-2019 , 16-Oct-2019 , 07-Jan-2020 , 1	6-Feb-2020 , 07-Ma	y-2020	
	Synopsis	National Institute on Drug Abuse (N	IDA) invites applications for small res	earch projects that	can be carried out	in a short

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		secondary analysis of existing data; sm development of new research technol	This program supports different types of nall, self-contained research projects; devogy. This Funding Opportunity Announce be related to the programmatic interesters.	velopment of re ement requires	esearch methodo s that at least 1 cli	logy; and inical trial be
074542	Development and Testing of Nove Prevention, Care, and Program In Optional)		National Institute on Drug Abuse/NIH/DHHS	PA-18-780	07-May-2019	450,000 USD
	Contact Telephone	Richard A. Jenkins, PhD 301-443-1923 jenkinsri@mail.nih.gov				
	Program URL	https://grants.nih.gov/grants/guide/p		2020 07 May	v 2020 16 lun 20	020 07 Son
	Deadline Dates (ALL)	2020 , 16-Oct-2020 , 07-Jan-2021 , 16-	019 , 16-Oct-2019 , 07-Jan-2020 , 16-Feb Feb-2021 , 07-May-2021	-2020 , 07-ivia	y-2020 , 16-Juli-20	J20 , 07-3ep-
	Synopsis	testing of interventions. Primary scien or adapted interventions that target H "intervention" may include behavioral approaches that prevent the acquisition	A) invites applications for formative resetific areas of focus include the feasibility, IIV prevention, treatment or services reset, social, or structural approaches, as well on and transmission of HIV infection, or it R34 Planning Grant award mechanism.	tolerability, ace earch. For the page as combinatio	cceptability and sa ourposes of this Fond on biomedical and	afety of novel OA, behavioral
074451	Pilot and Feasibility Studies in Pre Prevention Trials (R34 Clinical Trials)	paration for Drug and Alcohol Abuse al Optional)	National Institute on Drug Abuse/NIH/DHHS	PA-18-775	07-May-2019	450,000 USD
	Contact Telephone Contact Email	Jacqueline Lloyd, Ph.D. 301-443-8892 <u>lloydj2@nida.nih.gov</u>				
	Sponsor Website Program URL	https://grants.nih.gov/grants/guide/p	a-files/PA-18-775.html			
	_		019 , 16-Oct-2019 , 07-Jan-2020 , 16-Feb Feb-2021 , 07-May-2021	-2020 , 07-May	y-2020 , 16-Jun-20	)20 , 07-Sep-
	Synopsis	National Institute on Drug Abuse (NID	A) and National Institute on Alcohol Abus	se and Alcoholi	ism (NIAAA) invite	applications

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		for (a) pilot and/or feasibility testing of delay the initiation and onset of drug substance use disorder, reduce drinking (nonfatal and fatal), and the drug- or a diverse populations and settings; and, research. It is expected that research preparing and submitting subsequent related HIV prevention intervention stoof intervention protocols, manuals, or imbedded within a pilot/feasibility stupriorities and priority settings and sys	and alcohol use, the progression to ming and driving and deaths related to in alcohol-related acquisition or transmis (b) pre-trial feasibility and acceptability and acceptab	isuse or problem unpaired driving, possion of HIV infectivity testing for previousist of studies that do locations for which intervention devented.	use or alcohol and revent suicide attion and viral hepayention services a at are a pre-requisention and/or drunthe sole focus is elopment work mudresses current propertion and presses current presses current presses current presses current presses current presses current presses and presses are considered and presses are considered and presses are current presses are current presses and presses are current presses are curre	I other empts titis among nd systems ite for g- or alcohol- development ust be ublic health
074449	Pilot Health Services and Econom Alcohol, and Tobacco Use Disord	nic Research on the Treatment of Drug, ers (R34 Clinical Trial Optional)	National Institute on Drug Abuse/NIH/DHHS	PA-18-774	07-May-2019	450,000 USD
	Contact Name	Sarah Q. Duffy, Ph.D.				
	Contact Telephone	301-451- 4998				
	Contact Email	duffys@nida.nih.gov				
	Sponsor Website					
	Program URL	https://grants.nih.gov/grants/guide/p	a-files/PA-18-774.html			
	Deadline Dates (ALL)	07-May-2019 , 16-Jun-2019 , 07-Sep-2 2020 , 16-Oct-2020 , 07-Jan-2021 , 16-		Feb-2020 , 07-May	y-2020 , 16-Jun-20	020 , 07-Sep-
	Synopsis	National Institute on Drug Abuse (NID for pilot and preliminary research in pa wide range of approaches, including effectiveness, affordability and utilizate services for comorbid medical and meand those that are commonly used in feasibility, acceptability, and utility of NIH R34 Planning Grant grant mechan	reparation for larger-scale services resinterventions, practices, and policies and of drug, tobacco, or alcohol use dental disorder conditions. Relevant appractice but lack an evidence base. The these approaches, in addition to usua	search effectivene designed to optim isorder treatment proaches may incluis iis FOA provides re	ess trials. Relevant nize access to, and s and related serv ude both those th esources for asses	trials may test I the quality, vices, as well as at are novel, ssing the
060134	Functional Genetics, Epigenetics, Use Disorders (R21)	and Non-coding RNAs in Substance	National Institute on Drug Abuse/NIH/DHHS	PA-17-157	07-May-2019	275,000 USD

Contact Name John Satterlee, Ph.D.

Contact Telephone 301-435-1020

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Sponsor Website	satterleej@nida.nih.gov https://grants.nih.gov/grants/guide/pa	a-files/PA-17-157.html			
	Synopsis a	07-May-2019, 16-Jun-2019, 07-Sep-20 National Institute on Drug Abuse (NIDA areas: 1) functional validation to deter authentic role in SUDs, and 2) detailed genes/variants, particularly for those g Exploratory/Developmental Research (	A) invites applications for basic funct mine which candidate genes/varian elucidation of the molecular pathwa enes with an unanticipated role in S	ional genetic and g ts/epigenetic/non- ays and processes i	genomic research coding RNA featu modulated by can	res have an
059554	Basic Mechanisms of Brain Develo Dependence (R01)	pment Mediating Substance Use and	National Institute on Drug Abuse/NIH/DHHS	PA-17-119	07-May-2019	Not Specified
	Sponsor Website  Program URL I  Deadline Dates (ALL)  Synopsis I		2019, 05-Oct-2019, 07-Jan-2020 A) and National Institute on Alcohol A brain or brain areas that play significated and the propertion of the problems of the pr	ant roles in mediat pment are of interes of fundamental me f substance abuse of this initiative includents, and their corportant how exposorlying nervous systems.	ing emotional and est, but a new emechanisms of brain and co-morbidity ude, but are not linsequences on mecure to substances em development	d motivated phasis of the development with imited to, the emory, s of abuse and and neural
059555	Discovering Novel Targets: The Moand Related Co-Morbidities (R01)	plecular Genetics of Drug Addiction	National Institute on Drug Abuse/NIH/DHHS	PA-17-120	07-May-2019	Not Specified
	Contact Name	Jonathan D. Pollock, Ph.D.				

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Contact Telephone 30: Contact Email jpc	1435-1309 bllock@mail.nih.gov			
	Sponsor Website	-	files/PA-17-120 html		
Program URL https://grants.nih.gov/grants/guide/pa-files/PA-17-120.html Deadline Dates (ALL) 07-May-2019 , 05-Jun-2019 , 07-Sep-2019 , 05-Oct-2019 , 07-Jan-2020					
	cha infi enc cor Synopsis cas ger por por enc	aracterize loci, genetic variations and horm the likelihood of responsiveness to dophenotypes to assess the molecular orbidities and how they are related to emputational and large-scale genomic ase-control or family-based studies, and netics and genomics data. Data may be pulations, and/or animal models. Seco pulations, recent admixed populations couraged to include functional charact	invites applications for research projects that identification applications for research projects that identification applications that propose to examine genetics of drug addiction, addiction vulnerability adding addiction are especially encouraged. Also encouraged addiction are especially encouraged. Also encouraged approaches, which may include but are not limited to distribute and integration of data from other databases that may be collected from the general population, special popularity data analysis of data collected from the general population, gene and/or animal models is also appropriate for this activities are researched as a proposition, gene and appropriate for this activities.	addiction and that intermediate pher and/or their associouraged are genetical linkage, linkage of supplement substitutions, recent aral population, speciment interactions, and interactions.	potentially notypes or ated co-c as well as disequilibrium ance abuse dmixed ecial vestigators agene x

060133 Functional Genetics, Epigenetics, and Non-coding RNAs in Substance
Use Disorders (R01)

National Institute on Drug
Abuse/NIH/DHHS

the NIH Research Project (R01) award mechanism.

PA-17-155 07-May-2019

Not Specified

Contact Name John Satterlee, Ph.D.

Contact Telephone 301-435-1020

Contact Email <u>satterleej@nida.nih.gov</u>

Sponsor Website

Program URL https://grants.nih.gov/grants/guide/pa-files/PA-17-155.html

Deadline Dates (ALL) 07-May-2019, 05-Jun-2019, 07-Sep-2019, 05-Oct-2019, 07-Jan-2020, 05-Feb-2020, 07-May-2020

National Institute on Drug Abuse (NIDA) invites applications for basic functional genetic and genomic research in two areas: 1) functional validation to determine which candidate genes/variants/epigenetic/non-coding RNA features have an synopsis authentic role in SUDs, and 2) detailed elucidation of the molecular pathways and processes modulated by candidate genes/variants, particularly for those genes with an unanticipated role in SUDs. This FOA will use the NIH Research Project (R01) award mechanism.

077343 Imaging - Science Track Award for Research Transition (I/START) (R03 National Institute on Drug PAR-18- 07-May-2019 150,000



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Clinical Trial Optional)		Abuse/NIH/DHHS	918	USD
	Contact Name	Steven Grant, Ph.D.			
	Contact Telephone	301-443-4877			
	Contact Email	sgrant@nida.nih.gov			
	Sponsor Website				
	Program URL	https://grants.nih.gov/grants/guide	e/pa-files/PAR-18-918.html		
	Deadline Dates (ALL)	07-May-2019 , 16-Jun-2019 , 07-Sep 2020 , 16-Oct-2020 , 07-Jan-2021 , :	p-2019 , 16-Oct-2019 , 07-Jan-2020 , 1 16-Feb-2021 , 07-May-2021 , 16-Jun-2	.6-Feb-2020 , 07-May-2020 , 16-Jun-2 .021 , 07-Sep-2021	2020 , 07-Sep-
		National Institute on Drug Abuse (Napplications to facilitate the entry destablished investigators seeking to small "proof of concept" studies. The	IIDA) and National Institute of Biomed of investigators to the area of neuroim of adopt neuroimaging methodologies in RO3 is intended to support research ogram will use the NIH Small Research	lical Imaging and Bioengineering (NIE aging, including both new investigato in their research programs, to enable n projects that can be carried out in a	ors and the conduct of
68411	Neuroscience Research on Drug A	Abuse (R21 Clinical Trial Optional)	National Institute on Drug Abuse/NIH/DHHS	PA-18-078 07-May-2019	275,000 USD
	Contact Name	Roger Sorensen, Ph.D.			
	Contact Telephone	301- 443-3205			
	Contact Email	rsorense@nida.nih.gov			
	Sponsor Website				
	Program URL	https://grants.nih.gov/grants/guide	e/pa-files/PA-18-078.html		
	Deadline Dates (ALL)	07-May-2019 , 16-Jun-2019 , 07-Seរុ	p-2019 , 16-Oct-2019 , 07-Jan-2020		
	Synopsis	underlying substance use disorders dependence, withdrawal, and relap substance use disorders can help to	IIDA) invites applications for research, with special emphasis on identifying use to chronic substance use. An under identify targets for prevention and tres is appropriate. This program will use	changes and neuroadaptations that rstanding of the basic mechanisms uneatment interventions. Research util	occur during nderlying izing basic,
068407	Neuroscience Research on Drug A	Abuse (R01 Clinical Trial Optional)	National Institute on Drug Abuse/NIH/DHHS	PA-18-060 07-May-2019	Not Specified
	Contact Name	Roger Sorensen, Ph.D.			



	_					I
SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
			·			
	Contact Telephone	301- 443-3205				
	Contact Email	rsorense@nida.nih.gov				
	Sponsor Website					
Program URL https://grants.nih.gov/grants/guide/pa-files/PA-18-060.html  Deadline Dates (ALL) 07-May-2019, 05-Jun-2019, 07-Sep-2019, 05-Oct-2019, 07-Jan-2020						
National Institute on Drug Abuse (NIDA) invites applications for research to understand the neurobiological mechanic underlying substance use disorders, with special emphasis on identifying changes and neuroadaptations that occur dependence, withdrawal, and relapse to chronic substance use. An understanding of the basic mechanisms underlying substance use disorders can help to identify targets for prevention and treatment interventions. Research utilizing batterianslational, or clinical approaches is appropriate. This program will use the NIH Research Project (R01) award mechanisms						
077321	<u>Developing the Therapeutic Poter</u> <u>for Pain Treatment (R01 - Clinical</u>	ntial of the Endocannabinoid System Trial Optional)	National Institute on Drug Abuse/NIH/DHHS	PA-18-917	07-May-2019	Not Specified
	Contact Name	David Thomas, PhD				
	Contact Telephone	301-435-1313				
	Contact Email	dthomas1@nida.nih.gov				
	Sponsor Website					
	Program URL	https://grants.nih.gov/grants/guide/pa	a-files/PA-18-917.html			
	Deadline Dates (ALL)	07-May-2019 , 05-Jun-2019 , 07-Sep-2 2020 , 05-Oct-2020 , 07-Jan-2021 , 05-	019 , 05-Oct-2019 , 07-Jan-2020 , 05 Feb-2021 , 07-May-2021 , 05-Jun-20	i-Feb-2020 , 07-May 121 , 07-Sep-2021	y-2020 , 05-Jun-20	)20 , 07-Sep-
		National Institutes of Health (NIH) and elucidate the therapeutic potential of based therapies for pain. This FOA will	its participating Institutes and Cent the cannabinoids and endocannabin	ers invite applicatio noid system in the d	evelopment of m	
071785	Mechanistic investigations of Psyc Patterns (R01- Clinical Trial Option	chosocial Stress Effects on Opioid Use nal)	National Institute on Drug Abuse/NIH/DHHS	PAS-18- 624	07-May-2019	Not Specified
	Contact Name	Vani Pariyadath, Ph.D.				
	Contact Telephone	301-443-3209				
	Contact Email	vani.pariyadath@nih.gov				
	Sponsor Website					

Deadline Dates (ALL) 07-May-2019, 05-Jun-2019, 07-Sep-2019, 05-Oct-2019, 07-Jan-2020, 05-Feb-2020, 07-May-2020, 05-Jun-2020, 07-Sep-

Program URL <a href="https://grants.nih.gov/grants/guide/pa-files/PAS-18-624.html">https://grants.nih.gov/grants/guide/pa-files/PAS-18-624.html</a>

					_	
SPIN ID	Program Title	Sponsor Name	Sponsor Number		<b>Deadline Date</b>	Funding Amount
	Synopsis	psychosocial stress on affective/cogni FOA encourages research that elucida	DA) invites applications for innovative res tive functioning and/or pain processing as ites mechanisms of action and determinal jectories. Research using basic or clinical a mechanism.	s it relates to onthe standard series it relates to of the series it relates to of the series it relates to of	opioid use disorde bility and/or resilie	r (OUD). This ence by which
071788	Mechanistic investigations of psyconatterns (R21- Clinical Trial Option	chosocial stress effects on opioid use nal)	National Institute on Drug Abuse/NIH/DHHS	PAS-18- 625	07-May-2019	Not Specified
	Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL)	vani.pariyadath@nih.gov  https://grants.nih.gov/grants/guide/p 07-May-2019 , 16-Jun-2019 , 07-Sep-2 2020 National Institute on Drug Abuse (NII psychosocial stress on affective/cogni FOA encourages research that elucida psychosocial stress influence OUD traj	pa-files/PAS-18-625.html 2019, 16-Oct-2019, 07-Jan-2020, 16-February DA) invites applications for innovative restive functioning and/or pain processing astes mechanisms of action and determinal jectories. Research using basic or clinical atal Research Grant award mechanism.	earch to chara s it relates to onts of vulnera	acterize the conse opioid use disorde bility and/or resilie	quences of r (OUD). This ence by which
078460	Mechanism for Time-Sensitive Dr Optional)	ug Abuse Research (R21 Clinical Trial	National Institute on Drug Abuse/NIH/DHHS	PAR-19- 064	07-Jun-2019	275,000 USD
	Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL)	lopezmar@mail.nih.gov  https://grants.nih.gov/grants/guide/p 07-Jun-2019, 08-Nov-2019, 07-Feb-2	p <mark>a-files/PAR-19-064.html</mark> 020 , 08-Jun-2020 , 06-Nov-2020 , 08-Feb nent (FOA) will support pilot, feasibility or th services, including: 1) responses to sud		esearch in 5 priori re emerging drug i	ty areas in ssues (e.g. the

SPIN ID	Program	Sponsor Name	Sponsor Number		Deadline Date	Funding
SPIN ID	Title	Sponsor Name	Sponsor Number		Deadine Date	Amount
		responses to emerging marijuana trend time-sensitive prescription drug abuse and time-sensitive medical system issue system); and 5) responses to unexpecte structural level changes) that relate to knowledge gained from the proposed s	pike in opioid or synthetic cannabinoid of sand topics related to the shifting polic research opportunities (e.g., new state ces (e.g. opportunities to understand added and time-sensitive criminal or juveniled drug abuse and access and provision of budy is time-sensitive and that an expeding swered (i.e. an imminent policy change	y landscape; 3 or local efforts iction services e justice oppo nealth care se ited rapid rev	s) responses to unoperior, and the evolving here to in the evolving here tunities (e.g. new rvice. It should be iew and funding and tunding and tun	expected and unexpected ealth care system and/or clear that the re required in
079380	_	alth Research Using Existing Data from evelopment (ABCD) Study (R21-Clinical	National Institute on Drug Abuse/NIH/DHHS	PAR-19- 163	16-Jun-2019	275,000 USD
	Contact Name	Karen Sirocco				
	Contact Telephone	301-451-8661				
	Contact Email	siroccok@nida.nih.gov				
	Sponsor Website					
	Program URL	https://grants.nih.gov/grants/guide/pa	-files/PAR-19-163.html			
	Deadline Dates (ALL)	16-Jun-2019 , 07-Sep-2019 , 16-Oct-201 2020 , 07-Jan-2021 , 16-Feb-2021 , 07-N	.9 , 07-Jan-2020 , 16-Feb-2020 , 07-Мау <sup>.</sup> Иау-2021 , 16-Jun-2021 , 07-Sep-2021	-2020 , 16-Jun	-2020 , 07-Sep-20	20 , 16-Oct-
		substance use, cultural and environment years-old and following them longituding through the NIMH Data Archive. The pupilic use	oment (ABCD) Study is collecting data or ntal factors, and brain structure and fund nally to early adulthood. These data will prose of this Funding Opportunity Anno e dataset to increase knowledge of adole to be found on the ABCD Study web page	ction from you be made ava ouncement (FC escent health	oth starting when ilable to the scient DA) is to encourage and development.	they are 9-10 tific community e applications
079379	_	alth Research Using Existing Data from evelopment (ABCD) Study (R01-Clinical	National Institute on Drug Abuse/NIH/DHHS	PAR-19- 162	05-Jun-2019	1,250,000 USD
	Contact Name	Karen Sirocco				



Contact Telephone 301-451-8661

Contact Email <u>siroccok@nida.nih.gov</u>

SPIN ID	Program Title	Sponsor Name	Sponsor Number	•	Deadline Date	Funding Amount
	Sponsor Website	 				
	Program URL	https://grants.nih.gov/grants/guide/p	a-files/PAR-19-162.html			
	Deadline Dates (ALL)		019 , 07-Jan-2020 , 05-Feb-2020 , 07-May -May-2021 , 05-Jun-2021 , 07-Sep-2021	-2020 , 05-Jun-	-2020 , 07-Sep-20	20 , 05-Oct-
	The Adolescent Brain Cognitive Development (ABCD) Study is collecting data on health and mental health, cognitive functions from youth starting when they are 9 years-old and following them longitudinally to early adulthood. These data will be made available to the scientific common through the NIMH Data Archive. The purpose of this Funding Opportunity Announcement (FOA) is to encourage application proposing the analysis of this public use dataset to increase knowledge of adolescent health and development. More information about the ABCD Study may be found on the ABCD Study web page (www.abcdstudy.org).					
058238	Addressing the Etiology of Health Among Immigrant Populations (R	Disparities and Health Advantages 21)	National Institute on Minority Health and Health Disparities/NIH/DHHS	PA-17-042	07-May-2019	275,000 USD
	Contact Name	Priscilla Grant, JD				
	Contact Telephone					
	Contact Email	pg38h@nih.gov				
	Sponsor Website					
	Program URL	http://grants.nih.gov/grants/guide/pa	-files/PA-17-042.html			
	Deadline Dates (ALL)	07-May-2019 , 16-Jun-2019 , 07-Sep-2	019 , 16-Oct-2019 , 07-Jan-2020			
	Synopsis	understand uniquely associated factor	I its participating Institutes and Centers in rs (biological, behavioral, sociocultural, ar ng U.S. immigrant populations. This FOA warch Grant award mechanism.	ıd environmen	ital) that contribu	
058236	Addressing the Etiology of Health Among Immigrant Populations (R	Disparities and Health Advantages 01)	National Institute on Minority Health and Health Disparities/NIH/DHHS	PA-17-041	07-May-2019	Not Specified
	Contact Name	Priscilla Grant, JD				
	Contact Telephone	301-594-8412				
	Contact Email	pg38h@nih.gov				
	Sponsor Website					
	Program URL	http://grants.nih.gov/grants/guide/pa	-files/PA-17-041.html			
	Deadline Dates (ALL)	07-May-2019 , 05-Jun-2019 , 07-Sep-2	019 , 05-Oct-2019 , 07-Jan-2020			

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Synopsis	understand uniquely associated factor	l its participating Institutes and Centers in s (biological, behavioral, sociocultural, an g U.S. immigrant populations. This FOA v	nd environme	ntal) that contribu	te to health
068318	Addressing Health Disparities thro Immigrant Populations (R21 Clinic	ough Effective Interventions Among cal Trial Optional)	National Institute on Minority Health and Health Disparities/NIH/DHHS	PA-18-285	07-May-2019	275,000 USD
	Contact Telephone	dasr2@mail.nih.gov				
	Program URL	https://grants.nih.gov/grants/guide/p	a-files/PA-18-285.html			
	Deadline Dates (ALL)	07-May-2019 , 16-Jun-2019 , 07-Sep-2	019 , 16-Oct-2019 , 07-Jan-2020			
	Synopsis	develop and implement effective inter	lits participating Institutes and Centers in ventions to address health disparities an mental Research Grant award mechanism	nong U.S. imm		
068315	Addressing Health Disparities thro	ough Effective Interventions among cal Trial Optional)	National Institute on Minority Health and Health Disparities/NIH/DHHS	PA-18-284	07-May-2019	Not Specified
	Contact Name	Rina Das, PhD				
	Contact Telephone	301-496-3996				
	Contact Email	dasr2@mail.nih.gov				
	Sponsor Website					
	Program URL	https://grants.nih.gov/grants/guide/p	a-files/PA-18-284.html			
	Deadline Dates (ALL)	07-May-2019 , 05-Jun-2019 , 07-Sep-2	019 , 05-Oct-2019 , 07-Jan-2020			
		, ,	lits participating Institutes and Centers in ventions to address health disparities an vard mechanism.	• • •		
069883	Exploratory/Developmental Surgi Trial Optional)	ical Disparities Research (R21 Clinical	National Institute on Minority Health and Health Disparities/NIH/DHHS	PAR-18- 289	08-May-2019 [LOI/Pre-App] [Optional]	275,000 USD
_	Contact Name	Regina Smith James M.D.				

SPIN ID	Program Title	Sponsor Name	Sponsor Number		<b>Deadline Date</b>	Funding Amount
	Sponsor Website Program URL Deadline Dates (ALL)	rjames@mail.nih.gov  https://grants.nih.gov/grants/guide/pa 08-May-2019 [LOI/Pre-App][Optional], National Institutes of Health (NIH) and it collaborative research focused on under health disparity populations. While the	07-Jun-2019 its participating Institutes and Centers in erstanding and addressing disparities in s	surgical care a e effectivenes	nd outcomes, in m s of clinical interve	ninority and ention
		and systems level. This FOA will use the	NIH R21 Exploratory/Developmental Re	esearch Grant	-	n.
069882	Surgical Disparities Research (R01 Clinical	( linical Trial ( intional)	National Institute on Minority Health and Health Disparities/NIH/DHHS	PAR-18- 288	[LOI/Pre-App] [Optional]	Not Specified
	Contact Name	Regina Smith James M.D.				
	Contact Telephone	301-496-3462				
	Contact Email	rjames@mail.nih.gov				
	Sponsor Website					
	Program URL	https://grants.nih.gov/grants/guide/pa	-files/PAR-18-288.html			
	Deadline Dates (ALL)	08-May-2019 [LOI/Pre-App][Optional],	07-Jun-2019			
	Synopsis	collaborative research focused on unde health disparity populations. While the approaches for addressing surgical disp	its participating Institutes and Centers in erstanding and addressing disparities in s goal is to better understand and explore arities, this initiative will also seek to ide NIH Research Project (R01) award med	surgical care a e effectivenes entify multi-le	nd outcomes, in m s of clinical interve	ninority and ention
067712	Simulation Modeling and Systems (R01 Clinical Trial Not Allowed)	S Science to Address Health Disparities	National Institute on Minority Health and Health Disparities/NIH/DHHS	PAR-18- 331	07-Jun-2019	1,000,000 USD
-	Contact Name	Xinzhi Zhang, MD, PhD				



Contact Telephone 301-594-6136

Sponsor Website

Contact Email Xinzhi.Zhang@nih.gov

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount		
	_	https://grants.nih.gov/grants/guide/g 07-Jun-2019 , 07-Sep-2019			sia wa fa w iwa wati wat	ive and		
	National Institutes of Health (NIH) and its participating Institutes and Centers invite applications for investigative and Synopsis collaborative research focused on developing and evaluating simulation modeling and systems science to understand and address minority health and health disparities. This FOA will use the NIH Research Project (R01) award mechanism.							
061417	Mechanisms and Consequences o	of Sleep Disparities in the U.S. (R01)	National Institute on Minority Health and Health Disparities/NIH/DHHS	PAR-17- 234	11-Jun-2019 [LOI/Pre-App] [Optional]	Not Specified		
	Contact Name	Rina Das, Ph.D.						
	Contact Telephone	301-496-3996						
	Contact Email	dasr2@mail.nih.gov						
	Sponsor Website							
	Program URL	https://grants.nih.gov/grants/guide/p	pa-files/PAR-17-234.html					
	Deadline Dates (ALL)	11-Jun-2019 [LOI/Pre-App][Optional],	11-Jul-2019					
	Synopsis	the underlying mechanisms of sleep of	nd its participating Institutes and Centers in leficiencies among health disparity popula OA will use the NIH Research Project (R01	itions and hov	w sleep deficiencie			
073605		Opioid Epidemic in Minority Health the U.S. (R21 Clinical Trial Optional)	National Institute on Minority Health and Health Disparities/NIH/DHHS	PAR-18- 745	14-Jun-2019	275,000 USD		
	Contact Name	Andrew Louden, Ph.D.						
	Contact Telephone	301-594-9009						
	Contact Email	andrew.louden@nih.gov						
	Sponsor Website							
	Program URL	https://grants.nih.gov/grants/guide/p	pa-files/PAR-18-745.html					
	Deadline Dates (ALL)	14-Jun-2019 , 14-Nov-2019 , 15-Jun-2	020 , 13-Nov-2020					
	Deadline Dates (ALL) 14-Jun-2019, 14-Nov-2019, 15-Jun-2020, 13-Nov-2020  NIH and its participating Institutes and Centers invite applications for developmental and exploratory research focused of determining the mechanisms for the variation in the prevalence of Opioid Use Disorder (OUD), and understanding and reducing disparities in opioid care in minority health and health disparity populations in the U.S. This initiative will also see to identify multi-level intervention strategies at the institutional and systems level for addressing OUD in these population This FOA will use the NIH Research Project (R01) award mechanism.							

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
073603		Opioid Epidemic in Minority Health n the U.S. (R01 Clinical Trial Optional)	National Institute on Minority Health and Health Disparities/NIH/DHHS	PAR-18- 747	14-Jun-2019	Not Specified
	Contact Name	Andrew Louden, Ph.D.				
	Contact Telephone	301-594-9009				
	Contact Email	andrew.louden@nih.gov				
	Sponsor Website					
	Program URL	https://grants.nih.gov/grants/guide/p	a-files/PAR-18-747.html			
	Deadline Dates (ALL)	14-Jun-2019 , 14-Nov-2019 , 15-Jun-20	020 , 13-Nov-2020			
	Synopsis	determining the mechanisms for the varieties in opioid care in n	nd Centers invite applications for investiga variation in the prevalence of Opioid Use I ninority health and health disparity popul ategies at the institutional and systems le oject (R01) award mechanism.	Disorder (OUI ations in the	D), and understand U.S. This initiative	ling and will also seek
066436	Research on the Health of Transg Populations (R21)	ender and Gender Nonconforming	National Institutes of Health/DHHS	PA-17-477	07-May-2019	275,000 USD
	Contact Name	Della B. White, PhD				
	Contact Telephone	301-435-2712				
	Contact Email	whitede@mail.nih.gov				
	Sponsor Website					
	Program URL	https://grants.nih.gov/grants/guide/p	a-files/PA-17-477.html			
	Deadline Dates (ALL)	07-May-2019 , 16-Jun-2019 , 07-Sep-2 2020 , 16-Oct-2020 , 07-Jan-2021	2019 , 16-Oct-2019 , 07-Jan-2020 , 16-Feb	-2020 , 07-Ma	ay-2020 , 16-Jun-20	020 , 07-Sep-
	Synopsis	of transgender and gender nonconfor gender identity and those individuals the other. This group encompasses in	nd its participating Institutes and Centers ming people of all ages, including both you who are making or who have made a trandividuals whose gender identity differs from what is traditionally associated (R21) grant mechanism.	outh and adult esition from borns to the sex or	ts who are questio eing identified as o their original birt	ning their one gender to n certificate or
068663	Improving Individual and Family ( Coordination of Care in Hospice (	Outcomes through Continuity and RO1 Clinical Trial Optional)	National Institutes of Health/DHHS	PA-18-148	07-May-2019	Not Specified

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
•						
	Contact Name	Karen A. Kehl, Ph.D., R.N., F.P.C.N.				
	Contact Telephone	301-594-8010				
	Contact Email	kehlka@mail.nih.gov				
	Sponsor Website					
	Program URL	https://grants.nih.gov/grants/guide/pa	a-files/PA-18-148.html			
	Deadline Dates (ALL)	07-May-2019 , 05-Jun-2019 , 07-Sep-20	019 , 05-Oct-2019 , 07-Jan-2020			
	Synopsis	and family outcomes related to unwan related to high quality coordination of individuals who are receiving hospice of	n (NINR) invites applications for research ted transitions at the end of life and opt care of care of individuals who are enro care and their family caregivers, in any se te inpatient facility, an assisted living fac earch Project (RO1) award mechanism.	imizing the ind lled in hospice. etting where ho	lividual and family This FOA emphas ospice care is prov	y outcomes sizes vided, including
068664	Improving Individual and Family C Coordination of Care in Hospice (I		National Institutes of Health/DHHS	PA-18-166	07-May-2019	275,000 USD
	Contact Name	Karen A. Kehl, Ph.D., R.N., F.P.C.N.				
	Contact Telephone	301-594-8010				
	Contact Email	kehlka@mail.nih.gov				
	Sponsor Website					
	Program URL	https://grants.nih.gov/grants/guide/pa	a-files/PA-18-166.html			
	Deadline Dates (ALL)	07-May-2019 , 16-Jun-2019 , 07-Sep-20	019 , 16-Oct-2019 , 07-Jan-2020			
	Synopsis	and family outcomes related to unwan related to high quality coordination of individuals who are receiving hospice of their home, a relative's home, a hospic	n (NINR) invites applications for research ted transitions at the end of life and opt care of care of individuals who are enro- care and their family caregivers, in any se te inpatient facility, an assisted living fac Exploratory/Developmental Research G	imizing the ind lled in hospice. etting where ho ility, a short- o	lividual and family This FOA emphas ospice care is prov r long-term care f	y outcomes sizes vided, including
065196	Assay Development and Screening Therapeutic Agents (R01)	g for Discovery of Chemical Probes or	National Institutes of Health/DHHS	PAR-17- 438	07-May-2019	Not Specified
	Contact Name Contact Telephone	Suzanne Forry, Ph.D. 240-276-5922				

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Contact Email Sponsor Website	-	mail.nih.gov				
	Program URL	https://gr	ants.nih.gov/grants/guide/pa-f	iles/PAR-17-438.html			
	Deadline Dates (ALL)	07-May-2 2020	019 , 05-Jun-2019 , 07-Sep-201	9 , 05-Oct-2019 , 07-Jan-2020 , 05-Feb	-2020 , 07-May	y-2020 , 05-Jun-20	20 , 07-Sep-
	Synopsis	National Institutes of Health (NIH) and its participating Institutes and Centers invite applications for research in development of novel, small molecules for their potential use in studying disease treatment relevant to the mis participating NIH Institutes; and to generate new insight into the biology of relevant diseases and processes the bevalldated as important drug targets. Stages of discovery research covered by this FOA include: 1) assay development screen implementation to identify initial screening hits (high throughput target-focused screens, or most throughput screens); 3) hit validation using a series of assays and initial medicinal chemistry inspection to prior set. This FOA will use the NIH Research Project (R01) award mechanism.					
068705	Human Subjects Mechanistic and Optional)	Minimal R	isk Studies (R01 Clinical Trial N	lational Institutes of Health/DHHS	PA-18-351	07-May-2019	Not Specified
	Contact Name	Ellen Libe	rman, Ph.D.				
	Contact Telephone	301-451-2	2020				
	Contact Email	ellen.liber	man@nih.gov				
	Sponsor Website						
	Program URL	https://gr	ants.nih.gov/grants/guide/pa-f	iles/PA-18-351.html			
	Deadline Dates (ALL)	07-May-2 2020 , 05-	019 , 05-Jun-2019 , 07-Sep-201 Oct-2020 , 07-Jan-2021	9 , 05-Oct-2019 , 07-Jan-2020 , 05-Feb	-2020 , 07-May	y-2020 , 05-Jun-20	20 , 07-Sep-
		National applicatio	Eye Institute (NEI) invites appli ns that either involve human s	cations that seek to conduct studies of ubjects, but are not NIH-defined clinical address either: 1) mechanisms underl	al trials (see N	OT-OD-15-015); or	are NIH-

interventions that entail procedures with minimal risk to subjects. A mechanistic trial is defined as "A study designed to understand a biological or behavioral process, the pathophysiology of a disease, or the mechanism of action of an Synopsis intervention. "Minimal risk" means that the probability and magnitude of harm or discomfort anticipated in the research are

not greater in and of themselves than those ordinarily encountered in daily life or during the performance of routine physical or psychological examinations or tests. NIH-defined clinical trial applications that are neither mechanistic nor minimal risk are not eligible for this FOA. Large-scale clinical trials, human gene-transfer and stem cell therapy trials, and other complex or high resource- or safety-risk clinical trials are not appropriate for this FOA. Applicants are strongly advised to consult with NEI program staff prior to submitting an application with human subjects to determine the appropriate funding opportunity. This

		<u>.</u>	-			
SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		FOA will use the NIH Research Project	(R01) award mechanism.			
069753	NIH Pathway to Independence Av Clinical Trial Not Allowed)	vard (Parent K99/R00 - Independent	National Institutes of Health/DHHS	PA-18-398	07-May-2019	Not Specified
	Contact Name					
	Contact Telephone					
	Contact Email	grantinfo@nih.gov				
	Sponsor Website					
	Program URL	https://grants.nih.gov/grants/guide/p	pa-files/PA-18-398.html			
	Deadline Dates (ALL)	07-May-2019 , 12-Jun-2019 , 07-Sep-2 2020 , 12-Oct-2020 , 07-Jan-2021	2019 , 12-Oct-2019 , 07-Jan-2020 , 12-Feb	o-2020 , 07-Ma	y-2020 , 12-Jun-20	020 , 07-Sep-
	Synoncic	Independence Award (K99/R00) progretalented, NIH-supported, independent postdoctoral researchers with a researchependent, tenure-track or equivaled during this transition in order to help a comportunity Announcement (FOA) is confidented in the permitted to propose research experience.	It its participating Institutes and Centers in am. The award is designed to increase a transition in the award is designed to increase a transition in the award is designed to rehand/or clinical doctorate degree from antifaculty positions. The program will prowardees to launch competitive, independent of the specifically for applicants proposal feasibility study, or an ancillary study the ence in a clinical trial led by a mentor or search Transition Award funding mechan	nd maintain a son facilitate a ting mentored, por ovide independent research soing research to a clinical trial co-mentor. This	strong cohort of n mely transition of ostdoctoral resear dent NIH research careers. This Fun that does not invo I. Applicants to thi	ew and outstanding ch positions to support ding lve leading an s FOA are
069752	NIH Pathway to Independence Av Clinical Trial Required)	vard (Parent K99/R00 - Independent	National Institutes of Health/DHHS	PA-18-397	07-May-2019	Not Specified
	Contact Name					
	Contact Telephone					
	Contact Email	grantinfo@nih.gov				
	Sponsor Website					
	Program URL	https://grants.nih.gov/grants/guide/p	pa-files/PA-18-397.html			
	Deadline Dates (ALL)	07-May-2019 , 12-Jun-2019 , 07-Sep-2 2020 , 12-Oct-2020 , 07-Jan-2021	2019 , 12-Oct-2019 , 07-Jan-2020 , 12-Feb	o-2020 , 07-Ma	y-2020 , 12-Jun-20	020 , 07-Sep-
	Synancia	National Institutes of Health (NIH) and	d its participating Institutes and Centers ir ram. The award is designed to increase a			

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		postdoctoral researchers with a researchers with a researchers much a researcher with a researcher wit	t investigators. his program is designed to rch and/or clinical doctorate degree from ent faculty positions. The program will pro awardees to launch competitive, indepen designed specifically for applicants propos al feasibility study, or a separate ancillary s program will use the NIH K99/R00 Cared	mentored, po ovide independ dent research sing to serve as study to an ex	ostdoctoral researd dent NIH research careers. This Fund s the lead investig isting trial, as part	ch positions to support ding gator of an tof their
069437	Independent Scientist Award (Par Not Allowed)	ent KO2 - Independent Clinical Trial	National Institutes of Health/DHHS	PA-18-371	07-May-2019	Not Specified
	Contact Name Contact Telephone Contact Email Sponsor Website	grantinfo@nih.gov				
	Doadling Dates (ALL)	https://grants.nih.gov/grants/guide/p 07-May-2019, 12-Jun-2019, 07-Sep-2 2020, 12-Oct-2020, 07-Jan-2021	<del>a-files/PA-18-371.html</del> 019 , 12-Oct-2019 , 07-Jan-2020 , 12-Feb	-2020 , 07-May	y-2020 , 12-Jun-20	)20 , 07-Sep-
	Synopsis	National Institutes of Health (NIH) and Scientist Award. The award is intende potential to make significant contribu support and "protected time" for new research focus as a means of enhancing tailored to meet the individual needs specifically for applicants proposing refeasibility study, or an ancillary study	I its participating Institutes and Centers in d to foster the development of outstanding tions to their field of research. The KO2 average in the KO2 are ly independent scientists who can demorate their research careers. Each independent of the candidate. This Funding Opportunities earch that does not involve leading an interest to a clinical trial. Applicants to this FOA are tor. This FOA will utilize the NIH Independent.	ng scientists arward provides nstrate the need not scientist catty Announcemendependent clare permitted to	nd enable them to three to five years ed for a period of i reer award progra ent (FOA) is desig inical trial, a clinic p propose researd	expand their s of salary intensive am must be gned cal trial h experience in
069436	Independent Scientist Award (Par Required)	ent K02 - Independent Clinical Trial	National Institutes of Health/DHHS	PA-18-370	07-May-2019	Not Specified
	Contact Name					



Contact Telephone

Contact Email grantinfo@nih.gov

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount	
	Sponsor Website						
	Program URL	https://grants.nih.gov/grants/guide/p	a-files/PA-18-370.html				
	Deadline Dates (ALL)	07-May-2019 , 12-Jun-2019 , 07-Sep-2019 , 12-Oct-2019 , 07-Jan-2020 , 12-Feb-2020 , 07-May-2020 , 12-Jun-2 2020 , 12-Oct-2020 , 07-Jan-2021					
	Synopsis	Scientist Award. The award is intende potential to make significant contribu support and "protected time" for new research focus as a means of enhancitailored to meet the individual needs specifically for applicants proposing to	If its participating Institutes and Centers in detection to foster the development of outstanding tions to their field of research. The KO2 and independent scientists who can demong their research careers. Each independent of the candidate. This Funding Opportunities serve as the lead investigator of an independent an existing trial, as part of their research (KO2) mechanism.	ng scientists ar ward provides nstrate the nee ent scientist ca ity Announcem pendent clinica	nd enable them to three to five year ed for a period of reer award progra ent (FOA) is desig al trial, a clinical t	expand their s of salary intensive am must be gned rial feasibility	
IIhu/Ih I	Mentored Clinical Scientist Resea (Parent K08 - Independent Clinica		National Institutes of Health/DHHS	PA-18-373	07-May-2019	Not Specified	
	Contact Name						
	Contact Telephone	301-496-8580					
	Contact Email	grantinfo@nih.gov					
	Sponsor Website						
	Program URL	https://grants.nih.gov/grants/guide/g	a-files/PA-18-373.html				
	Deadline Dates (ALL)	07-May-2019 , 12-Jun-2019 , 07-Sep-2 2020 , 07-Jan-2021	2019 , 12-Oct-2019 , 07-Jan-2020 , 12-Feb	o-2020 , 07-May	y-2020 , 07-Sep-2	020 , 12-Oct-	
	Synopsis	Scientist Research Career Developme significant impact on the health-relate standing NIH program that provides s intensive, supervised research career translational research. This Funding O research that does not involve leading clinical trial. Applicants to this FOA are	nd its participating Institutes and Centers and Award. The award is designed to prepared research needs of the Nation. This proupport and "protected time" to individual development experience in the fields of I pportunity Announcement (FOA) is design an independent clinical trial, a clinical trial permitted to propose research experiencentored Clinical Scientist Research Career	are qualified indigram represent list with a clinical biomedical and specifically ial feasibility stace in a clinical	dividuals for cared ts the continuation al doctoral degree behavioral resea of for applicants produced trial led by a mer	ers that have a on of a long- e for an rch, including roposing ry study to a	
078383	NIH Small Research Grant Progra	m (Parent RO3 Clinical Trial Not	National Institutes of Health/DHHS	PA-19-052	07-May-2019	100,000	

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Allowed)				USD
	Contact Name				
	Contact Telephone				
	Contact Email	grantsinfo@nih.gov			
	Sponsor Website				
	Program URL	https://grants.nih.gov/grants/guide	/pa-files/PA-19-052.html		
	Deadline Dates (ALL)	2020 , 16-Oct-2020 , 07-Jan-2021 , 1	-2019 , 16-Oct-2019 , 07-Jan-2020 , 16-Fe 6-Feb-2021 , 07-May-2021 , 16-Jun-2021	, 07-Sep-2021 , 16-Oct-2021 , 07-	Jan-2022
		limited resources. This program sup of existing data; small, self-containe	am supports small research projects that a ports different types of projects including d research projects; development of resea apportunity Announcement does not acce	pilot and feasibility studies; seco arch methodology; and developm	ndary analysis nent of new
11/X544 -	Processing and Presentation of No Clinical Trial Not Allowed)	on-Conventional MHC Ligands (R01	National Institutes of Health/DHHS	PA-19-067 07-May-2019	Not Specified
	Contact Name	Timothy A. Gondré-Lewis, Ph.D.			
	Contact Telephone	240-627-3566			
	Contact Email	tglewis@niaid.nih.gov			
	Sponsor Website				
	Program URL	https://grants.nih.gov/grants/guide	/pa-files/PA-19-067.html		
	Deadline Dates (ALL)	07-May-2019 , 05-Jun-2019 , 07-Sep 2020 , 05-Oct-2020 , 07-Jan-2021 , 0	o-2019 , 05-Oct-2019 , 07-Jan-2020 , 05-Fe o5-Feb-2021 , 07-May-2021 , 05-Jun-2021	b-2020 , 07-May-2020 , 05-Jun-2 , 07-Sep-2021 , 05-Oct-2021 , 07-	020 , 07-Sep- Jan-2022
	Synopsis	This Funding Opportunity Announce mechanisms used in the generation class I and class II molecules, and to responses to infectious pathogens a induction/progression or preventior	ement (FOA) invites applications to charact of novel peptidic and non-peptidic ligands determine the contribution of these uniquely nd/or vaccines; pathogen-associated imment of immune-mediated diseases. These stund of immune-based therapeutics and vaccontributions	terize antigen processing and press presented by classical and non- ue antigenic ligands to: protective nune pathogenesis; and/or in the udies may facilitate the developm	esentation classical MHC e immune
11/X54h	Processing and Presentation of No Clinical Trial Not Allowed)	on-Conventional MHC Ligands (R21	National Institutes of Health/DHHS	PA-19-066 07-May-2019	275,000 USD
	Contact Name	Timothy A. Gondré-Lewis, Ph.D.			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Contact Telephone	240-627-3566			
	Contact Email	tglewis@niaid.nih.gov			
	Sponsor Website				
	Program URL	https://grants.nih.gov/grants/guide/pa-f	iles/PA-19-066.html		
			9 , 16-Oct-2019 , 07-Jan-2020 , 16-Feb-2020 , 07 b-2021 , 07-May-2021 , 16-Jun-2021 , 07-Sep-20		
	Synopsis	mechanisms used in the generation of no unique antigenic ligands to protective im associated immune pathogenesis; and/or	t (FOA) invites applications to determine antiger ovel peptidic and non-peptidic ligands and to det mune responses against infectious disease path r limit progression or induction of immune-medi and reagents to advance design of immune-bas	ermine the contribut ogens and/or vaccine ated diseases. These	ion of these s; pathogen- studies may
078396	NIH Exploratory/Developmental F Clinical Trial Required)	Research Grant Program (Parent R21 N	lational Institutes of Health/DHHS PA-19-0	54 07-May-2019	275,000 USD
	Contact Name				
	Contact Telephone				
	Contact Email	grantsinfo@nih.gov			
	Sponsor Website				
	=	https://grants.nih.gov/grants/guide/pa-f			
	Deadline Dates (ALL)		9		
	Synopsis	for the early and conceptual stages of the breakthrough in a particular area, or to that could have a major impact on a field Announcement requires that at least 1 cl interests of one or more of the participat	nt supports exploratory and developmental reserves projects. These studies may involve consider the development of novel techniques, agents, med of biomedical, behavioral, or clinical research. It inical trial be proposed. The proposed project noting NIH Institutes and Centers (ICs) based on the lotices) only accept applications proposing mechanding opportunity announcement.	able risk but may lead thodologies, models, his Parent Funding O nust be related to the eir scientific missions.	d to a or applications pportunity programmatic Applicants
078748	Midcareer Investigator Award in F Independent Basic Experimental S	Patient-Oriented Research (Parent K24 Noted to Note the Note	lational Institutes of Health/DHHS PA-19-0	88 07-May-2019	Not Specified
	Contact Name				

SPIN ID	Program Title	Sponsor Name	Sponsor Number		<b>Deadline Date</b>	Funding Amount
	1100					
	Contact Telephone					
	Contact Email					
	Sponsor Website					
	Program URL	https://grants.nih.gov/grants/guide/pa	a-files/PA-19-088.html			
	Deadline Dates (ALL)		019 , 12-Oct-2019 , 07-Jan-2020 , 12-Fel Feb-2021 , 07-May-2021 , 12-Jun-2021 ,			
	Synopsis	mentors primarily for clinical residents Announcement is for basic science exp basic science studies involving human meet the definition of basic research. prospectively assign human participan biomedical or behavioral outcomes in without specific application towards proposed to the specific application to the specific application towards proposed to the specific application to the specific applicatio	humans for the purpose of understandi rocesses or products in mind. Applicants , or proposing to gain research experier or, must apply to the 'Independent Clin he programmatic interests of one or mo	culty. This Pare ferred to in NO- the NIH definiti ed under this F nipulate indepe ng the fundame s not planning a nce in a clinical t ical Trial Not All	ent Funding Oppor T-OD-18-212 as "pon of a clinical tria OA include studie endent variables) ental aspects of plan independent cl trial or basic expe lowed' companior	tunity prospective al and also s that and that assess nenomena inical trial or rimental study of FOA The
	Mentored Clinical Scientist Resea	rch Career Development Award				Not
	*	xperimental Studies with Humans	National Institutes of Health/DHHS	PA-19-086	07-May-2019	Specified
	Required)	1				· 
	Contact Name					
	Contact Telephone					
	Contact Email					
	Sponsor Website					
	Program URL	https://grants.nih.gov/grants/guide/pa				
	Deadline Dates (ALL)		019 , 12-Oct-2019 , 07-Jan-2020 , 12-Fel Feb-2021 , 07-May-2021 , 12-Jun-2021 ,			
		The primary purpose of the NIH Mento prepare qualified individuals for careed This program represents the continuat	<del>-</del>	health-related r	research needs of	the Nation.

SPIN ID	Program	Sponsor Name	Sponsor Number	Deadline Date	Funding
SPIN ID	Title	Sponsor Name	Sponsor Number	Deadine Date	Amount

individuals with a clinical doctoral degree for an intensive, supervised research career development experience in the fields of biomedical and behavioral research, including translational research. This Parent Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as "prospective basic science studies involving human participants." These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion FOA.. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions.

Mentored Patient-Oriented Research Career Development Award 078747 (Parent K23 Independent Basic Experimental Studies with Humans Required)

National Institutes of Health/DHHS

PA-19-087 07-May-2019

Not Specified

Contact Name

Contact Telephone

Contact Email

Sponsor Website

Program URL https://grants.nih.gov/grants/guide/pa-files/PA-19-087.html

Deadline Dates (ALL)

07-May-2019, 12-Jun-2019, 07-Sep-2019, 12-Oct-2019, 07-Jan-2020, 12-Feb-2020, 07-May-2020, 12-Jun-2020, 07-Sep-2020, 12-Oct-2020, 07-Jan-2021, 12-Feb-2021, 07-May-2021, 12-Jun-2021, 07-Sep-2021, 12-Oct-2021, 07-Jan-2022

The purpose of the NIH Mentored Patient-Oriented Research Career Development Award (K23) is to support the career development of individuals with a clinical doctoral degree who have made a commitment to focus their research endeavors on patient-oriented research. This Parent Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as "prospective basic science studies involving human participants." These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that Synopsis should be submitted under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply

to the 'Independent Clinical Trial Not Allowed' companion FOA.. The proposed project must be related to the programmatic

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	ļi	interests of one or more of the partic	ipating NIH Institutes and Centers (ICs) b	ased on their so	cientific missions.	
078745	<u>Independent Scientist Award (Pare Experimental Studies with Humans</u>		National Institutes of Health/DHHS	PA-19-085	07-May-2019	Not Specified
	Contact Name					
	Contact Telephone					
	Contact Email	oer@od.nih.gov				
	Sponsor Website					
	Program URL	https://grants.nih.gov/grants/guide/p	pa-files/PA-19-085.html			
			2019 , 12-Oct-2019 , 07-Jan-2020 , 12-Fe -Feb-2021 , 07-May-2021 , 12-Jun-2021 ,			
	Synopsis	them to expand their potential to ma five years of salary support and "prot period of intensive research focus as program must be tailored to meet the for basic science experimental studies involving human participants." These basic research. Types of studies that participants to conditions (i.e., experi putcomes in humans for the purpose towards processes or products in min humans, or proposing to gain research investigator, must apply to the 'Indep	Scientist Award (KO2) is to foster the device significant contributions to their field ected time" for newly independent scient a means of enhancing their research care individual needs of the candidate. This is involving humans, referred to in NOT-O studies fall within the NIH definition of should be submitted under this FOA inclimentally manipulate independent variate of understanding the fundamental aspect of Applicants not planning an independent experience in a clinical trial or basic expendent Clinical Trial Not Allowed' compare of one or more of the participating NIH	of research. The tists who can deters. Each independent Funding D-18-212 as "pendent clinical trial and that as the cits of phenoment clinical trial coerimental studention FOA The	e KO2 award provi emonstrate the no pendent scientist of Opportunity Anno rospective basic so nd also meet the of t prospectively ass ssess biomedical of na without specifi or basic experiment by with humans lead proposed project	ides three to eed for a career award ouncement is cience studies definition of sign human or behavioral capplication intal study with d by another amust be
078744	Mentored Research Scientist Deve Independent Basic Experimental St		National Institutes of Health/DHHS	PA-19-084	07-May-2019	Not Specified
	Contact Name					
	Contact Telephone					
	Contact Email					

Sponsor Website

SPIN ID Program Title Sponsor Name Sponsor Number Deadline Date Amount

Program URL https://grants.nih.gov/grants/guide/pa-files/PA-19-084.html

Deadline Dates (ALL

07-May-2019, 12-Jun-2019, 07-Sep-2019, 12-Oct-2019, 07-Jan-2020, 12-Feb-2020, 07-May-2020, 12-Jun-2020, 07-Sep-2020, 12-Oct-2020, 07-Jan-2021, 12-Feb-2021, 07-May-2021, 12-Jun-2021, 07-Sep-2021, 12-Oct-2021, 07-Jan-2022

The purpose of the NIH Mentored Research Scientist Development Award (KO1) is to provide support and "protected time" (three to five years) for an intensive, supervised career development experience in the biomedical, behavioral, or clinical sciences leading to research independence. Although all of the participating NIH Institutes and Centers (ICs) use this support mechanism to support career development experiences that lead to research independence, some ICs use the K01 award for individuals who propose to train in a new field or for individuals who have had a hiatus in their research career because of illness or pressing family circumstances. Other ICs offer separate K01 FOAs intended to increase research workforce diversity. This Parent Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as "prospective basic science studies involving human participants." These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion FOA. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions.

Synopsis

078759 NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required)

National Institutes of Health/DHHS

PA-19-092 07-May-2019

275,000 USD

Contact Name

Contact Telephone 301-496-4000

Contact Email grantsinfo@od.nih.gov

Sponsor Website

Program URL https://grants.nih.gov/grants/guide/pa-files/PA-19-092.html

Deadline Dates (ALL)

07-May-2019, 16-Jun-2019, 07-Sep-2019, 16-Oct-2019, 07-Jan-2020, 16-Feb-2020, 07-May-2020, 16-Jun-2020, 07-Sep-2020, 16-Oct-2020, 07-Jan-2021, 16-Feb-2021, 07-May-2021, 16-Jun-2021, 07-Sep-2021, 16-Oct-2021, 07-Jan-2022

The NIH Exploratory/Developmental Grant supports exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to a Synopsis breakthrough in a particular area, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of biomedical, behavioral, or clinical research. This Parent Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as "prospective"

	SPIN ID	Program	Sponsor Name	Sponsor Number	Deadline Date	Funding
,	SPIN ID	Title	Sponsor Name	Sponsor Number	Deadine Date	Amount

basic science studies involving human participants." These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should submit under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Studies conducted with specific applications toward processes or products in mind should submit under the appropriate 'Clinical Trials Required' or 'Clinical Trial Optional' FOA. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions.

NIH Pathway to Independence Award (Parent K99/R00 Independent 078753 Basic Experimental Studies with Humans Required

National Institutes of Health/DHHS

PA-19-090 07-May-2019

Not **Specified** 

**Contact Name** 

Contact Telephone

**Contact Email** 

Sponsor Website

Program URL https://grants.nih.gov/grants/guide/pa-files/PA-19-090.html

Deadline Dates (ALL

2020, 12-Oct-2020, 07-Jan-2021, 12-Feb-2021, 07-May-2021, 12-Jun-2021, 07-Sep-2021, 12-Oct-2021, 07-Jan-2022 The purpose of the NIH Pathway to Independence Award (K99/R00) program is to increase and maintain a strong cohort of new and talented, NIH-supported, independent investigators. This program is designed to facilitate a timely transition of outstanding postdoctoral researchers with a research and/or clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIH research support during this transition in order to help awardees to launch competitive, independent research careers. This Parent Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as "prospective basic science studies involving human participants." These studies fall within the NIH definition of a Synopsis clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables)

and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion FOA.. The proposed project must be related to the programmatic interests of one or more of the participating

07-May-2019, 12-Jun-2019, 07-Sep-2019, 12-Oct-2019, 07-Jan-2020, 12-Feb-2020, 07-May-2020, 12-Jun-2020, 07-Sep-

078750 Mentored Quantitative Research Development Award (Parent K25

National Institutes of Health/DHHS

PA-19-089 07-May-2019

Not

NIH Institutes and Centers (ICs) based on their scientific missions.

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Independent Basic Experimental Studi	es with Humans Required)			Specified
	Contact Name				
	Contact Telephone				
	Contact Email				
	Sponsor Website				
		s://grants.nih.gov/grants/guide,			
			-2019 , 12-Oct-2019 , 07-Jan-2020 , 12 2-Feb-2021 , 07-May-2021 , 12-Jun-20		
	thos que and imagines reserved. Synopsis the und indefunde plan clini Tria	se investigators whose quantitat stions of health and disease. The research for productive professiging science, informatics, physicarch. This Parent Funding Opported to in NOT-OD-18-212 as "proposed to in NOT-OD-18-212 as "propose	titative Research Career Development ive science and engineering research he K25 award will provide support and "fonals with quantitative (e.g., mathematic, chemistry) and engineering backgrountunity Announcement is for basic science studies involving also meet the definition of basic respectively assign human participant ess biomedical or behavioral outcomes without specific application towards pull or basic experimental study with humans led by another investing proposed project must be related for the proposed project must be proposed project	ras thus far not been focused primar 'protected time" for a period of superatics, statistics, economics, compute unds to integrate their expertise with note experimental studies involving high human participants." These studies that should test to conditions (i.e., experimentally in humans for the purpose of under processes or products in mind. Applications, or proposing to gain research estigator, must apply to the 'Independent of the programmatic interests of one	ily on ervised study or science, h NIH-relevant numans, lies fall within be submitted manipulate rstanding the cants not experience in a ent Clinical

**Humans Required** 

National Institutes of Health/DHHS

PA-19-091 07-May-2019

Not Specified

Contact Name

Contact Telephone 301-496-4000

Contact Email grantsinfo@od.nih.gov

Sponsor Website

Program URL https://grants.nih.gov/grants/guide/pa-files/PA-19-091.html

Deadline Dates (ALL) 07-May-2019, 05-Jun-2019, 07-Sep-2019, 05-Oct-2019, 07-Jan-2020, 05-Feb-2020, 07-May-2020, 05-Jun-2020, 07-Sep-



078756

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	The NIH Research Project Grant so interests and competencies of the experimental studies involving humparticipants." These studies fall wiresearch. Types of studies that sho conditions (i.e., experimentally mahumans for the purpose of underst processes or products in mind. Stusubmit under the appropriate 'Clin	05-Feb-2021, 07-May-2021, 05-Jun-2021, upports a discrete, specified, circumscribed investigator(s). This Parent Funding Opport nans, referred to in NOT-OD-18-212 as "prothin the NIH definition of a clinical trial and ould submit under this FOA include studies inipulate independent variables) and that as canding the fundamental aspects of phenon dies conducted with specific applications to ical Trials Required' or 'Clinical Trial Options ne or more of the participating NIH Instituted	project in areas representing the cunity Announcement is for basic espective basic science studies in also meet the definition of basic that prospectively assign human assess biomedical or behavioral oward processes or products in mal' FOA. The proposed project mal' FOA.	e specific c science volving human c participants to utcomes in n towards nind should ust be related
078397	Research Project Grant (Parent RO	01 Clinical Trial Required)	National Institutes of Health/DHHS	PA-19-055 07-May-2019	Not Specified
	Contact Name				
	Contact Telephone				
	Contact Email	grantsinfo@nih.gov			
	Sponsor Website				
		https://grants.nih.gov/grants/guid			
			p-2019 , 05-Oct-2019 , 07-Jan-2020 , 05-Fel 05-Feb-2021 , 07-May-2021 , 05-Jun-2021 ,		
	Synopsis	interests and competencies of the clinical trial be proposed. The prop participating NIH Institutes and Cer	pports a discrete, specified, circumscribed pinvestigator(s). This Parent Funding Opport osed project must be related to the programeters (ICs) based on their scientific missions applications proposing mechanistic studies to the nnouncement.	cunity Announcement requires the mmatic interests of one or more so. Applicants should note that so	nat at least 1 of the me ICs
079124	Midcareer Investigator Award in F Independent Clinical Trial Require	Patient-Oriented Research (Parent F rd)	National Institutes of Health/DHHS	PA-19-121 07-May-2019	Not Specified
	Contact Name Contact Telephone				

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Contact Email g Sponsor Website	rantinfo@nih.gov				
		ttps://grants.nih.gov/grants/guide/pa 7-May-2019 , 12-Jun-2019 , 07-Sep-20 020 , 12-Oct-2020 , 07-Jan-2021 , 12-	n-files/PA-19-121.html 1919 , 12-Oct-2019 , 07-Jan-2020 , 12-Feb- Feb-2021 , 07-May-2021 , 12-Jun-2021 , 0	-2020 , 07-May 07-Sep-2021 , 1	/-2020 , 12-Jun-20 12-Oct-2021 , 07	)20 , 07-Sep- Jan-2022
	T h m Synopsis (I c n	he purpose of the NIH Midcareer Invented to the purpose of the NIH Midcareer Invented to professional doctorates for profesor primarily for clinical residents FOA) is designed specifically for applical linical trial feasibility study, or a separes	estigator Award in Patient-Oriented Rese sected time to devote to patient-oriented , clinical fellows and/or junior clinical fac ants proposing to serve as the lead inves ate ancillary clinical trial, as part of their ial, or proposing to gain research experie	arch (K24) is to d research (POI culty. This Fund stigator of an ir research and c	o provide support R) and to act as re ling Opportunity A ndependent clinic career developme	to mid-career esearch Announcement al trial, a ent. Applicants
079139	Mentored Quantitative Research De Independent Clinical Trial Required		National Institutes of Health/DHHS	PA-19-125 (	07-May-2019	Not Specified
	Sponsor Website	rantinfo@nih.gov	- Files /DA 40 425 html			
	Doadling Dates (ALL)		<del>-Tiles/PA-19-125.ntml</del> 019 , 12-Oct-2019 , 07-Jan-2020 , 12-Feb <sup>.</sup> May-2021 , 12-Jun-2021 , 07-Sep-2021 , 2			)20 , 07-Sep-
	T tl q a Synopsis ir re ir	he purpose of the Mentored Quantita nose investigators whose quantitative uestions of health and disease. The K nd research for productive profession maging science, informatics, physics, c esearch. This Funding Opportunity An nvestigator of an independent clinical esearch and career development. App	stive Research Career Development Awa science and engineering research has the 25 award will provide support and "prot als with quantitative (e.g., mathematics, themistry) and engineering backgrounds nouncement (FOA) is designed specifical trial, a clinical trial feasibility study, or a dicants not planning an independent clin ther investigator, must apply to companion	rd (K25) is to at nus far not been ected time" for statistics, ecor to integrate th ly for applicant separate ancilla ical trial, or pro	ttract to NIH-relet n focused primari r a period of supe nomics, computer eir expertise with ts proposing to se ary clinical trial, a oposing to gain re	ily on ervised study r science, n NIH-relevant erve as the lead as part of their
079149	Mentored Quantitative Research Don's Independent Clinical Trial Not Allow		National Institutes of Health/DHHS	PA-19-124 (	07-May-2019	Not Specified

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Contact Name					
	Contact Telephone	grantinfo@nih.gov				
	Sponsor Website					
	'	https://grants.nih.gov/grants/guide/pa-	files/PA-19-124.html			
	Deadline Dates (ALL)	07-May-2019 12-Jun-2019 07-Sen-201	 19 , 12-Oct-2019 , 07-Jan-2020 , 12-Feb			)20 , 07-Sep-
	Synopsis	The purpose of the Mentored Quantitat those investigators whose quantitative squestions of health and disease. The K2 and research for productive professional imaging science, informatics, physics, charesearch. This Funding Opportunity Annot involve leading an independent clinical trial or an ancillary clinical trial a	science and engineering research has t 25 award will provide support and "pro- als with quantitative (e.g., mathematics nemistry) and engineering backgrounds ouncement (FOA) is designed specifica cal trial, a clinical trial feasibility study, experience in a clinical trial led by a me	hus far not been tected time for a statistics, economics to integrate the large or an ancillary entor or co-me	en focused primar or a period of supe onomics, compute heir expertise with its proposing rese or clinical trial. App entor. Applicants p	ily on ervised study r science, n NIH-relevant arch that does licants to this
079132	Midcareer Investigator Award in I Independent Clinical Trial Not Allo	Patient-Oriented Research (Parent K24 owed)	National Institutes of Health/DHHS	PA-19-122	07-May-2019	Not Specified
	Contact Name					
	Contact Telephone					
	Contact Email	grantinfo@nih.gov				
	Sponsor Website					
	Program URL	https://grants.nih.gov/grants/guide/pa-				
	Deadline Dates (ALL)	07-May-2019 , 12-Jun-2019 , 07-Sep-20: 2020 , 12-Oct-2020 , 07-Jan-2021 , 12-Fe	19 , 12-Oct-2019 , 07-Jan-2020 , 12-Feb eb-2021 , 07-May-2021 , 12-Jun-2021 ,	o-2020 , 07-Ma 07-Sep-2021 ,	y-2020 , 12-Jun-20 12-Oct-2021 , 07-	)20 , 07-Sep- Jan-2022
		The purpose of the NIH Midcareer Investigation health-professional doctorates for protest mentors primarily for clinical residents, (FOA) is designed specifically for applical clinical trial feasibility study, or an ancill in a clinical trial led by another investigation, should apply to the compa	etigator Award in Patient-Oriented Rese ected time to devote to patient-oriente clinical fellows and/or junior clinical fa- ints proposing research that does not in ary clinical trial. Applicants to this FOA ator. Applicants proposing a clinical tria	earch (K24) is to d research (PC culty. This Fund nvolve leading are permitted	o provide support DR) and to act as re ding Opportunity a an independent c to propose reseal	to mid-career esearch Announcement linical trial, a rch experience

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Title				Amount
079178	Independent Scientist Award (Par Required)	rent K02 - Independent Clinical Trial	National Institutes of Health/DHHS	PA-19-131 07-May-2019	Not Specified
	Contact Name				
	Contact Telephone				
	Contact Email	grantinfo@nih.gov			
	Sponsor Website				
	Program URL	https://grants.nih.gov/grants/guide/p	pa-files/PA-19-131.html		
	Deadline Dates (ALL)		2019 , 12-Oct-2019 , 07-Jan-2020 , 12-Fel -Feb-2021 , 07-May-2021 , 12-Jun-2021 ,		
	· ·	five years of salary support and "prote period of intensive research focus as a program must be tailored to meet the designed specifically for applicants pro- feasibility study, or a separate ancillar planning an independent clinical trial, must apply to companion FOA (PA-19	ke significant contributions to their field ected time" for newly independent scien a means of enhancing their research care individual needs of the candidate. This oposing to serve as the lead investigator cy clinical trial, as part of their research a or proposing to gain research experience-132).	tists who can demonstrate the reers. Each independent scientist Funding Opportunity Announce of an independent clinical trial, and career development. Applica	need for a career award ment (FOA) is a clinical trial nts not r investigator,
079179	Independent Scientist Award (Par Not Allowed)	rent K02 - Independent Clinical Trial	National Institutes of Health/DHHS	PA-19-132 07-May-2019	Not Specified
	Contact Name				
	Contact Telephone				
	Contact Email	grantinfo@nih.gov			
	Sponsor Website				
	Program URL	https://grants.nih.gov/grants/guide/p	pa-files/PA-19-132.html		
	Deadline Dates (ALL)		2019 , 12-Oct-2019 , 07-Jan-2020 , 12-Fel -Feb-2021 , 07-May-2021 , 12-Jun-2021 ,		
	Synopsis	them to expand their potential to mal five years of salary support and "prote	Scientist Award (KO2) is to foster the dev ke significant contributions to their field ected time" for newly independent scien a means of enhancing their research care	of research. The KO2 award protists who can demonstrate the r	vides three to need for a

SPIN ID	Program	Sponsor Name	Sponsor Number	-	Deadline Date	Funding
	Title					Amount
		program must be tailored to meet the indesigned specifically for applicants propertial feasibility study, or a separate ancil in a clinical trial led by another investigation, should apply to the compa	osing research that does not involve le lary clinical trial. Applicants to this FOA ator. Applicants proposing a clinical tria	ading an indep are permitted	endent clinical tri I to propose resea	al, a clinical rch experience
079153	Mentored Research Scientist Dev Independent Clinical Trial Require		National Institutes of Health/DHHS	PA-19-127	07-May-2019	Not Specified
	Contact Name					
	Contact Telephone					
	Contact Email	grantsinfo@nih.gov				
	Sponsor Website					
	Program URL	https://grants.nih.gov/grants/guide/pa-				
	Deadline Dates (ALL)	07-May-2019 , 12-Jun-2019 , 07-Sep-20 2020 , 12-Oct-2020 , 07-Jan-2021	19 , 12-Oct-2019 , 07-Jan-2020 , 12-Feb	-2020 , 07-Ma	y-2020 , 12-Jun-20	)20 , 07-Sep-
	Synopsis	The purpose of the NIH Mentored Research (three to five years) for an intensive, supsciences leading to research independent mechanism to support career development individuals who propose to train in a neillness or pressing family circumstances. This Funding Opportunity Announcement investigator of an independent clinical to Opportunity Announcement (FOA) is defindependent clinical trial, a clinical trial career development. Applicants not placelinical trial led by another investigator,	pervised career development experience. Although all of the participating Ninent experiences that lead to research in which field or for individuals who have had Other ICs offer separate K01 FOAs into (FOA) is designed specifically for apprial, a clinical trial feasibility study, or a signed specifically for applicants proposes feasibility study, or a separate ancillary an independent clinical trial, or proposes.	te in the biome H Institutes andependence, a hiatus in the ended to increa- licants propos separate ancil sing to serve a clinical trial, a roposing to ga	edical, behavioral, and Centers (ICs) us some ICs use the ir research career ase research working to serve as the lary clinical trial. It is the lead investigs part of their research research working to serve as the lead investigs part of their research.	or clinical e this support K01 award for because of force diversity. e lead This Funding gator of an earch and
079159	Mentored Research Scientist Dev Independent Clinical Trial Not Alle		National Institutes of Health/DHHS	PA-19-126	07-May-2019	Not Specified
	Contact Name					
	Contact Telephone					
	Contact Email	grantsinfo@nih.gov				

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Sponsor Website					
	Program URL	https://grants.nih.gov/grants/guide/g	pa-files/PA-19-126.html			
	Deadline Dates (ALL)	07-May-2019 , 12-Jun-2019 , 07-Sep-2020 , 12-Oct-2020 , 07-Jan-2021	2019 , 12-Oct-2019 , 07-Jan-2020 , 12-Fel	o-2020 , 07-May	y-2020 , 12-Jun-20	)20 , 07-Sep-
	Synopsis	(three to five years) for an intensive, sciences leading to research independence mechanism to support career developed individuals who propose to train in a illness or pressing family circumstance. This Funding Opportunity Announcement of the propose research to propose research.	esearch Scientist Development Award (KC supervised career development experien dence. Although all of the participating N pment experiences that lead to research new field or for individuals who have had es. Other ICs offer separate KO1 FOAs inte ment (FOA) is designed specifically for app al trial, a clinical trial feasibility study, or a search experience in a clinical trial led by all as lead investigator, should apply to the	ce in the biome IH Institutes an independence, I a hiatus in the ended to increa blicants proposi a separate ancil a mentor or co	edical, behavioral, d Centers (ICs) us some ICs use the ir research career ase research working research that allary clinical trial.	or clinical e this support K01 award for because of force diversity. does not Applicants to
11/41/6	NIH Pathway to Independence Av Clinical Trial Not Allowed)	vard (Parent K99/R00 - Independent	National Institutes of Health/DHHS	PA-19-130	07-May-2019	Not Specified
	Contact Name					
	Contact Telephone					
	Contact Email	grantinfo@nih.gov				
	Sponsor Website					
	Program URL	https://grants.nih.gov/grants/guide/	pa-files/PA-19-130.html			
	Deadline Dates (ALL)		2019 , 12-Oct-2019 , 07-Jan-2020 , 12-Fel 2-Feb-2021 , 07-May-2021 , 12-Jun-2021 ,			
		new and talented, NIH-supported, incoutstanding postdoctoral researchers positions to independent, tenure-trac support during this transition in order Opportunity Announcement (FOA) is independent clinical trial, a clinical tripropose research experience in a clin	ndependence Award (K99/R00) program is dependent investigators. This program is swith a research and/or clinical doctorate ock or equivalent faculty positions. The program to help awardees to launch competitive designed specifically for applicants proposal feasibility study, or an ancillary clinical ical trial led by a mentor or co-mentor. All apply to the companion FOA (PA-19-12)	designed to face degree from no per moved to be degree from no per moved to be degree from the	cilitate a timely tra nentored, postdo ide independent I research careers. hat does not invo s to this FOA are	ensition of ctoral research NIH research This Funding live leading an permitted to

					_	
SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
079102	Mentored Clinical Scientist Resea (Parent K08 Independent Clinical		National Institutes of Health/DHHS	PA-19-117	07-May-2019	Not Specified
	Contact Name					
	Contact Telephone	301-496-8580				
	Contact Email	grantinfo@nih.gov				
	Sponsor Website					
	Program URL	https://grants.nih.gov/grants/guide	/pa-files/PA-19-117.html			
	Deadline Dates (ALL)	07-May-2019 , 12-Jun-2019 , 07-Sep 2020 , 12-Oct-2020 , 07-Jan-2021 , 1		b-2020 , 07-Ma , 07-Sep-2021 ,	ay-2020 , 12-Jun-2 , 12-Oct-2021 , 07-	020 , 07-Sep- -Jan-2022
	Synopsis	individuals with a clinical doctoral debiomedical and behavioral research designed specifically for applicants partial feasibility study, or an ancillary	pation of a long-standing NIH program that egree for an intensive, supervised research, including translational research. This Fund proposing research that does not involve by clinical trial. Applicants to this FOA are peentor. Applicants proposing a clinical trial (PA-19-116).	n career develo ding Opportun eading an inde rmitted to pro	opment experience nity Announcemen pendent clinical tr pose research exp	e in the fields o t (FOA) is ial, a clinical erience in a
079117	Mentored Patient-Oriented Research		National Institutes of Health/DHHS	ΡΔ-19-119	07-May-2019	Not
	(Parent K23 – Independent Clinica	al Trial Not Allowed)	Hadional moderates of ficulting 51m3	17(15 115		Specified
	Contact Name					
	Contact Telephone					
	Contact Email	grantinfo@nih.gov				
	Sponsor Website					
	Program URL	https://grants.nih.gov/grants/guide	/pa-files/PA-19-119.html			
	Deadline Dates (ALL)		-2019 , 12-Oct-2019 , 07-Jan-2020 , 12-Fe .2-Feb-2021 , 07-May-2021 , 12-Jun-2021 ,			
	Synopsis	development of individuals with a clon patient-oriented research. This F	Patient-Oriented Research Career Develop linical doctoral degree who have made a c unding Opportunity Announcement (FOA) ng an independent clinical trial, a clinical t	ommitment to is designed sp	focus their resear pecifically for applic	rch endeavors cants proposir

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		1	e permitted to propose research experie Il trial or an ancillary clinical trial as lead		•	
080196	Microbial-based Cancer Therapy Allowed)	- Bugs as Drugs (R21 Clinical Trial Not	National Institutes of Health/DHHS	PAR-19- 194	16-Jun-2019	550,000 USD
	Contact Name	Avi Rasooly, PhD				
	Contact Telephone	240-276-6196				
	Contact Email	rasoolya@mail.nih.gov				
	Sponsor Website					
	Program URL	https://grants.nih.gov/grants/guide/p	a-files/PAR-19-194.html			
	Deadline Dates (ALL)	16-Jun-2019 , 16-Oct-2019 , 16-Feb-20 2022	020 , 16-Jun-2020 , 16-Oct-2020 , 16-Feb	-2021 , 16-Jur	n-2021 , 16-Oct-202	21 , 16-Feb-
	Synopsis	microbial-based cancer therapies, esp poorly vascularized, hypoxic, solid tun tumors. Utilizing bacteria, archaebacteresearch projects designed to study thand immune system. The FOA also ain complement or synergize with current culture and animal models in accordand address both the microbial and the tuexploratory projects that are at an ear demonstrate core functional capabilities.	portunity announcement (FOA) is to stire ecially for conditions where conventional ors, dormant or slowly dividing cells reseria, bacteriophages and other non-virus are underlying mechanisms of the completes to support research into the use of microbial support basic, ince with the state of the science. Application aspects of microbial-based cancer the conceptual stage feasibility study (incomplete of the proposed approach. The proposed roughs in microbial-based cancer therage	al cancer there istant to curre intercorganism croorganisms mechanistic and the rapy. The Feption throughs and the rapy is a projects	apies are inadequated interventions, a sms, this initiative was between microorgal for cancer treatment preclinical studients to this FOA are each of the intended to each preliminary deve	te, such as and brain vill support ganisms, tumor, ent and to es in cell encouraged to ncourage
080193	Microbial-based Cancer Therapy Allowed)	-Bugs as Drugs (R01 Clinical Trial Not	National Institutes of Health/DHHS	PAR-19- 193	05-Jun-2019	Not Specified
	Contact Name	Avi Rasooly, PhD				
	Contact Telephone	240-276-6196				
	Contact Email	rasoolya@mail.nih.gov				
	Sponsor Website					

Program URL https://grants.nih.gov/grants/guide/pa-files/PAR-19-193.html

Contact Name

**Contact Telephone** 

Contact Email grantsinfo@nih.gov

Sponsor Website

Program URL https://grants.nih.gov/grants/guide/pa-files/PA-19-053.html

Deadline Dates (ALL)

07-May-2019, 16-Jun-2019, 07-Sep-2019, 16-Oct-2019, 07-Jan-2020, 16-Feb-2020, 07-May-2020, 16-Jun-2020, 07-Sep-2020, 16-Oct-2020, 07-Jan-2021, 16-Feb-2021, 07-May-2021, 16-Jun-2021, 07-Sep-2021, 16-Oct-2021, 07-Jan-2022

psis | f

The NIH Exploratory/Developmental Grant supports exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to a breakthrough in a particular area, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of biomedical, behavioral, or clinical research.

078398 NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)

National Institutes of Health/DHHS

PA-19-056 07-May-2019

Not



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
					Specified
	Contact Name				
	Contact Telephone				
	Contact Emai	grantsinfo@nih.gov			
	Sponsor Website				
	Program URL	https://grants.nih.gov/grants/guide/	pa-files/PA-19-056.html		
	Deadline Dates (ALL)		2019 , 05-Oct-2019 , 07-Jan-2020 , 05-Fe i-Feb-2021 , 07-May-2021 , 05-Jun-2021		
	Synopsis	interests and competencies of the inv	orts a discrete, specified, circumscribed prestigator(s). The proposed project must tutes and Centers (ICs) based on their scinications proposing clinical trial(s)	be related to the programmatic	interests of on
033794	NIH Generic Clone Program (non	-ASSIST) (Temporarily Suspended)	National Institutes of Health/DHHS	07-May-2019	Not Specified
	Contact Name				
	Contact Telephone				
	Contact Emai				
	Sponsor Website				
	Program URL	-			
	Deadline Dates (ALL)	07-May-2019 , 05-Jun-2019 , 07-Sep- 2020	2019 , 05-Oct-2019 , 07-Jan-2020 , 05-Fe	b-2020 , 07-May-2020 , 05-Jun-2	020 , 07-Sep-
	Synopsis	invites applications for This FOA will	use the NIH award mechanism.		
11/4164	NIH Pathway to Independence Av Clinical Trial Required)	ward (Parent K99/R00 Independent	National Institutes of Health/DHHS	PA-19-129 07-May-2019	Not Specified
	Contact Name				
	Contact Telephone				
	Contact Emai	grantinfo@nih.gov			
	Sponsor Website				
	Program URL	https://grants.nih.gov/grants/guide/	oa-files/PA-19-129.html		

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Synopsis	The purpose of the NIH Pathway to Ir new and talented, NIH-supported, incoutstanding postdoctoral researchers positions to independent, tenure-trac support during this transition in order Opportunity Announcement (FOA) is independent clinical trial, a clinical tricareer development. Applicants not proceed to the purpose of the NIH Pathway to Ir new and Ir new a	2019, 12-Oct-2019, 07-Jan-2020, 12-Feld-Feb-2021, 07-May-2021, 12-Jun-2021, adependence Award (K99/R00) program is with a research and/or clinical doctorate or equivalent faculty positions. The program is designed specifically for applicants proposal feasibility study, or a separate ancillary por, must apply to companion FOA (PA-19)	is to increase and designed to facil designed to facil e degree from mogram will provide, independent repsing to serve as y clinical trial, as proposing to gair	d maintain a stro litate a timely tra lentored, postdoo de independent N esearch careers. T the lead investig part of their rese	ong cohort of ansition of ctoral research NIH research This Funding gator of an earch and
079113	Mentored Patient-Oriented Resea (Parent K23 Independent Clinical		National Institutes of Health/DHHS	PA-19-118 C	)7-May-2019	Not Specified
	Sponsor Website Program URL Deadline Dates (ALL) Synopsis	2020, 12-Oct-2020, 07-Jan-2021, 12 The purpose of the NIH Mentored Pa development of individuals with a clir on patient-oriented research. This Fu to serve as the lead investigator of an trial, as part of their research and car	pa-files/PA-19-118.html 2019 , 12-Oct-2019 , 07-Jan-2020 , 12-Fel -Feb-2021 , 07-May-2021 , 12-Jun-2021 , tient-Oriented Research Career Developr nical doctoral degree who have made a conding Opportunity Announcement (FOA) independent clinical trial, a clinical trial eer development. Applicants not plannin trial led by another investigator, must ap	, 07-Sep-2021 , 1 ment Award (K23 ommitment to fo is designed spec feasibility study, ng an independer	.2-Oct-2021, 073) is to support the ocus their researd ifically for application a separate and clinical trial, or	Jan-2022 ne career ch endeavors cants proposing cillary clinical proposing to
079101	Mentored Clinical Scientist Resea (Parent K08 Independent Clinical		National Institutes of Health/DHHS	PA-19-116 C	07-May-2019	Not Specified
	Contact Name Contact Telephone	301-496-8580				

Contact Email grantinfo@nih.gov

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Sponsor Website					
	Program URL	https://grants.nih.gov/grants/guide/	pa-files/PA-19-116.html			
		•	2019 , 12-Oct-2019 , 07-Jan-2020 , 12-Feb-: 2-Feb-2021 , 07-May-2021 , 12-Jun-2021 , 0	-	•	•
	Synopsis	prepare qualified individuals for care This program represents the continuindividuals with a clinical doctoral debiomedical and behavioral research, designed specifically for applicants presearch, or a separate ancilla	tored Clinical Scientist Research Career Devers that have a significant impact on the heation of a long-standing NIH program that pagree for an intensive, supervised research cincluding translational research. This Fundiroposing to serve as the lead investigator or ry clinical trial, as part of their research and, or proposing to gain research experience 9-117).	ealth-related provides sup career devel ng Opportur f an indeper d career dev	research needs of port and "protecte opment experience nity Announcement dent clinical trial, a elopment. Applicar	the Nation. d time" to e in the fields o t (FOA) is a clinical trial nts not
074896	Computational Approaches to Cur Assets (R01 Clinical Trial Not Allow	ation at Scale for Biomedical Researced)	h National Library of Medicine/NIH/DHHS	PAR-18- 796	30-Jun-2019 [LOI/Pre-App] [Optional]	1,000,000 USD
	Contact Name	Alan VanBiervliet, PhD				
	Contact Telephone	301-594-4882				
	Contact Email	vanbiervlietaq@mail.nih.gov				
	Sponsor Website					
	Program URL	https://grants.nih.gov/grants/guide/	pa-files/PAR-18-796.html			
	Deadline Dates (ALL)	30-Jun-2019 [LOI/Pre-App][Optional]	, 31-Jul-2019 , 31-Dec-2019 [LOI/Pre-App][	Optional], 3	1-Jan-2020	
		sets and computational models that	invites applications to accelerate the availa can serve as the basis of transformative bio This FOA will use the NIH Research Project	medical disc	coveries by improvi	
078618	Data Science Research: Personal H Patients (R01 Clinical Trial Optiona		National Library of Medicine/NIH/DHHS	PAR-19- 072	28-Jun-2019 [LOI/Pre-App] [Optional]	1,000,000 USD
	Contact Name	Alan VanBiervliet, Ph.D.				

Contact Telephone 301-594-4882

Contact Email vanbiervlietag@mail.nih.gov

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Sponsor Website					
	Program URL	https://grants.nih.gov/grants/guide/p	a-files/PAR-19-072.html			
	Deadline Dates (ALL)		31-Jul-2019 , 17-Jan-2020 , 30-Jun-2020 [L 2021 , 30-Jun-2021 [LOI/Pre-App][Optiona			2020 , 18-Dec-
	Synopsis	individuals gather, manage and use da	s applications for novel informatics and da ata and information about their personal h nd the research community through broad data or resource sharing.	ealth. A goal	of this program is	to advance
076848		cal Informatics and Data Science (RO1	National Library of Medicine/NIH/DHHS	PAR-18-	07-May-2019	1,000,000
	<u>Clinical Trial Optional)</u>		National Library of Medicine, Will, Brills	896	07 Way 2013	USD
	Contact Name	Dr. Hua-Chuan Sim				
	Contact Telephone	301-594-4882				
	Contact Email	simh@mail.nih.gov				
	Sponsor Website					
	Program URL	https://grants.nih.gov/grants/guide/p	a-files/PAR-18-896.html			
	Deadline Dates (ALL)	07-May-2019 , 05-Jun-2019 , 07-Sep-2 2020 , 05-Oct-2020 , 07-Jan-2021 , 05-	.019 , 05-Oct-2019 , 07-Jan-2020 , 05-Feb-2021 , 07-May-2021 , 05-Jun-2021 , 0	2020 , 07-Ma 7-Sep-2021	y-2020 , 05-Jun-20	)20 , 07-Sep-
	Synopsis	National Library of Medicine (NLM) of data science. The scope of NLM's interapproaches to foster data driven discoverusable approaches to discovery, cur Biomedical informatics and data sciencomputer science and engineering, and biomedical research, clinical and transmanagement in disasters, and similar organization, management, integration data science as the interdisciplinary field.	fers support for innovative research and d rest in these research domains is broad, w overy in the biomedical and clinical health ation, analysis, organization and managem ce draw upon many fields, including mathe d social/behavioral sciences. Application of clational research, precision medicine, pub areas. NLM defines biomedical information in and presentation of information relevant celd of inquiry in which quantitative and an cowledge and insights from increasingly large	levelopment in the emphasis sciences as we nent of healthematics, statification inclusion health, bicks as the scient to human healytical approaps	on new methods a yell as domain-indon-related digital ob- istics, information de health care del osurveillance, heal ce of optimal repro- realth and biology.	and ependent, ojects. science, livery, basic th information esentation, NIH defines and systems
054791	Methodology and Measurement (R21)	n the Behavioral and Social Sciences	Office of Behavioral and Social Sciences Research/NIH/DHHS	PAR-16- 261	16-May-2019	275,000 USD



SPIN ID	Program Title	Sponsor Name	Sponsor Number		<b>Deadline Date</b>	Funding Amount		
	Contact Name	Deborah Hyman-Young, PhD						
	Contact Telephone	,						
		deborah.young-hyman@nih.gov						
	Sponsor Website							
	•	http://grants.nih.gov/grants/guide/pa-files/PAR-16-261.html						
	_	16-May-2019 , 05-Jun-2019 , 16-Sep-2019						
	Synopsis	National Institutes of Health (NIH) and its participating Institutes and Centers invite applications aimed at improving a developing methodology in the behavioral and social sciences through innovations in research design, measurement, collection and data analysis techniques. The participating NIH Institutes and Centers (ICs) encourage research that will improve the quality and scientific power of behavioral and social science data relevant to the IC missions. Applicants a strongly encouraged to contact the Scientific/Research Contact (see Section VII, Agency Contacts) of the IC that most matches their research focus to determine IC interest in the proposed research topic. This FOA will use the NIH Exploratory/Developmental (R21) grant mechanism.						
069602	Methodology and Measurement (R01 Clinical Trial Optional)	in the Behavioral and Social Sciences	Office of Behavioral and Social Sciences Research/NIH/DHHS	PAR-18- 352	07-May-2019	Not Specified		
	Contact Name	Elizabeth M. Ginexi, Ph.D.						
	Contact Telephone	301-594-4574						
	Contact Email	LGinexi@mail.nih.gov						
	Sponsor Website							
	Program URL	https://grants.nih.gov/grants/guide/p	a-files/PAR-18-352.html					
	Deadline Dates (ALL)	) 07-May-2019 , 05-Jun-2019 , 07-Sep-2019						
	Synopsis	developing methodology in the behavicollection and data analysis technique improve the quality and scientific powstrongly encouraged to contact the Scientific powstrongly encouraged to	its participating Institutes and Centers involved and social sciences through innovations. The participating NIH Institutes and Center of behavioral and social science data resentific/Research Contact (see Section VII, mine IC interest in the proposed research	ons in research sters (ICs) end elevant to the Agency Cont	ch design, measure courage research t e IC missions. Appl acts) of the IC tha	ement, data that will icants are t most closely		

Icahn School of Medicine at Mount Sinai	NIH Fundi

SPIN ID Program Title

**Sponsor Name** 

Sponsor

Number

Funding

Amount

Deadline

Date

SPIN ID	Program	Sponsor Name	Sponsor Number	Deadline Date	Funding	
	Title				Amount	
069614	Methodology and Measurement Clinical Trial Optional)	in the Behavioral and Social Sciences (R21	Office of Behavioral and Social Sciences P	PAR-18-378 07-May- 2019	275,000 USD	
	Contact Name	Elizabeth M. Ginexi, Ph.D.				
	Contact Telephone	301-594-4574				
	Contact Email	LGinexi@mail.nih.gov				
	Sponsor Website					
	Program URL	https://grants.nih.gov/grants/guide/pa-fil	<u>es/PAR-18-378.html</u>			
	Deadline Dates (ALL)	07-May-2019 , 16-Jun-2019 , 07-Sep-2019				
	National Institutes of Health (NIH) and its participating Institutes and Centers invite applications aimed at improving a developing methodology in the behavioral and social sciences through innovations in research design, measurement, collection and data analysis techniques. The participating NIH Institutes and Centers (ICs) encourage research that wi improve the quality and scientific power of behavioral and social science data relevant to the IC missions. Applicants strongly encouraged to contact the Scientific/Research Contact (see Section VII, Agency Contacts) of the IC that most matches their research focus to determine IC interest in the proposed research topic. This FOA will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.					
073264		Treatment and Prevention Regimens to	Office of Behavioral and Social Sciences	PA-18-723 07-May-	275,000 USD	
	Promote Health (R01 Clinical Tria	 I	Research/NIH/DHHS	2019	,	
		Wendy Nilsen, PhD				
	Contact Telephone					
		nelsonw@mail.nih.gov				
	Sponsor Website					
	Program URL	https://grants.nih.gov/grants/guide/pa-fil				
Deadline Dates (ALL) 07-May-2019 , 16-Jun-2019 , 07-Sep-2019 , 16-Oct-2019 , 07-Jan-2020 , 16-Feb-2020 , 07-May-2020 , 16-Jun-2020 , 2020 , 16-Oct-2020 , 07-Jan-2021 , 16-Feb-2021 , 07-May-2021						
	Synopsis	adherence to treatment and prevention regimen initiation, implementation, and/c adherence determinants at one or more le healthcare system, and community levels appropriate sample sizes, valid outcome necessity.	participating Institutes and Centers invite appearance or persistence by patients. Descriptive and intervels of ecologic influence, including the patients. Attention to scientific rigor in all applications neasures, and testing intervention mechanism d Centers are detailed within. This FOA accept	ations may address hea ervention research ma ent, caregiver/family, p s is paramount, with er ns of action. The specif	althcare y address rovider and/or mphasis on iic research	

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount	
		do not propose a clinical trial(s). This FOA mechanism.	will use the NIH R21 Exploratory/Developm	ental Research Grant awa	ard	
073256	Improving Patient Adherence to Promote Health (R01 Clinical Trial	Treatment and Prevention Regimens to al Optional)	Office of Behavioral and Social Sciences Research/NIH/DHHS	PA-18-722 07-May- 2019	Not Specified	
	Contact Name	Wendy Nilsen, PhD				
	Contact Telephone	240-276-6971				
	Contact Email	nelsonw@mail.nih.gov				
	Sponsor Website					
	Program URL	https://grants.nih.gov/grants/guide/pa-fi	les/PA-18-722.html			
	Deadline Dates (ALL) 07-May-2019 , 05-Jun-2019 , 07-Sep-2019 , 05-Oct-2019 , 07-Jan-2020 , 05-Feb-2020 , 07-May-2020 , 05-Jun-20					
National Institutes of Health (NIH) and its participating Institutes and Centers invite applications that address adherence to treatment and prevention regimens to promote health outcomes. Applications may address he regimen initiation, implementation, and/or persistence by patients. Descriptive and intervention research madherence determinants at one or more levels of ecologic influence, including the patient, caregiver/family, healthcare system, and community levels. Attention to scientific rigor in all applications is paramount, with eappropriate sample sizes, valid outcome measures, and testing intervention mechanisms of action. The specinterests of participating NIH Institutes and Centers are detailed within. This FOA accepts applications that edo not propose a clinical trial(s). This FOA will use the NIH Research Project (R01) award mechanism.					Ithcare	
079634		genic or Other Long-term Preservation and issued in the servation is senious series of the series of	Office of Research Infrastructure Programs/NIH/DHHS	PAR-19-176 16-Jun-202	19 275,000 USD	
	Contact Name	Sige Zou, Ph.D.				
	Contact Telephone	301-435-0749				
	Contact Email	zous@mail.nih.gov				
	Sponsor Website					
	Program URL	https://grants.nih.gov/grants/guide/pa-fi	les/PAR-19-176.html			
	, 16-Jun-2020 , 07-Sep-20 2021 , 07-Jan-2022 , 16-					
	Synopsis	This funding opportunity announcement	(FOA) supports exploratory research project	s aimed at developing cry	ogenic or	

SPII	N ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount	

other long-term preservation and revival approaches for Drosophila or zebrafish genetic stocks, which are essential laboratory animal models for biomedical research. The proposed project should address critical knowledge and technology gaps and describe approaches towards the development of reliable, easy-to-use and cost effective cryogenic or other longterm preservation and revival methods for wild-type and mutant strains of Drosophila or zebrafish.

070000	<u>Development of Animal Models and Related Biological Materials for</u>	Office of Research Infrastructure	PA-16-141	07-May-	275,000 USD
079890	Research (R21)	Programs/NIH/DHHS	PA-10-141	2019	275,000 030

Contact Name Sige Zou, Ph.D.

Contact Telephone 301-435-0749

Contact Email zous@mail.nih.gov

Sponsor Website

Program URL https://grants.nih.gov/grants/guide/pa-files/PA-16-141.html

**Synopsis** 

Deadline Dates (ALL) 07-May-2019, 16-Jun-2019, 07-Sep-2019

This funding opportunity announcement (FOA) encourages highly innovative research to develop, characterize or improve animal models and related biological materials for human health and disease or to improve diagnosis and control of diseases that might interfere with animal use for biomedical research purposes. The proposed project must fall within the categorical interests of two or more NIH institutions/centers. Applications to develop models that relate strictly to a specific disease or category of research will not be accepted and should be proposed to the appropriate categorical Institute or Center of the NIH.

SPIN ID	Program Title		Sponsor Name		Sponsor Number	Deadline Date	Funding Amount	
080079	Quantum Leap Challenge Ins	titutes (QLCI)	National Science Foundation	19-559	03-Jun-2019	25	,000,000 USD	
	Contact Name							
	Contact Telephone	703-292-4861						
	Contact Email	QLCI@nsf.gov						
	Sponsor Website	https://www.grants.gov	//web/grants/view-opportunity.html?oppl	ld=313033				
	Program URL	https://www.nsf.gov/pubs/2019/nsf19559/nsf19559.htm#toc						
	Deadline Dates (ALL)	03-Jun-2019 , 03-Jun-20 [LOI/Pre-App], 01-Feb-2	Jun-2019 , 03-Jun-2019 [LOI/Pre-App], 01-Aug-2019 [LOI/Pre-App], 02-Jan-2020 , 03-Aug-2020 [LOI/Pre-App], 01-Sep-20 II/Pre-App], 01-Feb-2021					
	Synopsis	Quantum Leap Challenge Institutes are large-scale interdisciplinary research projects that aim to advance the front quantum information science and engineering. Research at these Institutes will span the focus areas of quantum computation, quantum communication, quantum simulation and/or quantum sensing. The institutes are expected multidisciplinary approaches to specific scientific, technological, educational workforce development goals in these Two types of awards will be supported under this program: (i) 12-month Conceptualization Grants (CGs) to support envisioning subsequent Institute proposals and (ii) 5-year Challenge Institute (CI) awards to establish and operate C Leap Challenge Institutes. This activity is part of the Quantum Leap, one of the research Big Ideas promoted by the Science Foundation (NSF).						
081073	<u>Dear Colleague Letter: NSF C</u> <u>C-Accel)</u>	onvergence Accelerator	Pilot (NSF National Science Foundation	NSF 19-050	15-Apr-2019 [Lo App]	OI/Pre- 1,0	000,000 USD	
	Contact Name							
	Contact Telephone							
	Contact Email	C-Accel@nsf.gov						
	Sponsor Website							
	Program URL	https://www.nsf.gov/pu	ubs/2019/nsf19050/nsf19050.jsp?WT.mc	id=USNSF_2	25&WT.mc_ev=cl	<u>lick</u>		
	Deadline Dates (ALL) 15-Apr-2019 [LOI/Pre-App], 03-Jun-2019							
The National Science Foundation invites interested parties to participate in a new endeavor, the NSF Convergence (NSF C-Accel) Pilot. With this DCL, NSF's goals are to: (i) pilot a new NSF capability (the NSF Convergence) to accelerate use-inspired convergence research in areas of national importance, and (ii) initiate team-building capacity around exploratory, potentially high-risk proposals in three convergence topics (track research and education across all fields of science and engineering and with relationships with universities are agencies around the world, NSF is uniquely positioned to pilot this approach to accelerate discovery and innoverse.					ergence e convergence ss). As a funder of nd funding			

CDIN ID	Program Title	Sponsor Name	Sponsor	Deadline	Funding
SPIN ID	rrogram riue	Sponsor Name	Number	Date	Amount

Accel brings teams together to focus on grand challenges of national importance that require a convergence approach. The teams are multidisciplinary and leverage partnerships; the tracks relate to a grand challenge problem and have a high probability of resulting in deliverables that will benefit society within a fixed term. NSF C-Accel is modeled on acceleration and innovation activities from the most forward-looking companies and universities. The NSF C-Accel Pilot intends to support fundamental research while encouraging rapid advances through partnerships that include, or will include, multiple stakeholders (e.g., industry, academic, not-for-profits, government entities, and others). The NSF C-Accel Pilot will bring teams together in a cohort that are all focused on a common research goal of national importance but which may be pursuing many different approaches. NSF is planning to fund approximately 50 Phase 1 awards (up to 9 months and up to \$1 million each).

SPIN ID	Program Title	Sponsor	Name	Sponsor Number	Deadline	e Date	Funding Amount
080481	Military Medical Photonics Prog	gram	Air Force Office of Scientific	Research	FA9550-19-S- 0002	30-Jun- 2019	Not Specified
	Contact Name	Daniel Smith					
	Contact Telephone	703-588-8494					
	Contact Email	afosr.baa@us.af.mil					
	Sponsor Website						
	Program URL	https://www.grants.gov/w	veb/grants/view-opportunity.h	ntml?oppId=313509			
	Deadline Dates (ALL)	30-Jun-2019					
	Synopsis	aimed at using lasers and closely related materials so announcement is for a small	entific Research (AFOSR) invited ther light source technology for concess, with applications to consult number of individual award toward university-based medutes, and engineers.	to develop applicatior ombat casualty care a ls. It is complementar	ns in medicine, pho nd other military i y to ongoing and f	otobiology, medical pro uture plan	, surgery, and oblems. This ed broad based
072808	Research Grants for the Primary of Opioid Overdose (R01)	y or Secondary Prevention	National Center for Injury Pr Control/CDC/DHHS	evention and	RFA-CE-18-006	07-May- 2019	2,250,000 USD
	Contact Name	Susan Neurath, Ph.D.					_
	Contact Telephone	770-488-3368					
	Contact Email	SFN8@cdc.gov					
	Sponsor Website						
	Program URL	https://www.grants.gov/w	veb/grants/view-opportunity.h	ntml?oppId=299896			
	Deadline Dates (ALL)	07-May-2019 , 05-Jun-201 2020 , 05-Oct-2020 , 07-Ja	9 , 07-Sep-2019 , 05-Oct-2019 n-2021 , 05-Feb-2021 , 07-Ma	, 07-Jan-2020 , 05-Fe y-2021	b-2020 , 07-May-2	:020 , 05-Ju	un-2020 , 07-Sep-
	Synopsis	National Center for Injury advance our understandin	Prevention and Control (NCIPO g about what works to preven uating novel primary or secon	<ul><li>c) is soliciting investigate</li><li>t overdose from presentation</li></ul>	cription and illicit	opioids by	developing and

				1	
SPIN ID Progra	ım Title	Sponsor Name	Sponsor Number	<b>Deadline Date</b>	Funding Amount
006424	Foulkes Foundation Medal		Academy of Medical Sciences	21-Jun-2019	Not Specified
Contact Name Contact Telephone Contact Email Sponsor Website	Russell Crandon 020 3141 3204  russell.crandon@acmedsci.ac.uk https://acmedsci.ac.uk/about/obje	ctives/promoting-exceller	nce/foulkes-foundation-medal		
Program URL Deadline Dates (ALL)	21-Jun-2019				
Synopsis	The Foulkes Foundation Medal is a	varded to a rising star in b	piomedical research for making a signi	ficant impact on U	K bioscience.
024492	Vegetarian Nutrition Dietetic Practi Grant	ce Group Research	Academy of Nutrition and Dietetics Foundation	01-Jun-2019	10,000 USD
Contact Name	lisha Reichling, MS, RDN, LDN, Four	idation Program Coordina	tor		
Contact Telephone Contact Email Sponsor Website	ereichling@eatright.org https://eatrightfoundation.org/				
Program URL Deadline Dates (ALL)	https://eatrightfoundation.org/sch 01-Jun-2019	olarships-funding/grants/			



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
•					_

Synopsis This grant is given for innovative research relating to vegetarian nutrition.

098360	Singapore International Graduate Award	Agency for Science, Technology & Research	01-Jun-2019	Not Specified
Contact Name				
Contact Telephone	(65) 6826 6111			
Contact Email	singa_enquiries@hq.a-star.edu.sg			
Sponsor Website Program URL	https://www.a-star.edu.sg/Scholarships/For-Gradua	te-Studies/Singapore-International-Graduate-A	ward-SINGA	
Deadline Dates (ALL)	01-Jun-2019			
Synopsis	The Singapore International Graduate Award (SINGA (ASTAR), the National University of Singapore (NUS), in English at the recipient's chosen lab at ASTAR Reseworld-renowned researchers in these labs. Upon suc	and the Nanyang Technological University (NTUearch Institutes, NUS, or NTU. Students will be s	J). PhD training will upervised by disting	be carried out guished and
Synopsis 042399	(ASTAR), the National University of Singapore (NUS), in English at the recipient's chosen lab at ASTAR Rese	and the Nanyang Technological University (NTUearch Institutes, NUS, or NTU. Students will be s	J). PhD training will upervised by disting	be carried out guished and
, ,	(ASTAR), the National University of Singapore (NUS), in English at the recipient's chosen lab at ASTAR Rese world-renowned researchers in these labs. Upon suc	and the Nanyang Technological University (NTUearch Institutes, NUS, or NTU. Students will be seessful completion, students will be conferred a	J). PhD training will supervised by disting a PhD degree by eit	be carried out guished and her NUS or NTU.
, ,	(ASTAR), the National University of Singapore (NUS), in English at the recipient's chosen lab at ASTAR Rese world-renowned researchers in these labs. Upon suc	and the Nanyang Technological University (NTU earch Institutes, NUS, or NTU. Students will be s cessful completion, students will be conferred a American Academy of Otolaryngic	J). PhD training will supervised by disting a PhD degree by eit	be carried out guished and her NUS or NTU. Not
042399	(ASTAR), the National University of Singapore (NUS), in English at the recipient's chosen lab at ASTAR Rese world-renowned researchers in these labs. Upon suc Research Grants	and the Nanyang Technological University (NTU earch Institutes, NUS, or NTU. Students will be s cessful completion, students will be conferred a American Academy of Otolaryngic	J). PhD training will supervised by disting a PhD degree by eit	be carried out guished and her NUS or NTU. Not
042399  Contact Name	(ASTAR), the National University of Singapore (NUS), in English at the recipient's chosen lab at ASTAR Rese world-renowned researchers in these labs. Upon such Research Grants  Elizabeth Hertzfeld	and the Nanyang Technological University (NTU earch Institutes, NUS, or NTU. Students will be s cessful completion, students will be conferred a American Academy of Otolaryngic	J). PhD training will supervised by disting a PhD degree by eit	be carried out guished and her NUS or NTU Not
042399  Contact Name Contact	(ASTAR), the National University of Singapore (NUS), in English at the recipient's chosen lab at ASTAR Rese world-renowned researchers in these labs. Upon such Research Grants  Elizabeth Hertzfeld	and the Nanyang Technological University (NTU earch Institutes, NUS, or NTU. Students will be s cessful completion, students will be conferred a American Academy of Otolaryngic	J). PhD training will supervised by disting a PhD degree by eit	be carried out guished and her NUS or NTU Not
042399  Contact Name Contact Telephone	(ASTAR), the National University of Singapore (NUS), in English at the recipient's chosen lab at ASTAR Rese world-renowned researchers in these labs. Upon such Research Grants  Elizabeth Hertzfeld 202-955-5010 x 600	and the Nanyang Technological University (NTU earch Institutes, NUS, or NTU. Students will be s cessful completion, students will be conferred a American Academy of Otolaryngic	J). PhD training will supervised by disting a PhD degree by eit	be carried out guished and her NUS or NTU. Not

SPIN ID Progra	m Title	Sponsor Name	Sponsor N	umber	<b>Deadline Date</b>	Funding Amount
Deadline Dates (ALL)	Eeah7tgs5OA qg/popupform?local 01-Jun-2019	e=&_data=(formid:%2724	<u>28%27)</u>			
Synopsis	The AAOA Foundation awards grant	ts to promote scientificall	y rigorous research tha	: improves the	quality of life for tl	ne allergic patient.
045882	Outstanding Investigator Award for	Breast Cancer Research	American Association Research	for Cancer	30-Jun-2019	15,000 USD
Contact Name						
Contact Telephone Contact Email	215-440-9300 awards@aacr.org					
	- <del> </del>					
Sponsor Website	http://www.aacr.org					
Program URL	http://www.aacr.org/Research/Awa	ards/Pages/Awards-Detai	l.aspx?ItemId=15#.WKv	v1t krKM		
Deadline Dates (ALL)	30-Jun-2019					
Synopsis	The AACR Outstanding Investigator Award for Breast Cancer Research, funded by Susan G. Komen®, recognizes an investigator of no more than 50 years of age whose novel and significant work has had or may have a far-reaching impact on the etiology, detection, diagnosis, treatment, or prevention of breast cancer. Such work may involve any discipline across the continuum of biomedical research, including basic, translational, clinical and epidemiological studies.					
033846	<u>Distinguished Lecture on the Science</u> <u>Disparities</u>	e of Cancer Health	American Association Research	for Cancer	30-Jun-2019	5,000 USD
Contact Name						
Contact Telephone	215-446-7128					



**Contact Email** awards@aacr.org **Sponsor** Website http://www.aacr.org/Research/Awards/Pages/Awards-Detail.aspx?ItemId=10 Program URL **Deadline Dates** 30-Jun-2019 (ALL) Synopsis The AACR Distinguished Lecture on the Science of Cancer Health Disparities, funded by Susan G. Komen recognizes an investigator whose novel and significant work has had or may have a far-reaching impact on the etiology, detection, diagnosis, treatment or prevention of cancer health disparities. 023798 Elizabeth Barrett-Connor Research Award for Young 15-Jun-2019 1,000 USD American Heart Association **Investigators Contact Name** Contact 800-242-8721 Telephone council.awards@heart.org Contact Email http://my.americanheart.org/ **Sponsor** Website Program URL https://professional.heart.org/professional/MembershipCouncils/ScientificCouncils/UCM 322657 Elizabeth-Barrett-Connor-Research-Award-for-Young-Investigators.jsp 15-Jun-2019 Deadline Dates (ALL) The Elizabeth Barrett-Connor Research Award in Epidemiology recognizes excellence in research by early career investigators and trainees and encourages continued biomedical research careers broadly related to cardiovascular function and diseases, including basic science, integrated physiology and clinical problems. The first-prize winner will receive a plaque and \$1,000.

Sponsor Name

**Deadline Date** 

**Funding Amount** 

Sponsor Number



SPIN ID

**Program Title** 

SPIN ID Progra	m Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
080457	Award for Outstanding Doctoral Th	esis Research in	American Physical Society	03-Jun-2019	2,500 USD
	Biological Physics				
Contact Name					
Contact	301-209-3200				
Telephone					
Contact Email	honors@aps.org				
Sponsor	https://www.aps.org/programs/ho	nors/listings.cfm			
Website					
Program URL	https://www.aps.org/programs/ho	nors/prizes/biological.cfn	<u>1</u>		
Deadline Dates (ALL)	03-Jun-2019				
Synopsis	The Award for Outstanding Doctora	al Thesis Research in Biolo	ogical Physics recognizes doctoral thes	is research of outst	anding quality
	and achievement in any area of expension encourage effective written and or		I, engineering, or theoretical Biologica h results.	ll Physics, broadly c	onstrued, and to
003231	<u>Literature Awards - Award for Susta</u>	ained Contributions	American Society of Health- Systems Pharmacists Foundation	18-Jun-2019	5,000 USD
Contact Name					
Contact	301-664-8612				
Telephone					
Contact Email	foundation@ashp.org				
Sponsor Website	http://www.ashpfoundation.org/N	lainMenuCategories/Awa	rds/ASHPFoundationLiteratureAward	s.aspx	
Program URL			rds/ASHPFoundationLiteratureAward	s/AwardforSustaine	edContributionsto
	theLiteratureofPharmacyPractice.a	<u>spx</u>			



SPIN ID	Progra	m Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
Deadline	e Dates (ALL)	18-Jun-2019				
Sy	vnopsis		ons is made to an individual who has ary, peer-reviewed, biomedical literat	•	-	of consistently
032379		Literature Awards - Drug Therapy Re		Society of Health- narmacists Foundation	18-Jun-2019	4,000 USD
Contact	Name					
C	Contact	301-664-8612				
Tele	phone					
Contact	t Email	foundation@ashp.org				
Sp	ponsor	http://www.ashpfoundation.org/M	ainMenuCategories/Awards/			
	/ebsite					
Progra	ım URL	http://www.ashpfoundation.org/M	ainMenuCategories/Awards/ASHPFou	<u>undationLiteratureAwards</u>	s.aspx	
Deadline	Dates (ALL)	18-Jun-2019				
Sy	vnopsis	The Drug Therapy Research Award rethat address the therapeutic uses of	recognizes outstanding original contri f medications.	butions to the peer-reviev	ved, primary, biom	edical literature
032378		ASHP Foundation Literature Awards	s- <u>Innovation in</u> American S	Society of Health-	18-Jun-2019	Not
		Pharmacy Practice	Systems Ph	narmacists Foundation		Specified
Contact	Name					
С	Contact	301-664-8612				
Tele	phone					
Contact	t Email	foundation@ashp.org				



Sponsor Website Program URL Deadline Dates (ALL)	http://www.ashpfoundation.org/MainMenuCategories/Awards/ASHPFoundationLiteratureAwards.aspx  http://www.ashpfoundation.org/MainMenuCategories/Awards/ASHPFoundationLiteratureAwards/AwardforInnovationinPharmacyPractice 18-Jun-2019
Synopsis	The Award for Innovation in Pharmacy Practice is given for an outstanding contribution to the biomedical literature that describes an innovation in pharmacy practice in hospitals or health systems. The award is given annually to the author(s) of an noteworthy contribution of original research relevant to health-system pharmacy practice published during the calendar year preceding the ASHP Midyear Clinical Meeting at which the Award is presented.
032380	<u>Literature Awards - Pharmacy Practice Research Award</u> American Society of Health- Systems Pharmacists Foundation 4,000 USD
Contact Name	
Contact	301-664-8612
Telephone	
Contact Email	foundation@ashp.org
Sponsor Website	http://www.ashpfoundation.org/MainMenuCategories/Awards/ASHPFoundationLiteratureAwards.aspx
Program URL	http://www.ashpfoundation.org/MainMenuCategories/Awards/ASHPFoundationLiteratureAwards/PharmacyPracticeResearchAwards/ASHPFoundationLiteratureAwards/PharmacyPracticeResearchAwards/ASHPFoundationLiteratureAwards/PharmacyPracticeResearchAwards/ASHPFoundationLiteratureAwards/PharmacyPracticeResearchAwards/ASHPFoundationLiteratureAwards/PharmacyPracticeResearchAwards/ASHPFoundationLiteratureAwards/PharmacyPracticeResearchAwards/ASHPFoundationLiteratureAwards/PharmacyPracticeResearchAwards/ASHPFoundationLiteratureAwards/PharmacyPracticeResearchAwards/ASHPFoundationLiteratureAwards/PharmacyPracticeResearchAwards/ASHPFoundationLiteratureAwards/PharmacyPracticeResearchAwards/ASHPFoundationLiteratureAwards/PharmacyPracticeResearchAwards/ASHPFoundationLiteratureAwards/PharmacyPracticeResearchAwards/ASHPFoundationLiteratureAwards/PharmacyPracticeResearchAwards/Ph
Deadline Dates (ALL)	18-Jun-2019
Synopsis	The Pharmacy Practice Research Award recognizes an outstanding original contribution to the peer-reviewed biomedical literature related to pharmacy practice in hospitals and health systems. The award is given annually to the author(s) of an important contribution of original research relevant to health-system pharmacy practice published during the calendar year preceding the ASHP Midyear Clinical Meeting at which the Award is presented.

**Sponsor Name** 

Sponsor Number

**Deadline Date** 

**Funding Amount** 



SPIN ID

**Program Title** 


SPIN ID Pr	ogram Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		·			•
032382	ASHP Foundation Literature	Awards - Student Research	American Society of Health-	18-Jun-2019	2,500 USD
032382	Award	Awards - Student Nesearch	Systems Pharmacists Foundation	10-Juli-2019	2,300 030
Comtact No			Systems i namideists i dandation		
Contact Na					
Con					
Teleph					
Contact E				_	
Spor		n.org/MainMenuCategories/A	wards/ASHPFoundationLiterature Award	<u>ls.aspx</u>	
Web					
Program		n.org/MainMenuCategories/A	wards/ASHPFoundationLiterature Award	<u>ls/StudentResearch</u>	<u>Award</u>
Deadline Da					
(,	ALL)				
Syno	•		udent for a published paper that descril first through fourth professional years	•	• •
032660	Translational Research Train	ning in Hematology (TRTH)	American Society of Hematology	25-Jun-2019 [LOI/Pre-App	1,130 USD
				[LOI/FIE-App	
Contact Na					
Con					
Teleph					
Contact E	nail <u>training@ehaweb.org</u>				
Spor		rg/Awards/			
Web					
Program	URL <a href="https://www.hematology.org">https://www.hematology.org</a>	rg/Awards/Career-Training/43	<u>4.aspx</u>		



(ALL)

Deadline Dates 25-Jun-2019 [LOI/Pre-App]

SPIN ID	Progra	m Title	Sponsor Name	Sponsor Number	<b>Deadline Date</b>	Funding Amount
	nopsis	Translational Research Training in H researchers build successful careers and 10 from Europe) are selected to hematology. Topics covered include design.	in hematologic translational resea participate in the rigorous training biostatistics and biomarkers, gen	arch. Each year, 20 early-care g program led by faculty who etics and molecular biology,	eer scientists (10 from a scientists) are international ethics, and phase I	om North America leaders in clinical study
025810		Advances in Research Conference E. Support	arly Program Travel America	n Society of Nephrology	24-Jun-2019	1,000 USD
Tele Contact Sp	ontact phone t Email ponsor /ebsite m URL	202-640-4660  email@asn-online.org https://www.asn-online.org/ https://www.asn-online.org/grants/ 24-Jun-2019	/travel/			
Sy	rnopsis	Successful "Advances in Research Cocomplimentary registration to the ADC.				• •
011252		Fellowship Research Award	America Founda	n Surgical Association ion	15-Jun-2019	75,000 USD
Contact	Name					
Tele Contact Sp	ontact phone t Email consor /ebsite	978-927-8330 <a href="http://americansurgical.org/awards">http://americansurgical.org/awards</a>	. <u>.cgi</u>			
VV	CDSICC					



SPIN ID Progra	m Title	Sponsor Name	Sponsor Number	<b>Deadline Date</b>	Funding Amount	
Program URL Deadline Dates (ALL)	http://americansurgical.org/awards	<u>Fellowship.cgi</u>				
Synopsis	The purpose of the ASAF Fellowship academic surgery. Fellows will be su for a succeeding year.				•	
020664	Michael D. Hayre Fellowship in Publ	ic Outreach America	ins for Medical Progress	01-Jun-2019	7,000 USD	
Contact Name	Paula Clifford					
Contact	202-624-8810					
Telephone						
Contact Email	paula@amprogress.org					
Sponsor	https://www.amprogress.org/					
Website	haran da an	C.H. Alt.				
Program URL	https://www.amprogress.org/hayre	e-tellowship/				
Deadline Dates (ALL)	01-Jun-2019					
Synopsis	The Michael D. Hayre Fellowship in Public Outreach promotes peer education about animal research among students and young professionals. The aim of the Hayre Fellowships is to foster young voices to speak in support of science and advancing medical knowledge through responsible animal research. The programs created are designed to continue to influence research advocates, even after the Fellows complete their terms.					
022155	Ken Muirden Overseas Training Fell	owship Arthritis	Australia	07-Jun-2019	52,500 USD	
Contact Name						
Contact	(02) 9518 4441					
Telephone						
Contact Email	researchgrants@arthritisaustralia.c	<u>om.au</u>				



Sponsor	https://arthritisaustralia.com.au/programs-research/national-research-program/on-offer/overseas-awards/					
Website	https://arthritica.ustralia.com.au/programs.rosaarch/patiar	and recourse program (key dates how to	annly/			
Program URL Deadline Dates	https://arthritisaustralia.com.au/programs-research/natior 07-Jun-2019	iai-research-program/key-dates-now-to-	<u>appiy/</u>			
(ALL)	07-3411-2019					
Synopsis	The Ken Muirden Overseas Traingin Fellowship is designed training in Rheumatology within the last two years an oppoapproved institution in any country.	-	•			
073623	Stars Career Development Award	Arthritis Society	22-May-2019	Not		
			[LOI/Pre-App]	Specified		
Contact Name						
Contact	416-979-7228 x3320					
Telephone						
Contact Email	research@arthritis.ca					
Sponsor	http://www.arthritis.ca/researchers/how-to-apply					
Website		/.				
Program URL	http://www.arthritis.ca/researchers/current-funding-oppo	rtunities/stars-career-development-awar	<u>'d</u>			
Deadline Dates (ALL)	22-May-2019 [LOI/Pre-App], 26-Jun-2019					
Synopsis	The Stars Career Development award has been created to firmly establish the career of early career investigators. This salary and research funding represents a three-year commitment by the Arthritis Society, together with an additional three-year commitment by the applicant's Host Institution. The program is intended to promote creativity in all domains of arthritis-related research responsive to the Arthritis Society's strategic priorities. The maximum award per application is \$125,000 annually for up to three years (\$375,000 total), with an additional 3 years of support from the Host Institution of an equal value.					
012491	AAALAC International Fellowship Award	Association for Assessment and Accreditation of Laboratory Animal	01-Jun-2019	Not Specified		

Sponsor Number

**Deadline Date** 

**Funding Amount** 

Sponsor Name



SPIN ID Program Title

SPIN ID Progra	ım Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		Care			
Contact Name					
Contact Telephone	301-696-9626				
Contact Email	fellow@aaalac.org				
Sponsor Website	http://www.aaalac.org				
Program URL	http://www.aaalac.org/about/fell	owship.cfm			
Deadline Dates (ALL)	01-Jun-2019 , 01-Oct-2019	<del></del>			
Synopsis	The AAALAC International Technic AALAS Registered (RALAT, RLAT, R of laboratory animal care and use	RLATG, CMAR) — who have made	_	•	
036867	Research Grants	Ataxia	a UK	10-Jun-2019 [LOI/Pre-App]	Not Specified
Contact Name	Dr Julie Greenfield				<u>-</u>
Contact Telephone	020 7582 1444				
Contact Email	research@ataxia.org.uk				
Sponsor Website	https://www.ataxia.org.uk/				
Program URL	https://www.ataxia.org.uk/news/	apply-for-funding			
Deadline Dates	10-Jun-2019 [LOI/Pre-App]	-			



SPIN ID Progra	m Title	Sponsor Name	Sponsor Number	<b>Deadline Date</b>	Funding Amount
Synopsis	Ataxia UK funds research of releva principle symptom, and in which t spinocerebellar ataxias and other	he ataxia is likely to be progressi	ve. This includes conditions su		
061283	Gottschalk Medal	Aust	ralian Academy of Science	01-May-2019	Not Specified
Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL)  Synopsis	Dominic Burton + 61 (0)2 6201 9407  awards@science.org.au https://www.science.org.au/oppo https://www.science.org.au/oppo 01-May-2019 , 01-Jun-2019  The Gottschalk Medal recognises of	rtunities-scientists/recognition/h	onorific-awards/early-career-	-awards/gottschalk-n	nedal
061282	Fenner Medal	Aust	ralian Academy of Science	01-May-2019	Not Specified
Contact Name Contact Telephone	Dominic Burton + 61 (0)2 6201 9407				·
Contact Email Sponsor Website	awards@science.org.au https://www.science.org.au/oppo		•		-1
Program URL	https://www.science.org.au/oppo	rtunities-scientists/recognition/f	ionorific-awards/early-career-	-awards/теппет-med	<u>aı</u>



SPIN ID Progra	am Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
Deadline Dates (ALL)	•				
Synopsis	The Fenner Medal annually recognis years post PhD .	ses distinguished research in biology,	excluding the biomedical	sciences, by resear	chers up to 10
025851	AGA-Goethe Fellowship	Australian (	German Association	03-Jun-2019	Not Specified
Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL)	fellowship@aga.org.au http://www.aga.org.au/fellowship/ http://www.aga.org.au/fellowship/ 03-Jun-2019		erman Association and the	e Goethe-Institut. It	
	Australians a 12-week stay in Germa	any.			
096334	Frontiers of Knowledge Awards	BBVA Foun	dation	30-Jun-2019	452,000 USD
Contact Name Contact Telephone Contact Email Sponsor	+34 94 424 46 21 awards-info@fbbva.es	awards-fbbva.es/			



SPIN ID	Progra	m Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
Website						
		https://www.frontiersofknowledge	eawards-tbbva.es/conditions/			
Deadlin	e Dates (ALL)	30-Jun-2019				
Sı	ynopsis	The BBVA Foundation Frontiers of embedded in theoretical advances artificial or technological worlds, to interpretative styles in contempora deliver material progress with regacooperation.	, models and fundamental pers echnological innovations and de ary classical music. Awards also	pectives for an improved unders evelopments, and the creation of go to significant achievements the	tanding of the natu outstanding works nat advance our un	ral, social and or new artistic or derstanding or
089931		PhD Fellowships	Вое	hringer Ingelheim Fonds	01-Jun-2019	Not Specified
Contac	t Name					
(	Contact	+49 (0)6131 2750 80				
	ephone					
Contac	ct Email	secretariat@bifonds.de				
	ponsor	http://bifonds.de/fellowships-gran	ts/our-programmes.html			
	Vebsite	http://bifonds.do/followships.grap	ta/phd followshing btml			
Deadlin	am URL	http://bifonds.de/fellowships-gran 01-Jun-2019 , 01-Oct-2019	ts/pna-renowsnips.ntmi			
Deadiiii	(ALL)	01-Jun-2019 , 01-0ct-2019				
Sy	ynopsis	Boehringer Ingelheim Fonds awards PhD fellowships to outstanding junior scientists who wish to pursue an ambitious PhD project of approximately 3 years in basic biomedical research in an internationally leading laboratory.				
090492		<u>Travel Awards</u>	Brit	ish Infection Association	30-Jun-2019	1,320 USD
Contac	t Name					



**Program Title Funding Amount** Contact Telephone **Contact Email** c.chiu@imperial.ac.uk http://www.britishinfection.org/ Sponsor Website Program URL https://www.britishinfection.org/grant/ 30-Jun-2019, 27-Oct-2019 **Deadline Dates** (ALL) BIA provides awards to support travel to major national or international meetings, in particular, ASM, ICAAC, IDSA, and ECCMID, in **Synopsis** order to present original research where the abstract is already accepted. The award allows up to £1000 to be claimed in arrears within 1 year of the event. **Laboratory Visit Grant British Microcirculation Society** 005150 30-Jun-2019 Not **Specified Contact Name** Dr Jacqueline Whatmore, Honorary Secretary Contact +44(0) 1392 262944 Telephone J.L.Whatmore@exeter.ac.uk **Contact Email** http://www.microcirculation.org.uk/prizes-awards/ Sponsor Website http://www.microcirculation.org.uk/prize-award/laboratory-visit-grant/ Program URL **Deadline Dates** 30-Jun-2019 (ALL) Synopsis The sponsor provides support annually to assist an eligible postgraduate student or junior postdoctoral worker, either of whom must be a member of the British Microcirculation Society, to visit a laboratory in this country or abroad for the purpose of learning new techniques or other worthwhile scientific purposes related to microvascular research.

Sponsor Name

**Sponsor Number** 

**Deadline Date** 



SPIN ID	Progran	n Title	Sponsor Name	Sponsor Number	<b>Deadline Date</b>	<b>Funding Amount</b>
·						
005151	-	Terence Ryan Conference Grant	British M	licrocirculation Society	30-Jun-2019	660 USD
Contact I	Name	Dr Neena Kalia, Hon. Secretary				
Co	ontact					
Telep	ohone					
Contact	Email	n.kalia@bham.ac.uk				
•	onsor	http://www.microcirculation.org.uk	<u> </u>			
	ebsite					
Progran		http://www.microcirculation.org.uk	<u></u>			
Deadline		30-Jun-2019				
	(ALL)					
Syr	nopsis	The aim of this grant is to provide fi European Society for Microcirculation are held, and to assist student mem Society) on years when there is no E	on (ESM) Conferences or the Internates to attend a national microcirc	ational Micro-circulation Co ulation society meeting abr	onferences in the ye	ears when these
088573		Major Research Grant	•	coliosis Research	30-Jun-2019	264,000 USD
			Foundati	on		
Contact I	Name	Claire Curley, Data Protection Office	er			
Co	ontact	020 8964 5343				
Telep	ohone					
Contact	Email	grants@bsrf.co.uk				
•	onsor	http://www.bsrf.co.uk/				
	ebsite					
Progran		http://www.bsrf.co.uk/research-gra	ants/grant-options			
Deadline		30-Jun-2019				
	(ALL)					



SPIN IDProgram TitleSponsor NameSponsor NumberDeadline DateFunding Amount
---

Synopsis The BSRF Research Grant is open to appropriately qualified professionals such as scientists, clinicians, and allied health professionals (nurse, psychologists or physiotherapists) for research in any area of spinal deformity.

064543	Visiting Fellowships	British Society for Haematology	30-Jun-2019	7,920 USD
Contact Name				
Contact	020 7713 0990			
Telephone				
Contact Email	grants@b-s-h.org.uk			
Sponsor	https://www.b-s-h.org.uk/membership/grants	<u>s/</u>		
Website				
Program URL	https://www.b-s-h.org.uk/membership/grants	s/visiting-fellow/		
Deadline Dates (ALL)	30-Jun-2019			
()				
Synopsis	The British Society for Haematology (BSH) prodifferent field or to learn new research.	vides support for short term (less than one year) visit	ts overseas to gain ex	xperience in a
	,	vides support for short term (less than one year) visit  Canadian Society for Clinical Investigation	ts overseas to gain ex	xperience in a 2,250 USD
Synopsis	different field or to learn new research.	Canadian Society for Clinical	_	
Synopsis 053810	different field or to learn new research.	Canadian Society for Clinical	_	
Synopsis  053810  Contact Name	different field or to learn new research.	Canadian Society for Clinical	_	
Synopsis  053810  Contact Name Contact	different field or to learn new research.	Canadian Society for Clinical	_	



Website

Program URL <a href="http://www.csci-scrc.ca/?p=71">http://www.csci-scrc.ca/?p=71</a>

SPIN ID Progra	m Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
Deadline Dates (ALL)	03-Jun-2019				
Synopsis	a lecture and award to a Canadian s	al Investigation (CSCI) and The Royal C cientist who is notable for her/his cor nadian university. The award consists honorary membership in the CSCI.	ntribution to biomedical o	or related research	and who is
057236	<u>Distinguished Scientist Lecture Awa</u>		ociety for Clinical	03-Jun-2019	1,500 USD
Carled Name		Investigation	on		
Contact Name Contact	877-968-9449				
Telephone	admin @ assi sava sa				
Contact Email	admin@csci-scrc.ca				
Sponsor Website	http://www.csci-scrc.ca/?p=49				
Program URL	http://www.csci-scrc.ca/?p=795				
Deadline Dates (ALL)	03-Jun-2019				
Synopsis	contributions to new knowledge and	and Award is given to a Canadian M.D d is generally recognized in his/her fie a free one-year CSCI membership, a p	eld as expert, innovative, a		
057240	Joe Doupe Young Investigator Awar	<u>d</u> Canadian S Investigatio	ociety for Clinical	03-Jun-2019	750 USD
Contact Name					
Contact Telephone	877-968-9449				
Contact Email	admin@csci-scrc.ca				



SPIN ID Pro	gram Title	Sponsor Name		Sponsor Number	Deadline Date	Funding Amount
Spons	or http://www.csci-scrc.ca/?cat=49					
Websi						
Program U	RL <a href="http://www.csci-scrc.ca/?p=793">http://www.csci-scrc.ca/?p=793</a>					
Deadline Dat	es 03-Jun-2019					
(AI	L)					
Synop	sis The Joe Doupe Young Investigator the estimation of his/her department appointment. The award consists of	ental chair, has accomplish	hed a significa	int and innovative piece of	of work since this i	
061426	Scholarships for the Next Generation	on of Scientists	Cancer Rese	earch Society, Inc.	26-Apr-2019	Not
						Specified
Contact Nar	ne Lucille Beaudet, PhD, MBA					
Conta						
Telepho						
Contact Em	<u></u>					
Spons		<u>urlecancer.ca/en/what-we</u>	e-do/funding-	programs/schcolarship-fo	or-the-next-genera	ation-of-scientists
Websi		urla can car aa lan Iracaarah	aars/sabalarsk	sing for the next generat	ion of scientists	
Program U Deadline Dat		unecancer.ca/en/researci	iers/scrioiarsi	<u>iips-ior-tile-liext-generat</u>	lon-or-scientists	
Deadiine Dat (Al	•					
Synop	sis Scholarships for the Next Generation of Canadian researcher		r Research So	ciety funding program wi	ith the goal of supp	porting the future
060544	Research Grants - 21st Century Dev	velopment Grants	Cervical Spi	ne Research Society	07-Jun-2019	75,000 USD
Contact Nar	ne Zoher Ghogawala, MD					
Conta	ct 847-698-1626					



SPIN ID Progra	m Title	Sponsor Name		Sponsor Number	<b>Deadline Date</b>	<b>Funding Amount</b>
Telephone						
Contact Email	csrs@aaos.org					
Sponsor	http://www.csrs.org/					
Website						
Program URL	http://www.csrs.org/research/gran	its/				
Deadline Dates	07-Jun-2019					
(ALL)						
Synopsis	The CSRS Grant program will fund 2	•		•	. , , , ,	lications likely to
	make the greatest impact on cervice	al spine research. This gra	nt is limited	to basic science projects	only.	
053968	Response Mode Funding Scheme -	Translational Clinical	Chief Scien	tist Office - Scotland	28-Jun-2019	396,000 USD
	Studies Research Committee Grants	<u>s</u>				
Contact Name	Dr Alan McNair					
Contact	0131 244 8494					
Telephone						
Contact Email	alan.mcnair@gov.scot					
Sponsor	http://www.cso.scot.nhs.uk/fundin	g-2/response-mode-fund	ing-schemes	L		
Website	http://www.cco.ccot.phc.uk/fundin	a 2/response mode fund	ing schomos	/translational clinical ctu	dias rasaarsh samr	mittoo/
Program URL Deadline Dates	http://www.cso.scot.nhs.uk/fundin 28-Jun-2019	g-z/response-mode-rund	ing-scriemes	<u>/ transiational-cimical-stu</u>	<u>uies-research-comi</u>	mittee/
(ALL)	20-Juli-2019					
(ALL)						
Synopsis	The Translational Clinical Studies Re	esearch Committee consid	lers applicat	ions for research aimed a	t improving treatm	ents and / or



diagnostic approaches for conditions of clinical importance to the population of Scotland.

SPIN ID Progra	m Title	Sponsor Name	Sponsor Number	<b>Deadline Date</b>	Funding Amount
053972	Health Improvement Protection of	ad Comises Desearch	Chief Scientist Office - Scotland	28-Jun-2019	306 000 USD
053972	Health Improvement, Protection as Committee Grants	id Services Research	Chief Scientist Office - Scotland	28-Juli-2019	396,000 USD
Contact Name	Dr Tom Barlow				
Contact Telephone	0131 244 8350				
Contact Email	tom.barlow@gov.scot				
Sponsor Website	http://www.cso.scot.nhs.uk/fundin	ng-2/response-mode-fun	iding-schemes/		
Program URL	http://www.cso.scot.nhs.uk/fundircommittee/	ng-2/response-mode-fun	ding-schemes/health-improvement-	protection-and-servic	ces-research-
Deadline Dates (ALL)	28-Jun-2019				
Synopsis	•		n Committee considers applications for the constitution of the considers of healthcare of the constitution		improving or
062547	Sustainable Giving Initiative		Coopers Brewery Foundation	01-Jun-2019 [LOI/Pre-App	105,000 USD
Contact Name					
Contact Telephone	1300 664 344				
Contact Email	foundation@coopers.com.au				
Sponsor Website	https://coopers.com.au/foundatio	n/apply-for-funding			



Program URL <a href="https://coopers.com.au/docs/default-source/default-document-library/sust-giving-guidelines-2018.pdf?sfvrsn=0">https://coopers.com.au/docs/default-source/default-document-library/sust-giving-guidelines-2018.pdf?sfvrsn=0</a>

Deadline Dates (ALL)  Synopsis The Coopers Brewery Foundation has introduced an annual Sustainable Giving initiative to run in conjunction with the general giving program. Under the initiative, an eligible organisation will be selected and awarded \$50,000 a year for three years, providing it with a total of \$150,000. The program is designed to provide long-term certainty for the successful organisation.  O70774 Research Grants Diabetes Research and Wellness 30-Jun-2019 100,000 USD Foundation (U.S.)  Contact Name Contact Email Sponsor Website Program URL Deadline Dates (ALL)  Synopsis The Diabetes Research and Wellness Foundation (DRWF) accepts research applications related to finding the cause, prevention, treatment, and cure of diabetes and its complications. The maximum support of these grants is up to \$50,000 per year for up to two years.  O00642 Early-Career Small Grants for Basic Scientists Diabetes UK 01-Jun-2019 19,800 USD Contact Name Contact Email research@diabetes.org.uk  Sponsor https://www.diabetes.org.uk  https://www.diabetes.org.uk/	SPIN ID	Progra	m Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
program. Under the initiative, an eligible organisation will be selected and awarded \$50,000 a year for three years, providing it with a total of \$150,000. The program is designed to provide long-term certainty for the successful organisation.  Oronated Research Grants  Contact Name Contact Email Sponsor Website Program URL Deadline Dates (ALL)  Synopsis The Diabetes Research and Wellness Foundation (DRWF) accepts research applications related to finding the cause, prevention, treatment, and cure of diabetes and its complications. The maximum support of these grants is up to \$50,000 per year for up to two years.  O00642  Early-Career Small Grants for Basic Scientists  Diabetes Research and awarded \$50,000 a year for three years, providing it with a total of \$150,000 upon upon upon upon upon upon upon upon	Deadline		01-Jun-2019 [LOI/Pre-App], 01-Aug-	-2019			
Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL)  The Diabetes Research and Wellness Foundation (DRWF) accepts research applications related to finding the cause, prevention, treatment, and cure of diabetes and its complications. The maximum support of these grants is up to \$50,000 per year for up to two years.  Diabetes UK  O1-Jun-2019  19,800 USD  Contact Name Contact Telephone Contact Email Contact Contact Contact Contact Email Contact Email Contact Contact Contact Contact Contact Email Contact Contact Contact Contact Contact Email Contact Contact Contact Contact Contact Contact Email Contact Co	Sy	nopsis	program. Under the initiative, an eli	gible organisation will be selected an	d awarded \$50,000 a year	for three years, pr	
Contact Email Sponsor Website Program URL Deadline Dates (ALL)  Synopsis The Diabetes Research and Wellness Foundation (DRWF) accepts research applications related to finding the cause, prevention, treatment, and cure of diabetes and its complications. The maximum support of these grants is up to \$50,000 per year for up to two years.  000642  Early-Career Small Grants for Basic Scientists Diabetes UK D1-Jun-2019 D19,800 USD  Contact Name Contact Telephone Contact Email research@diabetes.org.uk	070774		Research Grants			30-Jun-2019	100,000 USD
Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL)  The Diabetes Research and Wellness Foundation (DRWF) accepts research applications related to finding the cause, prevention, treatment, and cure of diabetes and its complications. The maximum support of these grants is up to \$50,000 per year for up to two years.  Diabetes UK  O1-Jun-2019  19,800 USD  Contact Name Contact Telephone Contact Email  research@diabetes.org.uk	Contact	Name					
Contact Email Sponsor Website Program URL Deadline Dates (ALL)  Synopsis The Diabetes Research and Wellness Foundation (DRWF) accepts research applications related to finding the cause, prevention, treatment, and cure of diabetes and its complications. The maximum support of these grants is up to \$50,000 per year for up to two years.  O00642  Early-Career Small Grants for Basic Scientists Diabetes UK  O1-Jun-2019 19,800 USD  Contact Name Contact Telephone Contact Email  research@diabetes.org.uk							
Sponsor Website Program URL Deadline Dates (ALL)  Synopsis The Diabetes Research and Wellness Foundation (DRWF) accepts research applications related to finding the cause, prevention, treatment, and cure of diabetes and its complications. The maximum support of these grants is up to \$50,000 per year for up to two years.  Diabetes UK  O1-Jun-2019  19,800 USD  Contact Name Contact Telephone Contact Email research@diabetes.org.uk		•					
Website Program URL Deadline Dates (ALL)  Synopsis The Diabetes Research and Wellness Foundation (DRWF) accepts research applications related to finding the cause, prevention, treatment, and cure of diabetes and its complications. The maximum support of these grants is up to \$50,000 per year for up to two years.  O00642  Early-Career Small Grants for Basic Scientists Diabetes UK  O1-Jun-2019 19,800 USD  Contact Name Contact Telephone Contact Email research@diabetes.org.uk	Contact	t Email		<u>s.net</u>			
Program URL Deadline Dates (ALL)  Synopsis The Diabetes Research and Wellness Foundation (DRWF) accepts research applications related to finding the cause, prevention, treatment, and cure of diabetes and its complications. The maximum support of these grants is up to \$50,000 per year for up to two years.  Diabetes UK  O1-Jun-2019  19,800 USD  Contact Name Contact Telephone Contact Email  Contact Email  Contact Email  Contact Email  Contact Contact Email  Contact Email  Contact Email  Contact Email  Contact Email  Contact Email  Contact Contact Email  Contact Contact Email  Contact Email  Contact Contact Email  Contact Email  Contact Email  Contact Contact Email  Contact Emai		•	http://www.diabeteswellness.net				
Deadline Dates (ALL)  Synopsis The Diabetes Research and Wellness Foundation (DRWF) accepts research applications related to finding the cause, prevention, treatment, and cure of diabetes and its complications. The maximum support of these grants is up to \$50,000 per year for up to two years.  O00642 Early-Career Small Grants for Basic Scientists Diabetes UK 01-Jun-2019 19,800 USD  Contact Name Contact Contact Telephone Contact Email research@diabetes.org.uk			,,				
Synopsis The Diabetes Research and Wellness Foundation (DRWF) accepts research applications related to finding the cause, prevention, treatment, and cure of diabetes and its complications. The maximum support of these grants is up to \$50,000 per year for up to two years.    O00642   Early-Career Small Grants for Basic Scientists   Diabetes UK   O1-Jun-2019   19,800 USD	_			apply-funding			
treatment, and cure of diabetes and its complications. The maximum support of these grants is up to \$50,000 per year for up to two years.    000642   Early-Career Small Grants for Basic Scientists   Diabetes UK   01-Jun-2019   19,800 USD	Deadline		30-Jun-2019 , 30-Dec-2019				
Contact Name Contact 020 7424 1000 Telephone Contact Email research@diabetes.org.uk	Sy	nopsis/	treatment, and cure of diabetes and				
Contact 020 7424 1000 Telephone Contact Email research@diabetes.org.uk	000642		Early-Career Small Grants for Basic S	<u>Scientists</u> Diabetes U	K	01-Jun-2019	19,800 USD
Telephone Contact Email research@diabetes.org.uk	Contact	Name					
Contact Email research@diabetes.org.uk	C	Contact	020 7424 1000				
		•					
Sponsor <a href="https://www.diabetes.org.uk/">https://www.diabetes.org.uk/</a>	Contact	t Email					
	Sį	ponsor	https://www.diabetes.org.uk/				



SPIN ID Program	n litle	Sponsor Name		Sponsor Number	Deadline Date	Funding Amount
Website						
Program URL	https://www.diabetes.org.uk/resea	rch/for-researchers/apply	<u>/-for-a-grant/</u>	<u>small-grants</u>		
Deadline Dates (ALL)	01-Jun-2019 , 01-Dec-2019					
Synopsis	The Diabetes UK Early-Career Small projects related to diabetes.	Grant scheme for basic so	cientists supp	oorts early career-researc	hers to undertake	small research
061704	Healthcare Technologies Discipline	Hopping Call	Engineering Research Co	& Physical Sciences	27-Jun-2019	Not Specified
Contact Name	Kerry Young					
Contact	01793 444134					
Telephone						
Contact Email	Kerry.Young@epsrc.ac.uk					
Sponsor	https://epsrc.ukri.org/funding/calls	/htdisciplinehopping/				
Website Program URL						
Deadline Dates (ALL)	27-Jun-2019					
Synopsis	This open call is designed to enable end users so they can address the k		•			ner disciplines and
030970	Eppendorf & Science Prize for Neur	obiology	Eppendorf A	AG	15-Jun-2019	25,000 USD
Contact Name						
Contact	202-326-6550					
Telephone						



Contact Email Sponsor Website Program URL Deadline Dates (ALL)	<pre>eppendorfscienceprize@aaas.org http://corporate.eppendorf.com/de/unternehmen/wissenschaftliche-awards/global-award/ http://www.sciencemag.org/site/feature/data/prizes/eppendorf/howto.xhtml 15-Jun-2019</pre>
Synopsis	The International Eppendorf & Science Prize for Neurobiology is awarded annually to one young scientist for the most outstanding neurobiological research based on methods of molecular and cell biology conducted by him/her during the past three years, as described in a 1,000-word entrance essay. The essays are rated in two areas: scientific quality and significance, and clarity and style of the writing.
072699	<u>Joint Transnational Call for Proposals for Research Projects</u> ERA PerMed 17-Jun-2019 Not on Personalised Medicine – Multidisciplinary Research Specified
	<u>Towards Implementation</u>
Contact Name	Monika Frenzel
Contact Telephone	+33 (0) 1 73 54 83 32
Contact Email	ERAPerMed@agencerecherche.fr
Sponsor	http://www.erapermed.eu/joint-calls/
Website Program URL	http://www.erapermed.eu/joint-transnational-call-2019/
Deadline Dates (ALL)	17-Jun-2019
Synopsis	ERA PerMed is an ERA-NET Cofund, supported by 32 partners of 23 countries and cofunded by the European Commission (EC). To align national research strategies, promote excellence, reinforce the competitiveness of European players in Personalised Medicine (PM), and enhance the European collaboration with non-EU countries, 31 funding organisations have agreed to launch the second Joint Transnational Call for research projects in Personalised Medicine (PM). This represents the first of three potential additional calls non-

Sponsor Number

**Deadline Date** 

**Funding Amount** 



SPIN ID

**Program Title** 

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

cofunded by the EC. The funding organisations participating in this call particularly wish to promote innovative interdisciplinary collaboration and to encourage translational research proposals.

079625	<u>Call for Proposals for Biomarkers</u>	ERA-NET NEURON	27-Jun-2019	Not Specified
Contact Name	Dr. Anna Gossen, NEURON Call Secretariat			-
Contact Telephone	(+49) 228 3821 1684			
Contact Email	neuron@aei.gob.es			
Sponsor Website	http://www.neuron-eranet.org/			
Program URL	https://www.neuron-eranet.eu/en/865.php			
Deadline Dates (ALL)	27-Jun-2019			
Synopsis	Under the umbrella of NEURON, the aim of the call is to facunmet medical need for valid and reliable biomarkers for the treatment response and side effects in neurological and pseudoscients.	ne diagnosis, patient stratification, pro		
Synopsis 079327	unmet medical need for valid and reliable biomarkers for the treatment response and side effects in neurological and psecular for Multinational Research Projects On Personalised	ne diagnosis, patient stratification, pro ychi-atric diseases. EU Joint Programme –		nd prediction o
, .	unmet medical need for valid and reliable biomarkers for the treatment response and side effects in neurological and ps	ne diagnosis, patient stratification, pro ychi-atric diseases.	og-nosis, monitoring ar	nd prediction o
, .	unmet medical need for valid and reliable biomarkers for the treatment response and side effects in neurological and psecular for Multinational Research Projects On Personalised	ne diagnosis, patient stratification, pro ychi-atric diseases.  EU Joint Programme –  Neurodegenerative Disease	og-nosis, monitoring ar	nd prediction o
079327	unmet medical need for valid and reliable biomarkers for the treatment response and side effects in neurological and psecular for Multinational Research Projects On Personalised	ne diagnosis, patient stratification, pro ychi-atric diseases.  EU Joint Programme –  Neurodegenerative Disease	og-nosis, monitoring ar	nd prediction o
079327  Contact Name Contact Telephone	unmet medical need for valid and reliable biomarkers for the treatment response and side effects in neurological and psecular for Multinational Research Projects On Personalised Medicine for Neurodegenerative Diseases	ne diagnosis, patient stratification, pro ychi-atric diseases.  EU Joint Programme –  Neurodegenerative Disease	og-nosis, monitoring ar	nd prediction o
079327  Contact Name Contact	unmet medical need for valid and reliable biomarkers for the treatment response and side effects in neurological and psecular for Multinational Research Projects On Personalised	ne diagnosis, patient stratification, pro ychi-atric diseases.  EU Joint Programme –  Neurodegenerative Disease	og-nosis, monitoring ar	nd prediction of Not
079327  Contact Name Contact Telephone	unmet medical need for valid and reliable biomarkers for the treatment response and side effects in neurological and psecular for Multinational Research Projects On Personalised Medicine for Neurodegenerative Diseases	ne diagnosis, patient stratification, pro ychi-atric diseases.  EU Joint Programme – Neurodegenerative Disease Research (JPND)	25-Jun-2019 rsonalised-medicine-20	Not Specified



SPIN ID Prog	gram Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
Deadline Date (AL					
Synops	Commission – a call for "Multination	egenerative Disease Research (JPND) h nal research projects on Personalised ed by JPND member countries and the	Medicine for Neurodeger	nerative Diseases".	•
081054	European Hector Research Award ir	<u>1 HIV</u> European <i>A</i>	AIDS Clinical Society	30-Jun-2019	11,300 USD
Contact Nam	ne Prof. Dr. med. Jurgen Rockstroh, Pro	esident			
Conta	ct				
Telephor	ne				
Contact Ema	ail <u>info@eacsociety.org</u>				
Sponso	or <a href="http://www.eacsociety.org/education">http://www.eacsociety.org/education</a>	on/education/education.html			
Websit					
Program UF		ndex.php?article_id=177			
Deadline Date (AL					
Synops	is The H.W. & J. Hector Foundation, W the best scientific achievements in t	/einheim, is creating and announcing and the HIV research area in 2019.	a prize for European HIV 1	esearch, which wil	be awarded for
055678	<u>Pioneer Award</u>	European C Organisatio	Crohn's and Colitis on	03-Jun-2019	282,500 USD
Contact Nam	ne				
Conta	ct +43-(0)1-710 2242-0				
Telephor					
Contact Ema					
Sponso	or <a href="https://www.ecco-ibd.eu/index.php">https://www.ecco-ibd.eu/index.php</a>	o/science/fellowships-and-grants.htm	<u>[</u>		



SPIN ID Progra	m Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
Website Program URL Deadline Dates (ALL)	https://www.ecco-ibd.eu/index.php 03-Jun-2019 , 13-Aug-2019	p/science/fellowships-and-grants.htm	<u>l</u>		
Synopsis	•	rganisation (ECCO) offers Research Av a of Inflammatory Bowel Diseases (IBI		• •	
074983	Falling Walls Lab New Zealand	Falling Wal	ls Foundation	07-Jun-2019	Not
Carley Name	E-III - M-III I - N. Z. d. d				Specified
Contact Name	Falling Walls Lab New Zealand				
Contact	+64 4 470 5756				
Telephone Contact Email	International.Applications@royalso	cioty org nz			
	https://www.falling-walls.com/lab	iciety.org.nz			
Sponsor Website	nttps://www.failing-wails.com/fab				
Program URL	https://royalsociety.org.nz/what-w	e-do/funds-and-opportunities/falling-	walls-lah/ahout-falling-wa	alls-lah-new-zealan	d/
Deadline Dates	07-Jun-2019	e do rando ana opportamento, rannia	wans laby about raining we	and tab fiett zeatari	<u>u,</u>
(ALL)	0, Juli 2013				
Synopsis	Nations at the Falling Walls Lab Fina	e national competition to select a part ale in Berlin. Participating in Falling Wa It and present their innovative ideas.	•		
084169	Grants Program	Harley-Dav	idson Foundation	30-Jun-2019	Not
Contact Name					Specified
	414-343-4056				



SPIN ID Progra	m Title	Sponsor Name	Sponsor Number	<b>Deadline Date</b>	Funding Amount
Telephone					
Contact Email	FoundationApplications@harley-da	avidson.com			
Sponsor	https://www.harley-davidson.com/	/us/en/about-us/responsibility/found	ation.html		
Website					
Program URL	https://www.harley-davidson.com/ Davidson Foundation Online App	/content/dam/h-d/documents/respor	nsibility/foundation/The_l	<u>Harley-</u>	
Deadline Dates	30-Jun-2019 , 30-Sep-2019	ilication_FAQ_V2.pur			
(ALL)	30 Juli 2013 , 30 Sep 2013				
, ,					
Synopsis	The Harley-Davidson Foundation st	rives to improve the quality of life for	all by targeting our charit	table giving in the a	reas of greatest
	<del>-</del> , , , ,	he sponsor focuses their giving in the			•
		e they have corporate facilities and ta	_	-	ved populations.
0.46650	· · · · · · · · · · · · · · · · · · ·	ugh monetary grants, table/ event spo			100 000 1100
046658	<u>Translational Research Project Gran</u>	nts Heart Rese	earch UK	03-Jun-2019	198,000 USD
Contact Name	2442 224 242				
Contact Telephone	0113 234 7474				
Contact Email	grants@heartresearch.org.uk				
Sponsor	https://heartresearch.org.uk/apply	r-for-grants/research/			
Website	integration cocare morganic appropries	Tor grants/researchy			
Program URL	https://heartresearch.org.uk/grant	-posts/trp/			
Deadline Dates	03-Jun-2019				
(ALL)					
Synopsis	Translational Research Project Gran	nts aim to bridge the gap between lab	oratory-based scientific re	esearch and patien	t care.
·					
036963	Postdoctoral Research Fellowship	Indian Cou	incil of Medical Research	30-Jun-2019	Not



SPIN ID	Program	n Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	_		(ICMR)			Specified
Contact	t Name	Dr N.C. Jain, Scientist-G & Head				
C	Contact	011-26589384				
Tele	ephone					
Contac	t Email	drencejain@gmail.com				
	ponsor Vebsite	https://icmr.nic.in/				
Progra	am URL	https://icmr.nic.in/content/post-do	ctoral-research			
Deadline	e Dates (ALL)	30-Jun-2019 , 31-Dec-2019				
Sy	ynopsis	holders in the cutting edge areas of nutrition at ICMR Institutes/Centers	Ilowship Scheme provides high quality basic science, communicable and not so ICMR intends to offer fifty (50) such se fellowships will be allocated by Direction	on communicable disease on fellowships every year f	s, and reproductive or working in ICMR	health including Institutes/Centers
000390		William James Award		of Engineering and	28-Jun-2019	660 USD
Contact	t Name		Technolog	39		
	Contact	+44 (0)1438 767394				
	ephone	144 (0)1430 707334				
Contac	•	awards@theiet.org				
Sı	ponsor	https://www.theiet.org/impact-soc	iety/awards-scholarships/the-health	care-technologies-studer	nt-and-early-career-	awards/
W	Vebsite			-	·	<u> </u>
Progra	am URL	https://ietawards.secure-platform.c	com/a/solicitations/home/33			
Deadline	e Dates	28-Jun-2019				
	(ALL)					



Synopsis	The William James Award is presented to encourage, level of commitment and advanced understanding of		D students demons	trating a high
014004	Dennis Hill Award	Institution of Engineering and Technology	28-Jun-2019	528 USD
Contact Name		· · ·		
Contact Telephone				
Contact Email	awards@theiet.org			
Sponsor Website	https://www.theiet.org			
Program URL	https://www.theiet.org/impact-society/awards-schol	arships/the-healthcare-technologies-student-a	nd-early-career-aw	<u> ards/</u>
Deadline Dates (ALL)	28-Jun-2019			
(- :==)				
Synopsis	The Dennis Hill prize is awarded annually to the stude best final year project dissertation in the general field Electrical Engineering, Physics, Healthcare Technologic	of Biomedical Engineering and cognate subjec		
, ,	best final year project dissertation in the general field	of Biomedical Engineering and cognate subjec		
Synopsis	best final year project dissertation in the general field Electrical Engineering, Physics, Healthcare Technologi	I of Biomedical Engineering and cognate subjecties and Health Informatics).  International Society for Optics and	ts (including Electro	onic and
Synopsis 023519	best final year project dissertation in the general field Electrical Engineering, Physics, Healthcare Technologi	I of Biomedical Engineering and cognate subjecties and Health Informatics).  International Society for Optics and	ts (including Electro	onic and
Synopsis  023519  Contact Name Contact Telephone	best final year project dissertation in the general field Electrical Engineering, Physics, Healthcare Technological Electrical Engineering, Physics, Healthcare Electronic El	I of Biomedical Engineering and cognate subjecties and Health Informatics).  International Society for Optics and	ts (including Electro	onic and
Synopsis  023519  Contact Name Contact Telephone Contact Email	best final year project dissertation in the general field Electrical Engineering, Physics, Healthcare Technologi  Britton Chance Biomedical Optics Award  360-676-3290  awards@spie.org	I of Biomedical Engineering and cognate subjecties and Health Informatics).  International Society for Optics and Photonics	ts (including Electro	onic and
Synopsis  023519  Contact Name Contact Telephone	best final year project dissertation in the general field Electrical Engineering, Physics, Healthcare Technological Electrical Engineering, Physics, Healthcare Electronic El	I of Biomedical Engineering and cognate subjecties and Health Informatics).  International Society for Optics and Photonics	ts (including Electro	onic and

**Deadline Date** 

**Sponsor Number** 

**Funding Amount** 



**Program Title** 

SPIN ID Progra	m Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
Deadline Dates (ALL)	01-Jun-2019				
Synopsis	•	cs Award is presented annually in recolopment of innovative, high impact te	_	etime contribution	s to the field of
041826	Biophotonics Technology Innovator	Award Internation Photonics	al Society for Optics and	01-Jun-2019	2,000 USD
Contact Name Contact Telephone Contact Email Sponsor Website Program URL  Deadline Dates (ALL)  Synopsis	innovator-award 01-Jun-2019  The Biophotonics Technology Innov	programs  programs/current-award-winners/award  ator Award is presented annually for a	extraordinary achievemer	nts in biophotonics	
047828	ISTSS Student Travel Grant	Internation Stress Stud	al Society for Traumatic	28-Jun-2019	Not Specified
Contact Name Contact Telephone	Michael Hagedorn +1-847-686-2234				



SPIN ID Progra	m Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
Contact Email Sponsor Website Program URL Deadline Dates (ALL)	mhagedorn@istss.org http://www.istss.org/ http://www.istss.org/meetings-eve	ents/2018-istss-annual-meeting/istss-t	ravel-grant-program.aspx		
Synopsis	A limited number of student travel or travel costs.	grants are available from ISTSS each y	ear to support student me	mber Meeting att	endees with fees
047826	ISTSS Global Travel Grant		al Society for Traumatic	28-Jun-2019	Not
		Stress Stud	ies		Specified
Contact Name	Michael Hagedorn				
Contact	+1-847-686-2234				
Telephone					
Contact Email	mhagedorn@istss.org				
Sponsor	http://www.istss.org/				
Website					
Program URL		nts/2018-istss-annual-meeting/istss-t	ravel-grant-program.aspx		
Deadline Dates (ALL)	28-Jun-2019				
Synopsis	underserved regions of the world (a and experiencing financial hardship	Awards are available from ISTSS each ye.g., low and middle income countries, with fees or travel costs. ISTSS encoual Meeting to make a public mental he	; under resourced commur rages applications from inc	nities in higher inc dividuals who will	ome countries)



SPIN ID Progra	m Title	Sponsor Name	Sponsor Number	<b>Deadline Date</b>	Funding Amount
079198	Ninth Joint Call: Diagnostics and Su	rveillance of	Joint Programming Initiative on	17-Jun-2019	Not
	Antimicrobial Resistance: Development	ment of Tools,	Antimicrobial Resistance (JPIAMR)		Specified
	Technologies and Methods for Glob	bal Use			
Contact Name	JPIAMR Secretariat				
Contact	+46 8 546 44 000				
Telephone					
Contact Email	secretariat.jpiamr@vr.se				
Sponsor	https://www.jpiamr.eu/9thcall/				
Website					
Program URL		t/uploads/2018/12/JPI-A	MR Call-text 2019 Diagnostics-and-S	<u> urveillance final u</u>	pdated-
5 III 5 I	20181218.pdf				
Deadline Dates	17-Jun-2019				
(ALL)					
Synopsis	and surveillance tools, technologies	s and methods to detect a	transnational research projects addre antimicrobial resistance (AMR). Projec reillance of AMR in humans, animals a	ts should address t	he diagnosis of
	promotes projects with impact in lo	, .	•	nd the environmen	t. The Can
061435	Grants Program	or and imagic modific co	LEO Foundation	14-Jun-2019	Not
					Specified
Contact Name					
Contact					
Telephone					
Contact Email	applications@leo-foundation.org				
Sponsor	http://leo-foundation.org/en/				
Website					
Program URL	http://leo-foundation.org/en/resea	arch-grants-awards/apply	<u>-tor-a-grant/</u>		



cours to	m**1			D 111 D 1	- 1
SPIN ID Progr	am Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
Deadline Dates (ALL)	14-Jun-2019 , 20-Sep-2019				
Synopsis	LEO Foundation open competition	n grants are given to suppo	ort the best dermatology research pro	ojects worldwide.	
068211	Carlos and Marguerite Mason Tru	st Grants	Mason (Carlos and Marguerite) Trust	01-Jun-2019	Not Specified
Contact Name					
Contact					
Telephone					
Contact Email		<u>com</u>			
Sponsor Website					
Program URL		ate-foundations/mason-tr	ust		
Deadline Dates		·			
(ALL)					
Synopsis		Georgia that can provide f	ransplantation for needy Georgia res inancial assistance to needy Georgia		_
013262	Minimally Invasive Gynecologic Su (Arizona)	urgery Fellowship	Mayo Clinic College of Medicine	30-Jun-2019	Not Specified
Contact Name	Annette M. Lemire				·
Contact	480-342-2812				
Telephone					
Contact Email	lemire.annette@mayo.edu				



Program URL <a href="https://college.mayo.edu/academics/residencies-and-fellowships/minimally-invasive-gynecologic-surgery-fellowship-arizona/application-process/">https://college.mayo.edu/academics/residencies-and-fellowships/minimally-invasive-gynecologic-surgery-fellowship-arizona/application-process/</a> Deadline Dates 30-Jun-2019  (ALL)	
Synopsis The Minimally Invasive Gynecologic Surgery Fellowship at Mayo Clinic's campus in Phoenix, Arizona, gives fellowship-trained the opportunity to use innovative robotic and laparoscopic hysteroscopic technologies to treat benign and malignant gynecoconditions.	-
013058 Neurology - Clinical Neurophysiology, Electromyography Mayo Clinic College of Medicine 01-Jun-2019 N	Not
Fellowship - (Florida)	Specified
Contact Name Devon Rubin, M.D., Program Director	
Contact 904-953-0110	
Telephone	
Contact Email <u>rubin.devon@mayo.edu</u>	
Sponsor <a href="https://college.mayo.edu/academics/residencies-and-fellowships/">https://college.mayo.edu/academics/residencies-and-fellowships/</a> Website	
Program URL	

**Deadline Date** 

**Sponsor Number** 

**Funding Amount** 



SPIN ID

**Program Title** 

SPIN ID Progra	m Title	Sponsor Name	Sponsor Number	<b>Deadline Date</b>	Funding Amount
098689	W. Dale Dauphinee Fellowship	Medica	Council of Canada	01-Jun-2019	18,750 USD
Contact Name	Ms. Lauren Copp				
Contact	613-521-6012				
Telephone					
Contact Email	grants@mcc.ca				
Sponsor	https://mcc.ca/research-and-devel	opment/awards-fellowships/			
Website	https://www.desearch.com/desearch		a davelina a l		
Program URL	https://mcc.ca/research-and-devel	opment/awards-fellowsnips/w-dai	<u>e-aaupninee/</u>		
Deadline Dates (ALL)	01-Jun-2019				
(/ (22)					
	The W. Dale Dauphinee Fellowship educators to enhance their knowle leaders in assessment to study or g project related to the assessment of medicine. Up to one fellowship, value	dge and skills in physician assessmorain experience in the application of physician knowledge, skills, beha	ent. The fellowship will enal f new knowledge or techniq viours, and attitudes releva	ole the recipient to vulues or to further the	visit and work with eir pursuit of a
095946	MRC-NIHR Methodology Research		Research Council of the	19-Jun-2019	Not
		United	Kingdom		Specified
Contact Name					
Contact					
Telephone	AADDC as also Ole as de Was as a see al				
Contact Email	MRPGrants@headoffice.mrc.ac.uk		and and		
Sponsor Website	https://mrc.ukri.org/funding/scien	ce-areas/methodology-research/ov	<u>/erview/</u>		
Program URL	https://mrc.ukri.org/funding/dead	lines/			
Deadline Dates	19-Jun-2019 , 13-Nov-2019 , 17-Jur				
(ALL)		, · · · · · · · · · · · · · · · ·			



SPIN ID Progra	m Title	Sponsor Name	Sponsor Number	<b>Deadline Date</b>	Funding Amount
Synopsis			rovides support for research on methoopulation health sciences, health serv	•	•
071435	Health Systems Research Initiative Evidence to Strengthen Health Syst Middle-Income Countries (LMICs)		Medical Research Council of the United Kingdom	12-Jun-2019	Not Specified
Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL)	HSRI@headoffice.mrc.ac.uk https://mrc.ukri.org/funding/browsystems-in-low-and-middle-income 12-Jun-2019, 27-Jun-2019		ems-research-initiative-call-6-providir	ng-evidence-to-strer	ngthen-health-
Synopsis	Up to £5 million is available for function countries.	ding proposals for resear	ch on how to improve the health of po	eople living in low a	nd middle-income
080564	Next Generation Networks for Neu	roscience (NeuroNex)	Medical Research Council of the United Kingdom	14-Jun-2019 [LOI/Pre-App]	Not Specified
Contact Name Contact Telephone Contact Email Sponsor Website	Charlotte.inchley@mrc.ukri.org https://mrc.ukri.org/funding/brow	se/neuronex/next-genera	ation-networks-for-neuroscience-neu	ronex/	



SPIN ID Progra	m Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
Program URL Deadline Dates (ALL)	https://mrc.ukri.org/funding/brows 14-Jun-2019 [LOI/Pre-App], 13-Dec-	<del></del>	networks-for-neuroscience-neu	ronex/neuronex-uk-	guidance/
Synopsis	The MRC in collaboration with the Nanada, Fonds de Recherche du Quinvite proposals for the NeuroNex P	ebec (FRQ) of Quebec, and Dec			
	This initiative will provide funding for as part of larger networks with inte	• , ,	rch projects focused on address	sing grand challenge	s in neuroscience
	For the UK component of these net the UK Fund for International Collal engagement. It focuses on bilateral administered by UK Research and In	boration (FIC). FIC aims to enha and multilateral partnerships v	nce the UK's excellence in rese	arch and innovation	through global
004530	Discovery Award	Med Ore	lical Research Foundation of gon	21-Jun-2019	Not Specified
Contact Name Contact Telephone	Nicole Good, Sr. Executive Assistant	t			
Contact Email	goodn@ohsu.edu				
Sponsor Website	http://www.ohsu.edu/xd/about/fo	undation/about/medical-resea	rch-foundation/index.cfm		
Program URL	http://www.ohsu.edu/xd/about/fo	undation/about/medical-resea	rch-foundation/awards.cfm		
Deadline Dates (ALL)	21-Jun-2019				



Synopsis	The Discovery Award recognizes an Oregon in while working in Oregon.	nvestigator who has made significant, original contribu	utions to health-relat	ed research
022737	Incubator Grants	Multiple Sclerosis Research Australia	28-Jun-2019	17,500 USD
Contact Name	Grants Coordinator			
Contact Telephone	02 8413 7950			
Contact Email	grants@msra.org.au			
Sponsor Website	https://msra.org.au/annual-funding-opportu	nities/		
Program URL	https://msra.org.au/annual-funding-opportu	nities/types-of-grants/		
Deadline Dates				
(ALL)	28-Jun-2019			
	Incubator grants provide seed funding for the	e early stages of innovative new research efforts, with ions in order to support and accelerate research into f		
(ALL)	Incubator grants provide seed funding for the data needed to support future grant applicat	•		
(ALL) Synopsis	Incubator grants provide seed funding for the data needed to support future grant applicat for MS.	ions in order to support and accelerate research into f	finding better treatments	ents and a cure
(ALL) Synopsis 006454	Incubator grants provide seed funding for the data needed to support future grant applicat for MS.	ions in order to support and accelerate research into f	finding better treatments	ents and a cure
(ALL) Synopsis  006454  Contact Name Contact Telephone	Incubator grants provide seed funding for the data needed to support future grant applicat for MS.  Research Grants	ions in order to support and accelerate research into f	finding better treatments	ents and a cure
(ALL) Synopsis  006454  Contact Name Contact Telephone Contact Email	Incubator grants provide seed funding for the data needed to support future grant applicat for MS.  Research Grants  grants@mdausa.org	ions in order to support and accelerate research into f  Muscular Dystrophy Association	finding better treatments	ents and a cure
(ALL) Synopsis  006454  Contact Name Contact Telephone Contact Email Sponsor	Incubator grants provide seed funding for the data needed to support future grant applicat for MS.  Research Grants	ions in order to support and accelerate research into f  Muscular Dystrophy Association	finding better treatments	ents and a cure
(ALL) Synopsis  006454  Contact Name Contact Telephone Contact Email	Incubator grants provide seed funding for the data needed to support future grant applicat for MS.  Research Grants  grants@mdausa.org	Muscular Dystrophy Association  ortunities	finding better treatments	ents and a cure

**Deadline Date** 

**Sponsor Number** 

**Funding Amount** 



**Program Title** 

SPIN ID Progra	m Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
Deadline Dates (ALL)	15-Jun-2019 [LOI/Pre-App], 15-Jul-2	2019			
Synopsis	The Muscular Dystrophy Association understanding and treating neurom	n award research grants to independe Juscular disease.	ent, established investigato	ors to accelerate pr	ogress toward
067591	Mentored Research Fellowships	Myositis As	ssociation	15-May-2019 [LOI/Pre-App]	100,000 USD
Contact Name	Mary McGowan				
Contact	703-553-2631				
Telephone					
Contact Email	mcgowan@myositis.org				
Sponsor Website	https://www.myositis.org/				
Program URL	https://www.myositis.org/research	tma-grants-fellowships/research-fun/	ding-opportunities/		
Deadline Dates (ALL)	15-May-2019 [LOI/Pre-App], 15-Jun	-2019			
Synopsis		e designed to help promising junior inv ry level approved by the participating			
067593	Pilot Project Grants	Myositis As	ssociation	15-May-2019 [LOI/Pre-App]	100,000 USD
Contact Name	Mary McGowan, TMA Executive Dir	ector			
Contact Telephone	703-299-4850				
Contact Email	McGowan@myositis.org				



Sponsor	https://www.myositis.org/research/tma-grants-fellowships/g	research-funding-opportunities/		
Website				
Program URL	https://37fa343y5czt13hd4izqqhj1-wpengine.netdna-ssl.com	ı/wp-content/uploads/2019/01/Resear	ch-Guidelines-2019	<u>.pdf</u>
Deadline Dates	15-May-2019 [LOI/Pre-App], 15-Jun-2019			
(ALL)				
Synopsis	The Myositis Association is pleased to be able to offer fundin Grant Funding is designed to fund new and innovative resear (such as NIH). A competitive application will clearly delineate competitive application will clearly distinguish itself from the be clearly disclosed and a letter of support from the industry years and up to a maximum of \$100,000 annually, subject to	ch projects in the hope that they will at how this pilot funding will lead to futu- investigator's existing research program partner must be included. Pilot grants	ttract funding from re grant support. In m. Any industry par	other sources addition, a tnership must
079978	<u>Dissertation Grants</u>	National Center for Responsible	03-Jun-2019	2,000 USD
		Gaming		
Contact Name	Shayna Adams			
Contact	978-338-6610			
Telephone				
Contact Email	sadams@ncrg.org			
Sponsor	http://www.ncrg.org/			
Website				
Program URL	http://www.ncrg.org/research-center/apply-ncrg-funding-0			
Deadline Dates	03-Jun-2019			
(ALL)				
Synopsis	The Dissertation Grants support doctoral students by providi	ng funding for the costs of dissertation	research.	

**Funding Amount** 

**Deadline Date** 

**Sponsor Number** 



**Program Title** 

SPIN ID Prog	ram Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
023926	CRACK IT Challenges	N	ational Centre for the	19-Jun-2019	Not
		R	eplacement, Refinement and		Specified
			eduction of Animals in Research		•
		1)	NC3Rs)		
Contact Nam	e				
Contac	t 020 7611 2233				
Telephon	e				
Contact Ema	il <u>crackitenquiries@nc3rs.org.uk</u>				
Sponso	r <a href="http://www.nc3rs.org.uk/">http://www.nc3rs.org.uk/</a>				
Websit	e				
Program UR	L <a href="http://www.crackit.org.uk/crack-i">http://www.crackit.org.uk/crack-i</a>	<u>t-challenges</u>			
Deadline Date	s 19-Jun-2019				
(ALI	.)				
Synopsi	s CRACK IT Challenges is a challenge	e-led competition that funds o	ollaborations between industry, ac	ademics and SMFs	to solve husiness
Зупорз			mmercial benefits, either by impro		
	developing a commercialisable pr		mineralar benefits, etcher by impro	villa busiliess proc	23223 01
006742	Collegiate Inventors Competition	N	ational Inventors Hall of Fame	07-Jun-2019	Not
					Specified
Contact Nam	e The National Inventors Hall of Fan	ne Administrative Headquarte	rs		
Contac					
Telephon					
Contact Ema					
Sponso		tors-competition/			
Websit					
Program UR	L <a href="http://www.invent.org/challenge">http://www.invent.org/challenge</a>	/application-process/			



Deadline Dates 07-Jun-2019 (ALL)	
Synopsis The Collegiate Inventors Competition was founded in 1990 to encourage and drive innovation and entrepreneursh level. The competition brings together the nation's brightest college minds to showcase, recognize, and award the research and discovery.	
024390 National Medical Research Council 08-Jun-202 (Singapore)	9 365,000 USD
Contact Name Sharon Sim	
Contact 6325 9220	
Telephone Control of the Control of	
Contact Email sharon_sim@moh.gov.sg	
Sponsor <a href="http://www.nmrc.gov.sg/">http://www.nmrc.gov.sg/</a> Website	
Program URL http://www.nmrc.gov.sg/content/nmrc internet/home/top nav/grants/talent-development/nmrc-research-train	ng-fellowship.html
Deadline Dates 08-Jun-2019 (ALL)	
Synopsis The NMRC Research Training Fellowship is awarded to outstanding and talented clinicians and health science prof research training or to pursue a graduate degree in research.	essionals for
068408 Grants Program Noble (Samuel Roberts) 01-Jun-202 Foundation	9 Not Specified
Contact Name Stacy Newman, Program Officer	<u> </u>
Contact 580-224-6347	
Telephone	
Contact Email granting@noblefoundation.org	



SPIN ID Progra	ım Title	Sponsor Name		Sponsor Number	Deadline Date	Funding Amount
Sponsor	https://www.noble.org					
Website						
Program URL	https://www.noble.org/giving/guid	delines-for-grant-seekers/				
Deadline Dates (ALL)	01-Jun-2019					
Synopsis	The primary focus of the Noble Fou Institute. In addition, funding is pro communities.		_	~	•	
071459	First Nation, Metis and Inuit Bursar	TY.	Northern A Council	lberta Development	01-Jun-2019	Not Specified
Contact Name						,
Contact	780-624-6545					
Telephone						
Contact Email	nadc.bursary@gov.ab.ca					
Sponsor Website	http://nadc.ca/our-bursaries/					
Program URL	http://nadc.ca/our-bursaries/first-	nation-metis-and-inuit-bu	rsary/			
Deadline Dates (ALL)	01-Jun-2019 , 15-Nov-2019					
Synopsis	The First Nation, Métis and Inuit (F training, or in a certificate or diplor program can access \$10,000 per ye	na studies can access up t	o \$6,000 for		· ·	
053767	Soft Tissue Repair and Regeneratio	n Sports Medicine Grant	Orthopaedi Foundation	ic Research & Education	12-Apr-2019 [LOI/Pre-App]	225,000 USD
Contact Name						



SPIN IDProgram TitleSponsor NameSponsor NumberDeadline DateFunding Amount

Contact 847-430-5109

Telephone

Contact Email grants@oref.org

Sponsor <a href="https://www.oref.org/">https://www.oref.org/</a>

Website

Program URL https://www.oref.org/grants-and-awards/grant-programs

Deadline Dates 12-Apr-2019 [LOI/Pre-App], 17-Jun-2019

(ALL)

Synopsis This Funding Opportunity Announcement solicits investigator-initiated multidisciplinary research proposals focused on the

development of new cell and tissue-based strategies to prevent, repair, regenerate, or replace injured musculoskeletal tissues.

015066 Conference Support Grants Paykel (Maurice and Phyllis) Trust 01-Jun-2019 Not Specified

**Contact Name** 

Contact 64-9-300-7112

Telephone Contact Email

Sponsor http://www.paykeltrust.co.nz/

Website

Program URL <a href="http://www.paykeltrust.co.nz/conference-support-grants">http://www.paykeltrust.co.nz/conference-support-grants</a>

Deadline Dates 01-Jun-2019, 01-Oct-2019

(ALL)

Synopsis The Maurice and Phyllis Paykel Trust provides grants to support scientific conferences in health related fields organised by academic

institutions or professional organisations within New Zealand.



SPIN ID Progra	ım Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
022377	<u>Grants Program</u>	Potte	er (Ian) Foundation	19-Apr-2019	70,000 USD
				[LOI/Pre-App]	
Contact Name					
Contact	(+613) 9650 3188				
Telephone					
Contact Email	admin@ianpotter.org.au				
Sponsor	http://www.ianpotter.org.au/fund	<u>ling-rounds/</u>			
Website	http://www.iannottor.org.au/how	to apply for a grant/			
Program URL Deadline Dates	http://www.ianpotter.org.au/how 19-Apr-2019 [LOI/Pre-App], 04-Jun				
(ALL)	19-Apr-2019 [LOI/Pre-App], 04-Jun	1-2019			
,					
Synopsis	The Ian Potter Foundation makes g seven program areas: Arts, Commu Science.			•	-
006942	Career Development Awards	Rese	arch to Prevent Blindness	15-Jun-2019	300,000 USD
Contact Name					
Contact	646-892-9566				
Telephone					
Contact Email	pmoran@rpbusa.org				
Sponsor	http://www.rpbusa.org/rpb/grants	s-and-research/grants/overview,	<del>/</del>		
Website					
Program URL	http://www.rpbusa.org/rpb/grants	s-and-research/grants/grants-foi	<u>-individuals/career-developr</u>	nent-awards/	
Deadline Dates	15-Jun-2019 , 01-Jul-2019				
(ALL)					



SPIN ID Progra	m Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
Synopsis	The RPB Career Development Awa ophthalmology and support junion payable in equal annual installmen	r faculty who have demons			
050730	Sir Henry Dale Fellowship		Royal Society	13-Jun-2019	Not Specified
Contact Name					
Contact Telephone	+44 (0)20 7611 2020				
Contact Email	grantenquiries@wellcome.ac.uk				
Sponsor Website Program URL	https://royalsociety.org/grants-sc	hemes-awards/grants/hen	<u>ry-dale/</u>		
Deadline Dates (ALL)	13-Jun-2019 , 06-Aug-2019 [LOI/P	re-App], 17-Oct-2019 , 19-	Nov-2019 [LOI/Pre-App], 30-Jan-2	020	
Synopsis	The Sir Henry Dale Fellowship is for career addressing an important bi	~ '	al scientists wishing to build their	own UK-based, indepe	ndent research
023639	Bernice Grafstein Award for Outst in Mentoring	anding Accomplishments	Society for Neuroscience	07-Jun-2019	2,500 USD
Contact Name					
Contact	202-962-4000				
Telephone					
Contact Email	awards@sfn.org				
Sponsor	https://www.sfn.org/Initiatives/A	<u>wards</u>			
Website Program URL	https://www.sfn.org/Initiatives/A	wards/Bernice-Grafstein-A	<u>ward</u>		



SPIN ID Progra	am Title	Sponsor Name		Sponsor Number	Deadline Date	Funding Amount
Deadline Dates (ALL)	07-Jun-2019					
Synopsis	The Bernice Grafstein Award for Ou advancement in neuroscience throu (economy air or ground), and two n	gh mentorship. Recipien	ts receive a \$	\$2,500 award and complin		
023640	Louise Hanson Marshall Special Rec	ognition Award	Society for	Neuroscience	07-Jun-2019	Not Specified
Contact Name						
Contact	202-962-4000					
Telephone						
Contact Email	awards@sfn.org					
Sponsor	https://www.sfn.org/Initiatives/Awa	<u>ards</u>				
Website						
Program URL	https://www.sfn.org/Initiatives/Awa	ards/Louise-Hanson-Mar	shall-Award			
Deadline Dates (ALL)	07-Jun-2019					
Synopsis	The Louise Hanson Marshall Special development of women in neurosci necessarily related to research.	_			•	
066849	Mentored Clinical Scientist Research Award (K08)	Career Development	Society for	Vascular Surgery	12-Jun-2019	Not Specified
Contact Name	Jane D. Scott					
Contact	301-435-0535					
Telephone						
Contact Email	scottj2@nhlbi.nih.gov					



SPIN ID Progra	m Title	Sponsor Name	Sponsor Number	Deadline Date	<b>Funding Amount</b>
Sponsor Website Program URL Deadline Dates (ALL)	https://vascular.org/ https://vascular.org/career-tools-tr 12-Jun-2019 , 12-Oct-2019	raining/awards-and-schol	arships/mentored-clinical-scientist-	research-career	
Synopsis	The SVS Foundation offers this awaindividuals pursuing a career in vas mechanism.				
061172	Mentored Patient-Oriented Resear Award (K23)	ch Career Development	Society for Vascular Surgery	12-Jun-2019	Not Specified
Contact Name	Jane D. Scott, ScD, MSN, FAHA, Dire	ector,			
Contact	301-435-0535				
Telephone					
Contact Email	scottj2@nhlbi.nih.gov https://vascular.org/				
Sponsor Website	nttps://vascular.org/				
Program URL	https://vascular.org/career-tools-to	raining/awards-and-schol	arships/mentored-patient-oriented	-research-career-dev	elopment
Deadline Dates (ALL)	12-Jun-2019 , 12-Oct-2019				
Synopsis	The SVS Foundation provides supplicate Career Development Award (K23) of	_	dividual who receives an NHLBI Mer on scientists in the early stages of th		ed Research
066765	Pilot Research Program		Southwest National Primate	17-Jun-2019	Not
Contact Name	Dr. Suzette Tardif		Research Center		Specified
- Contact Hame	2 dazette Taran				



SPIN ID **Program Title Sponsor Number Deadline Date Funding Amount** Sponsor Name Contact 210-258-9400 Telephone **Contact Email** stardif@txbiomed.org http://snprc.org **Sponsor** Website http://snprc.org/pilot-research-grants/ Program URL **Deadline Dates** 17-Jun-2019 (ALL) The SNPRC Pilot Research program provides opportunities and support for investigators to use SNPRC nonhuman primate resources in highly focused, short-term studies with a high likelihood of enhancing the value, utility, feasibility, and attractiveness of nonhuman primates for biomedical research. High priority will be given to studies that propose to generate preliminary data for applications to the National Institutes of Health (NIH) for support of future research projects. Those proposing to develop new nonhuman primate models of disease, or develop and/or test new research methods, instrumentation, or approaches using nonhuman primates, also will be considered responsive to the goals of the program. Stanford University 067237 Stanford Molecular Imaging Scholars (SMIS) Program 03-Jun-2019 Not Specified Sofia Gonzales **Contact Name** Contact 650-724-9139 Telephone sofias@stanford.edu **Contact Email** http://med.stanford.edu/smisprogram.html **Sponsor** Website http://med.stanford.edu/smisprogram/about/qualifications.html Program URL **Deadline Dates** 03-Jun-2019



(ALL)

SPIN ID Progra	nm Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
Synopsis	The Stanford Molecular Imaging Scl at Stanford University that brings to Humanities and Sciences.		<u> </u>	• • • •	
037701	Emma and Leslie Reid Scholarship		University of Leeds	03-Jun-2019	47,520 USD
Contact Name					
Contact Telephone	+44 (0) 113 343 4077				
Contact Email	pg_scholarships@leeds.ac.uk				
Sponsor Website	http://scholarships.leeds.ac.uk/				
Program URL Deadline Dates (ALL)	03-Jun-2019				
Synopsis	Two Emma & Leslie Reid Scholarshi October 2019 in the area of disease the University of Leeds standard Uk	s of the heart or brain (o	r kindred diseases). The award wi	ll cover the full cost of	•
096603	Vilcek Prize for Creative Promise in	Biomedical Science	Vilcek Foundation	10-Jun-2019	50,000 USD
Contact Name					
Contact Telephone	212-472-2500				
Contact Email	info@vilcek.org				
Sponsor Website	http://www.vilcek.org				
Program URL	http://www.vilcek.org/prizes/creat	ive-promise/biomedical-s	cience.html		



SPIN ID Progr	ram Title	Sponsor Name	Sponsor Number	<b>Deadline Date</b>	Funding Amount		
Deadline Dates (ALL							
Synopsis		aree prizes of \$50,000 each to young figible work may be in basic, applied, an			nstrate		
086006	Sir Henry Wellcome Postdoctoral Fe	<u>ellowships</u> Wellcome	Trust	17-Apr-2019 [LOI/Pre-App]	396,000 USD		
Contact Name Contact Telephone Contact Emai	t +44 (0)20 7611 5757						
Sponsor Website							
Program URI Deadline Dates (ALL)	17-Apr-2019 [LOI/Pre-App], 27-Jun-	- <u>henry-wellcome-postdoctoral-fellow</u> 2019 , 08-Oct-2019 [LOI/Pre-App], 17					
Synopsis	This scheme offers recently qualified postdoctoral researchers the opportunity to start independent research careers, working in some of the best research environments in the world.						
049159	Career Re-Entry Fellowships	Wellcome '	Trust	17-Apr-2019 [LOI/Pre-App]	Not Specified		
Contact Name Contact Telephone Contact Emai	t +44 (0)20 7611 8888						



SPIN ID Progra	m Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amour			
Sponsor Website	http://www.wellcome.ac.uk/							
Program URL	https://wellcome.ac.uk/funding/research-career-re-entry-fellowships							
Deadline Dates (ALL)	17-Apr-2019 [LOI/Pre-App], 27-Jun-2019, 08-Oct-2019 [LOI/Pre-App], 17-Dec-2019							
Synopsis	This scheme offers postdoctoral research scientists the opportunity to re-establish their scientific careers after a continuous break from research of at least two years. These fellowships have a duration of four years.							
001134	Requests for Proposals in Leukemia	<u> </u>	n Everyone Survives dation, Inc.	01-Jun-2019	50,000 USI			
Contact Name								
Contact	770-595-3573							
Telephone								
Contact Email	contact@wheneveryonesurvives.org							
Sponsor Website	http://www.wheneveryonesurvives	.org/						
Program URL	http://www.wheneveryonesurvives	.org/grant_application						
Deadline Dates (ALL)	01-Jun-2019							
Synopsis	This request for proposals (RFP) is offered by the When Everyone Survives Foundation (WES Leukemia Research Foundation) to solicit innovative research in leukemia. Grants of \$50,000 for one year are offered to new and established investigators who are requesting support for laboratory, translational, or clinical research related to acute leukemia.							
	Grants Program	Wilki	ns (Catherine Holmes)	28-Jun-2019	5,000 USD			
068437	<u>Grants Frogram</u>	Found	dation					



SPIN ID Program Title Sponsor Name Sponsor Number Deadline Date Funding Amount

Contact 206-604-5374

Telephone

Contact Email <a href="mailto:healey7556@msn.com">healey7556@msn.com</a>
Sponsor <a href="http://fdnweb.org/wilkins/">http://fdnweb.org/wilkins/</a>

Website

Program URL <a href="http://fdnweb.org/wilkins/application-procedures/">http://fdnweb.org/wilkins/application-procedures/</a>

Deadline Dates 28-Jun-2019, 11-Oct-2019

(ALL)

Synopsis The Catherine Holmes Wilkins Foundation provides charitable grants to qualified medical research and social service agencies in the

Puget Sound region.